PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Grice, K; Cao, CQ; Love, GD; Bottcher, ME; Twitchett, RJ; Grosjean, E; Summons, RE; Turgeon, SC; Dunning, W; Jin, YG				Grice, K; Cao, CQ; Love, GD; Bottcher, ME; Twitchett, RJ; Grosjean, E; Summons, RE; Turgeon, SC; Dunning, W; Jin, YG			Photic zone euxinia during the Permian-Triassic superanoxic event	SCIENCE			English	Article							MOLECULAR INDICATORS; MASS EXTINCTION; ORGANIC GEOCHEMISTRY; BOUNDARY; SULFUR; ANOXIA; CARBON; ENRICHMENT; ISOTOPE; SULFATE	Carbon and sulfur isotopic data, together with biomarker and iron speciation analyses of the Hovea-3 core that was drilled in the Perth Basin, Western Australia, indicate that euxinic conditions prevailed in the paleowater column during the Permian-Triassic superanoxic event. Biomarkers diagnostic for anoxygenic photosynthesis, by Chlorobiaceae are particularly abundant at the boundary and into the Early Triassic. Similar conditions prevailed in the contemporaneous seas off South China. Our evidence for widespread photic-zone euxinic conditions suggests that sulfide toxicity was a driver of the extinction and a factor in the protracted recovery.	Curtin Univ Technol, Perth, WA 6001, Australia; MIT, Cambridge, MA 02139 USA; Nanjing Inst Geol & Palaeontol, Nanjing, Peoples R China; Max Planck Inst Marine Microbiol, Bremen, Germany; Univ Plymouth, Plymouth PL4 8AA, Devon, England; Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA	Curtin University; Massachusetts Institute of Technology (MIT); Chinese Academy of Sciences; Max Planck Society; University of Plymouth; United States Department of Energy (DOE); Oak Ridge National Laboratory	Grice, K (corresponding author), Curtin Univ Technol, Perth, WA 6001, Australia.	K.Grice@curtin.edu.au	Summons, Roger Everett/AAL-3789-2020; Böttcher, Michael/A-6746-2013	Grice, Kliti/0000-0003-2136-3508; Bottcher, Michael Ernst/0000-0002-8877-0303				Anderson TF, 2004, AM J SCI, V304, P203, DOI 10.2475/ajs.304.3.203; Benton MJ, 2003, TRENDS ECOL EVOL, V18, P358, DOI 10.1016/S0169-5347(03)00093-4; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; Foster C.B., 1997, APPEA J, V37, P472; Grice K, 1996, ORG GEOCHEM, V25, P131, DOI 10.1016/S0146-6380(96)00130-1; Grice K, 1996, GEOCHIM COSMOCHIM AC, V60, P3913, DOI 10.1016/0016-7037(96)00199-8; GRICE K, UNPUB; Hayes JM, 2001, REV MINERAL GEOCHEM, V43, P225, DOI 10.2138/gsrmg.43.1.225; Isozaki Y, 1997, SCIENCE, V276, P235, DOI 10.1126/science.276.5310.235; KAJIWARA Y, 1994, PALAEOGEOGR PALAEOCL, V111, P367, DOI 10.1016/0031-0182(94)90072-8; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; Koopmans MP, 1996, GEOCHIM COSMOCHIM AC, V60, P4467, DOI 10.1016/S0016-7037(96)00238-4; Korte C, 2004, INT J EARTH SCI, V93, P565, DOI 10.1007/s00531-004-0406-7; KUMP LR, 2003, GSA ANN M GEOL SOC A; LEWAN MD, 1982, GEOCHIM COSMOCHIM AC, V46, P2547, DOI 10.1016/0016-7037(82)90377-5; LOGAN GA, 1995, NATURE, V376, P53, DOI 10.1038/376053a0; Newton RJ, 2004, EARTH PLANET SC LETT, V218, P331, DOI 10.1016/S0012-821X(03)00676-9; Pancost RD, 2004, J GEOL SOC LONDON, V161, P353, DOI 10.1144/0016764903-059; Passier HF, 1999, NATURE, V397, P146, DOI 10.1038/16441; Schouten S, 1998, GEOCHIM COSMOCHIM AC, V62, P1397, DOI 10.1016/S0016-7037(98)00076-3; Schwab V, 2004, APPL GEOCHEM, V19, P55, DOI 10.1016/S0883-2927(03)00127-6; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; SUMMONS RE, 1987, GEOCHIM COSMOCHIM AC, V51, P557, DOI 10.1016/0016-7037(87)90069-X; Thomas BM, 2004, AUST J EARTH SCI, V51, P423, DOI 10.1111/j.1400-0952.2004.01066.x; TRULL TW, 2001, EOS T AM GEOPHYS UN, V82, P306; WIGNALL PB, 1992, PALAEOGEOGR PALAEOCL, V93, P21, DOI 10.1016/0031-0182(92)90182-5; Wignall PB, 1996, SCIENCE, V272, P1155, DOI 10.1126/science.272.5265.1155	28	591	650	3	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2005	307	5710					706	709		10.1126/science.1104323	http://dx.doi.org/10.1126/science.1104323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15661975	Green Submitted			2022-12-28	WOS:000226814900038
J	O'Donnell, M				O'Donnell, M			Why doctors don't read research papers - Scientific papers are not written to disseminate information	BMJ-BRITISH MEDICAL JOURNAL			English	Letter												michael@odonnell99.freeserve.co.uk						Barraclough K, 2004, BRIT MED J, V329, P1411, DOI 10.1136/bmj.329.7479.1411-a; HEALY JB, 1976, LANCET, V1, P204; Lamers HJ, 1998, BRIT J GEN PRACT, V48, P1819; MADDOX J, 1991, NOT OUR STYLE COMMUN, P51; SMITH R, 1998, GUARDIAN        0624	5	6	7	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2005	330	7485					256	256		10.1136/bmj.330.7485.256-a	http://dx.doi.org/10.1136/bmj.330.7485.256-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15677677	Green Published			2022-12-28	WOS:000226779400044
J	Lee, HN; Christen, HM; Chisholm, MF; Rouleau, CM; Lowndes, DH				Lee, HN; Christen, HM; Chisholm, MF; Rouleau, CM; Lowndes, DH			Strong polarization enhancement in asymmetric three-component ferroelectric superlattices	NATURE			English	Article							PULSED-LASER DEPOSITION; BATIO3/SRTIO3 SUPERLATTICES; INVERSION SYMMETRY; INTERFACE; FILMS	Theoretical predictions - motivated by recent advances in epitaxial engineering - indicate a wealth of complex behaviour arising in superlattices of perovskite-type metal oxides. These include the enhancement of polarization by strain(1,2) and the possibility of asymmetric properties in three-component superlattices(3). Here we fabricate superlattices consisting of barium titanate (BaTiO3), strontium titanate (SrTiO3) and calcium titanate (CaTiO3) with atomic-scale control by high-pressure pulsed laser deposition on conducting, atomically flat strontium ruthenate (SrRuO3) layers. The strain in BaTiO3 layers is fully maintained as long as the BaTiO3 thickness does not exceed the combined thicknesses of the CaTiO3 and SrTiO3 layers. By preserving full strain and combining heterointerfacial couplings, we find an overall 50% enhancement of the superlattice global polarization with respect to similarly grown pure BaTiO3, despite the fact that half the layers in the superlattice are nominally nonferroelectric. We further show that even superlattices containing only single-unit-cell layers of BaTiO3 in a paraelectric matrix remain ferroelectric. Our data reveal that the specific interface structure and local asymmetries play an unexpected role in the polarization enhancement.	Oak Ridge Natl Lab, Condensed Matter Sci Div, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory	Lee, HN (corresponding author), Oak Ridge Natl Lab, Condensed Matter Sci Div, Oak Ridge, TN 37831 USA.	hnlee@ornl.gov	Lee, Ho Nyung/K-2820-2012; Rouleau, Christopher M/Q-2737-2015; Chisholm, Matthew F./F-7198-2017; Kim, Yu Jin/A-2433-2012; Christen, Hans M/H-6551-2013	Lee, Ho Nyung/0000-0002-2180-3975; Rouleau, Christopher M/0000-0002-5488-3537; Chisholm, Matthew F./0000-0003-0546-5109; Christen, Hans M/0000-0001-8187-7469				Christen HM, 2003, REV SCI INSTRUM, V74, P4058, DOI 10.1063/1.1602962; Glinchuk MD, 2004, J PHYS-CONDENS MAT, V16, P3517, DOI 10.1088/0953-8984/16/21/002; Junquera J, 2003, NATURE, V422, P506, DOI 10.1038/nature01501; KAWASAKI M, 1994, SCIENCE, V266, P1540, DOI 10.1126/science.266.5190.1540; Kim J, 2002, APPL PHYS LETT, V80, P3581, DOI 10.1063/1.1477934; Lee HN, 2004, MATER RES SOC SYMP P, V784, P127; Lee HN, 2004, APPL PHYS LETT, V84, P4107, DOI 10.1063/1.1753650; Lee HN, 2002, SCIENCE, V296, P2006, DOI 10.1126/science.1069958; Muller DA, 2004, NATURE, V430, P657, DOI 10.1038/nature02756; Neaton JB, 2003, APPL PHYS LETT, V82, P1586, DOI 10.1063/1.1559651; Norton DP, 2004, MAT SCI ENG R, V43, P139, DOI 10.1016/j.mser.2003.12.002; O'Neill D, 2000, APPL PHYS LETT, V77, P1520, DOI 10.1063/1.1290691; Ogawa Y, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.217403; Okamoto S, 2004, NATURE, V428, P630, DOI 10.1038/nature02450; Pertsev NA, 2000, PHYS REV B, V61, pR825, DOI 10.1103/PhysRevB.61.R825; Rijnders G, 2004, APPL PHYS LETT, V84, P505, DOI 10.1063/1.1640472; Sai N, 2000, PHYS REV LETT, V84, P5636, DOI 10.1103/PhysRevLett.84.5636; Schlom DG, 2001, MAT SCI ENG B-SOLID, V87, P282, DOI 10.1016/S0921-5107(01)00726-7; Shimuta T, 2002, J APPL PHYS, V91, P2290, DOI 10.1063/1.1434547; TABATA H, 1994, APPL PHYS LETT, V65, P1970, DOI 10.1063/1.112837; Warusawithana MP, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.036802; Yamada H, 2004, SCIENCE, V305, P646, DOI 10.1126/science.1098867; Zheng H, 2004, SCIENCE, V303, P661, DOI 10.1126/science.1094207	23	596	604	25	481	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					395	399		10.1038/nature03261	http://dx.doi.org/10.1038/nature03261			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674286				2022-12-28	WOS:000226546200037
J	Fan, QR; Hendrickson, WA				Fan, QR; Hendrickson, WA			Structure of human follicle-stimulating hormone in complex with its receptor	NATURE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LEUCINE-RICH REPEATS; ALPHA-SUBUNIT; LUTEINIZING-HORMONE; HUMAN FOLLITROPIN; CRYSTAL-STRUCTURE; SELF-ASSOCIATION; BINDING DOMAIN; BETA-SUBUNIT; REGION	Follicle-stimulating hormone (FSH) is central to reproduction in mammals. It acts through a G-protein-coupled receptor on the surface of target cells to stimulate testicular and ovarian functions. We present here the 2.9-Angstrom-resolution structure of a partially deglycosylated complex of human FSH bound to the extracellular hormone-binding domain of its receptor (FSHRHB). The hormone is bound in a hand-clasp fashion to an elongated, curved receptor. The buried interface of the complex is large (2,600 Angstrom(2)) and has a high charge density. Our analysis suggests that all glycoprotein hormones bind to their receptors in this mode and that binding specificity is mediated by key interaction sites involving both the common alpha- and hormone-specific beta-subunits. On binding, FSH undergoes a concerted conformational change that affects protruding loops implicated in receptor activation. The FSH-FSHRHB complexes form dimers in the crystal and at high concentrations in solution. Such dimers may participate in transmembrane signal transduction.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	wayne@convex.hhmi.columbia.edu			NIGMS NIH HHS [R01 GM068671] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068671] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold CJ, 1998, BIOCHEMISTRY-US, V37, P1762, DOI 10.1021/bi971816o; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Dias JA, 2002, VITAM HORM, V64, P249, DOI 10.1016/S0083-6729(02)64008-7; DIAS JA, 1994, J BIOL CHEM, V269, P25289; ERICKSON LD, 1990, ENDOCRINOLOGY, V126, P2555, DOI 10.1210/endo-126-5-2555; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Heikoop JC, 1998, EUR J BIOCHEM, V253, P354, DOI 10.1046/j.1432-1327.1998.2530354.x; Hsu SYT, 2003, TRENDS ENDOCRIN MET, V14, P303, DOI 10.1016/S1043-2760(03)00106-1; Ji I, 2004, MOL ENDOCRINOL, V18, P968, DOI 10.1210/me.2003-0443; JI IH, 1993, J BIOL CHEM, V268, P22971; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEINUNG MC, 1991, P NATL ACAD SCI USA, V88, P9707, DOI 10.1073/pnas.88.21.9707; Liu C, 1996, ARCH BIOCHEM BIOPHYS, V329, P127, DOI 10.1006/abbi.1996.0200; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Remy JJ, 1996, MOL CELL ENDOCRINOL, V125, P79, DOI 10.1016/S0303-7207(96)03955-X; Roess DA, 2003, BIOL REPROD, V69, P1765, DOI 10.1095/biolreprod.103.018846; Schmidt A, 2001, J BIOL CHEM, V276, P23373, DOI 10.1074/jbc.M100057200; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Tao YX, 2004, J BIOL CHEM, V279, P5904, DOI 10.1074/jbc.M311162200; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Vischer HF, 2003, MOL ENDOCRINOL, V17, P1972, DOI 10.1210/me.2003-0172; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	50	431	455	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					269	277		10.1038/nature03206	http://dx.doi.org/10.1038/nature03206			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662415	Green Accepted			2022-12-28	WOS:000226381300045
J	Forman, JP; Rimm, EB; Stampfer, MJ; Curhan, GC				Forman, JP; Rimm, EB; Stampfer, MJ; Curhan, GC			Folate intake and the risk of incident hypertension among US women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVES ENDOTHELIAL FUNCTION; CORONARY-ARTERY DISEASE; BLOOD-PRESSURE CHANGE; MIDDLE-AGED MEN; FOLIC-ACID; DEPENDENT VASODILATION; NUTRITIONAL FACTORS; MILD HYPERTENSION; DIETARY FACTORS; CLINICAL-TRIAL	Context Folate has important beneficial effects on endothelial function, but there is limited information about folate intake and risk of incident hypertension. Objective To determine whether higher folate intake is associated with a lower risk of incident hypertension. Design, Setting, and Participants Two prospective cohort studies of 93803 younger women aged 27 to 44 years in the Nurses' Health Study II (1991-1999) and 62260 older women aged 43 to 70 years in the Nurses' Health Study I (1990-1998), who did not have a history of hypertension. Baseline information on dietary folate and supplemental folic acid intake was derived from semiquantitative food frequency questionnaires and was updated every 4 years. Main Outcome Measure Relative risk of incident self-reported hypertension during 8 years of follow-up. Results We identified 7373 incident cases of hypertension in younger women and 12347 cases in older women. After adjusting for multiple potential confounders, younger women who consumed at least 1000 mug/d of total folate (dietary plus supplemental) had a decreased risk of hypertension (relative risk [RR], 0.54; 95% confidence interval [CI], 0.45-0.66; P for trend <.001) compared with those who consumed less than 200 mu g/d. Younger women's absolute risk reduction (ARR) was approximately 8 cases per,1000 person-years (6.7 vs 14.8 cases). The multivariable RR for the same comparison in older women was 0.82 (95% CI, 0.69-0.97; P for trend =.05). Older women's ARR was approximately 6 cases per 1000 person-years (34.7 vs 40.4 cases). When the analysis was restricted to women with low dietary folate intake (<200 mug/d), the multivariable RR for younger women with total folate intake at least 800 mug/d compared with less than 200 mug/d was 0.55 (95% CI, 0.32-0.94; P for trend =.03), and 0.61 (95% CI, 0.34-1.11; P for trend =.05) in the older cohort. Among women who did not take folic acid-containing supplements, dietary folate intake of 400 mug/d or more was not significantly associated with risk of hypertension. Conclusion Higher total folate intake was associated with a decreased risk of incident hypertension, particularly in younger women.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Forman, JP (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 3rd Floor,181 Longwood Ave, Boston, MA 02115 USA.	jforman@partners.org			NATIONAL CANCER INSTITUTE [P01CA087969, R01CA050385] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL078093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052866] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allender PS, 1996, ANN INTERN MED, V124, P825, DOI 10.7326/0003-4819-124-9-199605010-00007; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Ascherio A, 1996, HYPERTENSION, V27, P1065, DOI 10.1161/01.HYP.27.5.1065; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Choumenkovitch SF, 2002, J NUTR, V132, P2792, DOI 10.1093/jn/132.9.2792; Colditz G A, 1995, J Am Med Womens Assoc (1972), V50, P40; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Curhan GC, 2002, ARCH INTERN MED, V162, P2204, DOI 10.1001/archinte.162.19.2204; Dedier J, 2002, HYPERTENSION, V40, P604, DOI 10.1161/01.HYP.0000035856.77718.DA; Doshi SN, 2002, CIRCULATION, V105, P22, DOI 10.1161/hc0102.101388; Doshi SN, 2001, ARTERIOSCL THROM VAS, V21, P1196, DOI 10.1161/hq0701.092000; ELIASSON K, 1992, J HYPERTENS, V10, P195, DOI 10.1097/00004872-199202000-00014; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; Fields LE, 2004, HYPERTENSION, V44, P398, DOI 10.1161/01.HYP.0000142248.54761.56; He J, 2004, J HYPERTENS, V22, P73, DOI 10.1097/00004872-200401000-00015; Hunsicker LG, 1997, KIDNEY INT, V51, P1908, DOI 10.1038/ki.1997.260; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mangoni AA, 2002, J INTERN MED, V252, P497, DOI 10.1046/j.1365-2796.2002.01059.x; MARGETTS BM, 1986, BRIT MED J, V293, P1468, DOI 10.1136/bmj.293.6560.1468; Miura K, 2004, AM J EPIDEMIOL, V159, P572, DOI 10.1093/aje/kwh085; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; Stamler J, 2003, J HUM HYPERTENS, V17, P655, DOI 10.1038/sj.jhh.1001608; Stamler J, 2002, HYPERTENSION, V39, P1000, DOI 10.1161/01.HYP.0000016178.80811.D9; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; Stroes ESG, 2000, CIRC RES, V86, P1129; Suitor CW, 2000, J AM DIET ASSOC, V100, P88, DOI 10.1016/S0002-8223(00)00027-4; Sundstrom J, 2003, HYPERTENSION, V42, P1100, DOI 10.1161/01.HYP.0000101690.58391.13; van Dijk RAJM, 2001, ARTERIOSCL THROM VAS, V21, P2072, DOI 10.1161/hq1201.100223; van Etten RW, 2002, DIABETOLOGIA, V45, P1004, DOI 10.1007/s00125-002-0862-1; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417; Verhaar MC, 1999, CIRCULATION, V100, P335, DOI 10.1161/01.CIR.100.4.335; Verhaar MC, 1998, CIRCULATION, V97, P237, DOI 10.1161/01.CIR.97.3.237; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; WALKER WG, 1993, AM J KIDNEY DIS, V22, P164; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; WHELTON PK, 1989, AM J CARDIOL, V63, pG26, DOI 10.1016/0002-9149(89)90215-4; Willett W.C., 1998, SAUPTIKAPARVAN MAHAB, DOI [10.1093/acprof:oso/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.003.11]; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Zhao LC, 2004, HYPERTENSION, V43, P1332, DOI 10.1161/01.HYP.0000128243.06502.bc	48	93	100	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					320	329		10.1001/jama.293.3.320	http://dx.doi.org/10.1001/jama.293.3.320			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657325				2022-12-28	WOS:000226358400026
J	Jones, RK; Purcell, A; Singh, S; Finer, LB				Jones, RK; Purcell, A; Singh, S; Finer, LB			Adolescents' reports of parental knowledge of adolescents' use of sexual health services and their reactions to mandated parental notification for prescription contraception	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY; AVAILABILITY; CARE; PHYSICIANS	Context Legislation has been proposed that would mandate parental notification for adolescents younger than 18 years (minors) obtaining prescription contraception from federally funded family planning clinics. Objective To determine the extent to which parents are currently aware that their teenage daughters are accessing reproductive health services and how minors would react in the face of mandated parental involvement laws for prescription birth control. Design, Setting, and Participants A total of 1526 female adolescents younger than 18 years seeking reproductive health services at a national sample of 79 family planning clinics were surveyed between May 2003,and February 2004. Main Outcome Measures Proportions of minor females who reported that a parent or guardian was aware that they were at the family planning clinic and, under conditions of mandated parental involvement, proportions of minors who would access prescription contraceptives at family planning clinics or engage in unsafe sex. Results Sixty percent of minors reported that a parent or guardian knew they were accessing sexual health services at the clinic. Fifty-nine percent of all adolescents would use the clinic for prescription contraception even if parental notification were mandated. This response was less common. (29.5%) among adolescents whose parents were unaware of their clinic visits and more common (79%) among those whose parents were aware. Many adolescents gave more than 1 response to mandated parental involvement. Forty-six percent would use an over-the-counter method, and 18% would go to a private physician. Seven percent said that they would stop having sex as one response, but only 1% indicated this would be their only reaction. One in 5 adolescents would use no contraception or rely on withdrawal as one response to mandated notification. Conclusions Most minor adolescent females seeking family planning services report that their parents are aware of their use of services. Most would continue to use clinic services if parental notification were mandated. However, mandated parental notification laws would likely increase risky or unsafe sexual behavior and, in turn, the incidence of adolescent pregnancy and sexually transmitted diseases.	Alan Guttmacher Inst, New York, NY 10005 USA		Jones, RK (corresponding author), Alan Guttmacher Inst, 120 Wall St, New York, NY 10005 USA.	rjones@guttmacher.org						*A GUTTM I, 2004, STATE POLICIES  0910; *A GUTTM I, 2004, STATE POLICIES  0901; *A GUTTM I, 2003, FAM PLANN ANN REP 20; Akinbami LJ, 2003, PEDIATRICS, V111, P394, DOI 10.1542/peds.111.2.394; DAYRINGER R, 1983, J FAM PRACTICE, V17, P267; FORD BM, 1983, OVERVIEW HOT DECK PR, V2; Ford C, 2004, J ADOLESCENT HEALTH, V35, P160, DOI 10.1016/j.jadohealth.2004.03.002; Frost JJ, 2004, PERSPECT SEX REPRO H, V36, P206, DOI 10.1111/j.1931-2393.2004.tb00024.x; Frost JJ, 2001, FAM PLANN PERSPECT, V33, P4, DOI 10.2307/2673736; FURSTENBERG FF, 1984, FAM PLANN PERSPECT, V16, P163, DOI 10.2307/2134897; Harper C, 2004, PERSPECT SEX REPRO H, V36, P20, DOI 10.1111/j.1931-2393.2004.tb00004.x; HULBERT RC, 1974, FAM PLANN PERSPECT, V6, P50, DOI 10.2307/2133622; NATHANSON CA, 1986, J MARRIAGE FAM, V48, P513, DOI 10.2307/352037; ORR MT, 1985, FAM PLANN PERSPECT, V17, P63, DOI 10.2307/2135262; Reddy DM, 2002, JAMA-J AM MED ASSOC, V288, P710, DOI 10.1001/jama.288.6.710; Santelli JS, 2004, J ADOLESCENT HEALTH, V35, P80, DOI 10.1016/j.jadohealth.2004.05.001; TORRES A, 1978, FAM PLANN PERSPECT, V10, P280, DOI 10.2307/2134380; TORRES A, 1980, FAM PLANN PERSPECT, V12, P284, DOI 10.2307/2134659; Zavodny M, 2004, AM J PUBLIC HEALTH, V94, P1347, DOI 10.2105/AJPH.94.8.1347	19	103	103	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					340	348		10.1001/jama.293.3.340	http://dx.doi.org/10.1001/jama.293.3.340			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888FA	15657327	Bronze			2022-12-28	WOS:000226358400028
J	Hirsch, IB				Hirsch, IB			Drug therapy: Insulin analogues	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TYPE-1 DIABETES-MELLITUS; IMPROVED GLYCEMIC CONTROL; REGULAR HUMAN INSULIN; BEDTIME NPH INSULIN; GLARGINE HOE 901; GLUCOSE CONTROL; SUBCUTANEOUS INJECTION; INDUCED HYPOGLYCEMIA; ACTION PROFILE; BASAL INSULIN		Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hirsch, IB (corresponding author), Univ Washington, Sch Med, Dept Med, 1959 NE Pacific St,Box 356176, Seattle, WA 98195 USA.	ihirsch@u.washington.edu	Boehm, Bernhard Otto/F-8750-2015					Albright ES, 2004, DIABETES CARE, V27, P632, DOI 10.2337/diacare.27.2.632; American Diabetes Association, 2004, DIABETES CARE, V27, pS15; Anderson JH, 1997, DIABETES, V46, P265, DOI 10.2337/diabetes.46.2.265; Bastyr EJ, 2000, DIABETES CARE, V23, P1236, DOI 10.2337/diacare.23.9.1236; Bhattacharyya A, 2001, QJM-INT J MED, V94, P255, DOI 10.1093/qjmed/94.5.255; Bolli GB, 1999, DIABETOLOGIA, V42, P1151, DOI 10.1007/s001250051286; Boskovic R, 2003, DIABETES CARE, V26, P1390, DOI 10.2337/diacare.26.5.1390; BOTT S, 2003, INT DIAB FED ABSTR V; Brunelle RL, 1998, DIABETES CARE, V21, P1726, DOI 10.2337/diacare.21.10.1726; Burge MR, 1997, DIABETES CARE, V20, P152, DOI 10.2337/diacare.20.2.152; Chase HP, 2003, J PEDIATR-US, V143, P737, DOI 10.1067/S0022-3476(03)00415-3; Clement S, 2004, METABOLISM, V53, P54, DOI 10.1016/j.metabol.2003.07.021; Colombel A, 1999, DIABETIC MED, V16, P319, DOI 10.1046/j.1464-5491.1999.00077.x; Colquitt J, 2003, DIABETIC MED, V20, P863, DOI 10.1046/j.1464-5491.2003.01018.x; Devendra D, 2004, BMJ-BRIT MED J, V328, P750, DOI 10.1136/bmj.328.7442.750; DeWitt DE, 2003, JAMA-J AM MED ASSOC, V289, P2254, DOI 10.1001/jama.289.17.2254; Fineberg NS, 1996, DIABETES, V45, P1750, DOI 10.2337/diabetes.45.12.1750; Fineberg SE, 2003, DIABETES CARE, V26, P89, DOI 10.2337/diacare.26.1.89; Fritsche A, 2003, ANN INTERN MED, V138, P952, DOI 10.7326/0003-4819-138-12-200306170-00006; Gabbe SG, 2003, OBSTET GYNECOL, V102, P857, DOI 10.1016/j.obstetgynecol.2003.07.001; Gale EAM, 2000, DIABETIC MED, V17, P209; Garg Satish K, 2003, Endocr Pract, V9, P187; Hamann A, 2003, DIABETES CARE, V26, P1738, DOI 10.2337/diacare.26.6.1738; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; Hayward RA, 1999, JAMA-J AM MED ASSOC, V281, P1989; Heinemann L, 2000, DIABETES CARE, V23, P644, DOI 10.2337/diacare.23.5.644; Heise T, 2002, DIABETIC MED, V19, P490, DOI 10.1046/j.1464-5491.2002.00723.x; Home PD, 1998, DIABETES CARE, V21, P1904, DOI 10.2337/diacare.21.11.1904; HOWEY DC, 1994, DIABETES, V43, P396, DOI 10.2337/diabetes.43.3.396; Jackson R, 1986, PHYSL MANAGEMENT DIA, P6; Joslin Elliott P., 1941, DIABETIC MANUAL MUTU; Kilo C, 2003, J DIABETES COMPLICAT, V17, P307, DOI 10.1016/S1056-8727(03)00076-X; Kitzmiller JL, 1999, DIABETES CARE, V22, P874, DOI 10.2337/diacare.22.5.874; Koivisto VA, 1999, DIABETES CARE, V22, P459, DOI 10.2337/diacare.22.3.459; Kurtzhals P, 2000, DIABETES, V49, P999, DOI 10.2337/diabetes.49.6.999; Kurtzhals P, 1995, BIOCHEM J, V312, P725, DOI 10.1042/bj3120725; Lalli C, 1999, DIABETES CARE, V22, P468, DOI 10.2337/diacare.22.3.468; Lepore M, 2000, DIABETES, V49, P2142, DOI 10.2337/diabetes.49.12.2142; Loukovaara S, 2003, DIABETES CARE, V26, P1193, DOI 10.2337/diacare.26.4.1193; Masson EA, 2003, DIABETIC MED, V20, P46, DOI 10.1046/j.1464-5491.2003.00840.x; Mohn A, 2000, DIABETES CARE, V23, P557, DOI 10.2337/diacare.23.4.557a; Mudaliar SR, 1999, DIABETES CARE, V22, P1501, DOI 10.2337/diacare.22.9.1501; Owens DR, 2000, DIABETES CARE, V23, P813, DOI 10.2337/diacare.23.6.813; Pfutzner A, 1996, EXP CLIN ENDOCR DIAB, V104, P25; Quagliaro L, 2003, DIABETES, V52, P2795, DOI 10.2337/diabetes.52.11.2795; Raskin P, 2000, DIABETES CARE, V23, P1666, DOI 10.2337/diacare.23.11.1666; Raskin P, 2001, J DIABETES COMPLICAT, V15, P295, DOI 10.1016/S1056-8727(01)00168-4; Rassam AG, 1999, DIABETES CARE, V22, P133, DOI 10.2337/diacare.22.1.133; Ratner RE, 2000, DIABETES CARE, V23, P639, DOI 10.2337/diacare.23.5.639; Renner R, 1999, DIABETES CARE, V22, P784, DOI 10.2337/diacare.22.5.784; Riddle MC, 2003, DIABETES CARE, V26, P3080, DOI 10.2337/diacare.26.11.3080; Rosenfeld L, 2002, CLIN CHEM, V48, P2270; Rosenstock J, 2001, DIABETES CARE, V24, P631, DOI 10.2337/diacare.24.4.631; Rossetti P, 2003, DIABETES CARE, V26, P1490, DOI 10.2337/diacare.26.5.1490; Rudolph Justen W, 2002, Endocr Pract, V8, P401; Schober E, 2002, J PEDIATR ENDOCR MET, V15, P369; SEIGLER DE, 1992, DIABETIC MED, V9, P826; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Simpson KL, 1999, DRUGS, V57, P759, DOI 10.2165/00003495-199957050-00013; Skyler JS, 2001, LANCET, V357, P331, DOI 10.1016/S0140-6736(00)03638-2; TUOMINEN JA, 1995, DIABETOLOGIA, V38, P106, DOI 10.1007/BF02369359; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vague P, 2003, DIABETES CARE, V26, P590, DOI 10.2337/diacare.26.3.590; Vignati L, 1997, CLIN THER, V19, P1408, DOI 10.1016/S0149-2918(97)80014-8; WARD WK, 1984, J CLIN INVEST, V74, P1318, DOI 10.1172/JCI111542; Yki-Jarvinen H, 2000, DIABETES CARE, V23, P1130, DOI 10.2337/diacare.23.8.1130; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005; Zinman B, 1997, DIABETES, V46, P1239	68	522	578	0	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					174	183		10.1056/NEJMra040832	http://dx.doi.org/10.1056/NEJMra040832			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647580				2022-12-28	WOS:000226251700010
J	Lange, BJ; Gerbing, RB; Feusner, J; Skolnik, J; Sacks, N; Smith, FO; Alonzo, TA				Lange, BJ; Gerbing, RB; Feusner, J; Skolnik, J; Sacks, N; Smith, FO; Alonzo, TA			Mortality in overweight and children with acute myeloid underweight leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECEIVING ADJUVANT CHEMOTHERAPY; BONE-MARROW TRANSPLANTATION; ADVERSE PROGNOSTIC FACTOR; CANCER GROUP; BREAST-CANCER; LYMPHOBLASTIC-LEUKEMIA; OBESITY; THERAPY; CYCLOPHOSPHAMIDE; INDUCTION	Context Current treatment for acute myeloid leukemia (AML) in children cures about half the patients. Of the other half, most succumb to leukemia, but 5% to 15% die of treatment-related complications. Overweight children with AML seem to experience excess life-threatening and fatal toxicity. Nothing is known about how weight affects outcomes in pediatric AML. Objective To compare survival rates in children with AML who at diagnosis are underweight (body mass index [BMI] less than or equal to10th percentile), overweight (BMI greater than or equal to95th percentile), or middleweight (BMI = 11th-94th percentiles). Design, Setting, and Participants Retrospective review of BMI and survival in 768 children and young adults aged 1 to 20 years enrolled in Children's Cancer Group-2961, an international cooperative group phase 3 trial for previously untreated AML conducted August 30, 1996, through December 4, 2002. Data were collected through January 9, 2004, with a median follow-up of 31 months (range, 0-78 months). Main Outcome Measures Hazard ratios (HRs) for survival and treatment-related mortality. Results Eighty-four of 768 patients (10.9%) were underweight and 114 (14.8%) were overweight. After adjustment for potentially confounding variables of age, race, leukocyte count, cytogenetics, and bone marrow transplantation, compared with middleweight patients, underweight patients were less likely to survive (HR, 1.85; 95% confidence interval [CI], 1.19-2.87; P=.006) and more likely to experience treatment-related mortality (HR, 2.66; 95% Cl, 1.38-5.11; P=.003). Similarly, overweight patients were less likely to survive (HR, 1.88; 95% Cl, 1.25-2.83; P=.002) and more likely to have treatment-related mortality (HR, 3.49; 95% Cl, 1.99-6.10; P<.001) than middleweight patients. Infections incurred during the first 2 courses of chemotherapy caused most treatment-related deaths. Conclusion Treatment-related complications significantly reduce survival in overweight and underweight children with AML.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Childrens Oncol Grp, Arcadia, CA USA; Childrens Hosp Oakland, Oakland, CA USA; Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; Univ So Calif, Los Angeles, CA USA; Childrens Oncol Grp, Los Angeles, CA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Children's Oncology Group (COG); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Cincinnati Children's Hospital Medical Center; University of Southern California; Children's Oncology Group (COG)	Lange, BJ (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ange@email.chop.edu			NATIONAL CANCER INSTITUTE [U10CA098543, U10CA098413] Funding Source: NIH RePORTER; NCI NIH HHS [CA098413, CA098543] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonzo TA, 2002, J PEDIAT HEMATOL ONC, V24, P627, DOI 10.1097/00043426-200211000-00006; Barnard DR, 1996, LEUKEMIA, V10, P5; BASTARRACHEA J, 1994, ANN INTERN MED, V120, P18, DOI 10.7326/0003-4819-120-1-199401010-00004; BENNETT JM, 1985, ANN INTERN MED, V103, P460, DOI 10.7326/0003-4819-103-3-460; BLOUIN RA, 1987, CLIN PHARMACY, V6, P706; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Cottam DR, 2003, OBES SURG, V13, P49, DOI 10.1381/096089203321136584; Cottam DR, 2002, OBES SURG, V12, P230, DOI 10.1381/096089202762552674; Creutzig U, 1999, BRIT J HAEMATOL, V104, P630, DOI 10.1046/j.1365-2141.1999.01304.x; de Jonge ME, 2002, CANCER CHEMOTH PHARM, V50, P251, DOI 10.1007/s00280-002-0494-7; Dickson T M, 1999, Biol Blood Marrow Transplant, V5, P299, DOI 10.1016/S1083-8791(99)70005-4; Dinndorf PA, 1997, J CLIN ONCOL, V15, P2780, DOI 10.1200/JCO.1997.15.8.2780; DONALDSON SS, 1981, AM J DIS CHILD, V135, P1107, DOI 10.1001/archpedi.1981.02130360015007; Dupuis LL, 2000, BONE MARROW TRANSPL, V26, P1143, DOI 10.1038/sj.bmt.1702700; Fleming DR, 1997, AM J MED, V102, P265, DOI 10.1016/S0002-9343(96)00450-0; GEORGIADIS MS, 1995, JNCI-J NATL CANCER I, V87, P361, DOI 10.1093/jnci/87.5.361; Gomez-Almaguer D, 1998, INT J CANCER, V78, P52, DOI 10.1002/(SICI)1097-0215(1998)78:11+<52::AID-IJC15>3.0.CO;2-3; Lange BJ, 2004, J CLIN ONCOL, V22, P150, DOI 10.1200/JCO.2004.04.016; LIND MJ, 1989, CANCER CHEMOTH PHARM, V25, P139, DOI 10.1007/BF00692355; Lobato Mendizabal E, 1990, Sangre (Barc), V35, P189; LOBATOMENDIZABAL E, 1989, LEUKEMIA RES, V13, P899, DOI 10.1016/0145-2126(89)90043-X; Meloni G, 2001, BONE MARROW TRANSPL, V28, P365, DOI 10.1038/sj.bmt.1703145; Meyerhardt JA, 2003, CANCER, V98, P484, DOI 10.1002/cncr.11544; Murry DJ, 1998, INT J CANCER, V78, P48; Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45; Poikonen P, 2001, ACTA ONCOL, V40, P67; POWIS G, 1987, CANCER CHEMOTH PHARM, V20, P219, DOI 10.1007/BF00570489; Raimondi SC, 1999, BLOOD, V94, P3707; Riley LC, 1999, BRIT J HAEMATOL, V106, P436, DOI 10.1046/j.1365-2141.1999.01550.x; RODVOLD KA, 1988, J CLIN ONCOL, V6, P1321, DOI 10.1200/JCO.1988.6.8.1321; Rosner GL, 1996, J CLIN ONCOL, V14, P3000, DOI 10.1200/JCO.1996.14.11.3000; Sekeres MA, 2004, BLOOD, V103, P4036, DOI 10.1182/blood-2003-09-3118; SMITH M, 1999, LEUKEMIA SEER PEDIAT; TALCOTT JA, 1988, ARCH INTERN MED, V148, P2561, DOI 10.1001/archinte.148.12.2561; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VIANA MB, 1994, ARCH DIS CHILD, V71, P304, DOI 10.1136/adc.71.4.304; Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x; WIERNIK PH, 1970, MEDICINE, V49, P505, DOI 10.1097/00005792-197011000-00004; Woods WG, 2001, BLOOD, V97, P3674; Woods WG, 2001, BLOOD, V97, P56, DOI 10.1182/blood.V97.1.56	41	198	202	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2005	293	2					203	211		10.1001/jama.293.2.203	http://dx.doi.org/10.1001/jama.293.2.203			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885QC	15644547	Bronze			2022-12-28	WOS:000226171000036
J	Connolly, HC				Connolly, HC			From stars to dust: Looking into a circumstellar disk through chondritic meteorites	SCIENCE			English	Article							ALUMINUM-RICH INCLUSIONS	One of the most fundamental questions in planetary science is, How did the solar system form? In this special issue, astronomical. observations and theories constraining circumstellar disks, their lifetimes, and the formation of planetary to subplanetary objects are reviewed. At present, it is difficult to observe what is happening within disks and to determine if another disk environment is comparable to the early solar system disk environment (called the protoplanetary disk). Fortunately, we have chondritic meteorites, which provide a record of the processes that operated and materials present within the protoplanetary disk.	Kingsborough Coll, Dept Phys Sci, Brooklyn, NY 11235 USA; CUNY, Grad Sch, Brooklyn, NY 11235 USA; Amer Museum Nat Hist, Dept Earth & Planetary Sci, New York, NY 10024 USA; Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08854 USA	City University of New York (CUNY) System; American Museum of Natural History (AMNH); Rutgers State University New Brunswick	Connolly, HC (corresponding author), Kingsborough Coll, Dept Phys Sci, Brooklyn, NY 11235 USA.	hconnolly@kbcc.cuny.edu						Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; BREARLEY AJ, 1988, REV MINERAL, V36; CONNOLLY HC, 2004, CHEM ERDE-GEOCHEM, V95, P95; DAVIS AM, 2004, CHONDRITES PROTOPLAN, P27; Desch SJ, 2004, ASTROPHYS J, V602, P528, DOI 10.1086/380831; Gladman B, 2005, SCIENCE, V307, P71, DOI 10.1126/science.1100553; Gounelle M, 2001, ASTROPHYS J, V548, P1051, DOI 10.1086/319019; Greaves JS, 2005, SCIENCE, V307, P68, DOI 10.1126/science.1101979; Haisch KE, 2001, ASTROPHYS J, V553, pL153, DOI 10.1086/320685; Hester JJ, 2004, SCIENCE, V304, P1116, DOI 10.1126/science.1096808; KITA NT, 2004, CHONDRITES PROTOPLAN, P97; KROT A, 2004, CHONDRITES PROTOPLAN, P232; MacPherson G.J., 1988, METEORITES EARLY SOL, P746; MCKEGAN KD, 2004, CHONDRITES PROTOPLAN, P123; REIPURTH B, 2004, CHONDRITES PROTOPLAN, P173	15	3	3	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2005	307	5706					75	76		10.1126/science.1108284	http://dx.doi.org/10.1126/science.1108284			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637268				2022-12-28	WOS:000226214300037
J	Maiese, K; Li, FQ; Chong, ZZ				Maiese, K; Li, FQ; Chong, ZZ			New avenues of exploration for erythropoietin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; CONGESTIVE-HEART-FAILURE; IN-VITRO; SUBCUTANEOUS ERYTHROPOIETIN; MICROGLIAL ACTIVATION; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; INTRAVENOUS IRON; RECEPTOR; BRAIN	Discovery that the hormone erythropoietin (EPO) and its receptor play a significant biological role in tissues outside of the hematopoietic system has fueled significant interest in EPO as a novel cytoprotective agent in both neuronal and vascular systems. Erythropoietin is now considered to have applicability in a variety of disorders that include cerebral ischemia, myocardial infarction, and chronic congestive heart failure. Erythropoietin modulates a broad array of cellular processes that include progenitor stem cell development, cellular integrity, and angiogenesis. As a result, cellular protection by EPO is robust and EPO inhibits the apoptotic mechanisms of injury, including the preservation of cellular membrane asymmetry to prevent inflammation. As the investigation into clinical applications for EPO that maximize efficacy and minimize toxicity progresses, a deeper appreciation for the novel roles that EPO plays in the brain and heart and throughout the entire body should be acquired.	Wayne State Univ, Sch Med, Dept Neurol, Ctr Mol Med & Genet,Inst Environm Hlth Sci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Ctr Mol Med & Genet,Inst Environm Hlth Sci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Div Cellular & Mol Cerebral Ischemia, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University	Maiese, K (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, Ctr Mol Med & Genet,Inst Environm Hlth Sci, 8C-1 UHC,4201 St Antoine, Detroit, MI 48201 USA.	aa2088@wayne.edu			NIEHS NIH HHS [P30 ES006639, P30 ES06639] Funding Source: Medline; NINDS NIH HHS [R01 NS053946, R01 NS053946-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053946] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ajmani RS, 2000, NEUROBIOL AGING, V21, P257, DOI 10.1016/S0197-4580(00)00118-4; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Bennett CL, 2004, NEW ENGL J MED, V351, P1403, DOI 10.1056/NEJMoa040528; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cai ZQ, 2004, CIRCULATION, V109, P2050, DOI 10.1161/01.CIR.0000127954.98131.23; CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113; Chong ZZ, 2005, HISTOL HISTOPATHOL, V20, P299, DOI 10.14670/HH-20.299; Chong ZZ, 2004, J CEREBR BLOOD F MET, V24, P728, DOI 10.1097/01.WCB.0000122746.72175.0E; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE; Chong ZZ, 2002, J HEMATOTH STEM CELL, V11, P863, DOI 10.1089/152581602321080529; Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Chonga ZZ, 2004, EXP CELL RES, V296, P196, DOI 10.1016/j.yexcr.2004.01.021; Dzietko M, 2004, NEUROBIOL DIS, V15, P177, DOI 10.1016/j.nbd.2003.10.006; Genc S, 2004, RESTOR NEUROL NEUROS, V22, P105; GOLDBERG N, 1992, AM HEART J, V124, P424, DOI 10.1016/0002-8703(92)90608-X; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223; Henry DH, 2004, ARCH INTERN MED, V164, P262, DOI 10.1001/archinte.164.3.262; Hewitson KS, 2004, CURR PHARM DESIGN, V10, P821, DOI 10.2174/1381612043452884; Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426; Jelkmann W, 2004, ANN HEMATOL, V83, P673, DOI 10.1007/s00277-004-0911-6; Kang JQ, 2003, MOL PHARMACOL, V64, P557, DOI 10.1124/mol.64.3.557; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; Maiese K, 2004, RESTOR NEUROL NEUROS, V22, P87; Mancini DM, 2003, CIRCULATION, V107, P294, DOI 10.1161/01.CIR.0000044914.42696.6A; Martinez-Estrada OM, 2003, EUR J NEUROSCI, V18, P2538, DOI 10.1046/j.1460-9568.2003.02987.x; Mitka M, 2003, JAMA-J AM MED ASSOC, V290, P1835, DOI 10.1001/jama.290.14.1835; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Olsen NV, 2003, CLIN INFECT DIS, V37, pS323, DOI 10.1086/376912; Parsa CJ, 2004, J BIOL CHEM, V279, P20655, DOI 10.1074/jbc.M314099200; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakamaki K, 2004, CURR NEUROVASC RES, V1, P305, DOI 10.2174/1567202043362072; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Silverberg DS, 2003, NEPHROL DIAL TRANSPL, V18, P141, DOI 10.1093/ndt/18.1.141; Silverberg DS, 2001, J AM COLL CARDIOL, V37, P1775, DOI 10.1016/S0735-1097(01)01248-7; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Uchida E, 1997, FREE RADICAL RES, V27, P311, DOI 10.3109/10715769709065769; van der Meer P, 2004, J AM COLL CARDIOL, V44, P63, DOI 10.1016/j.jacc.2004.03.052; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Wick A, 2002, J NEUROSCI, V22, P6401; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011	50	424	448	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					90	95		10.1001/jama.293.1.90	http://dx.doi.org/10.1001/jama.293.1.90			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632341	Green Accepted			2022-12-28	WOS:000226102100026
J	Poland, GA; Jacobson, RM				Poland, GA; Jacobson, RM			Prevention of hepatitis B with the hepatitis B vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YUPIK ESKIMO POPULATION; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; MULTIPLE-SCLEROSIS; RISK; IMMUNIZATION; IMMUNOGENICITY; TAIWAN; AGE; NONRESPONDERS		Mayo Clin & Mayo Fdn, Mayo Vaccine Res Grp, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Program Translat Immunovirol & Biodef, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Poland, GA (corresponding author), Mayo Clin & Mayo Fdn, Mayo Vaccine Res Grp, 611C Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.	poland.gregory@mayo.edu		Jacobson, Robert/0000-0002-6355-8752				[Anonymous], 2003, MMWR MORB MORTAL WKL, V52, P868; [Anonymous], 1985, MMWR-MORBID MORTAL W, V34, P113; [Anonymous], 2002, IMMUNIZATION SAFETY; [Anonymous], 1991, MMWR-MORBID MORTAL W, V40, P1; Ascherio A, 2001, NEW ENGL J MED, V344, P327, DOI 10.1056/NEJM200102013440502; Averhoff F, 1998, AM J PREV MED, V15, P1, DOI 10.1016/S0749-3797(98)00003-8; BEASLEY RP, 1975, LANCET, V2, P740; Bertino JS, 1997, J INFECT DIS, V175, P678, DOI 10.1093/infdis/175.3.678; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906; COLEMAN PJ, 1991, VACCINE, V9, P723, DOI 10.1016/0264-410X(91)90287-G; Confavreux C, 2001, NEW ENGL J MED, V344, P319, DOI 10.1056/NEJM200102013440501; Das H S, 2002, Trop Gastroenterol, V23, P120; DeStefano F, 2003, ARCH NEUROL-CHICAGO, V60, P504, DOI 10.1001/archneur.60.4.504; DESTER SC, 1990, C INSERM, P165; Duclos Philippe, 2003, Expert Opin Drug Saf, V2, P225, DOI 10.1517/14740338.2.3.225; *EPI, 1997, WKLY EPIDEMIOL REC, V72, P149; *FDA, 2001, MMWR-MORBID MORTAL W, V50, P806; Fisman DN, 2002, CLIN INFECT DIS, V35, P1368, DOI 10.1086/344271; Gall SA, 2003, OBSTET GYN CLIN N AM, V30, P623, DOI 10.1016/S0889-8545(03)00085-8; Global Advisory Committee on Vaccine Safety, 2002, WKLY EPIDEMIOL REC, V77, P389; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P766; Hall Andy, 1999, Vaccine, V17, P2473; Heineman TC, 1999, VACCINE, V17, P2769, DOI 10.1016/S0264-410X(99)00088-2; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1115, DOI 10.1093/oxfordjournals.aje.a116577; HSU HM, 1988, JAMA-J AM MED ASSOC, V260, P2231, DOI 10.1001/jama.260.15.2231; LEMON SM, 1986, J GEN INTERN MED, V11, P199; LINDSAY KL, 1985, HEPATOLOGY, V5, P1088, DOI 10.1002/hep.1840050605; Mast E., 2004, VACCINES, P299; MCMAHON BJ, 1993, HEPATITIS B VACCINES, P243; Meheus A, 2000, VACCINE, V18, pS26, DOI 10.1016/S0264-410X(99)00458-2; Patrick DM, 2003, PEDIATR INFECT DIS J, V22, P874, DOI 10.1097/01.inf.0000091291.14317.dc; Poland GA, 1997, JAMA-J AM MED ASSOC, V277, P1709, DOI 10.1001/jama.277.21.1709; Poland GA, 1998, AM J PREV MED, V15, P73; Rottinghaus ST, 2003, VACCINE, V21, P4604, DOI 10.1016/S0264-410X(03)00447-X; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WAINWRIGHT RB, 1991, ARCH INTERN MED, V151, P1634, DOI 10.1001/archinte.151.8.1634; WAINWRIGHT RB, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P762; Wilson JN, 1999, VACCINE, V17, P973, DOI 10.1016/S0264-410X(98)00313-2; Zuckerman AJ, 1997, NEW ENGL J MED, V336, P1906, DOI 10.1056/NEJM199706263362610; 1985, MMWR MORB MORTAL WKL, V34, P105; 2004, MMWR MORB MORTAL WKL, V52, P1252	43	189	201	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2832	2838		10.1056/NEJMcp041507	http://dx.doi.org/10.1056/NEJMcp041507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625334				2022-12-28	WOS:000226004300008
J	Ban, M; Hattori, M				Ban, M; Hattori, M			Delayed hypersensitivity due to epidural block with ropivacaine	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Hashima City Hosp, Hashima 5016206, Japan		Ban, M (corresponding author), Hashima City Hosp, 3-246 Shinseicho, Hashima 5016206, Japan.	masanoriban@k5.dion.ne.jp						Evans LA, 2002, MED J AUSTRALIA, V177, P522, DOI 10.5694/j.1326-5377.2002.tb04928.x; HOFMANN H, 1975, ARCH DERMATOL, V111, P266, DOI 10.1001/archderm.1975.01630140124022; KAUFMANN JM, 2002, DRUGS DERMATOL, V1, P192; Machley CL, 2003, ARCH DERMATOL, V139, P343; Suhonen R, 1997, Am J Contact Dermat, V8, P231, DOI 10.1016/S1046-199X(97)90076-2	5	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2005	330	7485					229	229		10.1136/bmj.330.7485.229	http://dx.doi.org/10.1136/bmj.330.7485.229			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15677657	Green Published, Bronze			2022-12-28	WOS:000226779400020
J	Dolan, JR				Dolan, JR			Marine ecology - Different measures of biodiversity	NATURE			English	Editorial Material							DIVERSITY		Univ Paris 06, Lab Oceanog Villefranche, Marine Microbial Ecol Grp, F-06230 Villefranche Sur Mer, France; CNRS UMR 7093 Stn Zool, F-06230 Villefranche Sur Mer, France	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU)	Dolan, JR (corresponding author), Univ Paris 06, Lab Oceanog Villefranche, Marine Microbial Ecol Grp, BP 28, F-06230 Villefranche Sur Mer, France.	dolan@obs-vlfr.fr	Dolan, John/GON-7388-2022; Dolan, John R/A-4513-2009; Langhamer, Olivia/J-3425-2012	Dolan, John/0000-0002-9454-1355; Dolan, John R/0000-0002-9454-1355; 				Cariou JB, 1999, J PLANKTON RES, V21, P1065, DOI 10.1093/plankt/21.6.1065; Gifford D.J., 2000, P193, DOI 10.1016/B978-012327645-2/50006-2; Irigoien X, 2004, NATURE, V429, P863, DOI 10.1038/nature02593; Morin PJ, 2004, NATURE, V429, P813, DOI 10.1038/429813a; [No title captured]	5	6	6	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					E9	E9		10.1038/nature03320	http://dx.doi.org/10.1038/nature03320			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674247				2022-12-28	WOS:000226546200029
J	Mathur, N				Mathur, N			Schrodinger's mousetrap - Part 2: Enter the detective.	NATURE			English	Editorial Material									Univ Cambridge, Dept Mat Sci & Met, Cambridge CB2 3QZ, England	University of Cambridge	Mathur, N (corresponding author), Univ Cambridge, Dept Mat Sci & Met, Pembroke St, Cambridge CB2 3QZ, England.								0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2005	433	7024					363	363		10.1038/433363a	http://dx.doi.org/10.1038/433363a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674271				2022-12-28	WOS:000226546200022
J	Willson, DF; Thomas, NJ; Markovitz, BP; Bauman, LA; DiCarlo, JV; Pon, S; Jacobs, BR; Jefferson, LS; Conaway, MR; Egan, EA				Willson, DF; Thomas, NJ; Markovitz, BP; Bauman, LA; DiCarlo, JV; Pon, S; Jacobs, BR; Jefferson, LS; Conaway, MR; Egan, EA		Pediat Acute Lung Injury Sepsis In	Effect of exogenous surfactant (Calfactant) in pediatric acute lung injury - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS-SYNDROME; BIOPHYSICAL ACTIVITY; PROTEIN; FAILURE; THERAPY; EXTRACT; MORTALITY; DISEASE; ADULTS; ARDS	Context Despite evidence that patients with acute lung injury (ALI) have pulmonary surfactant dysfunction, trials of several surfactant preparations to treat adults with ALI have not been successful. Preliminary studies in children with ALI have shown that instillation of a natural lung surfactant (calfactant) containing high levels of surfactant-specific protein B may be beneficial. Objective To determine if endotracheal instillation of calfactant in infants, children, and adolescents with ALI would shorten the course of respiratory failure. Design, Setting, and Patients A multicenter, randomized, blinded trial of calfactant compared with placebo in 153 infants, children, and adolescents with respiratory failure from ALI conducted from July 2000 to July 2003. Twenty-one tertiary care pediatric intensive care units participated. Entry criteria included age 1 week to 21 years, enrollment within 48 hours of endotracheal intubation, radiological evidence of bilateral lung disease, and an oxygenation index higher than 7. Premature infants and children with preexisting lung, cardiac, or central nervous system disease were excluded. Intervention Treatment with intratracheal instillation of 2 doses of 80 mL/m(2) calfactant or an equal volume of air placebo administered 12 hours apart. Main Outcome Measures Ventilator-free days and mortality; secondary outcome measures were hospital course, adverse events, and failure of conventional mechanical ventilation. Results The calfactant group experienced an acute mean (SD) decrease in oxygenation index from 20 (12.9) to 13.9 (9.6) after 12 hours compared with the placebo group's decrease from 20.5 (14.7) to 15.1 (9.0) (P=.01). Mortality was significantly greater in the placebo group compared with the calfactant group (27/75 vs 15/77; odds ratio, 2.32; 95% confidence interval, 1.15-4.85), although ventilator-free days were not different. More patients in the placebo group did not respond to conventional mechanical ventilation. There were no differences in long-term complications. Conclusions Calfactant acutely improved oxygenation and significantly decreased mortality in infants, children, and adolescents with ALI although no significant decrease in the course of respiratory failure measured by duration of ventilator therapy, intensive care unit, or hospital stay was observed.	Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA USA; Penn State Univ, Dept Pediat, Hershey, PA USA; Washington Univ, Dept Pediat, St Louis, MO 63130 USA; Wake Forest Univ, Baptist Med Ctr, Dept Pediat, Winston Salem, NC 27109 USA; Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA; Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; SUNY Buffalo, Dept Pediat, Buffalo, NY 14260 USA; ONY Inc, Amherst, NY USA	University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Washington University (WUSTL); Wake Forest University; Wake Forest Baptist Medical Center; Stanford University; Cornell University; University System of Ohio; University of Cincinnati; Baylor College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Willson, DF (corresponding author), Univ Virginia, Childrens Med Ctr, POB 800-386, Charlottesville, VA 22908 USA.	dfw4m@virginia.edu						Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; ASHBAUGH DG, 1967, LANCET, V2, P319; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; Betensky RA, 2001, BIOMETRICS, V57, P282, DOI 10.1111/j.0006-341X.2001.00282.x; Bloom BT, 1997, PEDIATRICS, V100, P31, DOI 10.1542/peds.100.1.31; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Ferring M, 1997, EUR RESPIR J, V10, P1297, DOI 10.1183/09031936.97.10061297; Gregory TJ, 1997, AM J RESP CRIT CARE, V155, P1309, DOI 10.1164/ajrccm.155.4.9105072; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; Gunther A, 1996, AM J RESP CRIT CARE, V153, P176; HALL SB, 1992, AM REV RESPIR DIS, V145, P24, DOI 10.1164/ajrccm/145.1.24; JOBE AH, 1993, NEW ENGL J MED, V328, P861; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Notter RH, 2002, CHEM PHYS LIPIDS, V114, P21, DOI 10.1016/S0009-3084(01)00197-9; NOTTER RH, 2000, LUNG SURFACTANTS, P207; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; SEEGER W, 1993, EUR RESPIR J, V6, P971; Spragg RG, 2004, NEW ENGL J MED, V351, P884, DOI 10.1056/NEJMoa033181; VELDHUIZEN RAW, 1995, AM J RESP CRIT CARE, V152, P1867, DOI 10.1164/ajrccm.152.6.8520748; Wang ZD, 1996, J LIPID RES, V37, P1749; Wang ZD, 1998, AM J RESP CRIT CARE, V158, P28, DOI 10.1164/ajrccm.158.1.9709041; WHITSETT JA, 1986, PEDIATR RES, V20, P460, DOI 10.1203/00006450-198605000-00016; Willson D, 2001, Expert Opin Pharmacother, V2, P1479, DOI 10.1517/14656566.2.9.1479; Willson DF, 1996, CRIT CARE MED, V24, P1316, DOI 10.1097/00003246-199608000-00008; Willson DF, 1999, CRIT CARE MED, V27, P188, DOI 10.1097/00003246-199901000-00050	28	281	314	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					470	476		10.1001/jama.293.4.470	http://dx.doi.org/10.1001/jama.293.4.470			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890DW	15671432	Bronze			2022-12-28	WOS:000226492900026
J	Irwin, DE; Bensch, S; Irwin, JH; Price, TD				Irwin, DE; Bensch, S; Irwin, JH; Price, TD			Speciation by distance in a ring species	SCIENCE			English	Article							WORLD LEAF WARBLERS; PHYLLOSCOPUS; GRADIENTS	Ring species, which consist of two reproductively isolated forms connected by a chain of intergrading populations, have often been described as examples of speciation despite gene flow between populations, but this has never been demonstrated. We used amplified fragment length polymorphism (AFLP) markers to study gene flow in greenish warblers (Phylloscopus trochiloides). These genetic markers show distinct differences between two reproductively isolated forms but gradual change through the ring connecting these forms. These findings provide the strongest evidence yet for "speciation by force of distance" in the face of ongoing gene flow.	Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Lund Univ, Dept Anim Ecol, S-22362 Lund, Sweden; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of British Columbia; Lund University; University of Chicago	Irwin, DE (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	irwin@zoology.ubc.ca	Irwin, Darren E./G-6183-2012	Irwin, Darren E./0000-0002-1050-5841				Badyaev AV, 1997, AUK, V114, P40, DOI 10.2307/4089063; Coyne J.A., 2004, SPECIATION; Dobzhansky T., 1958, CENTURY DARWIN, P19; Doebeli M, 2003, NATURE, V421, P259, DOI 10.1038/nature01274; Gavrilets S, 1998, P ROY SOC B-BIOL SCI, V265, P1483, DOI 10.1098/rspb.1998.0461; Irwin DE, 2000, EVOLUTION, V54, P998; Irwin DE, 2001, GENETICA, V112, P223, DOI 10.1023/A:1013319217703; Irwin DE, 2002, EVOLUTION, V56, P2383; Irwin DE, 2001, NATURE, V409, P333, DOI 10.1038/35053059; MARCHETTI K, 1993, NATURE, V362, P149, DOI 10.1038/362149a0; Marchetti K, 1997, OIKOS, V79, P410, DOI 10.2307/3546026; Mayr E, 1942, SYSTEMATICS ORIGIN S; Mueller UG, 1999, TRENDS ECOL EVOL, V14, P389, DOI 10.1016/S0169-5347(99)01659-6; Noest AJ, 1997, P ROY SOC B-BIOL SCI, V264, P1389, DOI 10.1098/rspb.1997.0193; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; RICHMAN AD, 1992, NATURE, V355, P817, DOI 10.1038/355817a0; Schneider CJ, 1999, P NATL ACAD SCI USA, V96, P13869, DOI 10.1073/pnas.96.24.13869; SLATKIN M, 1993, EVOLUTION, V47, P264, DOI 10.1111/j.1558-5646.1993.tb01215.x; Smith TB, 1997, SCIENCE, V276, P1855, DOI 10.1126/science.276.5320.1855; Ticehurst CB., 1938, SYSTEMATIC REV GENUS	20	146	169	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2005	307	5708					414	416		10.1126/science.1105201	http://dx.doi.org/10.1126/science.1105201			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662011				2022-12-28	WOS:000226492300043
J	Chen, Y; Emerson, JJ; Martin, TM				Chen, Y; Emerson, JJ; Martin, TM			Evolutionary genomics - Codon volatility does not detect selection	NATURE			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; PLASMODIUM-FALCIPARUM		Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Chen, Y (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57th St, Chicago, IL 60637 USA.		Emerson, J.J./D-8955-2011	Emerson, James/0000-0001-9474-0891				Akashi H, 2001, CURR OPIN GENET DEV, V11, P660, DOI 10.1016/S0959-437X(00)00250-1; Hughes AL, 2001, P ROY SOC B-BIOL SCI, V268, P1855, DOI 10.1098/rspb.2001.1759; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; Plotkin JB, 2004, NATURE, V428, P942, DOI 10.1038/nature02458; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; van Nimwegen E, 1999, P NATL ACAD SCI USA, V96, P9716, DOI 10.1073/pnas.96.17.9716	6	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					E6	E7		10.1038/nature03223	http://dx.doi.org/10.1038/nature03223			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662371				2022-12-28	WOS:000226381300032
J	Falini, B; Mecucci, C; Tiacci, E; Alcalay, M; Rosati, R; Pasqualucci, L; La Starza, R; Diverio, D; Colombo, E; Santucci, A; Bigerna, B; Pacini, R; Pucciarini, A; Liso, A; Vignetti, M; Fazi, P; Meani, N; Pettirossi, V; Saglio, G; Mandelli, F; Lo-Coco, F; Pelicci, P; Martelli, MF				Falini, B; Mecucci, C; Tiacci, E; Alcalay, M; Rosati, R; Pasqualucci, L; La Starza, R; Diverio, D; Colombo, E; Santucci, A; Bigerna, B; Pacini, R; Pucciarini, A; Liso, A; Vignetti, M; Fazi, P; Meani, N; Pettirossi, V; Saglio, G; Mandelli, F; Lo-Coco, F; Pelicci, P; Martelli, MF		GIMEMA Acute Leukemia Working	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TUMOR-SUPPRESSOR PROTEIN; MINIMAL-RESIDUAL-DISEASE; NON-HODGKINS-LYMPHOMA; FLT3 MUTATIONS; ADULT PATIENTS; FUSION GENE; RT-PCR; NPM	BACKGROUND: Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. METHODS: We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). We then correlated the presence of cytoplasmic NPM with clinical and biologic features of the disease. RESULTS: Cytoplasmic NPM was detected in 208 (35.2 percent) of the 591 specimens from patients with primary AML but not in 135 secondary AML specimens or in 980 hematopoietic or extrahematopoietic neoplasms other than AML. It was associated with a wide spectrum of morphologic subtypes of the disease, a normal karyotype, and responsiveness to induction chemotherapy, but not with recurrent genetic abnormalities. There was a high frequency of FLT3 internal tandem duplications and absence of CD34 and CD133 in AML specimens with a normal karyotype and cytoplasmic dislocation of NPM, but not in those in which the protein was restricted to the nucleus. AML specimens with cytoplasmic NPM carried mutations of the NPM gene that were predicted to alter the protein at its C-terminal; this mutant gene caused cytoplasmic localization of NPM in transfected cells. CONCLUSIONS: Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.	Univ Perugia, Monteluce Policlin, Inst Hematol, I-06122 Perugia, Italy; Univ Perugia, Dept Biochem & Mol Biotechnol, I-06122 Perugia, Italy; European Inst Oncol, Milan, Italy; Columbia Univ, Inst Canc Genet, New York, NY USA; Univ Roma La Sapienza, Inst Hematol, Rome, Italy; Univ Foggia, Inst Hematol, Foggia, Italy; Grp Italiano Malattie Ematol Adulto Data Ctr, Rome, Italy; Osped S Luigi, Div Internal Med & Hematol, Orbassano, Italy; Univ Roma Tor Vergata, Dept Biopathol, Rome, Italy	University of Perugia; University of Perugia; IRCCS European Institute of Oncology (IEO); Columbia University; Sapienza University Rome; University of Foggia; University of Rome Tor Vergata	Falini, B (corresponding author), Univ Perugia, Monteluce Policlin, Inst Hematol, I-06122 Perugia, Italy.	faliniem@unipg.it	Colombo, Emanuela/AAO-8113-2020; Alcalay, Myriam/AAB-4300-2019; La Starza, Roberta/ABD-0836-2022; Alcalay, Myriam/B-3182-2016; Rosati, Roberto/AAF-3708-2020; Liso, Arcangelo/AAL-2183-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Vignetti, Marco/HHS-9990-2022	Colombo, Emanuela/0000-0003-2079-7398; Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Rosati, Roberto/0000-0002-0475-3654; Liso, Arcangelo/0000-0001-5638-227X; Vignetti, Marco/0000-0003-1278-604X; FALINI, Brunangelo/0000-0002-7198-5965; Saglio, Giuseppe/0000-0002-1046-3514				Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Carnicer MJ, 2004, LEUKEMIA RES, V28, P19, DOI 10.1016/S0145-2126(03)00125-5; Chang JH, 1998, BIOCHEM J, V329, P539; Christiansen DH, 2001, LEUKEMIA, V15, P1848, DOI 10.1038/sj.leu.2402246; CIMINO G, 1995, CANCER RES, V55, P1625; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cordell JL, 1999, BLOOD, V93, P632, DOI 10.1182/blood.V93.2.632; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Crescenzi B, 2000, CANCER GENET CYTOGEN, V120, P25, DOI 10.1016/S0165-4608(99)00245-9; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; Falini B, 1999, BLOOD, V93, P2697; Falini B, 2002, BLOOD, V99, P409, DOI 10.1182/blood.V99.2.409; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Jaffe E.S., 2001, PATHOLOGY GENETICS T, VVolume 3; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Mitelman F, 1995, ISCN INT SYSTEM HUMA; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Nishimura Y, 2002, BIOSCI BIOTECH BIOCH, V66, P2239, DOI 10.1271/bbb.66.2239; Noguera N, 2002, LEUKEMIA, V16, P2185, DOI 10.1038/sj.leu.2402723; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; SOEKARMAN D, 1992, BLOOD, V79, P2990; Steudel C, 2003, GENE CHROMOSOME CANC, V37, P237, DOI 10.1002/gcc.10219; Umekawa H, 2001, J BIOCHEM-TOKYO, V130, P199, DOI 10.1093/oxfordjournals.jbchem.a002973; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; YonedaKato N, 1996, ONCOGENE, V12, P265	41	1314	1391	3	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					254	266		10.1056/NEJMoa041974	http://dx.doi.org/10.1056/NEJMoa041974			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659725	Bronze			2022-12-28	WOS:000226370500006
J	Hartmann, H; Schumacher, U				Hartmann, H; Schumacher, U			Medical mystery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kantonsspital Muensterlingen, CH-8596 Muensterlingen, Switzerland		Hartmann, H (corresponding author), Kantonsspital Muensterlingen, CH-8596 Muensterlingen, Switzerland.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					273	273		10.1056/NEJMicm030826	http://dx.doi.org/10.1056/NEJMicm030826			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659727				2022-12-28	WOS:000226370500008
J	Zeilinger, A; Weihs, G; Jennewein, T; Aspelmeyer, M				Zeilinger, A; Weihs, G; Jennewein, T; Aspelmeyer, M			Happy centenary, photon	NATURE			English	Review							QUANTUM KEY DISTRIBUTION; SINGLE-PHOTON; SUGGESTED INTERPRETATION; BELL INEQUALITIES; VIOLATION; LIGHT; TIME; TELEPORTATION; ATOM; ENTANGLEMENT	One hundred years ago Albert Einstein introduced the concept of the photon. Although in the early years after 1905 the evidence for the quantum nature of light was not compelling, modern experiments-especially those using photon pairs-have beautifully confirmed its corpuscular character. Research on the quantum properties of light ( quantum optics) triggered the evolution of the whole field of quantum information processing, which now promises new technology, such as quantum cryptography and even quantum computers.	Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria; Austrian Acad Sci, IQOQI, A-1090 Vienna, Austria	University of Vienna; Austrian Academy of Sciences	Zeilinger, A (corresponding author), Univ Vienna, Inst Expt Phys, Boltzmanngasse 5, A-1090 Vienna, Austria.	zeilinger-office@quantum.ca	Zeilinger, Anton/A-1170-2011; Aspelmeyer, Markus/C-4098-2017; Weihs, Gregor/G-2564-2013	Aspelmeyer, Markus/0000-0003-4499-7335; Weihs, Gregor/0000-0003-2260-3008				ASPECT A, 1982, PHYS REV LETT, V49, P91, DOI 10.1103/PhysRevLett.49.91; ASPECT A, 1982, PHYS REV LETT, V49, P1804, DOI 10.1103/PhysRevLett.49.1804; Aspelmeyer M, 2003, SCIENCE, V301, P621, DOI 10.1126/science.1085593; Bachor H.A., 2004, GUIDE EXPT QUANTUM O; Bell JS., 1964, PHYS, V1, P195, DOI [10.1103/PhysicsPhysiqueFizika.1.195, 10.1103/Physics-PhysiqueFizika.1.195, DOI 10.1103/PHYSICSPHYSIQUEFIZIKA.1.195]; BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Bennett CH., 1984, P IEEE INT C COMP SY, P175; Blinov BB, 2004, NATURE, V428, P153, DOI 10.1038/nature02377; BOHM D, 1952, PHYS REV, V85, P166, DOI 10.1103/PhysRev.85.166; BOHM D, 1952, PHYS REV, V85, P180, DOI 10.1103/PhysRev.85.180; Bohr N., 1949, A EINSTEIN PHILOS SC, P201; Bothe W, 1925, Z PHYS, V32, P639, DOI 10.1007/BF01331702; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Brattke S, 2001, PHYS REV LETT, V86, P3534, DOI 10.1103/PhysRevLett.86.3534; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Brukner C, 1997, PHYS REV LETT, V79, P2599, DOI 10.1103/PhysRevLett.79.2599; BURNHAM DC, 1970, PHYS REV LETT, V25, P84, DOI 10.1103/PhysRevLett.25.84; CLAUSER JF, 1974, PHYS REV D, V9, P853, DOI 10.1103/PhysRevD.9.853; Clauser JF, 2002, QUANTUM (UN)SPEAKABLES FROM BELL TO QUANTUM INFORMATION, P61; CLAUSER JF, 1972, PHYS REV A, V6, P49, DOI 10.1103/PhysRevA.6.49; COCCONI G, 1992, AM J PHYS, V60, P750, DOI 10.1119/1.17082; Compton AH, 1923, PHYS REV, V22, P0409, DOI 10.1103/PhysRev.22.409; DIEDRICH F, 1987, PHYS REV LETT, V58, P203, DOI 10.1103/PhysRevLett.58.203; Dirac PAM, 1927, P R SOC LOND A-CONTA, V114, P243, DOI 10.1098/rspa.1927.0039; DOPFER B, 1998, THESIS U INNSBRUCK; Einstein A, 1935, PHYS REV, V47, P0777, DOI 10.1103/PhysRev.47.777; Einstein A, 1905, ANN PHYS-BERLIN, V17, P132; Einstein A, 1905, ANN PHYS-BERLIN, V17, P891; EKERT AK, 1991, PHYS REV LETT, V67, P661, DOI 10.1103/PhysRevLett.67.661; Englert BG, 1996, PHYS REV LETT, V77, P2154, DOI 10.1103/PhysRevLett.77.2154; EVERETT H, 1957, REV MOD PHYS, V29, P454, DOI 10.1103/RevModPhys.29.454; Feynman R. P., 2010, FEYNMAN LECT PHYS, VNew; FORRESTER AT, 1955, PHYS REV, V99, P1691, DOI 10.1103/PhysRev.99.1691; FREEDMAN SJ, 1972, PHYS REV LETT, V28, P938, DOI 10.1103/PhysRevLett.28.938; Furusawa A, 1998, SCIENCE, V282, P706, DOI 10.1126/science.282.5389.706; Gasparoni S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.020504; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; GRANGIER P, 1986, EUROPHYS LETT, V1, P173, DOI 10.1209/0295-5075/1/4/004; Grangier P., 2004, NEW J PHYS, V6, P85; Greenberger DM, 1989, BELLS THEOREM QUANTU, P73; Grosshans F, 2003, NATURE, V421, P238, DOI 10.1038/nature01289; HONG CK, 1987, PHYS REV LETT, V59, P2044, DOI 10.1103/PhysRevLett.59.2044; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; Hughes ME, 2002, J HEALTH SOC BEHAV, V43, P1, DOI 10.2307/3090242; Jennewein T, 2000, PHYS REV LETT, V84, P4729, DOI 10.1103/PhysRevLett.84.4729; Jennewein T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.017903; Jennewein T, 2000, REV SCI INSTRUM, V71, P1675, DOI 10.1063/1.1150518; Julsgaard B, 2004, NATURE, V432, P482, DOI 10.1038/nature03064; Kim JS, 1999, APPL PHYS LETT, V74, P902, DOI 10.1063/1.123404; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; Klein Martin J., 1963, NATURAL PHILOS, V2, P59; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kuhn A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067901; Kurtsiefer C, 2002, NATURE, V419, P450, DOI 10.1038/419450a; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Lawrence EO, 1928, PHYS REV, V32, P0478, DOI 10.1103/PhysRev.32.478; Legero T, 2003, APPL PHYS B-LASERS O, V77, P797, DOI 10.1007/s00340-003-1337-x; Lenard P, 1902, ANN PHYS-BERLIN, V8, P149; Lewis GN, 1926, NATURE, V118, P874, DOI 10.1038/118874a0; Mattle K, 1996, PHYS REV LETT, V76, P4656, DOI 10.1103/PhysRevLett.76.4656; McKeever J, 2004, SCIENCE, V303, P1992, DOI 10.1126/science.1095232; Millikan RA, 1916, PHYS REV, V7, P0355, DOI 10.1103/PhysRev.7.355; MILLIKAN RA, 1949, REV MOD PHYS, V21, P343, DOI 10.1103/RevModPhys.21.343; Nogues G, 1999, NATURE, V400, P239, DOI 10.1038/22275; O'Brien JL, 2003, NATURE, V426, P264, DOI 10.1038/nature02054; PAIS A, 1979, REV MOD PHYS, V51, P861; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; Pittman TB, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.032316; Poppe A, 2004, OPT EXPRESS, V12, P3865, DOI 10.1364/OPEX.12.003865; Rauschenbeutel A, 2000, SCIENCE, V288, P2024, DOI 10.1126/science.288.5473.2024; Rauschenbeutel A, 1999, PHYS REV LETT, V83, P5166, DOI 10.1103/PhysRevLett.83.5166; Rowe MA, 2001, NATURE, V409, P791, DOI 10.1038/35057215; Sanaka K, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.017902; Schleich W. P., 2001, QUANTUM OPTICS PHASE; SCULLY MO, 1982, PHYS REV A, V25, P2208, DOI 10.1103/PhysRevA.25.2208; SHOR PW, 1996, P 37 S FDN COMP SCI, P15; SLUSHER RE, 1985, PHYS REV LETT, V55, P2409, DOI 10.1103/PhysRevLett.55.2409; Stachel John, 1989, COLLECTED PAPERS A E, V2, P134; Steane A, 1996, P ROY SOC A-MATH PHY, V452, P2551, DOI 10.1098/rspa.1996.0136; Stuewer Roger, 1975, COMPTON EFFECT; Taylor GI, 1910, P CAMB PHILOS SOC, V15, P114; Tittel W, 1998, PHYS REV LETT, V81, P3563, DOI 10.1103/PhysRevLett.81.3563; Tu LC, 2005, REP PROG PHYS, V68, P77, DOI 10.1088/0034-4885/68/1/R02; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; Ursin R, 2004, NATURE, V430, P849, DOI 10.1038/430849a; WALTHER P, IN PRESS NATURE; Weihs G, 1998, PHYS REV LETT, V81, P5039, DOI 10.1103/PhysRevLett.81.5039; WEINBERG S, 1975, PHYS TODAY, V28, P32, DOI 10.1063/1.3069003; Wheeler J. A., 1979, Proceedings of the International School of Physics `Enrico Fermi'. Course LXXII. Problems in the Foundations of Physics, P395; Zeilinger A, 1999, REV MOD PHYS, V71, pS288, DOI 10.1103/RevModPhys.71.S288; ZOU XY, 1991, PHYS REV LETT, V67, P318, DOI 10.1103/PhysRevLett.67.318; ZUKOWSKI M, 1993, PHYS REV LETT, V71, P4287, DOI 10.1103/PhysRevLett.71.4287	100	91	95	4	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					230	238		10.1038/nature03280	http://dx.doi.org/10.1038/nature03280			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662410				2022-12-28	WOS:000226381300040
J	Collins, JF; Lieberman, DA; Durbin, TE; Weiss, DG				Collins, JF; Lieberman, DA; Durbin, TE; Weiss, DG		Veterans Affairs Cooperative Study	Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: A comparison with recommended sampling practice	ANNALS OF INTERNAL MEDICINE			English	Article							COLORECTAL-CANCER; NATIONAL-SURVEY; FINGER; COLONOSCOPY; GUIDELINES; MORTALITY; ADULTS; IMPACT	Background: Many expert panels recommend colorectal cancer screening for average-risk asymptomatic individuals older than 50 years of age. Recent studies have found that 24% to 64% of primary care providers use only the digital fecal occult blood test (FOBT) as their primary screening test. The effectiveness of a single digital FOBT is unknown. Objective: To compare the sensitivity and specificity of digital FOBT and the recommended 6-sample at-home FOBT for advanced neoplasia in asymptomatic persons. Design: Prospective cohort study. Setting: 13 Veterans Affairs medical centers. Patients: 3121 asymptomatic patients 50 to 75 years of age Intervention: 2665 patients had 6-sample at-home FOBT and digital FOBT, followed by complete colonoscopy. Measurements: We measured the sensitivity of digital and 6-sample FOBT for advanced neoplasia and the specificity for no neoplasia. We calculated predictive values and likelihood ratios for advanced neoplasia, defined as tubular adenomas 10 mm or greater, adenomas with villous histology or high-grade dysplasia, or invasive cancer. Results: Of all participants, 96.8% were men; their average age was 63.1 years. The 6-sample FOBT and the single digital FOBT had specificities of 93.9% and 97.5%, respectively, as defined by studying 1656 patients with no neoplasia. Sensitivities for detection of advanced neoplasia in 284 patients were 23.9% for the 6-sample FOBT and 4.9% for the digital FOBT. The likelihood ratio for advanced neoplasia was 1.68 (95% Cl, 0.96 to 2.94) for positive results on digital FOBT and 0.98 (Cl, 0.95 to 1.01) for negative results. Limitations: Most patients were men. Conclusions: Single digital FOBT is a poor screening method for colorectal neoplasia and cannot be recommended as the only test. When digital FOBT is performed as part of a primary care physical examination, negative results do not decrease the odds of advanced neoplasia. Persons with these results should be offered at-home 6-sample FOBT or another type of screening test.	Dept Vet Affairs Med Ctr, Portland, OR USA; Dept Vet Affairs Med Ctr, Long Beach, CA USA; Dept Vet Affairs Med Ctr, Perry Point, MD USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System	Collins, JF (corresponding author), Portland VA Med Ctr, P3-GI,3710 SW Vet Hosp Rd,POB 1034, Portland, OR 97239 USA.							Bini EJ, 1999, ARCH INTERN MED, V159, P2022, DOI 10.1001/archinte.159.17.2022; BRINT SL, 1993, SOUTHERN MED J, V86, P601, DOI 10.1097/00007611-199306000-00001; Burke CA, 2001, AM J GASTROENTEROL, V96, P3175; EISNER MS, 1991, ARCH INTERN MED, V151, P2180, DOI 10.1001/archinte.151.11.2180; Faivre J, 2004, GASTROENTEROLOGY, V126, P1674, DOI 10.1053/j.gastro.2004.02.018; GOMEZ JA, 1992, AM J MED, V92, P603, DOI 10.1016/0002-9343(92)90777-9; Jorgensen OD, 2002, GUT, V50, P29, DOI 10.1136/gut.50.1.29; Klabunde CN, 2003, PREV MED, V36, P352, DOI 10.1016/S0091-7435(02)00066-X; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Lieberman DA, 2001, NEW ENGL J MED, V345, P555, DOI 10.1056/NEJMoa010328; LONGSTRETH GF, 1988, J CLIN GASTROENTEROL, V10, P133; Mandel JS, 2000, NEW ENGL J MED, V343, P1603, DOI 10.1056/NEJM200011303432203; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Nadel MR, 2005, ANN INTERN MED, V142, P86, DOI 10.7326/0003-4819-142-2-200501180-00007; Pickhardt PJ, 2004, ANN INTERN MED, V141, P352, DOI 10.7326/0003-4819-141-5-200409070-00009; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Smith RA, 2004, CA-CANCER J CLIN, V54, P41, DOI 10.3322/canjclin.54.1.41; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044	20	167	172	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2005	142	2					81	85		10.7326/0003-4819-142-2-200501180-00006	http://dx.doi.org/10.7326/0003-4819-142-2-200501180-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915LQ	15657155				2022-12-28	WOS:000228306100001
J	Higo, T; Hattori, M; Nakamura, T; Natsume, T; Michikawa, T; Mikoshiba, K				Higo, T; Hattori, M; Nakamura, T; Natsume, T; Michikawa, T; Mikoshiba, K			Subtype-specific and ER lumenal environment-dependent regulation of inositol 1,4,5-trisphosphate receptor type 1 by ERp44	CELL			English	Article							ENDOPLASMIC-RETICULUM; CELL-DEATH; CALCIUM; CA2+; TYPE-1; PH; CALRETICULIN; CHROMOGRANIN; RELEASE; ROLES	Inositol 1,4,5-trisphosphate receptors (IP(3)Rs) are intracellular channel proteins that mediate Ca2+ release from the endoplasmic reticulum (ER) and are involved in many biological processes and diseases. IP(3)Rs are differentially regulated by a variety of cytosolic proteins, but their regulation by ER lumenal protein(s) remains largely unexplored. In this study, we found that ERp44, an ER lumenal protein of the thioredoxin family, directly interacts with the third lumenal loop of IP3R type 1 (IP(3)R1) and that the interaction is dependent on pH, Call concentration, and redox state: the presence of free cysteine residues in the loop is required. Ca2+-imaging experiments and single-channel recording Of IP3R1 activity with a planar lipid bilayer system demonstrated that IP3R1 is directly inhibited by ERp44. Thus, ERp44 senses the environment in the ER lumen and modulates IP3R1 activity accordingly, which should in turn contribute to regulating both intralumenal conditions and the complex patterns of cytosolic Ca2+ concentrations.	Univ Tokyo, Dept Mol Neurobiol, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; JST, ICORP, Calcium Oscillat Project, Kawaguchi, Saitama 3320012, Japan; Japan Biol Informat Res Ctr, Prot Network Team, Funct Genome Grp, Koto Ku, Tokyo 1358073, Japan	University of Tokyo; RIKEN; Japan Science & Technology Agency (JST)	Mikoshiba, K (corresponding author), Univ Tokyo, Dept Mol Neurobiol, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	mikosiba@ims.u-tokyo.ac.jp	Hattori, Mitsuharu/F-3859-2010; Mikoshiba, Katsuhiko/N-7943-2015	Hattori, Mitsuharu/0000-0002-0503-4969; 				Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Caroppo R, 2003, J BIOL CHEM, V278, P39503, DOI 10.1074/jbc.M305823200; Choe CU, 2004, J BIOL CHEM, V279, P35551, DOI 10.1074/jbc.M311261200; FOYOUZIYOUSSEFI R, 2000, PO NATL ACAD SCI, V97, P5273; Hattori M, 2004, J BIOL CHEM, V279, P11967, DOI 10.1074/jbc.M311456200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Kamp F, 1998, BIOPHYS J, V74, P290, DOI 10.1016/S0006-3495(98)77786-0; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Knapp LT, 2002, J NEUROSCI RES, V70, P1, DOI 10.1002/jnr.10371; Li Y, 2004, J CELL BIOL, V164, P35, DOI 10.1083/jcb.200307010; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Paschen W, 2003, CELL CALCIUM, V34, P305, DOI 10.1016/S0143-4160(03)00138-6; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Ro HA, 2004, J BIOL CHEM, V279, P37115, DOI 10.1074/jbc.M403099200; Roderick HL, 1998, CELL CALCIUM, V24, P253, DOI 10.1016/S0143-4160(98)90049-5; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Stutzmann GE, 2004, J NEUROSCI, V24, P508, DOI 10.1523/JNEUROSCI.4386-03.2004; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Thrower EC, 2003, J BIOL CHEM, V278, P49699, DOI 10.1074/jbc.M309307200; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Xiang Y, 2002, NAT NEUROSCI, V5, P843, DOI 10.1038/nn899	35	289	296	2	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					85	98		10.1016/j.cell.2004.11.048	http://dx.doi.org/10.1016/j.cell.2004.11.048			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652484	Bronze			2022-12-28	WOS:000226365400013
J	Richly, H; Rape, M; Braun, S; Rumpf, S; Hoege, C; Jentsch, S				Richly, H; Rape, M; Braun, S; Rumpf, S; Hoege, C; Jentsch, S			A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting	CELL			English	Article							AAA-ATPASE CDC48/P97; TRANSCRIPTION FACTOR; DNA-REPAIR; CELL-CYCLE; PROTEIN; ER; RAD23; CHAIN; COMPLEX; DOMAIN	Protein degradation in eukaryotes usually requires multi-ubiquitylation and subsequent delivery of the tagged substrates to the proteasome. Recent studies suggest the involvement of the AAA ATPase CDC48, its cofactors, and other ubiquitin binding factors in protein degradation, but how these proteins work together is unclear. Here we show that these factors cooperate sequentially through protein-protein interactions and thereby escort ubiquitin-protein conjugates to the proteasome. Central to this pathway is the chaperone CDC48/p97, which coordinates substrate recruitment, E4-catalyzed multiubiquitin chain assembly, and proteasomal targeting. Concomitantly, CDC48 prevents the formation of excessive multiubiquitin chain sizes that are surplus to requirements for degradation. In yeast, this escort pathway guides a transcription factor from its activation in the cytosol to its final degradation and also mediates proteolysis at the endoplasmic reticulum by the ERAD pathway.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Jentsch, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	jentsch@biochem.mpg.de	Rumpf, Sebastian/AHC-9393-2022	Braun, Sigurd/0000-0001-6399-8574; Rape, Michael/0000-0003-4849-6343				Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brunger AT, 2003, FEBS LETT, V555, P126, DOI 10.1016/S0014-5793(03)01107-4; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Fu HY, 1999, MOL BIOL REP, V26, P137, DOI 10.1023/A:1006926322501; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; HUYTON T, 2003, J STRUCT BIOL, V102, P577; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kim I, 2004, MOL BIOL CELL, V15, P3357, DOI 10.1091/mbc.E03-11-0835; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Lambertson D, 1999, GENETICS, V153, P69; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Medicherla B, 2004, EMBO REP, V5, P692, DOI 10.1038/sj.embor.7400164; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Saeki Y, 2004, BIOCHEM BIOPH RES CO, V320, P840, DOI 10.1016/j.bbrc.2004.05.216; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang SR, 1999, GENETICS, V151, P473	48	401	418	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					73	84		10.1016/j.cell.2004.11.013	http://dx.doi.org/10.1016/j.cell.2004.11.013			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652483	Bronze			2022-12-28	WOS:000226365400012
J	Hu, YM; Meng, J; Wang, YQ; Li, CK				Hu, YM; Meng, J; Wang, YQ; Li, CK			Large Mesozoic mammals fed on young dinosaurs	NATURE			English	Article							ORIGIN	Mesozoic mammals are commonly portrayed as shrew- or rat-sized animals that were mainly insectivorous, probably nocturnal and lived in the shadow of dinosaurs(1-5). The largest known Mesozoic mammal represented by substantially complete remains is Repenomamus robustus, a triconodont mammal from the Lower Cretaceous of Liaoning, China(6,7). An adult individual of R. robustus was the size of a Virginia opossum. Here we report a new species of the genus, represented by a skeleton with most of the skull and postcranium preserved in articulation. The new species is 50% larger than R. robustus in skull length. In addition, stomach contents associated with a skeleton of R. robustus reveal remains of a juvenile Psittacosaurus, a ceratopsian dinosaur. Our discoveries constitute the first direct evidence that some triconodont mammals were carnivorous and fed on small vertebrates, including young dinosaurs, and also show that Mesozoic mammals had a much greater range of body sizes than previously known. We suggest that Mesozoic mammals occupied diverse niches and that some large mammals probably competed with dinosaurs for food and territory.	Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; CUNY, Grad Sch, Biol Program, New York, NY 10016 USA; CUNY City Coll, New York, NY 10016 USA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; American Museum of Natural History (AMNH); City University of New York (CUNY) System; City University of New York (CUNY) System; City College of New York (CUNY)	Hu, YM (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	yhu@amnh.org						ALEXANDER RM, 1979, J ZOOL, V189, P305; [Anonymous], 1999, WALKERS MAMMALS WORL; BAKKER RT, 1971, EVOLUTION, V25, P636, DOI 10.1111/j.1558-5646.1971.tb01922.x; Carbone C, 1999, NATURE, V402, P286, DOI 10.1038/46266; Clemens WA, 2003, J VERTEBR PALEONTOL, V23, P232, DOI 10.1671/0272-4634(2003)23[232:AESTFT]2.0.CO;2; COOMBS WP, 1982, PALAEONTOLOGY, V25, P89; Crompton A. W., 1980, COMP PHYSL PRIMITIVE, P1; CROMPTON AW, 1978, NATURE, V272, P333, DOI 10.1038/272333a0; Damuth J., 1990, P1; Eisenberg J.F., 1990, P25; Fischer MS, 2002, J EXP BIOL, V205, P1315; HOPSON JA, 1973, AM NAT, V107, P446, DOI 10.1086/282846; Jenkins F.A. Jr, 1988, Journal of Vertebrate Paleontology, V8, P1; JENKINS FA, 1971, J ZOOL, V165, P303; Jerison HJ., 1973, EVOLUTION BRAIN INTE; Li JL, 2000, CHINESE SCI BULL, V45, P1945, DOI 10.1007/BF02909683; Lillegraven JA, 1979, MESOZOIC MAMMALS 1ST, P1; Lillegraven JA, 1979, MESOZOIC MAMMALS 1 2; Reilly SM, 2001, COMP BIOCHEM PHYS A, V128, P397, DOI 10.1016/S1095-6433(00)00326-3; Rougier G.W., 1993, THESIS U NACL BUENOS; SILVA M, 1995, CRC HDB MAMMALIAN BO; Van Valkenburgh B, 2003, B AM MUS NAT HIST, P147, DOI 10.1206/0003-0090(2003)279<0147:C>2.0.CO;2; Van Valkenburgh Blaire, 2002, Paleontological Society Papers, V8, P267; VANWALKENBURGH B, 1990, BODY SIZE MAMMALIAN, P181; Wang SS, 2001, CHINESE SCI BULL, V46, P779, DOI 10.1007/BF03187222; Wang YQ, 2001, SCIENCE, V294, P357, DOI 10.1126/science.1063830; Wilson Robert W., 1987, Dakoterra, V3, P118; Xu Xing, 2004, Vertebrata Palasiatica, V42, P111; Zhou ZH, 2003, NATURE, V421, P807, DOI 10.1038/nature01420; 李传夔, 2003, [科学通报, Chinese science bulletin], V48, P177	30	144	158	1	54	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					149	152		10.1038/nature03102	http://dx.doi.org/10.1038/nature03102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650737	Green Published			2022-12-28	WOS:000226252200035
J	Bhattacharya, K; James, RD				Bhattacharya, K; James, RD			The material is the machine	SCIENCE			English	Editorial Material							FERROELECTRIC THIN-FILMS; TRANSFORMATIONS		CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; Univ Minnesota, Dept Aerosp Engn & Mech, Minneapolis, MN 55455 USA	California Institute of Technology; University of Minnesota System; University of Minnesota Twin Cities	Bhattacharya, K (corresponding author), CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA.	bhatta@caltech.edu; james@umn.edu		James, Richard/0000-0001-6019-6613; Bhattacharya, Kaushik/0000-0003-2908-5469				Bhattacharya K, 1999, J MECH PHYS SOLIDS, V47, P531, DOI 10.1016/S0022-5096(98)00043-X; Bhattacharya K, 2004, NATURE, V428, P55, DOI 10.1038/nature02378; Bhattacharya K., 2003, MICROSTRUCTURE MARTE; Boland SW, 2004, J MATER RES, V19, P1492, DOI 10.1557/JMR.2004.0199; Braides A., 2002, GAMMA CONVERGENCE BE; Dong JW, 2004, J APPL PHYS, V95, P2593, DOI 10.1063/1.1643199; Hafner A., UNPUB; Huang XY, 2003, NAT MATER, V2, P307, DOI 10.1038/nmat884; ISHIDA A, 1993, THIN SOLID FILMS, V228, P210, DOI 10.1016/0040-6090(93)90600-T; KRULEVITCH P, 1996, J MEMS, V5, P271; Nagarajan V, 2004, TOP APPL PHYS, V93, P47; Nagarajan V, 2003, NAT MATER, V2, P43, DOI 10.1038/nmat800; Olson G., 1992, MARTENSITE; OLSON GB, 1982, J PHYS-PARIS, V43, P855, DOI 10.1051/jphyscol:19824140; Park YB, 2004, APPL PHYS LETT, V85, P455, DOI 10.1063/1.1773373; POLLA DL, 1998, ANNU REV MATER SCI, V28, P536; Van Kessel PF, 1998, P IEEE, V86, P1687, DOI 10.1109/5.704274; Wolf RH, 1995, J MICROELECTROMECH S, V4, P206, DOI 10.1109/84.475547	18	191	193	5	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					53	54		10.1126/science.1100892	http://dx.doi.org/10.1126/science.1100892			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637259				2022-12-28	WOS:000226214300028
J	Grinspoon, S; Carr, A				Grinspoon, S; Carr, A			Medical progress - Cardiovascular risk and body-fat abnormalities in HIV-infected adults.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR THERAPY; CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; ATHEROGENIC LIPID PROFILE; INSULIN-RESISTANCE; HIV-1-INFECTED PATIENTS; LIPODYSTROPHY SYNDROME; COMBINATION THERAPY		Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; St Vincents Hosp, HIV Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; St Vincents Hospital Sydney	Grinspoon, S (corresponding author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,LON207, Boston, MA 02114 USA.	sgrinspoon@partners.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059535] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL65953] Funding Source: Medline; NIDDK NIH HHS [R01DK59535] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Badiou S, 2004, ATHEROSCLEROSIS, V172, P273, DOI 10.1016/j.atherosclerosis.2003.10.006; Barreiro P, 2000, AIDS, V14, P807, DOI 10.1097/00002030-200005050-00006; Barrios A, 2002, AIDS, V16, P2079, DOI 10.1097/00002030-200210180-00014; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Behrens GMN, 2002, J CLIN INVEST, V110, P1319, DOI 10.1172/JCI200215626; Ben-Romano R, 2003, AIDS, V17, P23, DOI 10.1097/00002030-200301030-00005; Bernasconi E, 2002, JAIDS-J ACQ IMM DEF, V31, P50, DOI 10.1097/00126334-200209010-00007; Bonnet E, 2001, J CLIN ENDOCR METAB, V86, P296, DOI 10.1210/jc.86.1.296; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; BROWN TT, 2004, P 11 C RETR OPP INF, P73; Calmy A, 2003, AIDS, V17, P770, DOI 10.1097/00002030-200303280-00022; Calza L, 2003, AIDS, V17, P851, DOI 10.1097/00002030-200304110-00010; Caron M, 2003, AIDS, V17, P2437, DOI 10.1097/00002030-200311210-00005; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 2004, LANCET, V363, P429, DOI 10.1016/S0140-6736(04)15489-5; Carr A, 1998, NEW ENGL J MED, V339, P1296, DOI 10.1056/NEJM199810293391806; Christeff N, 2002, EUR J CLIN INVEST, V32, P43, DOI 10.1046/j.0014-2972.2001.00940.x; Currier JS, 2003, JAIDS-J ACQ IMM DEF, V33, P506, DOI 10.1097/00126334-200308010-00012; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Dressman J, 2003, J CLIN INVEST, V111, P389, DOI 10.1172/JCI200316261; Driscoll SD, 2004, AIDS, V18, P465, DOI 10.1097/00002030-200402200-00013; Driscoll SD, 2004, J CLIN ENDOCR METAB, V89, P2171, DOI 10.1210/jc.2003-031858; Dube MP, 2002, ANTIVIR THER, V7, pL18; Engelson ES, 2002, J ACQ IMMUN DEF SYND, V30, P379, DOI 10.1097/01.QAI.0000020501.93209.1C; Fichtenbaum CJ, 2002, AIDS, V16, P569, DOI 10.1097/00002030-200203080-00008; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010; FriisMoller N, 2004, NEW ENGL J MED, V350, P955; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Galli M, 2003, JAIDS-J ACQ IMM DEF, V34, P58, DOI 10.1097/00126334-200309010-00008; Gan SK, 2002, DIABETES, V51, P3163, DOI 10.2337/diabetes.51.11.3163; Gelato MC, 2002, JAIDS-J ACQ IMM DEF, V31, P163, DOI 10.1097/00126334-200210010-00006; Gervasoni C, 1999, AIDS, V13, P465, DOI 10.1097/00002030-199903110-00004; Grunfeld C, 1997, J CLIN ENDOCR METAB, V82, P3734, DOI 10.1210/jc.82.11.3734; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; GRUNFELD C, 2002, 14 INT AIDS C BARC S, V81; Hadigan C, 2004, ANN INTERN MED, V140, P786, DOI 10.7326/0003-4819-140-10-200405180-00008; Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541; Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472; Hadigan C, 2002, J CLIN ENDOCR METAB, V87, P4611, DOI 10.1210/jc.2002-020709; Hadigan C, 2002, METABOLISM, V51, P1143, DOI 10.1053/meta.2002.34704; Hadigan C, 2001, J CLIN ENDOCR METAB, V86, P939, DOI 10.1210/jc.86.2.939; Heath KV, 2002, J ACQ IMMUN DEF SYND, V30, P440, DOI [10.1097/00042560-200208010-00010, 10.1097/01.QAI.0000021701.48448.20]; HELLERSTEIN MK, 1993, J CLIN ENDOCR METAB, V76, P559, DOI 10.1210/jc.76.3.559; Henry K, 1998, LANCET, V352, P1031, DOI 10.1016/S0140-6736(98)00022-1; Hsue PY, 2004, CIRCULATION, V109, P1603, DOI 10.1161/01.CIR.0000124480.32233.8A; John M, 2003, JAIDS-J ACQ IMM DEF, V33, P29, DOI 10.1097/00126334-200305010-00005; Jones SP, 2001, AIDS, V15, P2049, DOI 10.1097/00002030-200110190-00021; Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/00126334-200208150-00002; Koppel K, 2002, J ACQ IMMUN DEF SYND, V29, P441, DOI 10.1097/00042560-200204150-00003; Kotler DP, 2004, JAIDS-J ACQ IMM DEF, V35, P239, DOI 10.1097/00126334-200403010-00004; Koutkia P, 2004, JAMA-J AM MED ASSOC, V292, P210, DOI 10.1001/jama.292.2.210; Kurowski M, 2003, HIV Med, V4, P94, DOI 10.1046/j.1468-1293.2003.00143.x; LAW MG, 2004, P 11 C RETR OPP INF, P737; Lee GA, 2004, AIDS, V18, P641, DOI 10.1097/00002030-200403050-00008; Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9; Lenhard JM, 2000, ARTERIOSCL THROM VAS, V20, P2625, DOI 10.1161/01.ATV.20.12.2625; Liang JS, 2001, NAT MED, V7, P1327, DOI 10.1038/nm1201-1327; Lichtenstein KA, 2001, AIDS, V15, P1389, DOI 10.1097/00002030-200107270-00008; Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030-200305020-00005; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; Martinez E, 2003, ANTIVIR THER, V8, P403; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; Martinez E, 1999, AIDS, V13, P805, DOI 10.1097/00002030-199905070-00009; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010; Matthews GV, 2000, J ACQ IMMUN DEF SYND, V24, P310; Miller J, 2002, AIDS, V16, P2195, DOI 10.1097/00002030-200211080-00012; Miller J, 2003, HIV Med, V4, P293; Monforte AD, 2004, AIDS, V18, P1811, DOI 10.1097/00002030-200409030-00010; Moyle GJ, 2004, HIV MED, V5, P82, DOI 10.1111/j.1468-1293.2004.00190.x; Moyle GJ, 2003, JAIDS-J ACQ IMM DEF, V33, P22, DOI 10.1097/00126334-200305010-00004; Moyle GJ, 2001, AIDS, V15, P1503, DOI 10.1097/00002030-200108170-00007; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Murphy RL, 2003, AIDS, V17, P2603, DOI 10.1097/00002030-200312050-00007; Negredo E, 2002, AIDS, V16, P1383, DOI 10.1097/00002030-200207050-00010; Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007; Noor MA, 2002, AIDS, V16, pF1, DOI 10.1097/00002030-200203290-00002; NOOR MA, 2004, P 11 C RETR OPP INF, P702; Pace CS, 2003, ANTIVIR THER, V8, P323; Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700; Reiss P, 2004, HIV MED, V5, P11, DOI 10.1111/j.1468-1293.2004.00178.x; Riddler SA, 2003, JAMA-J AM MED ASSOC, V289, P2978, DOI 10.1001/jama.289.22.2978; Roche R, 2002, AIDS, V16, P13, DOI 10.1097/00002030-200201040-00003; Roubenoff R, 2002, CLIN INFECT DIS, V34, P390, DOI 10.1086/338402; Rudich A, 2001, DIABETES, V50, P1425, DOI 10.2337/diabetes.50.6.1425; Saint-Marc T, 1999, AIDS, V13, P1000, DOI 10.1097/00002030-199905280-00023; Schmitz M, 2001, J ACQ IMMUN DEF SYND, V26, P225, DOI 10.1097/00126334-200103010-00004; Shlay JC, 2003, ANTIVIR THER, V8, pL12; Stein JH, 2001, CIRCULATION, V104, P257, DOI 10.1161/01.CIR.104.3.257; Sutinen J, 2003, ANTIVIR THER, V8, P199; Sutinen J, 2002, AIDS, V16, P2183, DOI 10.1097/00002030-200211080-00011; Thoni GJ, 2002, DIABETES METAB, V28, P397; Tong Q, 2003, J CLIN ENDOCR METAB, V88, P1559, DOI 10.1210/jc.2002-021600; van der Valk M, 2001, AIDS, V15, P2407, DOI 10.1097/00002030-200112070-00008; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Woerle IJ, 2003, DIABETES, V52, P918, DOI 10.2337/diabetes.52.4.918	100	790	817	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					48	62		10.1056/NEJMra041811	http://dx.doi.org/10.1056/NEJMra041811			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635112				2022-12-28	WOS:000226112500007
J	Fletcher, SW; Elmore, JG				Fletcher, SW; Elmore, JG			False-positive mammograms - can the USA learn from Europe?	LANCET			English	Editorial Material							SCREENING MAMMOGRAPHY		Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Boston, MA 02115 USA; Univ Washington, Dept Med, Seattle, WA USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Washington; University of Washington Seattle	Fletcher, SW (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA.	suzanne_fletcher@hms.harvard.edu						Barton MB, 2001, J GEN INTERN MED, V16, P150, DOI 10.1111/j.1525-1497.2001.00329.x; BASSETT LW, 1994, AGENCY HLTH CARE POL; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; de Wolf CJ, 1996, EUROPEAN GUIDELINES; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; Elmore JG, 2003, JNCI-J NATL CANCER I, V95, P1384, DOI 10.1093/jnci/djg048; Hofvind S, 2004, CANCER-AM CANCER SOC, V101, P1501, DOI 10.1002/cncr.20528; Humphrey LL, 2002, ANN INTERN MED, V137, P347, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00012; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; JOY JE, 2004, SAVING WOMENS LIVES; Smith-Bindman R, 2003, JAMA-J AM MED ASSOC, V290, P2129, DOI 10.1001/jama.290.16.2129; Vainio H, 2002, IARC HDB CANC PREVEN, V7	12	16	16	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					7	8		10.1016/S0140-6736(04)17676-9	http://dx.doi.org/10.1016/S0140-6736(04)17676-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639661				2022-12-28	WOS:000226213100005
J	Joishy, M; Ashtekar, CS; Jain, A; Gonsalves, R				Joishy, M; Ashtekar, CS; Jain, A; Gonsalves, R			Do we need to treat vulvovaginitis in prepubertal girls?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CLINICAL-FEATURES; VAGINAL FLORA; GENITAL-TRACT; VULVOVAGINITIS; CHILDREN; INFECTIONS; MANAGEMENT; ETIOLOGY		Llandough Hosp, Dept Child Hlth, Cardiff CF64 2XX, S Glam, Wales; St Davids Hosp, Dept Community Child Hlth, Cardiff, S Glam, Wales; Gloucester Royal Hosp, Dept Obstet & Gynaecol, Gloucester, England; Royal Gwent Hosp, Dept Obstet & Gynaecol, Newport NPT 2VB, Gwent, Wales	Royal Gwent Hospital	Joishy, M (corresponding author), Llandough Hosp, Dept Child Hlth, Cardiff CF64 2XX, S Glam, Wales.	manoharj28@yahoo.co.uk						ALTCHEK A, 1984, J REPROD MED, V29, P359; ARSENAULT PS, 1986, PEDIATR ANN, V15, P577, DOI 10.3928/0090-4481-19860801-06; Baiulescu M, 2002, PEDIATR INFECT DIS J, V21, P170, DOI 10.1097/00006454-200202000-00019; Cuadros J, 2004, EUR J PEDIATR, V163, P105, DOI 10.1007/s00431-003-1373-x; DONALD FE, 1991, EPIDEMIOL INFECT, V106, P459, DOI 10.1017/S0950268800067509; EMANS SJ, 1980, PEDIATRICS, V65, P758; GERSTNER GJ, 1982, ARCH GYNECOL, V231, P247, DOI 10.1007/BF02110125; HAMMERSCHLAG MR, 1978, PEDIATRICS, V62, P56; HELLER RH, 1969, J PEDIATR, V74, P370, DOI 10.1016/S0022-3476(69)80193-9; HILL GB, 1995, CLIN INFECT DIS, V20, pS269, DOI 10.1093/clinids/20.Supplement_2.S269; Jaquiery A, 1999, ARCH DIS CHILD, V81, P64, DOI 10.1136/adc.81.1.64; Kairys SW, 1999, PEDIATRICS, V103, P186; Koumantakis E E, 1997, J Pediatr Adolesc Gynecol, V10, P39; LANG WR, 1955, NEW ENGL J MED, V253, P1153, DOI 10.1056/NEJM195512292532605; LINDNER JGEM, 1978, J MED MICROBIOL, V11, P233, DOI 10.1099/00222615-11-3-233; MACFARLANE DE, 1987, ACTA PAEDIATR SCAND, V76, P363, DOI 10.1111/j.1651-2227.1987.tb10479.x; MORRIS CA, 1971, J CLIN PATHOL, V24, P805, DOI 10.1136/jcp.24.9.805; ONDERDONK AB, 1977, AM J OBSTET GYNECOL, V128, P777, DOI 10.1016/0002-9378(77)90720-7; PARADISE JE, 1982, PEDIATRICS, V70, P193; PIERCE AM, 1992, ARCH DIS CHILD, V67, P509, DOI 10.1136/adc.67.4.509; Smith Yolanda R, 2002, J Pediatr Adolesc Gynecol, V15, P227, DOI 10.1016/S1083-3188(02)00160-2; STRAUMANIS JP, 1990, PEDIATR INFECT DIS J, V9, P845, DOI 10.1097/00006454-199011000-00013; Stricker T, 2003, ARCH DIS CHILD, V88, P324, DOI 10.1136/adc.88.4.324; Thomas A, 2002, SEX TRANSM INFECT, V78, P324, DOI 10.1136/sti.78.5.324; Vandeven A M, 1993, Pediatr Rev, V14, P141, DOI 10.1542/pir.14-4-141	25	40	44	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2005	330	7484					186	188		10.1136/bmj.330.7484.186	http://dx.doi.org/10.1136/bmj.330.7484.186			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891OQ	15661783	Green Published			2022-12-28	WOS:000226590800022
J	Rosen, S; Sanne, I; Collier, A; Simon, JL				Rosen, S; Sanne, I; Collier, A; Simon, JL			Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa	LANCET			English	Editorial Material							HIV; AIDS		Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA 02118 USA; Univ Witwatersrand, Clin HIV Res Unit, Johannesburg, South Africa	Boston University; University of Witwatersrand	Rosen, S (corresponding author), Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA 02118 USA.	sbrosen@bu.edu	Sanne, Ian/ABH-2231-2020	Simon, Jonathon/0000-0001-6740-549X; Rosen, Sydney/0000-0002-6560-2964				ATTAWELL K, 2003, PROVISION ANTIRETROV; Auvert B, 2004, JAIDS-J ACQ IMM DEF, V36, P613, DOI 10.1097/00126334-200405010-00010; Fleck F, 2004, BRIT MED J, V328, P1151, DOI 10.1136/bmj.328.7449.1151; *JICC, 2002, KENY NAT PROP ADDR R; KOMBE G, 2004, 29 ABT ASS INC; Loewenson R, 2004, BMJ-BRIT MED J, V328, P241, DOI 10.1136/bmj.328.7434.241; Mitka M, 2002, JAMA-J AM MED ASSOC, V288, P153, DOI 10.1001/jama.288.2.153; SAKYIADDO K, 2004, GHANA GIVES FREE ANT; STIGLITZ JE, 2004, EC PUBLIC SECTOR; Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004; World Health Organization, 2002, SCAL ANT THER RES LT; 2004, IRINPLUS NEWS   0305; 2004, IRINPLUS NEWS   0506; 2004, THIS DAY        0616; 2004, IRINPLUS NEWS   0128	15	37	38	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2005	365	9456					354	356						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664233				2022-12-28	WOS:000226449600041
J	Rhodes, CJ				Rhodes, CJ			Type 2 diabetes - A matter of beta-cell life and death?	SCIENCE			English	Editorial Material							INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; OXIDATIVE STRESS; FATTY-ACID; RESISTANCE; APOPTOSIS; KINASE; GROWTH; FAILURE; MASS	In type 2 diabetes, the beta cells of the pancreas fail to produce enough insulin to meet the body's demand, in part because of an acquired decrease in beta-cell mass. In adults, pancreatic beta-cell mass is controlled by several mechanisms, including beta-cell replication, neogenesis, hypertrophy, and survival. Here, I discuss evidence supporting the notion that increased beta-cell apoptosis is an important factor contributing to beta-cell loss and the onset of type 2 diabetes. Interestingly, a key signaling molecule that promotes beta-cell growth and survival, insulin receptor substrate 2 (IRS-2), is a member of a family of proteins whose inhibition contributes to the development of insulin resistance in the liver and other insulin-responsive tissues. Thus, the IRS-2 pathway appears to be a crucial participant in the tenuous balance between effective pancreatic beta-cell mass and insulin resistance.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	University of Washington; University of Washington Seattle	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	cjr@pnri.org	Northe, Hilda/I-1916-2012	Northe, Hilda/0000-0002-8873-5014	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055267] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-55267] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki E, 2003, EXP BIOL MED, V228, P1213, DOI 10.1177/153537020322801018; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Bonner-Weir S, 2000, ENDOCRINOLOGY, V141, P1926, DOI 10.1210/en.141.6.1926; Borge PD, 2003, J BIOL CHEM, V278, P11359, DOI 10.1074/jbc.M209521200; Bouwens L, 1996, VIRCHOWS ARCH, V427, P553; BRIAUD I, 2004, J BIOL CHEM     1109; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Dickson LM, 2004, AM J PHYSIOL-ENDOC M, V287, pE192, DOI 10.1152/ajpendo.00031.2004; Donath MY, 2004, DIABETOLOGIA, V47, P581, DOI 10.1007/s00125-004-1336-4; Donath MY, 2003, J MOL MED-JMM, V81, P455, DOI 10.1007/s00109-003-0450-y; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JCI200422098; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Hansson M, 2004, DIABETES, V53, P2603, DOI 10.2337/diabetes.53.10.2603; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Jaikaran ETAS, 2001, BBA-MOL BASIS DIS, V1537, P179, DOI 10.1016/S0925-4439(01)00078-3; Kahn SE, 2001, J CLIN ENDOCR METAB, V86, P4047, DOI 10.1210/jc.86.9.4047; Kajimoto Y, 2004, ANN NY ACAD SCI, V1011, P168, DOI 10.1196/annals.1293.017; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; LEAHY JL, 1990, DIABETES CARE, V13, P992, DOI 10.2337/diacare.13.9.992; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V209, P17, DOI 10.1016/j.mce.2003.08.003; Lingohr MK, 2002, TRENDS MOL MED, V8, P375, DOI 10.1016/S1471-4914(02)02377-8; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Maedler K, 2004, P NATL ACAD SCI USA, V101, P8138, DOI 10.1073/pnas.0305683101; Mandrup-Poulsen T, 2001, DIABETES, V50, pS58, DOI 10.2337/diabetes.50.2007.S58; MCLEAN N, 1955, DIABETES, V4, P367; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Rajagopal J, 2003, SCIENCE, V299, P363; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sorenson RL, 1997, HORM METAB RES, V29, P301, DOI 10.1055/s-2007-979040; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Weir GC, 2004, DIABETES, V53, pS16, DOI 10.2337/diabetes.53.suppl_3.S16; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Willaime-Morawek S, 2003, NEUROSCIENCE, V119, P387, DOI 10.1016/S0306-4522(02)00996-X; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wrede CE, 2003, J MOL ENDOCRINOL, V30, P271, DOI 10.1677/jme.0.0300271; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	55	684	755	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					380	384		10.1126/science.1104345	http://dx.doi.org/10.1126/science.1104345			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662003				2022-12-28	WOS:000226492300033
J	Coles, P				Coles, P			The state of the Universe	NATURE			English	Review							PROBE WMAP OBSERVATIONS; GALAXY REDSHIFT SURVEY; DARK-MATTER HALOS; LARGE-SCALE STRUCTURE; COSMOLOGICAL CONSTANT; INFLATIONARY UNIVERSE; ROTATION CURVES; ACCELERATING UNIVERSE; MICROWAVE; TEMPERATURE	The past 20 years have seen dramatic advances in cosmology, mostly driven by observations from new telescopes and detectors. These instruments have allowed astronomers to map out the large-scale structure of the Universe and probe the very early stages of its evolution. We seem to have established the basic parameters describing the behaviour of our expanding Universe, thereby putting cosmology on a firm empirical footing. But the emerging 'standard' model leaves many details of galaxy formation still to be worked out, and new ideas are emerging that challenge the theoretical framework on which the structure of the Big Bang is based. There is still a great deal left to explore in cosmology.	Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England	University of Nottingham	Coles, P (corresponding author), Univ Nottingham, Sch Phys & Astron, Univ Pk, Nottingham NG7 2RD, England.	Peter.Coles@nottingham.ac.uk		Coles, Peter/0000-0002-5535-2850				Abazajian K, 2003, ASTRON J, V126, P2081, DOI 10.1086/378165; Abel T, 2002, SCIENCE, V295, P93, DOI 10.1126/science.1063991; ALBRECHT A, 1982, PHYS REV LETT, V48, P1220, DOI 10.1103/PhysRevLett.48.1220; ALPHER RA, 1948, PHYS REV, V73, P803, DOI 10.1103/PhysRev.73.803; Balbi A, 2000, ASTROPHYS J, V545, pL1, DOI 10.1086/317323; Barkana R, 2001, PHYS REP, V349, P126, DOI 10.1016/s0370-1573(01)00019-9; Baugh CM, 1998, ASTROPHYS J, V498, P504, DOI 10.1086/305563; Becker RH, 2001, ASTRON J, V122, P2850, DOI 10.1086/324231; Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; Blain AW, 1999, MON NOT R ASTRON SOC, V302, P632, DOI 10.1046/j.1365-8711.1999.02178.x; BLUMENTHAL GR, 1984, NATURE, V311, P517, DOI 10.1038/311517a0; Bridle SL, 2003, SCIENCE, V299, P1532, DOI 10.1126/science.1082158; Bromm V, 2004, ANNU REV ASTRON ASTR, V42, P79, DOI 10.1146/annurev.astro.42.053102.134034; Casimir H. B. G., 1948, P KON NED AKAD WET, V51, P793; Cole S, 2000, MON NOT R ASTRON SOC, V319, P168, DOI 10.1046/j.1365-8711.2000.03879.x; Coles P, 2004, MON NOT R ASTRON SOC, V350, P989, DOI 10.1111/j.1365-2966.2004.07706.x; Coles P, 2002, CLASSICAL QUANT GRAV, V19, P3539, DOI 10.1088/0264-9381/19/13/311; COLES P, 1993, MON NOT R ASTRON SOC, V262, P1065, DOI 10.1093/mnras/262.4.1065; COLES P, 1994, NATURE, V370, P609, DOI 10.1038/370609a0; Colless M, 2001, MON NOT R ASTRON SOC, V328, P1039, DOI 10.1046/j.1365-8711.2001.04902.x; Cornish NJ, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.201302; DAVIS M, 1985, ASTROPHYS J, V292, P371, DOI 10.1086/163168; de Oliveira-Costa A, 2004, ASTROPHYS J, V606, pL89, DOI 10.1086/421293; DEBERNARDIS P, 2000, NATURE, V420, P763; DICKE RH, 1965, ASTROPHYS J, V142, P414, DOI 10.1086/148306; Efstathiou G, 2002, MON NOT R ASTRON SOC, V330, pL29, DOI 10.1046/j.1365-8711.2002.05215.x; Einstein A, 1915, SITZBER K PREUSS AKA, P844; EINSTEIN A, 1950, PRINCIPLE RELATIVITY, P177; Eriksen HK, 2004, ASTROPHYS J, V605, P14, DOI 10.1086/382267; Fan XH, 2002, ASTRON J, V123, P1247, DOI 10.1086/339030; Freedman WL, 2001, ASTROPHYS J, V553, P47, DOI 10.1086/320638; Friedman A, 1922, Z PHYS, V10, P377, DOI 10.1007/BF01332580; Fukushige T, 2004, ASTROPHYS J, V606, P625, DOI 10.1086/383192; Ghigna S, 2000, ASTROPHYS J, V544, P616, DOI 10.1086/317221; Gnedin NY, 2000, ASTROPHYS J, V535, P530, DOI 10.1086/308876; GUTH AH, 1981, PHYS REV D, V23, P347, DOI 10.1103/PhysRevD.23.347; GUTH AH, 1982, PHYS REV LETT, V49, P1110, DOI 10.1103/PhysRevLett.49.1110; Halverson NW, 2002, ASTROPHYS J, V568, P38, DOI 10.1086/338879; Hanany S, 2000, ASTROPHYS J, V545, pL5, DOI 10.1086/317322; Hinshaw G, 2003, ASTROPHYS J SUPPL S, V148, P135, DOI 10.1086/377225; Hubble E, 1929, P NATL ACAD SCI USA, V15, P168, DOI 10.1073/pnas.15.3.168; Jaffe AH, 2001, PHYS REV LETT, V86, P3475, DOI 10.1103/PhysRevLett.86.3475; Jeans JH, 1902, PHILOS T R SOC LOND, V199, P1, DOI 10.1098/rsta.1902.0012; Jenkins A, 1998, ASTROPHYS J, V499, P20, DOI 10.1086/305615; Jing YP, 2000, ASTROPHYS J, V529, pL69, DOI 10.1086/312463; Kaluza T, 1921, SITZBER K PREUSS AKA, P966; KAUFFMANN G, 1993, MON NOT R ASTRON SOC, V264, P201, DOI 10.1093/mnras/264.1.201; Khoury J, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.123522; Khoury J, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.086007; Klein O, 1926, Z PHYS, V37, P895, DOI 10.1007/BF01397481; Klypin A, 2001, ASTROPHYS J, V554, P903, DOI 10.1086/321400; Kogut A, 2003, ASTROPHYS J SUPPL S, V148, P161, DOI 10.1086/377219; KOSOWKSY A, 1999, NEW ASTRON REV, V48, P157; KOVAC JM, 2002, NATURE, V468, P46; Lahav O, 2002, MON NOT R ASTRON SOC, V333, P961, DOI 10.1046/j.1365-8711.2002.05485.x; Lange AE, 2001, PHYS REV D, V63, DOI 10.1103/PhysRevD.63.042001; Lee AT, 2001, ASTROPHYS J, V561, pL1, DOI 10.1086/324437; Lemaitre AG, 1930, MON NOT R ASTRON SOC, V91, P0483; Lifshitz E.M., 1946, J PHYS-USSR, V10, P116; LINDE AD, 1982, PHYS LETT B, V108, P389, DOI 10.1016/0370-2693(82)91219-9; LINDE AD, 1983, PHYS LETT B, V129, P177, DOI 10.1016/0370-2693(83)90837-7; LINDE AD, 1982, PHYS LETT B, V116, P335, DOI 10.1016/0370-2693(82)90293-3; Luminet JP, 2003, NATURE, V425, P593, DOI 10.1038/nature01944; Madau P, 1998, ASTROPHYS J, V498, P106, DOI 10.1086/305523; MATHER JC, 1994, ASTROPHYS J, V420, P439, DOI 10.1086/173574; Mellier Y, 1999, ANNU REV ASTRON ASTR, V37, P127, DOI 10.1146/annurev.astro.37.1.127; Moore B, 1999, MON NOT R ASTRON SOC, V310, P1147, DOI 10.1046/j.1365-8711.1999.03039.x; Navarro JF, 2004, MON NOT R ASTRON SOC, V349, P1039, DOI 10.1111/j.1365-2966.2004.07586.x; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Norberg P, 2001, MON NOT R ASTRON SOC, V328, P64, DOI 10.1046/j.1365-8711.2001.04839.x; Padin S, 2001, ASTROPHYS J, V549, pL1, DOI 10.1086/319142; Peacock JA, 2001, NATURE, V410, P169, DOI 10.1038/35065528; Peebles PJE, 2003, REV MOD PHYS, V75, P559, DOI 10.1103/RevModPhys.75.559; Percival WJ, 2001, MON NOT R ASTRON SOC, V327, P1297, DOI 10.1046/j.1365-8711.2001.04827.x; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; Randall L, 1999, PHYS REV LETT, V83, P3370, DOI 10.1103/PhysRevLett.83.3370; Riess AG, 2001, ASTROPHYS J, V560, P49, DOI 10.1086/322348; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Romanowsky AJ, 2003, SCIENCE, V301, P1696, DOI 10.1126/science.1087441; Sahni V, 2002, CLASSICAL QUANT GRAV, V19, P3435, DOI 10.1088/0264-9381/19/13/304; SMOOT GF, 1992, ASTROPHYS J, V396, pL1, DOI 10.1086/186504; SOMERVILLE RS, 1993, MON NOT R ASTRON SOC, V264, P201; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; STAROBINSKII AA, 1979, JETP LETT+, V30, P682; Tonry JL, 2003, ASTROPHYS J, V594, P1, DOI 10.1086/376865; van den Bosch FC, 2000, ASTRON J, V119, P1579, DOI 10.1086/301315; van den Bosch FC, 2001, MON NOT R ASTRON SOC, V325, P1017, DOI 10.1046/j.1365-8711.2001.04456.x; Wang LM, 2000, ASTROPHYS J, V530, P17, DOI 10.1086/308331; WEINBERG S, 1989, REV MOD PHYS, V61, P1, DOI 10.1103/RevModPhys.61.1; Zehavi I, 2002, ASTROPHYS J, V571, P172, DOI 10.1086/339893	97	41	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					248	256		10.1038/nature03282	http://dx.doi.org/10.1038/nature03282			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662412				2022-12-28	WOS:000226381300042
J	Stewart, I				Stewart, I			Schrodinger's mousetrap - Part 1: The trap is primed	NATURE			English	Editorial Material									Univ Warwick, Inst Math, Coventry CV4 7AL, W Midlands, England	University of Warwick	Stewart, I (corresponding author), Univ Warwick, Inst Math, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.								0	0	0	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					200	201		10.1038/433200a	http://dx.doi.org/10.1038/433200a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662394				2022-12-28	WOS:000226381300022
J	Redelmeier, DA				Redelmeier, DA			The cognitive psychology of missed diagnoses	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL RECORD; QUALITY; CARE; PROBABILITY; JUDGMENT	Cognitive psychology is the science that examines how people reason, formulate judgments, and make decisions. This case involves a patient given a diagnosis of pharyngitis, whose ultimate diagnosis of osteomyelitis was missed through a series of cognitive shortcuts. These errors include the availability heuristic (in which people judge likelihood by how easily examples spring to mind), the anchoring heuristic (in which people stick with initial impressions), framing effects (in which people make different decisions depending on how information is presented), blind obedience (in which people stop thinking when confronted with authority), and premature closure (in which several alternatives are not pursued). Rather than trying to completely eliminate cognitive shortcuts (which often serve clinicians well), becoming aware of common errors might lead to sustained improvement in patient care.	Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Redelmeier, DA (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Room G-151,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	dar@ices.on.ca						BARHILLEL M, 1973, ORGAN BEHAV HUM PERF, V9, P396, DOI 10.1016/0030-5073(73)90061-5; Bastardi A, 2000, CURR DIR PSYCHOL SCI, V9, P216, DOI 10.1111/1467-8721.00098; Chassin MR, 2002, ANN INTERN MED, V136, P826, DOI 10.7326/0003-4819-136-11-200206040-00012; Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015; DANIEL WG, 1991, NEW ENGL J MED, V324, P795, DOI 10.1056/NEJM199103213241203; DAVID R, 1987, RADIOL CLIN N AM, V25, P1171; FESSEL WJ, 1972, NEW ENGL J MED, V286, P134, DOI 10.1056/NEJM197201202860305; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; REDELMEIER DA, 1995, JAMA-J AM MED ASSOC, V273, P302, DOI 10.1001/jama.273.4.302; Redelmeier DA, 2001, CAN MED ASSOC J, V164, P358; Redelmeier DA, 1996, P NATL ACAD SCI USA, V93, P2895, DOI 10.1073/pnas.93.7.2895; ROMM FJ, 1981, MED CARE, V19, P310, DOI 10.1097/00005650-198103000-00006; Solomon DH, 2000, MED CARE, V38, P383, DOI 10.1097/00005650-200004000-00005; SOX HC, 1988, MED DECIS MAKING, P67; Sulmasy DP, 1996, J MED ETHICS, V22, P344, DOI 10.1136/jme.22.6.344; TVERSKY A, 1986, J BUS, V59, pS251, DOI 10.1086/296365; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; TVERSKY A, 1973, COGNITIVE PSYCHOL, V5, P207, DOI 10.1016/0010-0285(73)90033-9	18	201	204	1	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2005	142	2					115	120		10.7326/0003-4819-142-2-200501180-00010	http://dx.doi.org/10.7326/0003-4819-142-2-200501180-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	915LQ	15657159				2022-12-28	WOS:000228306100005
J	Niess, JH; Brand, S; Gu, XB; Landsman, L; Jung, S; McCormick, BA; Vyas, JM; Boes, M; Ploegh, HL; Fox, JG; Littman, DR; Reinecker, HC				Niess, JH; Brand, S; Gu, XB; Landsman, L; Jung, S; McCormick, BA; Vyas, JM; Boes, M; Ploegh, HL; Fox, JG; Littman, DR; Reinecker, HC			CX(3)CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance	SCIENCE			English	Article							PEYERS PATCH; IMMUNE-RESPONSES; FRACTALKINE; EPITHELIUM; LOCALIZATION; CHEMOKINE; SUBSETS; GUT	Dendritic cells (DCs) and macrophages are critical to innate and adaptive immunity to the intestinal bacterial microbiota. Here, we identify a myeloid-derived mucosal DC in mice, which populates the entire lamina propria of the small intestine. Lamina propria DCs were found to depend on the chemokine receptor CX(3)CR1 to form transepithelial dendrites, which enable the cells to directly sample luminal antigens. CX(3)CR1 was also found to control the clearance of entero-invasive pathogens by DCs. Thus, CX(3)C1-dependent processes, which control host interactions of specialized DCs with commensal and pathogenic bacteria, may regulate immunological tolerance and inflammation.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat Gastroenterol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; NYU, Sch Med, Howard Hughes Med Inst, Mol Pathogenesis Program,Skirball Inst Biomol Med, New York, NY 10016 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; MIT, Div Comparat Med, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Weizmann Institute of Science; Howard Hughes Medical Institute; New York University; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Reinecker, HC (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St, Boston, MA 02114 USA.	hans-christian-reinecker@hms.harvard.edu	Niess, Jan/E-8361-2017; Vyas, Jatin/Q-1627-2016; Jung, Steffen/K-1409-2012; Landsman, Limor/AAT-5982-2020	Niess, Jan/0000-0001-6902-5650; Vyas, Jatin/0000-0002-9985-9565; Jung, Steffen/0000-0003-4290-5716; Landsman, Limor/0000-0002-8974-1344; Boes, Marianne/0000-0003-2590-1692	NIAID NIH HHS [AI33856] Funding Source: Medline; NIDDK NIH HHS [DK54427, DK33506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506, R01DK054427] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banchereau J, 2003, ANN NY ACAD SCI, V987, P180, DOI 10.1111/j.1749-6632.2003.tb06047.x; Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Huang FP, 2002, J GEN VIROL, V83, P267, DOI 10.1099/0022-1317-83-1-267; Iwasaki A, 2000, J EXP MED, V191, P1381, DOI 10.1084/jem.191.8.1381; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; Jang MH, 2004, P NATL ACAD SCI USA, V101, P6110, DOI 10.1073/pnas.0400969101; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kelsall BL, 2002, NAT IMMUNOL, V3, P699, DOI 10.1038/ni0802-699; Lucas AD, 2001, AM J PATHOL, V158, P855, DOI 10.1016/S0002-9440(10)64034-5; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Maric I, 1996, J IMMUNOL, V156, P1408; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Uhlig HH, 2003, J CLIN INVEST, V112, P648, DOI 10.1172/JC1200319545; Zhao XY, 2003, J IMMUNOL, V171, P2797, DOI 10.4049/jimmunol.171.6.2797	18	1179	1224	1	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					254	258		10.1126/science.1102901	http://dx.doi.org/10.1126/science.1102901			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653504				2022-12-28	WOS:000226361900043
J	Yoshimura, T; Kawano, Y; Arimura, N; Kawabata, S; Kikuchi, A; Kaibuchi, K				Yoshimura, T; Kawano, Y; Arimura, N; Kawabata, S; Kikuchi, A; Kaibuchi, K			GSK-3 beta regulates phosphorylation of CRMP-2 and neuronal polarity	CELL			English	Article							RESPONSE MEDIATOR PROTEIN-2; ADENOMATOUS POLYPOSIS-COLI; SYNTHASE KINASE 3-BETA; HIPPOCAMPAL-NEURONS; LIGHT-CHAIN; MICROTUBULE STABILITY; NEURITE OUTGROWTH; SENSORY NEURONS; RHO-KINASE; GROWTH	Neurons are highly polarized and comprised of two structurally and functionally distinct parts, an axon and dendrites. We previously showed that collapsin response mediator protein-2 (CRMP-2) is critical for specifying axon/dendrite fate, possibly by promoting neurite elongation via microtubule assembly. Here, we showed that glycogen synthase kinase-3beta (GSK-3beta) phosphorylated CRMP-2 at Thr-514 and inactivated it. The expression of the nonphosphorylated form of CRMP-2 or inhibition of GSK-3beta induced the formation of multiple axon-like neurites in hippocampal neurons. The expression of constitutively active GSK-3beta impaired neuronal polarization, whereas the nonphosphorylated form of CRMP-2 counteracted the inhibitory effects of GSK-3beta, indicating that GSK-3beta regulates neuronal polarity through the phosphorylation of CRMP-2. Treatment of hippocampal neurons with neurotrophin-3 (NT-3) induced inactivation of GSK-3beta and dephosphorylation of CRMP-2. Knockdown of CRMP-2 inhibited NT-3-induced axon outgrowth. These results suggest that NT-3 decreases phosphorylated CRMP-2 and increases nonphosphorylated active CRMP-2, thereby promoting axon outgrowth.	Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan; Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan	Nagoya University; Hiroshima University	Kaibuchi, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	kaibuchi@med.nagoya-u.ac.jp	Kawano, Yoji/C-7484-2011; Yoshimura, Takeshi/F-3817-2012	Kawano, Yoji/0000-0003-0687-2777; Yoshimura, Takeshi/0000-0002-0316-8082				Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Baas PW, 1997, CURR OPIN CELL BIOL, V9, P29, DOI 10.1016/S0955-0674(97)80148-2; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; BRESNICK AR, 1995, BIOCHEMISTRY-US, V34, P12576, DOI 10.1021/bi00039a012; BROWN A, 1992, J CELL BIOL, V119, P867, DOI 10.1083/jcb.119.4.867; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DOTTI CG, 1988, J NEUROSCI, V8, P1454; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Frank L, 1996, EUR J NEUROSCI, V8, P1220, DOI 10.1111/j.1460-9568.1996.tb01290.x; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Goold RG, 1999, J CELL SCI, V112, P3373; Gordon-Weeks PR, 2000, MICROSC RES TECHNIQ, V48, P63, DOI 10.1002/(SICI)1097-0029(20000115)48:2<63::AID-JEMT2>3.0.CO;2-1; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; IP NY, 1993, J NEUROSCI, V13, P3394; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Jones DM, 2003, J NEUROCHEM, V86, P1116, DOI 10.1046/j.1471-4159.2003.01925.x; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; Labelle C, 2000, DEV BRAIN RES, V123, P1, DOI 10.1016/S0165-3806(00)00069-9; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Menager C, 2004, J NEUROCHEM, V89, P109, DOI 10.1046/j.1471-4159.2004.02302.x; MORFINI G, 1994, J NEUROSCI RES, V39, P219, DOI 10.1002/jnr.490390212; Munoz-Montano Juan Ramon, 1999, J Alzheimers Dis, V1, P361; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Tucker KL, 2002, PANMINERVA MED, V44, P325; UCHIDA Y, IN PRESS GENES CELLS; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	45	723	752	1	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					137	149		10.1016/j.cell.2004.11.012	http://dx.doi.org/10.1016/j.cell.2004.11.012			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652488	Bronze			2022-12-28	WOS:000226365400017
J	Annane, D; Bellissant, E; Cavaillon, JM				Annane, D; Bellissant, E; Cavaillon, JM			Septic shock	LANCET			English	Review							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; LEUKOCYTE ANTIGEN-DR; BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN; DISSEMINATED INTRAVASCULAR COAGULATION; SYSTEMIC INFLAMMATORY RESPONSE; GRAM-NEGATIVE BACTEREMIA; LOW-DOSE VASOPRESSIN; INTENSIVE-CARE-UNIT; ACUTE-RENAL-FAILURE	Septic shock, the most severe complication of sepsis, is a deadly disease. In recent years, exciting advances have been made in the understanding of its pathophysiology and treatment. Pathogens, via their microbial-associated molecular patterns, trigger sequential intracellular events in immune cells, epithelium, endothelium, and the neuroendocrine system. Proinflammatory mediators that contribute to eradication of invading microorganisms are produced, and anti-inflammatory mediators control this response. The inflammatory response leads to damage to host tissue, and the anti-inflammatory response causes leucocyte reprogramming and changes in immune status. The time-window for interventions is short, and treatment must promptly control the source of infection and restore haemodynamic homoeostasis. Further research is needed to establish which fluids and vasopressors are best. Some patients with septic shock might benefit from drugs such as corticosteroids or activated protein C. Other therapeutic strategies are under investigation, including those that target late proinflammatory mediators, endothelium, or the neuroendocrine system.	Univ Versailles St Quentin Yvelines, Fac Med Paris Ile France Ouest, Assistance Publ Hop Paris, Hop Raymond Poincare,Serv Reanimat, Garches, France; Univ Rennes 1, Fac Med, CHU Rennes,Hop Pontchaillou, Ctr Invest Clin,INSERM 0203,Unite Pharmacol Clin, Rennes, France; Inst Pasteur, UP Cytokines & Inflammat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Annane, D (corresponding author), Univ Versailles St Quentin Yvelines, Fac Med Paris Ile France Ouest, Assistance Publ Hop Paris, Hop Raymond Poincare,Serv Reanimat Med, 104 Blvd Raymond Poincare, F-92380 Garches, France.	djillali.annane@rpc.aphp.fr	Annane, Djillali/R-7947-2019					Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238; Adib-Conquy M, 2003, AM J RESP CRIT CARE, V168, P158, DOI 10.1164/rccm.200209-1077OC; Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; Alberti C, 2002, INTENS CARE MED, V28, P108, DOI 10.1007/s00134-001-1143-z; Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087; Annane D, 2004, BMJ-BRIT MED J, V329, P480, DOI 10.1136/bmj.38181.482222.55; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Annane D, 1999, AM J RESP CRIT CARE, V160, P458, DOI 10.1164/ajrccm.160.2.9810073; Annane D, 2000, LANCET, V355, P1143, DOI 10.1016/S0140-6736(00)02063-8; [Anonymous], 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Ayala A, 1998, BLOOD, V91, P1362, DOI 10.1182/blood.V91.4.1362; AYALA A, 1995, SHOCK, V3, P259, DOI 10.1097/00024382-199504000-00003; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Bernard B, 1999, HEPATOLOGY, V29, P1655, DOI 10.1002/hep.510290608; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Bogdan I, 1997, J INFECT DIS, V176, P693, DOI 10.1086/514092; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; BRACKETT DJ, 1990, AGENTS ACTIONS, V31, P263, DOI 10.1007/BF01997618; Brandtzaeg P, 1996, J EXP MED, V184, P51, DOI 10.1084/jem.184.1.51; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; BURCH RM, 1993, J IMMUNOL, V150, P3397; CAFIERO F, 1992, SURGERY, V112, P24; Cavaillon JM, 2004, CONTRIB NEPHROL, V144, P76; Cavaillon JM, 2003, SCAND J INFECT DIS, V35, P535, DOI 10.1080/00365540310015935; CAVAILLON JM, 1992, CIRC SHOCK, V38, P145; Christ-Crain M, 2004, LANCET, V363, P600, DOI 10.1016/S0140-6736(04)15591-8; Chrousos GP, 2000, ANN NY ACAD SCI, V917, P38, DOI 10.1111/j.1749-6632.2000.tb05371.x; Clair JMS, 2004, J CLIN INVEST, V113, P628, DOI 10.1172/JCI200419062; Colonna M, 2003, J INFECT DIS, V187, pS397, DOI 10.1086/374754; COOLENS JL, 1987, J STEROID BIOCHEM, V26, P197, DOI 10.1016/0022-4731(87)90071-9; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; DEAR K, 2004, COCHRANE DB SYST REV, V4; Delgado M, 1999, J IMMUNOL, V162, P2358; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Douzinas EE, 2000, CRIT CARE MED, V28, P8, DOI 10.1097/00003246-200001000-00002; Dunser MW, 2003, CIRCULATION, V107, P2313, DOI 10.1161/01.CIR.0000066692.71008.BB; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Echtenacher B, 2001, INFECT IMMUN, V69, P3550, DOI 10.1128/IAI.69.6.3550-3555.2001; EICHACKER PQ, 1993, J APPL PHYSIOL, V74, P1885, DOI 10.1152/jappl.1993.74.4.1885; Escoll P, 2003, BIOCHEM BIOPH RES CO, V311, P465, DOI 10.1016/j.bbrc.2003.10.019; Farmer P, 2000, AM J PHYSIOL-LUNG C, V279, pL675, DOI 10.1152/ajplung.2000.279.4.L675; Finfer S, 2004, NEW ENGL J MED, V350, P2247; FINGERLE G, 1993, BLOOD, V82, P3170; Fischer MB, 1997, J IMMUNOL, V159, P976; FOXWELL AR, 2004, COCHRANE DB SYST REV, V3; Franco RF, 2000, BLOOD, V96, P554; Fumeaux T, 2002, AM J RESP CRIT CARE, V166, P1475, DOI 10.1164/rccm.200203-217OC; Garnacho-Montero J, 2003, CRIT CARE MED, V31, P2742, DOI 10.1097/01.CCM.0000098031.24329.10; Gattas DJ, 2003, J CRIT CARE, V18, P52, DOI 10.1053/jcrc.2003.YJCRC11; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gibot S, 2004, NEW ENGL J MED, V350, P451, DOI 10.1056/NEJMoa031544; Gibot S, 2004, ANN INTERN MED, V141, P9, DOI 10.7326/0003-4819-141-1-200407060-00009; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; GRANOWITZ EV, 1993, J IMMUNOL, V151, P1637; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; GREENBERG RN, 1991, PROG CLIN BIOL RES, V367, P179; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; Han XN, 2004, SHOCK, V21, P261, DOI 10.1097/01.shk.0000112346.38599.10; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hernandez RD, 1999, NEUROIMMUNOMODULAT, V6, P187, DOI 10.1159/000026381; Heyland DK, 2001, JAMA-J AM MED ASSOC, V286, P944, DOI 10.1001/jama.286.8.944; Hollenberg SM, 2004, CRIT CARE MED, V32, P1928, DOI 10.1097/01.CCM.0000139761.05492.D6; Holub M, 2003, CLIN MICROBIOL INFEC, V9, P202, DOI 10.1046/j.1469-0691.2003.00518.x; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hubacek JA, 2001, CRIT CARE MED, V29, P557, DOI 10.1097/00003246-200103000-00015; Hurley JC, 2000, ARCH PATHOL LAB MED, V124, P1157; Ibbotson GC, 2001, NAT MED, V7, P465, DOI 10.1038/86539; Jaber BL, 2004, CYTOKINE, V25, P212, DOI 10.1016/j.cyto.2003.11.004; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Landry DW, 1997, CIRCULATION, V95, P1122; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Le Tulzo Y, 2004, AM J RESP CRIT CARE, V169, P1144, DOI 10.1164/rccm.200309-1329OC; Levi M, 2003, BLOOD, V101, P4823, DOI 10.1182/blood-2002-10-3254; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Levin M, 2000, LANCET, V356, P961, DOI 10.1016/S0140-6736(00)02712-4; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Lin MT, 2004, CRIT CARE MED, V32, P569, DOI 10.1097/01.CCM.0000110878.49476.42; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Lynn M, 2003, J INFECT DIS, V187, P631, DOI 10.1086/367990; MacArthur RD, 2004, CLIN INFECT DIS, V38, P284, DOI 10.1086/379825; Malay MB, 1999, J TRAUMA, V47, P699, DOI 10.1097/00005373-199910000-00014; Marie C, 1998, BLOOD, V91, P3439, DOI 10.1182/blood.V91.9.3439.3439_3439_3446; Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Martinez C, 2002, P NATL ACAD SCI USA, V99, P1053, DOI 10.1073/pnas.012367999; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Monneret G, 2003, CRIT CARE MED, V31, P2068, DOI 10.1097/01.CCM.0000069345.78884.0F; MORENO R, 2002, SEPSIS TEXT, P29; MULLNER M, 2004, COCHRANE DB SYST REV, V3; MUNOZ C, 1991, EUR J IMMUNOL, V21, P2177, DOI 10.1002/eji.1830210928; MURATA A, 1994, INFLAMMATION, V18, P337, DOI 10.1007/BF01534432; Muret J, 2000, SHOCK, V13, P169, DOI 10.1097/00024382-200003000-00001; Nakamura A, 2003, J EXP MED, V197, P669, DOI 10.1084/jem.20021824; Nakamura T, 1997, EUR J PHARMACOL, V322, P83, DOI 10.1016/S0014-2999(96)00987-9; Nierhaus A, 2003, INTENS CARE MED, V29, P646, DOI 10.1007/s00134-003-1666-6; Patel BM, 2002, ANESTHESIOLOGY, V96, P576, DOI 10.1097/00000542-200203000-00011; Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3; PETRUCCI N, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003844.PUB2; Prigent H, 2004, CRIT CARE, V8, P243, DOI 10.1186/cc2878; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; Rangel-Frausto MS, 1998, CLIN INFECT DIS, V27, P185, DOI 10.1086/514630; Reinhart K, 2004, CRIT CARE MED, V32, P1100, DOI 10.1097/01.CCM.0000124870.42312.C4; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Sappington PL, 2002, GASTROENTEROLOGY, V123, P790, DOI 10.1053/gast.2002.35391; Saravolatz LD, 2003, CLIN INFECT DIS, V36, P40, DOI 10.1086/345438; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Schrier RW, 2004, NEW ENGL J MED, V351, P159, DOI 10.1056/NEJMra032401; Schultz MJ, 2000, J INFECT DIS, V182, P1264, DOI 10.1086/315840; SEVERN A, 1992, J IMMUNOL, V148, P3441; Sharma VK, 2001, PANCREAS, V22, P28, DOI 10.1097/00006676-200101000-00005; Sharshar T, 2003, CRIT CARE MED, V31, P1752, DOI 10.1097/01.CCM.0000063046.82359.4A; Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4; Singer M, 2004, LANCET, V364, P545, DOI 10.1016/S0140-6736(04)16815-3; Song GY, 2001, AM J PHYSIOL-CELL PH, V281, pC662, DOI 10.1152/ajpcell.2001.281.2.C662; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; SPENGLER RN, 1990, J IMMUNOL, V145, P1430; SPINK WW, 1963, NATURE, V200, P475, DOI 10.1038/200475a0; Spronk PE, 2002, LANCET, V360, P1395, DOI 10.1016/S0140-6736(02)11393-6; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; TANAKA H, 1991, ANN SURG, V213, P81, DOI 10.1097/00000658-199101000-00014; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327, DOI 10.1055/s-0037-1616068; Tschaikowsky K, 2002, CRIT CARE MED, V30, P1015, DOI 10.1097/00003246-200205000-00010; Tsuneyoshi I, 2001, CRIT CARE MED, V29, P487, DOI 10.1097/00003246-200103000-00004; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; vanderPoll T, 1997, INFECT IMMUN, V65, P2378, DOI 10.1128/IAI.65.6.2378-2381.1997; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Vickers J, 1998, THROMB HAEMOSTASIS, V79, P1219, DOI 10.1055/s-0037-1615047; Vieillard-Baron A, 2003, AM J RESP CRIT CARE, V168, P1270, DOI 10.1164/rccm.200306-816CC; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; Warren HS, 2003, J INFECT DIS, V188, P1382, DOI 10.1086/379081; Weijer S, 2002, J INFECT DIS, V186, P1748, DOI 10.1086/345675; WOOD JJ, 1984, ANN SURG, V200, P311, DOI 10.1097/00000658-198409000-00008; Wu AH, 2004, SHOCK, V21, P210, DOI 10.1097/01.shk.0000111661.09279.82; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yan SB, 2001, CHEST, V120, P915, DOI 10.1378/chest.120.3.915; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; Zinyama RB, 2001, IMMUNOLOGY, V104, P439, DOI 10.1046/j.1365-2567.2001.01332.x	153	1020	1103	2	102	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					63	78		10.1016/S0140-6736(04)17667-8	http://dx.doi.org/10.1016/S0140-6736(04)17667-8			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639681				2022-12-28	WOS:000226213100030
J	Birch, K				Birch, K			ABC of sports and exercise medicine - Female athlete triad	BRITISH MEDICAL JOURNAL			English	Review									Univ Leeds, Dept Exercise & Sport Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Birch, K (corresponding author), Univ Leeds, Dept Exercise & Sport Sci, Leeds LS2 9JT, W Yorkshire, England.	k.m.birch@leeds.ac.uk	Birch, Karen/A-1468-2010	Birch, Karen/0000-0001-7796-8640				*AM COLL SPORTS ME, 1997, MED SCI SPORTS EXERC, V29, P1; De Souza MJ, 2003, MED SCI SPORT EXER, V35, P1553, DOI 10.1249/01.MSS.0000084530.31478.DF; DRINKWATER B, 2000, WOMEN SPORT ENCY SPO; Loucks AB, 1998, J APPL PHYSIOL, V84, P37, DOI 10.1152/jappl.1998.84.1.37; RUTHERFORD OM, 1993, J APPL PHYSIOL, V74, P2904, DOI 10.1152/jappl.1993.74.6.2904	5	39	40	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 29	2005	330	7485					244	246		10.1136/bmj.330.7485.244	http://dx.doi.org/10.1136/bmj.330.7485.244			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15677660	Green Published			2022-12-28	WOS:000226779400026
J	Martel, MJ; Rey, E; Beauchesne, MF; Perreault, S; Lefebvre, G; Forget, A; Blais, L				Martel, MJ; Rey, E; Beauchesne, MF; Perreault, S; Lefebvre, G; Forget, A; Blais, L			Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASTHMATIC WOMEN; PERINATAL OUTCOMES; DRUG-USE; INFORMATION; RECALL; MEDICATIONS; POPULATION; SELECTION; ACCURACY; DATABASE	Objective To determine whether the use of inhaled corticosteroids during pregnancy increases the risk of pregnancy induced hypertension and pre-eclampsia among asthmatic women. Design Nested case-control study. Setting Three administrative health databases from Quebec: RAMQ MED-ECHO, and Fichier des evenements demographiques. Participants 3505 women with asthma, totalling 4593 pregnancies, between 1990 and 2000. Main outcome measures Pregnancy induced hypertension and pre-eclampsia. Results 302 cases of pregnancy induced hypertension and 165 cases of pre-eclampsia were identified. Use of inhaled corticosteroids from conception until date of outcome was not associated with an increased risk of pregnancy induced hypertension (adjusted odds ratio 1.02, 95% confidence interval 0.77 to 1.34) or pre-eclampsia (1.06,0.74 to 1.53). No significant dose-response relation was observed between inhaled corticosteroids and pregnancy induced hypertension or pre-eclampsia. Oral corticosteroids were significantly associated with the risk of pregnancy induced hypertension (adjusted odds ratio 1.57, 1.02 to 2.41), and a trend was seen for pre-eclampsia (1.72, 0.98 to 3.02). Conclusion No significant increase of the risk of pregnancy induced hypertension or pre-eclampsia was detected among users of inhaled corticosteroids during pregnancy, while markers of uncontrolled and severe asthma were found to significantly increase the risks of pregnancy induced hypertension and pre-eclampsia.	Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Fac Med, Dept Obstet & Gynecol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Math & Stat, Montreal, PQ H3C 3J7, Canada; Hop Sacre Coeur, Res Ctr, Montreal, PQ H4J 1C5, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Blais, L (corresponding author), Univ Montreal, Fac Pharm, CP 6128,Succursale Centreville, Montreal, PQ H3C 3J7, Canada.	lucie.blais@umontreal.ca	Perreault, Sylvie/AAM-8009-2020	Perreault, Sylvie/0000-0002-0066-0127				Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; AVRON J, 1998, JAMA-J AM MED ASSOC, V279, P1458; BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; Blais L, 2000, ARCH INTERN MED, V160, P2363, DOI 10.1001/archinte.160.15.2363; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; Dombrowski MP, 2004, AM J OBSTET GYNECOL, V190, P737, DOI 10.1016/j.ajog.2003.09.071; Duley L, 2003, BRIT MED BULL, V67, P161, DOI 10.1093/bmb/ldg005; Garbe E, 1997, LANCET, V350, P979, DOI 10.1016/S0140-6736(97)03392-8; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; LEHRER S, 1993, AM J OBSTET GYNECOL, V168, P1463, DOI 10.1016/S0002-9378(11)90782-0; LEVY AR, 1995, AM J EPIDEMIOL, V142, P428, DOI 10.1093/oxfordjournals.aje.a117651; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; *NAT ASTHM ED PREV, 2 NIH NAT ASTHM ED P; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; *QUEB GOV, 1997, REG ASS MAL QUEB STA; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P115; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; STENIUSAARNIALA B, 1988, THORAX, V43, P12, DOI 10.1136/thx.43.1.12; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TILLEY BC, 1985, AM J EPIDEMIOL, V121, P269, DOI 10.1093/oxfordjournals.aje.a113997; Van den Berg LTWDJ, 1999, TERATOLOGY, V60, P33; VANDENBRANDT PA, 1991, PHARM WEEKBLAD, V13, P91, DOI 10.1007/BF01974987; Wen SW, 2001, ANN EPIDEMIOL, V11, P7, DOI 10.1016/S1047-2797(00)00077-6; WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563	29	96	101	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2005	330	7485					230	233		10.1136/bmj.38313.624352.8F	http://dx.doi.org/10.1136/bmj.38313.624352.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15659480	Green Published, Bronze			2022-12-28	WOS:000226779400021
J	Bar-Nahum, G; Epshtein, V; Ruckenstein, AE; Rafikov, R; Mustaev, A; Nudler, E				Bar-Nahum, G; Epshtein, V; Ruckenstein, AE; Rafikov, R; Mustaev, A; Nudler, E			A ratchet mechanism of transcription elongation and its control	CELL			English	Article							RNA-POLYMERASE-II; 3.3 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; STRUCTURAL BASIS; ACTIVE-CENTER; NUCLEOSIDE TRIPHOSPHATES; CATALYTIC RESIDUES; ALLOSTERIC BINDING; CRYSTAL-STRUCTURE; BASIC MECHANISMS	RNA chain elongation is a highly processive and accurate process that is finely regulated by numerous intrinsic and extrinsic signals. Here we describe a general mechanism that governs RNA polymerase (RNAP) movement and response to regulatory inputs such as pauses, terminators, and elongation factors. We show that E.coli RNAP moves by a complex Brownian ratchet mechanism, which acts prior to phosphodiester bond formation. The incoming substrate and the flexible F bridge domain of the catalytic center serve as two separate ratchet devices that function in concert to drive forward translocation. The adjacent G loop domain controls F bridge motion, thus keeping the proper balance between productive and inactive states of the elongation complex. This balance is critical for cell viability since it determines the rate, processivity, and fidelity of transcription.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; Rutgers State Univ, BioMaPS Inst Quantitat Biol, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Phys, Piscataway, NJ 08854 USA; Publ Hlth Res Inst, Newark, NJ 07103 USA	New York University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Nudler, E (corresponding author), NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA.	evgeny.nudler@med.nyu.edu	Rafikov, Ruslan/AAG-9352-2019	Nudler, Evgeny/0000-0002-8811-3071; Rafikov, Ruslan/0000-0001-5950-4076	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058750, P20GM064375] Funding Source: NIH RePORTER; NIGMS NIH HHS [P20 GM64375, R01 GM58750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Bar-Nahum G, 2001, CELL, V106, P443, DOI 10.1016/S0092-8674(01)00461-5; BUROVA E, 1995, J BACTERIOL, V177, P1388, DOI 10.1128/jb.177.5.1388-1392.1995; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Gusarov I, 2001, CELL, V107, P437, DOI 10.1016/S0092-8674(01)00582-7; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Landick R, 1996, ESCHERICHIA COLI SAL, P1263; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Mustaev A, 2003, METHOD ENZYMOL, V371, P191; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Neuman KC, 2003, CELL, V115, P437, DOI 10.1016/S0092-8674(03)00845-6; Nudler E, 2003, METHOD ENZYMOL, V371, P369; Nudler E, 2003, METHOD ENZYMOL, V371, P160; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Opalka N, 2003, CELL, V114, P335, DOI 10.1016/S0092-8674(03)00600-7; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; Roberts JW, 1998, COLD SPRING HARB SYM, V63, P319, DOI 10.1101/sqb.1998.63.319; SCHMIDT MC, 1984, BIOCHEMISTRY-US, V23, P197, DOI 10.1021/bi00297a004; Sosunova E, 2003, P NATL ACAD SCI USA, V100, P15469, DOI 10.1073/pnas.2536698100; Sousa R, 2001, TRENDS BIOCHEM SCI, V26, P695, DOI 10.1016/S0968-0004(01)02000-X; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Toulokhonov I, 2003, MOL CELL, V12, P1125, DOI 10.1016/S1097-2765(03)00439-8; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; VOGEL U, 1994, J BIOL CHEM, V269, P16236; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Zakharova N, 1998, J BIOL CHEM, V273, P24912, DOI 10.1074/jbc.273.38.24912; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	46	260	268	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					183	193		10.1016/j.cell.2004.11.045	http://dx.doi.org/10.1016/j.cell.2004.11.045			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680325	Bronze			2022-12-28	WOS:000226740000008
J	Casalino, LP				Casalino, LP			Disease management and the organization of physician practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMPROVING PRIMARY-CARE; CHRONIC ILLNESS; QUALITY; PROGRAMS; MODEL		Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA	University of Chicago	Casalino, LP (corresponding author), Univ Chicago, Dept Hlth Studies, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.	lcasalin@uchicago.edu	Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Congressional Budget Office, 2004, AN LIT DIS MAN PROGR; DeBusk RF, 1999, ARCH INTERN MED, V159, P2739, DOI 10.1001/archinte.159.22.2739; ENTHOVEN A, 2004, 21 CENTURY HLTH SYST; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; Fernandez A, 2001, J GEN INTERN MED, V16, P163, DOI 10.1046/j.1525-1497.2001.91226.x; Fonarow GC, 2004, CIRCULATION, V110, P3506, DOI 10.1161/01.CIR.0000151101.17629.20; FOOTE SM, 2003, HLTH AFF MILLWOOD; Grumbach K, 2004, JAMA-J AM MED ASSOC, V291, P1246, DOI 10.1001/jama.291.10.1246; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Neil Nancy, 2003, Jt Comm J Qual Saf, V29, P610; Nobel Jeremy J, 2003, Dis Manag, V6, P219, DOI 10.1089/109350703322682531; ROBINSON JC, 2004, HLTH AFF MILLWOOD; Rothman AA, 2003, ANN INTERN MED, V138, P256, DOI 10.7326/0003-4819-138-3-200302040-00034; Scott JC, 2004, J AM GERIATR SOC, V52, P1463, DOI 10.1111/j.1532-5415.2004.52408.x; SUPER N, MEDICARES CHRONIC CA; Villagra V, 2004, MED CARE, V42, P24, DOI 10.1097/01.mlr.0000119395.13327.e9; VILLAGRA V, 2004, HLTH AFF MILLWOOD; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wagner EH, 2004, ANN INTERN MED, V141, P644, DOI 10.7326/0003-4819-141-8-200410190-00015; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Welch WP, 2002, AM J MANAG CARE, V8, P353; Wilson Thomas W, 2004, Jt Comm J Qual Saf, V30, P614	25	91	91	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					485	488		10.1001/jama.293.4.485	http://dx.doi.org/10.1001/jama.293.4.485			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890DW	15671434				2022-12-28	WOS:000226492900028
J	Ponsonby, AL; van der Mei, I; Dwyer, T; Blizzard, L; Taylor, B; Kemp, A; Simmons, R; Kilpatrick, T				Ponsonby, AL; van der Mei, I; Dwyer, T; Blizzard, L; Taylor, B; Kemp, A; Simmons, R; Kilpatrick, T			Exposure to infant siblings during early life and risk of multiple sclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPSTEIN-BARR-VIRUS; BIRTH-ORDER; CELL RESPONSE; T-CELLS; INFECTIONS; ACTIVATION; ANTIBODIES; VARICELLA; CHILDREN; ANTIGEN	Context The "hygiene hypothesis" has implicated sibship as a marker of infection load during early life and suggests that exposure or reexposure to infections can influence the developing immune system. Viral infection has also been implicated in the pathogenesis of multiple sclerosis (MS). Objectives To evaluate whether exposure to infant siblings in early life is associated with the risk of MS, and to explore the possible mechanism for any apparent protective effect, including altered Epstein-Barr virus (EBV) infection patterns. Design, Setting, and Patients Population-based case-control study in Tasmania, Australia, from 1999 to 2001 based on 136 cases of magnetic resonance imaging confirmed MS and 272 community controls, matched on sex and year of birth. Main Outcome Measure Risk of MS by duration of contact with younger siblings aged less than 2 years in the first 6 years of life. Results Increasing duration of contact with a younger sibling aged less than 2 years in the first 6 years of life was associated with reduced MS risk (adjusted odds ratios [AORs]: <1 infant-year, 1.00 [reference); 1 to <3 infant-years, 0.57 (95% confidence interval (0), 0.33-0.98]; 3 to <5 infant-years, 0.40 (95% Cl. 0.19-0.92); >= 5 infant-years, 0.12 [95% Cl, 0.02-0.88); test for trend, P=.002). A history of exposure to infant siblings was associated with a reduced IgG response to EBV among controls. Controls with at least 1 infant-year contact had a reduced risk of infectious mononucleosis and a reduced risk of very high composite EBV IgG titers (AOR, 0.33; 95% Cl, 0.11-0.98) compared with other controls. The inverse association between higher infant contact and MS was independent of EBV IgG titer. Conclusion Higher infant sibling exposure in the first 6 years of life was associated with a reduced risk of MS, possibly by altering childhood infection patterns and related immune responses.	Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia; Royal Hobart Hosp, Hobart, Tas, Australia; Univ Sydney, Discipline Paediat & Child Hlth, Childrens Hosp Westmead, Sydney, NSW 2006, Australia; Canberra Hosp, Canberra, ACT, Australia; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic, Australia	Australian National University; University of Tasmania; Menzies Institute for Medical Research; Royal Hobart Hospital; University of Sydney; Australian National University; Canberra Hospital; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Ponsonby, AL (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.	anne-louise.ponsonby@anu.edu.au	van der Mei, Ingrid/J-7457-2014; van der Mei, Ingrid/AAI-2566-2020; Ponsonby, Anne-Louise/AAE-4351-2019	van der Mei, Ingrid/0000-0001-9009-7472; van der Mei, Ingrid/0000-0001-9009-7472; Kilpatrick, Trevor/0000-0003-3999-085X; Ponsonby, Anne-Louise/0000-0002-6581-3657				Aalto SM, 1998, J MED VIROL, V56, P186, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt;186::AID-JMV2&gt;3.0.CO;2-3; Adams CL, 2003, IMMUNOLOGY, V108, P274, DOI 10.1046/j.1365-2567.2003.01583.x; Alotaibi S, 2004, JAMA-J AM MED ASSOC, V291, P1875, DOI 10.1001/jama.291.15.1875; Amyes E, 2003, J EXP MED, V198, P903, DOI 10.1084/jem.20022058; ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; Ascherio A, 2001, JAMA-J AM MED ASSOC, V286, P3083, DOI 10.1001/jama.286.24.3083; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; CUOMO L, 1995, AIDS RES HUM RETROV, V11, P1241, DOI 10.1089/aid.1995.11.1241; DAGAN R, 1994, EUR J CLIN MICROBIOL, V13, P1029, DOI 10.1007/BF02111822; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; FARR TJ, 1990, EPIDEMIOL INFECT, V105, P603, DOI 10.1017/S095026880004824X; Gartner BC, 2003, CLIN DIAGN LAB IMMUN, V10, P78, DOI 10.1128/CDLI.10.1.78-82.2003; Haahr S, 1995, Mult Scler, V1, P73; Hernan MA, 2001, EPIDEMIOLOGY, V12, P301, DOI 10.1097/00001648-200105000-00009; Hernan MA, 2001, AM J EPIDEMIOL, V154, P69, DOI 10.1093/aje/154.1.69; Hollsberg P, 2003, CLIN EXP IMMUNOL, V132, P137, DOI 10.1046/j.1365-2249.2003.02114.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HOSMER DW, 2000, WILEY PS TX, P1; HUANG LM, 1993, ARCH DIS CHILD, V68, P408, DOI 10.1136/adc.68.3.408; ISAGER H, 1980, ACTA NEUROL SCAND, V61, P393; Kim BS, 2001, IMMUNOL RES, V24, P121, DOI 10.1385/IR:24:2:121; Knipe D, 2001, FIELDS VIROLOGY, V2; KOCHHENRIKSEN N, 1989, ACTA NEUROL SCAND, V124, pS1; LEIBOWITZ U, 1966, J NEUROL NEUROSUR PS, V29, P60, DOI 10.1136/jnnp.29.1.60; Levin LI, 2003, JAMA-J AM MED ASSOC, V289, P1533, DOI 10.1001/jama.289.12.1533; MATIASGUIU J, 1994, NEUROEPIDEMIOLOGY, V13, P129, DOI 10.1159/000110371; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; Olson JK, 2002, J IMMUNOL, V169, P2719, DOI 10.4049/jimmunol.169.5.2719; PATY DW, 1988, NEUROLOGY, V38, P180, DOI 10.1212/WNL.38.2.180; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P150; Rubio JP, 2002, AM J HUM GENET, V70, P1125, DOI 10.1086/339932; Savoldo B, 2002, J IMMUNOL, V168, P909, DOI 10.4049/jimmunol.168.2.909; Thomas SL, 2002, LANCET, V360, P678, DOI 10.1016/S0140-6736(02)09837-9; Ullrich SE, 2002, FRONT BIOSCI-LANDMRK, V7, pD684, DOI 10.2741/ullrich; van der Mei IAF, 2003, BRIT MED J, V327, P316, DOI 10.1136/bmj.327.7410.316; Villoslada P, 2003, NEUROLOGY, V60, P1944, DOI 10.1212/01.WNL.0000069461.53733.F7; VISSCHER BR, 1982, ACTA NEUROL SCAND, V66, P209, DOI 10.1111/j.1600-0404.1982.tb04518.x; Wedderburn LR, 2001, IMMUNOLOGY, V102, P301, DOI 10.1046/j.1365-2567.2001.01194.x; Wing K, 2003, EUR J IMMUNOL, V33, P579, DOI 10.1002/eji.200323701; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; ZILBER N, 1988, ACTA NEUROL SCAND, V78, P313, DOI 10.1111/j.1600-0404.1988.tb03662.x	42	117	120	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					463	469		10.1001/jama.293.4.463	http://dx.doi.org/10.1001/jama.293.4.463			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890DW	15671431	Bronze			2022-12-28	WOS:000226492900025
J	Nadelman, RB; Wormser, GP				Nadelman, RB; Wormser, GP			Poly-ticks: Blue State versus Red State for Lyme disease	LANCET			English	Editorial Material							AMBLYOMMA-AMERICANUM		New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA	New York Medical College	Nadelman, RB (corresponding author), New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA.	robert_nadelman@nymc.edu						Masters E, 1998, ARCH DERMATOL, V134, P955, DOI 10.1001/archderm.134.8.955; PIESMAN J, 1988, J MED ENTOMOL, V25, P336, DOI 10.1093/jmedent/25.5.336; SCHULZE TL, 1984, SCIENCE, V224, P601, DOI 10.1126/science.6710158; WORMSER GP, IN PRESS CLIN INFECT; [No title captured]	5	3	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2005	365	9456					280	280						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664208				2022-12-28	WOS:000226449600009
J	Sachs, JD; McArthur, JW				Sachs, JD; McArthur, JW			The Millennium Project: a plan for meeting the millennium development goals	LANCET			English	Article							CHILD; MORTALITY; HEALTH		UN Millennium Project, Low Lib 314, New York, NY 10027 USA		Sachs, JD (corresponding author), UN Millennium Project, Low Lib 314, 535 W 116th St, New York, NY 10027 USA.	jeffrey.sachs@unmillenniumproject.org						Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; SACHS JD, 2004, BROOKINGS PAPERS EC, V1, P117; UN Millennium Project, 2005, INV DEV PRACT PLAN A; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7	7	288	293	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					347	353						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664232				2022-12-28	WOS:000226449600040
J	Ranta, E; Kaitala, V				Ranta, E; Kaitala, V			A leap for lion populations	SCIENCE			English	Editorial Material									Univ Helsinki, Dept Biol & Environm Sci, Integrat Ecol Unit, FIN-00014 Helsinki, Finland	University of Helsinki	Ranta, E (corresponding author), Univ Helsinki, Dept Biol & Environm Sci, Integrat Ecol Unit, FIN-00014 Helsinki, Finland.	esa.ranta@heisinki.fi						Berryman, 2002, POPULATION CYCLES CA, DOI 10.1093/oso/9780195140989.001.0001; Packer C, 2005, SCIENCE, V307, P390, DOI 10.1126/science.1105122; Royama T., 1992, ANAL POPULATION ECOL; Schaller G. B., 1972, SERENGETI LION; SINCLAIR ARE, 1995, SERENGETI PAST PRESE, V2; Sutherland W.J., 1996, INDIVIDUAL BEHAV POP; Turchin Peter, 2003, Monographs in Population Biology, V35, pi	7	3	3	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					365	366		10.1126/science.1108599	http://dx.doi.org/10.1126/science.1108599			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15661998				2022-12-28	WOS:000226492300027
J	Sanchez, PA; Swaminathan, MS				Sanchez, PA; Swaminathan, MS			Cutting world hunger in half	SCIENCE			English	Editorial Material									Columbia Univ, Earth Inst, Palisades, NY 10964 USA; MS Swaminathan Res Fdn, Madras 600113, Tamil Nadu, India	Columbia University	Sanchez, PA (corresponding author), Columbia Univ, Earth Inst, Palisades, NY 10964 USA.	sanchez@iri.columbia.edu; msswami@mssrf.res.in						Food and Agriculture Organization of the United Nations, 2004, STAT FOOD INS WORLD; KADIYALA S, 2003, 159 INT FOOD POL RES; PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443; Sanchez PA, 2002, SCIENCE, V295, P2019, DOI 10.1126/science.1065256; *UN MILL PROJ, 2005, TASK FORC HUNG HALV; UN Millennium Project, 2005, INV DEV PRACT PLAN A	6	125	134	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					357	359		10.1126/science.1109057	http://dx.doi.org/10.1126/science.1109057			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15661994				2022-12-28	WOS:000226492300023
J	Lieberman, E; Hauert, C; Nowak, MA				Lieberman, E; Hauert, C; Nowak, MA			Evolutionary dynamics on graphs	NATURE			English	Article							SUBDIVIDED POPULATION; NETWORK FORMATION; FIXATION; PROBABILITY; COOPERATION; MODEL	Evolutionary dynamics have been traditionally studied in the context of homogeneous or spatially extended populations(1-4). Here we generalize population structure by arranging individuals on a graph. Each vertex represents an individual. The weighted edges denote reproductive rates which govern how often individuals place offspring into adjacent vertices. The homogeneous population, described by the Moran process(3), is the special case of a fully connected graph with evenly weighted edges. Spatial structures are described by graphs where vertices are connected with their nearest neighbours. We also explore evolution on random and scale-free networks(5-7). We determine the fixation probability of mutants, and characterize those graphs for which fixation behaviour is identical to that of a homogeneous population(7). Furthermore, some graphs act as suppressors and others as amplifiers of selection. It is even possible to find graphs that guarantee the fixation of any advantageous mutant. We also study frequency-dependent selection and show that the outcome of evolutionary games can depend entirely on the structure of the underlying graph. Evolutionary graph theory has many fascinating applications ranging from ecology to multi-cellular organization and economics.	Harvard Univ, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA; Harvard Univ, Dept Math, Program Evolutionary Dynam, Cambridge, MA 02138 USA; Harvard Univ, Dept Appl Math, Program Evolutionary Dynam, Cambridge, MA 02138 USA; MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada	Harvard University; Harvard University; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); University of British Columbia	Lieberman, E (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA.	erez@erez.com	Aiden, Erez Lieberman/A-2908-2010; Hauert, Christoph/E-5369-2011; Nowak, Martin A/A-6977-2008	Hauert, Christoph/0000-0002-1239-281X; 				Abramson G, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.030901; [Anonymous], 1988, LECT NOTES PARTICLE; Asavathiratham C, 2001, IEEE CONTR SYST MAG, V21, P52, DOI 10.1109/37.969135; Bala V, 2000, ECONOMETRICA, V68, P1181, DOI 10.1111/1468-0262.00155; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; BARTON NH, 1993, GENET RES, V62, P149, DOI 10.1017/S0016672300031748; Boyd S, 2004, SIAM REV, V46, P667, DOI [10.1137/S0036144503423264, 10.1137/s0036144503423264]; DURRETT R, 1994, THEOR POPUL BIOL, V46, P363, DOI 10.1006/tpbi.1994.1032; Ebel H, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.056118; ERDOS P, 1960, B INT STATIST INST, V38, P343; FISHER RA, 1950, HEREDITY, V4, P117, DOI 10.1038/hdy.1950.8; HASSELL MP, 1994, NATURE, V370, P290, DOI 10.1038/370290a0; Hauert C, 2004, NATURE, V428, P643, DOI 10.1038/nature02360; Hofbauer J, 1998, EVOLUTIONARY GAMES P; Jackson MO, 2002, GAME ECON BEHAV, V41, P265, DOI 10.1016/S0899-8256(02)00504-3; LIGGETT TM, 1999, STOCHASTIC INTERACTI; MARUYAMA T, 1970, Theoretical Population Biology, V1, P273, DOI 10.1016/0040-5809(70)90047-X; Moran P. A. P., 1958, P CAMB PHILOS SOC, V54, P60, DOI DOI 10.1017/S0305004100033193); NAGYLAKI T, 1980, GENETICS, V94, P497; Nakamaru M, 1997, J THEOR BIOL, V184, P65, DOI 10.1006/jtbi.1996.0243; Neuhauser C, 2001, NOTICES AM MATH SOC, V48, P1304; Newman MEJ, 2001, P NATL ACAD SCI USA, V98, P404, DOI 10.1073/pnas.021544898; Nowak MA, 1993, INT J BIFURCAT CHAOS, V3, P35, DOI 10.1142/S0218127493000040; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Skyrms B, 2000, P NATL ACAD SCI USA, V97, P9340, DOI 10.1073/pnas.97.16.9340; SLATKIN M, 1981, EVOLUTION, V35, P477, DOI 10.1111/j.1558-5646.1981.tb04911.x; Tilman D., 1997, SPATIAL ECOLOGY ROLE; Whitlock MC, 2003, GENETICS, V164, P767; Wright S, 1931, GENETICS, V16, P0097; Wright S, 1932, P INT C GENET, V6, P356	31	805	827	13	191	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					312	316		10.1038/nature03204	http://dx.doi.org/10.1038/nature03204			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662424				2022-12-28	WOS:000226381300055
J	't Hooft, G; Susskind, L; Witten, E; Fukugita, M; Randall, L; Smolin, L; Stachel, J; Rovelli, C; Ellis, G; Weinberg, S; Penrose, R				't Hooft, G; Susskind, L; Witten, E; Fukugita, M; Randall, L; Smolin, L; Stachel, J; Rovelli, C; Ellis, G; Weinberg, S; Penrose, R			A theory of everything?	NATURE			English	Editorial Material								In his later years, Einstein sought a unified theory that would extend general relativity and provide an alternative to quantum theory. There is now talk of a 'theory of everything' ( although Einstein himself never used the phrase). Fifty years after his death, how close are we to such a theory?	Univ Utrecht, Spinoza Inst, NL-3584 CE Utrecht, Netherlands; Univ Utrecht, Inst Theoret Phys, NL-3584 CE Utrecht, Netherlands; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; Univ Tokyo, Inst Cosm Ray Res, Kashiwa, Chiba 2778582, Japan; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Perimeter Inst, Waterloo, ON N2L 2Y5, Canada; Boston Univ, Dept Phys, Boston, MA 02215 USA; Univ Marseille, Ctr Theoret Phys, F-13288 Marseille 9, France; Univ Cape Town, Dept Math, ZA-7700 Rondebosch, Cape Town, South Africa; Univ Texas, Dept Phys, Austin, TX 78712 USA; Univ Oxford, Inst Math, Oxford OX1 3LB, England	Utrecht University; Utrecht University; Stanford University; Institute for Advanced Study - USA; University of Tokyo; Harvard University; Perimeter Institute for Theoretical Physics; Boston University; UDICE-French Research Universities; Aix-Marseille Universite; University of Cape Town; University of Texas System; University of Texas Austin; University of Oxford	't Hooft, G (corresponding author), Univ Utrecht, Spinoza Inst, Leuvenlaan 4, NL-3584 CE Utrecht, Netherlands.	g.thooft@phys.uu.nl; susskind@stanford.edu; witten@sns.ias.edu; fukugita@icrr.u-tokyo.ac.jp; randall@physics.harvard.edu; lsmolin@perimeterinstitute.ca; stachel@physics.bu.edu; rovelli@cpt.univ-mrs.fr; ellis@maths.uct.ac.za; weinberg@physics.utexas.edu; rouse@maths.ox.ac.uk	Rovelli, Carlo/AAD-3730-2019; Fukugita, Masataka/A-4438-2011	Rovelli, Carlo/0000-0003-1724-9737; 					0	17	18	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					257	259		10.1038/433257a	http://dx.doi.org/10.1038/433257a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662413				2022-12-28	WOS:000226381300043
J	Gatrad, AR; Sheikh, A				Gatrad, AR; Sheikh, A			Hajj: journey of a lifetime	BRITISH MEDICAL JOURNAL			English	Review							MUSLIM PILGRIMAGE		Manor Hosp, Walsall WS2 9PS, W Midlands, England; Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh, Midlothian, Scotland	University of Edinburgh	Gatrad, AR (corresponding author), Manor Hosp, Walsall WS2 9PS, W Midlands, England.	sec.garrad@walsallhospitas.nhs.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056				ADAM JM, 1986, TRAVELLERS HLTH, P238; Al-Ghamdi SM, 2003, SAUDI MED J, V24, P1073; Al-Harthi ASM, 2001, SAUDI MED J, V22, P523; Alzeer A, 1998, J INFECTION, V36, P303, DOI 10.1016/S0163-4453(98)94315-8; Carlyle Thomas, 1840, HEROES HERO WORSHIP, P49; CLARKE CRA, 1994, CLIN MED, P756; EATON G, 1985, ISLAM DESTINY MAN, P242; Figueira E., 2003, DIABETES TODAY, V6, P41; GHAZNAWI HI, 1987, ANN SAUDI MED, V7, P323, DOI 10.5144/0256-4947.1987.323; HENAHAN J, 1982, JAMA-J AM MED ASSOC, V247, P3302; JONES DM, 1990, J INFECTION, V21, P21, DOI 10.1016/0163-4453(90)90577-U; KEATINGE WR, 2000, CONCISE OXFORD TXB M, P1904; Khan SA, 2002, SAUDI MED J, V23, P1548; MOXHAM J, 1990, TXB MED, P77; SABIQ AS, 1992, FIGH US SUNNAH HAJJ, P5; SALISBURY D, 1996, IMMUNISATION INFECT, P146; SARWAR G, 1998, ISLAM BELIEFS TEACHI, P78; Seraj Mohamed E., 1992, Middle East Journal of Anesthesiology, V11, P407; WOLFE M, 1994, HADJ, P194	19	44	46	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 15	2005	330	7483					133	137		10.1136/bmj.330.7483.133	http://dx.doi.org/10.1136/bmj.330.7483.133			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889PM	15649928	Green Published, Green Submitted			2022-12-28	WOS:000226454900021
J	Kauppinen, R				Kauppinen, R			Porphyrias	LANCET			English	Review							ACUTE INTERMITTENT PORPHYRIA; CONGENITAL ERYTHROPOIETIC PORPHYRIA; GENOTYPE-PHENOTYPE CORRELATION; DELTA-AMINOLEVULINATE SYNTHASE; HOMOZYGOUS VARIEGATE PORPHYRIA; ACID DEHYDRATASE DEFICIENCY; MEDIATED GENE-TRANSFER; CHRONIC-RENAL-FAILURE; PORPHOBILINOGEN DEAMINASE; CUTANEA-TARDA	Seven different porphyrias form a group of inherited metabolic disorders, each resulting from a partial deficiency of a specific enzyme in the haem biosynthesis pathway. Clinically, the three most important entities are an acute porphyric attack and acute and chronic skin symptoms. Porphyrias are rare and sometimes misdiagnosed, because various symptoms and signs mimic other diseases. Once porphyria is suspected, biochemical analyses easily detect porphyrins and their precursors from blood, urine, or faeces. Mutation screening can be done at the quiescent phase of the disease. Pathogenetic mechanisms and clinical manifestations differ in individual porphyrias and most of them require a specific treatment. Early diagnosis and information about precipitating factors can diminish mortality and prevent subsequent attacks among patients with acute porphyrias, so mutation screening is recommended for family members.	Univ Helsinki, Biomedicum Helsinki, Res Program Mol Med, Helsinki 00029, Finland; Univ Cent Hosp Helsinki, Dept Med, Div Endocrinol, Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Kauppinen, R (corresponding author), Univ Helsinki, Biomedicum Helsinki, Res Program Mol Med, Box 700, Helsinki 00029, Finland.	rauli.kauppinen@hus.fi	PUY, HERVE/O-1785-2017	PUY, HERVE/0000-0003-3362-2634; Kauppinen, Raili/0000-0002-8799-3425				Aggarwal N, 2002, J OBSTET GYNAECOL RE, V28, P160, DOI 10.1046/j.1341-8076.2002.00024.x; Al-Karadaghi S, 1997, STRUCTURE, V5, P1501, DOI 10.1016/S0969-2126(97)00299-2; Albalate M, 2001, NEPHRON, V88, P170, DOI 10.1159/000045980; Andant C, 1997, AM J GASTROENTEROL, V92, P1389; ANDERSON KE, 1990, ARCH INTERN MED, V150, P1469, DOI 10.1001/archinte.150.7.1469; ANDERSON KE, 2001, METABOLIC MOL BASES, P2991; ANDERSSON C, 1995, J INTERN MED, V237, P301, DOI 10.1111/j.1365-2796.1995.tb01179.x; ANDERSSON C, 1994, J INTERN MED, V236, P169, DOI 10.1111/j.1365-2796.1994.tb01279.x; Andersson C, 1996, J INTERN MED, V240, P195, DOI 10.1046/j.1365-2796.1996.21847000.x; Andersson C, 2003, J INTERN MED, V254, P176, DOI 10.1046/j.1365-2796.2003.01172.x; Andersson C, 2000, SCAND J CLIN LAB INV, V60, P643; BEUKEVELD GJJ, 1990, J INHERIT METAB DIS, V13, P673, DOI 10.1007/BF01799566; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; Bonkovsky HL, 1998, SEMIN LIVER DIS, V18, P57, DOI 10.1055/s-2007-1007141; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BRODIE MJ, 1977, Q J MED, V46, P229; BROWNLIE PD, 1994, PROTEIN SCI, V3, P1644, DOI 10.1002/pro.5560031004; Bulaj ZJ, 2000, BLOOD, V95, P1565, DOI 10.1182/blood.V95.5.1565.005k42_1565_1571; Chen FP, 2002, CELL MOL BIOL, V48, P83; Christiansen L, 1999, HUM MUTAT, V14, P222, DOI 10.1002/(SICI)1098-1004(1999)14:3<222::AID-HUMU5>3.0.CO;2-V; Christiansen L, 2000, HUM GENET, V107, P612, DOI 10.1007/s004390000415; Cox TM, 1997, J INHERIT METAB DIS, V20, P258, DOI 10.1023/A:1005317124985; Crimlisk HL, 1997, J NEUROL NEUROSUR PS, V62, P319, DOI 10.1136/jnnp.62.4.319; Cruz-Rojo J, 2002, CELL MOL BIOL, V48, P845; Dabrowska E, 2001, Med Sci Monit, V7 Suppl 1, P190; Daimon M, 2001, AM J MED, V110, P240, DOI 10.1016/S0002-9343(00)00720-8; de Rooij WM, 2003, PORPHYRIN HDB, P211; DICHTER HN, 1977, BRAIN RES, V126, P189, DOI 10.1016/0006-8993(77)90229-3; DOSS M, 1982, CLIN BIOCHEM, V15, P52, DOI 10.1016/S0009-9120(82)90493-3; Doss MO, 2004, J INHERIT METAB DIS, V27, P529, DOI 10.1023/B:BOLI.0000037341.21975.9d; Doss MO, 2000, ALCOHOL ALCOHOLISM, V35, P109, DOI 10.1093/alcalc/35.2.109; Dsnick RJ, 2002, BRIT J HAEMATOL, V117, P779, DOI 10.1046/j.1365-2141.2002.03557.x; Egger NG, 1996, CHEM-BIOL INTERACT, V102, P69, DOI 10.1016/S0009-2797(96)03732-5; Elder GH, 1998, HEPATOLOGY, V27, P289, DOI 10.1002/hep.510270142; ELDER GH, 1995, J BIOENERG BIOMEMBR, V27, P207, DOI 10.1007/BF02110035; ELDER GH, 1978, NEW ENGL J MED, V299, P274, DOI 10.1056/NEJM197808102990603; Fontanellas A, 2001, GENE THER, V8, P618, DOI 10.1038/sj.gt.3301427; Forget F, 2001, SUPPORT CARE CANCER, V9, P465, DOI 10.1007/s005200000232; Frank J, 1998, J INVEST DERMATOL, V110, P452, DOI 10.1046/j.1523-1747.1998.00148.x; Fraser DJ, 2002, J BIOL CHEM, V277, P34717, DOI 10.1074/jbc.M204699200; Fraunberg MVZ, 2005, MEDICINE, V84, P35, DOI 10.1097/01.md.0000152455.38510.af; Fraunberg MVZ, 2002, EUR J HUM GENET, V10, P649, DOI 10.1038/sj.ejhg.5200860; Freesemann AG, 1997, ARCH DERMATOL RES, V289, P272, DOI 10.1007/s004030050192; Fritsch C, 1998, SKIN PHARMACOL APPL, V11, P347, DOI 10.1159/000029857; Gardlo K, 2003, EXP DERMATOL, V12, P843, DOI 10.1111/j.0906-6705.2003.00095.x; Geronimi F, 2003, J MOL MED, V81, P310, DOI 10.1007/s00109-003-0438-7; Gisbert JP, 2004, EUR J GASTROEN HEPAT, V16, P689, DOI 10.1097/01.meg.0000108318.52416.c9; Gisbert JP, 2003, J HEPATOL, V39, P620, DOI 10.1016/S0168-8278(03)00346-5; Gocmen A, 1989, Biomed Environ Sci, V2, P36; Gorchein A, 1997, BRIT J CLIN PHARMACO, V44, P427, DOI 10.1046/j.1365-2125.1997.t01-1-00609.x; GORCHEIN A, 1995, BRIT J CLIN PHARMACO, V40, P105, DOI 10.1111/j.1365-2125.1995.tb04548.x; Gouya L, 2004, HUM GENET, V114, P256, DOI 10.1007/s00439-003-1059-5; GRANDCHAMP B, 1989, P NATL ACAD SCI USA, V86, P661, DOI 10.1073/pnas.86.2.661; GREEN D, 1990, J LAB CLIN MED, V115, P144; Gross U, 1998, CLIN CHEM, V44, P1892; GROSS U, 1995, HORM METAB RES, V27, P379, DOI 10.1055/s-2007-979983; Halapi Eva, 2002, Expert Rev Mol Diagn, V2, P411, DOI 10.1586/14737159.2.5.411; Harada FA, 2001, J AM ACAD DERMATOL, V45, P279, DOI 10.1067/mjd.2001.114730; Herrmann G, 1996, J INVEST DERMATOL, V107, P398, DOI 10.1111/1523-1747.ep12363384; Hift RJ, 2004, BRIT J DERMATOL, V151, P465, DOI 10.1111/j.1365-2133.2004.06120.x; Hift RJ, 2004, CLIN CHEM, V50, P915, DOI 10.1373/clinchem.2003.025213; Hindmarsh JT, 1999, CLIN CHEM, V45, P1070; Hindmarsh JT, 1999, CLIN BIOCHEM, V32, P609, DOI 10.1016/S0009-9120(99)00067-3; Holroyd S, 1999, CLIN PHARMACOL THER, V66, P323, DOI 10.1016/S0009-9236(99)70041-X; Jeans JB, 1996, AM J MED GENET, V65, P269, DOI 10.1002/(SICI)1096-8628(19961111)65:4<269::AID-AJMG4>3.0.CO;2-K; JENSEN MP, 1992, HDB PAIN ASSESSMENT, P135; Johansson A, 2004, MOL THER, V10, P337, DOI 10.1016/j.ymthe.2004.05.018; Johansson A, 2003, MOL MED, V9, P193, DOI 10.2119/2004-00002.Johansson; Johansson A, 2004, MOL GENET METAB, V82, P20, DOI 10.1016/j.ymgme.2004.02.008; Johansson A, 2003, MOL CELL BIOCHEM, V250, P65, DOI 10.1023/A:1024946216776; Johansson A, 2002, SCAND J CLIN LAB INV, V62, P105, DOI 10.1080/003655102753611726; JORDAN PM, 1990, MOL ASPECTS MED, V11, P21, DOI 10.1016/0098-2997(90)90011-P; KAUPPINEN R, 1988, BRIT J CANCER, V57, P117, DOI 10.1038/bjc.1988.23; Kauppinen R, 2004, EXPERT REV MOL DIAGN, V4, P243, DOI 10.1586/14737159.4.2.243; KAUPPINEN R, 1992, MEDICINE, V71, P1; Kauppinen R, 2002, CLIN CHEM, V48, P1891; Kauppinen R, 2001, J INVEST DERMATOL, V116, P610, DOI 10.1046/j.1523-1747.2001.01293.x; Kirsch RE, 1998, SEMIN LIVER DIS, V18, P33, DOI 10.1055/s-2007-1007138; Koch M, 2004, EMBO J, V23, P1720, DOI 10.1038/sj.emboj.7600189; Kuhnel A, 2000, CLIN BIOCHEM, V33, P465, DOI 10.1016/S0009-9120(00)00159-4; KUSHNER JP, 1976, J CLIN INVEST, V58, P1089, DOI 10.1172/JCI108560; LAIWAH AACY, 1983, Q J MED, V52, P92; Lamoril J, 2002, CELL MOL BIOL, V48, P33; Lamoril J, 2001, AM J HUM GENET, V68, P1130, DOI 10.1086/320118; Lecha M, 2003, Dermatol Ther, V16, P65, DOI 10.1046/j.1529-8019.2003.01610.x; LIM CK, 1984, CLIN CHIM ACTA, V139, P55, DOI 10.1016/0009-8981(84)90192-X; Lindberg RLP, 1996, NAT GENET, V12, P195, DOI 10.1038/ng0296-195; Linet MS, 1999, AM J EPIDEMIOL, V149, P1010; LLEWELLYN DH, 1992, HUM GENET, V89, P97, DOI 10.1007/BF00207051; Ma Y, 2001, CLIN EXP IMMUNOL, V126, P47, DOI 10.1046/j.1365-2249.2001.01645.x; Mathews MAA, 2001, EMBO J, V20, P5832, DOI 10.1093/emboj/20.21.5832; MathewsRoth MM, 1996, BLOOD, V87, P4480, DOI 10.1182/blood.V87.10.4480.bloodjournal87104480; MAYNARD B, 1992, J CUTAN PATHOL, V19, P40, DOI 10.1111/j.1600-0560.1992.tb01557.x; Medlock AE, 2002, CELL MOL BIOL, V48, P71; Meerman L, 1999, EUR J GASTROEN HEPAT, V11, P431, DOI 10.1097/00042737-199904000-00012; Meerman L, 1999, GASTROENTEROLOGY, V117, P696, DOI 10.1016/S0016-5085(99)70464-6; Mendez M, 2000, HUM MUTAT, V16, DOI 10.1002/1098-1004(200009)16:3<269::AID-HUMU12>3.0.CO;2-#; Meyer UA, 1998, SEMIN LIVER DIS, V18, P43, DOI 10.1055/s-2007-1007139; Minder EI, 2002, CELL MOL BIOL, V48, P91; Moore M. R., 1987, DISORDERS PORPHYRIN; Murphy Gillian M, 2003, Dermatol Ther, V16, P57, DOI 10.1046/j.1529-8019.2003.01609.x; Murphy GM, 1999, BRIT J DERMATOL, V140, P573; Murphy GM, 2001, J PHOTOCH PHOTOBIO B, V64, P93, DOI 10.1016/S1011-1344(01)00228-7; MUSTAJOKI P, 1993, ARCH INTERN MED, V153, P2004; MUSTAJOKI P, 1989, SEMIN HEMATOL, V26, P1; Mustajoki S, 2000, MOL MED, V6, P670, DOI 10.1007/BF03402047; PASANEN AVO, 1980, INT J BIOCHEM, V12, P969; Pawliuk R, 1999, NAT MED, V5, P768, DOI 10.1038/10488; Phillips JD, 2001, P NATL ACAD SCI USA, V98, P259, DOI 10.1073/pnas.011481398; PISCHIK E, IN PRESS J NEUROL; Poh-Fitzpatrick MB, 2000, METHOD ENZYMOL, V319, P485; POHFITZPATRICK MB, 1986, PHOTODERMATOLOGY, V3, P148; POHFITZPATRICK MB, 1976, J LAB CLIN MED, V87, P362; Richard E, 2001, MOL THER, V4, P331, DOI 10.1006/mthe.2001.0467; Richard E, 2003, J GENE MED, V5, P737, DOI 10.1002/jgm.407; RIDLEY A, 1968, LANCET, V2, P708; Roberts AG, 1998, HUM MOL GENET, V7, P1921, DOI 10.1093/hmg/7.12.1921; Sarkany RPE, 2001, CLIN EXP DERMATOL, V26, P225, DOI 10.1046/j.1365-2230.2001.00825.x; Schneider-Yin X, 2000, EUR J PEDIATR, V159, P719, DOI 10.1007/s004310000494; SCHOENFELD N, 1995, CLIN SCI, V88, P365, DOI 10.1042/cs0880365; Shady AA, 2002, BRIT J HAEMATOL, V117, P980, DOI 10.1046/j.1365-2141.2002.03558.x; Shaw PH, 2001, BONE MARROW TRANSPL, V27, P101, DOI 10.1038/sj.bmt.1702738; Shieh S, 2000, J AM ACAD DERMATOL, V42, P645, DOI 10.1016/S0190-9622(00)90179-8; SIERSEMA PD, 1992, LIVER, V12, P56; SIMA AAF, 1981, CAN J NEUROL SCI, V8, P105, DOI 10.1017/S0317167100042992; Smith SJ, 1997, CELL MOL BIOL, V43, P103; SOLIS J A, 1982, Journal of Dermatology (Tokyo), V9, P131; Soonawalla ZF, 2004, LANCET, V363, P705, DOI 10.1016/S0140-6736(04)15646-8; Tandon SK, 2001, SCI TOTAL ENVIRON, V281, P177, DOI 10.1016/S0048-9697(01)00845-2; Tarner IH, 2004, TRENDS BIOTECHNOL, V22, P304, DOI 10.1016/j.tibtech.2004.04.001; THUNELL S, 1992, EUR J CLIN CHEM CLIN, V30, P599; THUNELL S, 1992, J STUD ALCOHOL, V53, P272, DOI 10.15288/jsa.1992.53.272; THUNELL S, 2000, PATIENTS DOCTORS GUI, P54; TIMONEN K, 1990, ARCH DERMATOL RES, V282, P108, DOI 10.1007/BF00493468; TIMONEN K, 1991, CLIN EXP DERMATOL, V16, P355, DOI 10.1111/j.1365-2230.1991.tb00400.x; Timonen K, 2000, J AM ACAD DERMATOL, V43, P489, DOI 10.1067/mjd.2000.107498; TODD DJ, 1994, BRIT J DERMATOL, V131, P751, DOI 10.1111/j.1365-2133.1994.tb08577.x; Warren L J, 1998, Australas J Dermatol, V39, P179, DOI 10.1111/j.1440-0960.1998.tb01278.x; Whatley SD, 2000, HUM GENET, V107, P243, DOI 10.1007/s004390000356; Whatley SD, 1999, AM J HUM GENET, V65, P984, DOI 10.1086/302586; Whitby FG, 1998, EMBO J, V17, P2463, DOI 10.1093/emboj/17.9.2463; Wiman A, 2003, J HUM GENET, V48, P70, DOI 10.1007/s100380300009; Yen PS, 2002, EUR NEUROL, V48, P119, DOI 10.1159/000062990; Zadra M, 1998, SEIZURE-EUR J EPILEP, V7, P415, DOI 10.1016/S1059-1311(05)80013-5	144	187	204	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					241	252						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652607				2022-12-28	WOS:000226309600030
J	Mwinga, A				Mwinga, A			Challenges and hope for the diagnosis of tuberculosis in infants and young children	LANCET			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; AFRICAN CHILDREN; INFECTION; IMPACT; HIV-1		Ctr Dis Control & Prevent, Global AIDS Program, Lusaka, Zambia		Mwinga, A (corresponding author), Ctr Dis Control & Prevent, Global AIDS Program, POB 31617, Lusaka, Zambia.	amwinga@zamnet.zm						ABADCO DL, 1992, PEDIATR INFECT DIS J, V11, P735, DOI 10.1097/00006454-199209000-00013; CHAN SP, 1994, PEDIATR INFECT DIS J, V13, P506, DOI 10.1097/00006454-199406000-00008; Chintu C, 2002, LANCET, V360, P985, DOI 10.1016/S0140-6736(02)11082-8; CHINTU C, 1993, PEDIATR INFECT DIS J, V12, P499, DOI 10.1097/00006454-199306000-00008; Demkow U, 2004, J Physiol Pharmacol, V55 Suppl 3, P57; Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038; KHAN EA, 1995, EMERG INFECT DIS, V1, P115, DOI 10.3201/eid0104.950402; Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2; Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011; Pillay T, 2004, INT J TUBERC LUNG D, V8, P59; Pillay T, 2004, LANCET INFECT DIS, V4, P155, DOI 10.1016/S1473-3099(04)00939-9; van Rheenen P, 2002, TROP MED INT HEALTH, V7, P435, DOI 10.1046/j.1365-3156.2002.00882.x	12	9	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					97	98		10.1016/S0140-6736(05)17713-7	http://dx.doi.org/10.1016/S0140-6736(05)17713-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639273				2022-12-28	WOS:000226170700002
J	Alkadhi, H; Garzoli, E				Alkadhi, H; Garzoli, E			Calcified filariasis of the breasts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Inst Diagnost Radiol, CH-8091 Zurich, Switzerland		Alkadhi, H (corresponding author), Inst Diagnost Radiol, CH-8091 Zurich, Switzerland.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					E2	E2		10.1056/ENEJMicm040651	http://dx.doi.org/10.1056/ENEJMicm040651			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647570				2022-12-28	WOS:000226251700012
J	Kinoshita, T; Cano-Delgado, AC; Seto, H; Hiranuma, S; Fujioka, S; Yoshida, S; Chory, J				Kinoshita, T; Cano-Delgado, AC; Seto, H; Hiranuma, S; Fujioka, S; Yoshida, S; Chory, J			Binding of brassinosteroids to the extracellular domain of plant receptor kinase BRI1	NATURE			English	Article							SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CRYSTAL-STRUCTURE; ARABIDOPSIS; PROTEIN; PERCEPTION; MUTANTS; PATHWAY	Both animals and plants use steroids as signalling molecules during growth and development. Animal steroids are principally recognized by members of the nuclear receptor superfamily of transcription factors(1). In plants, BRI1, a leucine-rich repeat (LRR) receptor kinase localized to the plasma membrane, is a critical component of a receptor complex for brassinosteroids(2,3). Here, we present the first evidence for direct binding of active brassinosteroids to BRI1 using a biotin-tagged photoaffinity castasterone (BPCS), a biosynthetic precursor of brassinolide (the most active of the brassinosteroids). Binding studies using BPCS, H-3-labelled brassinolide and recombinant BRI1 fragments show that the minimal binding domain for brassinosteroids consists of a 70-amino acid island domain (ID) located between LRR21 and LRR22 in the extracellular domain of BRI1, together with the carboxy-terminal flanking LRR (ID-LRR22). Our results demonstrate that brassinosteroids bind directly to the 94 amino acids comprising ID-LRR22 in the extracellular domain of BRI1, and define a new binding domain for steroid hormones.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8108560, Japan; RIKEN, Plant Funct Lab, Wako, Saitama 3510198, Japan; RIKEN, Plant Sci Ctr, Kanagawa 2300045, Japan	Howard Hughes Medical Institute; Salk Institute; Salk Institute; Kyushu University; RIKEN; RIKEN	Chory, J (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chory@salk.edu	Kinoshita, Toshinori/C-2891-2012	Kinoshita, Toshinori/0000-0001-7621-1259				Altmann T, 1999, PLANTA, V208, P1, DOI 10.1007/s004250050528; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Cano-Delgado A, 2004, DEVELOPMENT, V131, P5341, DOI 10.1242/dev.01403; Clouse SD, 2002, MOL CELL, V10, P973, DOI 10.1016/S1097-2765(02)00744-X; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Clouse SD, 1999, BRASSINOSTEROIDS, P163; Di Matteo A, 2003, P NATL ACAD SCI USA, V100, P10124, DOI 10.1073/pnas.1733690100; Friedrichsen DM, 2000, PLANT PHYSIOL, V123, P1247, DOI 10.1104/pp.123.4.1247; GALLAGHER S, 1992, CURRENT PROTOCOLS MO; He ZH, 2000, SCIENCE, V288, P2360, DOI 10.1126/science.288.5475.2360; Kauschmann A, 1996, PLANT J, V9, P701, DOI 10.1046/j.1365-313X.1996.9050701.x; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Konoki K, 2000, TETRAHEDRON, V56, P9003, DOI 10.1016/S0040-4020(00)00752-3; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; Noguchi T, 1999, PLANT PHYSIOL, V121, P743, DOI 10.1104/pp.121.3.743; Schumacher K, 2000, CURR OPIN PLANT BIOL, V3, P79, DOI 10.1016/S1369-5266(99)00038-2; Seto H, 2002, TETRAHEDRON, V58, P9741, DOI 10.1016/S0040-4020(02)01247-4; Seto H, 1998, TETRAHEDRON LETT, V39, P7525, DOI 10.1016/S0040-4039(98)01636-0; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Ward CW, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-4; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yin YH, 2002, P NATL ACAD SCI USA, V99, P9090, DOI 10.1073/pnas.152330799; Yin YH, 2002, CELL, V109, P181, DOI 10.1016/S0092-8674(02)00721-3	27	455	482	6	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					167	171		10.1038/nature03227	http://dx.doi.org/10.1038/nature03227			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650741				2022-12-28	WOS:000226252200040
J	Todd, MM; Hindman, BJ; Clarke, WR; Torner, JC; Todd, M; Hindman, B; Clarke, W; Chaloner, K; Torner, J; Davis, P; Howard, M; Tranel, D; Anderson, S; Todd, M; Hindman, B; Weeks, J; Moss, L; Winn, J; Clarke, W; Chaloner, K; Wichman, M; Peters, R; Hansen, M; Anderson, D; Lang, J; Yoo, B; Adams, H; Clifton, G; Gelb, A; Loftus, C; Schubert, A; Warner, D; Young, W; Frankowski, R; Kieburtz, K; Prough, D; Sternau, L; Marler, J; Moy, C; Matta, B; Kirkpatrick, P; Chatfield, D; Skilbeck, C; Kirollos, R; Rasulo, F; English, K; Duffy, C; Pedersen, K; Scurrah, N; Burnstein, R; Prabhu, A; Salmond, C; Blackwell, A; Birrell, J; Jackson, S; Kassell, N; Pajewski, T; Fraley, H; Morris, A; Alden, T; Shaffrey, M; Bogdonoff, D; Durieux, M; Zuo, Z; Littlewood, K; Nemergut, E; Bedford, R; Stone, D; Balestrieri, P; Mason, J; Henry, G; Ting, P; Shafer, J; Blount, T; Kim, L; James, A; Farace, E; Clark, L; Irons, M; Sasaki, T; Webb, K; Short, T; Mee, E; Ormrod, J; Jane, J; Alden, T; Heppner, P; Olson, S; Ellegala, D; Lind, C; Sheehan, J; Woodfield, M; Law, A; Harrison, M; Davies, P; Campbell, D; Robertson, N; Fry, R; Sage, D; Laurent, S; Bradfield, C; Pedersen, K; Smith, K; Young, Y; Chambers, C; Hodkinson, B; Biddulph, J; Jensen, L; Ogden, J; Thayer, Z; Lee, F; Crump, S; Quaedackers, J; Wray, A; Roelfsema, V; Greif, R; Kleinpeter, G; Lothaller, C; Knosp, E; Pfisterer, W; Schatzer, R; Salem, C; Kutalek, W; Tuerkkan, E; Koller, L; Weber, T; Buchmann, A; Merhaut, C; Graf, M; Rapf, B; Lam, A; Newell, D; Tanzi, P; Lee, L; Domino, K; Vavilala, M; Bramhall, J; Souter, M; Britz, G; Winn, H; Bybee, H; Costello, T; Murphy, M; Harris, K; Thien, C; Nye, D; Han, T; McNeill, P; O'Brien, B; Cormack, J; Wyss, A; Grauer, R; Popovic, R; Jones, S; Deam, R; Heard, G; Watson, R; Evered, L; Bardenhagen, F; Meade, C; Haartsen, J; Kruger, J; Wilson, M; Maktabi, M; Traynelis, V; McAllister, A; Leonard, P; Hindman, B; Brian, J; Mensink, F; From, R; Papworth, D; Schmid, P; Dehring, D; Howard, M; Hitchon, P; VanGilder, J; Weeks, J; Moss, L; Manzel, K; Anderson, S; Tack, R; Taggard, D; Lennarson, P; Menhusen, M; Gelb, A; Lownie, S; Craen, R; Novick, T; Ferguson, G; Duggal, N; Findlay, J; Ng, W; Cowie, D; Badner, N; Herrick, I; Smith, H; Heard, G; Peterson, R; Howell, J; Lindsey, L; Carriere, L; von Lewinski, M; Schaefer, B; Bisnaire, D; Doyle-Pettypiece, P; McTaggart, M; Giannotta, S; Zelman, V; Thomson, E; Babayan, E; McCleary, C; Fishback, D; Samra, S; Thompson, B; Chandler, W; Mcgillicuddy, J; Tremper, K; Turner, C; Smythe, P; Dy, E; Pai, S; Portman, V; Palmisano, J; Auer, D; Quigley, M; Giordani, B; Freymuth, A; Scott, P; Silbergleit, R; Hickenbottom, S; Litt, L; Lawton, M; Hannegan, L; Gupta, D; Bickler, P; Dodson, B; Talke, P; Rampil, I; Chen, B; Wright, P; Mitchell, J; Ryan, S; Walker, J; Quinnine, N; Applebury, C; Myles, P; Rosenfeld, J; Hunt, J; Wallace, S; D'Urso, P; Thien, C; McMahon, J; Wadanamby, S; Siu, K; Malham, G; Laidlaw, J; Salerno, S; Alatakis, S; Madder, H; Cairo, S; Konstantatos, A; Smart, J; Lindholm, D; Bain, D; Machlin, H; Moloney, J; Buckland, M; Silvers, A; Downey, G; Molnar, A; Langley, M; McIlroy, D; Daly, D; Bennett, P; Forlano, L; Testa, R; Burnett, W; Johnson, F; Angliss, M; Fletcher, H; Manninen, P; Wallace, M; Lukitto, K; Tymianski, M; Porter, P; Gentili, F; El-Beheiry, H; Mosa, M; Mak, P; Balki, M; Shaikh, S; Sawyer, R; Quader, K; Chelliah, R; Berklayd, P; Merah, N; Ghazali, G; McAndrews, M; Ridgley, J; Odukoya, O; Yantha, S; Wilson, J; Petrozza, P; Miller, C; O'Brien, K; Tong, C; Olympio, M; Reynolds, J; Colonna, D; Glazier, S; Nobles, S; Hill, D; Hulbert, H; Jenkins, W; Lanier, W; Piepgras, D; Wilson, R; Meyer, F; Atkinson, J; Link, M; Weglinski, M; Berge, K; McGregor, D; Trenerry, M; Smith, G; Walkes, J; Felmlee-Devine, M; Van Aken, H; Greiner, C; Freise, H; Brors, H; Hahnenkamp, K; de Oliveira, NM; Schul, C; Moskopp, D; Greiner, C; Woelfer, J; Hoenemann, C; Gramke, H; Bone, H; Gibmeier, I; Wirtz, S; Lohmann, H; Freyhoff, J; Bauer, B; Hogan, K; Dempsey, R; Rusy, D; Badie, B; Iskandar, B; Resnick, D; Deshmukh, P; Fitzpatrick, J; Sasse, F; Broderick, T; Willmann, K; Connery, L; Kish, J; Weasler, C; Page, N; Hermann, B; Jones, J; Dulli, D; Stanko, H; Geraghty, M; Elbe, R; Salevsky, F; Leblanc, R; Lapointe, N; Macgregor, H; Sinclair, D; Sirhan, D; Maleki, M; Abou-Madi, M; Chartrand, D; Angle, M; Milovan, D; Painchaud, Y; Mirski, M; Tamargo, R; Rice, S; Olivi, A; Kim, D; Rigamonti, D; Naff, N; Hemstreet, M; Berkow, L; Chery, P; Ulatowski, J; Moore, L; Cunningham, T; McBee, N; Hartman, T; Heidler, J; Hillis, A; Tuffiash, E; Chase, C; Kane, A; Greene-Chandos, D; Torbey, M; Ziai, W; Lane, K; Bhardwaj, A; Subhas, N; Schubert, A; Mayberg, M; Beven, M; Rasmussen, P; Bhatia, S; Ebrahim, Z; Lotto, M; Vasarhelyi, F; Munis, J; Graves, K; Woletz, J; Chelune, G; Samples, S; Evans, J; Blair, D; Abou-Chebl, A; Shutway, F; Manke, D; Beven, C; Fogarty-Mack, P; Stieg, P; Eliazo, R; Li, P; Riina, H; Lien, C; Ravdin, L; Wang, J; Kuo, Y; Jaffe, R; Steinberg, G; Luu, D; Chang, S; Giffard, R; Lemmens, H; Morgan, R; Mathur, A; Angst, M; Meyer, A; Yi, H; Karzmark, P; Bell-Stephens, T; Marcellus, M; Sneyd, J; Pobereskin, L; Salsbury, S; Whitfield, P; Sawyer, R; Dashfield, A; Struthers, R; Davies, P; Rushton, A; Petty, V; Harding, S; Richardson, E; Yonas, H; Gyulai, F; Kirby, L; Kassam, A; Bircher, N; Meng, L; Krugh, J; Seever, G; Hendrickson, R; Gebel, J; Cowie, D; Fabinyi, G; Poustie, S; Davis, G; Drnda, A; Chandrasekara, D; Sturm, J; Phan, T; Shelton, A; Clausen, M; Micallef, S; Sills, A; Steinman, F; Sutton, P; Sanders, J; Van Alstine, D; Leggett, D; Cunningham, E; Hamm, W; Frankel, B; Sorenson, J; Atkins, L; Redmond, A; Dalrymple, S; Black, S; Fisher, W; Hall, C; Wilhite, D; Moore, T; Blanton, IP; Sha, Z; Szmuk, P; Kim, D; Ashtari, A; Hagberg, C; Matuszczak, M; Shahen, A; Moise, O; Novy, D; Govindaraj, R; Jameson, L; Breeze, R; Awad, I; Mattison, R; Anderson, T; Salvia, L; Mosier, M; Loftus, C; Smith, J; Lilley, W; White, B; Lenaerts, M				Todd, MM; Hindman, BJ; Clarke, WR; Torner, JC; Todd, M; Hindman, B; Clarke, W; Chaloner, K; Torner, J; Davis, P; Howard, M; Tranel, D; Anderson, S; Todd, M; Hindman, B; Weeks, J; Moss, L; Winn, J; Clarke, W; Chaloner, K; Wichman, M; Peters, R; Hansen, M; Anderson, D; Lang, J; Yoo, B; Adams, H; Clifton, G; Gelb, A; Loftus, C; Schubert, A; Warner, D; Young, W; Frankowski, R; Kieburtz, K; Prough, D; Sternau, L; Marler, J; Moy, C; Matta, B; Kirkpatrick, P; Chatfield, D; Skilbeck, C; Kirollos, R; Rasulo, F; English, K; Duffy, C; Pedersen, K; Scurrah, N; Burnstein, R; Prabhu, A; Salmond, C; Blackwell, A; Birrell, J; Jackson, S; Kassell, N; Pajewski, T; Fraley, H; Morris, A; Alden, T; Shaffrey, M; Bogdonoff, D; Durieux, M; Zuo, Z; Littlewood, K; Nemergut, E; Bedford, R; Stone, D; Balestrieri, P; Mason, J; Henry, G; Ting, P; Shafer, J; Blount, T; Kim, L; James, A; Farace, E; Clark, L; Irons, M; Sasaki, T; Webb, K; Short, T; Mee, E; Ormrod, J; Jane, J; Alden, T; Heppner, P; Olson, S; Ellegala, D; Lind, C; Sheehan, J; Woodfield, M; Law, A; Harrison, M; Davies, P; Campbell, D; Robertson, N; Fry, R; Sage, D; Laurent, S; Bradfield, C; Pedersen, K; Smith, K; Young, Y; Chambers, C; Hodkinson, B; Biddulph, J; Jensen, L; Ogden, J; Thayer, Z; Lee, F; Crump, S; Quaedackers, J; Wray, A; Roelfsema, V; Greif, R; Kleinpeter, G; Lothaller, C; Knosp, E; Pfisterer, W; Schatzer, R; Salem, C; Kutalek, W; Tuerkkan, E; Koller, L; Weber, T; Buchmann, A; Merhaut, C; Graf, M; Rapf, B; Lam, A; Newell, D; Tanzi, P; Lee, L; Domino, K; Vavilala, M; Bramhall, J; Souter, M; Britz, G; Winn, H; Bybee, H; Costello, T; Murphy, M; Harris, K; Thien, C; Nye, D; Han, T; McNeill, P; O'Brien, B; Cormack, J; Wyss, A; Grauer, R; Popovic, R; Jones, S; Deam, R; Heard, G; Watson, R; Evered, L; Bardenhagen, F; Meade, C; Haartsen, J; Kruger, J; Wilson, M; Maktabi, M; Traynelis, V; McAllister, A; Leonard, P; Hindman, B; Brian, J; Mensink, F; From, R; Papworth, D; Schmid, P; Dehring, D; Howard, M; Hitchon, P; VanGilder, J; Weeks, J; Moss, L; Manzel, K; Anderson, S; Tack, R; Taggard, D; Lennarson, P; Menhusen, M; Gelb, A; Lownie, S; Craen, R; Novick, T; Ferguson, G; Duggal, N; Findlay, J; Ng, W; Cowie, D; Badner, N; Herrick, I; Smith, H; Heard, G; Peterson, R; Howell, J; Lindsey, L; Carriere, L; von Lewinski, M; Schaefer, B; Bisnaire, D; Doyle-Pettypiece, P; McTaggart, M; Giannotta, S; Zelman, V; Thomson, E; Babayan, E; McCleary, C; Fishback, D; Samra, S; Thompson, B; Chandler, W; Mcgillicuddy, J; Tremper, K; Turner, C; Smythe, P; Dy, E; Pai, S; Portman, V; Palmisano, J; Auer, D; Quigley, M; Giordani, B; Freymuth, A; Scott, P; Silbergleit, R; Hickenbottom, S; Litt, L; Lawton, M; Hannegan, L; Gupta, D; Bickler, P; Dodson, B; Talke, P; Rampil, I; Chen, B; Wright, P; Mitchell, J; Ryan, S; Walker, J; Quinnine, N; Applebury, C; Myles, P; Rosenfeld, J; Hunt, J; Wallace, S; D'Urso, P; Thien, C; McMahon, J; Wadanamby, S; Siu, K; Malham, G; Laidlaw, J; Salerno, S; Alatakis, S; Madder, H; Cairo, S; Konstantatos, A; Smart, J; Lindholm, D; Bain, D; Machlin, H; Moloney, J; Buckland, M; Silvers, A; Downey, G; Molnar, A; Langley, M; McIlroy, D; Daly, D; Bennett, P; Forlano, L; Testa, R; Burnett, W; Johnson, F; Angliss, M; Fletcher, H; Manninen, P; Wallace, M; Lukitto, K; Tymianski, M; Porter, P; Gentili, F; El-Beheiry, H; Mosa, M; Mak, P; Balki, M; Shaikh, S; Sawyer, R; Quader, K; Chelliah, R; Berklayd, P; Merah, N; Ghazali, G; McAndrews, M; Ridgley, J; Odukoya, O; Yantha, S; Wilson, J; Petrozza, P; Miller, C; O'Brien, K; Tong, C; Olympio, M; Reynolds, J; Colonna, D; Glazier, S; Nobles, S; Hill, D; Hulbert, H; Jenkins, W; Lanier, W; Piepgras, D; Wilson, R; Meyer, F; Atkinson, J; Link, M; Weglinski, M; Berge, K; McGregor, D; Trenerry, M; Smith, G; Walkes, J; Felmlee-Devine, M; Van Aken, H; Greiner, C; Freise, H; Brors, H; Hahnenkamp, K; de Oliveira, NM; Schul, C; Moskopp, D; Greiner, C; Woelfer, J; Hoenemann, C; Gramke, H; Bone, H; Gibmeier, I; Wirtz, S; Lohmann, H; Freyhoff, J; Bauer, B; Hogan, K; Dempsey, R; Rusy, D; Badie, B; Iskandar, B; Resnick, D; Deshmukh, P; Fitzpatrick, J; Sasse, F; Broderick, T; Willmann, K; Connery, L; Kish, J; Weasler, C; Page, N; Hermann, B; Jones, J; Dulli, D; Stanko, H; Geraghty, M; Elbe, R; Salevsky, F; Leblanc, R; Lapointe, N; Macgregor, H; Sinclair, D; Sirhan, D; Maleki, M; Abou-Madi, M; Chartrand, D; Angle, M; Milovan, D; Painchaud, Y; Mirski, M; Tamargo, R; Rice, S; Olivi, A; Kim, D; Rigamonti, D; Naff, N; Hemstreet, M; Berkow, L; Chery, P; Ulatowski, J; Moore, L; Cunningham, T; McBee, N; Hartman, T; Heidler, J; Hillis, A; Tuffiash, E; Chase, C; Kane, A; Greene-Chandos, D; Torbey, M; Ziai, W; Lane, K; Bhardwaj, A; Subhas, N; Schubert, A; Mayberg, M; Beven, M; Rasmussen, P; Bhatia, S; Ebrahim, Z; Lotto, M; Vasarhelyi, F; Munis, J; Graves, K; Woletz, J; Chelune, G; Samples, S; Evans, J; Blair, D; Abou-Chebl, A; Shutway, F; Manke, D; Beven, C; Fogarty-Mack, P; Stieg, P; Eliazo, R; Li, P; Riina, H; Lien, C; Ravdin, L; Wang, J; Kuo, Y; Jaffe, R; Steinberg, G; Luu, D; Chang, S; Giffard, R; Lemmens, H; Morgan, R; Mathur, A; Angst, M; Meyer, A; Yi, H; Karzmark, P; Bell-Stephens, T; Marcellus, M; Sneyd, J; Pobereskin, L; Salsbury, S; Whitfield, P; Sawyer, R; Dashfield, A; Struthers, R; Davies, P; Rushton, A; Petty, V; Harding, S; Richardson, E; Yonas, H; Gyulai, F; Kirby, L; Kassam, A; Bircher, N; Meng, L; Krugh, J; Seever, G; Hendrickson, R; Gebel, J; Cowie, D; Fabinyi, G; Poustie, S; Davis, G; Drnda, A; Chandrasekara, D; Sturm, J; Phan, T; Shelton, A; Clausen, M; Micallef, S; Sills, A; Steinman, F; Sutton, P; Sanders, J; Van Alstine, D; Leggett, D; Cunningham, E; Hamm, W; Frankel, B; Sorenson, J; Atkins, L; Redmond, A; Dalrymple, S; Black, S; Fisher, W; Hall, C; Wilhite, D; Moore, T; Blanton, IP; Sha, Z; Szmuk, P; Kim, D; Ashtari, A; Hagberg, C; Matuszczak, M; Shahen, A; Moise, O; Novy, D; Govindaraj, R; Jameson, L; Breeze, R; Awad, I; Mattison, R; Anderson, T; Salvia, L; Mosier, M; Loftus, C; Smith, J; Lilley, W; White, B; Lenaerts, M		IHAST Investigators	Mild intraoperative hypothermia during surgery for intracranial aneurysm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TEMPORARY ARTERIAL-OCCLUSION; MODERATE HYPOTHERMIA; BRAIN-DAMAGE; SUBARACHNOID HEMORRHAGE; SURGICAL-TREATMENT; ISCHEMIA; NORMOTHERMIA; PROTECTION; PROPOFOL	Background: Surgery for intracranial aneurysm often results in postoperative neurologic deficits. We conducted a randomized trial at 30 centers to determine whether intraoperative cooling during open craniotomy would improve the outcome among patients with acute aneurysmal subarachnoid hemorrhage. Methods: A total of 1001 patients with a preoperative World Federation of Neurological Surgeons score of I, II, or III ("good-grade patients''), who had had a subarachnoid hemorrhage no more than 14 days before planned surgical aneurysm clipping, were randomly assigned to intraoperative hypothermia (target temperature, 33 degreesC, with the use of surface cooling techniques) or normothermia (target temperature, 36.5 degreesC). Patients were followed closely postoperatively and examined approximately 90 days after surgery, at which time a Glasgow Outcome Score was assigned. Results: There were no significant differences between the group assigned to intraoperative hypothermia and the group assigned to normothermia in the duration of stay in the intensive care unit, the total length of hospitalization, the rates of death at follow-up (6 percent in both groups), or the destination at discharge (home or another hospital, among surviving patients). At the final follow-up, 329 of 499 patients in the hypothermia group had a Glasgow Outcome Score of 1 (good outcome), as compared with 314 of 501 patients in the normothermia group (66 percent vs. 63 percent; odds ratio, 1.14; 95 percent confidence interval, 0.88 to 1.48; P=0.32). Postoperative bacteremia was more common in the hypothermia group than in the normothermia group (5 percent vs. 3 percent, P=0.05). Conclusions: Intraoperative hypothermia did not improve the neurologic outcome after craniotomy among good-grade patients with aneurysmal subarachnoid hemorrhage.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesia, Iowa City, IA 52242 USA; Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Data Management Ctr, Iowa City, IA USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Todd, MM (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesia, 200 Hawkins Dr,6546 JCP, Iowa City, IA 52242 USA.	michael-todd@uiowa.edu	Littlewood, Keith E/H-4785-2013; Black, Sandra E./C-7294-2011; Sneyd, John/AFV-7887-2022; Prough, Donald S/G-5793-2013; Balki, Mrinalini/A-2669-2015; Robert, Greif/O-6392-2016; Schubert, Armin/D-3589-2011; Sneyd, John Robert/B-2957-2012; Littlewood, Keith/ABC-8858-2020; McAndrews, MP/GWV-3841-2022; Lind, Christopher/K-3629-2012; Burnstein, Rowan/AAF-3611-2021; D'Urso, Pietro/AAL-8919-2020; Giordani, Bruno/AAR-1910-2021; Sneyd, John/AFV-7886-2022; Zuo, Zhiyi/F-3950-2010	Sneyd, John/0000-0003-3546-9856; Prough, Donald S/0000-0001-7994-532X; Robert, Greif/0000-0003-0160-2073; Sneyd, John Robert/0000-0003-3546-9856; Littlewood, Keith/0000-0003-1049-3227; Lind, Christopher/0000-0001-9991-1725; Sneyd, John/0000-0003-3546-9856; Zuo, Zhiyi/0000-0002-3542-5047; Hindman, Bradley/0000-0003-2242-7980; Tymianski, Mike/0000-0002-6311-9565; Angst, Martin/0000-0002-1550-8136; Quaedackers, Josine/0000-0002-7873-6216; RASULO, Francesco Antonio/0000-0002-7187-5168; Jaffe, Richard/0000-0003-0443-495X; Burnstein, Rowan/0000-0003-2107-1433; Steinberg, Gary/0000-0001-6374-1058; Honemann, Christian/0000-0002-9658-253X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038554] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS38554] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052; BAKER CJ, 1992, J NEUROSURG, V77, P438, DOI 10.3171/jns.1992.77.3.0438; BAKER KZ, 1994, ANESTHESIOLOGY, V81, P361, DOI 10.1097/00000542-199408000-00014; BATJER HH, 1988, J NEUROSURG, V68, P234, DOI 10.3171/jns.1988.68.2.0234; Baumgardner JE, 1999, ANESTH ANALG, V89, P163, DOI 10.1097/00000539-199907000-00029; BENDTSEN AO, 1984, ACTA ANAESTH SCAND, V28, P473, DOI 10.1111/j.1399-6576.1984.tb02101.x; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Cheng MA, 1997, CRIT CARE CLIN, V13, P185, DOI 10.1016/S0749-0704(05)70301-8; Clifton G L, 1992, Tex Med, V88, P66; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DRAKE CG, 1988, J NEUROSURG, V68, P985; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; Fridriksson S, 2002, J NEUROSURG, V96, P515, DOI 10.3171/jns.2002.96.3.0515; GRIZZLE JE, 1969, BIOMETRICS, V25, P489, DOI 10.2307/2528901; Hindman BJ, 1999, NEUROSURGERY, V44, P23, DOI 10.1097/00006123-199901000-00009; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iwata T, 2003, BRIT J ANAESTH, V90, P32, DOI 10.1093/bja/aeg016; JENNETT B, 1975, LANCET, V1, P480; Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982; Kettner SC, 2003, ANESTH ANALG, V96, P1772, DOI 10.1213/01.ANE.0000062520.65192.C9; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LOUGHEED WM, 1955, J NEUROSURG, V12, P240, DOI 10.3171/jns.1955.12.3.0240; MAHONEY F I, 1965, Md State Med J, V14, P61; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCDERMOTT MW, 1989, NEUROSURGERY, V25, P54, DOI 10.1227/00006123-198907000-00010; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; OLGILVY CS, 1996, J NEUROSURG, V84, P785; Pemberton PL, 2003, ANAESTHESIA, V58, P370; Piepgras A, 2001, NEUROSURGERY, V48, P1128, DOI 10.1097/00006123-200105000-00033; RANKIN J, 1957, Scott Med J, V2, P200; RAVUSSIN P, 1993, NEUROSURGERY, V32, P236, DOI 10.1227/00006123-199302000-00013; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SAMSON D, 1994, NEUROSURGERY, V34, P22; Sato K, 2000, ACTA NEUROCHIR, V142, P1013, DOI 10.1007/s007010070056; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Wiebers D, 1999, NEW ENGL J MED, V340, P744; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; WITYK RJ, 1994, STROKE, V25, P1300; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; 1998, JAMA, V279, P1256	49	317	337	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					135	145		10.1056/NEJMoa040975	http://dx.doi.org/10.1056/NEJMoa040975			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647576				2022-12-28	WOS:000226251700006
J	Badou, A; Basavappa, S; Desai, R; Peng, YQ; Matza, D; Mehal, WZ; Kaczmarek, LK; Boulpaep, EL; Flavell, RA				Badou, A; Basavappa, S; Desai, R; Peng, YQ; Matza, D; Mehal, WZ; Kaczmarek, LK; Boulpaep, EL; Flavell, RA			RETRACTED: Requirement of voltage-gated calcium channel beta(4) subunit for T lymphocyte functions (Retracted Article. See vol 310, pg 1903, 2005)	SCIENCE			English	Article; Retracted Publication							CA2+ CHANNELS; TRANSCRIPTION FACTORS; MICE; CELL; ACTIVATION; INCREASES; SIGNAL	Calcium is known to play vital roles in diverse physiological processes, and it is known that voltage-gated calcium channels (Ca-v) mediate calcium influx in excitable cells. However, no consensus exists on the molecular identity of the calcium channels present in nonexcitable cells such as T lymphocytes. Here, we demonstrate that T lymphocytes express both regulatory beta(4) and pore-forming Ca(v)1 alpha(1) subunits of Ca-v channels. Ca-v beta(4)-mutant T lymphocytes fail to acquire normal functions and display impairment in the calcium response, activation of the transcription factor NFAT, and cytokine production. Although Ca(v)1 channels of lymphocytes retain their voltage dependency, T cell receptor stimulation dramatically increases channel opening, providing a new mechanism for calcium entry in lymphocytes.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Univ Rochester, Sch Med, Dept Med Pharmacol & Physiol, Digest Dis Unit, Rochester, NY 14627 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; University of Rochester	Flavell, RA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA.	richard.flavell@yale.edu		Badou, Abdallah/0000-0003-4849-9085				BADOU A, UNPUB; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dickie MM, 1964, MOUSE NEWS LETT, V30, P31; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUNG HC, 1976, AM J ANAT, V147, P255, DOI 10.1002/aja.1001470209; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Freise D, 2000, J BIOL CHEM, V275, P14476, DOI 10.1074/jbc.275.19.14476; Freise D, 1999, BIOL CHEM, V380, P897, DOI 10.1515/BC.1999.110; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Grafton G, 2001, IMMUNOLOGY, V104, P119, DOI 10.1046/j.0019-2805.2001.01321.x; Koschak A, 2001, J BIOL CHEM, V276, P22100, DOI 10.1074/jbc.M101469200; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; MORRISON DG, 1984, DEV COMP IMMUNOL, V8, P435, DOI 10.1016/0145-305X(84)90050-8; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Schjott JM, 2003, J BIOL CHEM, V278, P33936, DOI 10.1074/jbc.M302059200; Sidman RL., 1965, CATALOG NEUROLOGICAL, DOI [10.4159/harvard.9780674424326, DOI 10.4159/HARVARD.9780674424326]; TANAKA O, 1995, BRAIN RES MOL BRAIN, V30, P1, DOI DOI 10.1016/0169-328X(94)00265-G; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; WAARD MD, 1994, NEURON, V13, P495; Xu WF, 2001, J NEUROSCI, V21, P5944, DOI 10.1523/JNEUROSCI.21-16-05944.2001; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	32	18	24	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					117	121		10.1126/science.1100582	http://dx.doi.org/10.1126/science.1100582			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637280				2022-12-28	WOS:000226214300051
J	Xu, M; Arulandu, A; Struck, DK; Swanson, S; Sacchettini, JC; Young, R				Xu, M; Arulandu, A; Struck, DK; Swanson, S; Sacchettini, JC; Young, R			Disulfide isomerization after membrane release of its SAR domain activates P1 lysozyme	SCIENCE			English	Article							ESCHERICHIA-COLI; CELL-LYSIS; SWITCHES; SEQUENCE; HOLINS	The P1 lysozyme Lyz is secreted to the periplasm of Escherichia coli and accumulates in an inactive membra ne-tethered form. Genetic and biochemical experiments show that, when released from the bilayer, Lyz is activated by an intramolecular thiol-disulfide isomerization, which requires a cysteine in its N-terminal SAR (signal-arrest-release) domain. Crystal structures confirm the alternative disulfide linkages in the two forms of Lyz and reveal dramatic conformational differences in the catalytic domain. Thus, the exported P1 endolysin is kept inactive by three levels of control-topological, conformational, and covalent-until its release from the membrane is triggered by the P1 holin.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Young, R (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu; ryland@tamu.edu	Arulandu, Arockiasamy/C-1679-2009	Young, Ry/0000-0001-8001-2914; Arulandu, Arockiasamy/0000-0002-4606-8006	NIGMS NIH HHS [R01 GM027099, GM62410, GM27099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027099, P50GM062410, R01GM027099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONOVICH MT, 1991, J BACTERIOL, V173, P2897, DOI 10.1128/JB.173.9.2897-2905.1991; Grundling A, 2001, P NATL ACAD SCI USA, V98, P9348, DOI 10.1073/pnas.151247598; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; High S, 1997, TRENDS CELL BIOL, V7, P206; Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Khan AR, 1998, PROTEIN SCI, V7, P815; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Roberts MD, 2004, VIROLOGY, V318, P245, DOI 10.1016/j.virol.2003.09.020; Sao-Jos? C., 2003, RECENT RES DEV BACTE, V1, P103; Sao-Jose C, 2000, J BACTERIOL, V182, P5823, DOI 10.1128/JB.182.20.5823-5831.2000; Schmidt C, 1996, J BACTERIOL, V178, P1099, DOI 10.1128/jb.178.4.1099-1104.1996; Wang IN, 2000, ANNU REV MICROBIOL, V54, P799, DOI 10.1146/annurev.micro.54.1.799; Wu J, 1997, PROTEIN SCI, V6, P391; Xu M, 2004, P NATL ACAD SCI USA, V101, P6415, DOI 10.1073/pnas.0400957101; XU MW, UNPUB; Young R, 2000, TRENDS MICROBIOL, V8, P120, DOI 10.1016/S0966-842X(00)01705-4; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992	21	101	104	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					113	117		10.1126/science.1105143	http://dx.doi.org/10.1126/science.1105143			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637279				2022-12-28	WOS:000226214300050
J	Roberts, RJ; Burgess, IF				Roberts, RJ; Burgess, IF			New head-lice treatments: hope or hype?	LANCET			English	Editorial Material							SODIUM-CHANNEL GENE; KNOCKDOWN RESISTANCE; PERMETHRIN; KDR; MALATHION		Natl Publ Hlth Serv Wales, Mold, Flintshire, Wales; Insect Res & Dev Ltd, Royston, Herts, England		Roberts, RJ (corresponding author), Natl Publ Hlth Serv Wales, Mold, Flintshire, Wales.	roberts@doctors.org.uk	Burgess, Ian/N-2977-2013	Burgess, Ian/0000-0003-0747-3938				DODD CS, 2001, COCHRANE LIB; Downs AMR, 1999, BRIT J DERMATOL, V141, P508, DOI 10.1046/j.1365-2133.1999.03046.x; Gao JR, 2003, PESTIC BIOCHEM PHYS, V77, P115, DOI 10.1016/j.pestbp.2003.08.003; Lee SH, 2000, PESTIC BIOCHEM PHYS, V66, P130, DOI 10.1006/pest.1999.2460; Martinez-Torres D, 1998, INSECT MOL BIOL, V7, P179, DOI 10.1046/j.1365-2583.1998.72062.x; Miyazaki M, 1996, MOL GEN GENET, V252, P61, DOI 10.1007/BF02173205; Park Y, 1997, INSECT BIOCHEM MOLEC, V27, P9, DOI 10.1016/S0965-1748(96)00077-X; Pearlman DL, 2004, PEDIATRICS, V114, pE275, DOI 10.1542/peds.2003-0666-F; Roberts RJ, 2002, NEW ENGL J MED, V346, P1645, DOI 10.1056/NEJMcp012640; Roberts RJ, 2000, LANCET, V356, P540, DOI 10.1016/S0140-6736(00)02578-2; *UPD SOFTW LTD, 2004, NAT RES REG 2004	11	15	16	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					8	10		10.1016/S0140-6736(04)17677-0	http://dx.doi.org/10.1016/S0140-6736(04)17677-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639662				2022-12-28	WOS:000226213100006
J	Gill, SS; Rochon, PA; Herrmann, N; Lee, PE; Sykora, K; Gunraj, N; Normand, SLT; Gurwitz, JH; Marras, C; Wodchis, WP; Mamdani, M				Gill, SS; Rochon, PA; Herrmann, N; Lee, PE; Sykora, K; Gunraj, N; Normand, SLT; Gurwitz, JH; Marras, C; Wodchis, WP; Mamdani, M			Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CEREBROVASCULAR EVENTS; DEMENTIA; RISPERIDONE; MANAGEMENT; SYMPTOMS; ATTACK; TRIAL	Objective To compare the incidence of admissions to hospital for stroke among older adults with dementia,receiving atypical or typical ancipsychotics. Design Population based retrospective cohort study. Setting Ontario, Canada. Patients 32 7 10 older adults 65 years) with dementia (17 845 dispensed an atypical antipsychotic and 14 865 dispensed a typical antipsychotic). Main outcome measures Admission to hospital with the most responsible diagnosis (single most important condition responsible for the patients admission) of ischaemic stroke. Observation of patients until they were either admitted to hospital with ischaemic stroke, stopped taking antipsychotics, died, or the study ended. Results After adjustment for potential confounders, participants receiving atypical antipsychotics showed no significant increase in risk of ischaemic stroke compared with those receiving typical antipsychotics (adjusted hazard ratio 1.01, 95% confidence interval 0.81 to 1.26). This finding was consistent in a series of subgroup analyses, including ones of individual atypical antipsychotic drugs (risperidone, olanzapine, and quetiapine) and selected subpopulations of the main cohorts. Conclusion Older adults with dementia who take atypical antipsychotics have a similar risk of ischaemic stroke to those taking typical antipsychotics.	Inst Clin Evaluat Sci, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Div Geriatr Psychiat, Toronto, ON, Canada; Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Ctr, Toronto, ON M5T 2S8, Canada; Toronto Rehabil Inst, Toronto, ON, Canada; Univ British Columbia, Div Geriatr Med, Vancouver, BC V5Z 1M9, Canada; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Toronto; University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of British Columbia; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Gill, SS (corresponding author), St Marys Lake Hosp, Chapel Wing, Room 1-152,340 Union St, Kingston, ON K7L 5A2, Canada.	gills@pccchealth.org	Greiver, Michelle/N-8764-2015; Rochon, Paula A/J-2918-2016	Greiver, Michelle/0000-0001-8957-0285; Rochon, Paula A/0000-0002-5973-4151; Normand, Sharon-Lise/0000-0001-7027-4769; wodchis, walter/0000-0003-2494-7031				Brodaty H, 2003, J CLIN PSYCHIAT, V64, P134, DOI 10.4088/JCP.v64n0205; Brown TM, 2002, BMJ-BRIT MED J, V325, P644, DOI 10.1136/bmj.325.7365.644; *CALM AD, CALM AD TRIAL RAND C; *CEM CMO, CEMCMO20041; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COHEN CA, 1993, GERONTOLOGIST, V33, P714, DOI 10.1093/geront/33.6.714; Cohen-Mansfield J, 1998, J AM GERIATR SOC, V36, P7; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; Gladstone DJ, 2004, CAN MED ASSOC J, V170, P1099, DOI 10.1503/cmaj.1031349; Harrison-Woolrych M, 2004, BRIT MED J, V328, P1416, DOI 10.1136/bmj.328.7453.1416; Health Canada, IMP DRUG SAF INF RIS; Herrmann N, 2004, AM J PSYCHIAT, V161, P1113, DOI 10.1176/appi.ajp.161.6.1113; Hill MD, 2004, NEUROLOGY, V62, P2015, DOI 10.1212/01.WNL.0000129482.70315.2F; Hollander M, 2003, J NEUROL NEUROSUR PS, V74, P317, DOI 10.1136/jnnp.74.3.317; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; KOZMA CM, 2003 M INT COLL GER; Lee PE, 2004, BMJ-BRIT MED J, V329, P75, DOI 10.1136/bmj.38125.465579.55; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Liperoti R, 2003, J CLIN PSYCHIAT, V64, P1106, DOI 10.4088/JCP.v64n0918; LIPEROTI R, 2004 ANN M AM GER SO; LIPEROTI R, 200J ANN M AM GER SO; Mayo N E, 1994, Health Rep, V6, P62; Mowat D, 2004, BRIT MED J, V328, P1262, DOI 10.1136/bmj.328.7450.1262-b; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Schneider LS, 2001, AM J GERIAT PSYCHIAT, V9, P346, DOI 10.1176/appi.ajgp.9.4.346; Smith David A, 2004, J Am Med Dir Assoc, V5, P129, DOI 10.1097/01.JAM.0000113432.52383.E0; Straus SE, 2002, JAMA-J AM MED ASSOC, V288, P1388, DOI 10.1001/jama.288.11.1388; Tariot PN, 2001, CLIN GERIATR MED, V17, P359, DOI 10.1016/S0749-0690(05)70073-2; Teri L, 2002, MED CLIN N AM, V86, P641, DOI 10.1016/S0025-7125(02)00006-8; *US FDA, 2004, 2003 SAF AL RISPERDA; Wallaschofski H, 2001, J CLIN ENDOCR METAB, V86, P5912, DOI 10.1210/jc.86.12.5912; Wooltorton E, 2002, CAN MED ASSOC J, V167, P1269; Wooltorton E, 2004, CAN MED ASSOC J, V170, P1395, DOI 10.1503/cmaj.1040539; *WORK GROUP FAC OL, GUID MAN BEH PSYCH S; Zornberg GL, 2000, LANCET, V356, P1219, DOI 10.1016/S0140-6736(00)02784-7; WUETIAPINE EVALUATED	37	222	227	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 26	2005	330	7489					445	448B		10.1136/bmj.38330.470486.8F	http://dx.doi.org/10.1136/bmj.38330.470486.8F			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901XK	15668211	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000227315400016
J	Zhu, GP; Golding, GB; Dean, AM				Zhu, GP; Golding, GB; Dean, AM			The selective cause of an ancient adaptation	SCIENCE			English	Article							ISOCITRATE DEHYDROGENASE; ESCHERICHIA-COLI; 3-ISOPROPYLMALATE DEHYDROGENASE; DECARBOXYLATING DEHYDROGENASE; COFACTOR SPECIFICITY; NUCLEOTIDE-SEQUENCE; ADAPTIVE EVOLUTION; NATURAL-SELECTION; CRYSTAL-STRUCTURE; BRANCH POINT	Phylogenetic analysis reveals that the use of nicotinamide adenine dinucleotide phosphate (NADP) by prokaryotic isocitrate dehydrogenase (IDH) arose around the time eukaryotic mitochondria first appeared, about 3.5 billion years ago. We replaced the wild-type gene that encodes the NADP-dependent IDH of Escherichia coli with an engineered gene that possesses the ancestral NAD-dependent phenotype. The engineered enzyme is disfavored during competition for acetate. The selection intensifies in genetic backgrounds where other sources of reduced NADP have been removed. A survey of sequenced prokaryotic genomes reveals that those genomes that encode isocitrate lyase, which is essential for growth on acetate, always have an NADP-dependent IDH. Those with only an NAD-dependent IDH never have isocitrate lyase. Hence, the NADP dependence of prokaryotic IDH is an ancient adaptation to anabolic demand for reduced NADP during growth on acetate.	Univ Minnesota, Inst Biotechnol, St Paul, MN 55108 USA; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; McMaster University	Dean, AM (corresponding author), Univ Minnesota, Inst Biotechnol, St Paul, MN 55108 USA.	adean@biosci.umn.edu		Zhu, Guo-ping/0000-0002-1877-4501	NIGMS NIH HHS [GM060611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; CLARKE B, 1975, GENETICS, V79, P101; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dean AM, 1997, P NATL ACAD SCI USA, V94, P3104, DOI 10.1073/pnas.94.7.3104; DYKHUIZEN DE, 1993, METHOD ENZYMOL, V224, P613, DOI 10.1016/0076-6879(93)24046-W; FELSENSTEIN J, 1994, PHYLIP VER 3 5; Gaucher EA, 2003, NATURE, V425, P285, DOI 10.1038/nature01977; Golding GB, 1998, MOL BIOL EVOL, V15, P355, DOI 10.1093/oxfordjournals.molbev.a025932; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1994, STRUCTURE, V2, P1007, DOI 10.1016/S0969-2126(94)00104-9; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; KIRINO H, 1991, J BIOCHEM-TOKYO, V109, P852, DOI 10.1093/oxfordjournals.jbchem.a123470; Lunzer M, 2002, GENETICS, V162, P485; Madigan M. T., 2000, BROCK BIOL MICROORGA; Miller SP, 2000, J BIOL CHEM, V275, P833, DOI 10.1074/jbc.275.2.833; Miyazaki J, 2003, J BIOL CHEM, V278, P1864, DOI 10.1074/jbc.M205133200; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; Sauer U, 2004, J BIOL CHEM, V279, P6613, DOI 10.1074/jbc.M311657200; Shi YS, 2003, P NATL ACAD SCI USA, V100, P8308, DOI 10.1073/pnas.1532535100; Sivaraman J, 2003, J BIOL CHEM, V278, P43682, DOI 10.1074/jbc.M306344200; Suiter AM, 2003, P NATL ACAD SCI USA, V100, P12782, DOI 10.1073/pnas.2134994100; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; TIPTON PA, 1994, ARCH BIOCHEM BIOPHYS, V313, P15, DOI 10.1006/abbi.1994.1352; Voet D., 1995, BIOCHEMISTRY; WALSH K, 1984, J BIOL CHEM, V259, P9646; WALSH K, 1985, J BIOL CHEM, V260, P8430; Yasutake Y, 2003, J BIOL CHEM, V278, P36897, DOI 10.1074/jbc.M304091200; Zhang JZ, 2002, NAT GENET, V30, P411, DOI 10.1038/ng852; Zhao J, 2003, J BIOTECHNOL, V101, P101, DOI 10.1016/S0168-1656(02)00316-4; Zhu G., UNPUB	32	109	118	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	2005	307	5713					1279	1282		10.1126/science.1106974	http://dx.doi.org/10.1126/science.1106974			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	901WP	15653464				2022-12-28	WOS:000227313200050
J	Iqbal, MB; Taneja, AK; Lip, GYH; Flather, M				Iqbal, MB; Taneja, AK; Lip, GYH; Flather, M			Recent developments in atrial fibrillation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SINUS RHYTHM; RANDOMIZED-TRIAL; RISK-FACTORS; ELECTRICAL CARDIOVERSION; ANTITHROMBOTIC THERAPY; STROKE PREVENTION; PULMONARY VEIN; MANAGEMENT; EFFICACY; CONVERSION		Royal Brompton Hosp, Clin Trials & Evaluat Unit, London SW3 6NP, England; City Hosp, Univ Dept Med, Birmingham B18 7QH, W Midlands, England	Royal Brompton Hospital; University of Birmingham	Taneja, AK (corresponding author), Royal Brompton Hosp, Clin Trials & Evaluat Unit, London SW3 6NP, England.	a.taneja@rbh.nthames.nhs.uk						Albers GW, 2003, LANCET, V362, P1691; Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; Allessie MA, 1996, AM J CARDIOL, V77, pA10, DOI 10.1016/S0002-9149(97)89114-X; *AM COLL CARD AM H, 1998, J AM COLL CARDIOL, V32, P486; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; Benditt DG, 1999, AM J CARDIOL, V84, P270, DOI 10.1016/S0002-9149(99)00275-1; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Bernard EO, 2003, CRIT CARE MED, V31, P1031, DOI 10.1097/01.CCM.0000053555.78624.0F; Billman George E, 2003, Curr Opin Investig Drugs, V4, P352; Blackshear JL, 1996, ANN THORAC SURG, V61, P755, DOI 10.1016/0003-4975(95)00887-X; BORGEAT A, 1986, AM J CARDIOL, V58, P496, DOI 10.1016/0002-9149(86)90022-6; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; Carlsson J, 2003, J AM COLL CARDIOL, V41, P1690, DOI 10.1016/S0735-1097(03)00332-2; Connolly SJ, 2003, AM HEART J, V145, P418, DOI 10.1067/mhj.2003.84; Connolly SJ, 2001, AM J CARDIOL, V88, P974, DOI 10.1016/S0002-9149(01)01973-7; Copland M, 2001, ARCH INTERN MED, V161, P2125, DOI 10.1001/archinte.161.17.2125; Cox J L, 2000, Semin Thorac Cardiovasc Surg, V12, P15; Cox J L, 2000, Semin Thorac Cardiovasc Surg, V12, P2; Crijns HJGM, 1996, CARDIOVASC DRUG THER, V10, P145, DOI 10.1007/BF00823592; Daoud EG, 2000, CIRCULATION, V102, P1407, DOI 10.1161/01.CIR.102.12.1407; Falk RH, 1997, J AM COLL CARDIOL, V29, P385, DOI 10.1016/S0735-1097(96)00506-2; Fareh S, 1998, CIRCULATION, V98, P2202, DOI 10.1161/01.CIR.98.20.2202; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Fox KM, 2000, HEART, V83, P167, DOI 10.1136/heart.83.2.167; Freestone B, 2004, J HUM HYPERTENS, V18, P461, DOI 10.1038/sj.jhh.1001694; Freestone B, 2004, EXPERT OPIN INV DRUG, V13, P151, DOI 10.1517/eoid.13.2.151.26335; Fuster V, 2001, EUR HEART J, V22, P1852, DOI 10.1053/euhj.2001.2983; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; Galve E, 1996, J AM COLL CARDIOL, V27, P1079, DOI 10.1016/0735-1097(95)00595-1; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Greene HL, 2003, J AM COLL CARDIOL, V42, P20, DOI 10.1016/S0735-1097(03)00559-X; Gustafsson D, 2001, THROMB RES, V101, P171, DOI 10.1016/S0049-3848(00)00399-6; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; HALPERIN JL, 2003, P AM HEART ASS FLOR; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Herbert JM, 1998, BLOOD, V91, P4197, DOI 10.1182/blood.V91.11.4197.411k09_4197_4205; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; Hwang C, 1999, J CARDIOVASC ELECTR, V10, P636, DOI 10.1111/j.1540-8167.1999.tb00240.x; Jung J, 1997, AM J CARDIOL, V80, P1489, DOI 10.1016/S0002-9149(97)00733-9; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KAUMANN AJ, 1994, TRENDS PHARMACOL SCI, V15, P451, DOI 10.1016/0165-6147(94)90058-2; KUMAGAI K, 2000, PACING CLIN ELECTROP, V11, P1880; Lau CP, 1997, PACE, V20, P2442, DOI 10.1111/j.1540-8159.1997.tb06084.x; Lau CP, 2003, HEART, V89, P106, DOI 10.1136/heart.89.1.106; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lerman B B, 2001, J Cardiovasc Pharmacol Ther, V6, P237, DOI 10.1177/107424840100600304; LIP GYH, 1995, LANCET, V346, P1313, DOI 10.1016/S0140-6736(95)92339-X; Lip GYH, 2002, BRIT MED J, V325, P1022, DOI 10.1136/bmj.325.7371.1022; Mant JWF, 2003, BMC CARDIOVASC DISOR, V3, DOI 10.1186/1471-2261-3-9; Martinez-Marcos FJ, 2000, AM J CARDIOL, V86, P950, DOI 10.1016/S0002-9149(00)01128-0; McCarthy P M, 2000, Semin Thorac Cardiovasc Surg, V12, P25; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; Naccarelli GV, 1996, AM J CARDIOL, V77, pA53, DOI 10.1016/S0002-9149(97)89118-7; Opolski Grzegorz, 2003, Kardiol Pol, V59, P1; Oral H, 1999, NEW ENGL J MED, V340, P1849, DOI 10.1056/NEJM199906173402401; Pedersen OD, 2001, CIRCULATION, V104, P292, DOI 10.1161/01.CIR.104.3.292; PETERSEN P, 1989, LANCET, V1, P175; Pratt CM, 2004, J AM COLL CARDIOL, V43, P1211, DOI 10.1016/j.jacc.2003.10.057; Ruigomez A, 2002, J CLIN EPIDEMIOL, V55, P358, DOI 10.1016/S0895-4356(01)00478-4; Samsa GP, 2000, ARCH INTERN MED, V160, P967, DOI 10.1001/archinte.160.7.967; Sievert H, 2002, CIRCULATION, V105, P1887, DOI 10.1161/01.CIR.0000015698.54752.6D; Singh S, 2000, CIRCULATION, V102, P2385, DOI 10.1161/01.CIR.102.19.2385; Somberg JC, 2004, AM J CARDIOL, V93, P576, DOI 10.1016/j.amjcard.2003.11.021; STAFFURTH JS, 1977, BRIT MED J, V2, P688, DOI 10.1136/bmj.2.6088.688; Stambler BS, 1996, CIRCULATION, V94, P1613, DOI 10.1161/01.CIR.94.7.1613; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P153; Tan KT, 2003, EXPERT OPIN INV DRUG, V12, P799, DOI 10.1517/13543784.12.5.799; Touboul P, 2003, EUR HEART J, V24, P1481, DOI 10.1016/S0195-668X(03)00321-X; Tsai CF, 2000, CIRCULATION, V102, P67, DOI 10.1161/01.CIR.102.1.67; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; VANGELDER IC, 1991, AM J CARDIOL, V68, P41, DOI 10.1016/0002-9149(91)90707-R; VanGelder IC, 1996, ARCH INTERN MED, V156, P2585, DOI 10.1001/archinte.156.22.2585; Volgman A S, 1996, Am J Card Imaging, V10, P261; Wellens HJJ, 2000, CIRCULATION, V102, P2562; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Yamashita T, 2003, CIRC J, V67, P738; Yousef ZR, 2004, HEART, V90, P1259, DOI 10.1136/hrt.2003.023325; Yu WC, 1997, CIRCULATION, V96, P2992, DOI 10.1161/01.CIR.96.9.2992; Zaza Antonio, 2002, Curr Opin Investig Drugs, V3, P96; 1999, P R COLL PHYS EDIN S, V6, P2	83	42	48	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2005	330	7485					238	243		10.1136/bmj.330.7485.238	http://dx.doi.org/10.1136/bmj.330.7485.238			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15677659	Green Published			2022-12-28	WOS:000226779400025
J	Walker, P; Wisner, B; Leaning, J; Minear, L				Walker, P; Wisner, B; Leaning, J; Minear, L			Smoke and mirrors: deficiencies in disaster funding	BRITISH MEDICAL JOURNAL			English	Article									Tufts Univ, Friedman Sch Nutr Sci & Policy, Feinstein Int Famine Ctr, Medford, MA 02155 USA; Univ London London Sch Econ & Polit Sci, Inst Dev Studies, Crisis States Programme, London WC2A 2AE, England; Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA	Tufts University; University of London; London School Economics & Political Science; Harvard University; Harvard T.H. Chan School of Public Health	Walker, P (corresponding author), Tufts Univ, Friedman Sch Nutr Sci & Policy, Feinstein Int Famine Ctr, Medford, MA 02155 USA.	peter.walker@tufts.edu						CLAY E, INDIAN OCEAN TSUNAMI; *DTSCH PRESS AG, 2004, IND SENDS AID SRI LA; *IND TOG, EARTHQ GUJ; *INT FED RED CROSS, 2004, WORLD DIS REP 2004, P163; *INT FED RED CROSS, 2001, WORLD DIS REP 2001, P161; PATRICK S, 1998, CHECK IS MAIL IMPROV; REVKIN A, 2004, NY TIMES        1231, pA15; REYNOLDS P, 2005, BBC NEWS        0106; Stoddard Abby, 2003, 12 OV DEV I HUM POL; *US AG INT DEV, TSUN REL PAG; WISNER B, 2004, RISK NATURAL HAZARDS, P75	11	20	20	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 29	2005	330	7485					247	250		10.1136/bmj.330.7485.247	http://dx.doi.org/10.1136/bmj.330.7485.247			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15677661	Green Published			2022-12-28	WOS:000226779400027
J	Peake, JB				Peake, JB			Beyond the purple heart - Continuity of care for the wounded in Iraq.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Peake, JB (corresponding author), Project HOPE, Millwood, VA USA.								0	35	36	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					219	222		10.1056/NEJMp048312	http://dx.doi.org/10.1056/NEJMp048312			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659720				2022-12-28	WOS:000226370500001
J	Asarnow, JR; Jaycox, LH; Duan, N; LaBorde, AP; Rea, MM; Murray, P; Anderson, M; Landon, C; Tang, LQ; Wells, KB				Asarnow, JR; Jaycox, LH; Duan, N; LaBorde, AP; Rea, MM; Murray, P; Anderson, M; Landon, C; Tang, LQ; Wells, KB			Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COGNITIVE-BEHAVIORAL TREATMENT; MEDICATION ALGORITHM PROJECT; PLACEBO-CONTROLLED TRIAL; FORM HEALTH SURVEY; INTERPERSONAL PSYCHOTHERAPY; CHILDHOOD DEPRESSION; CHILDREN; DISORDER; EFFICACY; FLUOXETINE	Context Depression is a common condition associated with significant morbidity in adolescents. Few depressed adolescents receive effective treatment for depression in primary care settings. Objective To evaluate the effectiveness of a quality improvement intervention aimed at increasing access to evidence-based treatments for depression (particularly cognitive-behavior therapy and antidepressant medication), relative to usual care, among adolescents in primary care practices. Design, Setting, and Participants Randomized controlled trial conduced between 1999 and 2003 enrolling 418 primary care patients with current depressive symptoms, aged 13 through 21 years, from 5 health care organizations purposively selected to include managed care, public sector, and academic medical center clinics in the United States. Intervention Usual care (n=207) or 6-month quality improvement intervention (n=211) including expert,leader teams at each site, care managers who supported primary care clinicians in evaluating and managing patients' depression, training for care managers in manualized cognitive-behavior therapy for depression, and patient and clinician choice regarding treatment modality. Participating clinicians also received education regarding depression evaluation, management, and pharmacological and psychosocial treatment. Main Outcome Measures Depressive symptoms assessed by Center for Epidemiological Studies-Depression Scale (CES-D) score. Secondary outcomes were mental health-related quality of life assessed by Mental Health Summary Score (MCS-12) and satisfaction with mental health care assessed using a 5-point scale. Results Six months after baseline assessments, intervention patients, compared with usual care patients reported significantly fewer depressive symptoms (mean [SD] CES-D scores, 19.0 [11.9] vs 21.4 [13.1]; P=.02), higher mental health-related quality of life (mean [SD] MCS-12 scores, 44.6 [11.3] vs 42.8 [12.9] P=.03), and greater satisfaction with mental health care (mean [SD] scores 3.8 [0.9] vs 3.5 [1.0]; P=.004). Intervention patients also reported significantly higher rates of mental health care (32.1% vs 17.2%, P<.001) and psychotherapy or counseling (32.0% vs 21.2%, P=.007). Conclusions A 6-month quality improvement intervention aimed at improving access to evidence-based depression treatments through primary care was significantly more effective than usual care for depressed adolescents from diverse primary care practices. The greater uptake of counseling vs medication under the intervention reinforces the importance of practice interventions that include resources to enable evidence-based psychotherapy for depressed adolescents.	Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Mattell Childrens Hosp, Los Angeles, CA 90024 USA; RAND Corp, Hlth Program, Santa Monica, CA USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA; Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Venice Family Clin, Venice, CA USA; Ventura Cty Med Ctr, Landon Pediat, Ventura, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; University of California System; University of California Los Angeles; Kaiser Permanente; University of California System; University of California Davis; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Asarnow, JR (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, 760 Westwood Plaza, Los Angeles, CA 90024 USA.	jasamow@mednet.ucla.edu		Duan, Naihua/0000-0001-9411-2924	AHRQ HHS [HS09908] Funding Source: Medline; NIMH NIH HHS [MH068639] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH068639] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Achenbach T., 1997, MANUAL YOUTH SELF RE; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1995, J Adolesc Health, V16, P413; [Anonymous], 1997, COMP INT DIAGN INT C; Asarnow JR, 2002, CHILD ADOL PSYCH CL, V11, P477, DOI 10.1016/S1056-4993(02)00006-8; Asarnow JR, 2001, J CLIN CHILD PSYCHOL, V30, P33, DOI 10.1207/S15374424JCCP3001_5; ASARNOW JR, IN PRESS J ADOLESC H; ASARNOW JR, 1999, STRESS YOUR MOOD MAN; ASARNOW JR, 1999, YOUTH PARTNERS CARE; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; Berger VW., 2003, J MODERN APPL STAT M, V2, P8, DOI [10.22237/jmasm/1051747680, DOI 10.22237/JMASM/1051747680]; Birmaher B, 1998, J AM ACAD CHILD PSY, V37, P1234, DOI 10.1097/00004583-199811000-00029; Birmaher B, 1996, J AM ACAD CHILD PSY, V35, P1427, DOI 10.1097/00004583-199611000-00011; Brent DA, 1997, ARCH GEN PSYCHIAT, V54, P877; Brick J M, 1996, Stat Methods Med Res, V5, P215, DOI 10.1177/096228029600500302; *CDCP, 2002, YOUTH RISK BEH SURV; Clarke GN, 1999, J AM ACAD CHILD PSY, V38, P272, DOI 10.1097/00004583-199903000-00014; CLARKE GN, 1995, J AM ACAD CHILD PSY, V34, P312, DOI 10.1097/00004583-199503000-00016; DeBar L L, 2001, Ment Health Serv Res, V3, P73, DOI 10.1023/A:1011512901714; DOWRICK C, 1995, BMJ-BRIT MED J, V311, P1274, DOI 10.1136/bmj.311.7015.1274; Edlund MJ, 2003, HEALTH SERV RES, V38, P631, DOI 10.1111/1475-6773.00137; Emslie GJ, 2002, J AM ACAD CHILD PSY, V41, P1205, DOI 10.1097/00004583-200210000-00010; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; Emslie GJ, 2004, J AM ACAD CHILD PSY, V43, P519, DOI 10.1097/00004583-200405000-00005; Fisher RA, 1935, DESIGN EXPT; Good P, 2000, PERMUTATION TESTS PR; GOTLIB IH, 1995, J CONSULT CLIN PSYCH, V63, P90, DOI 10.1037/0022-006X.63.1.90; HORWITZ SM, 1992, PEDIATRICS, V89, P480; Horwitz SM, 2001, PSYCHIAT SERV, V52, P1088, DOI 10.1176/appi.ps.52.8.1088; Hughes CW, 1999, J AM ACAD CHILD PSY, V38, P1442, DOI 10.1097/00004583-199911000-00020; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P557, DOI 10.1097/00004583-199905000-00017; Kalton G, 1986, J OFF STAT, V2, P303; KANDEL DB, 1986, ARCH GEN PSYCHIAT, V43, P255; Kessler RC, 2002, HANDBOOK OF DEPRESSION, P23; Kovacs M, 1996, J AM ACAD CHILD PSY, V35, P705, DOI 10.1097/00004583-199606000-00010; Kramer T, 1998, BRIT J PSYCHIAT, V173, P508, DOI 10.1192/bjp.173.6.508; Lewinsohn P.M., 1990, ADOLESCENT COPING DE; LEWINSOHN PM, 1990, BEHAV THER, V21, P385, DOI 10.1016/S0005-7894(05)80353-3; Lewinsohn PM, 2002, HANDBOOK OF DEPRESSION, P541; Lewinsohn PM, 1999, J AM ACAD CHILD PSY, V38, P56, DOI 10.1097/00004583-199901000-00020; March J, 2004, JAMA-J AM MED ASSOC, V292, P807; Mufson L, 2004, ARCH GEN PSYCHIAT, V61, P577, DOI 10.1001/archpsyc.61.6.577; Mufson L, 1999, ARCH GEN PSYCHIAT, V56, P573, DOI 10.1001/archpsyc.56.6.573; Office of the Surgeon General, 2019, SURG GEN ADV MAR US; PITMAN E. J. G., 1937, J. Roy. Statist. Soc. 1937., (Suppl.), V4, P119; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAHDERT E, 1991, DHHS PUBL; ROBERTS RE, 1991, J AM ACAD CHILD PSY, V30, P58, DOI 10.1097/00004583-199101000-00009; Rossello J, 1999, J CONSULT CLIN PSYCH, V67, P734, DOI 10.1037/0022-006X.67.5.734; RUBENSTEIN L, 1996, PARTNERS CARE CLIN G; Rushton JL, 2001, ARCH PEDIAT ADOL MED, V155, P560, DOI 10.1001/archpedi.155.5.560; SHAFFER D, 2000, PRACTICE PARAMETERS; *STATACORP, 2003, STAT STAT SOFTW; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2; U.S. Food and Drug Administration, 2004, PUBL HLTH ADV SUIC C; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; *US PREV SERV TASK, SCREEN DEPR REC RAT; Vitiello B, 2004, NEW ENGL J MED, V350, P1489, DOI 10.1056/NEJMp038248; Wagner KD, 2004, AM J PSYCHIAT, V161, P1079, DOI 10.1176/appi.ajp.161.6.1079; Wagner KD, 2003, JAMA-J AM MED ASSOC, V290, P1033, DOI 10.1001/jama.290.8.1033; Ware J.E., 1995, SF 12 SCORE SF 12 PH; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weersing VR, 2002, J CONSULT CLIN PSYCH, V70, P299, DOI 10.1037//0022-006X.70.2.299; Weissman MM, 1999, JAMA-J AM MED ASSOC, V281, P1707, DOI 10.1001/jama.281.18.1707; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1; Whooley MA, 2000, J GEN INTERN MED, V15, P293, DOI 10.1046/j.1525-1497.2000.04319.x; Wood A, 1996, J CHILD PSYCHOL PSYC, V37, P737, DOI 10.1111/j.1469-7610.1996.tb01466.x; Zito JM, 2002, PEDIATRICS, V109, P721, DOI 10.1542/peds.109.5.721; Ziv A, 1999, PEDIATRICS, V104, P35, DOI 10.1542/peds.104.1.35	72	342	345	1	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					311	319		10.1001/jama.293.3.311	http://dx.doi.org/10.1001/jama.293.3.311			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888FA	15657324	Bronze			2022-12-28	WOS:000226358400025
J	Choudhry, NK; Detsky, AS				Choudhry, NK; Detsky, AS			A perspective on US drug reimportation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEVELOPMENT COSTS; PRICES; MEDICARE; BENEFITS; MARKET; PAY		Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Hlth Network, Toronto, ON, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Choudhry, NK (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	choudhry@fas.harvard.edu						ALEXANDER D, 2004, VANCOUVER SUN   0825, pA1; BAKER C, 2004, WORLD PRESCRIPTION D; Bartlett Donald L., 2004, TIME            0920, P51; COHEN JC, 2003, GLOBE MAIL      0826, pA17; CONNOLLY C, 2004, WASHINGTON POST 0219, pA10; CONNOLLY C, 2004, WASHINGTON POST 0423; Danzon PM, 1998, PHARMACOECONOMICS, V13, P293, DOI 10.2165/00019053-199813030-00004; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Frank RG, 2004, NEW ENGL J MED, V351, P1375, DOI 10.1056/NEJMp048158; Frank RG, 2003, HEALTH AFFAIR, V22, P46, DOI 10.1377/hlthaff.22.3.46; Frank RG, 2003, J HEALTH ECON, V22, P325, DOI 10.1016/S0167-6296(03)00002-X; Frank RG, 2001, HEALTH AFFAIR, V20, P115, DOI 10.1377/hlthaff.20.2.115; FRIESEN J, 2004, GLOBE MAIL      1111; Gibbons Moira, 2004, Manag Care, V13, P21; *HLTH CAN HLTH PRO, SUMM REP COMPL INSP; HUBBARD WK, 2003, CANADIAN PRESCRIPTIO; Huskamp HA, 2003, HEALTH AFFAIR, V22, P149, DOI 10.1377/hlthaff.22.3.149; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; KAMATH R, 2003, REPORT FEASIBILITY E; Kanavos P, 2003, HEALTH AFFAIR, V22, P16, DOI 10.1377/hlthaff.22.3.16; LESTER W, 3 AM SAY PAYING DRUG; LUECK S, 2004, WALL ST J       0108, pA4; MAJESKI T, 2004, ST PAUL PIONEER 0520, pB8; MARIMOW AE, 2004, CONTRA COSIA TI 0826; Maynard A, 2003, HEALTH AFFAIR, V22, P31, DOI 10.1377/hlthaff.22.3.31; Menon D, 2001, HEALTH AFFAIR, V20, P92, DOI 10.1377/hlthaff.20.3.92; Newhouse JP, 2004, HEALTH AFFAIR, V23, P89, DOI 10.1377/hlthaff.23.1.89; *NIH, 2000, NIH CONTR PHARM DEV; NITKIN D, 2004, BALTIMORE SUN   0331, pB1; PEAR R, 2004, NY TIMES        0422, pA23; *PUBL CIT C WATCH, AM OTH DRUG PROBL BN; Rector TS, 2004, HEALTH AFFAIR, V23, P213, DOI 10.1377/hlthaff.23.4.213; RICHER S, 2004, GLOBE MAIL      0517, pA1; Saatsoglou Paul, 2004, Manag Care, V13, P7; SAGER A, 2000, PRESCRIPTION DRUG PE; SAGER A, 2004, DO DRUG MAKERS LOSE; SANDERS B, 2003, INT PRESCRIPTION DRU; Scherer FM, 2004, NEW ENGL J MED, V351, P927, DOI 10.1056/NEJMhpr040117; Scherer FM, 2001, HEALTH AFFAIR, V20, P216, DOI 10.1377/hlthaff.20.5.216; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Soumerai SB, 2004, HEALTH AFFAIR, V23, P135, DOI 10.1377/hlthaff.23.1.135; STRAHINICH J, 2004, BOSTON HERALD   1118, P46; *US C OFF TECHN AS, 1993, OTAH522; *US DEP HHS, PRESCR DRUG COV SPEN; *US FDA, FDA US CUST IMP BLIT; *US GEN ACC OFF, 2003, NIH PRIV SECT PARTN; *US GEN ACC OFF, 2004, INT PHARM SOM POS SA; Wagner JL, 2004, ANNU REV PUBL HEALTH, V25, P475, DOI 10.1146/annurev.publhealth.25.101802.123042; Ward Christopher, 2004, Manag Care, V13, P17; Wilson JF, 2004, ANN INTERN MED, V140, P677, DOI 10.7326/0003-4819-140-8-200404200-00044; Wolfe W., 2004, MINNEAPOLIS STA 0514, p1B; WALL STREET U; 2004, AARP             JUL	53	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					358	362		10.1001/jama.293.3.358	http://dx.doi.org/10.1001/jama.293.3.358			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657329				2022-12-28	WOS:000226358400030
J	Weitz, J; Koch, M; Debus, J; Hohler, T; Galle, PR; Buchler, MW				Weitz, J; Koch, M; Debus, J; Hohler, T; Galle, PR; Buchler, MW			Colorectal cancer	LANCET			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; TOTAL MESORECTAL EXCISION; III COLON-CANCER; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MULTICENTER RANDOMIZED-TRIAL; INFLAMMATORY-BOWEL-DISEASE; LOW ANTERIOR RESECTION; IN-HOSPITAL MORTALITY; LOW RECTAL-CANCER; QUALITY-OF-LIFE	Every year, more than 945 000 people develop colorectal cancer worldwide, and around 492 000 patients die. This form of cancer develops sporadically, in the setting of hereditary cancer syndromes, or on the basis of inflammatory bowel diseases. Screening and prevention programmes are available for all these causes and should be more widely publicised. The adenoma-carcinoma sequence is the basis for development of colorectal cancer, and the underlying molecular changes have largely been identified. Prognosis depends on factors related to the patient, treatment, and tumour, and the expertise of the treatment team is one of the major determinants of outcome. New information on the molecular basis of this cancer have led to the development of targeted therapeutic options, which are being tested in clinical trials. Further clinical progress will largely depend on the broader implementation of multidisciplinary treatment strategies following the principles of evidence-based medicine.	Univ Heidelberg, Dept Surg, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Radiat Oncol, D-69120 Heidelberg, Germany; Univ Mainz, Dept Internal Med, D-6500 Mainz, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz	Buchler, MW (corresponding author), Univ Heidelberg, Dept Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	markus-buechler@med.uni-heidelberg.de	Galle, Peter/ABE-2872-2021; Galle, Peter R/T-5292-2018	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992				Adam R, 2004, SURG CLIN N AM, V84, P659, DOI 10.1016/j.suc.2003.12.005; Adlard JW, 2002, LANCET ONCOL, V3, P75, DOI 10.1016/S1470-2045(02)00648-4; Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044; Anderson ADG, 2003, BRIT J SURG, V90, P1497, DOI 10.1002/bjs.4371; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Asano TK, 2004, DIS COLON RECTUM, V47, P665, DOI 10.1007/s10350-003-0111-9; Bandipalliam P, 2004, GASTROENTEROLOGY, V126, P936, DOI 10.1053/j.gastro.2004.01.038; Basse L, 2003, SURG ENDOSC, V17, P1919, DOI 10.1007/s00464-003-9013-0; Basse L, 2004, DIS COLON RECTUM, V47, P271, DOI 10.1007/s10350-003-0055-0; Bembenek A, 2004, SURGERY, V135, P498, DOI 10.1016/j.surg.2003.10.004; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Bisgaard ML, 2004, GUT, V53, P266, DOI 10.1136/gut.2003.019042; Bosset JF, 2004, EUR J CANCER, V40, P219, DOI 10.1016/j.ejca.2003.09.032; Brandstrup B, 2003, ANN SURG, V238, P641, DOI 10.1097/01.sla.0000094387.50865.23; Braun AH, 2004, CANCER-AM CANCER SOC, V100, P1558, DOI 10.1002/cncr.20154; Brennan MF, 2004, BRIT J SURG, V91, P653, DOI 10.1002/bjs.4648; Brennan MF, 2003, BRIT J SURG, V90, P3, DOI 10.1002/bjs.4001; Brown G, 2004, BRIT J CANCER, V91, P23, DOI 10.1038/sj.bjc.6601871; Brown G, 2004, AM J ROENTGENOL, V182, P431, DOI 10.2214/ajr.182.2.1820431; Bulow S, 2004, GUT, V53, P381, DOI 10.1136/gut.2003.027771; Callahan MA, 2003, ANN SURG, V238, P629, DOI 10.1097/01.sla.0000089855.96280.4a; Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012; Carethers JM, 2004, GASTROENTEROLOGY, V126, P394, DOI 10.1053/j.gastro.2003.12.023; CASSIDY J, 2004, P AM SOC CLIN ONCOL; Cecil TD, 2004, DIS COLON RECTUM, V47, P1145, DOI 10.1007/s10350-004-0086-6; Chan R, 2004, CURR OPIN ONCOL, V16, P378, DOI 10.1097/01.cco.0000126577.04727.e9; Chau I, 2004, J CLIN ONCOL, V22, P1420, DOI 10.1200/JCO.2004.05.041; CHEATHAM ML, 1995, ANN SURG, V221, P469, DOI 10.1097/00000658-199505000-00004; Cohade C, 2003, J NUCL MED, V44, P1797; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; Cruz-Correa M, 2004, GASTROENTEROLOGY, V126, P964, DOI 10.1053/j.gastro.2003.12.051; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Delaney CP, 2003, ANN SURG, V238, P67, DOI 10.1097/01.sla.0000074967.53451.22; Diaz-Rubio E, 2004, ONCOLOGIST, V9, P282, DOI 10.1634/theoncologist.9-3-282; Diep CB, 2003, J CLIN ONCOL, V21, P820, DOI 10.1200/JCO.2003.05.190; Dimick JB, 2003, J SURG RES, V114, P50, DOI 10.1016/S0022-4804(03)00207-5; Engel J, 2003, ANN SURG, V238, P203, DOI 10.1097/01.sla.0000080823.38569.b0; Erlichman C, 2004, NEW ENGL J MED, V351, P391, DOI 10.1056/NEJMe048151; Feezor RJ, 2002, ANN SURG ONCOL, V9, P944, DOI 10.1245/ASO.2002.04.005; Fernandez FG, 2004, ANN SURG, V240, P438, DOI 10.1097/01.sla.0000138076.72547.b1; Figueredo A, 2004, J CLIN ONCOL, V22, P3395, DOI 10.1200/JCO.2004.03.087; Figueredo A, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-26; Finlayson EVA, 2003, J AM COLL SURGEONS, V196, P410, DOI 10.1016/S1072-7515(02)01753-2; Furst A, 2003, DIS COLON RECTUM, V46, P1161, DOI 10.1097/01.DCR.0000084415.52836.93; Galizia G, 2004, CLIN CANCER RES, V10, P3490, DOI 10.1158/1078-0432.CCR-0960-03; Gerard JP, 2004, J CLIN ONCOL, V22, P2404, DOI 10.1200/JCO.2004.08.170; Gertler R, 2004, J CLIN ONCOL, V22, P1807, DOI 10.1200/JCO.2004.09.160; Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059; Glehen J, 2004, BRIT J SURG, V91, P747, DOI 10.1002/bjs.4473; Goh V, 2004, CLIN RADIOL, V59, P215, DOI 10.1016/j.crad.2003.08.013; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Grady WM, 2003, GASTROENTEROLOGY, V124, P1574, DOI 10.1016/S0016-5085(03)00376-7; Graziano F, 2003, ANN ONCOL, V14, P1026, DOI 10.1093/annonc/mdg284; Greene FL, 2004, J CLIN ONCOL, V22, P1778, DOI 10.1200/JCO.2004.07.015; Greene FL, 2002, ANN SURG, V236, P416, DOI 10.1097/00000658-200210000-00003; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Guenaga KF, 2003, COCHRANE DB SYST REV, V2; Gunderson LL, 2004, J CLIN ONCOL, V22, P1785, DOI 10.1200/JCO.2004.08.173; Gunderson LL, 2003, SEMIN RADIAT ONCOL, V13, P419, DOI 10.1016/S1053-4296(03)00073-0; Half EE, 2004, CURR OPIN GASTROEN, V20, P32, DOI 10.1097/00001574-200401000-00008; Hannan EL, 2002, SURGERY, V131, P6, DOI 10.1067/msy.2002.120238; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; Harmon JW, 1999, ANN SURG, V230, P404, DOI 10.1097/00000658-199909000-00013; Hawk ET, 2004, GASTROENTEROLOGY, V126, P1423, DOI 10.1053/j.gastro.2004.03.002; Hermanek P, 2004, Colorectal Dis, V6, P10, DOI 10.1111/j.1463-1318.2004.00569.x; Hodgson DC, 2003, J NATL CANCER I, V95, P708, DOI 10.1093/jnci/95.10.708; Hurlstone DP, 2004, GUT, V53, P376, DOI 10.1136/gut.2003.029868; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Itzkowitz SH, 2004, GASTROENTEROLOGY, V126, P1634, DOI 10.1053/j.gastro.2004.03.025; Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004; Janson M, 2004, BRIT J SURG, V91, P409, DOI 10.1002/bjs.4469; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Jeffery GM, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002200; Jentzsch C, 2004, OSTEUROPA, V54, P8; Jesus Eliane Camargo de, 2003, Rev. Assoc. Med. Bras., V49, P214; Johnson FE, 2004, J CLIN ONCOL, V22, P1363, DOI 10.1200/JCO.2004.01.948; Jung B, 2004, GASTROENTEROLOGY, V126, P654, DOI 10.1053/j.gastro.2004.01.008; Kahi CJ, 2004, CANCER METAST REV, V23, P137, DOI 10.1023/A:1025871231346; Kahlenberg MS, 2003, SURG ONCOL, V12, P173, DOI 10.1016/S0960-7404(03)00006-9; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Kerr DJ, 2003, LANCET, V361, P368, DOI 10.1016/S0140-6736(03)12388-4; Kienle P, 2003, ANN SURG, V238, P324, DOI 10.1097/01.sla.0000086547.27615.e6; Kienle P, 2001, SEMIN SURG ONCOL, V20, P282, DOI 10.1002/ssu.1046; Kiesslich R, 2004, GUT, V53, P1222, DOI 10.1136/gut.2004.043281; Kiesslich R, 2004, GASTROENTEROLOGY, V127, P706, DOI 10.1053/j.gastro.2004.06.050; Kiesslich R, 2003, GASTROENTEROLOGY, V124, P880, DOI 10.1053/gast.2003.50146; Kinkel K, 2002, RADIOLOGY, V224, P748, DOI 10.1148/radiol.2243011362; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kiran RP, 2004, ARCH SURG-CHICAGO, V139, P39, DOI 10.1001/archsurg.139.1.39; Klump B, 2004, INT J COLORECTAL DIS, V19, P23, DOI 10.1007/s00384-003-0499-7; KOCH M, IN PRESS ANN SURG; Koehne CH, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.03.041; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Krok KL, 2004, CURR OPIN GASTROEN, V20, P43, DOI 10.1097/00001574-200401000-00009; Labianca R, 2004, JNCI-J NATL CANCER I, V96, P750, DOI 10.1093/jnci/djh132; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; Le Voyer TE, 2003, J CLIN ONCOL, V21, P2912, DOI 10.1200/JCO.2003.05.062; Leung KL, 2004, LANCET, V363, P1187, DOI 10.1016/S0140-6736(04)15947-3; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Lynch JP, 2002, HEMATOL ONCOL CLIN N, V16, P775, DOI 10.1016/S0889-8588(02)00029-1; Machado M, 2003, ANN SURG, V238, P214, DOI 10.1097/01.sla.0000080824.10891.e1; Marijnen CAM, 2003, INT J RADIAT ONCOL, V55, P1311, DOI 10.1016/S0360-3016(02)04291-8; Marijnen CAM, 2001, J CLIN ONCOL, V19, P1976, DOI 10.1200/JCO.2001.19.7.1976; Martenson JA, 2004, J CLIN ONCOL, V22, P3277, DOI 10.1200/JCO.2004.01.029; Mayer RJ, 2004, NEW ENGL J MED, V350, P2406, DOI 10.1056/NEJMe048098; McAndrew MR, 1999, AM SURGEON, V65, P205; Mitchell RJ, 2004, GUT, V53, P291, DOI 10.1136/gut.2003.027896; Nagtegaal ID, 2002, J CLIN ONCOL, V20, P1729, DOI 10.1200/JCO.2002.07.010; Nelson H, 2004, NEW ENGL J MED, V350, P2050; Nelson RL, 2004, DIS COLON RECTUM, V47, P739, DOI 10.1007/s10350-003-0113-7; Parc Y, 2004, ANN SURG, V239, P378, DOI 10.1097/01.sla.0000114216.90947.f6; Parc Y, 2004, GUT, V53, P371, DOI 10.1136/gut.2003.019190; Pfister DG, 2004, NEW ENGL J MED, V350, P2375, DOI 10.1056/NEJMcp010529; Popat S, 2004, J CLIN ONCOL, V22, P529, DOI 10.1200/JCO.2004.05.064; Punt CJA, 2002, LANCET, V360, P671, DOI 10.1016/S0140-6736(02)09836-7; Quah HM, 2002, BRIT J SURG, V89, P1551, DOI 10.1046/j.1365-2168.2002.02275.x; Rabeneck L, 2004, AM J GASTROENTEROL, V99, P668, DOI 10.1111/j.1572-0241.2004.04135.x; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rao M, 2004, INT J COLORECTAL DIS, V19, P1, DOI 10.1007/s00384-003-0511-2; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Renehan AG, 2004, BRIT MED J, V328, P81, DOI 10.1136/bmj.328.7431.81; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Renehan AG, 2002, BRIT MED J, V324, P1; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Rodel C, 2003, J CLIN ONCOL, V21, P3098, DOI 10.1200/JCO.2003.02.505; Rosenblatt KP, 2004, ANNU REV MED, V55, P97, DOI 10.1146/annurev.med.55.091902.105237; Russo MW, 2004, GASTROENTEROLOGY, V126, P1448, DOI 10.1053/j.gastro.2004.01.025; Saha S, 2004, SEMIN ONCOL, V31, P374, DOI 10.1053/j.seminoncol.2004.03.008; SALTZ LB, 2004, P AM SOC CLIN ONCOL; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Schrag D, 2000, JAMA-J AM MED ASSOC, V284, P3028, DOI 10.1001/jama.284.23.3028; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Shen P, 2004, ANN SURG ONCOL, V11, P178, DOI 10.1245/ASO.2004.05.009; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Simunovic M, 2003, BRIT J SURG, V90, P999, DOI 10.1002/bjs.4210; Sinicrope FA, 2004, CANCER METAST REV, V23, P63, DOI 10.1023/A:1025863029529; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Sobrero AF, 2004, J CLIN ONCOL, V22, P4, DOI 10.1200/JCO.2004.11.974; Soetikno RM, 2003, CURR OPIN GASTROEN, V19, P69, DOI 10.1097/00001574-200301000-00012; Staib L, 2002, WORLD J SURG, V26, P59; Stein CJ, 2004, BRIT J CANCER, V90, P299, DOI 10.1038/sj.bjc.6601509; Stewart BW, 2003, WORLD CANC REPORT, P198; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Ueno H, 2004, ANN SURG, V239, P34, DOI 10.1097/01.sla.0000103070.13030.eb; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Urbach DR, 2004, BRIT MED J, V328, P737, DOI 10.1136/bmj.38030.642963.AE; Van Cutsem E, 2004, BRIT J CANCER, V90, P1190, DOI 10.1038/sj.bjc.6601676; van den Brink M, 2004, J CLIN ONCOL, V22, P244, DOI 10.1200/JCO.2004.04.198; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Venesio T, 2004, GASTROENTEROLOGY, V126, P1681, DOI 10.1053/j.gastro.2004.02.022; Verwaal VJ, 2004, BRIT J SURG, V91, P739, DOI 10.1002/bjs.4516; Verwaal VJ, 2003, J CLIN ONCOL, V21, P3737, DOI 10.1200/JCO.2003.04.187; Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Weeks JC, 2002, JAMA-J AM MED ASSOC, V287, P321, DOI 10.1001/jama.287.3.321; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Z'graggen K, 2001, ANN SURG, V234, P780, DOI 10.1097/00000658-200112000-00009	163	961	1025	4	175	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					153	165		10.1016/S0140-6736(05)17706-X	http://dx.doi.org/10.1016/S0140-6736(05)17706-X			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639298				2022-12-28	WOS:000226170700031
J	Ellegala, DB; Day, AL				Ellegala, DB; Day, AL			Ruptured cerebral aneurysms	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TEMPORARY; ISCHEMIA		Brigham & Womens Hosp, Cerebrovasc Ctr, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ellegala, DB (corresponding author), Brigham & Womens Hosp, Cerebrovasc Ctr, 75 Francis St, Boston, MA 02115 USA.							Berman MF, 2003, STROKE, V34, P2200, DOI 10.1161/01.STR.0000086528.32334.06; Jane J A, 1977, Clin Neurosurg, V24, P176; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; SAMSON D, 1994, NEUROSURGERY, V34, P22; SELMAN WR, 1982, J NEUROSURG, V56, P685, DOI 10.3171/jns.1982.56.5.0685	5	20	22	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					121	124		10.1056/NEJMp048301	http://dx.doi.org/10.1056/NEJMp048301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647574				2022-12-28	WOS:000226251700004
J	Kusserow, A; Pang, K; Sturm, C; Hrouda, M; Lentfer, J; Schmidt, HA; Technau, U; von Haeseler, A; Hobmayer, B; Martindale, MQ; Holstein, TW				Kusserow, A; Pang, K; Sturm, C; Hrouda, M; Lentfer, J; Schmidt, HA; Technau, U; von Haeseler, A; Hobmayer, B; Martindale, MQ; Holstein, TW			Unexpected complexity of the Wnt gene family in a sea anemone	NATURE			English	Article							NEMATOSTELLA-VECTENSIS; EVOLUTION; ORIGINS; EXPRESSION; BRAIN; MESODERM; CNIDARIA; EMBRYOS; SYSTEM; PHYLUM	The Wnt gene family encodes secreted signalling molecules that control cell fate in animal development and human diseases(1). Despite its significance, the evolution of this metazoan-specific protein family is unclear. In vertebrates, twelve Wnt subfamilies were defined, of which only six have counterparts in Ecdysozoa (for example, Drosophila and Caenorhabditis)(2). Here, we report the isolation of twelve Wnt genes from the sea anemone Nematostella vectensis(3), a species representing the basal group(4) within cnidarians. Cnidarians are diploblastic animals and the sister-group to bilaterian metazoans(5). Phylogenetic analyses of N. vectensis Wnt genes reveal a thus far unpredicted ancestral diversity within the Wnt family(2,6,7). Cnidarians and bilaterians have at least eleven of the twelve known Wnt gene subfamilies in common; five subfamilies appear to be lost in the protostome lineage. Expression patterns of Wnt genes during N. vectensis embryogenesis indicate distinct roles of Wnts in gastrulation, resulting in serial overlapping expression domains along the primary axis of the planula larva. This unexpectedly complex inventory of Wnt family signalling factors evolved in early multicellular animals about 650 million years (Myr) ago, predating the Cambrian explosion by at least 100 Myr (refs 5, 8). It emphasizes the crucial function of Wnt genes in the diversification of eumetazoan body plans(9).	Univ Hawaii, Kewalo Marine Lab PBRC, Honolulu, HI 96813 USA; Tech Univ Darmstadt, Inst Zool, D-64287 Darmstadt, Germany; Univ Innsbruck, Inst Zool & Limnol, Ctr Mol Biosci Innsbruck, A-6020 Innsbruck, Austria; Forschungszentrum Julich, John von Neumann Inst Comp, D-52425 Julich, Germany; Univ Dusseldorf, Inst Bioinformat, D-40225 Dusseldorf, Germany; Univ Heidelberg, Dept Mol Evolut & genom, D-69120 Heidelberg, Germany	University of Hawaii System; Technical University of Darmstadt; University of Innsbruck; Helmholtz Association; Research Center Julich; Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg	Martindale, MQ (corresponding author), Univ Hawaii, Kewalo Marine Lab PBRC, 41 Ahui St, Honolulu, HI 96813 USA.	mqmartin@hawaii.edu; holstein@uni-hd.de	Schmidt, Heiko A/AAC-4650-2022; von Haeseler, Arndt/HCI-9958-2022	Schmidt, Heiko A/0000-0002-2311-8592; von Haeseler, Arndt/0000-0002-3366-4458; Technau, Ulrich/0000-0003-4472-8258; Holstein, Thomas/0000-0003-0480-4674				Angerer LM, 2003, CURR TOP DEV BIOL, V53, P159, DOI 10.1016/S0070-2153(03)53005-8; Ball EE, 2004, NAT REV GENET, V5, P567, DOI 10.1038/nrg1402; BRIDGE D, 1995, MOL BIOL EVOL, V12, P679; Christenson JC, 2001, J TRAVEL MED, V8, P1; Davidson B, 2003, P NATL ACAD SCI USA, V100, P11469, DOI 10.1073/pnas.1634991100; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Fritzenwanker JH, 2004, DEV BIOL, V275, P389, DOI 10.1016/j.ydbio.2004.08.014; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; Holland LZ, 2002, DEV BIOL, V241, P209, DOI 10.1006/dbio.2001.0503; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; Landesman Y, 1997, MECH DEVELOP, V63, P199, DOI 10.1016/S0925-4773(97)00041-5; Le Gouar M, 2004, DEV GENES EVOL, V214, P250, DOI 10.1007/s00427-004-0399-z; Lengyel JA, 2002, DEV BIOL, V243, P1, DOI 10.1006/dbio.2002.0577; Marsal M, 2003, GENE EXPR PATTERNS, V3, P489, DOI 10.1016/S1567-133X(03)00058-9; Martindale MQ, 2004, DEVELOPMENT, V131, P2463, DOI 10.1242/dev.01119; MCGREW LL, 1992, DEVELOPMENT, V115, P463; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Morris SC, 2000, P NATL ACAD SCI USA, V97, P4426, DOI 10.1073/pnas.97.9.4426; Nakagawa S, 2003, DEV BIOL, V260, P414, DOI 10.1016/S0012-1606(03)00320-8; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ng M, 2001, NAT REV GENET, V2, P186, DOI 10.1038/35056041; Nusse R, 2001, TRENDS GENET, V17, P443, DOI 10.1016/S0168-9525(01)02349-6; Peterson KJ, 2004, P NATL ACAD SCI USA, V101, P6536, DOI 10.1073/pnas.0401670101; Primus A, 2004, BIOESSAYS, V26, P474, DOI 10.1002/bies.20031; Prud'homme B, 2002, CURR BIOL, V12, P1395, DOI 10.1016/S0960-9822(02)01068-0; SALVINIPLAWEN LV, 1978, Z ZOOL SYST EVOL, V16, P40; Technau U, 2003, INT J DEV BIOL, V47, P531; Vinh LS, 2004, MOL BIOL EVOL, V21, P1565, DOI 10.1093/molbev/msh176	30	439	457	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					156	160		10.1038/nature03158	http://dx.doi.org/10.1038/nature03158			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650739				2022-12-28	WOS:000226252200037
J	Shahinian, VB; Kuo, Y; Freeman, JL; Goodwin, JS				Shahinian, VB; Kuo, Y; Freeman, JL; Goodwin, JS			Risk of fracture after androgen deprivation for prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVENT BONE LOSS; HORMONAL-THERAPY; OSTEOPOROSIS; MEDICARE; MEN; CARCINOMA; CLAIMS; SUPPRESSION; PATTERNS; SURVIVAL	Background: The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied. Methods: We studied the records of 50,613 men who were listed in the linked database of the Surveillance, Epidemiology, and End Results program and Medicare as having received a diagnosis of prostate cancer in the period from 1992 through 1997. The primary outcomes were the occurrence of any fracture and the occurrence of a fracture resulting in hospitalization. Cox proportional-hazards analyses were adjusted for characteristics of the patients and the cancer, other cancer treatment received, and the occurrence of a fracture or the diagnosis of osteoporosis during the 12 months preceding the diagnosis of cancer. Results: Of men surviving at least five years after diagnosis, 19.4 percent of those who received androgen-deprivation therapy had a fracture, as compared with 12.6 percent of those not receiving androgen-deprivation therapy (P<0.001). In the Cox proportional-hazards analyses, adjusted for characteristics of the patient and the tumor, there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fracture. Conclusions: Androgen-deprivation therapy for prostate cancer increases the risk of fracture.	Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Shahinian, VB (corresponding author), Univ Texas, Med Branch, Dept Internal Med, John Sealy Annex,Rm 4-200,301 Univ Blvd, Galveston, TX 77555 USA.	vbshahin@utmb.edu			NATIONAL CANCER INSTITUTE [P50CA105631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024832] Funding Source: NIH RePORTER; AHRQ HHS [R24HS51161] Funding Source: Medline; NCI NIH HHS [P50CA12385, P50 CA105631-01] Funding Source: Medline; NIA NIH HHS [P30 AG024832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Awodipe A, 2004, J AM GERIATR SOC, V52, pS162; Beahrs OH, 1988, MANUAL STAGING CANC, P177; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chodak GW, 2002, UROLOGY, V60, P201, DOI 10.1016/S0090-4295(02)01677-1; Cooper GS, 2000, MED CARE, V38, P411, DOI 10.1097/00005650-200004000-00008; Cooperberg MR, 2003, J NATL CANCER I, V95, P981, DOI 10.1093/jnci/95.13.981; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022-5347(05)68000-7; Diamond TH, 2004, CANCER-AM CANCER SOC, V100, P892, DOI 10.1002/cncr.20056; Du XL, 1999, J CLIN EPIDEMIOL, V52, P463, DOI 10.1016/S0895-4356(99)00011-6; Fleming ID, 1997, AJCC CANC STAGING MA, P219; Fowler FJ, 2002, CANCER-AM CANCER SOC, V95, P287, DOI 10.1002/cncr.10656; GREENE FL, 2002, AJCC CANC STAGING MA, P310; Harlan LC, 2001, J NATL CANCER I, V93, P1864, DOI 10.1093/jnci/93.24.1864; Huggins C, 1941, CANCER RES, V1, P293; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Lamont EB, 2002, MED CARE, V40, P201, DOI 10.1097/00005650-200203000-00004; Melton LJ, 2003, J UROLOGY, V169, P1747, DOI 10.1097/01.ju.0000059281.67667.97; Meng MV, 2002, UROLOGY, V60, P7, DOI 10.1016/S0090-4295(02)01560-1; Milbank AJ, 2002, UROLOGY, V60, P738, DOI 10.1016/S0090-4295(02)01867-8; Mittan D, 2002, J CLIN ENDOCR METAB, V87, P3656, DOI 10.1210/jc.87.8.3656; Morote J, 2003, EUR UROL, V44, P661, DOI 10.1016/S0302-2838(03)00379-8; Oefelein MG, 2002, J UROLOGY, V168, P1005, DOI 10.1016/S0022-5347(05)64561-2; Oefelein MG, 2001, J UROLOGY, V166, P1724, DOI 10.1016/S0022-5347(05)65661-3; RAY WA, 1992, J CLIN EPIDEMIOL, V45, P703, DOI 10.1016/0895-4356(92)90047-Q; Ross RW, 2002, J UROLOGY, V167, P1952, DOI 10.1016/S0022-5347(05)65060-4; Smith MR, 2002, UROLOGY, V60, P79, DOI 10.1016/S0090-4295(02)01579-0; Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95; Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845; Soloway MS, 2002, UROLOGY, V60, P735, DOI 10.1016/S0090-4295(02)01964-7; Townsend MF, 1997, CANCER, V79, P545, DOI 10.1002/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3; Virnig BA, 2002, MED CARE, V40, P49; Warren JL, 2002, MED CARE, V40, P3; Wei JT, 1999, UROLOGY, V54, P607, DOI 10.1016/S0090-4295(99)00301-5	35	966	983	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					154	164		10.1056/NEJMoa041943	http://dx.doi.org/10.1056/NEJMoa041943			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647578	Bronze			2022-12-28	WOS:000226251700008
J	Larsson, SC; Bergkvist, L; Wolk, A				Larsson, SC; Bergkvist, L; Wolk, A			Magnesium intake in relation to risk of colorectal cancer in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LARGE-BOWEL CARCINOGENESIS; METHYLAZOXYMETHANOL ACETATE; CELL-PROLIFERATION; C-PEPTIDE; HYDROXIDE; RATS; ASSOCIATION; COLON	Context Animal studies have suggested that dietary magnesium may play a role in the prevention of colorectal cancer, but data in humans are lacking. Objective To evaluate the hypothesis that a high magnesium intake reduces the risk of colorectal cancer in women. Design, Setting, and Participants The Swedish Mammography Cohort, a population-based prospective cohort of 61433 women aged 40 to 75 years without previous diagnosis of cancer at baseline from 1987 to 1990. Main Outcome Measure Incident invasive colorectal cancer. Results During a mean of 14.8 years (911042 person-years) of follow-up, 805 incident colorectal cancer cases were diagnosed. After adjustment for potential confounders, we observed an inverse association of magnesium intake with the risk of colorectal cancer (P for trend=.006). Compared with women in the lowest quintile of magnesium intake, the multivariate rate ratio (RR) was 0.59 (95% confidence interval [CI], 0.40-0.87) for those in the highest quintile. The inverse association was observed for both colon (RR, 0.66; 95% CI, 0.41-1.07) and rectal cancer (RR, 0.45; 95% CI, 0.22-0.89). Conclusion This population-based prospective study suggests that a high magnesium intake may reduce the occurrence of colorectal cancer in women.	Karolinska Inst, Natl Inst Environm Med, Div Nutr Epidemiol, SE-17177 Stockholm, Sweden; Cent Hosp Vasteras, Clin Res Ctr, Vasteras, Sweden; Cent Hosp Vasteras, Dept Surg, Vasteras, Sweden	Karolinska Institutet; Vasteras Central Hospital; Vasteras Central Hospital	Larsson, SC (corresponding author), Karolinska Inst, Natl Inst Environm Med, Div Nutr Epidemiol, POB 210, SE-17177 Stockholm, Sweden.	susanna.larsson@imm.ki.se	Larsson, Susanna C./F-6065-2015	Larsson, Susanna C./0000-0003-0118-0341				Bergstrom L., 1991, Var Foda, V43, P439; Cox D. R., 1984, ANAL SURVIVAL DATA; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Fung TT, 2003, J AM COLL NUTR, V22, P533, DOI 10.1080/07315724.2003.10719332; Gueux E, 1995, BRIT J NUTR, V74, P849, DOI 10.1079/BJN19950011; Hans CP, 2003, MAGNESIUM RES, V16, P13; Hartwig A, 2001, MUTAT RES-FUND MOL M, V475, P113, DOI 10.1016/S0027-5107(01)00074-4; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; Ma J, 2004, JNCI-J NATL CANCER I, V96, P546, DOI 10.1093/jnci/djh082; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MORI H, 1992, CANCER LETT, V62, P43, DOI 10.1016/0304-3835(92)90196-3; MORI H, 1993, BASIC LIFE SCI, V61, P111; PAOLISSO G, 1989, DIABETES CARE, V12, P265, DOI 10.2337/diacare.12.4.265; PAOLISSO G, 1992, AM J CLIN NUTR, V55, P1161, DOI 10.1093/ajcn/55.6.1161; Rothman K., 1998, MODERN EPIDEMIOLOGY; SJOGREN A, 1988, MAGNESIUM, V7, P117; Song YQ, 2004, DIABETES CARE, V27, P59, DOI 10.2337/diacare.27.1.59; TANAKA T, 1989, CARCINOGENESIS, V10, P613, DOI 10.1093/carcin/10.3.613; WANG A, 1994, CARCINOGENESIS, V15, P2661, DOI 10.1093/carcin/15.11.2661; WANG A, 1993, CANCER LETT, V75, P73, DOI 10.1016/0304-3835(93)90190-K; Willett W., 2012, NUTR EPIDEMIOLOGY; Wolk A, 1998, ARCH INTERN MED, V158, P41, DOI 10.1001/archinte.158.1.41	22	81	81	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					86	89		10.1001/jama.293.1.86	http://dx.doi.org/10.1001/jama.293.1.86			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632340	Bronze			2022-12-28	WOS:000226102100025
J	Astrup, A				Astrup, A			Super-sized and diabetic by frequent fast-food consumption?	LANCET			English	Editorial Material									RVA Univ, Ctr Adv Food Res, Dept Human Nutr, DK-1958 Frederiksberg C, Denmark		Astrup, A (corresponding author), RVA Univ, Ctr Adv Food Res, Dept Human Nutr, DK-1958 Frederiksberg C, Denmark.	ast@kvl.dk	Astrup, Arne/B-1407-2015	Astrup, Arne/0000-0001-8968-8996				Astrup A, 2004, Obes Rev, V5, P89, DOI 10.1111/j.1467-789X.2003.00129.x; Diliberti N, 2004, OBES RES, V12, P562, DOI 10.1038/oby.2004.64; Nielsen Samara Joy, 2003, JAMA (Journal of the American Medical Association), V289, P450, DOI 10.1001/jama.289.4.450; Prentice A M, 2003, Obes Rev, V4, P187, DOI 10.1046/j.1467-789X.2003.00117.x; Ranney C. K., 2004, NUTR TODAY, V39, P161, DOI DOI 10.1097/00017285-200407000-00006	5	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					4	5		10.1016/S0140-6736(04)17674-5	http://dx.doi.org/10.1016/S0140-6736(04)17674-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639659				2022-12-28	WOS:000226213100003
J	de Andrade, ALSS; Martelli, CMT				de Andrade, ALSS; Martelli, CMT			Globalisation of Hib vaccination - how far are we?	LANCET			English	Editorial Material							PNEUMONIA; CONJUGATE; BURDEN		Univ Fed Goias, Dept Saude Coletiva, BR-74605050 Goiania, Go, Brazil	Universidade Federal de Goias	de Andrade, ALSS (corresponding author), Univ Fed Goias, Dept Saude Coletiva, S Univ, BR-74605050 Goiania, Go, Brazil.	ana@iptsp.ufg.br		Turchi Martelli, Celina Maria/0000-0002-2491-0688				[Anonymous], 2004, Wkly Epidemiol Rec, V79, P173; de Andrade ALSS, 2004, INT J EPIDEMIOL, V33, P173, DOI 10.1093/ije/dyh025; DELAHOZ F, IN PRESS VACCINE; Djelantik IGG, 2003, PEDIATR INFECT DIS J, V22, P150, DOI 10.1097/00006454-200302000-00012; Levine OS, 1999, PEDIATR INFECT DIS J, V18, P1060, DOI 10.1097/00006454-199912000-00006; Madhi SA, 2002, PEDIATR INFECT DIS J, V21, P393, DOI 10.1097/00006454-200205000-00009; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Watt JP, 2003, J PEDIATR-US, V143, pS163, DOI 10.1067/S0022-3476(03)00576-6; *WHO, COUNTR IMPL ROUT CHI	9	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					5	7						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639660				2022-12-28	WOS:000226213100004
J	Gessner, BD; Sutanto, A; Linehan, M; Djelantik, IGG; Fletcher, T; Gerudug, IK; Ingerani; Mercer, D; Moniaga, V; Moulton, LH; Mulholland, K; Nelson, C; Soemohardjo, S; Steinhoff, M; Widjaya, A; Stoeckel, P; Maynard, J; Arjoso, S				Gessner, BD; Sutanto, A; Linehan, M; Djelantik, IGG; Fletcher, T; Gerudug, IK; Ingerani; Mercer, D; Moniaga, V; Moulton, LH; Mulholland, K; Nelson, C; Soemohardjo, S; Steinhoff, M; Widjaya, A; Stoeckel, P; Maynard, J; Arjoso, S			Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe	LANCET			English	Article							DEVELOPING-COUNTRIES; RESPIRATORY ILLNESS; CHILDHOOD MORTALITY; LOMBOK ISLAND; CONJUGATE; TRIAL; INFANTS; BURDEN; AGE; IMMUNOGENICITY	Background Most studies of Haemophilus influenzae type b (Hib) disease in Asia have found low rates, and few Asian countries use Hib vaccine in routine immunisation programmes. Whether Hib disease truly is rare or whether many cases remain undetected is unclear. Methods To estimate incidences of vaccine-preventable Hib pneumonia and meningitis among children younger than 2 years in Lombok, Indonesia, during 1998-2002, we undertook a hamlet-randomised, controlled, double-blind vaccine-probe study (818 hamlets). Children were immunised (WHO schedule) with diphtheria, tetanus, pertussis (DTP) or DTP-PRP-T (Hib conjugate) vaccine. Vaccine-preventable disease incidences were calculated as the difference in rates of clinical outcomes between DTP and DTP-PRP-T groups. Analyses included all children who received at least one vaccine dose. Findings We enrolled 55 073 children: 28 147 were assigned DTP-PRP-T and 26 926 DTP. The proportion of pneumonia outcomes prevented by vaccine ranged from less than 0 to 4.8%. Calculated incidences of vaccine-preventable Hib disease (per 10(5) child-years of observation) for outcome categories were: substantial alveolar consolidation or effusion, less than zero (-43 [95% CI -185 to 98]); all severe pneumonia, 264 (95% CI less than zero to 629); all clinical pneumonia, 1561 (270 to 2853); confirmed Hib meningitis, 16 (1.4 to 31); meningitis with cerebrospinal-fluid findings consistent with a bacterial aetiology, 67 (22 to 112); and admission for suspected meningitis or presenting to a clinic with convulsions, 158 (42 to 273). Interpretation Hib vaccine did not prevent the great majority of pneumonia cases, including those with alveolar consolidation. These results do not support a major role for Hib vaccine in overall pneumonia-prevention programmes. Nevertheless, the study identified high incidences of Hib meningitis and pneumonia; inclusion of Hib vaccine in routine infant immunisation programmes in Asia deserves consideration.	Inst Pasteur, Assoc Aide Med Prevent, F-75015 Paris, France; W Nusa Tenggara Prov Govt, Lombok, Indonesia; Program Appropriate Technol Hlth, Seattle, WA USA; Program Appropriate Technol Hlth, Jakarta, Indonesia; Program Appropriate Technol Hlth, Lombok, Indonesia; Indonesian Minist Hlth, Jakarta, Indonesia; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Univ Melbourne, Melbourne, Vic, Australia	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ministry of Health - Indonesia; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Melbourne	Gessner, BD (corresponding author), Inst Pasteur, Assoc Aide Med Prevent, 28 Rue Docteur Roux, F-75015 Paris, France.	106617.3011@compuserve.com		Moulton, Lawrence/0000-0001-7041-7387				Amir J, 1997, VACCINE, V15, P149, DOI 10.1016/S0264-410X(96)00162-4; BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; BANG AT, 1992, B WORLD HEALTH ORGAN, V70, P499; BLACKWELDER WC, 1993, STAT MED, V12, P691, DOI 10.1002/sim.4780120708; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; Corless CE, 2001, J CLIN MICROBIOL, V39, P1553, DOI 10.1128/JCM.39.4.1553-1558.2001; de Andrade ALSS, 2004, INT J EPIDEMIOL, V33, P173, DOI 10.1093/ije/dyh025; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; DECKER MD, 1998, PEDIAT INFECT DIS S, V17, pS92; Djelantik IGG, 2003, PEDIATR INFECT DIS J, V22, P150, DOI 10.1097/00006454-200302000-00012; Gessner BD, 2002, EUR J CLIN MICROBIOL, V21, P79, DOI 10.1007/s10096-001-0667-z; Gessner BD, 2002, EUR J CLIN MICROBIOL, V21, P569, DOI 10.1007/s10096-002-0787-0; Gessner BD, 1998, PEDIATR INFECT DIS J, V17, pS179, DOI 10.1097/00006454-199809001-00018; GRANOFF DM, 1992, J PEDIATR-US, V121, P187, DOI 10.1016/S0022-3476(05)81186-2; HUSSEY G, 1994, ANN TROP PAEDIATR, V14, P97, DOI 10.1080/02724936.1994.11747700; Lachenbruch PA, 1998, CONTROL CLIN TRIALS, V19, P569, DOI 10.1016/S0197-2456(98)00042-7; Levine OS, 1999, PEDIATR INFECT DIS J, V18, P1060, DOI 10.1097/00006454-199912000-00006; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Molyneux EM, 2002, LANCET, V360, P211, DOI 10.1016/S0140-6736(02)09458-8; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Nelson CM, 2000, J HEALTH POPUL NUTR, V18, P131; PANDEY MR, 1991, LANCET, V338, P993, DOI 10.1016/0140-6736(91)91847-N; Peltola H, 1999, B WORLD HEALTH ORGAN, V77, P878; Qureshi H, 2000, VACCINE, V18, P2956, DOI 10.1016/S0264-410X(00)00116-X; Sutanto A, 2002, AM J TROP MED HYG, V66, P175, DOI 10.4269/ajtmh.2002.66.175; Trotter CL, 2003, LANCET, V361, P1523, DOI 10.1016/S0140-6736(03)13172-8; *WHO, WHOEPIGEN9801 DEP VA; *WHO, WHOARI9120 PROGR CON; *WHO, WHOVB0218 DEP VACC B; *WHO, WHOCDSCSREDC997; *WHO, WHOVRDGEN9505 GLOB P; *WHO, WHOVB0135 DEP VACC B; *WHO, WHOVB0127 DEP VACC B; Wilson N, 2003, VACCINE, V21, P1907, DOI 10.1016/S0264-410X(02)00825-3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	35	152	161	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					43	52		10.1016/S0140-6736(04)17664-2	http://dx.doi.org/10.1016/S0140-6736(04)17664-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15643700				2022-12-28	WOS:000226213100027
J	Augenbraun, E				Augenbraun, E			Weapon of mass attraction	NATURE			English	Editorial Material							SCIENCE		ScienCentral, New York, NY 10001 USA		Augenbraun, E (corresponding author), ScienCentral, 248 W 35th St, New York, NY 10001 USA.							BORCHELT R, 2002, COMMUNICATING FUTURE, P61; Brown CP, 2004, SCI COMMUN, V25, P294, DOI 10.1177/1075547003262599; Miller J.D., 1997, PUBLIC PERCEPTIONS S; *NSF, 2004, NSF SCI ENG IND; Sternberg R. J., 2003, ATHEORY WISDOM INTEL; Sturgis P, 2004, PUBLIC UNDERST SCI, V13, P55, DOI 10.1177/0963662504042690; 2004, STATE NEWS MEDIA	7	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2005	433	7024					357	358		10.1038/433357a	http://dx.doi.org/10.1038/433357a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674266				2022-12-28	WOS:000226546200018
J	Hessa, T; Kim, H; Bihlmaier, K; Lundin, C; Boekel, J; Andersson, H; Nilsson, I; White, SH; von Heijne, G				Hessa, T; Kim, H; Bihlmaier, K; Lundin, C; Boekel, J; Andersson, H; Nilsson, I; White, SH; von Heijne, G			Recognition of transmembrane helices by the endoplasmic reticulum translocon	NATURE			English	Article							SEMLIKI-FOREST-VIRUS; MEMBRANE-PROTEIN; PEPTIDES; INTEGRATION; PREDICTION; INTERFACES; STABILITY; SEQUENCE; CHANNEL; DOMAIN	Membrane proteins depend on complex translocation machineries for insertion into target membranes. Although it has long been known that an abundance of nonpolar residues in transmembrane helices is the principal criterion for membrane insertion, the specific sequence-coding for transmembrane helices has not been identified. By challenging the endoplasmic reticulum Sec61 translocon with an extensive set of designed polypeptide segments, we have determined the basic features of this code, including a 'biological' hydrophobicity scale. We find that membrane insertion depends strongly on the position of polar residues within transmembrane segments, adding a new dimension to the problem of predicting transmembrane helices from amino acid sequences. Our results indicate that direct protein - lipid interactions are critical during translocon-mediated membrane insertion.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Karolinska Inst, NOVUM, Dept Biosci, SE-14157 Huddinge, Sweden	Stockholm University; University of California System; University of California Irvine; University of California System; University of California Irvine; Karolinska Institutet	von Heijne, G (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	gunnar@dbb.su.se	Nilsson, IngMarie/H-2887-2012; White, Stephen H/B-1053-2009; von Heijne, Gunnar/F-5576-2011; White, Stephen/N-1507-2019; von Heijne, Gunnar/AAH-9389-2019	White, Stephen H/0000-0001-8540-7907; von Heijne, Gunnar/0000-0002-4490-8569; Kallgren, Carolina/0000-0002-2372-9721; Boekel, Carolina/0000-0003-2862-6526				Alder NN, 2004, J BIOL CHEM, V279, P22787, DOI 10.1074/jbc.R400002200; Anthony V, 2002, CURR PROTEIN PEPT SC, V3, P485, DOI 10.2174/1389203023380503; Bechinger B, 2001, BIOPHYS J, V81, P2251, DOI 10.1016/S0006-3495(01)75872-9; Beuming T, 2004, BIOINFORMATICS, V20, P1822, DOI 10.1093/bioinformatics/bth143; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; DEGLIESPOSTI M, 1990, EUR J BIOCHEM, V190, P207, DOI 10.1111/j.1432-1033.1990.tb15566.x; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Jayasinghe S, 2001, J MOL BIOL, V312, P927, DOI 10.1006/jmbi.2001.5008; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; Lewis RNAH, 2001, BIOCHEMISTRY-US, V40, P12103, DOI 10.1021/bi010555m; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Lu LP, 1998, BIOPOLYMERS, V47, P41, DOI 10.1002/(SICI)1097-0282(1998)47:1<41::AID-BIP6>3.0.CO;2-X; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; Rapoport TA, 2004, TRENDS CELL BIOL, V14, P568, DOI 10.1016/j.tcb.2004.09.002; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Saaf A, 1998, EUR J BIOCHEM, V251, P821, DOI 10.1046/j.1432-1327.1998.2510821.x; Snapp EL, 2004, J CELL BIOL, V164, P997, DOI 10.1083/jcb.200312079; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Von Heijne G, 2003, ADV PROTEIN CHEM, V63, P1; von Heijne G, 1999, Q REV BIOPHYS, V32, P285, DOI 10.1017/S0033583500003541; Wallin E, 1997, PROTEIN SCI, V6, P808; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wimley WC, 1996, BIOCHEMISTRY-US, V35, P5109, DOI 10.1021/bi9600153; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Yohannan S, 2004, J MOL BIOL, V341, P1, DOI 10.1016/j.jmb.2004.06.025	36	776	797	1	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					377	381		10.1038/nature03216	http://dx.doi.org/10.1038/nature03216			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674282				2022-12-28	WOS:000226546200033
J	Hoskinson, E; Packard, RE; Haard, TM				Hoskinson, E; Packard, RE; Haard, TM			Oscillatory motion - Quantum whistling in superfluid helium-4	NATURE			English	Editorial Material							ROTATION		Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Hoskinson, E (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	packard@socrates.berkeley.edu						AVENEL O, 1985, PHYS REV LETT, V55, P2704, DOI 10.1103/PhysRevLett.55.2704; Avenel O, 1997, PHYS REV LETT, V78, P3602, DOI 10.1103/PhysRevLett.78.3602; Backhaus S, 1998, PHYS REV LETT, V81, P1893, DOI 10.1103/PhysRevLett.81.1893; Chui T, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.085301; Davis JC, 2002, REV MOD PHYS, V74, P741, DOI 10.1103/RevModPhys.74.741; PACKARD RE, 1992, PHYS REV B, V45, P2512, DOI 10.1103/PhysRevB.45.2512; PACKARD RE, 1992, PHYS REV B, V46, P3540, DOI 10.1103/PhysRevB.46.3540; Pereverzev SV, 1997, NATURE, V388, P449, DOI 10.1038/41277; Schwab K, 1997, NATURE, V386, P585, DOI 10.1038/386585a0; Simmonds RW, 2001, NATURE, V412, P55, DOI 10.1038/35083518; Sukhatme K, 2001, NATURE, V411, P280, DOI 10.1038/35077024; TILLEY DR, 1990, SUPERFLUIDITY SUPERC, pCH7; VanDuzer T., 1999, SUPERCONDUCTIVE DEVI	13	41	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					376	376		10.1038/433376a	http://dx.doi.org/10.1038/433376a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674281	Green Submitted, Bronze			2022-12-28	WOS:000226546200032
J	Quinlan, ME; Heuser, JE; Kerkhoff, E; Mullins, RD				Quinlan, ME; Heuser, JE; Kerkhoff, E; Mullins, RD			Drosophila Spire is an actin nucleation factor	NATURE			English	Article							MESSENGER-RNA LOCALIZATION; WISKOTT-ALDRICH-SYNDROME; ARP2/3 COMPLEX; FILAMENT NUCLEATION; WASP/SCAR PROTEINS; STRUCTURAL BASIS; FISSION YEAST; FORMINS; OOCYTE; RAB11	The actin cytoskeleton is essential for many cellular functions including shape determination, intracellular transport and locomotion. Previous work has identified two factors - the Arp2/3 complex and the formin family of proteins - that nucleate new actin filaments via different mechanisms. Here we show that the Drosophila protein Spire represents a third class of actin nucleation factor. In vitro, Spire nucleates new filaments at a rate that is similar to that of the formin family of proteins but slower than in the activated Arp2/3 complex, and it remains associated with the slow-growing pointed end of the new filament. Spire contains a cluster of four WASP homology 2 (WH2) domains, each of which binds an actin monomer. Maximal nucleation activity requires all four WH2 domains along with an additional actin-binding motif, conserved among Spire proteins. Spire itself is conserved among metazoans and, together with the formin Cappuccino, is required for axis specification in oocytes and embryos, suggesting that multiple actin nucleation factors collaborate to construct essential cytoskeletal structures.	Univ Calif San Francisco, Sch Med, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of California System; University of California San Francisco; Washington University (WUSTL); University of Wurzburg	Mullins, RD (corresponding author), Univ Calif San Francisco, Sch Med, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA.	dyche@mullinslab.ucsf.edu	Heuser, John/H-5940-2012					Abo A, 1998, CELL MOL LIFE SCI, V54, P1145, DOI 10.1007/s000180050242; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Dayel MJ, 2004, PLOS BIOL, V2, P476, DOI 10.1371/journal.pbio.0020091; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; Dollar G, 2002, DEVELOPMENT, V129, P517; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; Evangelista Marie, 2002, Nature Cell Biology, V4, P260; Fehrenbacher K, 2003, J EXP BIOL, V206, P1977, DOI 10.1242/jeb.00240; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; Hertzog M, 2002, J BIOL CHEM, V277, P14786, DOI 10.1074/jbc.M112064200; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Irobi E, 2004, EMBO J, V23, P3599, DOI 10.1038/sj.emboj.7600372; Jankovics F, 2001, GENETICS, V158, P1177; Kerkhoff E, 2001, CURR BIOL, V11, P1963, DOI 10.1016/S0960-9822(01)00602-9; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Manseau L, 1996, DEVELOPMENT, V122, P2109; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; O'Rourke DA, 2000, J AM SOC NEPHROL, V11, P2212, DOI 10.1681/ASN.V11122212; Otto IM, 2000, CURR BIOL, V10, P345, DOI 10.1016/S0960-9822(00)00388-2; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Paunola E, 2002, FEBS LETT, V513, P92, DOI 10.1016/S0014-5793(01)03242-2; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Schumacher N, 2004, GENE EXPR PATTERNS, V4, P249, DOI 10.1016/j.modgep.2003.11.006; Sept D, 2001, BIOPHYS J, V81, P667, DOI 10.1016/S0006-3495(01)75731-1; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Wellington A, 1999, DEVELOPMENT, V126, P5267; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	34	253	259	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					382	388		10.1038/nature03241	http://dx.doi.org/10.1038/nature03241			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674283				2022-12-28	WOS:000226546200034
J	Stone, JH; Hoffman, GS; Holbrook, JT; Meinert, CL; Dodge, J; Donithan, J; Min, N; Murrow, L; Oziemkowska, M; Smith, J; Tibbs, AK; Van Natta, M; Spiera, R; Abeynayake, I; Berman, R; Enuha, S; Merkel, PA; Gelbard, R; Nuite, M; Schiller, A; Hoffman, GS; Blumenthal, D; Bork, D; Clark, T; Crook, SL; Calabrese, LH; Farkas, S; Sridharan, S; Strom, K; Wilke, W; St Clair, EW; Allen, NB; Rodin, K; Scarlett, E; Stone, JH; Hellmann, DB; Marriott, MA; Moore, AM; Pinachos, L; Regan, MJ; Uhlfelder, ML; Specks, U; Bradt, K; Carlson, K; Fisher, S; Hammel, B; Mieras, K; Ytterberg, S; Davis, JC; Duhme, AM; Fitzpatrick, M; Fye, K; Lund, S; McCune, J; Coomer, BJ; Gilson, B; Haftel, H; Morrel-Samuels, A; Neckel, S; Rose, NR; Burek, CL; Barin, J; Talor, M; Canner, PL; Conn, DL; Klippel, JH; Landis, JR				Stone, JH; Hoffman, GS; Holbrook, JT; Meinert, CL; Dodge, J; Donithan, J; Min, N; Murrow, L; Oziemkowska, M; Smith, J; Tibbs, AK; Van Natta, M; Spiera, R; Abeynayake, I; Berman, R; Enuha, S; Merkel, PA; Gelbard, R; Nuite, M; Schiller, A; Hoffman, GS; Blumenthal, D; Bork, D; Clark, T; Crook, SL; Calabrese, LH; Farkas, S; Sridharan, S; Strom, K; Wilke, W; St Clair, EW; Allen, NB; Rodin, K; Scarlett, E; Stone, JH; Hellmann, DB; Marriott, MA; Moore, AM; Pinachos, L; Regan, MJ; Uhlfelder, ML; Specks, U; Bradt, K; Carlson, K; Fisher, S; Hammel, B; Mieras, K; Ytterberg, S; Davis, JC; Duhme, AM; Fitzpatrick, M; Fye, K; Lund, S; McCune, J; Coomer, BJ; Gilson, B; Haftel, H; Morrel-Samuels, A; Neckel, S; Rose, NR; Burek, CL; Barin, J; Talor, M; Canner, PL; Conn, DL; Klippel, JH; Landis, JR		WEGT Res Grp	Etanercept plus standard therapy for Wegener's granulomatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; FACTOR RECEPTOR; CROHNS-DISEASE; TNF-ALPHA; SYSTEMIC VASCULITIDES; RHEUMATOID-ARTHRITIS; RANDOMIZED-TRIAL; INFLIXIMAB; REGRESSION	BACKGROUND: The majority of patients with Wegener's granulomatosis have disease flares after conventional medications are tapered. There is no consistently safe, effective treatment for the maintenance of remission. METHODS: We conducted a randomized, placebo-controlled trial at eight centers to evaluate etanercept for the maintenance of remission in 180 patients with Wegener's granulomatosis. The primary outcome was sustained remission, defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis of 0 for at least six months (scores can range from 0 to 67, with higher scores indicating more active disease). In addition to etanercept or placebo, patients received standard therapy (glucocorticoids plus cyclophosphamide or methotrexate). After remission, standard medications were tapered according to the protocol. RESULTS: The mean follow-up for the overall cohort was 27 months. Of the 174 patients who could be evaluated, 126 (72.4 percent) had a sustained remission, but only 86 (49.4 percent) remained in remission for the remainder of the trial. There were no significant differences between the etanercept and control groups in the rates of sustained remission (69.7 percent vs. 75.3 percent, P=0.39), sustained periods of low-level disease activity (86.5 percent vs. 90.6 percent, P=0.32), or the time required to achieve those measures. Disease flares were common in both groups, with 118 flares in the etanercept group (23 severe and 95 limited) and 134 in the control group (25 severe and 109 limited). There was no significant difference between the etanercept and control groups in the relative risk of disease flares per 100 person-years of follow-up (0.89, P=0.54). During the study, 56.2 percent of patients in the etanercept group and 57.1 percent of those in the control group had at least one severe or life-threatening adverse event or died (P=0.90). Solid cancers developed in six patients in the etanercept group, as compared with none in the control group (P=0.01). CONCLUSIONS: Etanercept is not effective for the maintenance of remission in patients with Wegener's granulomatosis. Durable remissions were achieved in only a minority of the patients, and there was a high rate of treatment-related complications.	Johns Hopkins Vasculitis Ctr, Baltimore, MD 21224 USA; Cleveland Clin Fdn, Ctr Vasculitis Care & Res, Cleveland, OH USA; Johns Hopkins Univ, Ctr Clin Trials, Baltimore, MD 21218 USA; Beth Israel Med Ctr, New York, NY 10003 USA; Boston Univ, Boston, MA 02215 USA; Duke Univ, Durham, NC 27706 USA; Mayo Clin, Rochester, MN USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Immune Dis Lab, Baltimore, MD 21218 USA; Maryland Med Res Inst, Baltimore, MD USA; Emory Univ, Atlanta, GA 30322 USA; Arthrit Fdn, Atlanta, GA 30309 USA; Univ Penn, Philadelphia, PA 19104 USA	Johns Hopkins University; Cleveland Clinic Foundation; Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Boston University; Duke University; Mayo Clinic; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; Johns Hopkins University; Emory University; University of Pennsylvania	Stone, JH (corresponding author), Johns Hopkins Vasculitis Ctr, 5501 Hopkins Bayview Cir,JHAAC 1B-23, Baltimore, MD 21224 USA.	jstone@jhmi.edu	Spiera, Robert/W-7479-2019; Landis, J. Richard/A-9330-2010	Min, Yuan-I/0000-0003-2470-0004	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719, M01RR000533, M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR092240] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RRO-2719, M01-RRO-0042, M01-RRO-00533] Funding Source: Medline; NIAMS NIH HHS [N01-AR-9-2240] Funding Source: Medline; FDA HHS [FD-R-001652-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FDA HHS		Bartolucci P, 2002, RHEUMATOLOGY, V41, P1126, DOI 10.1093/rheumatology/41.10.1126; Booth A. D., 2003, Kidney & Blood Pressure Research, V26, P292; BRESLOW N, 1990, J AM STAT ASSOC, V85, P565, DOI 10.2307/2289799; CANNER PL, 1991, CONTROL CLIN TRIALS, V12, P359, DOI 10.1016/0197-2456(91)90016-F; COX DR, 1972, J R STAT SOC B, V34, P187; Davis JC, 2003, ARTHRITIS RHEUM, V48, P3230, DOI 10.1002/art.11325; Exley AR, 1997, ARTHRITIS RHEUM, V40, P371, DOI 10.1002/art.1780400222; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hopkins J, 2003, ARTHRITIS RHEUM-US, V48, P2299, DOI 10.1002/art.11075; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Lamprecht P, 2002, RHEUMATOLOGY, V41, P1303, DOI 10.1093/rheumatology/41.11.1303; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Ludviksson BR, 1998, J IMMUNOL, V160, P3602; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; MERKEL PA, IN PRESS ANN INTERN; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Nassonov EL, 1997, J RHEUMATOL, V24, P666; *NAT CANC I, TOX GRAD SCAL; NORONHA IL, 1993, KIDNEY INT, V43, P682, DOI 10.1038/ki.1993.98; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; ReinholdKeller E, 2000, ARTHRITIS RHEUM, V43, P2379; Sandborn WJ, 2001, GASTROENTEROLOGY, V121, P1088, DOI 10.1053/gast.2001.28674; *SEER, 2005, SEER PROGR DAT; Stone JH, 2002, CONTROL CLIN TRIALS, V23, P450; Stone JH, 2001, ARTHRITIS RHEUM, V44, P912, DOI 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5; Stone JH, 2001, ARTHRITIS RHEUM, V44, P1149, DOI 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.3.CO;2-6; Utz JP, 2003, CHEST, V124, P177, DOI 10.1378/chest.124.1.177; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	34	622	638	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					351	361						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673801				2022-12-28	WOS:000226535900007
J	Kurner, J; Frangakis, AS; Baumeister, W				Kurner, J; Frangakis, AS; Baumeister, W			Cryo-electron tomography reveals the cytoskeletal structure of Spiroplasma melliferum	SCIENCE			English	Article							ELECTRON TOMOGRAPHY; ESCHERICHIA-COLI; CELL-SHAPE; PROTEIN; ORGANIZATION; MOLLICUTES; BACTERIA; SEQUENCE; FIBRILS; MOTOR	Evidence has accumulated recently that not only eukaryotes but also bacteria can have a cytoskeleton. We used cryo-electron tomography to study the three-dimensional structure of Spiroplasma melliferum cells in a close-to-native state at similar to4-nanometer resolution. We showed that these cells possess two types of filaments arranged in three parallel ribbons underneath the cell membrane. These two filamentous structures are built of the fibril protein and possibly the actin-like protein MreB. On the basis of our structural data, we could model the motility modes of these cells and explain how helical Mollicutes can propel themselves by means of coordinated length changes of their cytoskeletal ribbons.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Biochem, Dept Biol Struct, D-82152 Martinsried, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Frangakis, AS (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	frangak@embl.de; baumeist@biochem.mpg.de		Frangakis, Achilleas/0000-0002-8067-6611				Baumeister W, 1999, TRENDS CELL BIOL, V9, P81, DOI 10.1016/S0962-8924(98)01423-8; DOI M, 1988, J BACTERIOL, V170, P4619, DOI 10.1128/jb.170.10.4619-4624.1988; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; Kimmel R, 1998, P NATL ACAD SCI USA, V95, P8431, DOI 10.1073/pnas.95.15.8431; Koster AJ, 1997, J STRUCT BIOL, V120, P276, DOI 10.1006/jsbi.1997.3933; KURNER J, UNPUB; NEIMARK H, 1983, YALE J BIOL MED, V56, P419; RUSS JC, 2002, IMAGE PROCESSING HDB, P496; TOWNSEND R, 1985, J GEN MICROBIOL, V131, P983; TOWNSEND R, 1983, J GEN MICROBIOL, V129, P199; TOWNSEND R, 1980, J BACTERIOL, V142, P694, DOI 10.1128/JB.142.2.694-700.1980; Trachtenberg S, 2003, J BACTERIOL, V185, P1987, DOI 10.1128/JB.185.6.1987-1994.2003; Trachtenberg S, 2001, MOL MICROBIOL, V41, P827, DOI 10.1046/j.1365-2958.2001.02527.x; Trachtenberg S, 1998, J STRUCT BIOL, V124, P244, DOI 10.1006/jsbi.1998.4063; Tully JG, 1992, ENCY MICROBIOLOGY, P181; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; WACHI M, 1987, J BACTERIOL, V169, P4935, DOI 10.1128/jb.169.11.4935-4940.1987; WILLIAMSON DL, 1991, J BACTERIOL, V173, P4353, DOI 10.1128/JB.173.14.4353-4362.1991; WILLIAMSON DL, 1974, J BACTERIOL, V117, P904, DOI 10.1128/JB.117.2.904-906.1974; Wolgemuth CW, 2003, BIOPHYS J, V85, P828, DOI 10.1016/S0006-3495(03)74523-8	20	163	167	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					436	438		10.1126/science.1104031	http://dx.doi.org/10.1126/science.1104031			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662018				2022-12-28	WOS:000226492300051
J	Cirillo, DJ; Wallace, RB; Rodabough, RJ; Greenland, P; LaCroix, AZ; Limacher, MC; Larson, JC				Cirillo, DJ; Wallace, RB; Rodabough, RJ; Greenland, P; LaCroix, AZ; Limacher, MC; Larson, JC			Effect of estrogen therapy on gallbladder disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPLACEMENT THERAPY; GALLSTONE DISEASE; POSTMENOPAUSAL; CHOLECYSTECTOMY; RISK; MANAGEMENT	Context Estrogen therapy is thought to promote gallstone formation and cholecystitis but most data derive from observational studies rather than randomized trials. Objective To determine the effect of estrogen therapy in healthy postmenopausal women on gallbladder disease outcomes. Design, Setting, and Participants Two randomized, double-blind, placebo-controlled trials conducted at 40 US clinical centers. The volunteer sample was 22 579 community-dwelling women aged 50 to 79 years without prior cholecystectomy. Intervention Women with hysterectomy were randomized to 0.625 mg/d of conjugated equine estrogens (CEE) or placebo (n=8376). Women without hysterectomy were randomized to estrogen plus progestin (E+P), given as CEE plus 2.5 mg/d of medroxyprogesterone acetate (n=14203). Main Outcome Measures Participants reported hospitalizations for gallbladder diseases and gallbladder-related procedures, with events ascertained through medical record review. Cox proportional hazards regression was used to assess hazard ratios (HRs) and 95% confidence intervals (Cls) using intention-to-treat and time-to-event methods. Results The CEE and the E+P groups were similar to their respective placebo groups at baseline. The mean follow-up times were 7.1 years and 5.6 years for the CEE and the E+P trials, respectively. The annual incidence rate for any gallbladder event was 78 events per 10000 person-years for the CEE group (vs 47/10000 person-years for placebo) and 55 per 10000 person-years for E+P (vs 35/10000 person-years for placebo). Both trials showed greater risk of any gallbladder disease or surgery with estrogen (CEE: HR, 1.67; 95% CI, 1.35-2.06; E+P: HR, 1.59; 95% CI, 1.28-1.97). Both trials indicated a higher risk for cholecystitis (CEE: HR, 1.80; 95% CI, 1.42-2.28; E+P: HR, 1.54; 95% CI 1.22-1.94); and for cholelithiasis (CEE: HR, 1.86; 95% CI, 1.48-2.35; E+P: HR, 1.68; 95% CI, 1.34-2.11) for estrogen users. Also, women undergoing estrogen therapy were more likely to receive cholecystectomy (CEE: HR, 1;93; 95% CI, 1.52-2.44; E+P: HR, 1.67; 95% Cl, 1.32-2.11), but not other biliary tract surgery (CEE: HR, 1.18; 95% CI, 0.68-2.04; E+P: HR, 1.49; 95% CI, 0.78-2.84). Conclusions These data suggest an increase in risk of biliary tract disease among postmenopausal women using estrogen therapy. The morbidity and cost associated with these outcomes may need to be considered in decisions regarding the use of estrogen therapy.	Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL USA	University of Iowa; University of Iowa; Fred Hutchinson Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; State University System of Florida; University of Florida	Wallace, RB (corresponding author), Dept Epidemiol C21NGH, 200 Hawkins Dr, Iowa City, IA 52242 USA.	robert-wallace@uiowa.edu	Greenland, Philip/ABD-5528-2021; Cirillo, Dominic J/B-4739-2008	Cirillo, Dominic J/0000-0001-7017-221X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal S, 2000, POSTGRAD MED, V108, P143, DOI 10.3810/pgm.2000.09.1.1212; Ahmed A, 2000, AM FAM PHYSICIAN, V61, P1673; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Boland LL, 2002, ANN EPIDEMIOL, V12, P131, DOI 10.1016/S1047-2797(01)00260-5; DEFRANCES CJ, 2004, ADV DATA VITAL HLTH, V342; Donovan JM, 1999, GASTROENTEROL CLIN N, V28, P75, DOI 10.1016/S0889-8553(05)70044-3; EVERSON RB, 1982, GASTROENTEROLOGY, V82, P4; GEORGE ED, 2000, CLIN FAM PRACT, V2, P155; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; JORGENSEN T, 1988, GUT, V29, P433, DOI 10.1136/gut.29.4.433; KAKAR F, 1988, AM J PUBLIC HEALTH, V78, P564, DOI 10.2105/AJPH.78.5.564; Mamdani MM, 2000, CAN MED ASSOC J, V162, P1421; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; OWINGS MF, 1996, AMBULATORY INPATIENT; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SANTEN S, 2001, CHOLECYSTITIS BILIAR; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; Sterling RK, 1998, AM J GASTROENTEROL, V93, P1405, DOI 10.1111/j.1572-0241.1998.01405.x; *SURG CONF GALLBL, 1974, NEW ENGL J MED, V290, P15; Uhler ML, 1998, J CLIN ENDOCR METAB, V83, P410, DOI 10.1210/jc.83.2.410	23	173	185	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					330	339		10.1001/jama.293.3.330	http://dx.doi.org/10.1001/jama.293.3.330			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657326	Green Published, Bronze			2022-12-28	WOS:000226358400027
J	Chen, LY; Widom, J				Chen, LY; Widom, J			Mechanism of transcriptional silencing in yeast	CELL			English	Article							RNA-POLYMERASE-II; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; IN-VIVO; REGULATORY PROTEIN; DNA-BINDING; CHROMATIN; GENE; ACCESSIBILITY; REPRESSION	Transcriptional silencing is a phenomenon in which the transcription of a gene by RNA polymerase 11 or III is repressed or not, dependent only on the gene's chromosomal location. Two prevailing models exist for silencing: (1) steric hindrance in silenced chromatin inhibits the binding of upstream activator proteins or polymerase or (2) silencing primarily blocks steps downstream of transcription preinitiation complex formation. Here, we test these models quantitatively for the case of SIR2-dependent silencing in budding yeast, using foreign and endogenous reporter proteins, at transgenic and endogenous loci. Our results contradict both models and show instead that transcriptional silencing at several URA3 transgenes, and at the naturally silenced endogenous HMRa and HMLalpha mating type genes, acts downstream of gene activator protein binding to strongly reduce the occupancy of TFIIB, RNA polymerase II, and TFIIE at the silenced promoters.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Widom, J (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	j-widom@northwestem.edu	Chen, Lingyi/G-6309-2013		NIGMS NIH HHS [GM54692, GM58617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054692, R01GM058617] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JD, 2000, J MOL BIOL, V296, P979, DOI 10.1006/jmbi.2000.3531; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; Buck SW, 2002, CELL, V111, P1003, DOI 10.1016/S0092-8674(02)01193-5; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Chen LY, 2004, BIOCHEM CELL BIOL, V82, P413, DOI 10.1139/O04-035; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Fitzgerald DP, 2001, MOL CELL BIOL, V21, P6585, DOI 10.1128/MCB.21.19.6585-6597.2001; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; LLOUBES R, 1991, J BIOL CHEM, V266, P2303; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; LOSSON R, 1985, J MOL BIOL, V185, P65, DOI 10.1016/0022-2836(85)90183-4; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Miller JA, 2003, MOL CELL BIOL, V23, P1623, DOI 10.1128/MCB.23.5.1623-1632.2003; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Ptashne M, 2004, GENETIC SWITCH PHAGE; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; SCHLOSSHERR J, 1994, MOL GEN GENET, V243, P453; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3	29	68	71	2	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					37	48		10.1016/j.cell.2004.11.030	http://dx.doi.org/10.1016/j.cell.2004.11.030			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652480	Bronze			2022-12-28	WOS:000226365400009
J	Umetsu, DT				Umetsu, DT			Revising the immunological theories of asthma and allergy	LANCET			English	Editorial Material							INDUCED AIRWAY HYPERREACTIVITY; DENDRITIC CELLS; T-CELLS; INFLAMMATION; ANTIGEN; TH1		Stanford Univ, Dept Pediat, Stanford, CA 94305 USA	Stanford University	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.	Umetsu@stanford.edu						Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Randolph DA, 1999, J IMMUNOL, V162, P2375; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303	11	19	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2005	365	9454					98	100		10.1016/S0140-6736(05)17714-9	http://dx.doi.org/10.1016/S0140-6736(05)17714-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639274				2022-12-28	WOS:000226170700003
J	Vargas, D; Garcia, L; Gilman, RH; Evans, C; Ticona, E; Navincopa, M; Luo, RF; Caviedes, L; Hong, C; Escombe, R; Moore, DAJ				Vargas, D; Garcia, L; Gilman, RH; Evans, C; Ticona, E; Navincopa, M; Luo, RF; Caviedes, L; Hong, C; Escombe, R; Moore, DAJ			Diagnosis of sputum-scarce HIV-associated pulmonary tuberculosis in Lima, Peru	LANCET			English	Article								Sputum induction, bronchoalveolar lavage, or gastric aspiration are often needed to produce adequate diagnostic respiratory samples from people with HIV in whom tuberculosis is suspected. Since these procedures are rarely appropriate in less-developed countries, we compared the performances of a simple string test and the gold-standard sputum induction. 160 HIV-positive adults under investigation for tuberculosis, and 52 asymptomatic HIV-positive control patients underwent the string test followed by sputum induction. The string test detected tuberculosis in 14 patients in whom this disease was suspected; sputum induction detected only eight of them (McNemar's test, p=0.03). These preliminary data suggest that the string test is safe and effective for retrieval of useful clinical specimens for diagnosis of pulmonary tuberculosis, and is at least as sensitive as sputum induction.	Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Ctr Clin Trop Med, London W12 0NN, England; Asociac Benefica Proyectos Informat Salud Med & A, Lima, Peru; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; Hosp Nacl Mayo, Lima, Peru; Univ Peruana Cayetano Heredia, Lima, Peru	Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Universidad Peruana Cayetano Heredia	Moore, DAJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Ctr Clin Trop Med, Hammersmith Campus,DuCane Rd, London W12 0NN, England.	daj.moore@imperial.ac.uk	Evans, Carlton/AAI-1653-2020; Vargas-Pacherrez, Daniel/N-9349-2016	Evans, Carlton/0000-0002-6873-5447; Navincopa, Marcos/0000-0002-9951-8234; Ticona, Eduardo/0000-0002-6556-1082; Vargas-Pacherrez, Daniel/0000-0003-0989-1199; Moore, David/0000-0002-3748-0154	PHS HHS [T35A107646] Funding Source: Medline; Wellcome Trust [064672, 057434] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome TrustEuropean Commission)		BEAL CB, 1970, AM J TROP MED HYG, V19, P349, DOI 10.4269/ajtmh.1970.19.349; Caviedes L, 2000, J CLIN MICROBIOL, V38, P1203, DOI 10.1128/JCM.38.3.1203-1208.2000; Conde MB, 2000, AM J RESP CRIT CARE, V162, P2238, DOI 10.1164/ajrccm.162.6.2003125; GILMAN RH, 1979, LANCET, V1, P795	4	47	48	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					150	152		10.1016/S0140-6736(05)17705-8	http://dx.doi.org/10.1016/S0140-6736(05)17705-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639297	Green Accepted			2022-12-28	WOS:000226170700030
J	Seshadri, R; Adrian, L; Fouts, DE; Eisen, JA; Phillippy, AM; Methe, BA; Ward, NL; Nelson, WC; Deboy, RT; Khouri, HM; Kolonay, JF; Dodson, RJ; Daugherty, SC; Brinkac, LM; Sullivan, SA; Madupu, R; Nelson, KT; Kang, KH; Impraim, M; Tran, K; Robinson, JM; Forberger, HA; Fraser, CM; Zinder, SH; Heidelberg, JF				Seshadri, R; Adrian, L; Fouts, DE; Eisen, JA; Phillippy, AM; Methe, BA; Ward, NL; Nelson, WC; Deboy, RT; Khouri, HM; Kolonay, JF; Dodson, RJ; Daugherty, SC; Brinkac, LM; Sullivan, SA; Madupu, R; Nelson, KT; Kang, KH; Impraim, M; Tran, K; Robinson, JM; Forberger, HA; Fraser, CM; Zinder, SH; Heidelberg, JF			Genome sequence of the PCE-dechlorinating bacterium Dehalococcoides ethenogenes	SCIENCE			English	Article							REDUCTIVE DEHALOGENASE; DEHALOSPIRILLUM-MULTIVORANS; ILLEGITIMATE RECOMBINATION; GENETIC-ANALYSIS; TETRACHLOROETHENE; ETHENE; ENZYME; DEHYDROGENASE; AMPLIFICATION; ACINETOBACTER	Dehalococcoides ethenogenes is the only bacterium known to reductively dechlorinate the groundwater pollutants, tetrachloroethene (PCE) and trichloroethene, to ethene. Its 1,469,720-base pair chromosome contains large dynamic duplicated regions and integrated elements. Genes encoding 17 putative reductive dehalogenases, nearly all of which were adjacent to genes for transcription regulators, and five hydrogenase complexes were identified. These findings, plus a limited repertoire of other metabolic modes, indicate that D. ethenogenes is highly evolved to utilize halogenated organic compounds and H-2. Diversification of reductive dehalogenase functions appears to have been mediated by recent genetic exchange and amplification. Genome analysis provides insights into the organism's complex nutrient requirements and suggests that an ancestor was a nitrogen-fixing autotroph.	Inst Genom Res, Rockville, MD 20850 USA; Tech Univ Berlin, Inst Biotechnol, Fachgebiet Tech Biochem, D-13353 Berlin, Germany; Johns Hopkins Univ, Baltimore, MD 21218 USA; Univ Maryland, Ctr Marine Biotechnol, Inst Biotechnol, Baltimore, MD 21202 USA; George Washington Univ, Sch Med, Dept Pharmacol & Microbiol, Washington, DC 20037 USA; George Washington Univ, Sch Med, Dept Trop Med, Washington, DC 20037 USA; Cornell Univ, Microbiol Sect, Ithaca, NY 14853 USA	J. Craig Venter Institute; Technical University of Berlin; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; George Washington University; George Washington University; Cornell University	Seshadri, R (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	rekha@tigr.org	Adrian, Lorenz/A-4443-2012; Eisen, Jonathan A./H-2706-2019; Phillippy, Adam M/U-5731-2018; Nelson, William C/E-9263-2016	Adrian, Lorenz/0000-0001-8205-0842; Eisen, Jonathan A./0000-0002-0159-2197; Phillippy, Adam M/0000-0003-2983-8934; Nelson, William C/0000-0002-1873-3929; Fraser, Claire/0000-0003-1462-2428; Heidelberg, John/0000-0003-0673-3224				Adrian L, 2000, NATURE, V408, P580, DOI 10.1038/35046063; Baumer S, 2000, J BIOL CHEM, V275, P17968, DOI 10.1074/jbc.M000650200; DISTEFANO TD, 1992, APPL ENVIRON MICROB, V58, P3622, DOI 10.1128/AEM.58.11.3622-3629.1992; Doukov TI, 2002, SCIENCE, V298, P567, DOI 10.1126/science.1075843; EHRLICH SD, 1993, GENE, V135, P161, DOI 10.1016/0378-1119(93)90061-7; Fennell DE, 2001, ENVIRON SCI TECHNOL, V35, P1830, DOI 10.1021/es0016203; Fennell DE, 2004, ENVIRON SCI TECHNOL, V38, P2075, DOI 10.1021/es034989b; He JZ, 2003, NATURE, V424, P62, DOI 10.1038/nature01717; Hendrickson ER, 2002, APPL ENVIRON MICROB, V68, P485, DOI 10.1128/AEM.68.2.485-495.2002; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Loffler FE, 2000, APPL ENVIRON MICROB, V66, P1369, DOI 10.1128/AEM.66.4.1369-1374.2000; Magnuson JK, 2000, APPL ENVIRON MICROB, V66, P5141, DOI 10.1128/AEM.66.12.5141-5147.2000; Magnuson JK, 1998, APPL ENVIRON MICROB, V64, P1270; Major DW, 2002, ENVIRON SCI TECHNOL, V36, P5106, DOI 10.1021/es0255711; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; Meuer J, 2002, P NATL ACAD SCI USA, V99, P5632, DOI 10.1073/pnas.072615499; NEUMANN A, 1994, ARCH MICROBIOL, V162, P295, DOI 10.1007/s002030050141; Neumann A, 2002, ARCH MICROBIOL, V177, P420, DOI 10.1007/s00203-002-0409-3; Reams AB, 2004, ANNU REV MICROBIOL, V58, P119, DOI 10.1146/annurev.micro.58.030603.123806; Reams AB, 2004, J MOL BIOL, V338, P643, DOI 10.1016/j.jmb.2004.03.031; Reams AB, 2003, MOL MICROBIOL, V47, P1291, DOI 10.1046/j.1365-2958.2003.03342.x; Sargent F, 2001, TRENDS MICROBIOL, V9, P196, DOI 10.1016/S0966-842X(01)02017-0; Schobert M, 2001, MICROBIOL-SGM, V147, P363, DOI 10.1099/00221287-147-2-363; Schumacher W, 1997, FEBS LETT, V409, P421, DOI 10.1016/S0014-5793(97)00520-6; SIMDT H, 2004, ANNU REV MICROBIOL, V58, P43; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; van der Meer JR, 2003, CURR OPIN BIOTECH, V14, P248, DOI 10.1016/S0958-1669(03)00058-2; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; Villemur R, 2002, CAN J MICROBIOL, V48, P697, DOI 10.1139/w02-057; Wagner C, 2002, INFECT IMMUN, V70, P6121, DOI 10.1128/IAI.70.11.6121-6128.2002; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; Zehr JP, 2003, ENVIRON MICROBIOL, V5, P539, DOI 10.1046/j.1462-2920.2003.00451.x; ZINDER SH, 2002, ENCY ENV MICROBIOLOG, P507	35	337	595	12	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					105	108		10.1126/science.1102226	http://dx.doi.org/10.1126/science.1102226			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637277	Green Submitted			2022-12-28	WOS:000226214300047
J	Benveniste, M; Dingledine, R				Benveniste, M; Dingledine, R			Limiting stroke-induced damage by targeting an acid channel	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SENSING ION CHANNELS; ISCHEMIA; CALCIUM		Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Tel Aviv University; Sackler Faculty of Medicine; Emory University	Benveniste, M (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		dingledine, Ray/F-5173-2011	Dingledine, Ray/0000-0001-7128-4520				Allen NJ, 2002, J PHYSIOL-LONDON, V543, P521, DOI 10.1113/jphysiol.2002.020297; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100	5	31	40	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					85	86		10.1056/NEJMcibr045010	http://dx.doi.org/10.1056/NEJMcibr045010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635119				2022-12-28	WOS:000226112500015
J	Mukamal, KJ; Ascherio, A; Mittleman, MA; Conigrave, KM; Camargo, CA; Kawachi, I; Stampfer, MJ; Willett, WC; Rimm, EB				Mukamal, KJ; Ascherio, A; Mittleman, MA; Conigrave, KM; Camargo, CA; Kawachi, I; Stampfer, MJ; Willett, WC; Rimm, EB			Alcohol and risk for ischemic stroke in men: The role of drinking patterns and usual beverage	ANNALS OF INTERNAL MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; MALE HEALTH-PROFESSIONALS; CORONARY HEART-DISEASE; CARDIOVASCULAR-HEALTH; LIPID-PEROXIDATION; CONSUMPTION; WINE; WOMEN; MORTALITY; ATHEROSCLEROSIS	Background: The association of light to moderate alcohol consumption with risk for ischemic stroke remains controversial, as do the roles of beverage type and drinking pattern. Objective: To assess the association of drinking patterns and beverage type with risk for ischemic stroke among men. Design: Prospective cohort study. Setting: United States. Participants: 38 156 male health professionals who were free of known cardiovascular disease or cancer at baseline in 1986. Measurements: With a semi-quantitative food-frequency questionnaire, the authors individually ascertained consumption of regular and light beer, red and white wine, and liquor every 4 years. Alcohol consumption was categorized as light (0.1 to 9.9 g/d, or < 1 drink daily), moderate (10.0 to 29.9 g/d, or 1 to 2 drinks daily), and heavier (>= 30.0 g/d, or >= 3 drinks daily). Results: During a follow-up period of 14 years, 412 cases of incident ischemic stroke were documented. Compared with abstainers, light drinkers had a multivariate-adjusted relative risk of 0.99 (95% CI, 0.72 to 1.37), moderate drinkers had a multivariate-adjusted relative risk of 1.26 (CI, 0.90 to 1.76), and heavier drinkers had a multivariate-adjusted relative risk of 1.42 (CI, 0.97 to 2.09; P = 0.01 for trend). Consumption of 10.0 to 29.9 g of alcohol per day on 3 to 4 days per week appeared to be associated with the lowest risk (relative risk, 0.68 [CI, 0.44 to 1.05]). Red wine consumption was inversely associated with risk in a graded manner (P = 0.02 for trend), but other beverages were not. The apparently higher risk for ischemic stroke with heavier alcohol use appeared to be most pronounced for the embolic subtype. Limitations: This study had limited power to examine specific drinking patterns and heavy drinking and could not assess risk for hemorrhagic stroke. Conclusions: In this sample of male health professionals, light and moderate average alcohol use was generally not associated with an increased risk for ischemic stroke, although drinking pattern and beverage type modified this relation. Intake of more than 2 drinks per day may be associated with a higher risk for ischemic stroke.	Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02115 USA; Univ Sydney, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia	Harvard University; Beth Israel Deaconess Medical Center; University of Sydney; University of Sydney	Mukamal, KJ (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,RO-114, Boston, MA 02115 USA.	kmukamal@bidmc.harvard.edu	Camargo, Carlos A./C-2145-2008; Mukamal, Kenneth/GVR-7978-2022	Camargo, Carlos A./0000-0002-5071-7654; Conigrave, Katherine/0000-0002-6428-1441; Mittleman, Murray/0000-0001-9788-7274	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011181] Funding Source: NIH RePORTER; NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; NIAAA NIH HHS [AA00299, AA11181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; Berger K, 1999, NEW ENGL J MED, V341, P1557, DOI 10.1056/NEJM199911183412101; Camargo CA, 1996, CLIN CHIM ACTA, V246, P107, DOI 10.1016/0009-8981(96)06231-6; COLDITZ GA, 1991, AM J CLIN NUTR, V54, P49, DOI 10.1093/ajcn/54.1.49; Conigrave KM, 2001, DIABETES, V50, P2390, DOI 10.2337/diabetes.50.10.2390; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Djousse L, 2002, STROKE, V33, P907, DOI 10.1161/hs0402.105245; Dulli DA, 2002, STROKE, V33, P890, DOI 10.1161/01.STR.0000013795.19904.73; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; Goldstein LB, 2001, CIRCULATION, V103, P163; HANSAGI H, 1995, STROKE, V26, P1768, DOI 10.1161/01.STR.26.10.1768; He K, 2002, JAMA-J AM MED ASSOC, V288, P3130, DOI 10.1001/jama.288.24.3130; HILLBLOM M, 1996, ALCOHOL CARDIOVASCUL; Hommel M, 1999, NEW ENGL J MED, V341, P1605, DOI 10.1056/NEJM199911183412109; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Jiang R, 2003, AM J EPIDEMIOL, V158, P760, DOI 10.1093/aje/kwg221; Klatsky AL, 1999, ALCOHOL RES HEALTH, V23, P15; Klatsky AL, 2001, AM J CARDIOL, V88, P703, DOI 10.1016/S0002-9149(01)01824-0; Leikert JF, 2002, CIRCULATION, V106, P1614, DOI 10.1161/01.CIR.0000034445.31543.43; Leppala JM, 1999, CIRCULATION, V100, P1209, DOI 10.1161/01.CIR.100.11.1209; Longstreth WT, 1998, ARCH NEUROL-CHICAGO, V55, P1217, DOI 10.1001/archneur.55.9.1217; Malarcher AM, 2001, STROKE, V32, P77, DOI 10.1161/01.STR.32.1.77; Mortensen EL, 2001, ARCH INTERN MED, V161, P1844, DOI 10.1001/archinte.161.15.1844; Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095; Mukamal KJ, 2001, STROKE, V32, P1939, DOI 10.1161/hs0901.095723; Nigdikar SV, 1998, AM J CLIN NUTR, V68, P258, DOI 10.1093/ajcn/68.2.258; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; Pickle LW, 1997, STROKE, V28, P1639, DOI 10.1161/01.STR.28.8.1639; Piriyawat P, 2003, STROKE, V34, P1242, DOI 10.1161/01.STR.0000067706.23777.04; Reynolds K, 2003, JAMA-J AM MED ASSOC, V289, P579, DOI 10.1001/jama.289.5.579; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stocker R, 2004, AM J CLIN NUTR, V79, P123; Tanasescu M, 2001, J AM COLL CARDIOL, V38, P1836, DOI 10.1016/S0735-1097(01)01655-2; Tjonneland A, 1999, AM J CLIN NUTR, V69, P49; Truelsen T, 1998, STROKE, V29, P2467, DOI 10.1161/01.STR.29.12.2467; *USDA, 1999, NUTR DAT STAND REF; Waddington E, 2004, AM J CLIN NUTR, V79, P54; Weinfeld, 1981, STROKE S1, V12, pI13	45	121	129	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2005	142	1					11	19		10.7326/0003-4819-142-1-200501040-00007	http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916DS	15630105				2022-12-28	WOS:000228366200002
J	Carpenter, RG; Waite, A; Coombs, RC; Daman-Willems, C; McKenzie, A; Huber, J; Emery, JL				Carpenter, RG; Waite, A; Coombs, RC; Daman-Willems, C; McKenzie, A; Huber, J; Emery, JL			Repeat sudden unexpected and unexplained infant deaths: natural or unnatural?	LANCET			English	Article							INTRAALVEOLAR HEMORRHAGE; RECURRENCE; RISK	Background There have been suggestions that when two or three unexpected unexplained infant deaths occur within a family they are more likely to be unnatural than natural. We aimed to estimate the probability that a second infant death is natural versus unnatural. Methods The Care of Next Infant programme (CONI) supports parents who have previously had an unexpected and apparently unexplained infant death and is currently available in over 90% of health districts in England, Wales, and Northern Ireland. We studied all deaths in 6373 infants who had completed the CONI programme by December, 1999. After a CONI death, we made detailed enquiries into the previous death and the CONI death, including a family interview, a review of autopsies, and case discussion. Findings 57 (8.9 per 1000) CONI infants died. Nine deaths were inevitable, and 48 were unexpected. 44 families lost one child, and two families lost two children. Of the 46 first CONI deaths, 40 were natural; the other six were probable homicides, five committed by one or both parents (two criminally convicted). The ratio of 40 natural to six unnatural deaths is 6.7 (95% CI 2.8-19.4). Enquiries identified 18 families with two SIDS (sudden infant death syndrome) deaths and two families with probable covert double homicides (ratio 9.0 [2.2 to 80.0]). There were no convictions in 13 incomplete cases. Families with three deaths are reported.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Med Stat Unit, London WC1E 7HT, England; Univ Sheffield, Sheffield Childrens Hosp, Acad Unit Child Hlth, Care Next Infant CONI Programme, Sheffield, S Yorkshire, England; Royal Hallamshire Hosp, Neonatal Intens Care Unit, Sheffield S10 2JF, S Yorkshire, England; Univ Hosp, London, England; Univ Hosp Children & Youth, Utrecht, Netherlands	University of London; London School of Hygiene & Tropical Medicine; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield; University of Sheffield; Wilhelmina Kinderziekenhuis	Carpenter, RG (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Med Stat Unit, Keppel St, London WC1E 7HT, England.	bob.carpenter@lshtm.ac.uk						BARRETT AM, 1954, RECENT ADV PAEDIATRI, P301; BEAL SM, 1988, ARCH DIS CHILD, V63, P924, DOI 10.1136/adc.63.8.924; Berry PJ, 1999, J CLIN PATHOL, V52, P553, DOI 10.1136/jcp.52.8.553; CARPENTER RG, 1977, ARCH DIS CHILD, V52, P606, DOI 10.1136/adc.52.8.606; DiMaio V J M, 1989, FORENSIC PATHOLOGY; EMERY JL, 1985, ARCH DIS CHILD, V60, P505, DOI 10.1136/adc.60.6.505; EMERY JL, 1986, LANCET, V1, P313; EMERY JL, 1993, AM J DIS CHILD, V147, P1097, DOI 10.1001/archpedi.1993.02160340083019; Firstman R, 2001, SUDDEN INFANT DEATH, P291; Fleming P., 2000, SUDDEN UNEXPECTED DE; GUNTHEROTH WG, 1990, J PEDIATR-US, V116, P520, DOI 10.1016/S0022-3476(05)81596-3; GUNTHEROTH WG, 1995, CRIB DEATH SUDDEN IN; KUKULL WA, 1977, AM J EPIDEMIOL, V106, P485, DOI 10.1093/oxfordjournals.aje.a112495; Levene S, 2004, ARCH DIS CHILD, V89, P443, DOI 10.1136/adc.2003.036202; LEVINE M, 1999, LEVINE CORONERS COUR; MCKENZIE A, 1995, HLTH VISITOR, V68, P239; Meadow R, 1999, ARCH DIS CHILD, V80, P7, DOI 10.1136/adc.80.1.7; MEADOW R, 1997, ABC CHILD ABUSE, P27; Oyen N, 1996, AM J EPIDEMIOL, V144, P300, DOI 10.1093/oxfordjournals.aje.a008925; PETERSON DR, 1980, J PEDIATR-US, V97, P265, DOI 10.1016/S0022-3476(80)80491-4; *PRES ROYAL STAT S, 2001, RSS NEWS         DEC; Splawski I, 1997, NEW ENGL J MED, V336, P1562, DOI 10.1056/NEJM199705293362204; Stanton AN, 2003, ARCH DIS CHILD, V88, P699, DOI 10.1136/adc.88.8.699; TAYLOR EM, 1983, BRIT MED J, V287, P871, DOI 10.1136/bmj.287.6396.871; TAYLOR EM, 1982, ARCH DIS CHILD, V57, P668, DOI 10.1136/adc.57.9.668; VALDESDAPENA MA, 1967, PEDIATRICS, V39, P123; Vege A., 1995, P67; WAITE A, 1998, REPORT 5000 BABIES U; WOLKIND S, 1993, ACTA PAEDIATR, V82, P873, DOI 10.1111/j.1651-2227.1993.tb12583.x; Yukawa N, 1999, J CLIN PATHOL, V52, P581, DOI 10.1136/jcp.52.8.581; [No title captured]	31	42	43	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					29	35		10.1016/S0140-6736(04)17662-9	http://dx.doi.org/10.1016/S0140-6736(04)17662-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639677				2022-12-28	WOS:000226213100025
J	Howell, A; Cuzick, J; Baum, M; Buzdar, A; Dowsett, M; Forbes, JF; Hoctin-Boes, G; Houghton, I; Locker, GY; Tobias, JS				Howell, A; Cuzick, J; Baum, M; Buzdar, A; Dowsett, M; Forbes, JF; Hoctin-Boes, G; Houghton, I; Locker, GY; Tobias, JS		ATAC Tralists' Grp	Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer	LANCET			English	Article							RANDOMIZED TRIAL	The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) and time-to-recurrence (402 vs 498, 0.79, 0.70-0.90, p=0.0005), and significantly reduced distant metastases (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 12-62, p=0.01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia. and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.	Christie Hosp, Manchester, Lancs, England; Canc Res UK, London, England; UCL, Dept Surg, Clin Trials Grp, London, England; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Royal Marsden Hosp, London SW3 6JJ, England; Univ Newcastle, Newcastle Mater Misericordiae Hosp, Newcastle, NSW 2308, Australia; AstraZeneca, Wilmington, DE USA; Northwestern Univ, Feinberg Sch Med, Evanston NW Healthcare, Evanston, IL USA; Middlesex Hosp, Meyerstein Inst Clin Oncol, London, England	Christie NHS Foundation Trust; Christie Hospital; Cancer Research UK; University of London; University College London; University of Texas System; UTMD Anderson Cancer Center; Royal Marsden NHS Foundation Trust; Calvary Mater Newcastle Hospital; University of Newcastle; AstraZeneca; NorthShore University Health System; Northwestern University; Feinberg School of Medicine; University of London; University College London	Howell, A (corresponding author), Christie Hosp, Manchester, Lancs, England.	anthony.howell@christie-tr.nwest.nhs.uk	WILLIAMS, Norman/C-2002-2008	WILLIAMS, Norman/0000-0001-6496-312X; Howell, Anthony/0000-0002-6233-719X				*ATAC TRIAL GROUP, 2003, CANCER, V98, P1802, DOI DOI 10.1002/CNCR.11745; Baum M, 2002, LANCET, V359, P2131; Clarke M, 1998, LANCET, V351, P1451; Fisher B, 2001, JNCI-J NATL CANCER I, V93, P684, DOI 10.1093/jnci/93.9.684; Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121	5	1754	1817	1	93	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					60	62		10.1016/s0140-6736(04)17666-6	http://dx.doi.org/10.1016/s0140-6736(04)17666-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639680				2022-12-28	WOS:000226213100029
J	Peter, U; Studer, A				Peter, U; Studer, A			Relapsing osteomyelitis of hands	LANCET			English	Editorial Material							CARPAL-TUNNEL SYNDROME		Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Studer, A (corresponding author), Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland.	ansgar.studer@nos.usz						ARATARI E, 1984, ARCH DERMATOL, V120, P517; BOUVIER M, 1979, REV RHUM, V46, P169; COX NH, 1992, BRIT J DERMATOL, V126, P611; TOSTI A, 1993, J AM ACAD DERMATOL, V29, P287, DOI 10.1016/0190-9622(93)70177-U	4	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					94	94		10.1016/S0140-6736(04)17671-X	http://dx.doi.org/10.1016/S0140-6736(04)17671-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639684				2022-12-28	WOS:000226213100033
J	Schroter, S; Tite, L; Smith, R				Schroter, S; Tite, L; Smith, R			Perceptions of open access publishing: interviews with journal authors	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To explore authors' attitudes towards open access publishing and author charges,their perceptions of journals that charge authors, and whether they would be willing to submit to these journals. Design Semistructured telephone interviews. Participants 28 randomly selected international authors who submitted to the BMJ in 2003. Results Authors were more aware of the concepts of open access publishing and author pays models than previously reported. Almost all authors supported the concept of open access, but few had submitted to an open access journal, other than BMJ. Reasons for not submitting included lack of awareness of which journals publish with open access, and journal quality taking a higher priority in decision making than the availability of open access. Authors disliked the idea of author charges without institutional support and were concerned about implications for authors from developing countries and those without research funding. However, many said they would probably continue to submit to journals they perceived as being of high quality even if they charged authors. Conclusions Authors consider perceived journal quality as more important than open access when deciding where to submit papers. New journals with open access may need to do more to reassure authors of the quality of their journals.	BMJ Editorial Off, London WC1 9JR, England		Schroter, S (corresponding author), BMJ Editorial Off, BMA House, London WC1 9JR, England.	sschroter@bmj.com	Schroter, Sara/G-3427-2012	Schroter, Sara/0000-0002-8791-8564				Cozzarelli NR, 2004, P NATL ACAD SCI USA, V101, P1111, DOI 10.1073/pnas.0307315101; *JISC OSI, J AUTH SURV REP; PELIZZARI E, ACAD STAFF USE PERCE; RICHARDSON M, 2004, EXPT OPEN ACCESS PUB; ROWLANDS I, SCHOLARLY COMMUNICAT	5	55	55	1	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					756	759		10.1136/bmj.38359.695220.82	http://dx.doi.org/10.1136/bmj.38359.695220.82			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15677363	Bronze, Green Published			2022-12-28	WOS:000228222900016
J	Hannan, SA; Sami, F; Wareing, MJ				Hannan, SA; Sami, F; Wareing, MJ			10-minute consultation - Tinnitus	BMJ-BRITISH MEDICAL JOURNAL			English	Article									St Bartholomews & Royal London Hosp, Dept Otolaryngol Head & Neck Surg, London EC1A 7BE, England; Moorings Practice, Surrey CR8 5DG, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Wareing, MJ (corresponding author), St Bartholomews & Royal London Hosp, Dept Otolaryngol Head & Neck Surg, London EC1A 7BE, England.	mw@otology.co.uk						Lockwood AH, 2002, NEW ENGL J MED, V347, P904, DOI 10.1056/NEJMra013395; WAREING MJ, 2004, GP MAGAZINE     0202, P41	2	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2005	330	7485					237	237		10.1136/bmj.330.7485.237	http://dx.doi.org/10.1136/bmj.330.7485.237			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15677658	Green Published, Bronze			2022-12-28	WOS:000226779400024
J	Aries, PM; Both, M				Aries, PM; Both, M			Destructive eye lesions in Wegener's granulomatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Rheumaklin Bad Bramstedt, D-24576 Bad Bramstedt, Germany; Univ Hosp Schleswig Holstein, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Aries, PM (corresponding author), Rheumaklin Bad Bramstedt, D-24576 Bad Bramstedt, Germany.		Both, Marcus/F-9633-2010; Aries, Peer/AAE-6166-2020						0	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					392	392		10.1056/NEJMicm040881	http://dx.doi.org/10.1056/NEJMicm040881			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673805				2022-12-28	WOS:000226535900011
J	Knorr, W; Prentice, IC; House, JI; Holland, EA				Knorr, W; Prentice, IC; House, JI; Holland, EA			Long-term sensitivity of soil carbon turnover to warming	NATURE			English	Article							ORGANIC-MATTER; TEMPERATURE-DEPENDENCE; CO2 EMISSIONS; DECOMPOSITION; RESPIRATION; CLIMATE; MINERALIZATION; CONSTRAINTS; RESPONSES; EXCHANGE	The sensitivity of soil carbon to warming is a major uncertainty in projections of carbon dioxide concentration and climate(1). Experimental studies overwhelmingly indicate increased soil organic carbon (SOC) decomposition(2-8) at higher temperatures, resulting in increased carbon dioxide emissions from soils. However, recent findings have been cited as evidence against increased soil carbon emissions in a warmer world(9,10). In soil warming experiments, the initially increased carbon dioxide efflux returns to pre-warming rates within one to three years(10-14), and apparent carbon pool turnover times are insensitive to temperature(15). It has already been suggested that the apparent lack of temperature dependence could be an artefact due to neglecting the extreme heterogeneity of soil carbon(16), but no explicit model has yet been presented that can reconcile all the above findings. Here we present a simple three-pool model that partitions SOC into components with different intrinsic turnover rates. Using this model, we show that the results of all the soil-warming experiments are compatible with long-term temperature sensitivity of SOC turnover: they can be explained by rapid depletion of labile SOC combined with the negligible response of non-labile SOC on experimental timescales. Furthermore, we present evidence that non-labile SOC is more sensitive to temperature than labile SOC, implying that the long-term positive feedback of soil decomposition in a warming world may be even stronger than predicted by global models(1,17-20).	Max Planck Inst Biogeochem, D-07701 Jena, Germany; Univ Bristol, Dept Earth Sci, QUEST, Bristol BS8 1RJ, Avon, England; Natl Ctr Atmospher Res, Boulder, CO 80305 USA	Max Planck Society; University of Bristol; National Center Atmospheric Research (NCAR) - USA	Knorr, W (corresponding author), Max Planck Inst Biogeochem, POB 100164, D-07701 Jena, Germany.	wknorr@bgc-jena.mpg.de	House, Joanna I/B-6477-2016	House, Joanna I/0000-0003-4576-3960; Holland, Elisabeth Ann/0000-0002-3570-621X				Agren GI, 2002, SOIL BIOL BIOCHEM, V34, P129, DOI 10.1016/S0038-0717(01)00156-0; Agren GI, 2000, AMBIO, V29, P55, DOI 10.1639/0044-7447(2000)029[0055:TDOOSO]2.0.CO;2; Bird MI, 1996, NATURE, V381, P143, DOI 10.1038/381143a0; Bosatta E, 1999, SOIL BIOL BIOCHEM, V31, P1889, DOI 10.1016/S0038-0717(99)00105-4; BURKE IC, 1989, SOIL SCI SOC AM J, V53, P800, DOI 10.2136/sssaj1989.03615995005300030029x; Cao MK, 1998, NATURE, V393, P249, DOI 10.1038/30460; Cox PM, 2000, NATURE, V408, P184, DOI 10.1038/35041539; Cramer W, 2001, GLOBAL CHANGE BIOL, V7, P357, DOI 10.1046/j.1365-2486.2001.00383.x; Dalias P, 2001, SOIL BIOL BIOCHEM, V33, P1049, DOI 10.1016/S0038-0717(01)00009-8; Davidson EA, 2000, NATURE, V408, P789, DOI 10.1038/35048672; Giardina CP, 2000, NATURE, V404, P858, DOI 10.1038/35009076; Grace J, 2000, NATURE, V404, P819, DOI 10.1038/35009170; Gu LH, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002119; Holland EA, 2000, GLOBAL BIOGEOCHEM CY, V14, P1137, DOI 10.1029/2000GB001264; Janssens IA, 2001, GLOBAL CHANGE BIOL, V7, P269, DOI 10.1046/j.1365-2486.2001.00412.x; Jarvis P, 2000, NATURE, V405, P904, DOI 10.1038/35016154; JENKINSON DS, 1977, SOIL SCI SOC AM J, V41, P912, DOI 10.2136/sssaj1977.03615995004100050020x; JENKINSON DS, 1991, NATURE, V351, P304, DOI 10.1038/351304a0; Jenny H, 1929, SOIL SCI, V27, P169, DOI 10.1097/00010694-192903000-00001; Katterer T, 1998, BIOL FERT SOILS, V27, P258, DOI 10.1007/s003740050430; Liski J, 1999, AMBIO, V28, P171; LLOYD J, 1994, FUNCT ECOL, V8, P315, DOI 10.2307/2389824; Luo YQ, 2001, NATURE, V413, P622, DOI 10.1038/35098065; Oechel WC, 2000, NATURE, V406, P978, DOI 10.1038/35023137; PETERJOHN WT, 1994, ECOL APPL, V4, P617, DOI 10.2307/1941962; Prentice IC, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P183; Rustad LE, 2001, OECOLOGIA, V126, P543, DOI 10.1007/s004420000544; Sanderman J, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2001GB001833; Trumbore S, 2000, ECOL APPL, V10, P399, DOI 10.1890/1051-0761(2000)010[0399:AOSOMA]2.0.CO;2; Trumbore SE, 1996, SCIENCE, V272, P393, DOI 10.1126/science.272.5260.393	30	873	972	25	657	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					298	301		10.1038/nature03226	http://dx.doi.org/10.1038/nature03226			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662420				2022-12-28	WOS:000226381300051
J	Casas, JP; Bautista, LE; Smeeth, L; Sharma, P; Hingorani, AD				Casas, JP; Bautista, LE; Smeeth, L; Sharma, P; Hingorani, AD			Homocysteine and stroke: evidence on a causal link from mendelian randomisation	LANCET			English	Article							ISCHEMIC-STROKE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; FOLIC-ACID; METAANALYSIS; RISK; GENES; INTERVENTION; POLYMORPHISM; PREVENTION	Background Individuals homozygous for the T allele of the MTHFR C677T polymorphism have higher plasma homocysteine concentrations (the phenotype) than those with the CC genotype, which, if pathogenetic, should put them at increased risk of stroke. Since this polymorphism is distributed randomly during gamete formation, its association with stroke should not be biased or confounded. We investigated consistency between the expected odds ratio for stroke among TT homozygotes, extrapolated from genotype-phenotype and phenotype-disease studies, and the observed odds ratio from a meta-analysis of genotype-disease association studies. Methods We searched MEDLINE and EMBASE up to June, 2003, for all relevant studies on the association between homocysteine concentration and the MTHFR polymorphism, and until December, 2003, for those on the association between the polymorphism and the risk of stroke. Pooled odds ratios and 95% CI were calculated by random-effects and fixed-effects models. Consistency between expected and observed odds ratios was assessed by interaction test. Findings 111 studies met the selection criteria. Among 15 635 people without cardiovascular disease, the weighted mean difference in homocysteine concentration between TT and CC homozygotes was 1.93 mumol/L (95% CI 1.38 to 2.47). The expected odds ratio for stroke corresponding to this difference based on previous observational studies was 1.20 (1.10 to 1.31). In our genetic meta-analysis (n=13 928) the odds ratio for stroke was 1.26 (1.14 to 1.40) for IT versus CC homozygotes, similar to the expected odds ratio (p=0.29). Consistency between the odds ratios was preserved in analyses by age-group, ethnic background, and geographical location. Interpretation The observed increase in risk of stroke among individuals homozygous for the MTHFR T allele is close to that predicted from the differences in homocysteine concentration conferred by this variant. This concordance is consistent with a causal relation between homocysteine concentration and stroke.	UCL, Royal Free & Univ Coll Med Sch, British Heart Fdn Labs, Dept Med,Ctr Clin Pharmacol, London WC1E 6JJ, England; Univ Wisconsin, Sch Med, Madison, WI USA; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England; Hammersmith Hosp, Acute Stroke Unit, London, England; Univ London Imperial Coll Sci Technol & Med, Dept Cellular & Mol Neurosci, London, England	University of London; University College London; University of Wisconsin System; University of Wisconsin Madison; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Imperial College London	Sharma, P (corresponding author), UCL, Royal Free & Univ Coll Med Sch, British Heart Fdn Labs, Dept Med,Ctr Clin Pharmacol, Rayne Bldg,5 Univ St, London WC1E 6JJ, England.	psharma@imperial.ac.uk; a.hingorani@ucl.ac.uk	; Smeeth, Liam/X-5862-2018	Hingorani, Aroon/0000-0001-8365-0081; Smeeth, Liam/0000-0002-9168-6022; Bautista, Leonelo/0000-0002-9151-6920	Medical Research Council [G108/492] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Baker RI, 2002, CEREBROVASC DIS, V13, P120; Bautista LE, 2002, J CLIN EPIDEMIOL, V55, P882, DOI 10.1016/S0895-4356(02)00434-1; Brattstrom L, 2000, AM J CLIN NUTR, V72, P315; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Casas JP, 2004, ARCH NEUROL-CHICAGO, V61, P1652, DOI 10.1001/archneur.61.11.1652; Clarke R, 2000, SEMIN THROMB HEMOST, V26, P341, DOI 10.1055/s-2000-8101; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Goldstein LB, 2001, CIRCULATION, V103, P163; Keavney B, 2002, INT J EPIDEMIOL, V31, P730, DOI 10.1093/ije/31.4.730; Keavney BD, 2000, CIRCULATION, V102, P852; Kelly PJ, 2002, NEUROLOGY, V59, P529, DOI 10.1212/WNL.59.4.529; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Little J, 2003, LANCET, V362, P930, DOI 10.1016/S0140-6736(03)14396-6; MANTEL N, 1959, J NATL CANCER I, V22, P719; Morgan T.H., 1913, HEREDITY SEX; Nallamothu BK, 2000, ARCH INTERN MED, V160, P3406, DOI 10.1001/archinte.160.22.3406; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; Russo GT, 2003, J NUTR, V133, P3416, DOI 10.1093/jn/133.11.3416; Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; Ueland PM, 2000, AM J CLIN NUTR, V72, P324; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Wald DS, 2001, ARCH INTERN MED, V161, P695, DOI 10.1001/archinte.161.5.695; Warlow CP, 1998, LANCET S3, V352, pSIII1, DOI DOI 10.1016/S0140-6736(98)90086-1; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Youngman LD, 2000, CIRCULATION, V102, P31	34	352	374	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					224	232		10.1016/S0140-6736(05)17742-3	http://dx.doi.org/10.1016/S0140-6736(05)17742-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652605				2022-12-28	WOS:000226309600028
J	Whitworth, JAG; Hewitt, KA				Whitworth, JAG; Hewitt, KA			Effect of malaria on HIV-1 progression and transmission	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; PLASMA VIRAL LOAD; FALCIPARUM-MALARIA; ADULTS; TUBERCULOSIS; RNA		Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England; Hlth Protect Agcy Ctr Infect, Emerging Infect & Zoonoses Sect, London, England	University of London; London School of Hygiene & Tropical Medicine; Health Protection Agency	Whitworth, JAG (corresponding author), Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.	j.whitworth@wellcome.ac.uk		Hewitt, Kirsty/0000-0003-3044-019X				Artzrouni M, 2002, AIDS, V16, pW1; Day JH, 2004, J INFECT DIS, V190, P1677, DOI 10.1086/424851; Grimwade K, 2004, AIDS, V18, P547, DOI 10.1097/00002030-200402200-00023; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Lawn SD, 2001, CLIN MICROBIOL REV, V14, P753, DOI 10.1128/CMR.14.4.753-777.2001; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Porter K, 2004, AIDS, V18, pS9, DOI 10.1097/00002030-200406002-00002; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Seage GR, 2002, J ACQ IMMUN DEF SYND, V30, P421, DOI [10.1097/01.QAI.0000021700.48448.69, 10.1097/00042560-200208010-00008]; Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41, DOI 10.4269/ajtmh.2004.71.41; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; Whalen CC, 2000, AIDS, V14, P1219, DOI 10.1097/00002030-200006160-00020; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6	13	38	39	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					196	197						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652587				2022-12-28	WOS:000226309600005
J	Keegan, BR; Feldman, JL; Begemann, G; Ingham, PW; Yelon, D				Keegan, BR; Feldman, JL; Begemann, G; Ingham, PW; Yelon, D			Retinoic acid signaling restricts the cardiac progenitor pool	SCIENCE			English	Article							ANTEROPOSTERIOR POLARITY; ZEBRAFISH HINDBRAIN; HEART MORPHOGENESIS; DIFFERENTIATION; PROLIFERATION; SPECIFICATION; SEGMENTATION; PATTERN; EMBRYO; RALDH2	Organogenesis begins with specification of a progenitor cell population, the size of which provides a foundation for the organ's final dimensions. Here, we present a new mechanism for regulating the number of progenitor cells by limiting their density within a competent region. We demonstrate that retinoic acid signaling restricts cardiac specification in the zebrafish embryo. Reduction of retinoic acid signaling causes formation of an excess of cardiomyocytes, via fate transformations that increase cardiac progenitor density within a multipotential zone. Thus, retinoic acid signaling creates a balance between cardiac and noncardiac identities, thereby refining the dimensions of the cardiac progenitor pool.	NYU, Sch Med, Skirball Inst Biomol Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Univ Konstanz, Lehrstuhl Zool Evolutionary Biol, D-78457 Constance, Germany; Univ Sheffield, Sch Med, Dept Biomed Sci, Ctr Dev Genet, Sheffield S10 2TN, S Yorkshire, England	New York University; New York University; University of Konstanz; University of Sheffield	Yelon, D (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Dev Genet Program, New York, NY 10016 USA.	yelon@saturn.med.nyu.edu	Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/G-9903-2011; Ingham, Philip W/E-6710-2010; Begemann, Gerrit/C-6223-2011	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958; Begemann, Gerrit/0000-0001-7822-7617				Begemann G, 2001, DEVELOPMENT, V128, P3081; Begemann G, 2004, DEV BIOL, V271, P119, DOI 10.1016/j.ydbio.2004.03.033; Brand T, 2003, DEV BIOL, V258, P1, DOI 10.1016/S0012-1606(03)00112-X; Chazaud C, 1999, DEVELOPMENT, V126, P2589; Chen THP, 2002, DEV BIOL, V250, P198, DOI 10.1006/dbio.2002.0796; Drysdale TA, 1997, DEV BIOL, V188, P205, DOI 10.1006/dbio.1997.8623; Goldstein AM, 1998, DEV BIOL, V201, P247, DOI 10.1006/dbio.1998.8976; Grandel H, 2002, DEVELOPMENT, V129, P2851; Hochgreb T, 2003, DEVELOPMENT, V130, P5363, DOI 10.1242/dev.00750; Keegan BR, 2004, DEVELOPMENT, V131, P3081, DOI 10.1242/dev.01185; Linville A, 2004, DEV BIOL, V270, P186, DOI 10.1016/j.ydbio.2004.02.022; Niederreither K, 2001, DEVELOPMENT, V128, P1019; Rones MS, 2000, DEVELOPMENT, V127, P3865; Schulze GE, 2001, TOXICOL SCI, V59, P297, DOI 10.1093/toxsci/59.2.297; Stafford D, 2002, CURR BIOL, V12, P1215, DOI 10.1016/S0960-9822(02)00929-6; STAINIER DYR, 1992, DEV BIOL, V153, P91, DOI 10.1016/0012-1606(92)90094-W; Stuckmann I, 2003, DEV BIOL, V255, P334, DOI 10.1016/S0012-1606(02)00078-7; YUTZEY KE, 1994, DEVELOPMENT, V120, P871	18	161	170	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					247	249		10.1126/science.1101573	http://dx.doi.org/10.1126/science.1101573			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653502				2022-12-28	WOS:000226361900040
J	Windrim, R				Windrim, R			Vaginal delivery in birth centre after previous caesarean section	LANCET			English	Editorial Material							UTERINE RUPTURE; RISK; DECISION; INTERVAL; LABOR		Mt Sinai Hosp, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Windrim, R (corresponding author), Mt Sinai Hosp, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada.	rwindrim@mtsinai.on.ca	Windrim, Rory/B-7617-2016; Windrim, Rory/ABD-6799-2021; Windrim, Rory/AAC-6038-2020					*AM COLL OBST GYN, 1999, ACOG PRACT B, V5; *AM COLL OBST GYN, 1988, GUID VAG BIRTH PREV; CRAGIN EB, 1916, NY STATE J MED, V104, P1; GRADY D, 2004, NY TIMES        1129, P1; Greene MF, 2001, NEW ENGL J MED, V345, P54, DOI 10.1056/NEJM200107053450108; Helmy WH, 2002, BJOG-INT J OBSTET GY, V109, P505, DOI 10.1016/S1470-0328(02)00491-3; Lieberman E, 2004, OBSTET GYNECOL, V104, P933, DOI 10.1097/01.AOG.0000143257.29471.82; Lydon-Rochelle M, 2001, NEW ENGL J MED, V345, P3, DOI 10.1056/NEJM200107053450101; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; Smith GCS, 2004, BRIT MED J, V329, P375, DOI 10.1136/bmj.38160.634352.55; Smith GCS, 2002, JAMA-J AM MED ASSOC, V287, P2684, DOI 10.1001/jama.287.20.2684; Thomas J, 2004, BRIT MED J, V328, P665, DOI 10.1136/bmj.38031.775845.7C	12	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2005	365	9454					106	107		10.1016/S0140-6736(05)17719-8	http://dx.doi.org/10.1016/S0140-6736(05)17719-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639279				2022-12-28	WOS:000226170700008
J	Jain, RK				Jain, RK			Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy	SCIENCE			English	Review							ENDOTHELIAL GROWTH-FACTOR; COLORECTAL-CANCER; FACTOR-RECEPTOR; BLOOD-VESSELS; SOLID TUMORS; FACTOR ANTIBODY; BREAST-CANCER; NUDE-MICE; ANGIOGENESIS; BEVACIZUMAB	Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature., The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis-that certain antiangiogenic agents. can also transiently "normalize" the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.	Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 7,100 Blossom St, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu	Zinn, Pascal O/A-6667-2010; Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548				Baffert F, 2004, CIRC RES, V94, P984, DOI 10.1161/01.RES.0000125295.43813.1F; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cobleigh MA, 2003, SEMIN ONCOL, V30, P117, DOI 10.1053/j.seminoncol.2003.08.013; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Fenton BM, 2004, RADIOTHER ONCOL, V72, P221, DOI 10.1016/j.radonc.2004.05.005; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Flintoft L, 2004, NAT REV CANCER, V4, P754, DOI 10.1038/nrc1459; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gazit Y, 1997, MICROCIRCULATION-LON, V4, P395, DOI 10.3109/10739689709146803; Goldman B, 2003, J NATL CANCER I, V95, P1744; Griffon-Etienne G, 1999, CANCER RES, V59, P3776; Gross S, 2003, NAT MED, V9, P1327, DOI 10.1038/nm940; GULLINO PM, 1982, BIOMEDICAL THERMOLOG, P1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hellmann K, 2003, CLIN EXP METASTAS, V20, P95, DOI 10.1023/A:1022632413888; Herbst RS, 2002, J CLIN ONCOL, V20, P3804, DOI 10.1200/JCO.2002.05.102; HICKLIN DJ, IN PRESS J CLIN ONCO; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jain RK, 1999, CLIN CANCER RES, V5, P1605; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; JAIN RK, 2004, CLIN ONCOLOGY, P153; Kadambi A, 2001, CANCER RES, V61, P2404; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Kim SJ, 2004, CANCER RES, V64, P4201, DOI 10.1158/0008-5472.CAN-03-3763; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Lee CG, 2000, CANCER RES, V60, P5565; Ma JG, 2001, CANCER RES, V61, P5491; Mayer RJ, 2004, NEW ENGL J MED, V350, P2406, DOI 10.1056/NEJMe048098; Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092; Murata R, 1997, INT J RADIAT ONCOL, V37, P1107, DOI 10.1016/S0360-3016(96)00628-1; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Rasey JS, 1996, INT J RADIAT ONCOL, V36, P417, DOI 10.1016/S0360-3016(96)00325-2; Ratner M, 2004, NAT BIOTECHNOL, V22, P1198, DOI 10.1038/nbt1004-1198; Relf M, 1997, CANCER RES, V57, P963; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Siemann DW, 2004, CANCER-AM CANCER SOC, V100, P2491, DOI 10.1002/cncr.20299; Teicher BA, 1996, CANCER METAST REV, V15, P247, DOI 10.1007/BF00437479; Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03; Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wildiers H, 2003, BRIT J CANCER, V88, P1979, DOI 10.1038/sj.bjc.6601005; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Xiong HQ, 2004, INVEST NEW DRUG, V22, P459, DOI 10.1023/B:DRUG.0000036688.96453.8d; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	57	3960	4196	28	735	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					58	62		10.1126/science.1104819	http://dx.doi.org/10.1126/science.1104819			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637262				2022-12-28	WOS:000226214300031
J	Angell, SY; Cetron, MS				Angell, SY; Cetron, MS			Health disparities among travelers visiting friends and relatives abroad	ANNALS OF INTERNAL MEDICINE			English	Article							NEW-YORK-CITY; EMERGING INFECTIONS; IMPORTED MALARIA; TUBERCULOSIS; CHILDREN; RISK; MEDICINE; COUNTRIES; MIGRANTS; SENTINEL	For an estimated 10 million trips abroad by U.S. residents in 2002, "visiting friends and relatives" (VFR) was a purpose for travel. Made up largely of foreign-born U.S. residents and their children, this population shows disparities in the number of reported cases of many preventable travel-related illnesses compared with people who travel for other purposes, such as tourism. High-risk illnesses in VFR travelers include childhood vaccine-preventable illnesses, hepatitis A and B, tuberculosis, malaria, and typhoid fever. Gaps in the prevalence of disease and access to care both between countries and within the United States uniquely influence disease risk in this population of travelers. We describe this population, a framework for understanding travel-related health disparities, and recommendations for improving the effective delivery of preventive travel-related care to VFR travelers. In addition to transnational efforts to control and eradicate disease, preventing illness in U.S. resident VFR travelers requires focused efforts to remove barriers to their care. In the United States, barriers exist at the systems level (for example, low insurance coverage), patient level (for example, misperception of disease risk), and provider level (for example, inadequate knowledge of travel medicine).	New York City Dept Hlth & Mental Hygiene, New York, NY 10007 USA; Robert Wood Johnson Clin Scholars Program, Ann Arbor, MI USA; Ctr Dis Control & Prevent, Atlanta, GA USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	Angell, SY (corresponding author), New York City Dept Hlth & Mental Hygiene, 2 Lafayette St,CN-46, New York, NY 10007 USA.	sangell@health.nyc.gov						Ackers ML, 2000, JAMA-J AM MED ASSOC, V283, P2668, DOI 10.1001/jama.283.20.2668; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], CENSUS 2000 SPECIAL; Bacaner N, 2004, JAMA-J AM MED ASSOC, V291, P2856, DOI 10.1001/jama.291.23.2856; Backer H, 2001, J TRAVEL MED, V8, P247; BEHRENS RH, 1995, BRIT MED J, V311, P193, DOI 10.1136/bmj.311.6998.193a; Brook M G, 1993, Commun Dis Rep CDR Rev, V3, pR28; Chatterjee S, 1999, J TRAVEL MED, V6, P7, DOI 10.2310/7060.1999.00003; Cobelens FGJ, 2000, LANCET, V356, P461, DOI 10.1016/S0140-6736(00)02554-X; dos Santos CC, 1999, CAN MED ASSOC J, V160, P195; Freedman DO, 1999, J TRAVEL MED, V6, P94, DOI 10.1111/j.1708-8305.1999.tb00839.x; Gibson Campbell J., 1999, HIST CENSUS STAT FOR; Halfon N, 1997, JAMA-J AM MED ASSOC, V277, P636, DOI 10.1001/jama.277.8.636; Huang F Y, 1997, Matern Child Health J, V1, P69, DOI 10.1023/A:1026266205885; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Kambili C, 2004, AM J TROP MED HYG, V70, P408, DOI 10.4269/ajtmh.2004.70.408; Keystone, 1994, J Travel Med, V1, P72, DOI 10.1111/j.1708-8305.1994.tb00566.x; KEYSTONE J, 2003, TRAVEL MED; Leonard L, 2001, J Immigr Health, V3, P31, DOI 10.1023/A:1026610602073; Lobato MN, 1998, AM J RESP CRIT CARE, V158, P1871, DOI 10.1164/ajrccm.158.6.9804106; Ormerod LP, 2001, J INFECTION, V43, P132, DOI 10.1053/jinf.2001.0872; Pol Louis G, 2002, J Immigr Health, V4, P103, DOI 10.1023/A:1014502710289; Provost S, 2001, J TRAVEL MED, V8, P66, DOI 10.2310/7060.2001.24323; Robinson P, 2001, J TRAVEL MED, V8, P76, DOI 10.2310/7060.2001.24309; Saiman L, 2001, PEDIATRICS, V107, P999, DOI 10.1542/peds.107.5.999; Schlagenhauf P, 2003, J TRAVEL MED, V10, P106, DOI 10.2310/7060.2003.31764; SCHMIDELY AD, 2001, CURRENT POPULATION R; Scolari C, 2002, J TRAVEL MED, V9, P160, DOI 10.2310/7060.2002.23177; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Strine TW, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.2.e15; THAMER M, 1998, PUBLIC PRIVATE HLTH; *US DEP HOM SEC, 2004, YB IMM STAT 2002; Weis SE, 2001, AM J RESP CRIT CARE, V164, P953, DOI 10.1164/ajrccm.164.6.2102132; Wilson ME, 2003, J APPL MICROBIOL, V94, p1S; 2003, MMWR MORB MORTAL WKL, V52, P958; 1997, MMWR MORB MORTAL WKL, V46, P963; 2004, MMWR SURVEIL SUMM, V53, P22	38	148	153	1	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2005	142	1					67	72		10.7326/0003-4819-142-1-200501040-00013	http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00013			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916DS	15630110				2022-12-28	WOS:000228366200007
J	Falagas, ME; Vergidis, PI				Falagas, ME; Vergidis, PI			Narrative review: Diseases that masquerade as infectious cellulitis	ANNALS OF INTERNAL MEDICINE			English	Review							CUTANEOUS LUPUS-ERYTHEMATOSUS; FAMILIAL MEDITERRANEAN FEVER; PERIFOLLICULITIS-CAPITIS-ABSCEDENS; NECROLYTIC MIGRATORY ERYTHEMA; DEEP VENOUS THROMBOSIS; RELAPSING POLYCHONDRITIS; WELLS-SYNDROME; SWEETS-SYNDROME; POLYARTERITIS-NODOSA; TOPICAL PROVOCATION	For cellulitis that does not respond to conventional antimicrobial treatment, clinicians should consider, among other explanations, several noninfectious disorders that might masquerade as infectious cellulitis. Diseases that commonly masquerade as this condition include thrombophlebitis, contact dermatitis, insect stings, drug reactions, eosinophilic cellulitis (the Wells syndrome), gouty arthritis, carcinoma erysipelatoides, familial Mediterranean fever, and foreign-body reactions. Diseases that uncommonly masquerade as infectious cellulitis include urticaria, lymphedema, lupus erythematosus, sarcoidosis, lymphoma, leukemia, Paget disease, and panniculitis. Clinicians should do an initial diagnostic work-up directed by the findings from a detailed history and complete physical examination. In many cases, skin biopsy is the only tool that helps identify the correct diagnosis. Special tests may also be needed.	Alfa Healthcare, Athens 15123, Greece; Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts University	Falagas, ME (corresponding author), Alfa Healthcare, 9 Neapoleos St, Athens 15123, Greece.	matthew.falagas@tufts.edu						ALANKO K, 1994, CONTACT DERMATITIS, V31, P25, DOI 10.1111/j.1600-0536.1994.tb01900.x; Alexander EK, 2002, CLIN ENDOCRINOL, V57, P827, DOI 10.1046/j.1365-2265.2002.01660.x; Antezana M, 2003, IMMUNOL ALLERGY CLIN, V23, P269, DOI 10.1016/S0889-8561(03)00027-4; Arch-Ferrer JE, 2003, SURGERY, V134, P941, DOI 10.1016/j.surg.2003.07.001; Ascher Enrico, 2003, Vasc Endovascular Surg, V37, P421, DOI 10.1177/153857440303700606; Baddour LM, 2001, CUTIS, V68, P223; Baker WF, 1998, MED CLIN N AM, V82, P459, DOI 10.1016/S0025-7125(05)70005-5; Barzilai A, 2000, J AM ACAD DERMATOL, V42, P791, DOI 10.1067/mjd.2000.103048; Bogenrieder T, 1997, BRIT J DERMATOL, V137, P978, DOI 10.1111/j.1365-2133.1997.tb01563.x; Brook I, 2002, J MED MICROBIOL, V51, P808, DOI 10.1099/0022-1317-51-10-808; Bruce AJ, 2002, J AM ACAD DERMATOL, V46, P187, DOI 10.1067/mjd.2002.119101; Burrall B, 1999, Dermatol Online J, V5, P8; Callen JP, 2002, BEST PRACT RES CL RH, V16, P245, DOI 10.1053/berh.2001.0224; Carrasco L, 2001, AM J DERMATOPATH, V23, P283, DOI 10.1097/00000372-200108000-00001; Cavalli F, 1998, ANN ONCOL, V9, P109, DOI 10.1023/A:1008478627637; CHEN K-R, 1989, Journal of Dermatology (Tokyo), V16, P429; CHICARILLI ZN, 1987, ANN PLAS SURG, V18, P230, DOI 10.1097/00000637-198703000-00009; Cohen JB, 2002, INT J DERMATOL, V41, P182, DOI 10.1046/j.1365-4362.2002.01409.x; Cohen Philip R, 2002, Am J Clin Dermatol, V3, P117, DOI 10.2165/00128071-200203020-00005; Cohen PR, 2003, INT J DERMATOL, V42, P761, DOI 10.1046/j.1365-4362.2003.01891.x; COPEMAN PWM, 1985, J ROY SOC MED, V78, P43; COPPOLA M, 1992, ANN EMERG MED, V21, P81, DOI 10.1016/S0196-0644(05)82246-2; Crum NF, 2003, CUTIS, V71, P469; CURTIN JP, 1990, GYNECOL ONCOL, V39, P374, DOI 10.1016/0090-8258(90)90269-Q; Davis MDP, 2000, ARCH DERMATOL, V136, P330, DOI 10.1001/archderm.136.3.330; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; DOMPMARTIN A, 1991, INT J DERMATOL, V30, P644, DOI 10.1111/j.1365-4362.1991.tb03491.x; Erdmann SM, 2003, HAUTARZT, V54, P331, DOI 10.1007/s00105-003-0517-2; Erhardt A, 2000, J HEPATOL, V33, P677, DOI 10.1034/j.1600-0641.2000.033004677.x; Fabbri P, 2003, AM J CLIN DERMATOL, V4, P449, DOI 10.2165/00128071-200304070-00002; Falagas ME, 2004, INT J CLIN PRACT, V58, P720, DOI 10.1111/j.1368-5031.2004.00269.x; FALAGAS ME, IN PRESS CLIN MICROB; FALANGA V, 1990, ARCH DERMATOL, V126, P609, DOI 10.1001/archderm.126.5.609; Fanning J, 1999, AM J OBSTET GYNECOL, V180, P24, DOI 10.1016/S0002-9378(99)70143-2; Fine A, 2002, KIDNEY INT, V61, P2210, DOI 10.1046/j.1523-1755.2002.00375.x; FITZPATRICK BT, 2000, COLOR ATLAS SYNOPSIS; Fonacier L, 2003, CURR ALLERGY ASTHM R, V3, P283, DOI 10.1007/s11882-003-0088-4; Frazee BW, 1999, AM J EMERG MED, V17, P271, DOI 10.1016/S0735-6757(99)90123-7; Fu W, 2001, AM J CLIN ONCOL-CANC, V24, P397, DOI 10.1097/00000421-200108000-00019; Gniadecka M, 1998, J AM ACAD DERMATOL, V39, P966, DOI 10.1016/S0190-9622(98)70271-3; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; Guillevin L, 1998, ARTHRITIS RHEUM, V41, P2100, DOI 10.1002/1529-0131(199812)41:12<2100::AID-ART3>3.3.CO;2-A; Gushi A, 2000, J Dermatol, V27, P778; Hassink RI, 1997, EUR J PEDIATR, V156, P851, DOI 10.1007/s004310050728; HAZELRIGG DE, 1977, ARCH DERMATOL, V113, P69, DOI 10.1001/archderm.113.1.69; Hope MJ, 2004, J ORTHOP TRAUMA, V18, P220, DOI 10.1097/00005131-200404000-00005; Hughes Laura B, 2002, Curr Rheumatol Rep, V4, P75, DOI 10.1007/s11926-002-0027-8; Int Soc Lymphology, 2003, LYMPHOLOGY, V36, P84; Johnson SM, 2003, J AM ACAD DERMATOL, V49, P325, DOI 10.1067/S0190-9622(02)61774-8; Kacinski BM, 2001, ANN NY ACAD SCI, V941, P194; Katta R, 2002, AM FAM PHYSICIAN, V65, P1581; Kennedy D, 2001, EMERG MED CLIN N AM, V19, P869, DOI 10.1016/S0733-8627(05)70223-6; KHAN AJ, 1994, CUTIS, V54, P98; Khan JH, 1999, J AM ACAD DERMATOL, V41, P299, DOI 10.1016/S0190-9622(99)70369-5; King R, 2001, ARCH DERMATOL, V137, P969; KIRSNER RS, 1993, J AM ACAD DERMATOL, V28, P623, DOI 10.1016/0190-9622(93)70085-8; Kjus T, 2003, ACTA DERM-VENEREOL, V83, P462, DOI 10.1080/00015550310015004; Klosterhalfen B, 2003, EUR SURG, V35, P16, DOI DOI 10.1046/J.1563-2563.2003.03011.X; KURZROCK R, 1991, AM J MED, V91, P416, DOI 10.1016/0002-9343(91)90160-Y; Langevitz P, 1999, ISRAEL MED ASSOC J, V1, P31; LEDO A, 1985, J AM ACAD DERMATOL, V13, P1058, DOI 10.1016/S0190-9622(85)80504-1; Letko E, 2002, SEMIN ARTHRITIS RHEU, V31, P384, DOI 10.1053/sarh.2002.32586; Levin C, 2000, CONTACT DERMATITIS, V43, P317, DOI 10.1034/j.1600-0536.2000.043006317.x; Loprinzi CL, 1996, MAYO CLIN PROC, V71, P552, DOI 10.4065/71.6.552; Ludwig RJ, 2003, J AM ACAD DERMATOL, V48, pS60, DOI 10.1067/mjd.2003.20; Mahboob A, 1998, INT J DERMATOL, V37, P833, DOI 10.1046/j.1365-4362.1998.00451.x; MAJEED HA, 1990, Q J MED, V75, P607; MALLETT RB, 1995, BRIT J DERMATOL, V132, P263; Marshall JK, 2003, CANCER, V97, P2142, DOI 10.1002/cncr.11337; Martens PB, 1999, J RHEUMATOL, V26, P68; Martin B G, 1999, J Am Osteopath Assoc, V99, pS11; Matthews BD, 2002, AM SURGEON, V68, P660; McBean J, 2003, CUTIS, V71, P205; McCarthy L, 2002, TRANSFUSION, V42, P1245, DOI 10.1046/j.1537-2995.2002.00210.x; McDermott EM, 1997, MAYO CLIN PROC, V72, P806, DOI 10.4065/72.9.806; Mert A, 2004, SCAND J INFECT DIS, V36, P424, DOI 10.1080/00365540410027184; Michiels JJ, 1997, SEMIN THROMB HEMOST, V23, P441, DOI 10.1055/s-2007-996121; Moossavi M, 2003, INT J DERMATOL, V42, P62, DOI 10.1046/j.1365-4362.2003.01705.x; Naschitz J E, 1993, Cardiovasc Surg, V1, P524; O'Neill J H Jr, 1991, Del Med J, V63, P683; Ozkaya-Bayazit E, 1999, CONTACT DERMATITIS, V41, P185, DOI 10.1111/j.1600-0536.1999.tb06127.x; Ozkaya-Bayazit E, 2003, J AM ACAD DERMATOL, V49, P1003, DOI 10.1016/S0190-9622(03)01588-3; Patel P, 2002, DERMATOL CLIN, V20, P373, DOI 10.1016/S0733-8635(02)00016-5; PETERS MS, 1989, MED CLIN N AM, V73, P1113, DOI 10.1016/S0025-7125(16)30622-8; Petit A, 1996, J AM ACAD DERMATOL, V34, P521, DOI 10.1016/S0190-9622(96)90466-1; Preiss JC, 2002, DIGESTION, V66, P193, DOI 10.1159/000066758; Psychos DN, 2000, CLIN RHEUMATOL, V19, P212, DOI 10.1007/s100670050159; Raake W, 2002, Hamostaseologie, V22, P149; Ramzi DW, 2004, AM FAM PHYSICIAN, V69, P2841; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; Requena Luis, 2002, Dermatol Online J, V8, P4; Russell-Jones R, 2000, SEMIN CUTAN MED SURG, V19, P100, DOI 10.1016/S1085-5629(00)80006-1; Russo Glenn, 1994, Comprehensive Therapy, V20, P418; Scheinfeld Noah S, 2003, Dermatol Online J, V9, P8; SCHEWACHMILLET M, 1986, J AM ACAD DERMATOL, V15, P1291, DOI 10.1016/S0190-9622(86)80042-1; Seckin D, 2001, INT J DERMATOL, V40, P138, DOI 10.1046/j.1365-4362.2001.01177-3.x; Sehgal VN, 2002, INT J DERMATOL, V41, P467, DOI 10.1046/j.1365-4362.2002.01469.x; Serra A, 1998, ACTA DERM-VENEREOL, V78, P198; SHAFFER N, 1992, ARCH DERMATOL, V128, P1329, DOI 10.1001/archderm.128.10.1329; Sheahan P, 2001, J LARYNGOL OTOL, V115, P1032; SIEGELMAN ES, 1993, NEW ENGL J MED, V328, P885; Siva C, 2003, AM FAM PHYSICIAN, V68, P83; Soto-Romero I, 2002, PEDIATR DERMATOL, V19, P60, DOI 10.1046/j.1525-1470.2002.00014.x; Stawiski M A, 1985, Emerg Med Clin North Am, V3, P785; Swan A, 2002, ANN RHEUM DIS, V61, P493, DOI 10.1136/ard.61.6.493; Szuba A, 1998, Vasc Med, V3, P145, DOI 10.1177/1358836X9800300209; Tagalakis V, 2002, AM J MED, V113, P146, DOI 10.1016/S0002-9343(02)01163-4; TERCEDOR J, 1992, INT J DERMATOL, V31, P598, DOI 10.1111/j.1365-4362.1992.tb02731.x; Terkeltaub RA, 2003, NEW ENGL J MED, V349, P1647, DOI 10.1056/NEJMcp030733; Tiwari A, 2002, BRIT J SURG, V89, P397, DOI 10.1046/j.0007-1323.2002.02063.x; Vigan M, 1996, ANN DERMATOL VENER, V123, P686; Watabe H, 2002, J DERMATOL, V29, P748, DOI 10.1111/j.1346-8138.2002.tb00215.x; Weiss G, 2001, INT J DERMATOL, V40, P148, DOI 10.1046/j.1365-4362.2001.11776.x; WILLIAMSON LM, 1982, Q J MED, V51, P469; Wilmer WA, 2002, SEMIN DIALYSIS, V15, P172, DOI 10.1046/j.1525-139X.2002.00052.x; WINKELMANN RK, 1993, MAYO CLIN PROC, V68, P122, DOI 10.1016/S0025-6196(12)60158-X; Witte CL, 2000, RADIOGRAPHICS, V20, P1697, DOI 10.1148/radiographics.20.6.g00nv141697; Wozniacka A, 2002, LUPUS, V11, P71, DOI 10.1191/0961203302lu147rr; Yim JH, 1997, ANN SURG ONCOL, V4, P287, DOI 10.1007/BF02303576; Young RJ, 2001, INT J DERMATOL, V40, P249, DOI 10.1046/j.1365-4362.2001.01151.x; ZEMER D, 1974, NEW ENGL J MED, V291, P932, DOI 10.1056/NEJM197410312911803	121	71	72	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2005	142	1					47	55		10.7326/0003-4819-142-1-200501040-00011	http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916DS	15630108				2022-12-28	WOS:000228366200005
J	Brice, A				Brice, A			How much does dardarin contribute to Parkinson's disease?	LANCET			English	Editorial Material							AUTOSOMAL-DOMINANT PARKINSONISM; ALPHA-SYNUCLEIN; MUTATIONS; LOCUS; GENE; DUPLICATION; PATHOLOGY		Grp Hosp Pitie Salpetriere, INSERM, U679, F-75651 Paris 13, France; Assistance Publ Hop Paris, Grp Hosp Pitie Salpetriere, Dept Genet Cytogenet & Embryol, Paris, France; Grp Hosp Pitie Salpetriere, IFR Neurosci, Paris, France; Univ Paris 06, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Brice, A (corresponding author), Grp Hosp Pitie Salpetriere, INSERM, U679, F-75651 Paris 13, France.	brice@ccr.jussieu.fr	Brice, Alexis/A-2170-2009; brice, alexis/AAE-8275-2019	brice, alexis/0000-0002-0941-3990				Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Giasson BI, 2003, SCIENCE, V300, P636, DOI 10.1126/science.1082324; Hardy J, 2003, LANCET NEUROL, V2, P221, DOI 10.1016/S1474-4422(03)00350-8; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Wszolek ZK, 2004, NEUROLOGY, V62, P1619, DOI 10.1212/01.WNL.0000125015.06989.DB; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005; Zimprich A, 2004, AM J HUM GENET, V74, P11, DOI 10.1086/380647	10	15	17	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					363	364						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680438				2022-12-28	WOS:000226610900005
J	Pignotti, MS; Indolfi, G; Ciuti, R; Donzelli, G				Pignotti, MS; Indolfi, G; Ciuti, R; Donzelli, G			Lesson of the week - Perinatal asphyxia and inadvertent neonatal intoxication from local anaesthetics given to the mother during labour	BRITISH MEDICAL JOURNAL			English	Review							LIDOCAINE		Anna Meyer Childrens Hosp, Dept Paediat, I-50132 Florence, Italy; Careggi Hosp, Toxicol Lab, Florence, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliero Universitaria Careggi	Pignotti, MS (corresponding author), Anna Meyer Childrens Hosp, Dept Paediat, Via L Giordano 13, I-50132 Florence, Italy.	m.pignotti@mcyer.it	Pignotti, Maria Serenella/H-8387-2013; Indolfi, Giuseppe/AAK-5548-2020	Indolfi, Giuseppe/0000-0003-3830-9823				DEPRAETER C, 1991, EUR J PEDIATR, V150, P685, DOI 10.1007/BF02072637; Edwards AD, 1998, BMJ-BRIT MED J, V317, P1537, DOI 10.1136/bmj.317.7172.1537; PHILIPSON EH, 1984, AM J OBSTET GYNECOL, V149, P403, DOI 10.1016/0002-9378(84)90154-6; SINCLAIR JC, 1965, NEW ENGL J MED, V273, P1173, DOI 10.1056/NEJM196511252732201; Volpe JJ, 2001, NEUROLOGY NEWBORN, P178; WALSON PD, 1982, PEDIATR PHARMACOL, V2, P341	6	5	5	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 1	2005	330	7481					34	35		10.1136/bmj.330.7481.34	http://dx.doi.org/10.1136/bmj.330.7481.34			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15626804	Green Published			2022-12-28	WOS:000226176700019
J	Kapur, N; Cooper, J; Rodway, C; Kelly, J; Guthrie, E; Mackway-Jones, K				Kapur, N; Cooper, J; Rodway, C; Kelly, J; Guthrie, E; Mackway-Jones, K			Predicting the risk of repetition after self harm: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Ctr Suicide Prevent, Dept Psychiat & Behav Sci, Manchester M13 9PL, Lancs, England; Manchester Royal Infirm, Dept Psychiat & Behav Sci, Manchester M13 9WL, Lancs, England; Manchester Royal Infirm, Dept Emergency Med, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester; University of Manchester	Kapur, N (corresponding author), Univ Manchester, Ctr Suicide Prevent, Dept Psychiat & Behav Sci, Manchester M13 9PL, Lancs, England.	nav.kapur@manchester.ac.uk		Guthrie, Elspeth/0000-0002-5834-6616; Rodway, Cathryn/0000-0003-0007-0124				[Anonymous], 2004, SELF HARM SHORT TERM; Hawton K, 1999, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001764, 10.1002/14651858.CD001764]; Kapur N, 2003, SOC PSYCH PSYCH EPID, V38, P390, DOI 10.1007/s00127-003-0647-y; Owens D, 2002, BRIT J PSYCHIAT, V181, P193, DOI 10.1192/bjp.181.3.193; Taylor C, 1999, ACTA PSYCHIAT SCAND, V100, P309, DOI 10.1111/j.1600-0447.1999.tb10866.x	5	43	43	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2005	330	7488					394	395		10.1136/bmj.38337.584225.82	http://dx.doi.org/10.1136/bmj.38337.584225.82			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15677364	Green Published, Bronze			2022-12-28	WOS:000227220400019
J	Bacon, PA				Bacon, PA			The spectrum of Wegener's granulomatosis and disease relapse	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Birmingham, Birmingham, W Midlands, England	University of Birmingham	Bacon, PA (corresponding author), Univ Birmingham, Birmingham, W Midlands, England.								0	98	107	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					330	332		10.1056/NEJMp048338	http://dx.doi.org/10.1056/NEJMp048338			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673799				2022-12-28	WOS:000226535900004
J	Kiessling, W				Kiessling, W			Long-term relationships between ecological stability and biodiversity in Phanerozoic reefs	NATURE			English	Article							DIVERSITY; PRODUCTIVITY; EXTINCTIONS; RESILIENCE	High biodiversity has been shown to enhance ecological stability on small spatial scales and over intervals of weeks to decades(1-4.) It remains unclear, however, whether this diversity - stability relationship can be scaled up to regional scales, or to longer timescales(5). Without empirical validation at larger scales, the implications of the diversity - stability relationship for both ecology and long-term conservation strategies cannot readily be resolved. Here I show that in biogenic reefs, ecological stability is related to taxonomic diversity on million-year timescales. The higher the mean reef diversity in a particular time interval, the smaller the change in skeletal density, style of reef building and biotic reef types in the subsequent time interval. Because the relationships apply to a wide spectrum of disturbance regimes and reef types, these results support the hypothesis that species richness itself promotes ecological stability(3). Carbonate production by reefs, while closely correlated with reef diversity without temporal lag, is not stabilized by reef diversity over these long timescales. This suggests that ecological stability and productivity may be decoupled in natural ecosystems.	Humboldt Univ, Museum Nat Hist, D-10115 Berlin, Germany	Humboldt University of Berlin	Kiessling, W (corresponding author), Humboldt Univ, Museum Nat Hist, Invalidenstr 43, D-10115 Berlin, Germany.	wolfgang.kiessling@museum.hu-berlin.de	Kiessling, Wolfgang/E-2259-2015	Kiessling, Wolfgang/0000-0002-1088-2014				Alroy J, 2004, EVOL ECOL RES, V6, P1; Bellwood DR, 2003, ECOL LETT, V6, P281, DOI 10.1046/j.1461-0248.2003.00432.x; Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; Bellwood DR, 2001, SCIENCE, V292, P1532, DOI 10.1126/science.1058635; Flugel E., 2002, PHANEROZOIC REEF PAT, V72, P391, DOI DOI 10.2110/PEC.02.72.0391; Golonka J., 2002, PHANEROZOIC REEF PAT, V72, P11, DOI [10.2110/pec.02.72.0011, DOI 10.2110/PEC.02.72, DOI 10.2110/PEC.02.72.0011]; JABLONSKI D, 1986, SCIENCE, V231, P129, DOI 10.1126/science.231.4734.129; Kiessling W, 2000, GEOL SOC SPEC PUBL, V178, P191, DOI 10.1144/GSL.SP.2000.178.01.13; KIESSLING W, 2002, SEPM SPEC PUBL, V72, P77; Kiessling W., 2002, SEPM SPECIAL PUBLICA, V72, P625; Kirchner JW, 2000, NATURE, V404, P177, DOI 10.1038/35004564; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; MCKINNEY M L, 1989, Palaios, V4, P3, DOI 10.2307/3514729; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; Nystrom M, 2000, TRENDS ECOL EVOL, V15, P413, DOI 10.1016/S0169-5347(00)01948-0; Pandolfi JM, 1999, AM ZOOL, V39, P113; Pandolfi JM, 2003, SCIENCE, V301, P955, DOI 10.1126/science.1085706; Pfisterer AB, 2002, NATURE, V416, P84, DOI 10.1038/416084a; Sankaran M, 1999, NATURE, V401, P691, DOI 10.1038/44368; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Tilman D, 2001, SCIENCE, V294, P843, DOI 10.1126/science.1060391; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0; Webb GE, 1996, SEDIMENTOLOGY, V43, P947, DOI 10.1111/j.1365-3091.1996.tb01513.x; Wood R., 1999, REEF EVOLUTION; Yachi S, 1999, P NATL ACAD SCI USA, V96, P1463, DOI 10.1073/pnas.96.4.1463	27	65	71	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					410	413		10.1038/nature03152	http://dx.doi.org/10.1038/nature03152			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674290	Green Published			2022-12-28	WOS:000226546200041
J	Xing, HY; Wilkerson, DC; Mayhew, CN; Lubert, EJ; Skaggs, HS; Goodson, ML; Hong, YL; Park-Sarge, OK; Sarge, KD				Xing, HY; Wilkerson, DC; Mayhew, CN; Lubert, EJ; Skaggs, HS; Goodson, ML; Hong, YL; Park-Sarge, OK; Sarge, KD			Mechanism of hsp70i gene bookmarking	SCIENCE			English	Article							CHROMOSOME CONDENSATION; TRANSCRIPTION FACTORS; ACTIVATION; COMPLEXES; PROMOTER; PROTEIN; PHOSPHORYLATION	In contrast to most genomic DNA in mitotic cells, the promoter regions of some genes, such as the stress-inducible hsp70i gene that codes for a heat shock protein, remain uncompacted, a phenomenon called bookmarking. Here we show that hsp70i bookmarking is mediated by a transcription factor called HSF2, which binds this promoter in mitotic cells, recruits protein phosphatase 2A, and interacts with the CAP-G subunit of the condensin enzyme to promote efficient dephosphorylation and inactivation of condensin complexes in the vicinity, thereby preventing compaction at this site. Blocking HSF2-mediated bookmarking by HSF2 RNA interference decreases hsp70i induction and survival of stressed cells in the G, phase, which demonstrates the biological importance of gene bookmarking.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY 40536 USA; Univ Cincinnati, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Battelle Mem Inst, Columbus, OH 43201 USA; Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA	University of Kentucky; University of Kentucky; University System of Ohio; University of Cincinnati; Battelle Memorial Institute; University of California System; University of California Davis	Sarge, KD (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	kdsarge@uky.edu	Goodson, Michael L/G-4175-2010; Mayhew, Christopher N/AGB-4929-2022	Goodson, Michael/0000-0002-3464-490X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041609, R01HD036879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061053, R01GM064606] Funding Source: NIH RePORTER; NICHD NIH HHS [HD36879, HD41609] Funding Source: Medline; NIGMS NIH HHS [GM64606, GM61053] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Deroo BJ, 2001, MOL BIOL CELL, V12, P3365, DOI 10.1091/mbc.12.11.3365; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hirano T, 2004, CELL CYCLE, V3, P26; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; John S, 1998, BIOESSAYS, V20, P275, DOI 10.1002/(SICI)1521-1878(199804)20:4<275::AID-BIES1>3.3.CO;2-6; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Li TH, 2000, NUCLEIC ACIDS RES, V28, P3031, DOI 10.1093/nar/28.16.3031; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Michelotti EF, 1997, NATURE, V388, P895, DOI 10.1038/42282; Morano KA, 1999, GENE EXPRESSION, V7, P271; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Strunnikov Alexander V, 2003, Prog Cell Cycle Res, V5, P361; Sun FL, 2000, P NATL ACAD SCI USA, V97, P5340, DOI 10.1073/pnas.090530797; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Takemoto A, 2004, J BIOL CHEM, V279, P4551, DOI 10.1074/jbc.M310925200; Wang TY, 2002, J IMMUNOL, V169, P795, DOI 10.4049/jimmunol.169.2.795; Yokomori K, 2003, CURR TOP MICROBIOL, V274, P79	25	127	131	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					421	423		10.1126/science.1106478	http://dx.doi.org/10.1126/science.1106478			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662014				2022-12-28	WOS:000226492300046
J	Chan, FKL; Ching, JYL; Hung, LCT; Wong, VWS; Leung, VKS; Kung, NNS; Hui, AJ; Wu, JCY; Leung, WK; Lee, VWY; Lee, KKC; Lee, YT; Lau, JYW; To, KF; Chan, HLY; Chung, SCS; Sung, JJY				Chan, FKL; Ching, JYL; Hung, LCT; Wong, VWS; Leung, VKS; Kung, NNS; Hui, AJ; Wu, JCY; Leung, WK; Lee, VWY; Lee, KKC; Lee, YT; Lau, JYW; To, KF; Chan, HLY; Chung, SCS; Sung, JJY			Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE ASPIRIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACUTE CORONARY SYNDROMES; ST-SEGMENT ELEVATION; PEPTIC-ULCER; HELICOBACTER-PYLORI; UNSTABLE ANGINA; RISK; CURE	BACKGROUND: Concurrent therapy with a proton-pump inhibitor is a standard treatment for patients receiving aspirin who are at risk for ulcer. Current U.S. guidelines also recommend clopidrogel for patients who have major gastrointestinal intolerance of aspirin. We compared clopidogrel with aspirin plus esomeprazole for the prevention of recurrent bleeding from ulcers in high-risk patients. METHODS: We studied patients who took aspirin to prevent vascular diseases and who presented with ulcer bleeding. After the ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either 75 mg of clopidogrel daily plus esomeprazole placebo twice daily or 80 mg of aspirin daily plus 20 mg of esomeprazole twice daily for 12 months. The end point was recurrent ulcer bleeding. RESULTS: We enrolled 320 patients (161 patients assigned to receive clopidogrel and 159 to receive aspirin plus esomeprazole). Recurrent ulcer bleeding occurred in 13 patients receiving clopidogrel and 1 receiving aspirin plus esomeprazole. The cumulative incidence of recurrent bleeding during the 12-month period was 8.6 percent (95 percent confidence interval, 4.1 to 13.1 percent) among patients who received clopidogrel and 0.7 percent (95 percent confidence interval, 0 to 2.0 percent) among those who received aspirin plus esomeprazole (difference, 7.9 percentage points; 95 percent confidence interval for the difference, 3.4 to 12.4; P=0.001). CONCLUSIONS: Among patients with a history of aspirin-induced ulcer bleeding whose ulcers had healed before they received the study treatment, aspirin plus esomeprazole was superior to clopidogrel in the prevention of recurrent ulcer bleeding. Our finding does not support the current recommendation that patients with major gastrointestinal intolerance of aspirin be given clopidogrel.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Therapeut, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Sch Pharm, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; United Christian Hosp, Med Unit, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; United Christian Hospital	Chan, FKL (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China.	fklchan@cuhk.edu.hk	Wu, Justin/N-6916-2015; Chan, Henry Lik-Yuen/B-9636-2008; Lee, Vivian WY/B-9389-2008; Lee, Yeong Yeh/G-2470-2010; Lau, James Y. W./O-2612-2016; Leung, Wai Keung/B-8140-2011; Lee, Vivian WY/ABE-2416-2021; Sung, Joseph J. Y./R-3203-2018; Wong, Vincent WS/K-3864-2014; Chan, Francis K. L./F-4851-2010	Chan, Henry Lik-Yuen/0000-0002-7790-1611; Lee, Vivian WY/0000-0001-5802-8899; Lee, Yeong Yeh/0000-0002-6486-7717; Lau, James Y. W./0000-0003-0122-4068; Leung, Wai Keung/0000-0002-5993-1059; Lee, Vivian WY/0000-0001-5802-8899; Sung, Joseph J. Y./0000-0003-3125-5199; Wong, Vincent WS/0000-0003-2215-9410; Chan, Francis K. L./0000-0001-7388-2436				American College of Cardiology, ACC AHA 2002 GUID UP; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; Chan FKL, 2001, NEW ENGL J MED, V344, P967, DOI 10.1056/NEJM200103293441304; Chan HLY, 2001, GASTROINTEST ENDOSC, V53, P438, DOI 10.1067/mge.2001.112840; *CLOP UNST ANG PRE, 2001, NEW ENGL J MED, V345, P1716; *CLOP UNST ANG PRE, 2001, NEW ENGL J MED, V345, P1506; CTR DRUG EVALUATION, Patent No. 20839SE1019; Derry S, 2000, BMJ-BRIT MED J, V321, P1183, DOI 10.1136/bmj.321.7270.1183; Fork FT, 2000, SCAND J GASTROENTERO, V35, P464; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hammer J, 2004, ALIMENT PHARM THER, V19, P1105, DOI 10.1111/j.1365-2036.2004.01949.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Katz PO, 2004, ALIMENT PHARM THERAP, V20, P399, DOI 10.1111/j.1365-2036.2004.02079.x; Lai KC, 2002, NEW ENGL J MED, V346, P2033, DOI 10.1056/NEJMoa012877; Laine L, 2001, GASTROENTEROLOGY, V120, P594, DOI 10.1053/gast.2001.21907; Lanas A, 2000, NEW ENGL J MED, V343, P834, DOI 10.1056/NEJM200009213431202; Ma L, 2001, P NATL ACAD SCI USA, V98, P6470, DOI 10.1073/pnas.111150798; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Ng FH, 2003, ALIMENT PHARM THER, V18, P443, DOI 10.1046/j.1365-2036.2003.01693.x; Peters RJG, 2003, CIRCULATION, V108, P1682, DOI 10.1161/01.CIR.0000091201.39590.CB; Peura D. A., 2004, Alimentary Pharmacology & Therapeutics, V19, P77, DOI 10.1111/j.0953-0673.2004.01828.x; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; RODRIGUEZ LAG, 1994, LANCET, V343, P1048; Rodriguez LAG, 1999, EPIDEMIOLOGY, V10, P228, DOI 10.1097/00001648-199905000-00006; ROEBRUCK P, 1995, STAT MED, V14, P1583, DOI 10.1002/sim.4780141409; Steinhubl SR, 2003, JAMA-J AM MED ASSOC, V289, P987; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; Yusuf S, 2001, NEW ENGL J MED, V345, P494	28	398	436	0	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					238	244		10.1056/NEJMoa042087	http://dx.doi.org/10.1056/NEJMoa042087			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659723	Bronze			2022-12-28	WOS:000226370500004
J	Kempf, S; Srama, R; Horanyi, M; Burton, M; Helfert, S; Moragas-Klostermeyer, G; Roy, M; Grun, E				Kempf, S; Srama, R; Horanyi, M; Burton, M; Helfert, S; Moragas-Klostermeyer, G; Roy, M; Grun, E			High-velocity streams of dust originating from Saturn	NATURE			English	Article							ULYSSES SPACECRAFT; JUPITER; EJECTION; GRAINS	High-velocity submicrometre-sized dust particles expelled from the jovian system have been identified by dust detectors on board several spacecraft(1,2). On the basis of periodicities in the dust impact rate, Jupiter's moon Io was found to be the dominant source of the streams(3). The grains become positively charged within the plasma environment of Jupiter's magnetosphere, and gain energy from its co-rotational electric field(4). Outside the magnetosphere, the dynamics of the grains are governed by the interaction with the interplanetary magnetic field that eventually forms the streams(5). A similar process was suggested for Saturn(6). Here we report the discovery by the Cassini spacecraft of bursts of high-velocity dust particles (greater than or equal to100 km s(-1)) within similar to70 million kilometres of Saturn. Most of the particles detected at large distances appear to originate from the outskirts of Saturn's outermost main ring. All bursts of dust impacts detected within 150 Saturn radii are characterized by impact directions markedly different from those measured between the bursts, and they clearly coincide with the spacecraft's traversals through streams of compressed solar wind.	Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; Univ Colorado, Dept Phys, Boulder, CO 80309 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA	Max Planck Society; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Hawaii System	Kempf, S (corresponding author), Max Planck Inst Kernphys, Saupfercheckweg 1, D-69117 Heidelberg, Germany.	Sascha.Kempf@mpi-hd.mpg.de		KEMPF, SASCHA/0000-0001-5236-3004				CHOW VW, 1993, J GEOPHYS RES-SPACE, V98, P19065, DOI 10.1029/93JA02014; GOLLER JR, 1989, PLANET SPACE SCI, V37, P1197, DOI 10.1016/0032-0633(89)90014-7; Graps AL, 2000, NATURE, V405, P48, DOI 10.1038/35011008; GRUN E, 1993, NATURE, V362, P428, DOI 10.1038/362428a0; Grun E, 1996, NATURE, V381, P395, DOI 10.1038/381395a0; HAMILTON DP, 1993, NATURE, V364, P695, DOI 10.1038/364695a0; HORANYI M, 1993, NATURE, V363, P144, DOI 10.1038/363144a0; Horanyi M, 2000, PHYS PLASMAS, V7, P3847, DOI 10.1063/1.1288909; HORANYI M, 1993, J GEOPHYS RES-SPACE, V98, P21245, DOI 10.1029/93JA02588; RICHARDSON JD, 1995, GEOPHYS RES LETT, V22, P1177, DOI 10.1029/95GL01018; SRAMA R, IN PRESS SPACE SCI R; Wehry A, 1999, ASTRON ASTROPHYS, V341, P296; Zook HA, 1996, SCIENCE, V274, P1501, DOI 10.1126/science.274.5292.1501	13	78	78	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					289	291		10.1038/nature03218	http://dx.doi.org/10.1038/nature03218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662418				2022-12-28	WOS:000226381300048
J	Berwick, DM				Berwick, DM			My right knee	ANNALS OF INTERNAL MEDICINE			English	Article							REGIONAL-VARIATIONS; CARE	Despite some impressive recent gains, improving the glaring deficiencies in health care quality is proving to be very hard. Improvement is local, rather than system-wide, and is sustained with difficulty, rather than becoming an intrinsic feature of care. My right knee will probably need to be replaced soon. This has given me the opportunity to define, in very personal terms, 5 specific dimensions of "total quality" that I will require from the medical institution that does my surgery and that every patient has the right to require of their encounters with the health care system. Don't kill me (no needless deaths). Do help me, and don't hurt me (no needless pain). Don't make me feel helpless. Don't keep me waiting. And don't waste resources, mine or anyone else's. Given my requirements, it is not clear that any health care institution in the United States will want to take me on as a patient. Although at this point individual institutions can meet some of these requirements, no single institution can deliver on all of them. Generating the energy, insight, and courage we need to get to "total quality" may require those of us who work in health care to get much better at seeing images of ourselves in the people we help. As Gandhi said, "You must be the change you wish to see in the world."	Inst Healthcare Improvement, Cambridge, MA 02138 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 20 Univ Rd,7th Floor, Cambridge, MA 02138 USA.	dberwick@ihi.org						Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; *I HLTH CAR IMPR, PRIM CAR ACC; Institute of Medicine, 2001, CROSSING QUALITY CHA; JULIUSSON R, 1984, ARCH ORTHOP TRAUM SU, V103, P42, DOI 10.1007/BF00451317; McManus ML, 2003, ANESTHESIOLOGY, V98, P1491, DOI 10.1097/00000542-200306000-00029; *PA HLTH CAR COST, 1999, TOT HIP KNEE REPL SU; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.3.10; SCHWARTZ DE, 1995, ANESTHESIOLOGY, V82, P367, DOI 10.1097/00000542-199502000-00007; *SWED BOARD HLTH, NAT REG KNEE INJ; Wennberg JE, 1998, DARTMOUTH ATLAS HLTH; *WI COLL HEALTHC Q, 2003, PERF PROGR REP	12	19	20	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2005	142	2					121	125		10.7326/0003-4819-142-2-200501180-00011	http://dx.doi.org/10.7326/0003-4819-142-2-200501180-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915LQ	15657160				2022-12-28	WOS:000228306100006
J	Horton, R				Horton, R			Threats to human survival: a WIRE to warn the world	LANCET			English	Editorial Material							TSUNAMI; DISASTER		Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, London NW1 7BY, England.							[Anonymous], 2005, LANCET, V365, P95; ASARI Y, 2000, PREHOSP DISASTERMED, V15, P81; Crichton M., 2004, STATE OF FEAR; Dawson AG, 2004, ENVIRON INT, V30, P577, DOI 10.1016/j.envint.2003.10.005; Diamond J., 2011, COLLAPSE SOC CHOOSE, V4th ed; DIAMOND J, 2005, GUARDIAN G2     0106, P4; El Arifeen S, 2004, LANCET, V364, P1595, DOI 10.1016/S0140-6736(04)17312-1; Holian AC, 1998, MED J AUSTRALIA, V169, P606, DOI 10.5694/j.1326-5377.1998.tb123433.x; Horton R, 2002, LANCET, V360, P582, DOI 10.1016/S0140-6736(02)09809-4; King D., 2005, IEE Seminar on Cosmic Radiation Single Event Effects and Avionics; LACHMAN R, 1961, SCIENCE, V133, P1405, DOI 10.1126/science.133.3462.1405; Lomborg B., 2004, GLOBAL CRISES GLOBAL; LOMBORG B, 2005, SUNDAY TIMES    0102, P14; MCGUIRE B, 2004, GUARDIAN        1230, P18; Nanayama F, 2003, NATURE, V424, P660, DOI 10.1038/nature01864; Sachs SE, 2004, LANCET, V364, P1404, DOI 10.1016/S0140-6736(04)17220-6; Taylor RP, 1998, MED J AUSTRALIA, V169, P602, DOI 10.5694/j.1326-5377.1998.tb123432.x; World Health Organization, 2004, WORLD HLTH REP 2004; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20	19	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					191	193						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652585				2022-12-28	WOS:000226309600003
J	Rothwell, PM				Rothwell, PM			Treating Individuals 2 - Subgroup analysis in randomised controlled trials: importance, indications, and interpretation	LANCET			English	Review							ANTILYMPHOCYTE INDUCTION THERAPY; ANTIHYPERTENSIVE DRUG-TREATMENT; RENAL-ALLOGRAFT SURVIVAL; EVIDENCE-BASED MEDICINE; CAROTID-ENDARTERECTOMY; CLINICAL-TRIALS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; BLOOD-PRESSURE	Large pragmatic trials provide the most reliable data about the effects of treatments, but should be designed, analysed, and reported to enable the most effective use of treatments in routine practice. Subgroup analyses are important if there are potentially large differences between groups in the risk of a poor outcome with or without treatment, if there is potential heterogeneity of treatment effect in relation to pathophysiology, if there are practical questions about when to treat, or if there are doubts about benefit in specific groups, such as elderly people, which are leading to potentially inappropriate undertreatment. Analyses must be predefined, carefully justified, and limited to a few clinically important questions, and post-hoc observations should be treated with scepticism irrespective of their statistical significance. If important subgroup effects are anticipated, trials should either be powered to detect them reliably or pooled analyses of several trials should be undertaken. Formal rules for the planning, analysis, and reporting of subgroup analyses are proposed.	Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Allder SJ, 1999, LANCET, V354, P1523, DOI 10.1016/S0140-6736(99)04360-3; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AMERY A, 1986, J HYPERTENS, V4, pS642; ANASTOS K, 1991, ANN INTERN MED, V115, P287, DOI 10.7326/0003-4819-115-4-287; ANDERSEN MP, 1979, LANCET, V2, P865; [Anonymous], 1982, Lancet, V2, P1173; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; BAILEY KR, 1994, CONTROL CLIN TRIALS, V15, P15, DOI 10.1016/0197-2456(94)90024-8; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Barratt PL, 2002, LANCET, V360, P1381, DOI 10.1016/S0140-6736(02)11402-4; Biller J, 1998, STROKE, V29, P554, DOI 10.1161/01.STR.29.2.554; Black D, 1998, J ROY COLL PHYS LOND, V32, P23; BOISSEL JP, 1993, J CARDIOVASC PHARM, V22, P356, DOI 10.1097/00005344-199309000-00003; Bond R, 2003, STROKE, V34, P2290, DOI 10.1161/01.STR.0000087785.01407.CC; Brookes S T, 2001, Health Technol Assess, V5, P1; Brown MJ, 2001, HEART, V86, P113, DOI 10.1136/heart.86.1.113; BUNDAJ A, 2002, CIRCULATION, V106, P1622; Burdett S, 1998, LANCET, V352, P257; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; Caplan LR, 2001, J NEUROL NEUROSUR PS, V71, P569, DOI 10.1136/jnnp.71.5.569; CHALMERS I, 2000, CLIN RISK, V6, P227; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; CLELAND JGF, 1995, BRIT HEART J, V74, P215; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; COLLINS R, 1995, LANCET, V345, P669; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Collins R, 1996, OXFORD TXB MED, V1, P21; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; Cui Lu, 2002, J Biopharm Stat, V12, P347, DOI 10.1081/BIP-120014565; Early Breast Cancer Trialists' Collaborative Group, 2001, COCHRANE DB SYST REV, V1; EGGER M, 1994, LANCET, V343, P1355, DOI 10.1016/S0140-6736(94)92490-2; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485; EVANS JG, 1995, AGE AGEING, V24, P461, DOI 10.1093/ageing/24.6.461; Fahey T, 1998, BRIT J GEN PRACT, V48, P1173; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Feinstein AR, 1998, J CLIN EPIDEMIOL, V51, P297, DOI 10.1016/S0895-4356(98)00004-3; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; FrasureSmith N, 1997, LANCET, V350, P473, DOI 10.1016/S0140-6736(97)02142-9; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FURBERG CD, 1983, CIRCULATION, V67, P98; GALE RP, 1990, BONE MARROW TRANSPL, V6, P357; GELBER RD, 1987, STAT MED, V6, P371, DOI 10.1002/sim.4780060331; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Grubb RL, 1998, JAMA-J AM MED ASSOC, V280, P1055, DOI 10.1001/jama.280.12.1055; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; Hacke W, 1999, NEUROLOGY, V53, pS3; Hahn S, 2000, STAT MED, V19, P3325, DOI 10.1002/1097-0258(20001230)19:24<3325::AID-SIM827>3.0.CO;2-D; Hampton JR, 2002, STAT MED, V21, P2807, DOI 10.1002/sim.1284; Herrington DM, 2002, NEW ENGL J MED, V346, P967, DOI 10.1056/NEJMoa012952; Holmvang L, 2003, J AM COLL CARDIOL, V41, P905, DOI 10.1016/S0735-1097(02)02970-4; Intercollegiate Stroke Working Party, 2000, NAT CLIN GUID STROK; Ioannidis JPA, 1997, J CLIN EPIDEMIOL, V50, P1089, DOI 10.1016/S0895-4356(97)00149-2; Ioannidis JPA, 1998, J CLIN EPIDEMIOL, V51, P709, DOI 10.1016/S0895-4356(98)00042-0; KALOW W, 1959, ANN HUM GENET, V23, P239, DOI 10.1111/j.1469-1809.1959.tb01467.x; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Li W, 1998, ARCH MAL COEUR VAISS, V91, P1059; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mant D, 1999, LANCET, V353, P743, DOI 10.1016/S0140-6736(98)09102-8; McAlister FA, 2002, CAN J CARDIOL, V18, P625; Moreira ED, 2001, BRAZ J MED BIOL RES, V34, P1441, DOI 10.1590/S0100-879X2001001100011; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; *MULT INT STUD, 1977, BMJ-BRIT MED J, V2, P419; Neumann FJ, 2001, LANCET, V357, P2085, DOI 10.1016/S0140-6736(00)05181-3; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; PETO R, 1981, TREATMENT CANC; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSE G, 1989, ANN MED, V21, P409, DOI 10.3109/07853898909149231; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rothwell PM, 2003, STROKE, V34, P2583, DOI 10.1161/01.STR.0000094424.38761.56; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; Rothwell PM, 1996, STROKE, V27, P266, DOI 10.1161/01.STR.27.2.266; Rudd A, 2002, CLIN MED, V2, P231; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; SACKETT DL, 1995, J CLIN EPIDEMIOL, V48, P61, DOI 10.1016/0895-4356(94)00085-5; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Sandercock P, 1997, LANCET, V349, P1569; Sanmuganathan PS, 2001, HEART, V85, P265, DOI 10.1136/heart.85.3.265; SELIGMANN M, 1994, LANCET, V343, P871; Senn S, 1998, BRIT MED J, V317, P537; Shepherd J, 1996, LANCET, V348, P1339; Smith GD, 1997, BMJ-BRIT MED J, V315, P1610, DOI 10.1136/bmj.315.7122.1610; STALLONES RA, 1987, PREV MED, V16, P183, DOI 10.1016/0091-7435(87)90082-X; Sullivan FM, 1996, LANCET, V348, P941, DOI 10.1016/S0140-6736(96)05219-1; Swales JD, 1999, J HYPERTENS, V17, P1511, DOI 10.1097/00004872-199917110-00002; Szczech LA, 1997, J AM SOC NEPHROL, V8, P1771; Szczech LA, 1998, ANN INTERN MED, V128, P817, DOI 10.7326/0003-4819-128-10-199805150-00004; TAKARO T, 1976, CIRCULATION, V54, P107; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206; Taylor DW, 1999, LANCET, V353, P2179, DOI 10.1016/S0140-6736(99)05388-X; Telenti A, 2002, LANCET, V359, P722, DOI 10.1016/S0140-6736(02)07899-6; TUKEY JW, 1962, ANN MATH STAT, V33, P1, DOI 10.1214/aoms/1177704711; VANDERGROND J, 1995, STROKE, V26, P822, DOI 10.1161/01.STR.26.5.822; VANGIJN J, 1995, CEREBROVASC DIS, V5, P159, DOI 10.1159/000107844; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401; Wijeysundera HC, 2003, AM HEART J, V146, P291, DOI 10.1016/S0002-8703(03)00171-6; WITTES RE, 1987, STAT MED, V6, P269, DOI 10.1002/sim.4780060312; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	127	644	653	3	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					176	186		10.1016/S0140-6736(05)17709-5	http://dx.doi.org/10.1016/S0140-6736(05)17709-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639301				2022-12-28	WOS:000226170700034
J	Batchelor, TT; Buchbinder, BR; Harris, NL				Batchelor, TT; Buchbinder, BR; Harris, NL			A 35-year-old woman with difficulty walking, headache, and nausea - Primary diffuse large-B-cell lymphoma of the brain.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CENTRAL-NERVOUS-SYSTEM; PRIMARY CNS LYMPHOMA; NON-HODGKINS-LYMPHOMA; MALIGNANT-LYMPHOMA; HISTOGENETIC SUBSETS; CHEMOTHERAPY; SURVIVAL; BCL-6; EXPRESSION; METHOTREXATE		Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Batchelor, TT (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.							Abrey LE, 2003, J CLIN ONCOL, V21, P4151, DOI 10.1200/JCO.2003.05.024; Abrey LE, 1998, J CLIN ONCOL, V16, P859, DOI 10.1200/JCO.1998.16.3.859; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ATLAS SW, 2002, MAGNETIC RESONANCE I, P565; Bataille B, 2000, J NEUROSURG, V92, P261, DOI 10.3171/jns.2000.92.2.0261; Batchelor T, 2003, J CLIN ONCOL, V21, P1044, DOI 10.1200/JCO.2003.03.036; BATCHELOR TT, 2004, LYMPHOMA NERVOUS SYS; BHAN AK, 1981, J EXP MED, V154, P737, DOI 10.1084/jem.154.3.737; Blay JY, 1998, J CLIN ONCOL, V16, P864, DOI 10.1200/JCO.1998.16.3.864; Braaten KM, 2003, CLIN CANCER RES, V9, P1063; Buhring U, 2001, NEUROLOGY, V57, P393, DOI 10.1212/WNL.57.3.393; Carbone A, 1998, BLOOD, V91, P747; Carbone A, 2001, BLOOD, V97, P744, DOI 10.1182/blood.V97.3.744; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; *CENTR BRAIN TUM R, 2002, STAT REP PRIM BRAIN; Chan WC, 1997, BLOOD, V89, P3909; Cote TR, 1996, J NATL CANCER I, V88, P675, DOI 10.1093/jnci/88.10.675; Coulon A, 2002, EUR RADIOL, V12, P329, DOI 10.1007/s003300101037; DEANGELIS LM, 1990, NEUROLOGY, V40, P80, DOI 10.1212/WNL.40.1.80; EBY NL, 1988, CANCER, V62, P2461, DOI 10.1002/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO;2-M; Engelhard M, 1997, BLOOD, V89, P2291; Erdag N, 2001, AM J ROENTGENOL, V176, P1319, DOI 10.2214/ajr.176.5.1761319; Ferreri AJM, 2003, J CLIN ONCOL, V21, P2407, DOI 10.1200/JCO.2003.01.135; Ferreri AJM, 2003, J CLIN ONCOL, V21, P266, DOI 10.1200/JCO.2003.09.139; HENRY JM, 1974, CANCER, V34, P1293, DOI 10.1002/1097-0142(197410)34:4<1293::AID-CNCR2820340441>3.0.CO;2-P; Jenkins CNJ, 1998, CLIN RADIOL, V53, P428, DOI 10.1016/S0009-9260(98)80271-7; Johnson BA, 1997, AM J NEURORADIOL, V18, P563; Kadan-Lottick NS, 2002, CANCER, V95, P193, DOI 10.1002/cncr.10643; Koeller KK, 1997, RADIOGRAPHICS, V17, P1497, DOI 10.1148/radiographics.17.6.9397461; LENNERT K, 1975, BRIT J CANCER, V31, P29; Mavrommatis CG, 1998, EUR J OBSTET GYN R B, V79, P95, DOI 10.1016/S0301-2115(98)00024-4; McAllister LD, 2000, NEUROSURGERY, V46, P51, DOI 10.1093/neurosurgery/46.1.51; MILLER DC, 1994, CANCER-AM CANCER SOC, V74, P1383, DOI 10.1002/1097-0142(19940815)74:4<1383::AID-CNCR2820740432>3.0.CO;2-1; MURRAY K, 1986, J NEUROSURG, V65, P600, DOI 10.3171/jns.1986.65.5.0600; NELSON DF, 1992, INT J RADIAT ONCOL, V23, P9, DOI 10.1016/0360-3016(92)90538-S; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Plotkin SR, 2001, LANCET ONCOL, V2, P455; Plotkin SR, 2004, CLIN CANCER RES, V10, P5643, DOI 10.1158/1078-0432.CCR-04-0159; ROMANGOLDSTEIN SM, 1992, AM J NEURORADIOL, V13, P1207; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Ruiz A, 1997, NEUROIMAG CLIN N AM, V7, P281; Soussain C, 2004, B CANCER, V91, P189	42	4	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					185	194		10.1056/NEJMcpc049033	http://dx.doi.org/10.1056/NEJMcpc049033			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647582				2022-12-28	WOS:000226251700013
J	Zeman, A				Zeman, A			Tales from the temporal lobe	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ORIGIN		Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Zeman, A (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.			Zeman, Adam/0000-0003-4875-658X				BANCAUD J, 1994, BRAIN, V117, P71, DOI 10.1093/brain/117.1.71; Blanke O, 2004, BRAIN, V127, P719; Blanke O, 2004, BRAIN, V127, P243, DOI 10.1093/brain/awh040; HODGES JR, 1992, BRAIN, V115, P1783, DOI 10.1093/brain/115.6.1783; JACKSON JH, 1880, BRAIN, V3, P206; Zeman AZJ, 1998, J NEUROL NEUROSUR PS, V64, P435, DOI 10.1136/jnnp.64.4.435	6	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					119	121		10.1056/NEJMp048219	http://dx.doi.org/10.1056/NEJMp048219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647573				2022-12-28	WOS:000226251700003
J	Indjeian, VB; Stern, BM; Murray, AW				Indjeian, VB; Stern, BM; Murray, AW			The centromeric protein Sgo1 is required to sense lack of tension on mitotic chromosomes	SCIENCE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; SISTER-CHROMATID COHESION; BUDDING YEAST; AURORA-B; KINETOCHORES; ANAPHASE; MEIOSIS; ACTIVATE; MEI-S332; REVEALS	,Chromosome alignment on the mitotic spindle is monitored by the. spindle checkpoint. We identify Sgo1, a protein involved in meiotic chromosome cohesion, as spindle checkpoint component. Budding yeast cells with mutations in SGO1 respond normally to microtubule depolymerization but not to lack of tension at-the kinetochore, and they have difficulty attaching sister chromatids to opposite boles of the spindle. Sgo1 is thus required for sensing tension between sister chromatids during mitosis, and its degradation when they separate may prevent, cell cycle arrest and chromosome loss in anaphase, a time when sister chromatids are no longer under tension.	Harvard Univ, Biol Labs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Murray, AW (corresponding author), Harvard Univ, Biol Labs, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.	amurray@mcb.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043987, R37GM043987] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM043987, GM043987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; INDJEIAN VB, UNPUB; Katis VL, 2004, CURR BIOL, V14, P560, DOI 10.1016/j.cub.2004.03.001; KERREBROCK AW, 1992, GENETICS, V130, P827; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Marston AL, 2004, SCIENCE, V303, P1367, DOI 10.1126/science.1094220; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; PALFRAMAN W, UNPUB; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rudner AD, 2000, J CELL BIOL, V149, P1361, DOI 10.1083/jcb.149.7.1361; Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016; Stern BM, 2001, CURR BIOL, V11, P1462, DOI 10.1016/S0960-9822(01)00451-1; STERN BM, UNPUB; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	29	145	152	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					130	133		10.1126/science.1101366	http://dx.doi.org/10.1126/science.1101366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637284				2022-12-28	WOS:000226214300055
J	McNamara, BR; Nulsen, PEJ; Wise, MW; Rafferty, DA; Carilli, C; Sarazin, CL; Blanton, EL				McNamara, BR; Nulsen, PEJ; Wise, MW; Rafferty, DA; Carilli, C; Sarazin, CL; Blanton, EL			The heating of gas in a galaxy cluster by X-ray cavities and large-scale shock fronts	NATURE			English	Article							COOLING FLOWS; RADIO; ENERGY; MODELS	Most of the baryons in galaxy clusters reside between the galaxies in a hot, tenuous gas(1). The densest gas in their centres should cool and accrete onto giant central galaxies at rates of 10-1,000 solar masses per year(1). No viable repository for this gas, such as clouds or new stars, has been found(1). New X-ray observations, however, have revealed far less cooling below X-ray temperatures than expected(2), altering the previously accepted picture of cooling flows. As a result, most of the gas must be heated to and maintained at temperatures above similar to2 keV (ref. 3). The most promising heating mechanism is powerful radio jets emanating from supermassive black holes in the central galaxies of clusters(4). Here we report the discovery of giant cavities and shock fronts in a distant (z=0.22) cluster caused by an interaction between a radio source and the hot gas surrounding it. The energy involved is similar to6x10(61) erg, the most powerful radio outburst known. This is enough energy to quench a cooling flow for several Gyr, and to provide similar to1/3 keV per particle of heat to the surrounding cluster.	Ohio Univ, Clippinger Labs, Inst Astrophys, Athens, OH 45701 USA; Ohio Univ, Clippinger Labs, Dept Phys & Astron, Athens, OH 45701 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; MIT, Ctr Space Res, Cambridge, MA 02139 USA; Natl Radio Astron Observ, Very Large Array, Socorro, NM 87801 USA; Univ Virginia, Dept Astron, Charlottesville, VA 22903 USA; Boston Univ, Inst Astrophys Res, Boston, MA 02215 USA	University System of Ohio; Ohio University; University System of Ohio; Ohio University; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Massachusetts Institute of Technology (MIT); National Radio Astronomy Observatory (NRAO); University of Virginia; Boston University	McNamara, BR (corresponding author), Ohio Univ, Clippinger Labs, Inst Astrophys, Athens, OH 45701 USA.	mcnamarb@ohio.edu	Blanton, Elizabeth/H-4501-2014	Nulsen, Paul/0000-0003-0297-4493; Blanton, Elizabeth/0000-0002-0485-6573; Wise, Michael/0000-0002-6470-2285				Bicknell GV, 1997, ASTROPHYS J, V485, P112, DOI 10.1086/304400; Birzan L, 2004, ASTROPHYS J, V607, P800, DOI 10.1086/383519; Churazov E, 2002, MON NOT R ASTRON SOC, V332, P729, DOI 10.1046/j.1365-8711.2002.05332.x; Churazov E, 2001, ASTROPHYS J, V554, P261, DOI 10.1086/321357; Clarke TE, 2001, ASTROPHYS J, V547, pL111, DOI 10.1086/318896; Condon JJ, 1998, ASTRON J, V115, P1693, DOI 10.1086/300337; DEYOUNG DS, 1993, ASTROPHYS J, V405, pL13, DOI 10.1086/186754; DONAHUE M, 1992, ASTROPHYS J, V385, P49, DOI 10.1086/170914; DONAHUE M, 1995, ASTROPHYS J, V449, P554, DOI 10.1086/176079; Edge AC, 2001, MON NOT R ASTRON SOC, V328, P762, DOI 10.1046/j.1365-8711.2001.04802.x; Fabian AC, 2003, MON NOT R ASTRON SOC, V344, pL43, DOI 10.1046/j.1365-8711.2003.06902.x; FABIAN AC, 1994, ANNU REV ASTRON ASTR, V32, P277, DOI 10.1146/annurev.aa.32.090194.001425; FABIAN AC, 2001, MNRAS, V321, P20; Ferrarese L, 2000, ASTROPHYS J, V539, pL9, DOI 10.1086/312838; FORMAN W, IN PRESS ASTROPHYS J; Furlanetto SR, 2001, ASTROPHYS J, V556, P619, DOI 10.1086/321630; Gebhardt K, 2000, ASTROPHYS J, V539, pL13, DOI 10.1086/312840; Heckman TM, 2004, ASTROPHYS J, V613, P109, DOI 10.1086/422872; Kronberg PP, 2001, ASTROPHYS J, V560, P178, DOI 10.1086/322767; Markevitch M, 1998, ASTROPHYS J, V504, P27, DOI 10.1086/306080; McNamara BR, 2000, ASTROPHYS J, V534, pL135, DOI 10.1086/312662; MCNAMARA BR, 1989, ASTRON J, V98, P2018, DOI 10.1086/115275; NULSEN PEJ, UNPUB ASTROPHYS J; Peterson JR, 2003, ASTROPHYS J, V590, P207, DOI 10.1086/374830; SCHEUER PAG, 1974, MON NOT R ASTRON SOC, V166, P513, DOI 10.1093/mnras/166.3.513; Soker M, 2001, ASTROPHYS J, V549, P832, DOI 10.1086/319433; STOCKE JT, 1991, ASTROPHYS J SUPPL S, V76, P813, DOI 10.1086/191582; Wu KKS, 2000, MON NOT R ASTRON SOC, V318, P889, DOI 10.1046/j.1365-8711.2000.03828.x	29	333	334	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					45	47		10.1038/nature03202	http://dx.doi.org/10.1038/nature03202			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635404				2022-12-28	WOS:000226117100030
J	Rothstein, JD; Patel, S; Regan, MR; Haenggeli, C; Huang, YH; Bergles, DE; Jin, L; Hoberg, MD; Vidensky, S; Chung, DS; Toan, SV; Bruijn, LI; Su, ZZ; Gupta, P; Fisher, PB				Rothstein, JD; Patel, S; Regan, MR; Haenggeli, C; Huang, YH; Bergles, DE; Jin, L; Hoberg, MD; Vidensky, S; Chung, DS; Toan, SV; Bruijn, LI; Su, ZZ; Gupta, P; Fisher, PB			beta-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression	NATURE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CEREBROSPINAL-FLUID; PROLONGS SURVIVAL; MOTOR-NEURONS; RAT-BRAIN; MODEL; ALS; GLT-1; EAAT2; MICE	Glutamate is the principal excitatory neurotransmitter in the nervous system. Inactivation of synaptic glutamate is handled by the glutamate transporter GLT1 (also known as EAAT2; refs 1, 2), the physiologically dominant astroglial protein. In spite of its critical importance in normal and abnormal synaptic activity, no practical pharmaceutical can positively modulate this protein. Animal studies show that the protein is important for normal excitatory synaptic transmission, while its dysfunction is implicated in acute and chronic neurological disorders, including amyotrophic lateral sclerosis (ALS)(3), stroke(4), brain tumours(5) and epilepsy(6). Using a blinded screen of 1,040 FDA-approved drugs and nutritionals, we discovered that many beta-lactam antibiotics are potent stimulators of GLT1 expression. Furthermore, this action appears to be mediated through increased transcription of the GLT1 gene(7). beta-Lactams and various semi-synthetic derivatives are potent antibiotics that act to inhibit bacterial synthetic pathways(8). When delivered to animals, the beta-lactam ceftriaxone increased both brain expression of GLT1 and its biochemical and functional activity. Glutamate transporters are important in preventing glutamate neurotoxicity(1,9- 11). Ceftriaxone was neuroprotective in vitro when used in models of ischaemic injury and motor neuron degeneration, both based in part on glutamate toxicity(11). When used in an animal model of the fatal disease ALS, the drug delayed loss of neurons and muscle strength, and increased mouse survival. Thus these studies provide a class of potential neurotherapeutics that act to modulate the expression of glutamate neurotransmitter transporters via gene activation.	Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21287 USA; ALS Assoc, Palm Harbor, FL 34685 USA; Columbia Univ Coll Phys & Surg, Med Ctr, Dept Pathol Neurosurg & Urol, New York, NY 10032 USA	Johns Hopkins University; Johns Hopkins University; Columbia University	Rothstein, JD (corresponding author), Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.	jrothste@jhmi.edu	Bergles, Dwight/U-8343-2019; Huang, Yanhua/P-1583-2015; rothstein, jeffrey d/C-9470-2013	Bergles, Dwight/0000-0002-7133-7378; Huang, Yanhua/0000-0003-1770-0196; 				Brown J.H., 2001, GOODMAN GILMANS PHAR, V10th ed., P10; Canton T, 2001, J PHARMACOL EXP THER, V299, P314; CHANDRASEKAR PH, 1984, J ANTIMICROB CHEMOTH, V14, P427, DOI 10.1093/jac/14.4.427; Chen WZ, 2002, J NEUROSCI, V22, P2142, DOI 10.1523/JNEUROSCI.22-06-02142.2002; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Gong SC, 2002, GENOME RES, V12, P1992, DOI 10.1101/gr.476202; Guo H, 2003, HUM MOL GENET, V12, P2519, DOI 10.1093/hmg/ddg267; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; KAZRAGIS R, 1996, ANTIMICROB AGENTS CH, V38, P2632; NAU R, 1993, ANTIMICROB AGENTS CH, V37, P1518, DOI 10.1128/AAC.37.7.1518; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; Romera C, 2004, J NEUROSCI, V24, P1350, DOI 10.1523/JNEUROSCI.1596-03.2004; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; ROTHSTEIN JD, 1995, J NEUROCHEM, V65, P643; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Spalloni A, 2004, NEUROBIOL DIS, V15, P340, DOI 10.1016/j.nbd.2003.11.012; Su ZZ, 2003, P NATL ACAD SCI USA, V100, P1955, DOI 10.1073/pnas.0136555100; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999	26	1156	1239	1	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					73	77		10.1038/nature03180	http://dx.doi.org/10.1038/nature03180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635412				2022-12-28	WOS:000226117100038
J	Evans, MG; Kalra, D				Evans, MG; Kalra, D			Healthcare computer systems - global approaches	LANCET			English	Editorial Material							INFORMATION-SYSTEMS		Camden & Islington Mental Hlth & Social Care Trus, Mental Hlth Care Older People, London NW3 2BN, England; UCL, Royal Free & Univ Coll Med Sch, London, England	University of London; University College London	Evans, MG (corresponding author), Camden & Islington Mental Hlth & Social Care Trus, Mental Hlth Care Older People, London NW3 2BN, England.	Matt.evans@nhs.net	Tao, Youyou/D-2367-2014; Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067; Evans, Matthew/0000-0003-0904-7051				ALVARES R, 2004, P 7 ANN M CAN SOC TE; Audit Commission, 2001, SPOONF SUG MED MAN; *AUSTR DEP HLTH AG, 2004, HEALTHCONNECT OV; Department of Health, 2002, DEL 21 CENT IT SUPP; *I MED, 2000, ERR IS HUM; KALRA D, 2002, P MOB HLTH EUR BOST; KALRA D, 2003, THESIS U LONDON; Littlejohns P, 2003, BRIT MED J, V326, P860, DOI 10.1136/bmj.326.7394.860; *MED UK, 2004, BBC SURF NPFIT; Patterson D, 1999, CLIN GOVERNANCE MAKI; Poulymenakou A, 1996, EUR J INFORM SYST, V5, P34, DOI 10.1057/ejis.1996.10; Smith R, 1996, BRIT MED J, V313, P1062; UK Government, 2021, GP IT FUTURES SYSTEM; VERSEL N, 2004, E HLTH INSIDER  0910; Waegemann CP, 1999, P EL HLTH REC EUR 99, P147	15	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 1	2005	365	9453					10	11		10.1016/S0140-6736(04)17678-2	http://dx.doi.org/10.1016/S0140-6736(04)17678-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639663				2022-12-28	WOS:000226213100007
J	Steele, DJR; Michaels, PJ; Goes, N; Cornell, LD				Steele, DJR; Michaels, PJ; Goes, N; Cornell, LD			A woman with long-standing hematuria - Nephropathy with thin and focally disrupted glomerular basement membranes and decreased alpha 3 and alpha 5 chains of type IV collagen, consistent with a carrier state of X-linked Alport's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ISOLATED MICROSCOPIC HEMATURIA; IGA NEPHROPATHY; DISEASE; ADULTS; GENE		Massachusetts Gen Hosp, Dept Med, Renal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Steele, DJR (corresponding author), Massachusetts Gen Hosp, Dept Med, Renal Unit, Boston, MA 02114 USA.							Ahmed Z, 1997, MED CLIN N AM, V81, P641, DOI 10.1016/S0025-7125(05)70537-X; Buzza M, 2001, KIDNEY INT, V59, P1670, DOI 10.1046/j.1523-1755.2001.0590051670.x; Cohen RA, 2003, NEW ENGL J MED, V348, P2330, DOI 10.1056/NEJMcp012694; Donadio JV, 2002, NEW ENGL J MED, V347, P738, DOI 10.1056/NEJMra020109; Gharavi AG, 2000, NAT GENET, V26, P354, DOI 10.1038/81677; Hebert LA, 1996, KIDNEY INT, V49, P168, DOI 10.1038/ki.1996.23; Heidet L, 2001, J AM SOC NEPHROL, V12, P97, DOI 10.1681/ASN.V12197; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; Kashtan CE, 1996, KIDNEY INT, V50, P1445, DOI 10.1038/ki.1996.459; KITAMOTO Y, 1993, NEPHRON, V64, P32, DOI 10.1159/000187274; KOHLER H, 1991, KIDNEY INT, V40, P115, DOI 10.1038/ki.1991.188; Lajoie G, 2001, ARCH PATHOL LAB MED, V125, P631; Liapis H, 2002, HUM PATHOL, V33, P836, DOI 10.1053/hupa.2002.125374; McGregor DO, 1998, CLIN NEPHROL, V49, P345; MYERS JC, 1990, AM J HUM GENET, V46, P1024; ROGERS PW, 1973, ARCH INTERN MED, V131, P257, DOI 10.1001/archinte.131.2.257; RUMPELT HJ, 1982, J PEDIATR, V101, P358; Sakai K, 2003, CLIN TRANSPLANT, V17, P4, DOI 10.1034/j.1399-0012.17.s10.5.x; Savige J, 2003, KIDNEY INT, V64, P1169, DOI 10.1046/j.1523-1755.2003.00234.x; Takemura T, 2003, CLIN NEPHROL, V60, P195; Tanaka H, 1996, AM J NEPHROL, V16, P412, DOI 10.1159/000169034; TIEBOSCH ATMG, 1989, NEW ENGL J MED, V320, P14, DOI 10.1056/NEJM198901053200103; TOPHAM PS, 1994, Q J MED, V87, P329	23	1	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2851	2859		10.1056/NEJMcpc049031	http://dx.doi.org/10.1056/NEJMcpc049031			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625337				2022-12-28	WOS:000226004300012
J	Tolar, J; Teitelbaum, SL; Orchard, PJ				Tolar, J; Teitelbaum, SL; Orchard, PJ			Mechanisms of disease: Osteopetrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AUTOSOMAL-DOMINANT OSTEOPETROSIS; COLONY-STIMULATING FACTOR; ANHYDRASE-II DEFICIENCY; OSTEOCLAST DIFFERENTIATION FACTOR; BONE-MARROW TRANSPLANTATION; ALBERS-SCHONBERG-DISEASE; CLCN7 GENE-MUTATIONS; FACTOR-KAPPA-B; TARGETED DISRUPTION; CHLORIDE CHANNEL		Univ Minnesota, Dept Pediat, Program Blood & Marrow Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Washington Univ, Dept Pathol & Immunol, St Louis, MO USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Washington University (WUSTL)	Orchard, PJ (corresponding author), Univ Minnesota, Dept Pediat, Program Blood & Marrow Transplantat, 660D CCR3,MMC 366,420 Delaware St SE, Minneapolis, MN 55455 USA.	orcha001@umn.edu		Teitelbaum, Steven/0000-0002-4054-6679; Tolar, Jakub/0000-0002-0957-4380				Albers-Schonberg H.E., 1904, MUNCH MED WOCHENSCHR, V5, P365; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Benichou OD, 2000, BONE, V26, P87, DOI 10.1016/S8756-3282(99)00244-6; Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521-1878(199810)20:10<837::AID-BIES9>3.3.CO;2-4; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; BOLLERSLEV J, 1993, CLIN ORTHOP RELAT R, P45; BOLLERSLEV J, 1989, ACTA ORTHOP SCAND, V60, P110, DOI 10.3109/17453678909150106; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Campos-Xavier AB, 2003, HUM GENET, V112, P186, DOI 10.1007/s00439-002-0861-9; Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842; Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861; COCCIA PF, 1980, NEW ENGL J MED, V302, P701, DOI 10.1056/NEJM198003273021301; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Deng WJ, 2001, J BONE MINER RES, V16, P1136, DOI 10.1359/jbmr.2001.16.6.1136; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945-053X(00)00051-2; ELTAWIL T, 1993, SKELETAL RADIOL, V22, P587; Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924; Fasth A, 1999, Pediatr Transplant, V3 Suppl 1, P102; FATHALLAH DM, 1994, HUM GENET, V94, P581; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; Felix R, 1996, J CELL PHYSIOL, V166, P311, DOI 10.1002/(SICI)1097-4652(199602)166:2<311::AID-JCP9>3.0.CO;2-S; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740; GERRITSEN EJA, 1994, PEDIATRICS, V93, P247; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hofbauer LC, 2001, CANCER-AM CANCER SOC, V92, P460, DOI 10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D; Hollberg K, 2002, EXP CELL RES, V279, P227, DOI 10.1006/excr.2002.5612; HOLTROP ME, 1981, METAB BONE DIS RELAT, V3, P123, DOI 10.1016/0221-8747(81)90030-8; Hou P, 2004, BONE, V34, P37, DOI 10.1016/j.bone.2003.08.011; HU PY, 1994, AM J HUM GENET, V54, P602; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jentsch T. J., 2002, PHYSL REV, V82, p[503, 1A]; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kaija H, 2002, BIOCHEM BIOPH RES CO, V292, P128, DOI 10.1006/bbrc.2002.6615; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; KURIHARA N, 1990, J IMMUNOL, V144, P4226; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LORIACORTES R, 1977, J PEDIATR-US, V91, P43, DOI 10.1016/S0022-3476(77)80441-1; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; McMahon C, 2001, BLOOD, V97, P1947, DOI 10.1182/blood.V97.7.1947; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Motyckova Gabriela, 2002, Current Molecular Medicine (Hilversum), V2, P407, DOI 10.2174/1566524023362401; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; ORCHARD PJ, 1992, EXP HEMATOL, V20, P103; Rajapurohitam V, 2001, BONE, V28, P513, DOI 10.1016/S8756-3282(01)00416-1; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756-3282(02)00672-5; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; SCHMITZ PE, 1986, BONE, V7, P473, DOI 10.1016/8756-3282(86)90006-2; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; SEIFERT MF, 1987, TISSUE CELL, V19, P29, DOI 10.1016/0040-8166(87)90054-1; SHAPIRO F, 1993, CLIN ORTHOP RELAT R, P34; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Taichman RS, 1998, STEM CELLS, V16, P7, DOI 10.1002/stem.160007; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002-9440(10)63798-4; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; TETI A, 1989, J CLIN INVEST, V83, P227, DOI 10.1172/JCI113863; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; Vaananen HK, 2000, J CELL SCI, V113, P377; Van Hul E, 2002, J BONE MINER RES, V17, P1111, DOI 10.1359/jbmr.2002.17.6.1111; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Waguespack SG, 2003, J BONE MINER RES, V18, P1513, DOI 10.1359/jbmr.2003.18.8.1513; WALKER DG, 1973, SCIENCE, V180, P875, DOI 10.1126/science.180.4088.875; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; WALKER DG, 1972, ENDOCRINOLOGY, V91, P916, DOI 10.1210/endo-91-4-916; WHYTE MP, 1993, CLIN ORTHOP RELAT R, P52; Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110; WIKTORJEDRZEJCZAK W, 1991, P NATL ACAD SCI USA, V88, P5937; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WLODARSKI KH, 1990, CLIN ORTHOP RELAT R, P276; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	100	369	386	1	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2839	2849		10.1056/NEJMra040952	http://dx.doi.org/10.1056/NEJMra040952			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625335				2022-12-28	WOS:000226004300009
J	Dogra, N; Connin, S; Gill, P; Spencer, J; Turner, M				Dogra, N; Connin, S; Gill, P; Spencer, J; Turner, M			Teaching of cultural diversity in medical schools in the United Kingdom and Republic of Ireland: cross sectional questionnaire survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Leicester, Greenwood Inst Child Hlth, Leicester LE3 0QU, Leics, England; E Kent Hosp NHS Trust, Canterbury, Kent, England; Univ Birmingham, Birmingham B15 2TT, W Midlands, England; Univ Newcastle Upon Tyne, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; St Georges Med Sch, London, England	University of Leicester; University of Birmingham; Newcastle University - UK; St Georges University London	Dogra, N (corresponding author), Univ Leicester, Greenwood Inst Child Hlth, Leicester LE3 0QU, Leics, England.	nd13@1e.ac.uk						Azad N, 2002, ACAD MED, V77, P222, DOI 10.1097/00001888-200203000-00009; Flores G, 2000, ACAD MED, V75, P451, DOI 10.1097/00001888-200005000-00015; General Medical Council, 1993, TOM DOCT; Gill PS, 1996, BRIT J GEN PRACT, V46, P704; ROBINS S, 1995, MULTICULTURAL HLTH C	5	33	34	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2005	330	7488					403	404		10.1136/bmj.38338.661493.AE	http://dx.doi.org/10.1136/bmj.38338.661493.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15644554	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000227220400022
J	Heikenwalder, M; Zeller, N; Seeger, H; Prinz, M; Klohn, PC; Schwarz, P; Ruddle, NH; Weissmann, C; Aguzzi, A				Heikenwalder, M; Zeller, N; Seeger, H; Prinz, M; Klohn, PC; Schwarz, P; Ruddle, NH; Weissmann, C; Aguzzi, A			Chronic lymphocytic inflammation specifies the organ tropism of prions	SCIENCE			English	Article							FOLLICULAR DENDRITIC CELLS; CREUTZFELDT-JAKOB-DISEASE; NONOBESE DIABETIC MICE; LYMPHOID NEOGENESIS; SCRAPIE; LYMPHOTOXIN; PROTEIN; PATHOGENESIS; REPLICATION; EXPRESSION	Prions typically accumulate in nervous and lymphoid tissues. Because proinflammatory cytokines and immune cells are required for lymphoid prion replication, we tested whether inflammatory conditions affect prion pathogenesis. We administered prions to mice with five inflammatory diseases of the kidney, pancreas, or liver. In all cases, chronic lymphocytic inflammation enabled prion accumulation in otherwise prion-free organs. Inflammatory foci consistently correlated with lymphotoxin up-regulation and ectopic induction of FDC-M1(+) cells expressing the normal cellular prion protein PrPc. By contrast, inflamed organs of mice lacking lymphotoxin-alpha or its receptor did not accumulate the abnormal isoform PrPsc, nor did they display infectivity upon prion inoculation. By expanding the tissue distribution of prions, chronic inflammatory conditions may act as modifiers of natural and iatrogenic prion transmission.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Inst Neurol, Dept Neurodegenerat Dis, MRC, Prion Unit, London WC1N 3BG, England; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA	University of Zurich; University Zurich Hospital; University of London; University College London; Yale University; Yale University	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Aguzzi, Adriano/A-3351-2008; Heikenwalder, Mathias/AAA-2269-2020; Kloehn, Peter/AAS-3719-2021	Aguzzi, Adriano/0000-0002-0344-6708	NCI NIH HHS [R01 CA 16885] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016885] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguzzi A, 2004, NAT CELL BIOL, V6, P290, DOI 10.1038/ncb0404-290; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Fan L, 2000, J IMMUNOL, V164, P3955, DOI 10.4049/jimmunol.164.8.3955; FAVEEUW C, 1994, J IMMUNOL, V152, P5969; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; HANNINEN A, 1993, J CLIN INVEST, V92, P2509, DOI 10.1172/JCI116859; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Kaiserling E, 2001, LYMPHOLOGY, V34, P22; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Mabbott NA, 2002, J VIROL, V76, P5131, DOI 10.1128/JVI.76.10.5131-5139.2002; Magliozzi R, 2004, J NEUROIMMUNOL, V148, P11, DOI 10.1016/j.jneuroim.2003.10.056; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; PICARELLA DE, 1992, P NATL ACAD SCI USA, V89, P10036, DOI 10.1073/pnas.89.21.10036; Prinz M, 2003, NATURE, V425, P957, DOI 10.1038/nature02072; Prinz M, 2002, P NATL ACAD SCI USA, V99, P919, DOI 10.1073/pnas.022626399; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; Robinson CP, 1998, ARTHRITIS RHEUM, V41, P150, DOI 10.1002/1529-0131(199801)41:1<150::AID-ART18>3.3.CO;2-K; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Vernau W, 1997, VET PATHOL, V34, P222, DOI 10.1177/030098589703400307; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Wells GAH, 1998, VET REC, V142, P103, DOI 10.1136/vr.142.5.103	33	158	161	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1107	1110		10.1126/science.1106460	http://dx.doi.org/10.1126/science.1106460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15661974				2022-12-28	WOS:000227197300048
J	Forterre, Y; Skotheim, JM; Dumais, J; Mahadevan, L				Forterre, Y; Skotheim, JM; Dumais, J; Mahadevan, L			How the Venus flytrap snaps	NATURE			English	Article							DIONAEA-MUSCIPULA ELLIS; MECHANISM; MOVEMENT; CLOSURE; GROWTH; PLANTS	The rapid closure of the Venus flytrap (Dionaea muscipula) leaf in about 100 ms is one of the fastest movements in the plant kingdom. This led Darwin to describe the plant as "one of the most wonderful in the world"(1). The trap closure is initiated by the mechanical stimulation of trigger hairs. Previous studies(2-7) have focused on the biochemical response of the trigger hairs to stimuli and quantified the propagation of action potentials in the leaves. Here we complement these studies by considering the post-stimulation mechanical aspects of Venus flytrap closure. Using high-speed video imaging, non-invasive microscopy techniques and a simple theoretical model, we show that the fast closure of the trap results from a snap-buckling instability, the onset of which is controlled actively by the plant. Our study identifies an ingenious solution to scaling up movements in nonletters muscular engines and provides a general framework for understanding nastic motion in plants.	Harvard Univ, Biol Labs, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Univ Aix Marseille 1, CNRS, IUSTI, F-13453 Marseille 13, France; Univ Cambridge, Ctr Math Sci, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Cambridge; Harvard University	Mahadevan, L (corresponding author), Harvard Univ, Biol Labs, Dept Organism & Evolutionary Biol, 16 Divin Ave, Cambridge, MA 02138 USA.	lm@deas.harvard.edu	Skotheim, Jan/C-3238-2015; Dumais, Jacques/H-7950-2013	Skotheim, Jan/0000-0001-8420-6820; Dumais, Jacques/0000-0003-2344-4766				ASHIDA JOJI, 1934, MEM COLL SCI KYOTO IMP UNIV SER B, V9, P141; Biot MA, 1941, J APPL PHYS, V12, P155, DOI 10.1063/1.1712886; Brown WH, 1916, AM J BOT, V3, P68, DOI 10.2307/2435207; Burdon-Sanderson JS, 1882, PHILOS T R SOC LOND, V173, P1; Darwin C., 1875, INSECTIVOROUS PLANTS; Dumais J, 2002, PLANT J, V31, P229, DOI 10.1046/j.1365-313X.2001.01350.x; FRENSCH J, 1989, PLANT PHYSIOL, V91, P719, DOI 10.1104/pp.91.2.719; GREEN PB, 1991, PLANTA, V185, P502, DOI 10.1007/BF00202959; HILL BS, 1981, Q REV BIOPHYS, V14, P173, DOI 10.1017/S0033583500002249; HODICK D, 1988, PLANTA, V174, P8, DOI 10.1007/BF00394867; HODICK D, 1989, PLANTA, V179, P32, DOI 10.1007/BF00395768; Juniper B.E., 1989, CARNIVOROUS PLANTS; Love A.E.H., 1906, TREATISE MATH THEORY; Mansfield E.H., 1989, BENDING STRETCHING P; Morillon R, 2001, PLANT PHYSIOL, V127, P720, DOI 10.1104/pp.010732; Sibaoka T., 1969, ANNU REV PLANT PHYS, V20, P165; Skotheim JM, 2004, P ROY SOC A-MATH PHY, V460, P1995, DOI 10.1098/rspa.2003.1270; STUHLMAN O, 1950, SCIENCE, V111, P491, DOI 10.1126/science.111.2888.491; STUHLMAN O, 1948, B TORREY BOT CLUB, V7, P22; WILLIAMS SE, 1982, SCIENCE, V218, P1120, DOI 10.1126/science.218.4577.1120	20	668	682	27	489	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					421	425		10.1038/nature03185	http://dx.doi.org/10.1038/nature03185			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674293				2022-12-28	WOS:000226546200044
J	Nelson, WA; McCauley, E; Wrona, FJ				Nelson, WA; McCauley, E; Wrona, FJ			Stage-structured cycles promote genetic diversity in a predator-prey system of Daphnia and algae	NATURE			English	Article							LIFE-HISTORY EVOLUTION; CLONAL DIVERSITY; POPULATIONS; PULEX; PLANKTON; ECOLOGY; MODELS	Competition theory predicts that population fluctuations can promote genetic diversity when combined with density-dependent selection(1,2). However, this stabilizing mechanism has rarely been tested, and was recently rejected as an explanation for maintaining diversity in natural populations of the freshwater herbivore Daphnia pulex(3). The primary limitation of competition theory is its failure to account for the alternative types of population cycles that are caused by size- or stage-dependent population vital rates - even though such structure both explains the fluctuating dynamics of many species(4) and may alter the outcome of competition(5). Here we provide the first experimental test of whether alternative types of cycles affect natural selection in predator - prey systems. Using competing Daphnia genotypes, we show that internally generated, stage-structured cycles substantially reduce the magnitude of selection ( thereby contributing to the maintenance of genetic diversity), whereas externally forced cycles show rapid competitive exclusion. The change in selection is ecologically significant, spanning the observed range in natural populations(3). We argue that structured cycles reduce selection through a combination of stalled juvenile development and stage-specific mortality. This potentially general fitness-equalizing mechanism may reduce the need for strong stabilizing mechanisms to explain the maintenance of genetic diversity in natural systems.	Univ Calgary, Div Ecol, Calgary, AB T2N 1N4, Canada; Univ Victoria, Natl Water Res Inst, Water & Climate Impacts Res Ctr, Victoria, BC V8W 3P5, Canada	University of Calgary; Environment & Climate Change Canada; National Water Research Institute; University of Victoria	Nelson, WA (corresponding author), Univ Calgary, Div Ecol, Calgary, AB T2N 1N4, Canada.	wanelson@ucalgary.ca	Wrona, Frederick J/B-8258-2014; Nelson, William A/D-1405-2013	Wrona, Frederick J/0000-0003-1894-351X; 				ARMSTRONG RA, 1980, AM NAT, V115, P151, DOI 10.1086/283553; CARVALHO GR, 1987, J ANIM ECOL, V56, P469, DOI 10.2307/5061; Chesson P, 2000, ANNU REV ECOL SYST, V31, P343, DOI 10.1146/annurev.ecolsys.31.1.343; De Roos AM, 2003, ECOL LETT, V6, P473, DOI 10.1046/j.1461-0248.2003.00458.x; de Roos AM, 2003, THEOR POPUL BIOL, V63, P1, DOI 10.1016/S0040-5809(02)00009-6; DUFRESNE F, 1995, HEREDITY, V75, P45, DOI 10.1038/hdy.1995.102; HARDIN G, 1960, SCIENCE, V131, P1292, DOI 10.1126/science.131.3409.1292; Hebert P.D.N, 1993, ZOOLOGY, V32; HEBERT PDN, 1980, SCIENCE, V207, P1363, DOI 10.1126/science.207.4437.1363; HEBERT PDN, 1983, HEREDITY, V51, P353, DOI 10.1038/hdy.1983.40; HEBERT PDN, 1977, J ANIM ECOL, V46, P399, DOI 10.2307/3819; Huisman J, 1999, NATURE, V402, P407, DOI 10.1038/46540; Kilham SS, 1998, HYDROBIOLOGIA, V377, P147, DOI 10.1023/A:1003231628456; LOARING JM, 1981, OECOLOGIA, V51, P162, DOI 10.1007/BF00540595; LYNCH M, 1984, EVOLUTION, V38, P465, DOI 10.1111/j.1558-5646.1984.tb00312.x; LYNCH M, 1987, GENETICS, V115, P657; McCauley E, 1999, NATURE, V402, P653, DOI 10.1038/45223; MCCAULEY E, 1987, AM NAT, V129, P97, DOI 10.1086/284624; McCauley E, 1996, ECOL MONOGR, V66, P479, DOI 10.2307/2963491; Mitchell SE, 1998, ERGEB LIMNOL, V52, P185; MORT MA, 1991, TRENDS ECOL EVOL, V6, P41, DOI 10.1016/0169-5347(91)90120-M; Murdoch WW, 2002, NATURE, V417, P541, DOI 10.1038/417541a; NELSON WA, 2004, THESIS U CALGARY; Persson L, 1999, OIKOS, V87, P139, DOI 10.2307/3547005; SPITZE K, 1991, EVOLUTION, V45, P82, DOI [10.2307/2409484, 10.1111/j.1558-5646.1991.tb05268.x]; WATSON S, 1992, CAN J FISH AQUAT SCI, V49, P2605, DOI 10.1139/f92-288; WEIDER LJ, 1985, J PLANKTON RES, V7, P101, DOI 10.1093/plankt/7.1.101; Yee TW, 1996, J ROY STAT SOC B MET, V58, P481	28	36	37	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					413	417		10.1038/nature03212	http://dx.doi.org/10.1038/nature03212			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674291				2022-12-28	WOS:000226546200042
J	Rong, HS; Liu, AS; Jones, R; Cohen, O; Hak, D; Nicolaescu, R; Fang, A; Paniccia, M				Rong, HS; Liu, AS; Jones, R; Cohen, O; Hak, D; Nicolaescu, R; Fang, A; Paniccia, M			An all-silicon Raman laser	NATURE			English	Article							1.54 MU-M; OPTICAL GAIN; 2-PHOTON ABSORPTION; SI NANOCRYSTALS; WAVE-GUIDES; AMPLIFICATION; LUMINESCENCE; EMISSION; PHOTOLUMINESCENCE	The possibility of light generation and/or amplification in silicon has attracted a great deal of attention(1) for silicon-based optoelectronic applications owing to the potential for forming inexpensive, monolithic integrated optical components. Because of its indirect bandgap, bulk silicon shows very inefficient band-to-band radiative electron-hole recombination. Light emission in silicon has thus focused on the use of silicon engineered materials such as nanocrystals(2-5), Si/SiO2 superlattices(6), erbium-doped silicon-rich oxides(7-10), surface-textured bulk silicon(11) and Si/SiGe quantum cascade structures(12). Stimulated Raman scattering (SRS) has recently been demonstrated as a mechanism to generate optical gain in planar silicon waveguide structures(13-21). In fact, net optical gain in the range 2-11 dB due to SRS has been reported in centimetre-sized silicon waveguides using pulsed pumping(18-21). Recently, a lasing experiment involving silicon as the gain medium by way of SRS was reported, where the ring laser cavity was formed by an 8-m-long optical fibre(22). Here we report the experimental demonstration of Raman lasing in a compact, all-silicon, waveguide cavity on a single silicon chip. This demonstration represents an important step towards producing practical continuous-wave optical amplifiers and lasers that could be integrated with other optoelectronic components onto CMOS-compatible silicon chips.	Intel Corp, Santa Clara, CA 95054 USA; Intel Corp, IL-91031 Jerusalem, Israel	Intel Corporation; Intel Corporation	Rong, HS (corresponding author), Intel Corp, 2200 Mission Coll Blvd,CHP3-109, Santa Clara, CA 95054 USA.	haisheng.rong@intel.com						Agrawal G.P., 2006, NONLINEAR FIBER OPTI, V4th; Boyraz O., 2004, IEICE Electronics Express, V1, DOI 10.1587/elex.1.429; Boyraz O, 2004, OPT EXPRESS, V12, P5269, DOI 10.1364/OPEX.12.005269; Brongersma ML, 1998, APPL PHYS LETT, V72, P2577, DOI 10.1063/1.121423; Claps R, 2003, OPT EXPRESS, V11, P1731, DOI 10.1364/OE.11.001731; Claps R, 2002, OPT EXPRESS, V10, P1305, DOI 10.1364/OE.10.001305; Dehlinger G, 2000, SCIENCE, V290, P2277, DOI 10.1126/science.290.5500.2277; Dinu M, 2003, APPL PHYS LETT, V82, P2954, DOI 10.1063/1.1571665; Espinola RL, 2004, OPT EXPRESS, V12, P3713, DOI 10.1364/OPEX.12.003713; Fujii M, 1997, APPL PHYS LETT, V71, P1198, DOI 10.1063/1.119624; Han HS, 2001, APPL PHYS LETT, V79, P4568, DOI 10.1063/1.1419035; Iacona F, 2000, J APPL PHYS, V87, P1295, DOI 10.1063/1.372013; Kik PG, 2000, APPL PHYS LETT, V76, P2325, DOI 10.1063/1.126334; Liang TK, 2004, APPL PHYS LETT, V84, P2745, DOI 10.1063/1.1702133; Liang TK, 2004, APPL PHYS LETT, V85, P3343, DOI 10.1063/1.1807960; Liu AS, 2004, OPT EXPRESS, V12, P4261, DOI 10.1364/OPEX.12.004261; Lockwood DJ, 1996, PHYS REV LETT, V76, P539, DOI 10.1103/PhysRevLett.76.539; LOMBARDO S, 1993, APPL PHYS LETT, V63, P1942, DOI 10.1063/1.110608; Pavesi L, 2000, NATURE, V408, P440, DOI 10.1038/35044012; PAVESI L, 2003, NATO SCI SERIES; Reed G. T., 2004, SILICON PHOTONICS IN; Rong HS, 2004, APPL PHYS LETT, V85, P2196, DOI 10.1063/1.1794862; SHIMIZUIWAYAMA T, 1994, J APPL PHYS, V75, P7779, DOI 10.1063/1.357031; SOREF RA, 1986, IEEE J QUANTUM ELECT, V22, P873, DOI 10.1109/JQE.1986.1073057; Trupke T, 2003, APPL PHYS LETT, V82, P2996, DOI 10.1063/1.1572473; Tsang HK, 2002, APPL PHYS LETT, V80, P416, DOI 10.1063/1.1435801; Xu QF, 2004, OPT EXPRESS, V12, P4437, DOI 10.1364/OPEX.12.004437	27	726	773	6	324	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					292	294		10.1038/nature03273	http://dx.doi.org/10.1038/nature03273			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15635371				2022-12-28	WOS:000226381300049
J	Jarvis, JN; Centola, M				Jarvis, JN; Centola, M			Gene-expression profiling: time for clinical application?	LANCET			English	Editorial Material									Univ Oklahoma, Coll Med, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Jarvis, JN (corresponding author), Univ Oklahoma, Coll Med, Oklahoma City, OK 73104 USA.	james-jarvis@ouhsc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015577, P20RR016478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR048378] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P20 RR15577, 1 P20 RR16478] Funding Source: Medline; NIAMS NIH HHS [R21-AR-48378] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Clarke PA, 2004, EUR J CANCER, V40, P2560, DOI 10.1016/j.ejca.2004.07.024; Cuesta IA, 2000, ARCH PEDIAT ADOL MED, V154, P122, DOI 10.1001/archpedi.154.2.122; Dozmorov I, 2003, BIOINFORMATICS, V19, P204, DOI 10.1093/bioinformatics/19.2.204; Jarvis JN, 2004, ARTHRITIS RES THER, V6, pR15, DOI 10.1186/ar1018; Kim AS, 2004, COMB CHEM HIGH T SCR, V7, P183; KRAAN TCV, 2003, GENES IMMUNITY, V0004; March L, 2001, BEST PRACT RES CL RH, V15, P171, DOI 10.1053/berh.2000.0132; Nell VPK, 2004, RHEUMATOLOGY, V43, P906, DOI 10.1093/rheumatology/keh199; Olsen NJ, 2004, ANN RHEUM DIS, V63, P1387, DOI 10.1136/ard.2003.017194	10	12	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					199	200						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652589				2022-12-28	WOS:000226309600007
J	Oransky, I				Oransky, I			Lauriston Taylor - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					210	210						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15657983				2022-12-28	WOS:000226309600015
J	Barger, LK; Cade, BE; Ayas, NT; Cronin, JW; Rosner, B; Speizer, FE; Czeisler, CA				Barger, LK; Cade, BE; Ayas, NT; Cronin, JW; Rosner, B; Speizer, FE; Czeisler, CA		Harvard Work Hours Hlth Safety Grp	Extended work shifts and the risk of motor vehicle crashes among interns	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFORMANCE DEGRADATION; SLEEP RESTRICTION; NATIONAL-SURVEY; DOSE-RESPONSE; RESIDENTS; WAKEFULNESS	Background: Long work hours and work shifts of an extended duration (greater/equal 24 hours) remain a hallmark of medical education in the United States. Yet their effect on health and safety has not been evaluated with the use of validated measures. Methods: We conducted a prospective nationwide, Web-based survey in which 2737 residents in their first postgraduate year (interns) completed 17,003 monthly reports that provided detailed information about work hours, work shifts of an extended duration, documented motor vehicle crashes, near-miss incidents, and incidents involving involuntary sleeping. Results: The odds ratios for reporting a motor vehicle crash and for reporting a near-miss incident after an extended work shift, as compared with a shift that was not of extended duration, were 2.3 (95 percent confidence interval, 1.6 to 3.3) and 5.9 (95 percent confidence interval, 5.4 to 6.3), respectively.In a prospective analysis, every extended work shift that was scheduled in a month increased the monthly risk of a motor vehicle crash by 9.1 percent (95 percent confidence interval, 3.4 to 14.7 percent) and increased the monthly risk of a crash during the commute from work by 16.2 percent (95 percent confidence interval, 7.8 to 24.7 percent).In months in which interns worked five or more extended shifts, the risk that they would fall asleep while driving or while stopped in traffic was significantly increased (odds ratios, 2.39 [95 percent confidence interval, 2.31 to 2.46] and 3.69 [95 percent confidence interval, 3.60 to 3.77], respectively). Conclusions: Extended-duration work shifts, which are currently sanctioned by the Accreditation Council for Graduate Medical Education, pose safety hazards for interns. These results have implications for medical residency programs, which routinely schedule physicians to work more than 24 consecutive hours.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Sleep Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of British Columbia; Vancouver Coastal Health Research Institute	Czeisler, CA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Sleep Med, 221 Longwood Ave, Boston, MA 02115 USA.	caczeisler@hms.harvard.edu	Cade, Brian/J-6770-2019	Cade, Brian/0000-0003-1424-0673; Czeisler, Charles Andrew/0000-0002-7408-1849	AHRQ HHS [R01 HS12032, F32 HS14130] Funding Source: Medline; NHLBI NIH HHS [T32 HL079010] Funding Source: Medline; NIOSH CDC HHS [1 R01 OH07567] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [F32HS014130, R01HS012032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH007567] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIOSH CDC HHS; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		*ACCR COUNC GRAD M, NUMB PROGR SPEC; Baldwin DC, 2003, ACAD MED, V78, P1154, DOI 10.1097/00001888-200311000-00018; Brotherton SE, 2002, JAMA-J AM MED ASSOC, V288, P1073, DOI 10.1001/jama.288.9.1073; Cassell EJ, 1999, JAMA-J AM MED ASSOC, V281, P1231, DOI 10.1001/jama.281.13.1231; CZEISLER CA, 1982, SCIENCE, V217, P460, DOI 10.1126/science.7089576; Daugherty SR, 1998, JAMA-J AM MED ASSOC, V279, P1194, DOI 10.1001/jama.279.15.1194; Dement WC, 1997, NEW ENGL J MED, V337, P783, DOI 10.1056/NEJM199709113371111; *DEP TRANSP, 2000, FED REGISTER, V65, P25541; FRIEDMAN RC, 1971, NEW ENGL J MED, V285, P201, DOI 10.1056/NEJM197107222850405; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; *NAT TRANSP SAF BO, 1990, NTSB PUBL; Niederee MJ, 2003, ARCH SURG-CHICAGO, V138, P663, DOI 10.1001/archsurg.138.6.663; Rosner B., 2000, FUNDAMENTALS BIOSTAT; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; SUBRAMANIAN R, 2003, 809695 DOT HS NAT HI; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Van Dongen HPA, 2004, SLEEP, V27, P600; Whang EE, 2003, J AM COLL SURGEONS, V197, P624, DOI 10.1016/S1072-7515(03)00602-1; Wyatt JK, 2004, SLEEP, V27, P374, DOI 10.1093/sleep/27.3.374	22	603	614	0	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					125	134		10.1056/NEJMoa041401	http://dx.doi.org/10.1056/NEJMoa041401			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647575	Bronze			2022-12-28	WOS:000226251700005
J	Higuchi, T; Uhlmann, F				Higuchi, T; Uhlmann, F			Stabilization of microtubule dynamics at anaphase onset promotes chromosome segregation	NATURE			English	Article							BUDDING YEAST ANAPHASE; MITOTIC SPINDLE; SACCHAROMYCES-CEREVISIAE; PRECOCIOUS SEPARATION; METAPHASE; PROTEIN; COHESIN; KINASE; CDC14; DESTRUCTION	Microtubules of the mitotic spindle form the structural basis for chromosome segregation. In metaphase, microtubules show high dynamic instability, which is thought to aid the 'search and capture' of chromosomes for bipolar alignment on the spindle. Microtubules suddenly become more stable at the onset of anaphase, but how this change in microtubule behaviour is regulated and how important it is for the ensuing chromosome segregation are unknown(1-4). Here we show that in the budding yeast Saccharomyces cerevisiae, activation of the phosphatase Cdc14 at anaphase onset is both necessary and sufficient for silencing microtubule dynamics. Cdc14 is activated by separase, the protease that triggers sister chromatid separation, linking the onset of anaphase to microtubule stabilization(5,6). If sister chromatids separate in the absence of Cdc14 activity, microtubules maintain high dynamic instability; this correlates with defects in both the movement of chromosomes to the spindle poles (anaphase A) and the elongation of the anaphase spindle (anaphase B). Cdc14 promotes localization of microtubule-stabilizing proteins to the anaphase spindle, and dephosphorylation of the kinetochore component Ask1 contributes to both the silencing of microtubule turnover and successful anaphase A.	Canc Res UK London Res Inst, Chromosome Segregat Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK	Uhlmann, F (corresponding author), Canc Res UK London Res Inst, Chromosome Segregat Lab, Lincolns Inn Fields Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.	frank.uhlmann@cancer.org.uk		Uhlmann, Frank/0000-0002-3527-6619	Cancer Research UK [A3592] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; Kline-Smith SL, 2004, MOL CELL, V15, P317, DOI 10.1016/j.molcel.2004.07.012; Kosco KA, 2001, MOL BIOL CELL, V12, P2870, DOI 10.1091/mbc.12.9.2870; Li YM, 2003, CELL CYCLE, V2, P143, DOI 10.4161/cc.2.2.336; Maddox PS, 2000, NAT CELL BIOL, V2, P36, DOI 10.1038/71357; Maiato H, 2003, CELL, V113, P891, DOI 10.1016/S0092-8674(03)00465-3; Mallavarapu A, 1999, CURR BIOL, V9, P1423, DOI 10.1016/S0960-9822(00)80090-1; Miller RK, 1998, MOL BIOL CELL, V9, P2051, DOI 10.1091/mbc.9.8.2051; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Murray AW, 1996, P NATL ACAD SCI USA, V93, P12327, DOI 10.1073/pnas.93.22.12327; Parry DH, 2003, CURR BIOL, V13, P647, DOI 10.1016/S0960-9822(03)00242-2; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Sullivan M, 2004, CELL, V117, P471, DOI 10.1016/S0092-8674(04)00415-5; Sullivan M, 2004, J BIOL CHEM, V279, P1191, DOI 10.1074/jbc.M309761200; Sullivan M, 2003, NAT CELL BIOL, V5, P249, DOI 10.1038/ncb940; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; van Breugel M, 2003, J CELL BIOL, V161, P359, DOI 10.1083/jcb.200211097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; Yin HW, 2002, MOL BIOL CELL, V13, P1881, DOI 10.1091/mbc.01-09-0458; Zeng XM, 1999, J CELL BIOL, V146, P415, DOI 10.1083/jcb.146.2.415; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721	30	146	151	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					171	176		10.1038/nature03240	http://dx.doi.org/10.1038/nature03240			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650742	Green Accepted			2022-12-28	WOS:000226252200041
J	Jee, SH; Ohrr, H; Sull, JW; Yun, JE; Ji, M; Samet, JM				Jee, SH; Ohrr, H; Sull, JW; Yun, JE; Ji, M; Samet, JM			Fasting serum glucose level and cancer risk in Korean men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETES-MELLITUS; PANCREATIC-CANCER; PROSTATE-CANCER; BREAST-CANCER; FOLLOW-UP; SMOKING; MORTALITY; DEATH; COHORT; TYPE-2	Context Diabetes is a serious and costly disease that is becoming increasingly common in many countries. The role of diabetes as a cancer risk factor remains unclear. Objective To examine the relationship between fasting serum glucose and diabetes and risk of all cancers and specific cancers in men and women in Korea. Design, Setting, and Participants Ten-year prospective cohort study of 1298 385 Koreans (829770 men and 468615 women) aged 30 to 95 years who received health insurance from the National Health Insurance Corp and had a biennial medical evaluation in 1992-1995 (with follow-up for up to 10 years). Main Outcome Measures Death from cancer and registry-documented incident cancer or hospital admission for cancer. Results During the 10 years of follow-up, there were 20566 cancer deaths in men and 5907 cancer deaths in women. Using Cox proportional hazards models and controlling for smoking and alcohol use, the stratum with the highest fasting serum glucose (greater than or equal to140 mg/dL [greater than or equal to7.8 mmol/L]) had higher death rates from all cancers combined (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.22-1.37 in men and HR, 1.23; 95% Cl, 1.09-1.39 in women) compared with the stratum with the lowest level (<90 mg/dL [<5.0 mmol/L]). By cancer site, the association was strongest for pancreatic cancer, comparing the highest and lowest strata in men (HR, 1.91; 95% Cl, 1.52-2.41) and in women (HR, 2.05; 95% Cl, 1.43-2.93). Significant associations were also found for cancers of the esophagus, liver, and colon/ rectum in men and of the liver and cervix in women, and there were significant trends with glucose level for cancers of the esophagus, colon/rectum, liver, pancreas, and bile duct in men and of the liver and pancreas in women. Of the 26473 total cancer deaths in men and women, 848 were estimated as attributable to having a fasting serum glucose level of less than 90 mg/dL. For cancer incidence, the general patterns reflected those found for mortality. For persons with a diagnosis of diabetes or a fasting serum glucose level greater than 125 mg/dL (6.9 mmol/L), risks for cancer incidence and mortality were generally elevated compared with those without diabetes. Conclusion In Korea, elevated fasting serum glucose levels and a diagnosis of diabetes are independent risk factors for several major cancers, and the risk tends to increase with an increased level of fasting serum glucose.	Yonsei Univ, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Prevent Med & Publ Hlth, Seoul, South Korea; Yonsei Univ, Grad Sch, Dept Publ Hlth, Seoul 120749, South Korea; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Jee, SH (corresponding author), Yonsei Univ, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul 120749, South Korea.	jsunha@yumc.yonsei.ac.kr			NCI NIH HHS [1R03 CA94771-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA094771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bjornholt JV, 1999, DIABETES CARE, V22, P45, DOI 10.2337/diacare.22.1.45; Cho N.H, 2001, DIABETES, V25, P1; COX DR, 1972, J R STAT SOC B, V34, P187; EVERHART J, 1995, JAMA-J AM MED ASSOC, V273, P1605, DOI 10.1001/jama.273.20.1605; Gapstur SM, 2000, JAMA-J AM MED ASSOC, V283, P2552, DOI 10.1001/jama.283.19.2552; Gavin JR, 1997, DIABETES CARE, V20, P1183; GRULICH AE, 1995, INT J CANCER, V63, P164, DOI 10.1002/ijc.2910630203; Hjalgrim H, 1997, J INTERN MED, V241, P471; Hu FB, 1999, JNCI-J NATL CANCER I, V91, P542, DOI 10.1093/jnci/91.6.542; International Agency for Research on Cancer (IARC), 2002, IARC SCI PUBL, V8; Jee SH, 1999, JAMA-J AM MED ASSOC, V282, P2149, DOI 10.1001/jama.282.22.2149; Jee SH, 2004, JNCI-J NATL CANCER I, V96, P1851, DOI 10.1093/jnci/djh334; Jee SH, 2004, CANCER CAUSE CONTROL, V15, P341, DOI 10.1023/B:CACO.0000027481.48153.97; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; KIM HS, 2000, KOREAN J NURS, V30, P1479; LaVecchia C, 1997, INT J CANCER, V73, P204, DOI 10.1002/(SICI)1097-0215(19971009)73:2<204::AID-IJC7>3.0.CO;2-#; Lee SY, 2002, J HYPERTENS, V20, P617, DOI 10.1097/00004872-200204000-00017; Michels KB, 2003, DIABETES CARE, V26, P1752, DOI 10.2337/diacare.26.6.1752; National Institute of Diabetes and Digestive and Kidney Disorders, 2004, NAT DIAB INF CLEAR N; Rosenberg DJ, 2002, CANCER INVEST, V20, P157, DOI 10.1081/CNV-120001141; Sathiakumar N, 1998, J OCCUP ENVIRON MED, V40, P808, DOI 10.1097/00043764-199809000-00010; SMITH GD, 1992, AM J EPIDEMIOL, V136, P1110, DOI 10.1093/oxfordjournals.aje.a116576; Strickler H D, 2001, Diabetes Technol Ther, V3, P263, DOI 10.1089/152091501300209633; Szklo M., 2019, EPIDEMIOLOGY BASICS, V4; W.H. Organization, 1999, DEFINITION DIAGNOSIS; Weiderpass E, 1997, INT J CANCER, V71, P360, DOI 10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W; Weiderpass E, 2002, INT J CANCER, V102, P258, DOI 10.1002/ijc.10685; WHO, 2002, DIAB MELL, P138; Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360; Will JC, 1999, EPIDEMIOLOGY, V10, P313, DOI 10.1097/00001648-199905000-00021	30	706	740	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2005	293	2					194	202		10.1001/jama.293.2.194	http://dx.doi.org/10.1001/jama.293.2.194			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885QC	15644546	Bronze			2022-12-28	WOS:000226171000035
J	Chollet, M; Guerin, L; Uchida, N; Fukaya, S; Shimoda, H; Ishikawa, T; Matsuda, K; Hasegawa, T; Ota, A; Yamochi, H; Saito, G; Tazaki, R; Adachi, S; Koshihara, S				Chollet, M; Guerin, L; Uchida, N; Fukaya, S; Shimoda, H; Ishikawa, T; Matsuda, K; Hasegawa, T; Ota, A; Yamochi, H; Saito, G; Tazaki, R; Adachi, S; Koshihara, S			Gigantic photoresponse in 1/4-filled-band organic salt (EDO-TTF)(2)PF6	SCIENCE			English	Article							PHASE-TRANSITION; HUBBARD-MODEL; CONDUCTORS; CRYSTALS	We report that the organic salt (EDO-TTF)(2)PF6 with 3/4-filled-band (1/4-filled in terms of holes), which forms an organic metal with strong electron and lattice correlation, shows a highly sensitive response to photoexcitation. An ultrafast, photoinduced phase transition from the insulator phase to the metal phase can be induced with very weak excitation intensity at near room temperature. This response makes the material attractive for applications in switching devices with room-temperature operation. The observed photoinduced spectroscopic change shows that this photoinduced phase transition process is caused by the cooperative melting of charge ordering assisted by coherent phonon generation.	Tokyo Inst Technol, Dept Mat Sci, Meguro Ku, Tokyo 1528551, Japan; Univ Rennes 1, Grp Mat Condensee & Mat, CNRS, UMR 6626, Rennes, France; Kanagawa Acad Sci & Technol, Takatsu Ku, Kawasaki, Kanagawa 2130012, Japan; Japan Sci & Technol Agcy, PRESTO, Takatsu Ku, Kawasaki, Kanagawa 2130012, Japan; Tokyo Inst Technol, Dept Phys, Tokyo 152, Japan; Kyoto Univ, Div Chem, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Res Ctr Low Temp & Mat Sci, Sakyo Ku, Kyoto 6068502, Japan; High Energy Accelerator Res Org, Tsukuba, Ibaraki 3050801, Japan; JST, ERATO, Tsukuba, Ibaraki 3050801, Japan; Chiba Univ, Grad Sch Sci & Technol, Inage Ku, Chiba 2638522, Japan	Tokyo Institute of Technology; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Kanagawa Academy Science & Technology; Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Kyoto University; Kyoto University; High Energy Accelerator Research Organization (KEK); Japan Science & Technology Agency (JST); Chiba University	Koshihara, S (corresponding author), Tokyo Inst Technol, Dept Mat Sci, Meguro Ku, 2-12-1 Oh Okayama, Tokyo 1528551, Japan.	skoshi@cms.titech.ac.jp	Ishikawa, Tadahiko/B-9878-2015; Matsuda, Kazunari/C-3217-2008; Koshihara, Shinya/ABA-1213-2021; Guérin, Laurent/C-4353-2015; Koshihara, Shinya/B-5095-2015	Ishikawa, Tadahiko/0000-0001-7018-654X; Guérin, Laurent/0000-0002-0509-8444; Adachi, Shin-ichi/0000-0002-3676-1165; Koshihara, Shinya/0000-0002-7119-2017				Aoyagi S, 2004, ANGEW CHEM INT EDIT, V43, P3670, DOI 10.1002/anie.200454075; BECHGAARD K, 1980, SOLID STATE COMMUN, V33, P1119, DOI 10.1016/0038-1098(80)91088-1; Cavalleri A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.237401; Drozdova O, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.075107; Drozdova O, 2003, SYNTHETIC MET, V133, P277, DOI 10.1016/S0379-6779(02)00400-9; Fiebig M, 1998, SCIENCE, V280, P1925, DOI 10.1126/science.280.5371.1925; HIRSCH JE, 1983, PHYS REV LETT, V50, P1168, DOI 10.1103/PhysRevLett.50.1168; Ishiguro T., 1998, ORGANIC SUPERCONDUCT, V2nd; Iwai S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.057401; Iwai S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.057402; Jerome D, 2002, ADV PHYS, V51, P293, DOI 10.1080/00018730110116362; Karutz FO, 1998, PHYS REV LETT, V81, P140, DOI 10.1103/PhysRevLett.81.140; KOSHIHARA S, 1998, OPTICAL PROPERTIES L, V2, pCH3; Koshino K, 1998, J PHYS SOC JPN, V67, P2174, DOI 10.1143/JPSJ.67.2174; Matsui H, 2001, J PHYS SOC JPN, V70, P2501, DOI 10.1143/JPSJ.70.2501; Monceau P, 2001, PHYS REV LETT, V86, P4080, DOI 10.1103/PhysRevLett.86.4080; NASU K, 2004, PHOTOINDUCED PHASE T; Ogasawara T, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.180407; Ogasawara T, 2002, J PHYS SOC JPN, V71, P2380, DOI 10.1143/JPSJ.71.2380; Ota A, 2002, J MATER CHEM, V12, P2600, DOI 10.1039/b206293c; PENC K, 1994, PHYS REV B, V49, P9670, DOI 10.1103/PhysRevB.49.9670; Rousse A, 2001, REV MOD PHYS, V73, P17, DOI 10.1103/RevModPhys.73.17; SAITO K, IN PRESS CHEM PHYS L; Schmeltzer D, 1999, PHYS REV B, V59, P4541, DOI 10.1103/PhysRevB.59.4541; Seo H, 1997, J PHYS SOC JPN, V66, P1249, DOI 10.1143/JPSJ.66.1249; Shimizu Y, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.107001; Sokolowski-Tinten K, 2003, NATURE, V422, P287, DOI 10.1038/nature01490; Tanimura K, 2001, J LUMIN, V94, P483, DOI 10.1016/S0022-2313(01)00314-3; Tomimoto S, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.035106; Yonemitsu K, 2004, J PHYS SOC JPN, V73, P2887, DOI 10.1143/JPSJ.73.2887; YU G, 1992, PHYS REV B, V45, P4964, DOI 10.1103/PhysRevB.45.4964	31	294	296	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					86	89		10.1126/science.1105067	http://dx.doi.org/10.1126/science.1105067			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637272				2022-12-28	WOS:000226214300041
J	Narayan, R; Quataert, E				Narayan, R; Quataert, E			Black hole accretion	SCIENCE			English	Review							ELECTROMAGNETIC EXTRACTION; MAGNETICALLY DRIVEN; RADIO; MODELS; ENERGY; GALAXY; FLOWS; JETS; SIMULATIONS; INSTABILITY	Black holes are most often detected by the radiation produced when they gravitationally pull in surrounding gas, in a process called accretion. The efficiency with which the hot gas radiates its thermal energy strongly influences the geometry and dynamics of the accretion flow. Both radiatively efficient thin disks and radiatively inefficient thick disks are observed. When the accreting gas gets close to the central black hole, the radiation it produces becomes sensitive to the spin of the hole and the presence of an event horizon. Analysis of the luminosities and spectra of accreting black holes has yielded tantalizing evidence for both rotating holes and event horizons. Numerical simulations imply that the relativistic jets often seen from accreting black holes may be powered in part by the spin of the hole.	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of California System; University of California Berkeley	Narayan, R (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	narayan@cfa.harvard.edu; eliot@astron.berkeley.edu		Narayan, Ramesh/0000-0002-1919-2730				ABRAMOWICZ MA, 1988, ASTROPHYS J, V332, P646, DOI 10.1086/166683; Balbus SA, 1998, REV MOD PHYS, V70, P1, DOI 10.1103/RevModPhys.70.1; BLANDFORD RD, 1982, MON NOT R ASTRON SOC, V199, P883, DOI 10.1093/mnras/199.4.883; BLANDFORD RD, 1977, MON NOT R ASTRON SOC, V179, P433, DOI 10.1093/mnras/179.3.433; Blandford RD, 1999, MON NOT R ASTRON SOC, V303, pL1, DOI 10.1046/j.1365-8711.1999.02358.x; De Villiers JP, 2003, ASTROPHYS J, V599, P1238, DOI 10.1086/379509; DOELEMAN S, 2004, GALACTIC CTR NEWSLET, V18; Elvis M, 2002, ASTROPHYS J, V565, pL75, DOI 10.1086/339197; Fabian AC, 2003, MON NOT R ASTRON SOC, V344, pL43, DOI 10.1046/j.1365-8711.2003.06902.x; Falcke H, 2000, ASTROPHYS J, V528, pL13, DOI 10.1086/312423; Ferrarese L, 2000, ASTROPHYS J, V539, pL9, DOI 10.1086/312838; FRANK J, 2000, ACCRETION POWER ASTR; Freeman K, 2002, ANNU REV ASTRON ASTR, V40, P487, DOI 10.1146/annurev.astro.40.060401.093840; Gallo E, 2003, MON NOT R ASTRON SOC, V344, P60, DOI 10.1046/j.1365-8711.2003.06791.x; GARCIA MR, 2001, APJ, V553, P47; Gebhardt K, 2000, ASTROPHYS J, V539, pL13, DOI 10.1086/312840; GHEZ AM, IN PRESS ASTROPHYS J; Ghosh P, 1997, MON NOT R ASTRON SOC, V292, P887, DOI 10.1093/mnras/292.4.887; GOLDREICH P, 1969, ASTROPHYS J, V157, P869, DOI 10.1086/150119; Goldreich P, 2004, ANNU REV ASTRON ASTR, V42, P549, DOI 10.1146/annurev.astro.42.053102.134004; Hardcastle MJ, 2003, ASTROPHYS J, V593, P169, DOI 10.1086/376519; Hartle J.B., 2003, GRAVITY INTRO EINSTE; Hawley JF, 2002, ASTROPHYS J, V573, P738, DOI 10.1086/340765; Heger A, 2003, ASTROPHYS J, V591, P288, DOI 10.1086/375341; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; Kaiser CR, 2003, MON NOT R ASTRON SOC, V338, P837, DOI 10.1046/j.1365-8711.2003.06131.x; Kato S, 2001, PUBL ASTRON SOC JPN, V53, P1, DOI 10.1093/pasj/53.1.1; King A, 2003, ASTROPHYS J, V596, pL27, DOI 10.1086/379143; Koide S, 2004, ASTROPHYS J, V606, pL45, DOI 10.1086/420976; Komissarov SS, 2004, MON NOT R ASTRON SOC, V350, P1431, DOI 10.1111/j.1365-2966.2004.07738.x; Livio M, 1999, ASTROPHYS J, V512, P100, DOI 10.1086/306777; Magorrian J, 1998, ASTRON J, V115, P2285, DOI 10.1086/300353; Maraschi L, 2003, ASTROPHYS J, V593, P667, DOI 10.1086/342118; MCCLINTOCK JE, IN PRESS COMPACT STE; McKinney JC, 2004, ASTROPHYS J, V611, P977, DOI 10.1086/422244; Melia F, 2001, ANNU REV ASTRON ASTR, V39, P309, DOI 10.1146/annurev.astro.39.1.309; Merloni A, 2003, MON NOT R ASTRON SOC, V345, P1057, DOI 10.1046/j.1365-2966.2003.07017.x; Meszaros P, 2002, ANNU REV ASTRON ASTR, V40, P137, DOI 10.1146/annurev.astro.40.060401.093821; Miller MC, 2004, INT J MOD PHYS D, V13, P1, DOI 10.1142/S0218271804004426; Mirabel IF, 1999, ANNU REV ASTRON ASTR, V37, P409, DOI 10.1146/annurev.astro.37.1.409; Misner C.W., 1973, GRAVITATION; MURRAY N, IN PRESS ASTROPHYS J; Nagar NM, 2002, ASTRON ASTROPHYS, V392, P53, DOI 10.1051/0004-6361:20020874; Narayan R, 2000, ASTROPHYS J, V539, P798, DOI 10.1086/309268; Narayan R, 2003, ASTRON GEOPHYS, V44, P22, DOI 10.1046/j.1468-4004.2003.44622.x; Narayan R, 2001, ASTROPHYS J, V557, P949, DOI 10.1086/322267; Narayan R., 1998, THEORY BLACK HOLE AC, P148; Penrose R., 1969, Rivista del Nuovo Cimento, V1, P252, DOI 10.1023/A:1016578408204; Popham R, 1999, ASTROPHYS J, V518, P356, DOI 10.1086/307259; Quataert E, 2002, ASTROPHYS J, V577, P524, DOI 10.1086/342174; Reynolds CS, 2003, PHYS REP, V377, P389, DOI 10.1016/S0370-1573(02)00584-7; REYNOLDS CS, IN PRESS XRAY BINARI; Schodel R, 2002, NATURE, V419, P694, DOI 10.1038/nature01121; Semenov V, 2004, SCIENCE, V305, P978, DOI 10.1126/science.1100638; SHU FH, 1987, ANNU REV ASTRON ASTR, V25, P23, DOI 10.1146/annurev.aa.25.090187.000323; Silk J, 1998, ASTRON ASTROPHYS, V331, pL1; SOLTAN A, 1982, MON NOT R ASTRON SOC, V200, P115, DOI 10.1093/mnras/200.1.115; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; Yu QJ, 2002, MON NOT R ASTRON SOC, V335, P965, DOI 10.1046/j.1365-8711.2002.05532.x; Zensus JA, 1997, ANNU REV ASTRON ASTR, V35, P607, DOI 10.1146/annurev.astro.35.1.607	61	40	40	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					77	80		10.1126/science.1105746	http://dx.doi.org/10.1126/science.1105746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637269				2022-12-28	WOS:000226214300038
J	Christie, AM; Lilley, SJ; Staunton, E; Andreev, YG; Bruce, PG				Christie, AM; Lilley, SJ; Staunton, E; Andreev, YG; Bruce, PG			Increasing the conductivity of crystalline polymer electrolytes	NATURE			English	Article							IONIC-CONDUCTIVITY; TRANSPORT; PEO6-LIXF6; BATTERIES; SB	Polymer electrolytes consist of salts dissolved in polymers ( for example, polyethylene oxide, PEO), and represent a unique class of solid coordination compounds. They have potential applications in a diverse range of all-solid-state devices, such as rechargeable lithium batteries, flexible electrochromic displays and smart windows(1-5). For 30 years, attention was focused on amorphous polymer electrolytes in the belief that crystalline polymer: salt complexes were insulators. This view has been overturned recently by demonstrating ionic conductivity in the crystalline complexes PEO6: LiXF6 (X=P, As, Sb); however, the conductivities were relatively low(6,7). Here we demonstrate an increase of 1.5 orders of magnitude in the conductivity of these materials by replacing a small proportion of the XF6- anions in the crystal structure with isovalent N(SO2CF3)(2)(-) ions. We suggest that the larger and more irregularly shaped anions disrupt the potential around the Li+ ions, thus enhancing the ionic conductivity in a manner somewhat analogous to the AgBr1-xIx ionic conductors(8). The demonstration that doping strategies can enhance the conductivity of crystalline polymer electrolytes represents a significant advance towards the technological exploitation of such materials.	Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland	University of St Andrews	Bruce, PG (corresponding author), Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland.	p.g.bruce@st-and.ac.uk	Bruce, Peter/AAB-2011-2019	Bruce, Peter/0000-0001-6748-3084	Engineering and Physical Sciences Research Council [GR/T08890/01, GR/S76120/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		ANGELL CA, 1993, NATURE, V362, P137, DOI 10.1038/362137a0; [Anonymous], 1995, SOLID STATE ELECTROC; Barnes A, 1998, SMART MATER STRUCT, V7, P752, DOI 10.1088/0964-1726/7/6/003; BERTHIER C, 1983, SOLID STATE IONICS, V11, P91, DOI 10.1016/0167-2738(83)90068-1; Forsyth M, 2000, J MATER CHEM, V10, P2259, DOI 10.1039/b003168m; Gadjourova Z, 2001, CHEM MATER, V13, P1282, DOI 10.1021/cm000949k; Gadjourova Z, 2001, NATURE, V412, P520, DOI 10.1038/35087538; Gray F.M., 1997, RSC MAT MONOGRAPHS; MacFarlane DR, 1999, NATURE, V402, P792, DOI 10.1038/45514; Ratner M. A., 1987, POLYM ELECTROLYTE RE, V1, P173; RATNER MA, 1988, CHEM REV, V88, P109, DOI 10.1021/cr00083a006; SCROSATI B, 1993, APPL ELECTROACTIVE P; SHAHI K, 1980, APPL PHYS LETT, V37, P757, DOI 10.1063/1.92023; Stoeva Z, 2003, J AM CHEM SOC, V125, P4619, DOI 10.1021/ja029326t; SYLLA S, 1992, ELECTROCHIM ACTA, V37, P1699, DOI 10.1016/0013-4686(92)80141-8; Tarascon JM, 2001, NATURE, V414, P359, DOI 10.1038/35104644	16	367	378	12	562	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					50	53		10.1038/nature03186	http://dx.doi.org/10.1038/nature03186			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635406				2022-12-28	WOS:000226117100032
J	Iglehart, JK				Iglehart, JK			The emergence of physician-owned specialty hospitals	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE-SYSTEMS; MARKET FORCES; CHARGES											Abelson Reed, 2003, N Y Times Web, P18; Butler SM, 2004, HEALTH AFFAIR, V23, P22, DOI 10.1377/hlthaff.23.2.22; Casalino LP, 2003, HEALTH AFFAIR, V22, P56, DOI 10.1377/hlthaff.22.6.56; CUELLER AE, 2005, HLTH AFF MILLWOOD, V24, P215; DEVERS KJ, 2003, COMMUNICATION   0415; DEVERS KJ, 2003, SPECIALTY HOSP FOCUS; DOBSON A, 2002, STUDIES MEDCATH HEAR; Enthoven AC, 2004, HEALTH AFFAIR, V23, P25, DOI 10.1377/hlthaff.23.2.25; FISHMAN LE, 2004, C SPEC HOSP AMB SURG; *GEN ACC OFF, 1994, GAOHEHS952; *GEN ACC OFF, 2003, GAO04167, P1; *GEN ACC OFF, 2003, GAO03683R; Goldsmith J, 2004, HEALTH AFFAIR, V23, P149, DOI 10.1377/hlthaff.23.6.149; HILLMAN BJ, 1992, JAMA-J AM MED ASSOC, V268, P2050, DOI 10.1001/jama.268.15.2050; *HLTH SERV RES, 2003, LONG CHANG COMM HLTH; Iglehart JK, 2004, NEW ENGL J MED, V350, P826, DOI 10.1056/NEJMhpr045002; MANNING J, 2004, MILWAUKEE J SEN 0126; *MED PAYM ADV COMM, 2004, SPEC HOSP STUD M BRI; *MED PAYM ADV COMM, 2004, PUBL M WASH DC MED P; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P2055, DOI 10.1001/jama.268.15.2055; Nichols LM, 2004, HEALTH AFFAIR, V23, P8, DOI 10.1377/hlthaff.23.2.8; REXWALLER J, 2004, C SPEC HOSP AMB SURG; Robinson JC, 2004, HEALTH AFFAIR, V23, P11, DOI 10.1377/hlthaff.23.6.11; SULLIVAN J, 1996, 975 EPW C RES SERV; THOMAS B, 2001, COMMUNICATION   0719; WALSH B, 2003, NEW ORLEANS TIM 1020, P1; Winslow Ron, 1999, WALL STREET J   0622, pA1; 2004, AHA NEWS        0920	28	74	74	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					78	84		10.1056/NEJMhpr043631	http://dx.doi.org/10.1056/NEJMhpr043631			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635118				2022-12-28	WOS:000226112500014
J	Lukela, M; DeGuzman, D; Weinberger, S; Saint, S				Lukela, M; DeGuzman, D; Weinberger, S; Saint, S			Unfashionably late	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; FEATURES		Univ Michigan, Dept Internal Med, Div Gen Med, Taubman Ctr 3119R, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA; Univ Michigan Hlth Syst, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Lukela, M (corresponding author), Univ Michigan, Dept Internal Med, Div Gen Med, Taubman Ctr 3119R, Ann Arbor, MI 48109 USA.	mlukela@umich.edu	Saint, Sanjay/AAF-5126-2019		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BAEHNER RL, 1967, SCIENCE, V155, P835, DOI 10.1126/science.155.3764.835; BAEHNER RL, 1976, BLOOD, V48, P309; Barton LL, 1998, CLIN PEDIATR, V37, P231, DOI 10.1177/000992289803700403; BERENDES H, 1957, Minn Med, V40, P309; BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; Cale CM, 2000, CLIN EXP IMMUNOL, V120, P351, DOI 10.1046/j.1365-2249.2000.01234.x; GALLIN JI, 1991, NEW ENGL J MED, V324, P509; Jirapongsananuruk O, 2003, J ALLERGY CLIN IMMUN, V111, P374, DOI 10.1067/mai.2003.58; Johnston RB, 2001, CURR OPIN HEMATOL, V8, P17, DOI 10.1097/00062752-200101000-00004; Malech HL, 1999, J INFECT DIS, V179, pS318, DOI 10.1086/513852; MOUY R, 1989, J PEDIATR-US, V114, P555, DOI 10.1016/S0022-3476(89)80693-6; QUIE PG, 1967, J CLIN INVEST, V46, P668, DOI 10.1172/JCI105568; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	14	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					64	69		10.1056/NEJMcps041234	http://dx.doi.org/10.1056/NEJMcps041234			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635114				2022-12-28	WOS:000226112500010
J	Bath, PMW; Gray, LJ				Bath, PMW; Gray, LJ			Association between hormone replacement therapy and subsequent stroke: a meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED-TRIALS; WOMEN; RISK; ESTROGEN; DISEASE	Objectives To review completed trials assessing effect of hormone replacement therapy on subsequent risk of stroke, assessing stroke by pathological type, severity, and outcome. Design Systematic review of randomised controlled trials identified from the Cochrane Library, Embase, and Medline; reviews; and reference lists of relevant papers. Studies reviewed 28 trials, with 39 769 subjects, were identified. Review measures Rates for cerebrovascular events analysed with a random effects model. Sensitivity analyses for heterogeneity included phase of prevention (primary or secondary), type of hormone replacement therapy (oestrogen alone or combined with progesterone), type of oestrogen (estradiol or conjugated equine oestrogen), size of trial (< 5000 or > 5000 patients), length of follow up (less than or equal to3 years or > 3 years), sex (women only or men only), and trial quality (high or low). Results Hormone replacement therapy was associated with significant increases in total stroke (odds ratio 1.29 (95% confidence interval 1.13 to 1.47), n = 28), non-fatal stroke (1.23 (1.06 to 1.44), n = 21), stroke leading to death or disability (1.56 (1.11 to 2.20), n = 14), ischaemic stroke (1.29 (1.06 to 1.56), n = 16), and a trend to more fatal stroke (1.28 (0.87 to 1.88), n =, 22). It was not associated with haemorrhagic stroke (1.07 (0.65 to 1.75), n = 17) or transient ischaemic attack (1.02 (0.78 to 1.34), n = 22). Statistical heterogeneity was not present in any analysis. Conclusions Hormone replacement therapy was associated with an increased risk of stroke, particularly of ischaemic type. Among subjects who had a stroke, those taking hormone replacement therapy seemed to have a worse outcome. Hormone replacement therapy can-not be recommended for the primary or secondary prevention of stroke.	Univ Nottingham, Queens Med Ctr, Inst Neurosci, Div Stroke Med, Nottingham NG7 2UH, England	University of Nottingham	Bath, PMW (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Neurosci, Div Stroke Med, Nottingham NG7 2UH, England.	philip.bath@nottingham.ac.uk	Bath, Philip/F-9020-2011	Bath, Philip/0000-0003-2734-5132; Gray, Laura/0000-0002-9284-9321				Badimon L, 1999, HUM REPROD UPDATE, V5, P191, DOI 10.1093/humupd/5.3.191; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Collins P, 2002, AM J CARDIOL, V90, p30F, DOI 10.1016/S0002-9149(01)02220-2; Collins R, 2002, LANCET, V360, P1618, DOI 10.1016/S0140-6736(02)11650-3; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Glazier MG, 2001, ARCH INTERN MED, V161, P1161, DOI 10.1001/archinte.161.9.1161; Kannel WB, 1994, HEART, P185; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Paganini-Hill A, 2001, MATURITAS, V38, P243, DOI 10.1016/S0378-5122(01)00167-0; Salpeter SR, 2004, J GEN INTERN MED, V19, P791, DOI 10.1111/j.1525-1497.2004.30281.x; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Wren BG, 1998, DRUG AGING, V12, P343, DOI 10.2165/00002512-199812050-00001; Zec RF, 2002, CLIMACTERIC, V5, P122, DOI 10.1080/713605231	15	129	131	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 12	2005	330	7487					342	344A		10.1136/bmj.38331.655347.8F	http://dx.doi.org/10.1136/bmj.38331.655347.8F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15640250	Green Published, Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000227015800020
J	Yin, YH; Vafeados, D; Tao, Y; Yoshida, S; Asami, T; Chory, J				Yin, YH; Vafeados, D; Tao, Y; Yoshida, S; Asami, T; Chory, J			A new class of transcription factors mediates brassinosteroid-regulated gene expression in Arabidopsis	CELL			English	Article							PLANT-GROWTH; SIGNAL-TRANSDUCTION; KINASE; RECEPTOR; BRI1; DNA; BIOSYNTHESIS; PERCEPTION; MEMBRANE; THALIANA	Brassinosteroids (BRs) signal through a plasma membrane-localized receptor kinase to regulate plant growth and development. We showed previously that a novel protein, BES1, accumulates in the nucleus in response to BRs, where it plays a role in BR-regulated gene expression; however, the mechanism by which BES1 regulates gene expression is unknown. In this study, we dissect BES1 subdomains and establish that BES1 is a transcription factor that binds to and activates BR target gene promoters both in vitro and in vivo. BES1 interacts with a basic helix-loop-helix protein, BIM1, to synergistically bind to E box (CANNTG) sequences present in many BR-induced promoters. Loss-of-function and gain-of-function mutants of BIM1 and its close family members display BR response phenotypes. Thus, BES1 defines a new class of plant-specific transcription factors that cooperate with transcription factors such as BIM1 to regulate BR-induced genes.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; RIKEN, Plant Funct Lab, Inst Phys & Chem Res, Wako, Saitama 351098, Japan	Howard Hughes Medical Institute; Salk Institute; Salk Institute; RIKEN	Chory, J (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chory@salk.edu	Tao, Yi/B-7718-2012	Tao, Yi/0000-0002-7460-7927	NIGMS NIH HHS [F32 GM020558, R01 GM060519] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Asami T, 2000, PLANT PHYSIOL, V123, P93, DOI 10.1104/pp.123.1.93; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Cano-Delgado A, 2004, DEVELOPMENT, V131, P5341, DOI 10.1242/dev.01403; Choe S, 2002, PLANT PHYSIOL, V130, P1506, DOI 10.1104/pp.010496; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Clouse SD, 2002, MOL CELL, V10, P973, DOI 10.1016/S1097-2765(02)00744-X; Clouse SD, 1996, PLANT J, V10, P1, DOI 10.1046/j.1365-313X.1996.10010001.x; Clouse SD, 1998, ANNU REV PLANT PHYS, V49, P427, DOI 10.1146/annurev.arplant.49.1.427; Coll-Garcia D, 2004, FEBS LETT, V563, P82, DOI 10.1016/S0014-5793(04)00255-8; Friedrichsen DM, 2000, PLANT PHYSIOL, V123, P1247, DOI 10.1104/pp.123.4.1247; Friedrichsen DM, 2002, GENETICS, V162, P1445; Goda H, 2002, PLANT PHYSIOL, V130, P1319, DOI 10.1104/pp.011254; Goda H, 2004, PLANT PHYSIOL, V134, P1555, DOI 10.1104/pp.103.034736; He JX, 2002, P NATL ACAD SCI USA, V99, P10185, DOI 10.1073/pnas.152342599; He ZH, 2000, SCIENCE, V288, P2360, DOI 10.1126/science.288.5475.2360; Iliev EA, 2002, PLANT PHYSIOL, V130, P770, DOI 10.1104/pp.008680; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; LI J, 1999, J EXP BOT, V50, P332; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Li JM, 2002, SCIENCE, V295, P1299; Li JM, 2001, PLANT PHYSIOL, V127, P14, DOI 10.1104/pp.127.1.14; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.arplant.39.1.23; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Mora-Garcia S, 2004, GENE DEV, V18, P448, DOI 10.1101/gad.1174204; Mussig C, 2002, PLANT PHYSIOL, V129, P1241, DOI 10.1104/pp.011003; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; Nemhauser JL, 2004, PLOS BIOL, V2, P1460, DOI 10.1371/journal.pbio.0020258; Perez-Perez JM, 2002, DEV BIOL, V242, P161, DOI 10.1006/dbio.2001.0543; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Spinner DS, 2002, J MOL BIOL, V317, P431, DOI 10.1006/jmbi.2002.5440; Toledo-Ortiz G, 2003, PLANT CELL, V15, P1749, DOI 10.1105/tpc.013839; Wang ZY, 2002, DEV CELL, V2, P505, DOI 10.1016/S1534-5807(02)00153-3; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; YIN YH, 1995, PLANT J, V7, P969, DOI 10.1046/j.1365-313X.1995.07060969.x; Yin YH, 2002, CELL, V109, P181, DOI 10.1016/S0092-8674(02)00721-3	48	513	593	11	140	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					249	259		10.1016/j.cell.2004.11.044	http://dx.doi.org/10.1016/j.cell.2004.11.044			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680330	Bronze			2022-12-28	WOS:000226740000013
J	Stainforth, DA; Aina, T; Christensen, C; Collins, M; Faull, N; Frame, DJ; Kettleborough, JA; Knight, S; Martin, A; Murphy, JM; Piani, C; Sexton, D; Smith, LA; Spicer, RA; Thorpe, AJ; Allen, MR				Stainforth, DA; Aina, T; Christensen, C; Collins, M; Faull, N; Frame, DJ; Kettleborough, JA; Knight, S; Martin, A; Murphy, JM; Piani, C; Sexton, D; Smith, LA; Spicer, RA; Thorpe, AJ; Allen, MR			Uncertainty in predictions of the climate response to rising levels of greenhouse gases	NATURE			English	Article							MODEL; CONSTRAINTS	The range of possibilities for future climate evolution(1-3) needs to be taken into account when planning climate change mitigation and adaptation strategies. This requires ensembles of multi-decadal simulations to assess both chaotic climate variability and model response uncertainty(4-9). Statistical estimates of model response uncertainty, based on observations of recent climate change(10-13), admit climate sensitivities - defined as the equilibrium response of global mean temperature to doubling levels of atmospheric carbon dioxide - substantially greater than 5 K. But such strong responses are not used in ranges for future climate change(14) because they have not been seen in general circulation models. Here we present results from the 'climateprediction.net' experiment, the first multi-thousand-member grand ensemble of simulations using a general circulation model and thereby explicitly resolving regional details(15-21). We find model versions as realistic as other state-of-the-art climate models but with climate sensitivities ranging from less than 2 K to more than 11 K. Models with such extreme sensitivities are critical for the study of the full range of possible responses of the climate system to rising greenhouse gas levels, and for assessing the risks associated with specific targets for stabilizing these levels.	Univ Oxford, Dept Phys, Oxford OX1 3PU, England; Univ Oxford, Comp Lab, Oxford OX1 3QD, England; Hadley Ctr Climate Predict & Res, Met Off, Exeter EX1 3PB, Devon, England; Rutherford Appleton Lab, Didcot OX11 0QX, Oxon, England; Univ London London Sch Econ & Polit Sci, London WC2A 2AE, England; Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England; Univ Reading, Dept Meteorol, Reading RG6 6BB, Berks, England	University of Oxford; University of Oxford; Met Office - UK; Hadley Centre; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; University of London; London School Economics & Political Science; Open University - UK; University of Reading	Stainforth, DA (corresponding author), Univ Oxford, Dept Phys, Parks Rd, Oxford OX1 3PU, England.	d.stainforth1@physics.ox.ac.uk	Allen, Myles R/A-5172-2012; Frame, Dave/R-6169-2016; Frame, Dave/A-8918-2014; Christensen, Carl M/F-7562-2015; Collins, Matthew/F-8473-2011	Frame, Dave/0000-0002-0949-3994; Christensen, Carl M/0000-0003-3388-3914; Collins, Matthew/0000-0003-3785-6008; Stainforth, David/0000-0001-6476-733X	Natural Environment Research Council [NER/A/S/2002/00881, NER/J/S/2002/00737, NER/T/S/2001/00968] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Allen M, 1999, NATURE, V401, P642, DOI 10.1038/44266; Allen MR, 2000, NATURE, V407, P617, DOI 10.1038/35036559; Allen MR, 2002, NATURE, V419, P224, DOI 10.1038/nature01092; Andronova NG, 2001, J GEOPHYS RES-ATMOS, V106, P22605, DOI 10.1029/2000JD000259; Collins M, 2002, J CLIMATE, V15, P3104, DOI 10.1175/1520-0442(2002)015<3104:ATRROI>2.0.CO;2; Covey C, 2003, GLOBAL PLANET CHANGE, V37, P103, DOI 10.1016/S0921-8181(02)00193-5; CUBASCH U, 2001, CLIMATE CHANGE 2001, P527; Forest CE, 2002, SCIENCE, V295, P113, DOI 10.1126/science.1064419; Giorgi F, 2000, GEOPHYS RES LETT, V27, P1295, DOI 10.1029/1999GL011016; Gregory JM, 2002, J CLIMATE, V15, P3117, DOI [10.1175/1520-0442(2002)015<3117:AOBEOT>2.0.CO;2, 10.1175/1520-0442(2002)015&lt;3117:AOBEOT&gt;2.0.CO;2]; Hansen JA, 2001, GLOB WARM INT CTR M, P187; Kennedy MC, 2001, J R STAT SOC B, V63, P425, DOI 10.1111/1467-9868.00294; Knutti R, 2002, NATURE, V416, P719, DOI 10.1038/416719a; McAvaney BJ, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P471; Morgan M G, 1995, Environ Sci Technol, V29, p468A, DOI [10.1021/es00010a753, 10.1021/es00010a003]; Murphy JM, 2004, NATURE, V430, P768, DOI 10.1038/nature02771; Palmer TN, 2000, REP PROG PHYS, V63, P71, DOI 10.1088/0034-4885/63/2/201; Palmer TN, 2002, NATURE, V415, P512, DOI 10.1038/415512a; Pope VD, 2000, CLIM DYNAM, V16, P123, DOI 10.1007/s003820050009; Reilly J, 2001, SCIENCE, V293, P430; Schneider SH, 2001, NATURE, V411, P17, DOI 10.1038/35075167; Smith LA, 2002, P NATL ACAD SCI USA, V99, P2487, DOI 10.1073/pnas.012580599; SMITH LA, 2000, DISENTANGLING UNCERT, pCH2; Stainforth D., 2002, Proceedings of the 14th IASTED International Conference Parallel and Distributed Computing and Systems, P32; Stainforth D, 2002, COMPUT SCI ENG, V4, P82, DOI 10.1109/5992.998644; STAINFORTH D, 2004, ENV ONLINE COMMUNICA, pCH12; Stott PA, 2002, NATURE, V416, P723, DOI 10.1038/416723a; Wigley TML, 2001, SCIENCE, V293, P451, DOI 10.1126/science.1061604; Williams KD, 2001, J CLIMATE, V14, P2659, DOI 10.1175/1520-0442(2001)014<2659:TCCITH>2.0.CO;2	29	787	803	2	244	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					403	406		10.1038/nature03301	http://dx.doi.org/10.1038/nature03301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674288				2022-12-28	WOS:000226546200039
J	Olson, TM; Michels, VV; Ballew, JD; Reyna, SP; Karst, ML; Herron, KJ; Horton, SC; Rodeheffer, RJ; Anderson, JL				Olson, TM; Michels, VV; Ballew, JD; Reyna, SP; Karst, ML; Herron, KJ; Horton, SC; Rodeheffer, RJ; Anderson, JL			Sodium channel mutations and susceptibility to heart failure and atrial fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; LONG-QT SYNDROME; CONDUCTION-SYSTEM DISEASE; LAMIN A/C GENE; VENTRICULAR-FIBRILLATION; CARDIAC-ARRHYTHMIAS; BRUGADA-SYNDROME; SCN5A; FREQUENCY; RELATIVES	Context Dilated cardiomyopathy (DCM), a genetically heterogeneous disorder, causes heart failure and rhythm disturbances. The majority of identified DCM genes encode structural proteins of the contractile apparatus and cytoskeleton. Recently, genetic defects in,calcium and potassium regulation have been discovered in patients with DCM, implicating an alternative disease mechanism. The full spectrum of genetic defects in DCM, however, has not been established. Objectives To identify a novel gene for DCM at a previously mapped locus, define the spectrum of mutations in this gene within a DCM cohort and determine the frequency of DCM among relatives inheriting a mutation in this gene. Design, Setting, and Participants Refined mapping of a DCM locus on chromosome 3p,in a multigenerational family and mutation scanning in 156 unrelated probands with DCM, prospectively identified at the Mayo Clinic between 1987 and 2004. Relatives underwent screening echocardiography and electrocardiography and DNA sample procurement. Main Outcome Measure Correlation of identified mutations with cardiac phenotype. Results Refined locus mapping revealed SCN5A, encoding the cardiac sodium channel, as a candidate gene. Mutation scans identified a missense mutation (D1275N) that cosegregated with an age-dependent, variably expressed phenotype of DCM, atrial fibrillation, impaired automaticity, and conduction delay. In the DCM, cohort, additional missense (T2201, R814W, D1595H) and truncation (2550-2551insTG) SCN5A mutations, segregating with cardiac disease or arising de novo, were discovered in unrelated probands. Among individuals with an SCN5A mutation 27% had early features of DCM (mean age at diagnosis, 20.3 years), 38% had DCM (mean age at diagnosis, 47.9 years), and 43% had atrial fibrillation (mean age at diagnosis, 27.8 years). Conclusions Heritable SCN5A defects are associated with susceptibility to early-onset DCM and atrial fibrillation. Similar or even identical mutations may lead to heart failure, arrhythmia, or both.	Mayo Clin & Mayo Fdn, Coll Med, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Pediat & Adolescent Med, Div Pediat Cardiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Med Genet, Rochester, MN 55905 USA; Univ Utah, Latter Day St Hosp, Cardiovasc Dept, Salt Lake City, UT 84143 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Utah System of Higher Education; University of Utah	Olson, TM (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Internal Med, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	olson.timothy@mayo.edu		Olson, Timothy/0000-0003-2716-9423	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071225] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071225, R01 HL071225-03, R01 HL71225] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akai J, 2000, FEBS LETT, V479, P29, DOI 10.1016/S0014-5793(00)01875-5; Baig MK, 1998, J AM COLL CARDIOL, V31, P195, DOI 10.1016/S0735-1097(97)00433-6; Benson DW, 2003, J CLIN INVEST, V112, P1019, DOI 10.1172/JCI200318062; Bers DM, 2003, CARDIOVASC RES, V57, P897, DOI 10.1016/S0008-6363(02)00656-9; Bezzina CR, 2003, CIRC RES, V92, P159, DOI 10.1161/01.RES.0000052672.97759.36; Bienengraeber M, 2004, NAT GENET, V36, P382, DOI 10.1038/ng1329; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Chen S, 2002, J MED GENET, V39, P913, DOI 10.1136/jmg.39.12.913; Chen YH, 2003, SCIENCE, V299, P251, DOI 10.1126/science.1077771; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Flesch M, 2001, CARDIOVASC DRUG THER, V15, P379, DOI 10.1023/A:1013329203750; Grant AO, 2002, J CLIN INVEST, V110, P1201, DOI 10.1172/JCI200215570; GREENLEE PR, 1986, WESTERN J MED, V144, P33; Groenewegen WA, 2003, CIRC RES, V92, P14, DOI 10.1161/01.RES.0000050585.07097.D7; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; Michels VV, 2003, AM J CARDIOL, V91, P1389, DOI 10.1016/S0002-9149(03)00341-2; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Olson TM, 2002, CIRCULATION, V105, P431, DOI 10.1161/hc0402.102930; Papadatos GA, 2002, P NATL ACAD SCI USA, V99, P6210, DOI 10.1073/pnas.082121299; Pieske B, 2003, CARDIOVASC RES, V57, P871, DOI 10.1016/S0008-6363(02)00849-0; Plassart Emmanuelle, 1994, European Journal of Human Genetics, V2, P110; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Schott JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; Tan HL, 2003, CARDIOVASC RES, V57, P961, DOI 10.1016/S0008-6363(02)00714-9; Taylor MRG, 2003, J AM COLL CARDIOL, V41, P771, DOI 10.1016/S0735-1097(02)02954-6; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; Viswanathan PC, 2004, TRENDS CARDIOVAS MED, V14, P28, DOI 10.1016/j.tcm.2003.10.001; Wang DW, 2002, CIRCULATION, V105, P341, DOI 10.1161/hc0302.102592; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; ZIPES DP, 1997, HEART DIS TXB CARDIO, P597	38	391	413	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					447	454		10.1001/jama.293.4.447	http://dx.doi.org/10.1001/jama.293.4.447			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890DW	15671429	Green Accepted, Bronze			2022-12-28	WOS:000226492900023
J	Wisloff, U; Najjar, SM; Ellingsen, O; Haram, PM; Swoap, S; Al-Share, Q; Fernstrom, M; Rezaei, K; Lee, SJ; Koch, LG; Britton, SL				Wisloff, U; Najjar, SM; Ellingsen, O; Haram, PM; Swoap, S; Al-Share, Q; Fernstrom, M; Rezaei, K; Lee, SJ; Koch, LG; Britton, SL			Cardiovascular risk factors emerge after artificial selection for low aerobic capacity	SCIENCE			English	Article							INSULIN-RESISTANCE; CARDIAC REHABILITATION; YOUNG ADULTHOOD; HEART-FAILURE; MORTALITY; DYSFUNCTION; CHILDHOOD; PARENTS; DISEASE	In humans, the strong statistical association between fitness and survival suggests a link between impaired oxygen metabolism and disease. We hypothesized that artificial selection of rats based on low and high intrinsic exercise capacity would yield models that also contrast for disease risk. After 11 generations, rats with low aerobic capacity scored high on cardiovascular risk factors that constitute the metabolic syndrome. The decrease in aerobic capacity was associated with decreases in the amounts of transcription factors required for mitochondrial biogenesis and in the amounts of oxidative enzymes in skeletal muscle. Impairment of mitochondrial function may link reduced fitness to cardiovascular and metabolic disease.	Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7489 Trondheim, Norway; St Olavs Hosp, Dept Cardiol, N-7006 Trondheim, Norway; Med Coll Ohio, Dept Pharmacol Cardiovasc Biol & Metab Dis, Toledo, OH USA; Williams Coll, Dept Biol, Williamstown, MA 01267 USA; Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Williams College; University of Michigan System; University of Michigan	Wisloff, U (corresponding author), Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Olav Kyrres Gt 3, N-7489 Trondheim, Norway.	ulrik.wisloff@medisin.ntnu.no	Najjar, Sonia M/GXW-2217-2022; Wisloff, Ulrik/K-2899-2012; Koch, Lauren/D-1258-2010	Al-Share, Qusai/0000-0002-2306-6198; Wisloff, Ulrik/0000-0002-7211-3587	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR017718] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054254, R21DK057497] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 17718] Funding Source: Medline; NHLBI NIH HHS [HL 64270] Funding Source: Medline; NIDDK NIH HHS [DK 57497, DK 54254] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Hambrecht R, 2000, JAMA-J AM MED ASSOC, V283, P3095, DOI 10.1001/jama.283.23.3095; Kavanagh T, 2003, J AM COLL CARDIOL, V42, P2139, DOI 10.1016/j.jacc.2003.07.028; Kavanagh T, 2002, CIRCULATION, V106, P666, DOI 10.1161/01.CIR.0000024413.15949.ED; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Koch LG, 2001, PHYSIOL GENOMICS, V5, P45, DOI 10.1152/physiolgenomics.2001.5.1.45; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; Srinivasan SR, 2003, METABOLISM, V52, P443, DOI 10.1053/meta.2003.50065; Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521; WISLOFF U, 2001, AM J PHYSIOL, V280, pH1302; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Youssef AA, 2002, ANN EPIDEMIOL, V12, P553, DOI 10.1016/S1047-2797(01)00286-1; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	18	482	492	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2005	307	5708					418	420		10.1126/science.1108177	http://dx.doi.org/10.1126/science.1108177			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662013				2022-12-28	WOS:000226492300045
J	Wik, L; Kramer-Johansen, J; Myklebust, H; Sorebo, H; Svensson, L; Fellows, B; Steen, PA				Wik, L; Kramer-Johansen, J; Myklebust, H; Sorebo, H; Svensson, L; Fellows, B; Steen, PA			Quality of cardiopulmonary resuscitation during out-of-hospital cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOMATED EXTERNAL DEFIBRILLATOR; CORONARY BLOOD-FLOW; BASIC LIFE-SUPPORT; VENTRICULAR-FIBRILLATION; CPR PERFORMANCE; COMPRESSION; RETENTION; SKILLS; GUIDELINES; SURVIVAL	Context Cardiopulmonary resuscitation (CPR) guidelines recommend target values for compressions, ventilations, and CPR-free intervals allowed for rhythm analysis and defibrillation. There is little information on adherence to these guidelines during advanced cardiac life support in the field. Objective To measure the quality of out-of-hospital CPR performed by ambulance personnel, as measured by adherence to CPR guidelines. Design and Setting Case series of 176 adult patients with out-of-hospital cardiac arrest treated by paramedics and nurse anesthetists in Stockholm Sweden, London, England, and Akershus, Norway, between March 2002 and October 2003. The defibrillators recorded chest compressions via a sternal pad fitted with an accelerometer and ventilations by changes in thoracic impedance between the defibrillator pads, in addition to standard event and electrocardiographic recordings. Main Outcome Measure Adherence to international guidelines for CPR. Results Chest compressions were not given 48% (95% CI, 45%-51%) of the time without spontaneous circulation; this percentage was 38% (95% CI, 36%-41%) when subtracting the time necessary for electrocardiographic analysis and defibrillation. Combining these data with a mean compression rate of 121/min (95% CI, 118-124/min) when compressions were given resulted in a mean compression rate of 64/min (95% CI, 61-67/min). Mean compression depth was 34 mm (95% CI, 33-35 mm), 28% (95% CI, 24%-32%) of the compressions had a depth of 38 mm to 51 mm (guidelines recommendation), and the compression part of the duty cycle was 42% (95% CI, 41%-42%). A mean of 11 (95% Cl, 11-12) ventilations were given per minute. Sixty-one patients (35%) had return of spontaneous circulation, and 5 of 6 patients discharged alive from the hospital had normal neurological outcomes. Conclusions In this study of CPR during out-of-hospital cardiac arrest, chest compressions were not delivered half of the time, and most compressions were too shallow. Electrocardiographic analysis and defibrillation accounted for only small parts of intervals without chest compressions.	Ullevaal Univ Hosp, Expt Med Res Inst, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Natl Competence Ctr Emergency Med, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Div Prehosp Emergency Med, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Div Surg, N-0407 Oslo, Norway; Norwegian Air Ambulance, Dept Res & Educ Acute Med, Drobak, Norway; Laerdal Med Corp, Stavanger, Norway; Soder Sjukhuset, S-10064 Stockholm, Sweden; London Ambulance Serv NHS Trust, London, England	University of Oslo; University of Oslo; University of Oslo; University of Oslo; Sodersjukhuset Hospital	Wik, L (corresponding author), Ullevaal Univ Hosp, Expt Med Res Inst, N-0407 Oslo, Norway.		Kramer-Johansen, Jo/P-5132-2018	Kramer-Johansen, Jo/0000-0002-7881-1757				Aase SO, 2002, IEEE T BIO-MED ENG, V49, P263, DOI 10.1109/10.983461; ANDERSEN HS, 2003, THESIS STAVANGER U S; [Anonymous], 2000, GUID 2000 CARD RES E; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BELLAMY RF, 1984, CIRCULATION, V69, P174, DOI 10.1161/01.CIR.69.1.174; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Broomfield R, 1996, J ADV NURS, V23, P1016; Chamberlain DA, 2003, RESUSCITATION, V59, P11, DOI 10.1016/j.resuscitation.2003.08.011; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Donnelly P, 2000, RESUSCITATION, V45, P195, DOI 10.1016/S0300-9572(00)00186-6; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GEDDES LA, 1989, PRINCIPLES APPL BIO; Handley AJ, 2003, RESUSCITATION, V57, P57, DOI 10.1016/S0300-9572(02)00400-8; KAYE W, 1986, CRIT CARE MED, V14, P620, DOI 10.1097/00003246-198607000-00007; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Liberman M, 1999, RESUSCITATION, V42, P47, DOI 10.1016/S0300-9572(99)00082-9; MAIER GW, 1986, CIRCULATION, V74, P51; Marn-Pernat A, 2001, CRIT CARE MED, V29, P2360, DOI 10.1097/00003246-200112000-00019; MOSER DK, 1992, HEART LUNG, V21, P372; ORNATO JP, 1989, ANN EMERG MED, V18, P732, DOI 10.1016/S0196-0644(89)80005-8; Pellis T, 2002, CRIT CARE MED, V30, pS176, DOI 10.1097/00003246-200204001-00012; Standards for cardiopulmonary resuscitation (CPR) and emergency cardiac care (ECC), 1974, JAMA-J AM MED ASSOC, V227, P864; Sunde K, 1998, RESUSCITATION, V39, P197, DOI 10.1016/S0300-9572(98)00139-7; Sunde K, 1997, RESUSCITATION, V34, P235, DOI 10.1016/S0300-9572(96)01087-8; van Alem AP, 2003, ANN EMERG MED, V42, P449, DOI 10.1067/S0196-0644(03)00383-4; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; Wik L, 2001, RESUSCITATION, V50, P167, DOI 10.1016/S0300-9572(01)00331-8; WOLFE JA, 1988, J THORAC CARDIOV SUR, V95, P523; World Medical Association, 1964, DECL HELS; Yu T, 2002, CIRCULATION, V106, P368, DOI 10.1161/01.CIR.0000021429.22005.2E; 2000, RESUSCITATION, V46, P1	33	957	1020	1	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					299	304		10.1001/jama.293.3.299	http://dx.doi.org/10.1001/jama.293.3.299			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657322	Green Published, Bronze			2022-12-28	WOS:000226358400023
J	Brogden, KA; Guthmiller, JM; Taylor, CE				Brogden, KA; Guthmiller, JM; Taylor, CE			Human polymicrobial infections	LANCET			English	Review							RESPIRATORY SYNCYTIAL VIRUS; STAPHYLOCOCCUS-AUREUS; HUMAN METAPNEUMOVIRUS; STREPTOCOCCUS-PNEUMONIAE; HTLV-II; ASSOCIATION; BIOFILMS; COLONIZATION; CAVITIES; IMPACT	Context Polymicrobial diseases, caused by combinations of viruses, bacteria, fungi, and parasites, are being recognised with increasing frequency. In these infections, the presence of one micro-organism generates a niche for other pathogenic micro-organisms to colonise, one micro-organism predisposes the host to colonisation by other micro-organisms, or two or more non-pathogenic micro-organisms together cause disease. Starting point Recently, Gill Regev-Yochay (JAMA 2004; 292: 716-20) and Debby Bogaert (Lancet 2004; 363: 1871-72), and their colleagues, suggested another interaction: microbial interference-the ability of Streptococcus pneumoniae carriage to protect against Staphylococcus aureus carriage, and the inverse effect of pneumococcal conjugate vaccination on the increased carriage of Staph aureus and Staph-aureus-related disease. Strep pneumoniae carriage protected against Staph aureus carriage, and the bacterial interference could be disrupted by vaccinating children with pneumococcal conjugate vaccines that reduced nasopharyngeal carriage of vaccine-type Strep pneumoniae. Where next The medical community is recognising the significance of polymicrobial diseases and the major types of microbial community interactions associated with human health and disease. Many traditional therapies are just starting to take into account the polymicrobial cause of diseases and the repercussions of treatment and prevention.	Univ Iowa, Coll Dent, Dept Periodont, Iowa City, IA 52242 USA; Univ Iowa, Coll Dent, Dows Inst Dent Res, Iowa City, IA 52242 USA; NIAID, NIH, Bethesda, MD 20892 USA	University of Iowa; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Brogden, KA (corresponding author), Univ Iowa, Coll Dent, Dept Periodont, Iowa City, IA 52242 USA.	kim-brogden@uiowa.edu			NIDCR NIH HHS [R13 DE015562-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R13DE015562] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Allory Y, 2000, HUM PATHOL, V31, P69, DOI 10.1016/S0046-8177(00)80201-4; Antonio MAD, 2003, J CLIN MICROBIOL, V41, P1881, DOI 10.1128/JCM.41.5.1881-1887.2003; Bakaletz LO, 2002, POLYMICROBIAL DISEASES, P259; Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5; Chan PKS, 2003, EMERG INFECT DIS, V9, P1058; Cheadle WG, 2003, AM J SURG, V186, p15S, DOI 10.1016/j.amjsurg.2003.10.003; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Cuevas LE, 2003, EMERG INFECT DIS, V9, P1626, DOI 10.3201/eid0912.030522; D'Souza AL, 2002, BRIT MED J, V324, P1361, DOI 10.1136/bmj.324.7350.1361; Fontes R A Jr, 2000, J Am Acad Orthop Surg, V8, P151; Greensill J, 2003, EMERG INFECT DIS, V9, P372, DOI 10.3201/eid0903.020289; Haahr S, 2000, J NEUROVIROL, V6, pS76; Harbarth S, 2002, ANTIMICROB AGENTS CH, V46, P1619, DOI 10.1128/AAC.46.6.1619-1628.2002; Heikkinen T, 2003, CLIN MICROBIOL REV, V16, P230, DOI 10.1128/CMR.16.2.230-241.2003; Kolenbrander PE, 2000, ANNU REV MICROBIOL, V54, P413, DOI 10.1146/annurev.micro.54.1.413; Laupland KB, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.5.e60; Lawn SD, 2004, J INFECTION, V48, P1, DOI 10.1016/j.jinf.2003.09.001; Lewis MJ, 2000, J IMMUNOL, V165, P4127, DOI 10.4049/jimmunol.165.7.4127; Murphy EL, 2004, EMERG INFECT DIS, V10, P109, DOI 10.3201/eid1001.020714; Myers RP, 2002, POLYMICROBIAL DISEASES, P51; Palmer RJ, 2001, INFECT IMMUN, V69, P5794, DOI 10.1128/IAI.69.9.5794-5804.2001; Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35; Poynard T, 2003, J HEPATOL, V38, P257, DOI 10.1016/S0168-8278(02)00413-0; Regev-Yochay G, 2004, JAMA-J AM MED ASSOC, V292, P716, DOI 10.1001/jama.292.6.716; Relman DA, 2002, J INFECT DIS, V186, pS254, DOI 10.1086/344935; Rogers GB, 2003, J CLIN MICROBIOL, V41, P3548, DOI 10.1128/JCM.41.8.3548-3558.2003; Sauer K, 2002, J BACTERIOL, V184, P1140, DOI 10.1128/jb.184.4.1140-1154.2002; Slifka MK, 2003, J CLIN INVEST, V111, P805, DOI 10.1172/JCI200313603; TUOMANEN E, 1986, INFECT IMMUN, V54, P905, DOI 10.1128/IAI.54.3.905-908.1986; Uehara Y, 2001, CLIN INFECT DIS, V32, P1408, DOI 10.1086/320179; Uehara Y, 2000, J HOSP INFECT, V44, P127, DOI 10.1053/jhin.1999.0680; Wang M, 2003, VIRAL IMMUNOL, V16, P45, DOI 10.1089/088282403763635447; Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845; Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107	34	227	236	0	52	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					253	255		10.1016/S0140-6736(05)70155-0	http://dx.doi.org/10.1016/S0140-6736(05)70155-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652608	Green Published			2022-12-28	WOS:000226309600031
J	Takyar, S; Hickerson, RP; Noller, HF				Takyar, S; Hickerson, RP; Noller, HF			MRNA helicase activity of the ribosome	CELL			English	Article							ELONGATION-FACTOR TU; SECONDARY STRUCTURE; COLI RIBOSOME; TRANSLOCATION; COMPLEXES; SUBUNIT; SITE; MECHANISM; PROTEIN; MODEL	Most mRNAs contain secondary structure, yet their codons must be in single-stranded form to be translated. Until now, no helicase activity has been identified which could account for the ability of ribosomes to translate through downstream mRNA secondary structure. Using an oligonucleotide displacement assay, together with a stepwise in vitro translation system made up of purified components, we show that ribosomes are able to disrupt downstream helices, including a perfect 27 base pair helix of predicted T-m = 70degrees. Using helices of different lengths and registers, the helicase active site can be localized to the middle of the downstream tunnel, between the head and shoulder of the 30S subunit. Mutation of residues in proteins S3 and S4 that line the entry to the tunnel impairs helicase activity. We conclude that the ribosome itself is an mRNA helicase and that proteins S3 and S4 may play a role in its processivity.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Ctr Mol Biol, RNA, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Noller, HF (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.	harry@nuvolari.ucsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017129, R37GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Alam SL, 1999, P NATL ACAD SCI USA, V96, P14177, DOI 10.1073/pnas.96.25.14177; BIRERLEY L, 2001, COLD SPRING HARB SYM, P233; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; Culver GM, 1999, RNA, V5, P832, DOI 10.1017/S1355838299990714; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; DOTY P., 1959, PROC NATL ACAD SCI, V45, P482, DOI 10.1073/pnas.45.4.482; FAVRE A, 1975, EUR J BIOCHEM, V57, P147, DOI 10.1111/j.1432-1033.1975.tb02285.x; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Fredrick K, 2003, SCIENCE, V300, P1159, DOI 10.1126/science.1084571; Fredrick K, 2002, MOL CELL, V9, P1125, DOI 10.1016/S1097-2765(02)00523-3; GAVRILOV.LP, 1971, FEBS LETT, V17, P324, DOI 10.1016/0014-5793(71)80177-1; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HOLDER JW, 1975, BIOCHEMISTRY-US, V14, P4209, DOI 10.1021/bi00690a009; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P3405, DOI 10.1093/nar/16.8.3405; Min Jou W, 1972, Nature, V237, P82; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; Nakano S, 1999, NUCLEIC ACIDS RES, V27, P2957, DOI 10.1093/nar/27.14.2957; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; PESTKA S, 1969, J BIOL CHEM, V244, P1533; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; Southworth DR, 2002, J MOL BIOL, V324, P611, DOI 10.1016/S0022-2836(02)01196-8; VANHIMBERGEN J, 1993, NUCLEIC ACIDS RES, V21, P1713, DOI 10.1093/nar/21.8.1713; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Xia TB, 1998, BIOCHEMISTRY-US, V37, P14719, DOI 10.1021/bi9809425; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	34	363	370	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					49	58		10.1016/j.cell.2004.11.042	http://dx.doi.org/10.1016/j.cell.2004.11.042			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652481	Bronze			2022-12-28	WOS:000226365400010
J	Fynbo, HOU; Diget, CA; Bergmann, UC; Borge, MJG; Cederkall, J; Dendooven, P; Fraile, LM; Franchoo, S; Fedosseev, VN; Fulton, BR; Huang, WX; Huikari, J; Jeppesen, HB; Jokinen, AS; Jones, P; Jonson, B; Koster, U; Langanke, K; Meister, M; Nilsson, T; Nyman, G; Prezado, Y; Riisager, K; Rinta-Antila, S; Tengblad, O; Turrion, M; Wang, YB; Weissman, L; Wilhelmsen, K; Aysto, J				Fynbo, HOU; Diget, CA; Bergmann, UC; Borge, MJG; Cederkall, J; Dendooven, P; Fraile, LM; Franchoo, S; Fedosseev, VN; Fulton, BR; Huang, WX; Huikari, J; Jeppesen, HB; Jokinen, AS; Jones, P; Jonson, B; Koster, U; Langanke, K; Meister, M; Nilsson, T; Nyman, G; Prezado, Y; Riisager, K; Rinta-Antila, S; Tengblad, O; Turrion, M; Wang, YB; Weissman, L; Wilhelmsen, K; Aysto, J		ISOLDE Collaboration	Revised rates for the stellar triple-alpha process from measurement of C-12 nuclear resonances	NATURE			English	Article							BETA-DECAY; NUCLEOSYNTHESIS; PARTICLES; STARS; ASTROPHYSICS; ELEMENTS; B-12	In the centres of stars where the temperature is high enough, three alpha-particles (helium nuclei) are able to combine to form C-12 because of a resonant reaction leading to a nuclear excited state(1). (Stars with masses greater than similar to0.5 times that of the Sun will at some point in their lives have a central temperature high enough for this reaction to proceed.) Although the reaction rate is of critical significance for determining elemental abundances in the Universe(1), and for determining the size of the iron core of a star just before it goes supernova(2), it has hitherto been insufficiently determined(2). Here we report a measurement of the inverse process, where a C-12 nucleus decays to three alpha-particles. We find a dominant resonance at an energy of similar to11 MeV, but do not confirm the presence of a resonance at 9.1 MeV (ref. 3). We show that interference between two resonances has important effects on our measured spectrum. Using these data, we calculate the triple-a rate for temperatures from 10(7) K to 10(10) K and find significant deviations from the standard rates(3). Our rate below similar to5 x 10(7) K is higher than the previous standard, implying that the critical amounts of carbon that catalysed hydrogen burning in the first stars are produced twice as fast as previously believed(4). At temperatures above 10(9) K, our rate is much less, which modifies predicted nucleosynthesis in supernovae(5,6).	Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark; CERN, CH-1211 Geneva 23, Switzerland; CSIC, Inst Estructura Mat, E-28006 Madrid, Spain; Univ Groningen, Kernfys Versneller Inst, NL-9747 AA Groningen, Netherlands; Univ York, Dept Phys, York YO10 5DD, N Yorkshire, England; Univ Jyvaskyla, Dept Phys, FIN-40351 Jyvaskyla, Finland; Univ Helsinki, Helsinki Inst Phys, FIN-00014 Helsinki, Finland; Chalmers, S-41296 Gothenburg, Sweden; Gothenburg Univ, S-41296 Gothenburg, Sweden	Aarhus University; European Organization for Nuclear Research (CERN); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); University of Groningen; University of York - UK; University of Jyvaskyla; Helsinki Institute of Physics; University of Helsinki; Chalmers University of Technology; University of Gothenburg	Fynbo, HOU (corresponding author), Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark.	fynbo@phys.au.dk	Jones, Pete/AAC-9580-2019; Fraile, Luis M/B-8668-2011; Diget, Christian Aaen/D-8063-2016; Nilsson, Thomas/B-7705-2009; Tengblad, Olof/O-5852-2015; Köster, Ulli/N-3016-2017; Jokinen, Ari/C-2477-2017; prezado, yolanda/B-8455-2009; Turrión, Manuela/B-2280-2017; prezado, yolanda/O-7376-2014; Jonson, Bjorn N.G./B-2816-2014; Fedosseev, Valentin/A-6240-2010	Jones, Pete/0000-0001-7480-6603; Fraile, Luis M/0000-0002-6281-3635; Diget, Christian Aaen/0000-0002-9778-8759; Nilsson, Thomas/0000-0002-6990-947X; Tengblad, Olof/0000-0002-5813-0022; Jokinen, Ari/0000-0002-0451-125X; prezado, yolanda/0000-0001-5957-2327; Turrión, Manuela/0000-0003-4941-3378; Rinta-Antila, Sami/0000-0003-4198-1960; Dendooven, Peter/0000-0003-1859-1315; Jonson, Bjorn/0000-0002-9697-9115; Fedosseev, Valentin/0000-0001-8767-1445				AJZENBERGSELOVE F, 1990, NUCL PHYS A, V506, P1, DOI 10.1016/0375-9474(90)90271-M; AUSTIN S, IN PRESS NUCL PHYS A; Aysto J, 2001, NUCL PHYS A, V693, P477, DOI 10.1016/S0375-9474(01)00923-X; BARKER FC, 1988, NUCL PHYS A, V487, P269, DOI 10.1016/0375-9474(88)90613-6; Bergmann UC, 2003, NUCL INSTRUM METH A, V515, P657, DOI 10.1016/j.nima.2003.07.016; COOK CW, 1957, PHYS REV, V107, P508, DOI 10.1103/PhysRev.107.508; COOK CW, 1958, PHYS REV, V111, P567, DOI 10.1103/PhysRev.111.567; DELANO MD, 1971, ASTROPHYS SPACE SCI, V10, P203, DOI 10.1007/BF00704083; DUNBAR DNF, 1953, PHYS REV, V92, P649, DOI 10.1103/PhysRev.92.649; FOWLER WA, 1984, REV MOD PHYS, V56, P149, DOI 10.1103/RevModPhys.56.149; FROHLICH C, UNPUB ASTROPHYS J; Fynbo HOU, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.082502; Herwig F, 2004, ASTROPHYS J, V613, pL73, DOI 10.1086/424872; HOYLE F, 1953, PHYS REV, V92, P1095; Itoh M, 2004, NUCL PHYS A, V738, P268, DOI 10.1016/j.nuclphysa.2004.04.044; John B, 2003, PHYS REV C, V68, DOI 10.1103/PhysRevC.68.014305; Kappeler F, 1998, ANNU REV NUCL PART S, V48, P175, DOI 10.1146/annurev.nucl.48.1.175; Kugler E, 2000, HYPERFINE INTERACT, V129, P23, DOI 10.1023/A:1012603025802; LANE AM, 1958, REV MOD PHYS, V30, P257, DOI 10.1103/RevModPhys.30.257; MORINAGA H, 1956, PHYS REV, V101, P254, DOI 10.1103/PhysRev.101.254; PRUET J, UNPUB ASTROPHYS J; Schatz H, 1998, PHYS REP, V294, P167, DOI 10.1016/S0370-1573(97)00048-3; Schlattl H, 2004, ASTROPHYS SPACE SCI, V291, P27, DOI 10.1023/B:ASTR.0000029953.05806.47; SCHWALM D, 1966, NUCL PHYS, V89, P401, DOI 10.1016/S0029-5582(66)80101-3; Siess L, 2002, ASTROPHYS J, V570, P329, DOI 10.1086/339733; Tengblad O, 2004, NUCL INSTRUM METH A, V525, P458, DOI 10.1016/j.nima.2004.01.082; Wallerstein G, 1997, REV MOD PHYS, V69, P995, DOI 10.1103/RevModPhys.69.995; WEAVER TA, 1993, PHYS REP, V227, P65, DOI 10.1016/0370-1573(93)90058-L; Woosley SE, 2004, ASTROPHYS J SUPPL S, V151, P75, DOI 10.1086/381533	30	196	199	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					136	139		10.1038/nature03219	http://dx.doi.org/10.1038/nature03219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650733				2022-12-28	WOS:000226252200031
J	Kenward, B; Weir, AAS; Rutz, C; Kacelnik, A				Kenward, B; Weir, AAS; Rutz, C; Kacelnik, A			Tool manufacture by naive juvenile crows	NATURE			English	Editorial Material									Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Kenward, B (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	alex.kacelnik@zoology.ox.ac.uk	Kenward, Ben/A-5558-2009; Weir, Alex/B-4664-2008	Rutz, Christian/0000-0001-5187-7417	Biotechnology and Biological Sciences Research Council [BB/C517392/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Celli ML, 2004, INT J PRIMATOL, V25, P1267, DOI 10.1023/B:IJOP.0000043962.60837.16; Hunt GR, 2004, P ROY SOC B-BIOL SCI, V271, pS88, DOI 10.1098/rsbl.2003.0085; Hunt GR, 1996, NATURE, V379, P249, DOI 10.1038/379249a0; Hunt GR, 2003, P ROY SOC B-BIOL SCI, V270, P867, DOI 10.1098/rspb.2002.2302; Kenward B, 2004, IBIS, V146, P652, DOI 10.1111/j.1474-919x.2004.00299.x; SPAULDING B, IN PRESS ANIM BEHAV; Tebbich S, 2001, P ROY SOC B-BIOL SCI, V268, P2189, DOI 10.1098/rspb.2001.1738; Tomasello M, 1999, ANNU REV ANTHROPOL, V28, P509, DOI 10.1146/annurev.anthro.28.1.509; Weir AAS, 2002, SCIENCE, V297, P981, DOI 10.1126/science.1073433; WESTERGAARD GC, 1987, J COMP PSYCHOL, V101, P159, DOI 10.1037/0735-7036.101.2.159; WESTERGAARD GC, 1989, PERCEPT MOTOR SKILL, V68, P558, DOI 10.2466/pms.1989.68.2.558	11	154	161	0	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					121	121		10.1038/433121a	http://dx.doi.org/10.1038/433121a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650729	Bronze			2022-12-28	WOS:000226252200025
J	Walsh, RW				Walsh, RW			How is the solar corona heated?	SCIENCE			English	Editorial Material							LOOPS; OSCILLATIONS; MICROFLARES; NANOFLARES; TRACE		Univ Cent Lancashire, Dept Phys Astron & Math, Preston PR1 2HE, Lancs, England	University of Central Lancashire	Walsh, RW (corresponding author), Univ Cent Lancashire, Dept Phys Astron & Math, Preston PR1 2HE, Lancs, England.	rwwalsh@uclan.ac.uk		Walsh, Robert/0000-0002-1025-9863				Aschwanden MJ, 2000, ASTROPHYS J, V535, P1027, DOI 10.1086/308866; Benz AO, 2002, ASTROPHYS J, V568, P413, DOI 10.1086/338807; De Moortel I, 2000, ASTRON ASTROPHYS, V355, pL23; Galsgaard K, 1996, J GEOPHYS RES-SPACE, V101, P13445, DOI 10.1029/96JA00428; Gudiksen BV, 2002, ASTROPHYS J, V572, pL113, DOI 10.1086/341600; HUDSON HS, 1991, SOL PHYS, V133, P357, DOI 10.1007/BF00149894; Nakariakov VM, 1999, SCIENCE, V285, P862, DOI 10.1126/science.285.5429.862; PARKER EN, 1988, ASTROPHYS J, V330, P474, DOI 10.1086/166485; PORTER LJ, 1994, ASTROPHYS J, V435, P502, DOI 10.1086/174831; Priest E. R., 2000, MAGNETIC RECONNECTIO; Walsh RW, 2003, ASTRON ASTROPHYS REV, V12, P1, DOI 10.1007/s00159-003-0021-9	11	3	3	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2005	307	5706					51	53		10.1126/science.1105460	http://dx.doi.org/10.1126/science.1105460			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637258				2022-12-28	WOS:000226214300027
J	Wenger, OS; Leigh, BS; Villahermosa, RM; Gray, HB; Winkler, JR				Wenger, OS; Leigh, BS; Villahermosa, RM; Gray, HB; Winkler, JR			Electron tunneling through organic molecules in frozen glasses	SCIENCE			English	Article							RANDOMLY DISTRIBUTED ACCEPTORS; DISTANCE DEPENDENCE; ENERGY-TRANSFER; PROTEINS; IONS; RECOMBINATION; MONOLAYERS; FERROCENE; EXCHANGE; SOLVENT	Reaction rates extracted from measurements of donor luminescence-quenching by randomly dispersed electron acceptors reveal an exponential decay constant of 1.23 per angstrom for electron tunneling through a frozen toluene glass (with a barrier to tunneling of 1.4 electron volts). The decay is 1.62 per angstrom (the barrier, 2.6 electron volts) in a frozen 2-methyl-tetrahydrofuran glass. Comparison to decay constants for tunneling across covalently linked xylyl (0.76 per angstrom) and alkyl (1.0 per angstrom) bridges leads to conclusion that tunneling between solvent molecules leads to the conclusion that tunneling between solvent molecules separated by similar to2 angstroms (van der WaaLs contact) is 20 to 50 times slower than tunneling through a comparable length of a covalently bonded bridge. Our results provide experimental confirmation that covalently bonded pathway ways can facilitate electron flow through folded polypeptide structures.	CALTECH, Beckman Inst, Pasadena, CA 91125 USA	California Institute of Technology	Gray, HB (corresponding author), CALTECH, Beckman Inst, Pasadena, CA 91125 USA.	hbgray@caltech.edu; winklerj@caltech.edu	Winkler, Jay R/B-7372-2009					ATWOOD JL, 1984, INORG CHEM, V23, P4050, DOI 10.1021/ic00192a042; Balabin IA, 2000, SCIENCE, V290, P114, DOI 10.1126/science.290.5489.114; BLUMEN A, 1980, J CHEM PHYS, V72, P2632, DOI 10.1063/1.439408; BLUMEN A, 1979, J CHEM PHYS, V71, P4694, DOI 10.1063/1.438253; Brunschwig B.S., 1987, COMMENTS INORG CHEM, V6, P209; Burel L, 1999, J PHYS CHEM A, V103, P5882, DOI 10.1021/jp991087h; CHANG IJ, 1991, J AM CHEM SOC, V113, P7056, DOI 10.1021/ja00018a064; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; DEVAULT D, 1967, NATURE, V215, P642, DOI 10.1038/215642a0; DORFMAN RC, 1989, J PHYS CHEM-US, V93, P6388, DOI 10.1021/j100354a023; DRABOWICZ W, 1990, Z NATURFORSCH A, V45, P1342, DOI 10.1515/zna-1990-11-1218; ESAKI L, 1974, SCIENCE, V183, P1149, DOI 10.1126/science.183.4130.1149; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FUKUZUMI S, 1987, J AM CHEM SOC, V109, P305, DOI 10.1021/ja00236a003; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Gray HB, 2003, Q REV BIOPHYS, V36, P341, DOI 10.1017/S0033583503003913; GUARR T, 1985, J AM CHEM SOC, V107, P5104, DOI 10.1021/ja00304a015; HALPERN J, 1960, DISCUSS FARADAY SOC, P32; HELMS A, 1992, J AM CHEM SOC, V114, P6227, DOI 10.1021/ja00041a047; INOKUTI M, 1965, J CHEM PHYS, V43, P1978, DOI 10.1063/1.1697063; JOHNSON MD, 1989, J PHYS CHEM-US, V93, P1173, DOI 10.1021/j100341a001; JORGENSEN WL, 1993, J COMPUT CHEM, V14, P206, DOI 10.1002/jcc.540140208; Kumar K, 1998, J PHYS CHEM A, V102, P5529, DOI 10.1021/jp980113t; LANGEN R, 1995, SCIENCE, V268, P1733, DOI 10.1126/science.7792598; Lewis FD, 2002, P NATL ACAD SCI USA, V99, P12536, DOI 10.1073/pnas.192432899; MCCONNELL H, 1961, J CHEM PHYS, V35, P508, DOI 10.1063/1.1731961; MILLER JR, 1982, J AM CHEM SOC, V104, P6488, DOI 10.1021/ja00388a002; MILLER JR, 1984, J AM CHEM SOC, V106, P5057, DOI 10.1021/ja00330a004; MILLER JR, 1975, J PHYS CHEM-US, V79, P1070, DOI 10.1021/j100578a007; Napper AM, 2001, J PHYS CHEM B, V105, P7699, DOI 10.1021/jp0105140; OEVERING H, 1987, J AM CHEM SOC, V109, P3258, DOI 10.1021/ja00245a014; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; Ponce A, 2000, J AM CHEM SOC, V122, P8187, DOI 10.1021/ja000017h; Skourtis SS, 1999, ADV CHEM PHYS, V106, P377, DOI 10.1002/9780470141656.ch8; Smalley JF, 2003, J AM CHEM SOC, V125, P2004, DOI 10.1021/ja028458j; SMITH DC, 1990, COORDIN CHEM REV, V100, P169, DOI 10.1016/0010-8545(90)85009-H; STRAUCH S, 1983, J PHYS CHEM-US, V87, P3579, DOI 10.1021/j100242a001; Tezcan FA, 2001, P NATL ACAD SCI USA, V98, P5002, DOI 10.1073/pnas.081072898; VILLAHERMOSA RM, 2002, THESIS CALTECH; Weidemaier K, 1997, J PHYS CHEM A, V101, P1887, DOI 10.1021/jp962973k; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007	41	133	136	3	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					99	102		10.1126/science.1103818	http://dx.doi.org/10.1126/science.1103818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637275				2022-12-28	WOS:000226214300045
J	Hartmann, LC				Hartmann, LC			The octogenarian's plan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					15	16		10.1001/jama.293.1.15	http://dx.doi.org/10.1001/jama.293.1.15			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632320				2022-12-28	WOS:000226102100001
J	Gasche, Y; Daali, Y; Fathi, M; Chiappe, A; Cottini, S; Dayer, P; Desmeules, J				Gasche, Y; Daali, Y; Fathi, M; Chiappe, A; Cottini, S; Dayer, P; Desmeules, J			Codeine intoxication associated with ultrarapid CYP2D6 metabolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVERSE DRUG-REACTIONS; RENAL-FAILURE; DEBRISOQUINE; MORPHINE; PHARMACOKINETICS; PHARMACOGENETICS; HYDROXYLATORS; IMPACT	Life-threatening opioid intoxication developed in a patient after he was given small doses of codeine for the treatment of a cough associated with bilateral pneumonia. Codeine is bioactivated by CYP2D6 into morphine, which then undergoes further glucuronidation. CYP2D6 genotyping showed that the patient had three or more functional alleles, a finding consistent with ultrarapid metabolism of codeine. We attribute the toxicity to this genotype, in combination with inhibition of CYP3A4 activity by other medications and a transient reduction in renal function.	Univ Hosp Geneva, Div Med Intens Care, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Div Clin Pharmacol & Toxicol, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Div Clin Chem, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Anesthesiol Pharmacol & Surg Intens Care, Div Surg Intens Care, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Gasche, Y (corresponding author), Univ Hosp Geneva, Dept Anesthesiol Pharmacol & Surg Intens Care, Div Surg Intens Care, 24 Rue Micheli du Crest, CH-1211 Geneva, Switzerland.	yvan.gasche@medecine.unige.ch	Youssef, Daali/I-4735-2019	Youssef, Daali/0000-0002-8391-9383				Bertilsson L, 2002, BRIT J CLIN PHARMACO, V53, P111, DOI 10.1046/j.0306-5251.2001.01548.x; Caraco Y, 1999, J PHARMACOL EXP THER, V290, P413; DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516; DAYER P, 1988, BIOCHEM BIOPH RES CO, V152, P411, DOI 10.1016/S0006-291X(88)80729-0; DESMEULES J, 1991, EUR J CLIN PHARMACOL, V41, P23, DOI 10.1007/BF00280101; Di Marco MP, 2002, LIFE SCI, V71, P1149, DOI 10.1016/S0024-3205(02)01799-X; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Meyer UA, 2000, LANCET, V356, P1667, DOI 10.1016/S0140-6736(00)03167-6; Muller B, 2003, CLIN CHEM, V49, P1624, DOI 10.1373/49.10.1624; OSBORNE RJ, 1986, BRIT MED J, V292, P1548, DOI 10.1136/bmj.292.6535.1548; SAWE J, 1987, EUR J CLIN PHARMACOL, V32, P377, DOI 10.1007/BF00543973; Schanzle G, 1999, J CHROMATOGR B, V721, P55, DOI 10.1016/S0378-4347(98)00438-1; Sindrup SH, 1995, PHARMACOGENETICS, V5, P335, DOI 10.1097/00008571-199512000-00001; Yue QY, 1997, THER DRUG MONIT, V19, P539, DOI 10.1097/00007691-199710000-00010; YUE QY, 1991, BRIT J CLIN PHARMACO, V31, P635, DOI 10.1111/j.1365-2125.1991.tb05585.x	16	463	479	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2827	2831		10.1056/NEJMoa041888	http://dx.doi.org/10.1056/NEJMoa041888			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625333				2022-12-28	WOS:000226004300007
J	Tornoczky, T; Ajtay, Z				Tornoczky, T; Ajtay, Z			Fatal free-floating left atrial thrombus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Pecs Univ Sci, H-7624 Pecs, Hungary	University of Pecs	Tornoczky, T (corresponding author), Pecs Univ Sci, H-7624 Pecs, Hungary.								0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					E25	E25		10.1056/ENEJMicm030642	http://dx.doi.org/10.1056/ENEJMicm030642			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625327				2022-12-28	WOS:000226004300011
J	Qiu, XD; Kumbalasiri, T; Carlson, SM; Wong, KY; Krishna, V; Provencio, I; Berson, DM				Qiu, XD; Kumbalasiri, T; Carlson, SM; Wong, KY; Krishna, V; Provencio, I; Berson, DM			Induction of photosensitivity by heterologous expression of melanopsin	NATURE			English	Article							RETINAL GANGLION-CELLS; TRP CHANNELS; RESPONSES; PHOTOTRANSDUCTION; MELANOPHORES; CURRENTS; OPSIN	Melanopsin(1-8) has been proposed to be the photopigment of the intrinsically photosensitive retinal ganglion cells (ipRGCs)(7-15); these photoreceptors of the mammalian eye drive circadian and pupillary adjustments through direct projections to the brain(5,6,8 - 14,16 - 18). Their action spectrum (lambda(max) approximate to 480 nm) implicates an opsin(10) and melanopsin is the only opsin known to exist in these cells. Melanopsin is required for ipRGC photosensitivity(13) and for behavioural photoresponses that survive disrupted rod and cone function(14,17). Heterologously expressed melanopsin apparently binds retinaldehyde and mediates photic activation of G proteins(19). However, its amino- acid sequence differs from vertebrate photosensory opsins(1,20) and some have suggested that melanopsin may be a photoisomerase, providing retinoid chromophore to an unidentified opsin(3,20). To determine whether melanopsin is a functional sensory photopigment, here we transiently expressed it in HEK293 cells that stably expressed TRPC3 channels. Light triggered a membrane depolarization in these cells and increased intracellular calcium. The light response resembled that of ipRGCs, with almost identical spectral sensitivity (lambda(max) approximate to 479 nm). The phototransduction pathway included Gq or a related G protein, phospholipase C and TRPC3 channels. We conclude that mammalian melanopsin is a functional sensory photopigment, that it is the photopigment of ganglion-cell photoreceptors, and that these photoreceptors may use an invertebrate-like phototransduction cascade.	Brown Univ, Dept Neurosci, Providence, RI 02912 USA; Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Grad Program Neurosci, Bethesda, MD 20814 USA	Brown University; Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	Berson, DM (corresponding author), Brown Univ, Dept Neurosci, Box 1953, Providence, RI 02912 USA.	David_Berson@brown.edu		Provencio, Ignacio/0000-0003-1175-920X; Wong, Kwoon/0000-0001-9279-7827				Belenky MA, 2003, J COMP NEUROL, V460, P380, DOI 10.1002/cne.10652; Bellingham J, 2002, MOL BRAIN RES, V107, P128, DOI 10.1016/S0169-328X(02)00454-0; Bellingham J, 2002, CELL TISSUE RES, V309, P57, DOI 10.1007/s00441-002-0573-4; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Berson DM, 2003, TRENDS NEUROSCI, V26, P314, DOI 10.1016/S0166-2236(03)00130-9; Brueggemann LI, 2002, J GEN PHYSIOL, V119, P593, DOI 10.1085/jgp.20018495; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Gooley JJ, 2003, J NEUROSCI, V23, P7093, DOI 10.1523/JNEUROSCI.23-18-07093.2003; Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768; Hannibal J, 2002, ANN MED, V34, P401, DOI 10.1080/078538902320772151; Hannibal J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0002.2002; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Isoldi MC, 2005, P NATL ACAD SCI USA, V102, P1217, DOI 10.1073/pnas.0409252102; LAMB TD, 1995, VISION RES, V35, P3083, DOI 10.1016/0042-6989(95)00114-F; Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; Newman LA, 2003, BIOCHEMISTRY-US, V42, P12734, DOI 10.1021/bi035418z; Oh EJ, 2003, J NEUROPHYSIOL, V90, P2069, DOI 10.1152/jn.00026.2003; Panda S, 2005, SCIENCE, V307, P600, DOI 10.1126/science.1105121; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Rollag MD, 2000, METHOD ENZYMOL, V316, P291; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; Warren EJ, 2003, EUR J NEUROSCI, V17, P1727, DOI 10.1046/j.1460-9568.2003.02594.x; Wong SKF, 2003, NEUROSIGNALS, V12, P1, DOI 10.1159/000068914; Yoshimura T, 1996, J COMP PHYSIOL A, V178, P797	32	321	369	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					745	749		10.1038/nature03345	http://dx.doi.org/10.1038/nature03345			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15674243				2022-12-28	WOS:000227039200040
J	Park, BJ; Kang, JW; Lee, SW; Choi, SJ; Shin, YK; Ahn, YH; Choi, YH; Choi, DH; Lee, KS; Kim, S				Park, BJ; Kang, JW; Lee, SW; Choi, SJ; Shin, YK; Ahn, YH; Choi, YH; Choi, DH; Lee, KS; Kim, S			The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR	CELL			English	Article							TRANSFER-RNA SYNTHETASE; CELL-CYCLE; DNA-DAMAGE; CHECKPOINT PATHWAY; CANCER CELLS; ATM; GENE; COMPLEX; MICE; PHOSPHORYLATION	p18 was first identified as a factor associated with a macromolecular tRNA synthetase complex. Here we describe the mouse p18 loss-of-function phenotype and a role for p18 in the DNA damage response. Inactivation of both p18 alleles caused embryonic lethality, while heterozygous mice showed high susceptibility to spontaneous tumors. p18 was induced and translocated to the nucleus in response to DNA damage. Expression of p18 resulted in elevated p53 levels, while p18 depletion blocked p53 induction. p18 directly interacted with ATM/ATR in response to DNA damage. The activity of ATM was dependent on the level of p18, suggesting the requirement of p18 for the activation of ATM. Low p18 expression was frequently observed in different human cancer cell lines and tissues. These results suggest that p18 is a haploinsufficient tumor suppressor and a key factor for ATM/ATR-mediated p53 activation.	Seoul Natl Univ, Natl Creat Res Initiat Ctr ARS Network, Coll Pharm, Seoul 151742, South Korea; Soonchunhyang Univ, Dept Surg, Coll Med, Seoul 140743, South Korea; Hanyang Univ, Dept Surg, Coll Med, Seoul 133791, South Korea; Korea Res Inst Biosci & Biotechnol, Genome Res Ctr, Taejon, South Korea	Seoul National University (SNU); Soonchunhyang University; Hanyang University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kim, S (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr ARS Network, Coll Pharm, Seoul 151742, South Korea.	sungkim@snu.ac.kr	Shin, Young Kee/C-8929-2011; Kim, Sunghoon/AAE-8314-2020	Shin, Young Kee/0000-0003-0896-718X; Ahn, Young Ha/0000-0002-6843-5444				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Baumgartner AK, 2003, LAB INVEST, V83, P1509, DOI 10.1097/01.LAB.0000090157.13040.58; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; French JE, 2001, CARCINOGENESIS, V22, P99, DOI 10.1093/carcin/22.1.99; Han JM, 2003, BIOCHEM BIOPH RES CO, V303, P985, DOI 10.1016/S0006-291X(03)00485-6; Ide F, 2003, AM J PATHOL, V163, P1729, DOI 10.1016/S0002-9440(10)63531-6; ISAACS WB, 1991, CANCER RES, V51, P4716; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; Ko YG, 2002, PROTEOMICS, V2, P1304, DOI 10.1002/1615-9861(200209)2:9<1304::AID-PROT1304>3.0.CO;2-E; Ko YG, 2001, J BIOL CHEM, V276, P23028, DOI 10.1074/jbc.M101544200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin WC, 2001, GENE DEV, V15, P1833; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Park SG, 2002, J BIOL CHEM, V277, P45243, DOI 10.1074/jbc.M207934200; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Takai H, 2000, GENE DEV, V14, P1439; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang VW, 2001, CANCER RES, V61, P4169; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	38	108	117	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					209	221		10.1016/j.cell.2004.11.054	http://dx.doi.org/10.1016/j.cell.2004.11.054			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680327	Bronze			2022-12-28	WOS:000226740000010
J	Mendelson, TC; Shaw, KL				Mendelson, TC; Shaw, KL			Sexual behaviour: Rapid speciation in an arthropod	NATURE			English	Editorial Material							SELECTION; DIVERSITY		Univ Maryland, Dept Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Mendelson, TC (corresponding author), Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18015 USA.	tamram@lehigh.edu	Mendelson, Tamra/GSN-8151-2022					Carson Hampton L., 1995, P14; Coyne J.A., 2004, SPECIATION; Knight ME, 2004, P ROY SOC B-BIOL SCI, V271, P675, DOI 10.1098/rspb.2003.2639; Losos JB, 2000, NATURE, V408, P847, DOI 10.1038/35048558; McCune Amy R., 1997, P585; Mendelson TC, 2004, MOL ECOL, V13, P3787, DOI 10.1111/j.1365-294X.2004.02375.x; Mendelson TC, 2002, GENETICA, V116, P301, DOI 10.1023/A:1021244812270; Otte D., 1994, CRICKETS HAWAII ORIG; Parsons YM, 2001, MOL ECOL, V10, P1765, DOI 10.1046/j.1365-294X.2001.01318.x; Pomiankowski A, 1998, P NATL ACAD SCI USA, V95, P5106, DOI 10.1073/pnas.95.9.5106; Schluter D, 2001, TRENDS ECOL EVOL, V16, P372, DOI 10.1016/S0169-5347(01)02198-X; Shaw Kerry L., 1995, P39; WESTEBERHARD MJ, 1983, Q REV BIOL, V58, P155, DOI 10.1086/413215	13	312	317	2	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					375	376		10.1038/433375a	http://dx.doi.org/10.1038/433375a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674280				2022-12-28	WOS:000226546200031
J	Young, A; Dinan, S				Young, A; Dinan, S			ABC of sports and exercise medicine - Activity in later life	BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Derby, Derby DE22 1GB, England; Northwick Pk Hosp & Clin Res Ctr, Olympic Med Inst, Harrow, Middx, England; Univ Loughborough, Loughborough, Leics, England	University of Edinburgh; University of Derby; Imperial College London; Loughborough University	Young, A (corresponding author), Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland.	a.young@ed..ac.uk; s.dinan@pcps.ucl.ac.uk							0	27	29	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 22	2005	330	7484					189	191		10.1136/bmj.330.7484.189	http://dx.doi.org/10.1136/bmj.330.7484.189			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891OQ	15661784	Green Published			2022-12-28	WOS:000226590800025
J	Holt, NE; Zigmantas, D; Valkunas, L; Li, XP; Niyogi, KK; Fleming, GR				Holt, NE; Zigmantas, D; Valkunas, L; Li, XP; Niyogi, KK; Fleming, GR			Carotenoid cation formation and the regulation of photosynthetic light harvesting	SCIENCE			English	Article							PHOTOSYSTEM-II; ARABIDOPSIS MUTANTS; XANTHOPHYLL CYCLE; PURPLE BACTERIA; PSBS PROTEIN; ENERGY; PLANTS; PHOTOPROTECTION; COMPLEXES; STATE	Photosynthetic light harvesting in excess light is regulated by a process known as feedback deexcitation. Femtosecond transient absorption measurements on thylakoid membranes show selective formation of a carotenoid radical cation upon excitation of chlorophyll under conditions of maximum, steady-state feedback deexcitation. Studies on transgenic Arabidopsis thaliana plants confirmed that this carotenoid radical cation formation is correlated with feedback deexcitation and requires the presence of zeaxanthin, the specific carotenoid synthesized during high light exposure. These results indicate that energy transfer from chlorophyll molecules to a chlorophyll-zeaxanthin heterodimer, which then undergoes charge separation, is the mechanism for excess energy dissipation during feedback deexcitation.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Fleming, GR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	grfleming@lbl.gov	Zigmantas, Donatas/E-5541-2014	Zigmantas, Donatas/0000-0003-2007-5256				BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; Dreuw A, 2003, PHYS CHEM CHEM PHYS, V5, P3247, DOI 10.1039/b304944b; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Jeevarajan JA, 1996, J PHYS CHEM-US, V100, P5637, DOI 10.1021/jp9530663; Kodis G, 2004, J PHYS CHEM B, V108, P414, DOI 10.1021/jp036139o; Kulheim C, 2002, SCIENCE, V297, P91, DOI 10.1126/science.1072359; Li XP, 2004, J BIOL CHEM, V279, P22866, DOI 10.1074/jbc.M402461200; Li XP, 2002, FUNCT PLANT BIOL, V29, P1131, DOI 10.1071/FP02065; Li XP, 2002, P NATL ACAD SCI USA, V99, P15222, DOI 10.1073/pnas.232447699; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Ma YZ, 2003, P NATL ACAD SCI USA, V100, P4377, DOI 10.1073/pnas.0736959100; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Nield J, 2000, PHILOS T R SOC B, V355, P1337, DOI 10.1098/rstb.2000.0695; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Pan JX, 2004, J AM CHEM SOC, V126, P3066, DOI 10.1021/ja031775l; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Polivka T, 2004, J PHYS CHEM B, V108, P15398, DOI 10.1021/jp0483019; Polivka T, 2002, J PHYS CHEM B, V106, P11016, DOI 10.1021/jp025752p; Tracewell CA, 2003, BIOCHEMISTRY-US, V42, P9127, DOI 10.1021/bi0345844; Zigmantas D, 2002, P NATL ACAD SCI USA, V99, P16760, DOI 10.1073/pnas.262537599	25	620	639	7	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					433	436		10.1126/science.1105833	http://dx.doi.org/10.1126/science.1105833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662017				2022-12-28	WOS:000226492300050
J	Packer, C; Hilborn, R; Mosser, A; Kissui, B; Borner, M; Hopcraft, G; Wilmshurst, J; Mduma, S; Sinclair, ARE				Packer, C; Hilborn, R; Mosser, A; Kissui, B; Borner, M; Hopcraft, G; Wilmshurst, J; Mduma, S; Sinclair, ARE			Ecological change, group territoriality, and population dynamics in Serengeti lions	SCIENCE			English	Article							AFRICAN LIONS; PANTHERA-LEO	Territorial behavior is expected to buffer populations against short-term environmental perturbations, but we have found that group living in African lions causes a complex response to long-term ecological change. Despite numerous gradual changes in prey availability and vegetative cover, regional populations of Serengeti lions remained stable for 10- to 20-year periods and only shifted to new equilibria in sudden leaps. Although gradually improving environmental conditions provided sufficient resources to permit the subdivision of preexisting territories, regional lion populations did not expand until short-term conditions supplied enough prey to generate large cohorts of surviving young. The results of a simulation model show that the observed pattern of "saltatory equilibria" results from the lions' grouping behavior.	Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; Univ Washington, Sch Aquat & Fishery Sci, Seattle, WA 98105 USA; Frankfurt Zool Soc, Arusha, Tanzania; Pk Canada, Ecosyst Serv, Winnipeg, MB R3B 0R9, Canada; Univ British Columbia, Ctr Biodivers Res, Vancouver, BC VLT 1Z4, Canada; Tanzanian Wildlife Res Inst, Arusha, Tanzania	University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; University of British Columbia	Packer, C (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, 1987 Upper Buford Circle, St Paul, MN 55108 USA.	packer@cbs.umn.edu	Hilborn, Ray W/D-6332-2013					Hanby J. P., 1995, SERENGETI, P315; Hanby JP, 1979, SERENGETI DYNAMICS E, P249; HAWKINS D. M., 1998, CUMULATIVE SUM CONTR; Hawkins DM, 2002, STAT MED, V21, P1913, DOI 10.1002/sim.1013; Heinsohn R, 1996, P ROY SOC B-BIOL SCI, V263, P475, DOI 10.1098/rspb.1996.0071; HEINSOHN R, 1995, SCIENCE, V269, P1260, DOI 10.1126/science.7652573; HOPCRAFT JGC, IN PRESS J ANIM ECOL; Kissui BM, 2004, P ROY SOC B-BIOL SCI, V271, P1867, DOI 10.1098/rspb.2004.2797; KREBS CJ, 1972, ECOLOGY EXPT ANAL DI; KREBS J R, 1971, Ecology (Washington D C), V52, P2, DOI 10.2307/1934734; Kruuk H., 1985, P521; MCCOMB K, 1994, ANIM BEHAV, V47, P379, DOI 10.1006/anbe.1994.1052; PACKER C, 1991, CONSERV BIOL, V5, P219, DOI 10.1111/j.1523-1739.1991.tb00127.x; Packer C., 1988, P363; Packer C, 2001, SCIENCE, V293, P690, DOI 10.1126/science.1062320; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; RoelkeParker ME, 1996, NATURE, V379, P441, DOI 10.1038/379441a0; Sinclair A. R. E., 1979, SERENGETI DYNAMICS E, P82; VANORSDOL KG, 1985, J ZOOL, V206, P97; Wynne-Edwards V. C., 1962, pUnpaginated	20	178	181	4	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2005	307	5708					390	393		10.1126/science.1105122	http://dx.doi.org/10.1126/science.1105122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662005				2022-12-28	WOS:000226492300036
J	Dickinson, M; Farman, G; Frye, M; Bekyarova, T; Gore, D; Maughan, D; Irving, T				Dickinson, M; Farman, G; Frye, M; Bekyarova, T; Gore, D; Maughan, D; Irving, T			Molecular dynamics of cyclically contracting insect flight muscle in vivo	NATURE			English	Article							X-RAY-DIFFRACTION; DROSOPHILA-MELANOGASTER; MYOSIN-FILAMENTS; CROSS-BRIDGES; TARGET ZONES; ACTIN; REFLECTIONS; ACTIVATION; EFFICIENCY; STRETCH	Flight in insects-which constitute the largest group of species in the animal kingdom-is powered by specialized muscles located within the thorax. In most insects each contraction is triggered not by a motor neuron spike but by mechanical stretch imposed by antagonistic muscles(1). Whereas 'stretch activation' and its reciprocal phenomenon 'shortening deactivation' are observed to varying extents in all striated muscles, both are particularly prominent in the indirect flight muscles of insects(1). Here we show changes in thick-filament structure and actin-myosin interactions in living, flying Drosophila with the use of synchrotron small-angle X-ray diffraction. To elicit stable flight behaviour and permit the capture of images at specific phases within the 5-ms wingbeat cycle, we tethered flies within a visual flight simulator(2). We recorded images of 340 mus duration every 625 mus to create an eight-frame diffraction movie, with each frame reflecting the instantaneous structure of the contractile apparatus. These time-resolved measurements of molecular-level structure provide new insight into the unique ability of insect flight muscle to generate elevated power at high frequency.	IIT, Dept BCPS, BioCAT, Chicago, IL 60616 USA; CALTECH, Dept Bioengn, Pasadena, CA 91125 USA; IIT, Dept BCPS, CSRRI, Chicago, IL 60616 USA; Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	Illinois Institute of Technology; California Institute of Technology; Illinois Institute of Technology; University of Vermont	Irving, T (corresponding author), IIT, Dept BCPS, BioCAT, Chicago, IL 60616 USA.	irving@iit.edu		Frye, Mark/0000-0003-3277-3094				Agianian B, 2004, EMBO J, V23, P772, DOI 10.1038/sj.emboj.7600097; ALEXANDER RM, 1977, NATURE, V265, P114, DOI 10.1038/265114a0; ALKHAYAT HA, 1995, J MOL BIOL, V252, P611, DOI 10.1006/jmbi.1995.0524; Chan WP, 1996, J EXP BIOL, V199, P2767; DICKINSON MH, 1995, SCIENCE, V268, P87, DOI 10.1126/science.7701346; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Huxley HE, 1998, ADV EXP MED BIOL, V453, P281; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; Huxley HE, 2003, BIOPHYS J, V84, p139A; Irving M, 2000, NAT STRUCT BIOL, V7, P482, DOI 10.1038/75890; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; Irving TC, 2000, NUCL INSTRUM METH A, V448, P250, DOI 10.1016/S0168-9002(99)00732-9; Irving TC, 2000, BIOPHYS J, V78, P2511, DOI 10.1016/S0006-3495(00)76796-8; Josephson RK, 2000, J EXP BIOL, V203, P2713; Juanhuix J, 2001, BIOPHYS J, V80, P1429, DOI 10.1016/S0006-3495(01)76115-2; Lehmann FO, 1997, J EXP BIOL, V200, P1133; Linari M, 2004, BIOPHYS J, V87, P1101, DOI 10.1529/biophysj.103.037374; Littlefield KP, 2003, AM J PHYSIOL-CELL PH, V284, pC1031, DOI 10.1152/ajpcell.00474.2002; MENETRET JF, 1990, J MUSCLE RES CELL M, V11, P1, DOI 10.1007/BF01833321; MILLER A, 1970, NATURE, V226, P1060, DOI 10.1038/2261060a0; Reedy MC, 2000, J CELL SCI, V113, P3551; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; REEDY MK, 1985, J MOL BIOL, V185, P145, DOI 10.1016/0022-2836(85)90188-3; SPARROW J, 1991, J CELL SCI, P73; Squire J, 1981, STRUCTURAL BASIS MUS; Taylor KA, 1999, CELL, V99, P421, DOI 10.1016/S0092-8674(00)81528-7; Tregear RT, 2004, BIOPHYS J, V86, P3009, DOI 10.1016/S0006-3495(04)74350-7; Tregear RT, 1998, BIOPHYS J, V74, P1439, DOI 10.1016/S0006-3495(98)77856-7; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; WEISFOGH T, 1965, 12TH P INT C ENT, P186	30	64	67	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					330	333		10.1038/nature03230	http://dx.doi.org/10.1038/nature03230			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662427				2022-12-28	WOS:000226381300059
J	Kotera, E; Tasaka, M; Shikanai, T				Kotera, E; Tasaka, M; Shikanai, T			A pentatricopeptide repeat protein is essential for RNA editing in chloroplasts	NATURE			English	Article							NUCLEUS-ENCODED FACTOR; CYCLIC ELECTRON FLOW; MESSENGER-RNA; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; RESTORES FERTILITY; PHOTOSYSTEM-I; SITE; PLANTS	RNA editing is a process of RNA maturation involved in the insertion, deletion or modification of nucleotides(1). In organellar transcripts of higher plants, specific cytidine residues are converted into uridine residues. In many cases, editing results in the restoration of conserved amino acid residues, a process that is essential for protein function in plastids(2,3). Despite the technical breakthrough in establishing systems in vivo(4) and in vitro(5) for analysing RNA editing, its machinery still remains to be identified in higher plants. Here we introduce a genetic approach and report the discovery of a gene responsible for the specific RNA editing event in the chloroplast.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Kyushu Univ, Grad Sch Agr, Fukuoka 8128581, Japan	Nara Institute of Science & Technology; Kyushu University	Shikanai, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan.	shikanai@agr.kyushu-u.ac.jp	Shikanai, Toshiharu/AAK-9112-2020					Aubourg S, 2000, PLANT MOL BIOL, V42, P603, DOI 10.1023/A:1006352315928; Bentolila S, 2002, P NATL ACAD SCI USA, V99, P10887, DOI 10.1073/pnas.102301599; BOCK R, 1994, EMBO J, V13, P4623, DOI 10.1002/j.1460-2075.1994.tb06784.x; Chateigner-Boutin AL, 2003, NUCLEIC ACIDS RES, V31, P2586, DOI 10.1093/nar/gkg354; CHAUDHURI S, 1995, EMBO J, V14, P2951, DOI 10.1002/j.1460-2075.1995.tb07295.x; Coffin JW, 1997, CURR GENET, V32, P273, DOI 10.1007/s002940050277; del Campo EM, 2002, J BIOL CHEM, V277, P36457, DOI 10.1074/jbc.M204500200; Fisk DG, 1999, EMBO J, V18, P2621, DOI 10.1093/emboj/18.9.2621; GLEGE P, 1999, P NATL ACAD SCI USA, V96, P15324; Guera A, 2000, PLANT CELL PHYSIOL, V41, P49, DOI 10.1093/pcp/41.1.49; Hashimoto M, 2003, PLANT J, V36, P541, DOI 10.1046/j.1365-313X.2003.01900.x; Hirose T, 1997, EMBO J, V16, P6804, DOI 10.1093/emboj/16.22.6804; Hirose T, 2001, EMBO J, V20, P1144, DOI 10.1093/emboj/20.5.1144; Kazama T, 2003, FEBS LETT, V544, P99, DOI 10.1016/S0014-5793(03)00480-0; Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584; Koizuka N, 2003, PLANT J, V34, P407, DOI 10.1046/j.1365-313X.2003.01735.x; LURIN C, PLANT CELL, V16, P2089; Lutz KA, 2001, CURR GENET, V40, P214, DOI 10.1007/s002940100242; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; Meierhoff K, 2003, PLANT CELL, V15, P1480, DOI 10.1105/tpc.010397; Miyamoto T, 2004, P NATL ACAD SCI USA, V101, P48, DOI 10.1073/pnas.0307163101; Munekaga Y, 2004, NATURE, V429, P579, DOI 10.1038/nature02598; NECKERMANN K, 1994, GENE, V146, P177, DOI 10.1016/0378-1119(94)90290-9; Sasaki Y, 2001, J BIOL CHEM, V276, P3937, DOI 10.1074/jbc.M008166200; Shikanai T, 1998, P NATL ACAD SCI USA, V95, P9705, DOI 10.1073/pnas.95.16.9705; Shikanai T, 1999, PLANT CELL PHYSIOL, V40, P1134, DOI 10.1093/oxfordjournals.pcp.a029498; Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0; Smith HC, 1997, RNA, V3, P1105; Williams PM, 2003, PLANT J, V36, P675, DOI 10.1046/j.1365-313X.2003.01915.x; Yamazaki H, 2004, PLANT J, V38, P152, DOI 10.1111/j.1365-313X.2004.02035.x	30	419	451	2	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					326	330		10.1038/nature03229	http://dx.doi.org/10.1038/nature03229			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662426				2022-12-28	WOS:000226381300058
J	Slater, EE				Slater, EE			Today's FDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DRUG DEVELOPMENT; SAFETY; LESSONS											Abraham J, 2002, LANCET, V360, P1498, DOI 10.1016/S0140-6736(02)11477-2; Angell M, 1996, NEW ENGL J MED, V334, P1513, DOI 10.1056/NEJM199606063342306; Bennett DA, 2003, LANCET, V361, P1402, DOI 10.1016/S0140-6736(03)13147-9; Benson JO, 2000, J ACQ IMMUN DEF SYND, V25, P130, DOI 10.1097/00126334-200010010-00007; BONE HG, 2001, 37 ANN M DRUG INF AS; *DEP AGR, 2004, OFF MAN BUDG; *DEP HLTH HUM SERV, 2004, OFF MAN BUDG; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093; *FDA, 2004, FDA RUL REQ BAR COD; *FOOD DRUG ADM, 2003, REP PDUFA GOALS OR N; *FOOD DRUG ADM, 2002, EFF US FEES DRUG APP; *FOOD DRUG ADM, 2003, FY 2004 JUST EST APP; Friedman MA, 1999, JAMA-J AM MED ASSOC, V281, P1728, DOI 10.1001/jama.281.18.1728; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Galson S, 2001, LANCET, V358, P415, DOI 10.1016/S0140-6736(01)05560-X; *GEN ACC OFF, 2003, GAO03101, P46; HALVORSON GC, 2003, EPIDEMIC CARE CALL S; Henderson JA, 2003, FOOD DRUG LAW J, V58, P251; HILTS PJ, 2003, PROTECTING AM HLTH F, pR15; Horton R, 2001, LANCET, V357, P1544, DOI 10.1016/S0140-6736(00)04776-0; *MASS TECHN COLL, 2003, ADV TECHN LOW HLTH C; MATHEWS AW, 2004, WALL STREET J   0908, pB1; MCAUSLANE N, 2004, CHANGING REGULATORY; McClellan MB, 2003, FOOD DRUG LAW J, V58, P191; MCCLELLAN MB, 2003, FOOD DRUG ADM STRATE; MCCLELLAN MB, 2003, COMMUNICATION    NOV; MERCK, 2004, MERCK ANN VOL WORLDW; Rawlins MD, 2004, NEW ENGL J MED, V351, P1383, DOI 10.1056/NEJMp048221; SINCLAIR U, 2006, JUNGLE, P102; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; Temple R, 2002, STAT MED, V21, P2939, DOI 10.1002/sim.1298; Temple RJ, 2002, JAMA-J AM MED ASSOC, V287, P2273, DOI 10.1001/jama.287.17.2273; Trontell A, 2004, NEW ENGL J MED, V351, P1385, DOI 10.1056/NEJMp048187; *TUFTS CTR STUD DR, 2003, RIS DRUGS SPEND SPUR; *TUFTS CTR STUD DR, 2003, FDAS FAST TRACK IN C; *TUFTS CTR STUD DR, 2003, DRUG CO DEEMPH BLOCK; Walter LC, 2004, JAMA-J AM MED ASSOC, V291, P2466, DOI 10.1001/jama.291.20.2466; Zuger A, 2003, NEW ENGL J MED, V349, P2188, DOI 10.1056/NEJMp038196; [No title captured]; 2004, FED REG, V69, P26393; 2004, PINK SHEET, V66, P1	42	14	14	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					293	297		10.1056/NEJMsb042278	http://dx.doi.org/10.1056/NEJMsb042278			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659733				2022-12-28	WOS:000226370500014
J	Lee, KJ; Thompson, SG				Lee, KJ; Thompson, SG			Clustering by health professional in individually randomised trials	BRITISH MEDICAL JOURNAL			English	Article							MULTICENTER; DESIGN; COSTS		Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	MRC Biostatistics Unit; University of Cambridge	Lee, KJ (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.	kjl27@cam.ac.uk	Lee, Katherine J/A-2519-2016					CRITSCHRISTOPH P, 1991, J CONSULT CLIN PSYCH, V59, P20, DOI 10.1037/0022-006X.59.1.20; Dey P, 2002, BRIT MED J, V324, P507, DOI 10.1136/bmj.324.7336.507; Greenfield S, 2002, ANN INTERN MED, V136, P111, DOI 10.7326/0003-4819-136-2-200201150-00008; Hoover DR, 2002, STAT MED, V21, P1351, DOI 10.1002/sim.1139; Jarman B, 2002, BRIT MED J, V324, P1072, DOI 10.1136/bmj.324.7345.1072; Jones B, 1998, STAT MED, V17, P1767, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1767::AID-SIM978>3.0.CO;2-H; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Koning S, 2002, BMJ-BRIT MED J, V324, P203, DOI 10.1136/bmj.324.7331.203; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; MARTINDALE C, 1978, J CONSULT CLIN PSYCH, V46, P1526, DOI 10.1037/0022-006X.46.6.1526; PAUL SR, 1992, STAT MED, V11, P159, DOI 10.1002/sim.4780110203; Roberts C, 1999, STAT MED, V18, P2605, DOI 10.1002/(SICI)1097-0258(19991015)18:19<2605::AID-SIM237>3.0.CO;2-N; Senn S, 1998, STAT MED, V17, P1753; Wallace P, 2002, LANCET, V359, P1961, DOI 10.1016/S0140-6736(02)08828-1	14	78	78	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 15	2005	330	7483					142	144		10.1136/bmj.330.7483.142	http://dx.doi.org/10.1136/bmj.330.7483.142			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889PM	15649931	Green Published			2022-12-28	WOS:000226454900027
J	Cooper, TA				Cooper, TA			Alternative splicing regulation impacts heart development	CELL			English	Editorial Material								SR proteins serve multiple roles in the posttranscriptional control of gene expression, including as regulators of alternative splicing. In this issue of CeII, Xu et al. (2005) demonstrate that a heart-specific knockout of one SR protein, ASF/SF2, produces cardiomyopathy and misregulation of specific alternative splicing events during early postnatal development.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Cooper, TA (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.							Bayer KM, 2001, BIOCHEM BIOPH RES CO, V289, P917, DOI 10.1006/bbrc.2001.6063; BLACK DL, 2003, ANNU REV BIOCHEM, V27, P27; Ding JH, 2004, EMBO J, V23, P885, DOI 10.1038/sj.emboj.7600054; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036	10	29	29	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					1	2		10.1016/j.cell.2004.12.030	http://dx.doi.org/10.1016/j.cell.2004.12.030			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652472	Bronze			2022-12-28	WOS:000226365400001
J	Xu, XD; Yang, DM; Ding, JH; Wang, W; Chu, PH; Dalton, ND; Wang, HY; Bermingham, JR; Ye, Z; Liu, F; Rosenfeld, MG; Manley, JL; Ross, J; Chen, J; Xiao, RP; Cheng, HP; Fu, XD				Xu, XD; Yang, DM; Ding, JH; Wang, W; Chu, PH; Dalton, ND; Wang, HY; Bermingham, JR; Ye, Z; Liu, F; Rosenfeld, MG; Manley, JL; Ross, J; Chen, J; Xiao, RP; Cheng, HP; Fu, XD			ASF/SF2-Regulated CaMKII delta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle	CELL			English	Article							PROTEIN-KINASE-II; MESSENGER-RNA; DILATED CARDIOMYOPATHY; ISOFORM; ASF/SF2; GENE; SC35; HYPERTROPHY; DISRUPTION; MECHANISMS	The transition from juvenile to adult life is accompanied by programmed remodeling in many tissues and organs, which is key for organisms to adapt to the demand of the environment. Here we report a novel regulated alternative splicing program that is crucial for postnatnal heart remodeling in the mouse. We identify the essential splicing factor ASF/SF2 as a key component of the program, regulating a restricted set of tissue-specific alternative splicing events during heart remodeling. Cardiomyocytes deficient in ASF/SF2 display an unexpected hypercontraction phenotype due to a defect in postnatal splicing switch of the Ca2+/calmodulin-dependent kinase IIdelta (CaMKIIdelta) transcript. This failure results in mistargeting of the kinase to sarcolemmal membranes, causing severe excitation-contraction coupling defects. Our results validate ASF/SF2 as a fundamental splicing regulator in the reprogramming pathway and reveal the central contribution of ASF/SF2-regulated CaMKIIdelta alternative splicing to functional remodeling in developing heart.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; NIA, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Columbia University	Fu, XD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	xdfu@ucsd.edu	Chu, Pao-Hsien/P-5249-2019; Chen, Ju/E-5579-2011; Xiao, Rui-Ping/AAE-2629-2019; Chu, Pao-Hsien/G-3685-2010; Yimei, Wang/AAE-4083-2019; wang, wang/GWQ-7272-2022; Heping, Cheng/AAE-2680-2019; cheng, heping/A-7299-2011	Chu, Pao-Hsien/0000-0003-0361-6348; Heping, Cheng/0000-0002-9604-6702; Manley, James/0000-0002-8341-1459; Wang, Wang/0000-0001-9093-412X; Xu, Xiangdong/0000-0003-2220-0890	NHLBI NIH HHS [R01 HL066100, R01 HL66100] Funding Source: Medline; NIGMS NIH HHS [R01 GM49369, R37 GM48259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048259, R01GM049369] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson ME, 2004, TRENDS CARDIOVAS MED, V14, P152, DOI 10.1016/j.tcm.2004.02.005; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bayer KM, 2001, BIOCHEM BIOPH RES CO, V289, P917, DOI 10.1006/bbrc.2001.6063; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; Chen J, 1998, DEVELOPMENT, V125, P1943; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Ding JH, 2004, EMBO J, V23, P885, DOI 10.1038/sj.emboj.7600054; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; Haddock PS, 1999, CIRC RES, V85, P415, DOI 10.1161/01.RES.85.5.415; HAJLHOSSEINI MK, 2001, P NATL ACAD SCI USA, V98, P3855; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; Huang CQ, 2003, J BIOL CHEM, V278, P7360, DOI 10.1074/jbc.M211875200; Huang XP, 1999, CIRC RES, V84, P1; Huang YQ, 2004, P NATL ACAD SCI USA, V101, P9666, DOI 10.1073/pnas.0403533101; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Jensen KB, 2000, P NATL ACAD SCI USA, V97, P5740, DOI 10.1073/pnas.090553997; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Jin JP, 1996, BIOCHEM BIOPH RES CO, V225, P883, DOI 10.1006/bbrc.1996.1267; Jumaa H, 1999, CURR BIOL, V9, P899, DOI 10.1016/S0960-9822(99)80394-7; Kim S, 2003, NUCLEIC ACIDS RES, V31, P1955, DOI 10.1093/nar/gkg286; Lai MC, 2004, J BIOL CHEM, V279, P31745, DOI 10.1074/jbc.C400173200; Lemaire R, 2002, GENE DEV, V16, P594, DOI 10.1101/gad.939502; Li L, 1997, J PHYSIOL-LONDON, V501, P17, DOI 10.1111/j.1469-7793.1997.017bo.x; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Maier LS, 2003, CIRC RES, V92, P904, DOI 10.1161/01.RES.0000069685.20258.F1; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; REISER PJ, 1994, AM J PHYSIOL-HEART C, V267, pH1589; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; Siedner S, 2003, J PHYSIOL-LONDON, V548, P493, DOI 10.1113/JPHYSIOL.2002.036509; SIMMERMAN HK, 1998, PHYSIOL REV, V78, P9231; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Wang HY, 2001, MOL CELL, V7, P331, DOI 10.1016/S1097-2765(01)00181-2; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; XIAO RP, 2001, SCI STKE RE15, DOI DOI 10.1126/STKA.2001.104.RE15; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5; Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou YY, 1997, AM J PHYSIOL-HEART C, V273, pH1611, DOI 10.1152/ajpheart.1997.273.3.H1611; Zhu WZ, 2003, J CLIN INVEST, V111, P617, DOI 10.1172/JCI200316326	54	413	433	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					59	72		10.1016/j.cell.2004.11.036	http://dx.doi.org/10.1016/j.cell.2004.11.036			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652482	Bronze			2022-12-28	WOS:000226365400011
J	Singh, N; Armstrong, DG; Lipsky, BA				Singh, N; Armstrong, DG; Lipsky, BA			Preventing foot ulcers in patients with diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOWER-EXTREMITY AMPUTATION; QUALITY-OF-LIFE; LIMITED JOINT MOBILITY; HIGH-RISK; PERIPHERAL NEUROPATHY; TUNING FORK; THERAPEUTIC FOOTWEAR; CLINICAL EXAMINATION; SCREENING PATIENTS; SURGICAL-TREATMENT	Context Among persons diagnosed as having diabetes mellitus, the prevalence of foot ulcers is 4% to 10%, the annual population-based incidence is 1.0% to 4.1%, and the lifetime incidence may be as high as 25%. These ulcers frequently become infected, cause great morbidity, engender considerable financial costs, and are the usual first step to lower extremity amputation. Objective To systematically review the evidence on the efficacy of methods advocated for preventing diabetic foot ulcers in the primary care setting. Data Sources, Study Selection, and Data Extraction The EBSCO, MEDLINE, and the National Guideline Clearinghouse databases were searched for articles published between January 1980 and April 2004 using database-specific keywords. Bibliographies of retrieved articles were also searched, along with the Cochrane Library and relevant Web sites. We reviewed the retrieved literature for pertinent information, paying particular attention to prospective cohort studies and randomized clinical trials. Data Synthesis Prevention of diabetic foot ulcers begins with screening for loss of protective sensation, which is best accomplished in the primary care setting with a brief history and the Semmes-Weinstein monofilament. Specialist clinics may quantify neuropathy with biothesiometry, measure plantar foot pressure, and assess lower extremity vascular status with Doppler ultrasound and ankle-brachial blood pressure indices. These measurements, in conjunction with other findings from the history and physical examination, enable clinicians to stratify patients based on risk and to determine the type of intervention. Educating patients about proper foot care and periodic foot examinations are effective interventions to prevent ulceration. Other possibly effective clinical interventions include optimizing glycemic control, smoking cessation, intensive podiatric care, debridement of calluses, and certain types of prophylactic foot surgery. The value of various types of prescription footwear for ulcer prevention is not clear. Conclusions Substantial evidence supports screening all patients with diabetes to identify those at risk for foot ulceration. These patients might benefit from certain prophylactic interventions, including patient education, prescription footwear, intensive podiatric care, and evaluation for surgical interventions.	Vet Affairs Puget Sound Healthcare Syst, Dept Med, Div Endocrinol & Metab, Seattle, WA 98108 USA; Vet Affairs Puget Sound Healthcare Syst, Dept Med, Div Gen Internal Med & Infect Dis, Seattle, WA 98108 USA; Univ Washington, Sch Med, Seattle, WA USA; Rosalind Franklin Univ Med & Sci, Dr William M Scholl Coll Podiatr Med, Ctr Lower Extrem Ambulatory Res, Chicago, IL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; Chicago Medical School; Rosalind Franklin University Medical & Science	Singh, N (corresponding author), Vet Affairs Puget Sound Healthcare Syst, Dept Med, Div Endocrinol & Metab, Mailcode S-111-ENDO,1660 S Columbian Way, Seattle, WA 98108 USA.	Nalini.Singh2@med.va.gov	Lipsky, Benjamin A/B-4645-2013	Lipsky, Benjamin A./0000-0001-9886-5114				ALTMAN MI, 2000, WOUNDS SB, V12, pB64; American Diabetes Association, 2004, DIABETES CARE S1, V27, pS31; Anarella JJ, 2001, J AM PODIAT MED ASSN, V91, P325, DOI 10.7547/87507315-91-6-325; Armstrong D G, 1998, J Foot Ankle Surg, V37, P303; Armstrong D G, 1996, J Foot Ankle Surg, V35, P585; Armstrong D G, 1999, J Foot Ankle Surg, V38, P79; Armstrong D G, 1998, J Foot Ankle Surg, V37, P460; Armstrong DG, 1998, DIABETES CARE, V21, P855, DOI 10.2337/diacare.21.5.855; Armstrong DG, 2000, DIABETES CARE, V23, P887, DOI 10.2337/diacare.23.7.887; Armstrong DG, 1998, ARCH INTERN MED, V158, P289, DOI 10.1001/archinte.158.3.289; Armstrong DG, 2003, DIABETES CARE, V26, P3284, DOI 10.2337/diacare.26.12.3284; Armstrong DG, 2003, DIABETIC MED, V20, P329, DOI 10.1046/j.1464-5491.2003.00933.x; Armstrong DG, 1997, SOUTHERN MED J, V90, P384, DOI 10.1097/00007611-199704000-00004; Armstrong DG, 1999, J BONE JOINT SURG AM, V81A, P535, DOI 10.2106/00004623-199904000-00011; Armstrong DG, 1997, DIABETIC MED, V14, P357, DOI 10.1002/(SICI)1096-9136(199705)14:5<357::AID-DIA341>3.3.CO;2-#; Association A.D., 1999, DIABETES CARE, V22, P1354, DOI DOI 10.2337/DIACARE.22.8.1354; BARRY DC, 1993, J AM PODIAT MED ASSN, V83, P96, DOI 10.7547/87507315-83-2-96; BARTH R, 1991, DIABETIC MED, V8, P111, DOI 10.1111/j.1464-5491.1991.tb01555.x; BLOOMGARDEN ZT, 1987, DIABETES CARE, V10, P263, DOI 10.2337/diacare.10.3.263; Blume PA, 2002, PLAST RECONSTR SURG, V109, P601, DOI 10.1097/00006534-200202000-00029; Boike AM, 2002, CLEV CLIN J MED, V69, P342, DOI 10.3949/ccjm.69.4.342; Booth J, 2000, DIABETES CARE, V23, P984, DOI 10.2337/diacare.23.7.984; Boulton AJM, 2004, NEW ENGL J MED, V351, P48, DOI 10.1056/NEJMcp032966; Boyko EJ, 1999, DIABETES CARE, V22, P1036, DOI 10.2337/diacare.22.7.1036; Brod M, 1998, QUAL LIFE RES, V7, P365; Bruckner M, 1999, AM J MANAG CARE, V5, P609; Busch K, 2003, DIABETIC MED, V20, P665, DOI 10.1046/j.1464-5491.2003.01003.x; Catanzariti A R, 1995, J Foot Ankle Surg, V34, P23; Cavanagh PR, 2002, JAMA-J AM MED ASSOC, V288, P1231, DOI 10.1001/jama.288.10.1231; CAVANAGH PR, 2000, FOOT DIABETES BIBLIO; Chaturvedi N, 2002, DIABETIC MED, V19, P99, DOI 10.1046/j.1464-5491.2002.00583.x; Chincholikar Dipali A, 2002, Indian J Pathol Microbiol, V45, P15; Clark N, 2003, DIABETES CARE, V26, P3333; COLAGIURI S, 1995, DIABETES RES CLIN PR, V28, P29, DOI 10.1016/0168-8227(95)01050-N; Coppini DV, 1998, DIABETIC MED, V15, P765, DOI 10.1002/(SICI)1096-9136(199809)15:9<765::AID-DIA663>3.0.CO;2-1; Faglia E, 2002, J INTERN MED, V252, P225, DOI 10.1046/j.1365-2796.2002.01015.x; Feinglass J, 1999, AM J PUBLIC HEALTH, V89, P1222, DOI 10.2105/AJPH.89.8.1222; FERNANDO DJS, 1991, DIABETES CARE, V14, P8, DOI 10.2337/diacare.14.1.8; Fleischli JE, 1999, FOOT ANKLE INT, V20, P80, DOI 10.1177/107110079902000203; FRYKBERG RG, 2000, J FOOT ANKLE SURG, V39, pS2; Ganiats TG, 2000, J FAM PRACTICE, V49, P505; Geerlings SE, 1999, FEMS IMMUNOL MED MIC, V26, P259, DOI 10.1111/j.1574-695X.1999.tb01397.x; GERR FE, 1988, BRIT J IND MED, V45, P635; Gin H, 2002, DIABETES METAB, V28, P457; GIURINI JM, 1991, J AM PODIAT MED ASSN, V81, P167, DOI 10.7547/87507315-81-4-167; GIURINI JM, 1993, J AM PODIAT MED ASSN, V83, P101, DOI 10.7547/87507315-83-2-101; Gordois A, 2003, DIABETES CARE, V26, P1790, DOI 10.2337/diacare.26.6.1790; Gregg EW, 2004, DIABETES CARE, V27, P1591, DOI 10.2337/diacare.27.7.1591; Gudas C J, 1987, Clin Podiatr Med Surg, V4, P445; Gupta AK, 2000, EUR J DERMATOL, V10, P379; HaVan G, 1996, DIABETES CARE, V19, P1257, DOI 10.2337/diacare.19.11.1257; HUTCHINSON A, 2000, CLIN GUIDELINES TYPE; *INT WORK GROUP DI, 2003, EP DIAT FOOT INF POP; *INT WORK GROUP DI, 1999, INT CONS DOAB FOOT P; International Working Group on the Diabetic Foot, 2003, INT CONS DIAB FOOT S; Jbour AS, 2003, SAUDI MED J, V24, P761; Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507; Khoury A, 1998, M D COMPUT, V15, P307; Kruger S, 1992, Diabetes Educ, V18, P487, DOI 10.1177/014572179201800606; Lavery LA, 2003, DIABETES CARE, V26, P1069, DOI 10.2337/diacare.26.4.1069; Lavery LA, 1998, ARCH INTERN MED, V158, P157, DOI 10.1001/archinte.158.2.157; Lavery LA, 2003, DIABETES CARE, V26, P1435, DOI 10.2337/diacare.26.5.1435; Lin SS, 1996, ORTHOPEDICS, V19, P465; LINIGER C, 1990, DIABETIC MED, V7, P859, DOI 10.1111/j.1464-5491.1990.tb01319.x; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; Lobmann R, 2002, DIABETOLOGIA, V45, P1011, DOI 10.1007/s00125-002-0868-8; Macfarlane RM, 1997, DIABETIC MED, V14, P867, DOI 10.1002/(SICI)1096-9136(199710)14:10<867::AID-DIA475>3.0.CO;2-L; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; Maluf KS, 2003, CLIN BIOMECH, V18, P567, DOI 10.1016/S0268-0033(03)00118-9; Mason J, 1999, DIABETIC MED, V16, P889, DOI 10.1046/j.1464-5491.1999.00137.x; Mayfield JA, 2000, J FAM PRACTICE, V49, P499; Mayser P, 2004, EXP CLIN ENDOCR DIAB, V112, P264, DOI 10.1055/s-2004-817974; MAZZUCA SA, 1986, DIABETES CARE, V9, P1, DOI 10.2337/diacare.9.1.1; Meijer JWG, 2001, DISABIL REHABIL, V23, P336; Mueller MJ, 2004, DIABETES CARE, V27, P1559, DOI 10.2337/diacare.27.7.1559; Mueller MJ, 2003, J BONE JOINT SURG AM, V85A, P1436, DOI 10.2106/00004623-200308000-00003; Mueller MJ, 2003, J BIOMECH, V36, P1009, DOI 10.1016/S0021-9290(03)00078-2; Ortegon MM, 2004, DIABETES CARE, V27, P901, DOI 10.2337/diacare.27.4.901; PECORARO RE, 1990, DIABETES CARE, V13, P513, DOI 10.2337/diacare.13.5.513; Perkins BA, 2001, DIABETES CARE, V24, P250, DOI 10.2337/diacare.24.2.250; Pham H, 2000, DIABETES CARE, V23, P606, DOI 10.2337/diacare.23.5.606; Piaggesi A, 1998, DIABETIC MED, V15, P412, DOI 10.1002/(SICI)1096-9136(199805)15:5<412::AID-DIA584>3.3.CO;2-T; PIEBER TR, 1995, DIABETIC MED, V12, P349, DOI 10.1111/j.1464-5491.1995.tb00491.x; Pitei D L, 1999, J Foot Ankle Surg, V38, P251; PITEI DL, 2000, WOUNDS S6, V12, pB19; Plank J, 2003, DIABETES CARE, V26, P1691, DOI 10.2337/diacare.26.6.1691; Ramsey SD, 1999, DIABETES CARE, V22, P382, DOI 10.2337/diacare.22.3.382; Rauwerda JA, 2004, DIABETES-METAB RES, V20, pS41, DOI 10.1002/dmrr.475; Reiber G.E., 2001, DIABETIC FOOT, P13; Reiber GE, 1996, DIABETIC MED, V13, pS6, DOI 10.1002/dme.1996.13.s1.6; Reiber GE, 1999, DIABETES CARE, V22, P157, DOI 10.2337/diacare.22.1.157; Reiber GE, 2002, JAMA-J AM MED ASSOC, V287, P2552, DOI 10.1001/jama.287.19.2552; Rith-Najarian S, 1998, J FAM PRACTICE, V47, P127; RITHNAJARIAN SJ, 1992, DIABETES CARE, V15, P1386, DOI 10.2337/diacare.15.10.1386; Ronnemaa T, 1997, DIABETES CARE, V20, P1833, DOI 10.2337/diacare.20.12.1833; Rosenblum B I, 1994, J Foot Ankle Surg, V33, P557; ROSENBLUM BI, 2000, WOUNDS S, V12, pB7; SANDERS LJ, 1994, J AM PODIAT MED ASSN, V84, P322, DOI 10.7547/87507315-84-7-322; SCHER KS, 1988, SURGERY, V104, P661; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIJTONEN OI, 1993, DIABETES CARE, V16, P16, DOI 10.2337/diacare.16.1.16; Simon SR, 2000, J BONE JOINT SURG AM, V82A, P939, DOI 10.2106/00004623-200007000-00005; Smieja M, 1999, J GEN INTERN MED, V14, P418, DOI 10.1046/j.1525-1497.1999.05208.x; Soulier S M, 1987, Diabetes Educ, V13, P130, DOI 10.1177/014572178701300212; Sumpio Bauer E, 2003, Clin Podiatr Med Surg, V20, P689, DOI 10.1016/S0891-8422(03)00088-0; Tennvall GR, 2004, CLIN INFECT DIS, V39, pS132, DOI 10.1086/383275; Tennvall GR, 2001, DIABETOLOGIA, V44, P2077; Tennvall GR, 2000, J DIABETES COMPLICAT, V14, P235; Tennvall GR, 2000, PHARMACOECONOMICS, V18, P225, DOI 10.2165/00019053-200018030-00003; THIVOLET C, 1990, DIABETES CARE, V13, P1077, DOI 10.2337/diacare.13.10.1077; Trautner C, 1996, DIABETES CARE, V19, P1006, DOI 10.2337/diacare.19.9.1006; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Tyrrell W, 1999, J Wound Care, V8, P530; UCCIOLI L, 1995, DIABETES CARE, V18, P1376, DOI 10.2337/diacare.18.10.1376; *US VET HLTH ADM, 2003, CLIN PRACT GUID DIAB; Valk GD, 2002, ENDOCRIN METAB CLIN, V31, P633, DOI 10.1016/S0889-8529(02)00021-X; VANPUTTEN M, 2003, INT CONS DIAB FOOT M; VEVES A, 1992, DIABETOLOGIA, V35, P660, DOI 10.1007/BF00400259; Vileikyte L, 2001, DIABETES-METAB RES, V17, P246, DOI 10.1002/dmrr.216; Vileikyte L, 2000, WOUNDS SB, V12, p43B; Wagner F W Jr, 1981, Foot Ankle, V2, P64; Wang JC, 2002, J AM PODIAT MED ASSN, V92, P429, DOI 10.7547/87507315-92-8-429; Wheatley C, 2001, J CLIN GOVT, V9, P93; Wieman TJ, 1998, AM J SURG, V176, P436, DOI 10.1016/S0002-9610(98)00235-9; YOUNG MJ, 1994, DIABETES CARE, V17, P557, DOI 10.2337/diacare.17.6.557; YOUNG MJ, 1992, DIABETIC MED, V9, P55, DOI 10.1111/j.1464-5491.1992.tb01714.x; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697; Zimny S, 2004, DIABETES CARE, V27, P942, DOI 10.2337/diacare.27.4.942	128	1694	1819	15	265	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2005	293	2					217	228		10.1001/jama.293.2.217	http://dx.doi.org/10.1001/jama.293.2.217			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885QC	15644549				2022-12-28	WOS:000226171000038
J	Wilson, EO				Wilson, EO			Environment - Early ant plagues in the New World	NATURE			English	Editorial Material									Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA	Harvard University	Wilson, EO (corresponding author), Harvard Univ, Museum Comparat Zool, 26 Oxford St, Cambridge, MA 02138 USA.	ewilson@oeb.harvard.edu						CASALES J, 1804, PHIL T R SOC LOND, V16, P688; DELASCAS E, 1975, HIST LOS, V3, P270; HOSSDOBLER B, 1990, ANTS; LOFGREN CS, 1985, FIRE ANTS LEAFCUTTIN; SCHAMBURGK RH, 1843, HIST BECHADES 540; WHEELER WM, 1925, TRANSSTICA HIST FERM, P232; WILSAM EO, 2003, EPHYS NEW WORLD	7	19	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2005	433	7021					32	32		10.1038/433032a	http://dx.doi.org/10.1038/433032a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635401	Bronze			2022-12-28	WOS:000226117100025
J	He, X				He, X			Antagonizing Wnt and FGF receptors: an enemy from within (the ER)	CELL			English	Editorial Material							NEURAL INDUCTION; ENDOPLASMIC-RETICULUM; XENOPUS	In this issue of Cell, Yamamoto et al. (2005) describe a novel molecule, Shisa, which functions in the endoplastic reticulum (ER) to prevent maturation of Frizzled (Fz) serpentine receptors and fibroblast growth factor receptor (FGFR). Shisa thus antagonizes Wnt and FGF signaling cell-autonomously, thereby promoting anterior patterning in Xenopus.	Harvard Univ, Sch Med, Div Neurosci, Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	He, X (corresponding author), Harvard Univ, Sch Med, Div Neurosci, Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.							De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Harland R, 2000, CURR OPIN GENET DEV, V10, P357, DOI 10.1016/S0959-437X(00)00096-4; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kuroda H, 2004, PLOS BIOL, V2, P623, DOI 10.1371/journal.pbio.0020092; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Niehrs C, 2004, NAT REV GENET, V5, P425, DOI 10.1038/nrg1347; Yamamoto A, 2005, CELL, V120, P223, DOI 10.1016/j.cell.2004.11.051	9	4	6	2	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 28	2005	120	2					156	158		10.1016/j.cell.2005.01.006	http://dx.doi.org/10.1016/j.cell.2005.01.006			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680320	Bronze			2022-12-28	WOS:000226740000003
J	Ballen, KK; Hasserjian, RP				Ballen, KK; Hasserjian, RP			A 39-year-old woman with headache, stiff neck, and photophobia - AML, not otherwise categorized, with normal karyotype, mutation of the FLT3 tyrosine kinase domain, and cytoplasmic localization of NPM.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE MYELOID-LEUKEMIA; MENINGITIS; THERAPY; CLASSIFICATION; REARRANGEMENT; CYTOGENETICS; LIGAND; CELLS		Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Ballen, KK (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA.							Abdou SMH, 2002, LEUKEMIA LYMPHOMA, V43, P89, DOI 10.1080/10428190290000437; Arber DA, 2003, AM J CLIN PATHOL, V119, P672, DOI 10.1309/EM7KCOR4GLMHRCX4; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERGER R, 1987, CANCER GENET CYTOGEN, V29, P9, DOI 10.1016/0165-4608(87)90026-4; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; Castagnola C, 1997, HAEMATOLOGICA, V82, P577; Ellerin TB, 2004, LANCET, V363, P1772, DOI 10.1016/S0140-6736(04)16303-4; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Gamerdinger U, 2003, GENE CHROMOSOME CANC, V36, P261, DOI 10.1002/gcc.10168; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; JOFFE AM, 1989, AM J MED, V87, P332, DOI 10.1016/S0002-9343(89)80160-3; Kochar DK, 2000, NEUROL INDIA, V48, P170; Kong XT, 1997, BLOOD, V90, P1192; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MALDONADO JE, 1965, MAYO CLIN PROC, V40, P248; National Comprehensive Cancer Network, 2003, J Natl Compr Canc Netw, V1, P520; Shi GP, 1997, CANCER GENET CYTOGEN, V96, P58, DOI 10.1016/S0165-4608(96)00293-2; Shurin MR, 1998, CYTOKINE GROWTH F R, V9, P37, DOI 10.1016/S1359-6101(97)00035-X; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; SPANOS A, 1989, JAMA-J AM MED ASSOC, V262, P2700, DOI 10.1001/jama.262.19.2700; Tchinda J, 2003, LEUKEMIA LYMPHOMA, V44, P1843, DOI 10.1080/10428190310001603605; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vardiman J., 2001, WHO CLASSIFICATION T, V3; WIERNIK PH, 1992, BLOOD, V79, P313	28	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					274	283		10.1056/NEJMcpc049034	http://dx.doi.org/10.1056/NEJMcpc049034			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659728				2022-12-28	WOS:000226370500009
J	Coleman, P; Schofield, AJ				Coleman, P; Schofield, AJ			Quantum criticality	NATURE			English	Article							FERMI-LIQUID BEHAVIOR; PHASE; ANTIFERROMAGNETISM; DISORDER; ORDER	As we mark the centenary of Albert Einstein's seminal contribution to both quantum mechanics and special relativity, we approach another anniversary-that of Einstein's foundation of the quantum theory of solids. But 100 years on, the same experimental measurement that puzzled Einstein and his contemporaries is forcing us to question our understanding of how quantum matter transforms at ultra-low temperatures.	Rutgers State Univ, Ctr Mat Theory, Piscataway, NJ 08854 USA; Univ Birmingham, Sch Phys & Astron, Birmingham B15 2TT, W Midlands, England	Rutgers State University New Brunswick; University of Birmingham	Coleman, P (corresponding author), Rutgers State Univ, Ctr Mat Theory, Piscataway, NJ 08854 USA.	coleman@physics.rutgers.edu; ajs@bham.ac.uk	Drummond, Peter D/B-4674-2010; Schofield, Andy/AAL-7382-2020; Schofield, Andy J/C-5004-2009; Sachdev, Subir/Y-3037-2019; Sachdev, Subir/A-8781-2013; Chaturvedi, Subhash/F-3260-2011	Drummond, Peter D/0000-0003-4763-8549; Schofield, Andy/0000-0002-1218-8560; Schofield, Andy J/0000-0002-1218-8560; Sachdev, Subir/0000-0002-2432-7070; Sachdev, Subir/0000-0002-2432-7070; 				Amitsuka H, 2002, PHYSICA B, V312, P390, DOI 10.1016/S0921-4526(01)01343-6; Belitz D, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.155701; Chandra P, 2002, NATURE, V417, P831, DOI 10.1038/nature00795; Chapline G., 2002, Artificial black holes, P179, DOI 10.1142/9789812778178_0007; Coleman P, 2001, J PHYS-CONDENS MAT, V13, pR723, DOI 10.1088/0953-8984/13/35/202; Custers J, 2003, NATURE, V424, P524, DOI 10.1038/nature01774; Doiron-Leyraud N, 2003, NATURE, V425, P595, DOI 10.1038/nature01968; Domb C., 1996, CRITICAL POINT HIST; Grigera SA, 2004, SCIENCE, V306, P1154, DOI 10.1126/science.1104306; Grigera SA, 2001, SCIENCE, V294, P329, DOI 10.1126/science.1063539; HERTZ JA, 1976, PHYS REV B, V14, P1165, DOI 10.1103/PhysRevB.14.1165; Julian SR, 1996, J PHYS-CONDENS MAT, V8, P9675, DOI 10.1088/0953-8984/8/48/002; Kim KH, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.256401; Laughlin RB, 2001, ADV PHYS, V50, P361, DOI 10.1080/00018730110098534; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; MILLIS AJ, 1993, PHYS REV B, V48, P7183, DOI 10.1103/PhysRevB.48.7183; PAIS A, 1982, SUBTLE LORD SCI LIFE, P389; Petrovic C, 2001, EUROPHYS LETT, V53, P354, DOI 10.1209/epl/i2001-00161-8; Rosch A, 1999, PHYS REV LETT, V82, P4280, DOI 10.1103/PhysRevLett.82.4280; Sachdev S., 1999, QUANTUM PHASE TRANSI; Schroder A, 2000, NATURE, V407, P351, DOI 10.1038/35030039; Senthil T, 2004, SCIENCE, V303, P1490, DOI 10.1126/science.1091806; Si QM, 2001, NATURE, V413, P804, DOI 10.1038/35101507; VONLOHNEYSEN H, 1994, PHYS REV LETT, V72, P3262, DOI 10.1103/PhysRevLett.72.3262	25	407	411	4	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					226	229		10.1038/nature03279	http://dx.doi.org/10.1038/nature03279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662409	Green Submitted, Green Published			2022-12-28	WOS:000226381300039
J	Nielsen, R; Hubisz, MJ				Nielsen, R; Hubisz, MJ			Evolutionary genomics - Detecting selection needs comparative data	NATURE			English	Editorial Material							ESCHERICHIA-COLI; CODON USAGE; SEQUENCE; GENES		Univ Copenhagen, Ctr Bioinformat, DK-2100 Copenhagen, Denmark; Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA	University of Copenhagen; Cornell University	Nielsen, R (corresponding author), Univ Copenhagen, Ctr Bioinformat, Univ Pk 15, DK-2100 Copenhagen, Denmark.	rasmus@binf.ku.dk	Nielsen, Rasmus/D-4405-2009	Nielsen, Rasmus/0000-0003-0513-6591; Hubisz, Melissa/0000-0002-9561-6830				Akashi H, 2002, P NATL ACAD SCI USA, V99, P3695, DOI 10.1073/pnas.062526999; Grantham R., 1981, NUCLEIC ACIDS RES, V9, P43; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; Lio P, 1998, GENOME RES, V8, P1233, DOI 10.1101/gr.8.12.1233; Plotkin JB, 2004, NATURE, V428, P942, DOI 10.1038/nature02458; SHARP PM, 1991, J MOL EVOL, V33, P23, DOI 10.1007/BF02100192	7	17	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					E6	E6		10.1038/nature03222	http://dx.doi.org/10.1038/nature03222			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662372				2022-12-28	WOS:000226381300031
J	Hankey, GJ; Eikelboom, JW				Hankey, GJ; Eikelboom, JW			Homocysteine and stroke	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; FOLIC-ACID; DISEASE; RISK; THERAPY; FOLATE		Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6001, Australia; Royal Perth Hosp, Sch Med & Pharmacol, Dept Haematol, Perth, WA 6001, Australia	Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6001, Australia.	gjhankey@cyllene.uwa.edu.au	Eikelboom, John/AAG-6117-2019; Hankey, Graeme/H-4968-2014	Eikelboom, John/0000-0003-4126-1285; Hankey, Graeme/0000-0002-6044-7328				Baker RI, 2002, CEREBROVASC DIS, V13, P120; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Faraci FM, 2004, STROKE, V35, P345, DOI 10.1161/01.STR.0000115161.10646.67; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; Hankey GJ, 2004, STROKE, V35, P1995, DOI 10.1161/01.STR.0000135228.20619.ad; He K, 2004, STROKE, V35, P169, DOI 10.1161/01.STR.0000106762.55994.86; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Lange H, 2004, NEW ENGL J MED, V350, P2673, DOI 10.1056/NEJMoa032845; Lawlor DA, 2004, LANCET, V363, P1724, DOI 10.1016/S0140-6736(04)16260-0; Lucock M, 2004, BMJ-BRIT MED J, V328, P211, DOI 10.1136/bmj.328.7433.211; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	16	33	33	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					194	196						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652586				2022-12-28	WOS:000226309600004
J	Mosam, A; Goga, Y; Thejpal, R; Cassol, E; Page, T; Cassol, S; Aboobaker, J; Coovadia, HM				Mosam, A; Goga, Y; Thejpal, R; Cassol, E; Page, T; Cassol, S; Aboobaker, J; Coovadia, HM			Lymphadenopathy, pneumonia, and HIV - a common trio, an uncommon outcome	LANCET			English	Article									Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Dermatol, Durban, South Africa; Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Paediat, Durban, South Africa; Univ Kwazulu Natal, Nelson R Mandela Sch Med, Africa Ctr Hlth & Populat Studies, Mol Virol & Bioinformat Unit, Durban, South Africa; Univ Kwazulu Natal, Nelson R Mandela Sch Med, Victor Daitz Chair HIV AIDS Res, Durban, South Africa	University of Kwazulu Natal; University of Kwazulu Natal; University of Kwazulu Natal; University of Kwazulu Natal	Mosam, A (corresponding author), Sch Med, Dept Dermatol, Room 327,3rd Floor,Private Bag 7, ZA-4013 Congella, Durban, South Africa.	mosama@ukzn.ac.za		Goga, Yasmin/0000-0002-6740-2376; Green, Taryn Natalie/0000-0001-9527-5960				He J, 1998, J INFECT DIS, V178, P1787, DOI 10.1086/314512; McCarthy GA, 1996, ARCH DIS CHILD, V74, P455, DOI 10.1136/adc.74.5.455; McCarty K. A., 1995, Central African Journal of Medicine, V41, P330	3	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					266	266						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652610				2022-12-28	WOS:000226309600033
J	Buttner, T; Geier, J; Frison, G; Harmer, J; Calle, C; Schweiger, A; Schonberg, H; Grutzmacher, H				Buttner, T; Geier, J; Frison, G; Harmer, J; Calle, C; Schweiger, A; Schonberg, H; Grutzmacher, H			A stable aminyl radical metal complex	SCIENCE			English	Article							LIGANDS; CATALYSIS; ANILINO	Metal-stabilized phenoxyl radicals appear to be important intermediates in a variety of enzymatic oxidations. We report that transition metal coordination also supports an aminyl radical, resulting in a stable crystalline complex: [Rh(I)(trop(2)N(.))(bipy)]+OTf (-) (where trop is 5-H-dibenzo[a,d]cycloheptene-5-yl, bipy is 2,2'-bipyridyl, OTf- is trifluorosulfonate). It is accessible under mild conditions by one-electron oxidation of the amide complex [Rh(I)(trop(2)N)(bipy)], at a potential of -0.55 volt versus ferrocene/ferrocenium. Both electron paramagnetic resonance spectroscopy and density functional theory support 57% localization of the unpaired spin at N. In reactions with H-atom donors, the Rh-coordinated aminyl behaves as a nucleophilic radical.	ETH Honggerberg, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Grutzmacher, H (corresponding author), ETH Honggerberg, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland.	gruetzmacher@inorg.chem.ethz.ch	Harmer, Jeffrey/AAR-1851-2021; Frison, Gilles/B-7458-2011; Harmer, Jeffrey R/B-7417-2011	Harmer, Jeffrey/0000-0003-4583-2401; Frison, Gilles/0000-0002-5677-3569; Harmer, Jeffrey R/0000-0003-4583-2401				Adamo C, 1998, J CHEM PHYS, V109, P10244, DOI 10.1063/1.477720; BORDWELL FG, 1988, ACCOUNTS CHEM RES, V21, P456, DOI 10.1021/ar00156a004; Buttner T, 2004, CHEM COMMUN, P2820, DOI 10.1039/b409981h; Chaudhuri P, 2001, PROG INORG CHEM, V50, P151; DANEN WC, 1970, J AM CHEM SOC, V92, P5235, DOI 10.1021/ja00720a049; ESKER JL, 1993, ADV HETEROCYCL CHEM, V58, P1, DOI 10.1016/S0065-2725(08)60283-4; Frantz S, 2003, DALTON T, P3370, DOI 10.1039/b305311c; Gerisch M, 2001, J AM CHEM SOC, V123, P5818, DOI 10.1021/ja005857a; GROSS R, 1985, ANGEW CHEM INT EDIT, V24, P856, DOI 10.1002/anie.198508561; Ha C, 1997, J ORG CHEM, V62, P2704, DOI 10.1021/jo962396w; Kaim W, 2003, DALTON T, P761, DOI 10.1039/b210193a; Kaim W, 2002, INORG CHIM ACTA, V337, P163, DOI 10.1016/S0020-1693(02)01081-2; LAND EJ, 1961, J CHEM SOC, P3540; Maxwell BJ, 1998, CHEM FREE RADICALS, P663; MCMILLEN DF, 1982, ANNU REV PHYS CHEM, V33, P493, DOI 10.1146/annurev.pc.33.100182.002425; Merenyi G, 1998, CHEM FREE RADICALS, P599; Miura Y, 2000, J ORG CHEM, V65, P7889, DOI 10.1021/jo000901q; Miura Y, 2001, CHEM COMMUN, P627, DOI 10.1039/b100698n; Penkert FN, 2000, J AM CHEM SOC, V122, P9663, DOI 10.1021/ja001637l; Roberts BP, 1999, CHEM SOC REV, V28, P25, DOI 10.1039/a804291h; Schweiger A., 2001, PRINCIPLES PULSE ELE; SELLMANN D, 1982, ANGEW CHEM INT EDIT, V21, P691, DOI 10.1002/anie.198206911; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; TEDDER JM, 1982, ANGEW CHEM INT EDIT, V21, P401, DOI 10.1002/anie.198204011; WILLIAMS DE, 1966, J AM CHEM SOC, V88, P5665, DOI 10.1021/ja00975a064	26	169	169	2	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					235	238		10.1126/science.1106070	http://dx.doi.org/10.1126/science.1106070			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653498				2022-12-28	WOS:000226361900036
J	Petkova, AT; Leapman, RD; Guo, ZH; Yau, WM; Mattson, MP; Tycko, R				Petkova, AT; Leapman, RD; Guo, ZH; Yau, WM; Mattson, MP; Tycko, R			Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; STRUCTURAL MODEL; COMMON MECHANISM; PRION PROTEIN; PEPTIDE; STATE; PROTOFIBRILS; CONSTRAINTS; MICROSCOPY; NANOWIRES	Amyloid fibrils commonly exhibit multiple distinct morphologies in electron microscope and atomic force microscope images, often within a single image field. By using electron microscopy and solid-state nuclear magnetic resonance measurements on fibrils formed by the 40-residue beta-amyloid peptide of Alzheimer's disease (Abeta(1-40)), we show that different fibril morphologies have different underlying molecular structures, that the predominant structure can be controlled by subtle variations in fibril growth conditions, and that both morphology and molecular structure are self-propagating when fibrils grow from preformed seeds. Different Abeta(1-40) fibril morphologies also have significantly different toxicities in neuronal cell cultures. These results have implications for the mechanism of amyloid formation, the phenomenon of strains in prion diseases, the role of amyloid fibrils in amyloid diseases, and the development of amyloid-based nanomaterials.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA; NIA, Neurosci Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Tycko, R (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.	rt46d@nih.gov	Mattson, Mark P/F-6038-2012	Leapman, Richard/0000-0002-8575-4084	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029029, ZIADK029029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000312, ZIAAG000312] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD011017] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; Balbach JJ, 2002, BIOPHYS J, V83, P1205, DOI 10.1016/S0006-3495(02)75244-2; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Burkoth TS, 2000, J AM CHEM SOC, V122, P7883, DOI 10.1021/ja000645z; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Goldsbury CS, 2000, J STRUCT BIOL, V130, P217, DOI 10.1006/jsbi.2000.4259; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Jaroniec CP, 2001, J AM CHEM SOC, V123, P3507, DOI 10.1021/ja003266e; Jaroniec CP, 2004, P NATL ACAD SCI USA, V101, P711, DOI 10.1073/pnas.0304849101; Jimenez JL, 2002, P NATL ACAD SCI USA, V99, P9196, DOI 10.1073/pnas.142459399; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Scheibel T, 2003, P NATL ACAD SCI USA, V100, P4527, DOI 10.1073/pnas.0431081100; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; Wishart DS, 2001, METHOD ENZYMOL, V338, P3	30	1357	1379	6	354	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					262	265		10.1126/science.1105850	http://dx.doi.org/10.1126/science.1105850			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653506				2022-12-28	WOS:000226361900045
J	Kirch, PV; Sharp, WD				Kirch, PV; Sharp, WD			Coral Th-230 dating of the imposition of a ritual control hierarchy in precontact Hawaii	SCIENCE			English	Article								In proto-historic Hawaii (1500-1795 A.D.), as in many other evolving polities, temples functioned as centers for control over production and the extraction of surplus food and goods. Thorium-230 dates (uncertainty +/- similar to10 years) on branch coral dedicatory offerings from temples in the Kahikinui district (Maui) indicate that its temple system was constructed within 60 years, far more rapidly than indicated by radiocarbon dating. Introduction of the temple system in 1580-1640 A.D. coincided with predatory expansion and,consolidation of the Maui polity to form an incipient archaic state.	Univ Calif Berkeley, Dept Anthropol, Berkeley, CA 94720 USA; Berkeley Geochronol Ctr, Berkeley, CA 94709 USA	University of California System; University of California Berkeley; Berkeley Geochronolgy Center	Kirch, PV (corresponding author), Univ Calif Berkeley, Dept Anthropol, 232 Kroeber Hall, Berkeley, CA 94720 USA.	kirch@sscl.berkeley.edu						ABAD CKC, 2000, THESIS U HAWAII HONO; Allen J., 1992, NZ J ARCHAEOLOGY, V14, P45; [Anonymous], 1985, KINGSHIP SACRIFICE R; Cheng H, 2000, CHEM GEOL, V169, P17, DOI 10.1016/S0009-2541(99)00157-6; Cobb KM, 2003, EARTH PLANET SC LETT, V210, P91, DOI 10.1016/S0012-821X(03)00138-9; Cordy R., 2000, EXALTED SITS CHIEF A; Dean J.S., 1978, ADV ARCHAEOLOGICAL M, V1, P223; Dye T., 1992, NZ J ARCHAEOL, V14, P113; EDWARDS RL, 1988, EARTH PLANET SC LETT, V90, P371, DOI 10.1016/0012-821X(88)90136-7; Edwards RL, 2003, REV MINERAL GEOCHEM, V52, P363, DOI 10.2113/0520363; Flannery KV, 1972, ANNU REV ECOL SYST, V3, P399, DOI DOI 10.1146/ANNUREV.ES.03.110172.002151; Flannery KV., 1998, ARCHAIC STATES, P15; Gulko D., 1998, HAWAIIAN CORAL REEF; HUH CA, 1989, GEOCHIM COSMOCHIM AC, V53, P1357, DOI 10.1016/0016-7037(89)90068-9; Kirch P.V., 1984, EVOLUTION POLYNESIAN; Kirch P.V., 1985, FEATHERED GODS FISHH; KIRCH PV, 1990, J WORLD PREHIST, V4, P311, DOI 10.1007/BF00974883; Kirch PV, 2004, P NATL ACAD SCI USA, V101, P9936, DOI 10.1073/pnas.0403470101; Kirch PV, 2004, ANTIQUITY, V78, P102, DOI 10.1017/S0003598X00092966; Kolb M.J., 1992, ASIAN PERSPECT, V31, P9; KOLB MJ, 1994, CURR ANTHROPOL, V35, P521, DOI 10.1086/204315; RoyBarman M, 1996, EARTH PLANET SC LETT, V139, P351, DOI 10.1016/0012-821X(96)00017-9; Sahlins MarshallD., 1972, STONE AGE EC; Spencer C.S., 1998, CULT DYN, V10, P5, DOI [DOI 10.1177/092137409801000101, 10.1177/092137409801000101]; Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172; Taylor RE, 1987, RADIOCARBON DATING A; Weisler M., 1985, N Z J ARCHAEOL, V7, P129; Wright HenryT., 1986, AM ARCHAEOLOGY FUTUR, P323	28	56	56	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					102	104		10.1126/science.1105432	http://dx.doi.org/10.1126/science.1105432			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637276				2022-12-28	WOS:000226214300046
J	Coxall, HK; Wilson, PA; Palike, H; Lear, CH; Backman, J				Coxall, HK; Wilson, PA; Palike, H; Lear, CH; Backman, J			Rapid stepwise onset of Antarctic glaciation and deeper calcite compensation in the Pacific Ocean	NATURE			English	Article							CENOZOIC GLACIATION; CHAOTIC DIFFUSION; OLIGOCENE; EVOLUTION; RECORDS; MODEL; MG/CA	The ocean depth at which the rate of calcium carbonate input from surface waters equals the rate of dissolution is termed the calcite compensation depth. At present, this depth is,4,500 m, with some variation between and within ocean basins. The calcite compensation depth is linked to ocean acidity, which is in turn linked to atmospheric carbon dioxide concentrations and hence global climate(1). Geological records of changes in the calcite compensation depth show a prominent deepening of more than 1 km near the Eocene/Oligocene boundary (similar to34 million years ago)(2) when significant permanent ice sheets first appeared on Antarctica(3-6), but the relationship between these two events is poorly understood. Here we present ocean sediment records of calcium carbonate content as well as carbon and oxygen isotopic compositions from the tropical Pacific Ocean that cover the Eocene/Oligocene boundary. We find that the deepening of the calcite compensation depth was more rapid than previously documented and occurred in two jumps of about 40,000 years each, synchronous with the stepwise onset of Antarctic ice-sheet growth. The glaciation was initiated, after climatic preconditioning(7), by an interval when the Earth's orbit of the Sun favoured cool summers. The changes in oxygen-isotope composition across the Eocene/Oligocene boundary are too large to be explained by Antarctic ice-sheet growth alone and must therefore also indicate contemporaneous global cooling and/or Northern Hemisphere glaciation.	Southampton Oceanog Ctr, Sch Ocean & Earth Sci, Southampton SO14 3ZH, Hants, England; Univ Stockholm, S-10691 Stockholm, Sweden; Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA	NERC National Oceanography Centre; University of Southampton; Stockholm University; Rutgers State University New Brunswick	Wilson, PA (corresponding author), Southampton Oceanog Ctr, Sch Ocean & Earth Sci, European Way, Southampton SO14 3ZH, Hants, England.	paw1@soc.soton.ac.uk	Palike, Heiko/A-6560-2008; Lear, Caroline/D-2582-2009	Palike, Heiko/0000-0003-3386-0923; Coxall, Helen/0000-0002-2843-2898; Wilson, Paul/0000-0001-6425-8906; Lear, Caroline/0000-0002-7533-4430				ARCHER D, 1994, NATURE, V367, P260, DOI 10.1038/367260a0; Billups K, 2003, EARTH PLANET SC LETT, V209, P181, DOI 10.1016/S0012-821X(03)00067-0; Broecker WS, 1987, GLOBAL BIOGEOCHEM CY, V1, P15, DOI 10.1029/GB001i001p00015; Davies R, 2001, NATURE, V410, P917, DOI 10.1038/35073551; DeConto RM, 2003, NATURE, V421, P245, DOI 10.1038/nature01290; EHRMANN WU, 1992, PALAEOGEOGR PALAEOCL, V93, P85, DOI 10.1016/0031-0182(92)90185-8; Harrison KG, 2000, PALEOCEANOGRAPHY, V15, P292, DOI 10.1029/1999PA000427; HINDMARSH RCA, 1990, T ROY SOC EDIN-EARTH, V81, P371, DOI 10.1017/S0263593300020861; Huybrechts P, 2002, QUATERNARY SCI REV, V21, P203, DOI 10.1016/S0277-3791(01)00082-8; Ivany LC, 2000, NATURE, V407, P887, DOI 10.1038/35038044; KENNETT JP, 1976, NATURE, V260, P513, DOI 10.1038/260513a0; Kump L. R., 1997, TECTONIC UPLIFT CLIM, P399, DOI [DOI 10.1007/978-1-4615-5935-1, DOI 10.1007/978-1-4615-5935-1_18]; Laskar J, 2004, ICARUS, V170, P343, DOI 10.1016/j.icarus.2004.04.005; Lear CH, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2004PA001039; Lear CH, 2000, SCIENCE, V287, P269, DOI 10.1126/science.287.5451.269; LYLE M, 2002, P OCEAN DRILLING PRO, V199, P1, DOI DOI 10.2973/ODP.PROC.IR.199.104.2002; Lythe MB, 2001, J GEOPHYS RES-SOL EA, V106, P11335, DOI 10.1029/2000JB900449; MILLER KG, 1991, J GEOPHYS RES-SOLID, V96, P6829, DOI 10.1029/90JB02015; Opdyke BN, 1988, PALEOCEANOGRAPHY, V3, P685, DOI 10.1029/PA003i006p00685; Palike H, 2004, GEOLOGY, V32, P929, DOI 10.1130/G20750.1; Pekar SF, 2002, GEOLOGY, V30, P903, DOI 10.1130/0091-7613(2002)030<0903:CBEEFB>2.0.CO;2; PETERSON LS, 1990, P OCEAN DRILLING PRO, V0115; Ravizza G, 2003, EARTH PLANET SC LETT, V210, P151, DOI 10.1016/S0012-821X(03)00137-7; Salamy KA, 1999, PALAEOGEOGR PALAEOCL, V145, P61, DOI 10.1016/S0031-0182(98)00093-5; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; VANANDEL TH, 1975, EARTH PLANET SC LETT, V26, P187, DOI 10.1016/0012-821X(75)90086-2; Winterer E.L., 1974, INT ASS SEDIMENTOLOG, P11, DOI [10.1002/9781444304855.ch2, DOI 10.1002/9781444304855.CH2]; Zachos JC, 1996, PALEOCEANOGRAPHY, V11, P251, DOI 10.1029/96PA00571; Zachos JC, 1999, CHEM GEOL, V161, P165, DOI 10.1016/S0009-2541(99)00085-6; Zeebe RE, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2003GC000538	30	486	509	5	163	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					53	57		10.1038/nature03135	http://dx.doi.org/10.1038/nature03135			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635407				2022-12-28	WOS:000226117100033
J	Fang, CM; Smith, P; Moncrieff, JB; Smith, JU				Fang, CM; Smith, P; Moncrieff, JB; Smith, JU			Similar response of labile and resistant soil organic matter pools to changes in temperature	NATURE			English	Article							TRACE GAS FLUXES; MICROBIAL RESPIRATION; CARBON STORAGE; N AVAILABILITY; NET NITROGEN; MINERALIZATION; DECOMPOSITION; DEPENDENCE; BIOMASS	Our understanding of the relationship between the decomposition of soil organic matter (SOM) and soil temperature affects our predictions of the impact of climate change on soil-stored carbon(1). One current opinion is that the decomposition of soil labile carbon is sensitive to temperature variation whereas resistant components are insensitive(2-4). The resistant carbon or organic matter in mineral soil is then assumed to be unresponsive to global warming(2,4). But the global pattern and magnitude of the predicted future soil carbon stock will mainly rely on the temperature sensitivity of these resistant carbon pools. To investigate this sensitivity, we have incubated soils under changing temperature. Here we report that SOM decomposition or soil basal respiration rate was significantly affected by changes in SOM components associated with soil depth, sampling method and incubation time. We find, however, that the temperature sensitivity for SOM decomposition was not affected, suggesting that the temperature sensitivity for resistant organic matter pools does not differ significantly from that of labile pools, and that both types of SOM will therefore respond similarly to global warming.	Univ Aberdeen, Sch Biol Sci, Aberdeen AB24 3UU, Scotland; Univ Edinburgh, Sch Geosci, Edinburgh EH9 3JU, Midlothian, Scotland	University of Aberdeen; University of Edinburgh	Fang, CM (corresponding author), Univ Aberdeen, Sch Biol Sci, Aberdeen AB24 3UU, Scotland.	c.fang@abdn.ac.uk	Smith, Pete/G-1041-2010; Smith, Jo U/F-7763-2012	Smith, Pete/0000-0002-3784-1124; Smith, Jo U/0000-0001-6984-6766				ALLEN SE, 1974, CHEM ANAL ECOLOGICAL, P137; Coleman K, 1996, NATO ASI SERIES 1, V38, P237; Dalias P, 2001, GLOBAL CHANGE BIOL, V7, P181, DOI 10.1046/j.1365-2486.2001.00386.x; Fang C, 2001, SOIL BIOL BIOCHEM, V33, P155, DOI 10.1016/S0038-0717(00)00125-5; Fierer N, 2003, GLOBAL CHANGE BIOL, V9, P1322, DOI 10.1046/j.1365-2486.2003.00663.x; Giardina CP, 2000, NATURE, V404, P858, DOI 10.1038/35009076; Grisi B, 1998, SOIL BIOL BIOCHEM, V30, P1309, DOI 10.1016/S0038-0717(98)00016-9; IPCC, 2000, SPEC REP EM SCEN; Jobbagy EG, 2000, ECOL APPL, V10, P423, DOI 10.1890/1051-0761(2000)010[0423:TVDOSO]2.0.CO;2; Lenton TM, 2003, GLOBAL CHANGE BIOL, V9, P1333, DOI 10.1046/j.1365-2486.2003.00674.x; Liski J, 1999, AMBIO, V28, P171; Lomander A, 1998, SOIL BIOL BIOCHEM, V30, P2017, DOI 10.1016/S0038-0717(98)00076-5; Lovell RD, 1998, SOIL BIOL BIOCHEM, V30, P2077, DOI 10.1016/S0038-0717(98)00084-4; MACDONALD NW, 1995, SOIL SCI SOC AM J, V59, P233, DOI 10.2136/sssaj1995.03615995005900010036x; Martin-Olmedo P, 1999, BIOL FERT SOILS, V29, P386, DOI 10.1007/s003740050569; OHLINGER R, 1995, METHODS SOIL BIOL, P56; PETERJOHN WT, 1994, ECOL APPL, V4, P617, DOI 10.2307/1941962; PETERJOHN WT, 1993, OECOLOGIA, V93, P18, DOI 10.1007/BF00321185; Reichstein M, 2000, SOIL BIOL BIOCHEM, V32, P947, DOI 10.1016/S0038-0717(00)00002-X; ROSS DJ, 1993, SOIL BIOL BIOCHEM, V25, P477, DOI 10.1016/0038-0717(93)90073-K; Rustad LE, 2001, OECOLOGIA, V126, P543, DOI 10.1007/s004420000544; Sanderman J, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2001GB001833; Schlesinger WH, 2000, BIOGEOCHEMISTRY, V48, P7, DOI 10.1023/A:1006247623877; Thornley JHM, 2001, ANN BOT-LONDON, V87, P591, DOI 10.1006/anbo.2001.1372; Trumbore SE, 1996, SCIENCE, V272, P393, DOI 10.1126/science.272.5260.393; Winkler JP, 1996, SOIL BIOL BIOCHEM, V28, P1067, DOI 10.1016/0038-0717(96)00076-4	26	526	628	24	543	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					57	59		10.1038/nature03138	http://dx.doi.org/10.1038/nature03138			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635408				2022-12-28	WOS:000226117100034
J	Loftus, BJ; Fung, E; Roncaglia, P; Rowley, D; Amedeo, P; Bruno, D; Vamathevan, J; Miranda, M; Anderson, IJ; Fraser, JA; Allen, JE; Bosdet, IE; Brent, MR; Chiu, R; Doering, TL; Dontin, MJ; D'Souza, CA; Fox, DS; Grinberg, V; Fu, JM; Fukushima, M; Haas, BJ; Huang, JC; Janbon, G; Jones, SJM; Koo, HL; Krzywinski, MI; Kwon-Chung, JK; Lengeler, KB; Maiti, R; Marra, MA; Marra, RE; Mathewson, CA; Mitchell, TG; Pertea, M; Riggs, FR; Salzberg, SL; Schein, JE; Shvartsbeyn, A; Shin, H; Shumway, M; Specht, CA; Suh, BB; Tenney, A; Utterback, TR; Wickes, BL; Wortman, JR; Wye, NH; Kronstad, JW; Lodge, JK; Heitman, J; Davis, RW; Fraser, CM; Hyman, RW				Loftus, BJ; Fung, E; Roncaglia, P; Rowley, D; Amedeo, P; Bruno, D; Vamathevan, J; Miranda, M; Anderson, IJ; Fraser, JA; Allen, JE; Bosdet, IE; Brent, MR; Chiu, R; Doering, TL; Dontin, MJ; D'Souza, CA; Fox, DS; Grinberg, V; Fu, JM; Fukushima, M; Haas, BJ; Huang, JC; Janbon, G; Jones, SJM; Koo, HL; Krzywinski, MI; Kwon-Chung, JK; Lengeler, KB; Maiti, R; Marra, MA; Marra, RE; Mathewson, CA; Mitchell, TG; Pertea, M; Riggs, FR; Salzberg, SL; Schein, JE; Shvartsbeyn, A; Shin, H; Shumway, M; Specht, CA; Suh, BB; Tenney, A; Utterback, TR; Wickes, BL; Wortman, JR; Wye, NH; Kronstad, JW; Lodge, JK; Heitman, J; Davis, RW; Fraser, CM; Hyman, RW			The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; EVOLUTION; SEQUENCE	Cryptococcus neoformans is a basidionnycetous yeast ubiquitous in the environment, a model for fungal pathogenesis, and an opportunistic human pathogen of global importance. We have sequenced its similar to20-megabase genome, which contains similar to6500 intron-rich gene structures and encodes a transcriptome abundant in alternatively spliced and antisense messages. The genome is rich in transposons, many of which cluster at candidate centromeric regions. The presence of these transposons may drive karyotype instability and phenotypic variation. C. neoformans encodes unique genes that may contribute to its unusual virulence properties, and comparison of two phenotypically distinct strains reveals variation in gene content in addition to sequence polymorphisms between the genomes.	Inst Genom Res, Rockville, MD 20850 USA; Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; Scuola Int Super Studi Avanzati, SISSA, I-34014 Trieste, Italy; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Genome Sci Ctr, Vancouver, BC V5Z 4S6, Canada; Washington Univ, Lab Computat Genom, St Louis, MO 63130 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Childrens Hosp, Louisiana State Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70118 USA; Childrens Hosp, Louisiana State Hlth Sci Ctr, Res Inst Children, New Orleans, LA 70118 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA; Inst Pasteur, Unite Mycol Mol, Paris 15, France; NIAID, Mol Microbiol Sect, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; Univ Dusseldorf, Inst Mikrobiol, D-4000 Dusseldorf, Germany; Connecticut Agr Expt Stn, New Haven, CT 06511 USA; Boston Univ, Dept Med, Boston, MA 02118 USA; Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA; J Craig Venter Fdn, Joint Technol Ctr, Rockville, MD 20850 USA	J. Craig Venter Institute; Stanford University; International School for Advanced Studies (SISSA); Duke University; Washington University (WUSTL); Washington University (WUSTL); Saint Louis University; University of British Columbia; Children's Hospital of New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Children's Hospital of New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Texas System; University of Texas Health San Antonio; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Heinrich Heine University Dusseldorf; Connecticut Agricultural Experiment Station; Boston University; University of California System; University of California Santa Cruz; J. Craig Venter Institute	Loftus, BJ (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	bjloftus@tigr.org	Jones, Steven J/C-3621-2009; Janbon, Guilhem/AAW-7398-2021; Salzberg, Steven/Q-6514-2019; Fraser, James A/B-4918-2012; Brent, Michael/AAK-3702-2020; Salzberg, Steven L/F-6162-2011; Mitchell, Thomas G./A-2356-2008; Heitman, Joseph/ABC-6006-2021; Marra, Marco A/B-5987-2008; Marra, Robert E/G-4220-2011; Schein, Jacquie E/G-3674-2015; Pertea, Mihaela/AAT-2705-2021; Janbon, Guilhem/AAL-6607-2021	Jones, Steven J/0000-0003-3394-2208; Janbon, Guilhem/0000-0002-4788-1154; Salzberg, Steven/0000-0002-8859-7432; Fraser, James A/0000-0001-5724-5285; Brent, Michael/0000-0002-8689-0299; Salzberg, Steven L/0000-0002-8859-7432; Marra, Marco A/0000-0001-7146-7175; Pertea, Mihaela/0000-0003-0762-8637; loftus, brendan/0000-0001-8871-8356; Donlin, Maureen/0000-0001-7312-079X; Wickes, Brian/0000-0001-5909-5815; Vamathevan, Jessica/0000-0003-2016-9754; Lodge, Jennifer/0000-0002-2526-1210; Roncaglia, Paola/0000-0002-2825-0621; Allen, Jonathan/0000-0002-4359-8263; Fraser, Claire/0000-0003-1462-2428; Wortman, Jennifer/0000-0002-8713-1227	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000057, R01AI050184, U01AI047087, U01AI048594] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL088905, R01 HL088905-04A2] Funding Source: Medline; NIAID NIH HHS [R01 AI050184-05, AI48594, R01 AI050184, AI47087] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bose I, 2003, EUKARYOT CELL, V2, P655, DOI 10.1128/EC.2.4.655-663.2003; Cambareri EB, 1998, MOL CELL BIOL, V18, P5465, DOI 10.1128/MCB.18.9.5465; Casadevall A, 2000, CURR OPIN MICROBIOL, V3, P354, DOI 10.1016/S1369-5274(00)00103-X; Casadevall A, 1998, CRYPTOCOCCUS NEOFORM; FRASER JD, UNPUB; Gorlach JM, 2002, MICROBIOL-SGM, V148, P213, DOI 10.1099/00221287-148-1-213; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; Jones T, 2004, P NATL ACAD SCI USA, V101, P7329, DOI 10.1073/pnas.0401648101; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; KWONCHUNG KJ, 1978, AM J EPIDEMIOL, V108, P337, DOI 10.1093/oxfordjournals.aje.a112628; Lengeler KB, 2002, EUKARYOT CELL, V1, P704, DOI 10.1128/EC.1.5.704-718.2002; Martinez D, 2004, NAT BIOTECHNOL, V22, P695, DOI 10.1038/nbt967; Shahinian S, 2000, MOL MICROBIOL, V35, P477, DOI 10.1046/j.1365-2958.2000.01713.x	13	542	1296	2	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2005	307	5713					1321	1324		10.1126/science.1103773	http://dx.doi.org/10.1126/science.1103773			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	901WP	15653466	Green Accepted, Green Submitted			2022-12-28	WOS:000227313200062
J	Sage, C; Huang, MQ; Karimi, K; Gutierrez, G; Vollrath, MA; Zhang, DS; Garcia-Anoveros, J; Hinds, PW; Corwin, JT; Corey, DP; Chen, ZY				Sage, C; Huang, MQ; Karimi, K; Gutierrez, G; Vollrath, MA; Zhang, DS; Garcia-Anoveros, J; Hinds, PW; Corwin, JT; Corey, DP; Chen, ZY			Proliferation of functional hair cells in vivo in the absence of the retinoblastoma protein	SCIENCE			English	Article							INNER-EAR; FATE DETERMINATION; ACOUSTIC TRAUMA; RB; MOUSE; GENE; MUTATION; REGENERATION; SURVIVAL; NEUROGENESIS	In mammals, hair cell loss causes irreversible hearing and balance impairment because hair cells are terminally differentiated and do not regenerate spontaneously. By profiling gene expression in developing mouse vestibular organs, we identified the retinoblastorna protein (pRb) as a candidate regulator of cell cycle exit in hair cells. Differentiated and functional mouse hair cells with a targeted deletion of Rb1 undergo mitosis, divide, and cycle, yet continue to become highly differentiated and functional. Moreover, acute loss of Rb1 in postnatal hair cells caused cell cycle reentry. Manipulation of the pRb pathway may ultimately lead to mammalian hair cell regeneration.	Massachusetts Gen Hosp, MGH HMS Ctr Nervous Syst Repair, Neurol Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA; Tufts New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northwestern Univ, Inst Neurosci, Dept Anesthesiol, Chicago, IL 60611 USA; Northwestern Univ, Inst Neurosci, Dept Physiol, Chicago, IL 60611 USA; Northwestern Univ, Inst Neurosci, Dept Neurol, Chicago, IL 60611 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Virginia; Tufts Medical Center; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Northwestern University; Northwestern University; Northwestern University	Chen, ZY (corresponding author), Massachusetts Gen Hosp, MGH HMS Ctr Nervous Syst Repair, Neurol Serv, Boston, MA 02114 USA.	zhengyi@helix.mgh.harvard.edu		Garcia-Anoveros, Jaime/0000-0001-6561-9048; Corey, David/0000-0003-4497-6016; Gutierrez, Gabriel/0000-0001-8487-0414	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004546] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC-04546, DC-00200, DC-AG20208] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Chen P, 2003, NAT CELL BIOL, V5, P422, DOI 10.1038/ncb976; Chen P, 2002, DEVELOPMENT, V129, P2495; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; Gale JE, 2001, J NEUROSCI, V21, P7013, DOI 10.1523/JNEUROSCI.21-18-07013.2001; Geleoc GSG, 2003, NAT NEUROSCI, V6, P1019, DOI 10.1038/nn1120; Goodyear RJ, 2003, J NEUROSCI, V23, P9208; Holt JR, 1999, J NEUROPHYSIOL, V81, P1881, DOI 10.1152/jn.1999.81.4.1881; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Marino S, 2003, DEVELOPMENT, V130, P3359, DOI 10.1242/dev.00553; Meyers JR, 2003, J NEUROSCI, V23, P4054; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Vollrath MA, 2003, J NEUROPHYSIOL, V90, P2676, DOI 10.1152/jn.00893.2002; Vooijs M, 2002, ONCOGENE, V21, P4635, DOI 10.1038/sj.onc.1205575; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285; WOODS AL, 1991, HISTOPATHOLOGY, V19, P21, DOI 10.1111/j.1365-2559.1991.tb00890.x; Xiang MQ, 1998, DEVELOPMENT, V125, P3935; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318; Zheng LL, 2000, CELL, V102, P377, DOI 10.1016/S0092-8674(00)00042-8	30	193	230	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1114	1118		10.1126/science.1106642	http://dx.doi.org/10.1126/science.1106642			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15653467				2022-12-28	WOS:000227197300050
J	Olsen, AH; Njor, SH; Vejborg, I; Schwartz, W; Dalgaard, P; Jensen, MB; Tange, UB; Blichert-Toft, M; Rank, F; Mouridsen, H; Lynge, E				Olsen, AH; Njor, SH; Vejborg, I; Schwartz, W; Dalgaard, P; Jensen, MB; Tange, UB; Blichert-Toft, M; Rank, F; Mouridsen, H; Lynge, E			Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SWEDISH RANDOMIZED TRIALS; DENMARK	Objectives To evaluate the effect on breast cancer mortality during the first 10 years of the mammography service screening programme that was introduced in Copenhagen in 1991. Design Cohort study. Setting The mammography service screening programme in Copenhagen, Denmark. Participants All women ever invited to mammography screening in the first 10 years of the programme. Historical, national, and historical national control groups were used. Main outcome measures The main outcome measure was breast cancer mortality. We compared breast cancer mortality in the study group with rates in the control groups, adjusting for age, time period, and region. Results Breast cancer mortality in the screening period was reduced by 25% (relative risk 0.75,95% confidence interval 0.63 to 0.89) compared with what we would expect in the absence of screening. For women actually participating in screening, breast cancer mortality was reduced by 37%. Conclusions In the Copenhagen programme, breast cancer mortality was reduced without severe negative side effects for the participants.	Univ Copenhagen, Inst Publ Hlth, DK-2200 Copenhagen N, Denmark; Copenhagen Univ Hosp, Ctr Diagnost Imaging, DK-2100 Copenhagen O, Denmark; Copenhagen Univ Hosp, Dept Oncol, DK-2100 Copenhagen O, Denmark; Copenhagen Univ Hosp, Dept Pathol, DK-2100 Copenhagen O, Denmark; Copenhagen Univ Hosp, Danish Breast Canc Cooperat Grp, DK-2100 Copenhagen O, Denmark; Odense Univ Hosp, Mammog Screening Clin, DK-5000 Odense, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; Danish Breast Cancer Cooperative Group (DBCG); University of Copenhagen; University of Southern Denmark; Odense University Hospital	Olsen, AH (corresponding author), Univ Copenhagen, Inst Publ Hlth, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	a.h.olsen@pubhealth.ku.dk	Njor, Sisse Helle/S-4486-2017	Njor, Sisse Helle/0000-0003-0429-4176; Lynge, Elsebeth/0000-0003-4785-5236				Alexander FE, 1999, LANCET, V353, P1903, DOI 10.1016/S0140-6736(98)07413-3; Andreasen A H, 1994, Ugeskr Laeger, V156, P6512; ANDREASEN AH, 1994, BRIT J CANCER, V70, P133, DOI 10.1038/bjc.1994.262; Blanks RG, 2000, BRIT MED J, V321, P665, DOI 10.1136/bmj.321.7262.665; *COP HOSP CORP MAM, 1998, APMIS S83, V106, P1; Duffy SW, 2002, CANCER-AM CANCER SOC, V95, P458, DOI 10.1002/cncr.10765; FISCHERMAN K, 1988, ACTA ONCOL, V27, P593, DOI 10.3109/02841868809091756; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; Jonsson H, 2001, J MED SCREEN, V8, P152, DOI 10.1136/jms.8.3.152; Njor Sisse Helle, 2003, APMIS Suppl, P1; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Olsen AH, 2003, BRIT J CANCER, V88, P362, DOI 10.1038/sj.bjc.6600712; OLSEN AH, 2005, IN PRESS ACTA ONCOLO; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Otto SJ, 2003, LANCET, V361, P1411, DOI 10.1016/S0140-6736(03)13132-7; Vejborg I, 2002, J MED SCREEN, V9, P115, DOI 10.1136/jms.9.3.115	17	137	147	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2005	330	7485					220	222A		10.1136/bmj.38313.639236.82	http://dx.doi.org/10.1136/bmj.38313.639236.82			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15649904	Bronze, Green Published			2022-12-28	WOS:000226779400016
J	Yusuf, S; Mehta, SR; Xie, CC; Ahmed, RJ; Xavier, D; Pais, P; Zhu, J; Liu, LS				Yusuf, S; Mehta, SR; Xie, CC; Ahmed, RJ; Xavier, D; Pais, P; Zhu, J; Liu, LS		CREATE Trial Grp Investigators	Effects of reviparin, a low-molecular-heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; WEIGHT HEPARIN; INTRAVENOUS HEPARIN; THERAPY; THROMBOLYSIS; ASPIRIN; PATENCY; TRIALS	Context Although reperfusion therapy, aspirin, beta-blockers, and angiotensin-converting enzyme inhibitors reduce mortality when used early in patients with acute myocardial infarction (MI), mortality and morbidity remain high. No antithrombotic or newer antiplatelet drug has been shown to reduce mortality in acute MI. Objective To evaluate the effects of reviparin, a low-molecular-weight heparin, when initiated early and given for 7 days in addition to usual therapy on the primary composite outcome of death, myocardial reinfarction, or strokes at 7 and 30 days. Design, Setting, and Patients A randomized, double-blind, placebo-controlled trial (Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation [CREATE]) of 15570 patients with ST-segment elevation or new left bundle-branch block, presenting within 12 hours of symptom onset at 341 hospitals in India and China from July 2001 through July 2004. Intervention Reviparin or placebo subcutaneously twice daily for 7 days. Main Outcome Measure Primary composite outcome of death, myocardial reinfarction, or stroke at 7 and 30 days. Results The primary composite outcome was significantly reduced from 854 (11.0%) of 7790 patients in the placebo group to 745 (9.6%) of 7780 in the reviparin group (hazard ratio [HR], 0.87; 95% Cl, 0.79-0.96; P=.005). These benefits persisted at 30 days (1056 [13.6%] vs 921 [11.8%] patients; HR, 0.87; 95% CI, 0.79-0.95; P=.001)with significant reductions in 30-day mortality (877 (11.3%) vs 766 [9.8%); HR, 0.87; 95% Cl, 0.79-0.96; P=.005) and reinfarction (199 [2-6%] vs 154 [2.0%]; HR. 0.77; 95% Cl. 0.62-0.95; P=.01), and no significant differences in strokes (64 (0.8%] vs 80 (1.0%]; P=.19). Reviparin treatment was significantly better when it was initiated very early after symptom onset at 7 days (<2 hours: HR, 0.70; 95% Cl, 0.52-0.96; P=.03; 30/1000 events prevented; 2 to <4 hours: HR, 0.81; 95% Cl, 0.67-0.98; P=.03; 21/1000 events ore-vented; 4 to <8 hours: HR, 0.85; 95% Cl, 0.73-0.99; P=.05; 16/1000 events prevented; and >= 8 hours: HR, 1.06; 95% Cl, 0.86-1.30; P=58; P=.04 for trend). There was an increase in life-threatening bleeding at 7 days with reviparin and placebo (17 (0.2%) vs 7 [0.1%], respectively; P=.07), but the absolute excess was small (I more per 1000) vs reductions in the primary outcome (18 fewer per 1000) or mortality (15 fewer per 1000). Conclusions In patients with acute ST-segment elevation or new Left bundle-branch block MI, reviparin reduces mortality and reinfarction, without a substantive increase in overall stroke rates. There is a small absolute excess of life-threatening bleeding but the benefits outweigh the risks.	Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; McMaster Univ, Hamilton, ON L8L 2X2, Canada; St Johns Natl Acad Hlth Sci, Inst Populat Hlth & Clin Res, Bangalore, Karnataka, India; Cardiovasc Inst, Beijing, Peoples R China; Fu Wai Hosp, Chinese Hypertens League Inst, Beijing, Peoples R China; Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada	McMaster University; Population Health Research Institute; McMaster University; St. John's National Academy of Health Sciences; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Hypertension League; McMaster University; Population Health Research Institute	Yusuf, S (corresponding author), Hamilton Gen Hosp, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusuf@mcmaster.ca		Yusuf, Salim/0000-0003-4776-5601				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V2, P57; ANTMAN EM, IN PRESS AM HEART J; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; Breddin HK, 2001, NEW ENGL J MED, V344, P626, DOI 10.1056/NEJM200103013440902; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; COLLINS R, 1995, LANCET, V345, P669; DEBONO DP, 1992, BRIT HEART J, V67, P122; Fareed J, 1998, AM J CARDIOL, V82, p3L, DOI 10.1016/S0002-9149(98)00105-2; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; ISIS-3 (Third International Study of Infarct Survival) Collaborative Group, 1992, LANCET, V339, P1; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Mahaffey KW, 1996, AM J CARDIOL, V77, P551, DOI 10.1016/S0002-9149(97)89305-8; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P437; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 2001, LANCET, V358, P605; Wallentin L, 1996, LANCET, V347, P561; Wallentin L, 2003, CIRCULATION, V108, P135, DOI 10.1161/01.CIR.0000081659.72985.A8; White HD, 2001, LANCET, V358, P1855; Wong GC, 2003, JAMA-J AM MED ASSOC, V289, P331, DOI 10.1001/jama.289.3.331; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2004, AM HEART J, V148, P1068, DOI 10.1016/j.ahj.2004.08.033; Yusuf S, 2002, LANCET, V359, P294	26	111	123	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					427	436						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890DW	15671427				2022-12-28	WOS:000226492900021
J	Budakian, R; Mamin, HJ; Chui, BW; Rugar, D				Budakian, R; Mamin, HJ; Chui, BW; Rugar, D			Creating order from random fluctuations in small spin ensembles	SCIENCE			English	Article							RESONANCE FORCE MICROSCOPY; RELAXATION	We demonstrate the ability to create spin order by using a magnetic resonance force microscope to harness the naturally occurring statistical fluctuations in small ensembles of electron spins. In one method, we hyperpolarized the spin system by selectively capturing the transient spin order created by the statistical fluctuations. In a second method, we took a more active approach and rectified the spin fluctuations by applying real-time feedback to the entire spin ensemble. The created spin order can be stored in the laboratory frame for a period on the order of the longitudinal relaxation time of 30 seconds and then read out.	IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA	International Business Machines (IBM)	Budakian, R (corresponding author), IBM Corp, Almaden Res Ctr, Div Res, 650 Harry Rd, San Jose, CA 95120 USA.	budakian@us.ibm.com						ALBRECHT TR, 1991, J APPL PHYS, V69, P668, DOI 10.1063/1.347347; Berman GP, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.094402; Berman GP, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.094425; Berman GP, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.023405; Brun TA, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.032301; CASTLE JG, 1963, PHYS REV, V130, P577, DOI 10.1103/PhysRev.130.577; Chui B. W., 2003, 12 INT C SOL STAT SE, P1120; DIVINCENZO DP, 1995, SCIENCE, V270, P255, DOI 10.1126/science.270.5234.255; Gassmann H, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.115419; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Mamin HJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.207604; MAXWELL JC, 1880, THEORY HEAT; Mozyrsky D, 2003, APPL PHYS LETT, V82, P1278, DOI 10.1063/1.1554769; Rugar D, 2004, NATURE, V430, P329, DOI 10.1038/nature02658; Slichter C. P., 1996, PRINCIPLES MAGNETIC; Steane A, 1998, REP PROG PHYS, V61, P117, DOI 10.1088/0034-4885/61/2/002; Stipe BC, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.277602	17	23	24	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2005	307	5708					408	411		10.1126/science.1106718	http://dx.doi.org/10.1126/science.1106718			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662009				2022-12-28	WOS:000226492300041
J	Sawai, S; Thomason, PA; Cox, EC				Sawai, S; Thomason, PA; Cox, EC			An autoregulatory circuit for long-range self-organization in Dictyostelium cell populations	NATURE			English	Article							SPIRAL WAVES; ADENYLYL-CYCLASE; CAMP; AGGREGATION; PROPAGATION; FEEDBACK; KINASE	Nutrient-deprived Dictyostelium amoebae aggregate to form a multicellular structure by chemotaxis, moving towards propagating waves of cyclic AMP that are relayed from cell to cell. Organizing centres are not formed by founder cells, but are dynamic entities consisting of cores of outwardly rotating spiral waves(1-4) that self-organize in a homogeneous cell population. Spiral waves are ubiquitously observed in chemical reactions as well as in biological systems(5-8). Although feedback control of spiral waves in spatially extended chemical reactions has been demonstrated in recent years(9,10), the mechanism by which control is achieved in living systems is unknown. Here we show that mutants of the cyclic AMP/protein kinase A pathway show periodic signalling, but fail to organize coherent long-range wave territories, owing to the appearance of numerous spiral cores. A theoretical model suggests that autoregulation of cell excitability mediated by protein kinase A acts to optimize the number of signalling centres.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Sawai, S (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	ssawai@molbio.princeton.edu; ecox@princeton.edu	Sawai, Satoshi/AAX-8536-2020	Sawai, Satoshi/0000-0003-3764-219X; Thomason, Peter/0000-0003-3104-8392				DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; FEY P, 1995, GENE, V165, P127, DOI 10.1016/0378-1119(95)00430-E; FOERSTER P, 1990, DEVELOPMENT, V109, P11; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; Gray RA, 1998, NATURE, V392, P75, DOI 10.1038/32164; GROSS JD, 1976, J CELL SCI, V22, P645; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; Iranfar N, 2003, EUKARYOT CELL, V2, P664, DOI 10.1128/EC.2.4.664-670.2003; Kim M, 2001, SCIENCE, V292, P1357, DOI 10.1126/science.1059478; Laub MT, 1998, MOL BIOL CELL, V9, P3521, DOI 10.1091/mbc.9.12.3521; Lauzeral J, 1997, P NATL ACAD SCI USA, V94, P9153, DOI 10.1073/pnas.94.17.9153; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEE KJ, 2001, PHYS REV LETT, V87; Levine H, 1996, P NATL ACAD SCI USA, V93, P6382, DOI 10.1073/pnas.93.13.6382; Maeda M, 2004, SCIENCE, V304, P875, DOI 10.1126/science.1094647; MARTIEL JL, 1987, BIOPHYS J, V52, P807, DOI 10.1016/S0006-3495(87)83275-7; Palsson E, 1997, P NATL ACAD SCI USA, V94, P13719, DOI 10.1073/pnas.94.25.13719; Patel H, 2000, EMBO J, V19, P2247, DOI 10.1093/emboj/19.10.2247; Saran S, 2002, J MUSCLE RES CELL M, V23, P793, DOI 10.1023/A:1024483829878; SEGALL JE, 1995, J CELL BIOL, V128, P405, DOI 10.1083/jcb.128.3.405; SIEGERT F, 1989, J CELL SCI, V93, P325; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; Sucgang R, 1997, DEV BIOL, V192, P181, DOI 10.1006/dbio.1997.8720; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Tung CK, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.248302; Wessels DJ, 2000, MOL BIOL CELL, V11, P2803, DOI 10.1091/mbc.11.8.2803	28	130	132	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					323	326		10.1038/nature03228	http://dx.doi.org/10.1038/nature03228			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662425				2022-12-28	WOS:000226381300057
J	Stachel, J				Stachel, J			1905 and all that	NATURE			English	Editorial Material							BODY	How Einstein claimed his place in the changing landscape of physics during his annus mirabilis.	Boston Univ, Dept Phys, Boston, MA 02215 USA; Boston Univ, Ctr Einstein Studies, Boston, MA 02215 USA	Boston University; Boston University	Stachel, J (corresponding author), Boston Univ, Dept Phys, 590 Commonwealth Ave, Boston, MA 02215 USA.	stachel@physics.bu.edu						Einstein A, 1905, ANN PHYS-BERLIN, V18, P639; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; Einstein A, 1906, ANN PHYS-BERLIN, V19, P289, DOI 10.1002/andp.19063240204; Einstein A, 1905, ANN PHYS-BERLIN, V17, P132; Einstein A, 1905, ANN PHYS-BERLIN, V17, P891; EINSTEIN A, 1993, COLLECTED PAPERS A E, V1, P31; EINSTEIN A, 1987, COLLECTED PAPERS A E, V1; KUHN TS, 1978, BLACK BODY THEORY QU, pCH9; STACHEL J, 2004, 283 M PLANCK I WISS	9	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					215	217		10.1038/433215a	http://dx.doi.org/10.1038/433215a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662405				2022-12-28	WOS:000226381300035
J	Bejsovec, A				Bejsovec, A			Wnt pathway activation: New relations and locations	CELL			English	Review							RECEPTORS; WINGLESS; PROTEIN; DOMAIN	Recent advances in the Writ signaling field reveal new components, such as a G protein and an atypical receptor tyrosine kinase, and novel connections between known components. In addition, different subcellular localization of receptors may help to explain distinctions between canonical and noncanonical Writ pathway activity.	Duke Univ, Dept Biol, Durham, NC 27708 USA	Duke University	Bejsovec, A (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.	bejsovec@duke.edu		Bejsovec, Amy/0000-0002-8019-5789				Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Chen CM, 2004, P NATL ACAD SCI USA, V101, P15961, DOI 10.1073/pnas.0407103101; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; Inoue T, 2004, CELL, V118, P795, DOI 10.1016/j.cell.2004.09.001; Jones WM, 2003, CURR BIOL, V13, pR479, DOI 10.1016/S0960-9822(03)00407-X; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; McEwen DG, 2000, CURR BIOL, V10, pR562, DOI 10.1016/S0960-9822(00)00611-4; Rulifson EJ, 2000, MOL CELL, V6, P117, DOI 10.1016/S1097-2765(00)00013-7; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu J, 2004, PLOS BIOL, V2, P1004, DOI 10.1371/journal.pbio.0020158; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522	16	93	106	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					11	14		10.1016/S0092-8674(04)01246-2	http://dx.doi.org/10.1016/S0092-8674(04)01246-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652476	Bronze			2022-12-28	WOS:000226365400005
J	Chao, A; Thun, MJ; Connell, CJ; McCullough, ML; Jacobs, EJ; Flanders, WD; Rodriguez, C; Sinha, R; Calle, EE				Chao, A; Thun, MJ; Connell, CJ; McCullough, ML; Jacobs, EJ; Flanders, WD; Rodriguez, C; Sinha, R; Calle, EE			Meat consumption and risk of colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							II NUTRITION COHORT; COLO-RECTAL CANCER; LARGE-BOWEL-CANCER; HETEROCYCLIC AMINES; UNITED-STATES; RED MEAT; FOOD GROUPS; N-NITROSATION; GASTROINTESTINAL CANCERS; GENETIC SUSCEPTIBILITY	Context Consumption of red and processed meat has been associated with colorectal cancer in many but not all epidemiological studies; few studies have examined risk in relation to long-term meat intake or the association of meat with rectal cancer. Objective To examine the relationship between recent and long-term meat consumption and the risk of incident colon and rectal cancer. Design, Setting, and Participants A cohort of 148610 adults aged 50 to 74 years (median, 63 years), residing in 21 states with population-based cancer registries, who provided information on meat consumption in 1982 and again in 1992/1993 when enrolled in the Cancer Prevention Study II (CPS II) Nutrition Cohort. Follow-up from time of enrollment in 1992/1993 through August 31, 2001, identified 1667 incident colorectal cancers. Participants contributed person-years at risk until death or a diagnosis of colon or rectal cancer. Main Outcome Measure Incidence rate ratio (RR) of colon and rectal cancer. Results High intake of red and processed meat reported in 1992/1993 was associated with higher risk of colon cancer after adjusting for age and energy intake but not after further adjustment for body mass index, cigarette smoking, and other covariates. When long-term consumption was considered, persons in the highest tertile of consumption in both 1982 and 1992/1993 had higher risk of distal colon cancer associated with processed meat (RR, 1.50; 95% confidence interval [CI], 1.04-2.17), and ratio of red meat to poultry and fish (RR, 1.53; 95% Cl, 1.08-2.18) relative to those persons in the lowest tertile at both time points. Long-term consumption of poultry and fish was inversely associated with risk of both proximal and distal colon cancer. High consumption of red meat reported in 1992/1993 was associated with higher risk of rectal cancer (RR, 1.71; 95% Cl, 1.15-2.52; P=.007 for trend), as was high consumption reported in both 1982 and 1992/1993 (RR, 1.43; 95% Cl, 1.00-2.05). Conclusions Our results demonstrate the potential value of examining long-term meat consumption in assessing cancer risk and strengthen the evidence that prolonged high consumption of red and processed meat may increase the risk of cancer in the distal portion of the large intestine.	Amer Canc Soc, Atlanta, GA 30329 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; NCI, Div Canc Epidemiol & Genet, Rockville, MD USA	American Cancer Society; Emory University; Rollins School Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thun, MJ (corresponding author), Amer Canc Soc, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.	mthun@cancer.org	Sinha, Rashmi/G-7446-2015	Sinha, Rashmi/0000-0002-2466-7462; McCullough, Marjorie/0000-0003-3025-6341	NATIONAL CANCER INSTITUTE [ZIACP010127, Z01CP010127, K07CA075062] Funding Source: NIH RePORTER; NCI NIH HHS [K07CA75062] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Taie OH, 2003, NUTR CANCER, V46, P125, DOI 10.1207/S15327914NC4602_04; Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1; BENITO E, 1990, INT J CANCER, V45, P69, DOI 10.1002/ijc.2910450114; Bergmann MM, 1998, AM J EPIDEMIOL, V147, P556; BIDOLI E, 1992, INT J CANCER, V50, P223, DOI 10.1002/ijc.2910500211; Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013; BLOCK G, 1989, HLTH HABITS HIST QUE; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; Boutron-Ruault MC, 1999, EUR J CANCER PREV, V8, P229, DOI 10.1097/00008469-199906000-00011; Butler LM, 2003, AM J EPIDEMIOL, V157, P434, DOI 10.1093/aje/kwf221; Calle EE, 2002, CANCER-AM CANCER SOC, V94, P2490, DOI 10.1002/cncr.101970; Chen J, 1998, CANCER RES, V58, P3307; Cross AJ, 2003, CANCER RES, V63, P2358; DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408; English DR, 2004, CANCER EPIDEM BIOMAR, V13, P1509; Fernandez-Banares F, 2002, AM J GASTROENTEROL, V97, P2103, DOI 10.1111/j.1572-0241.2002.05930.x; Flagg EW, 2000, EPIDEMIOLOGY, V11, P462, DOI 10.1097/00001648-200007000-00017; Flood A, 2003, AM J EPIDEMIOL, V158, P59, DOI 10.1093/aje/kwg099; Gaard M, 1996, EUR J CANCER PREV, V5, P445; GIOVANNUCCI E, 1992, JNCI-J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GOLDBOHM RA, 1994, CANCER RES, V54, P718; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; Greenland S, 1990, Epidemiology, V1, P421, DOI 10.1097/00001648-199011000-00003; GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B; HAENSZEL W, 1980, JNCI-J NATL CANCER I, V64, P17; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; Hsing AW, 1998, INT J CANCER, V77, P549, DOI 10.1002/(SICI)1097-0215(19980812)77:4&lt;549::AID-IJC13&gt;3.0.CO;2-1; HU JF, 1991, INT J EPIDEMIOL, V20, P362, DOI 10.1093/ije/20.2.362; Hughes R, 2002, NUTR CANCER, V42, P70, DOI 10.1207/S15327914NC421_10; Hughes R, 2001, CARCINOGENESIS, V22, P199, DOI 10.1093/carcin/22.1.199; Jarvinen R, 2001, BRIT J CANCER, V85, P357, DOI 10.1054/bjoc.2001.1906; Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15; KAMPMAN E, 1995, CANCER CAUSE CONTROL, V6, P225, DOI 10.1007/BF00051794; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; Kato T, 2002, CANCER LETT, V187, P169, DOI 10.1016/S0304-3835(02)00432-9; Kipnis V, 2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091; Knekt P, 1999, INT J CANCER, V80, P852, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;852::AID-IJC9&gt;3.0.CO;2-S; Kune S, 1987, Nutr Cancer, V9, P21; LAVECCHIA C, 1988, INT J CANCER, V41, P492, DOI 10.1002/ijc.2910410404; LaVecchia C, 1996, INT J CANCER, V66, P60, DOI 10.1002/(SICI)1097-0215(19960328)66:1&lt;60::AID-IJC11&gt;3.0.CO;2-F; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; LeMarchand L, 1997, CANCER CAUSE CONTROL, V8, P637, DOI 10.1023/A:1018406716115; Levi F, 1999, BRIT J CANCER, V79, P1283, DOI 10.1038/sj.bjc.6690206; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; McCullough ML, 2003, CANCER CAUSE CONTROL, V14, P1, DOI 10.1023/A:1022591007673; MILLER AB, 1983, INT J CANCER, V32, P155, DOI 10.1002/ijc.2910320204; Murata M, 1999, JPN J CANCER RES, V90, P711, DOI 10.1111/j.1349-7006.1999.tb00805.x; Murtaugh MA, 2004, J NUTR, V134, P776, DOI 10.1093/jn/134.4.776; Narayanan BA, 2003, CANCER RES, V63, P972; National Cattlemen's Beef Association, 2001, US BEEF IND DEM SPEN; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; PETERS RK, 1992, CANCER CAUSE CONTROL, V3, P457, DOI 10.1007/BF00051359; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; PICKLE LW, 1984, CANCER RES, V44, P363; Pierre F, 2003, CARCINOGENESIS, V24, P1683, DOI 10.1093/carcin/bgg130; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894; RobertsThomson IC, 1996, LANCET, V347, P1372, DOI 10.1016/S0140-6736(96)91012-0; Rothman K., 1998, MODERN EPIDEMIOLOGY, P253; Sandhu MS, 2001, CANCER EPIDEM BIOMAR, V10, P439; Seow A, 2002, CANCER-AM CANCER SOC, V95, P2390, DOI 10.1002/cncr.10971; Sesink ALA, 1999, CANCER RES, V59, P5704; Shannon J, 1996, CANCER EPIDEM BIOMAR, V5, P495; Singh PN, 1998, AM J EPIDEMIOL, V148, P761, DOI 10.1093/oxfordjournals.aje.a009697; Sinha R, 1997, MUTAT RES-FUND MOL M, V376, P195, DOI 10.1016/S0027-5107(97)00043-2; Sinha R, 1999, CANCER RES, V59, P4320; SINHA R, 1995, CANCER RES, V55, P4516; TAJIMA K, 1985, JPN J CANCER RES, V76, P705; *TEX CATTL FEED AS, CAP MEAT CONS POUNDS; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; Tiemersma EW, 2002, CANCER CAUSE CONTROL, V13, P383, DOI 10.1023/A:1015236701054; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; VLAJINAC H, 1987, Archiv fuer Geschwulstforschung, V57, P493; Weisburger JH, 2002, MUTAT RES-FUND MOL M, V506, P9, DOI 10.1016/S0027-5107(02)00147-1; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WOHLLEB JC, 1990, INT J CANCER, V46, P22, DOI 10.1002/ijc.2910460107; World Health Organisation, 1977, INT CLASS DIS 9 REV; World Health Organization, 1992, INT CLASS DIS 10 REV; Yang CX, 2003, EUR J CANCER PREV, V12, P109, DOI 10.1097/00008469-200304000-00004	83	385	407	0	79	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2005	293	2					172	182		10.1001/jama.293.2.172	http://dx.doi.org/10.1001/jama.293.2.172			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885QC	15644544	Bronze			2022-12-28	WOS:000226171000033
J	Graves, JAM				Graves, JAM			Recycling the Y chromosome	SCIENCE			English	Editorial Material							SEX; GENES		Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia	Australian National University	Graves, JAM (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia.	jenny.graves@anu.edu.au	Graves, Jennifer A.M./A-1387-2008	Graves, Jennifer/0000-0001-6480-7856				Arakawa Y, 2002, CYTOGENET GENOME RES, V99, P303, DOI 10.1159/000071608; Carvalho AB, 2005, SCIENCE, V307, P108, DOI 10.1126/science.1101675; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; Graves JAM, 2002, TRENDS GENET, V18, P259, DOI 10.1016/S0168-9525(02)02666-5; Grutzner F, 2004, NATURE, V432, P913, DOI 10.1038/nature03021; Hackstein JHP, 1996, BIOESSAYS, V18, P317, DOI 10.1002/bies.950180410; JUST W, 1995, NAT GENET, V11, P117, DOI 10.1038/ng1095-117; Ogata M, 2003, GENETICS, V164, P613; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Veyrunes F, 2004, CHROMOSOME RES, V12, P369, DOI 10.1023/B:CHRO.0000034098.09885.e6	10	10	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					50	51		10.1126/science.1107295	http://dx.doi.org/10.1126/science.1107295			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637257				2022-12-28	WOS:000226214300026
J	Menendez-Jandula, B; Souto, JC; Oliver, A; Montserrat, I; Quintana, M; Glch, I; Bonfill, X; Fontcuberta, J				Menendez-Jandula, B; Souto, JC; Oliver, A; Montserrat, I; Quintana, M; Glch, I; Bonfill, X; Fontcuberta, J			Comparing self-management of oral anticoagulant therapy with clinic management - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							HEART-VALVE REPLACEMENT; HEMORRHAGIC COMPLICATIONS; BLEEDING COMPLICATIONS; INCEPTION-COHORT; WARFARIN; QUALITY; CARE; OUTCOMES; ISCOAT	Background: control of oral anticoagulant treatment has been reported to be suboptimal, but previous studies suggest that patient self-management improves control. Objective: To compare the quality of control and the clinical outcomes of oral anticoagulant treatment in self-managed patients versus patients following conventional management. Design: Randomized, controlled trial. Setting: University-affiliated hospital in Spain. Patients: 737 patients with indications for anticoagulant treatment. Intervention: The self-management group (n = 368) received simple instructions for using a portable coagulometer weekly and self-adjusting treatment dose. The conventional management group (n = 369) received usual care in an anticoagulation clinic (monthly measurement and control of international normalized ratio [INR], managed by hematologists). Measurements: Percentage of INR values within the target range and major related complications. Results: The median follow-up period was 11.8 months (range, 0.3 to 16.9 months). The unadjusted percentages of in-range INRs were 58.6% in the self-management group and 55.6% in the conventional management group (difference, 3.0 percentage points [95% CI, 0.4 to 5.4 percentage points]). Twenty-seven patients (7.3%) in the conventional management group and 8 (2.2%) in the self-management group had major complications related to anticoagulant treatment. The unadjusted risk difference for major complications between groups was 5.1 percentage points (exact 95% CI, 1.7 to 8.5 percentage points). Fewer patients had minor hemorrhages in the self-management group (14.9%) than in the conventional management group (36.4%). Fifteen patients (4.1%) in the conventional management group and 6 (1.6%) in the self-management group died (unadjusted risk difference, 2.5 percentage points [exact 95% CI, 0.0 to 5.1 percentage points]). Limitations: The trial was performed at only 1 center and was not blinded. The dropout rate in the intervention group was 21%. Conclusions: Compared with conventional management by an anticoagulation clinic, self-management of oral anticoagulant treatment achieved a similar level of control. Of note, major complications and minor hemorrhages were less common in the self-management group.	Hosp Santa Creu & Sant Pau, Unitat Hemostasia & Trombosi, Barcelona 08025, Spain; Fdn Puigvert, Barcelona, Spain	Hospital of Santa Creu i Sant Pau; Fundacio Puigvert	Souto, JC (corresponding author), Hosp Santa Creu & Sant Pau, Unitat Hemostasia & Trombosi, St Antoni Maria Claret 167, Barcelona 08025, Spain.	jsouto@hsp.santpau.es		Bonfill Cosp, Xavier/0000-0003-1530-3509; Gich, Ignasi/0000-0003-3975-6588				Ansell J, 2001, CHEST, V119, p22S, DOI 10.1378/chest.119.1_suppl.22S; Ansell JE, 1999, JAMA-J AM MED ASSOC, V281, P182, DOI 10.1001/jama.281.2.182; ANSELL JE, 1995, ARCH INTERN MED, V155, P2185, DOI 10.1001/archinte.155.20.2185; Bernardo A, 2001, DEUT MED WOCHENSCHR, V126, P346, DOI 10.1055/s-2001-12092; Beyth RJ, 2000, ANN INTERN MED, V133, P687, DOI 10.7326/0003-4819-133-9-200011070-00010; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; Chiquette E, 1998, ARCH INTERN MED, V158, P1641, DOI 10.1001/archinte.158.15.1641; CORTELAZZO S, 1993, THROMB HAEMOSTASIS, V69, P316; Cromheecke ME, 2000, LANCET, V356, P97, DOI 10.1016/S0140-6736(00)02470-3; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; Gadisseur APA, 2003, ARCH INTERN MED, V163, P2639, DOI 10.1001/archinte.163.21.2639; Gadisseur APA, 2004, J THROMB HAEMOST, V2, P584, DOI 10.1111/j.1538-7836.2004.00659.x; Goldman DP, 2002, P NATL ACAD SCI USA, V99, P10929, DOI 10.1073/pnas.162086599; Hirsh J, 2001, CHEST, V119, p8S, DOI 10.1378/chest.119.1_suppl.8S; Horstkotte, 1998, J Thromb Thrombolysis, V5 Suppl 1, P19, DOI 10.1023/A:1013228718768; Koertke H, 2003, CIRCULATION, V108, P75, DOI 10.1161/01.cir.0000089185.80318.3f; Kortke H, 2001, ANN THORAC SURG, V72, P44, DOI 10.1016/S0003-4975(01)02656-X; Latham C E, 1998, J Am Soc Nephrol, V9, pS141; Levine MN, 2001, CHEST, V119, p108S, DOI 10.1378/chest.119.1_suppl.108S; Morsdorf S, 1999, SEMIN THROMB HEMOST, V25, P109, DOI 10.1055/s-2007-996433; MULLERBEISSENHI.W, 1997, J LAB MED, V21, P558; Murray E, 2004, BRIT MED J, V328, P437, DOI 10.1136/bmj.328.7437.437; Palareti G, 1997, THROMB HAEMOSTASIS, V78, P1438; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Piette JD, 2001, EVIDENCE BASED DIABE, P207; Piso B, 2002, THROMB RES, V106, P101, DOI 10.1016/S0049-3848(02)00098-1; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Samsa GP, 2000, J THROMB THROMBOLYS, V9, P283, DOI 10.1023/A:1018778914477; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Sawicki PT, 2003, J INTERN MED, V254, P515, DOI 10.1046/j.1365-2796.2003.01215.x; Sidhu P, 2001, ANN THORAC SURG, V72, P1523, DOI 10.1016/S0003-4975(01)03049-1; Siebenhofer A, 2004, THROMB HAEMOSTASIS, V91, P225, DOI 10.1160/TH03-09-0598; Taborski U, 1999, SEMIN THROMB HEMOST, V25, P103, DOI 10.1055/s-2007-996432; Watzke HH, 2000, THROMB HAEMOSTASIS, V83, P661; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730	36	140	144	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2005	142	1					1	10		10.7326/0003-4819-142-1-200501040-00006	http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916DS	15630104				2022-12-28	WOS:000228366200001
J	Cepeda, JA; Whitehouse, T; Cooper, B; Hails, J; Jones, K; Kwaku, F; Taylor, L; Hayman, S; Cookson, B; Show, S; Kibbler, C; Singer, M; Bellingan, G; Wilson, APR				Cepeda, JA; Whitehouse, T; Cooper, B; Hails, J; Jones, K; Kwaku, F; Taylor, L; Hayman, S; Cookson, B; Show, S; Kibbler, C; Singer, M; Bellingan, G; Wilson, APR			Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive-care units: prospective two-centre study	LANCET			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; FIELD GEL-ELECTROPHORESIS; NOSOCOMIAL INFECTION; CONTACT ISOLATION; RISK-FACTORS; ACQUISITION; OUTBREAK; HOSPITALS; PREVALENCE; BACTERIA	Background Hospital-acquired infection due to meticillin-resistant Staphylococcus aureus (MRSA) is common within intensive-care units. Single room or cohort isolation of infected or colonised patients is used to reduce spread, but its benefit over and above other contact precautions is not known. We aimed to assess the effectiveness of moving versus not moving infected or colonised patients in intensive-care units to prevent transmission of MRSA. Methods We undertook a prospective 1-year study in the intensive-care units of two teaching hospitals. Admission and weekly screens were used to ascertain the incidence of MRSA colonisation. In the middle 6 months, MRSA-positive patients were not moved to a single room or cohort nursed unless they were carrying other multiresistant or notifiable pathogens. Standard precautions were practised throughout. Hand hygiene was encouraged and compliance audited. Findings Patients' characteristics and MRSA acquisition rates were similar in the periods when patients were moved and not moved. The crude (unadjusted) Cox proportional-hazards model showed no evidence of increased transmission during the non-move phase (0.73 [95% CI 0.49-1.10], p = 0.94 one-sided). There were no changes in transmission of any particular strain of MRSA nor in handwashing frequency between management phases. Interpretation Moving MRSA-positive patients into single rooms or cohorted bays does not reduce crossinfection. Because transfer and isolation of critically ill patients in single rooms carries potential risks, our findings suggest that re-evaluation of isolation policies is required in intensive-care units where MRSA is endemic, and that more effective means of preventing spread of MRSA in such settings need to be found.	UCL Hosp, Windeyer Inst Med Sci, Dept Clin Microbiol, London W1T 4JF, England; UCL, Dept Med, Bloomsbury Inst Intens Care Med, London W1T 3AA, England; Royal Free Hosp, Dept Med Microbiol, London NW3 2QG, England; Royal Free Hosp, Intens Care Unit, London NW3 2QG, England; Hlth Protect Agcy, Specialist & Reference Microbiol Div, London NW9 5HT, England	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Health Protection Agency	Wilson, APR (corresponding author), UCL Hosp, Windeyer Inst Med Sci, Dept Clin Microbiol, 46 Cleveland St, London W1T 4JF, England.	peter.wilson@uclh.nhs.uk	Singer, Mervyn/J-4425-2012; Whitehouse, Tony/AAC-1215-2020; Cooper, Ben/HGC-7082-2022; Singer, Mervyn/Q-6142-2019	Singer, Mervyn/0000-0002-1042-6350; Whitehouse, Tony/0000-0002-4387-3421; Singer, Mervyn/0000-0002-1042-6350; Cooper, Ben/0000-0002-9445-7217; Wilson, Andrew Peter Richard/0000-0003-1109-5650	NIAID NIH HHS [1R21AI55825] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI055825] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aucken HM, 2002, J CLIN MICROBIOL, V40, P292, DOI 10.1128/JCM.40.1.292-293.2002; Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6; Barrett SP, 1998, J HOSP INFECT, V39, P85, DOI 10.1016/S0195-6701(98)90322-X; Boyce JM, 2002, AM J INFECT CONTROL, V30, pS1, DOI 10.1067/mic.2002.130391; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; Bronzwaer S L, 2001, Euro Surveill, V6, P2; Cepeda JA, 2004, J ANTIMICROB CHEMOTH, V53, P345, DOI 10.1093/jac/dkh048; Chaix C, 1999, JAMA-J AM MED ASSOC, V282, P1745, DOI 10.1001/jama.282.18.1745; Christensen A, 2001, SCAND J INFECT DIS, V33, P663, DOI 10.1080/00365540110026944; Cook PP, 2004, J ANTIMICROB CHEMOTH, V53, P853, DOI 10.1093/jac/dkh163; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; CULLEN DJ, 1994, CRIT CARE MED, V22, P1406, DOI 10.1097/00003246-199409000-00009; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; Duck WM, 2003, J CLIN MICROBIOL, V41, P3035, DOI 10.1128/JCM.41.7.3035-3042.2003; Esveld M I, 1999, Ned Tijdschr Geneeskd, V143, P205; Evans HL, 2003, SURGERY, V134, P180, DOI 10.1067/msy.2003.222; Farrington M, 1998, QJM-MON J ASSOC PHYS, V91, P539, DOI 10.1093/qjmed/91.8.539; Fluit AC, 2001, EUR J CLIN MICROBIOL, V20, P617; Garner JS, 1996, AM J INFECT CONTROL, V24, P24; Gastmeier P, 2004, INFECT CONT HOSP EP, V25, P109, DOI 10.1086/502359; Gastmeier P, 2002, INFECTION, V30, P198, DOI 10.1007/s15010-002-2043-z; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; Hails J, 2003, INTENS CARE MED, V29, P481, DOI 10.1007/s00134-003-1645-y; *HOSP INF CONTR PR, 1996, AM J INFECT CONTROL, V24, P32; Jernigan JA, 1996, AM J EPIDEMIOL, V143, P496, DOI 10.1093/oxfordjournals.aje.a008770; Khatib M, 1999, CHEST, V116, P172, DOI 10.1378/chest.116.1.172; Kirkland KB, 1999, LANCET, V354, P1177, DOI 10.1016/S0140-6736(99)04196-3; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; Korn G P, 2001, Braz J Infect Dis, V5, P1; Lucet JC, 2003, ARCH INTERN MED, V163, P181, DOI 10.1001/archinte.163.2.181; Marshall C, 2004, J HOSP INFECT, V57, P245, DOI 10.1016/j.jhin.2004.03.024; Marshall C, 2003, INFECT CONT HOSP EP, V24, P322, DOI 10.1086/502215; Moreno R, 1998, CHEST, V113, P752, DOI 10.1378/chest.113.3.752; Murchan S, 2003, J CLIN MICROBIOL, V41, P1574, DOI 10.1128/JCM.41.4.1574-1585.2003; *NAT AUD OFF, 2004, IMPR PAT CAR RED RIS; *NAT AUD OFF, 2000, MAN CONTR HOSP ACQ I; Nijssen S, 2003, ARCH INTERN MED, V163, P2785, DOI 10.1001/archinte.163.22.2785; O'Connell NH, 2000, J HOSP INFECT, V45, P255, DOI 10.1053/jhin.2000.0768; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Takeda S, 2000, INT J ANTIMICROB AG, V14, P39, DOI 10.1016/S0924-8579(99)00148-X; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Theaker C, 2001, J HOSP INFECT, V48, P98, DOI 10.1053/jhin.2001.0960; Thompson BL, 1997, INFECT CONT HOSP EP, V18, P97; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; Waddell G, 1975, Nurs Times, V71, P1937; Warren DK, 2004, INFECT CONT HOSP EP, V25, P99, DOI 10.1086/502357; Yap FHY, 2004, CLIN INFECT DIS, V39, P511, DOI 10.1086/422641	49	231	237	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					295	304		10.1016/S0140-6736(05)17783-6	http://dx.doi.org/10.1016/S0140-6736(05)17783-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664224				2022-12-28	WOS:000226449600032
J	Schwartz, MW; Porte, D				Schwartz, MW; Porte, D			Diabetes, obesity, and the brain	SCIENCE			English	Editorial Material							SEIP CONGENITAL LIPODYSTROPHY; INSULIN-RECEPTOR SUBSTRATE-2; ACTIVATED PROTEIN-KINASE; ACID SYNTHASE INHIBITOR; DIET-INDUCED OBESITY; REDUCES FOOD-INTAKE; GLUCOSE-PRODUCTION; ARCUATE NUCLEUS; BODY-WEIGHT; BETA-CELLS	Recent evidence suggests a key role for the brain in the control of both body fat content and glucose metabolism. Neuronal systems that regulate energy intake, energy expenditure, and endogenous glucose production sense and respond to input from hormonal and nutrient-related signals that convey information regarding both body energy stores and current energy availability. In response to this input, adaptive changes occur that promote energy homeostasis and the maintenance of blood glucose levels in the normal range. Defects in this control system are implicated in the link between obesity and type 2 diabetes.	Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98110 USA; Harborview Med Ctr, Seattle, WA 98110 USA; Univ Calif San Diego, Div Endocrinol Diabet & Metab, San Diego, CA 92161 USA; VA San Diego Hlth Care Syst, Div Endocrinol Diabet & Metab, San Diego, CA 92161 USA	University of Washington; University of Washington Seattle; Harborview Medical Center; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Schwartz, MW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98110 USA.	mschwart@u.washington.edu	Schwartz, Michael W/H-9950-2012		NIDDK NIH HHS [DK52989, DK683840] Funding Source: Medline; NINDS NIH HHS [NS32273] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032273, R29NS032273] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adage T, 2001, J NEUROSCI, V21, P3639, DOI 10.1523/JNEUROSCI.21-10-03639.2001; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Bates SH, 2004, J MOL MED, V82, P12, DOI 10.1007/s00109-003-0494-z; Bernard, 1854, LECONS PHYSL EXPT AP; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; CLARK JT, 1985, ENDOCRINOLOGY, V117, P2435, DOI 10.1210/endo-117-6-2435; Cone RD, 1999, TRENDS ENDOCRIN MET, V10, P211, DOI 10.1016/S1043-2760(99)00153-8; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Deeney JT, 2000, SEMIN CELL DEV BIOL, V11, P267, DOI 10.1006/scdb.2000.0175; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Harris RBS, 1998, ENDOCRINOLOGY, V139, P8, DOI 10.1210/en.139.1.8; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Hu ZY, 2003, P NATL ACAD SCI USA, V100, P12624, DOI 10.1073/pnas.1834402100; Joffe BI, 2001, LANCET, V357, P1379, DOI 10.1016/S0140-6736(00)04616-X; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Kotz CM, 1998, AM J PHYSIOL-REG I, V275, pR471, DOI 10.1152/ajpregu.1998.275.2.R471; Kubota N, 2004, J CLIN INVEST, V114, P917, DOI 10.1172/JCI200421484; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585; Marks JL, 1997, J NEUROENDOCRINOL, V9, P99, DOI 10.1046/j.1365-2826.1997.00554.x; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Okamoto H, 2004, J CLIN INVEST, V114, P214, DOI 10.1172/JCI200421645; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; POCAI A, IN PRESS CELL METAB; Porte D, 2001, DIABETES-METAB RES, V17, P181; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; Schwartz MW, 2004, J CLIN ENDOCR METAB, V89, P5889, DOI 10.1210/jc.2004-0906; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 1997, DIABETES, V46, P2119, DOI 10.2337/diabetes.46.12.2119; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Seaquist ER, 2001, DIABETES, V50, P2203, DOI 10.2337/diabetes.50.10.2203; Seeley RJ, 2003, NAT REV NEUROSCI, V4, P901, DOI 10.1038/nrn1245; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Takahashi KA, 2004, ENDOCRINOLOGY, V145, P184, DOI 10.1210/en.2003-0337; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; van den Hoek AM, 2004, DIABETES, V53, P2529, DOI 10.2337/diabetes.53.10.2529; Van Maldergem L, 2002, J MED GENET, V39, P722, DOI 10.1136/jmg.39.10.722; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Yaney GC, 2003, DIABETOLOGIA, V46, P1297, DOI 10.1007/s00125-003-1207-4; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	610	635	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2005	307	5708					375	379		10.1126/science.1104344	http://dx.doi.org/10.1126/science.1104344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662002				2022-12-28	WOS:000226492300032
J	Yoon, B; Hakkinen, H; Landman, U; Worz, AS; Antonietti, JM; Abbet, S; Judai, K; Heiz, U				Yoon, B; Hakkinen, H; Landman, U; Worz, AS; Antonietti, JM; Abbet, S; Judai, K; Heiz, U			Charging effects on bonding and catalyzed oxidation of CO on Au-8 clusters on MgO	SCIENCE			English	Article							CARBON-MONOXIDE; GOLD CLUSTERS; ABSORPTION SPECTROSCOPY; MODEL CATALYSTS; SUPPORTED GOLD; ADSORPTION; SURFACES; NOBLE; NANOPARTICLES; STATES	Gold octamers (Au-8) bound to oxygen-vacancy F-center defects on Mg(001) are the smallest clusters to catalyze the low-temperature oxidation of CO to CO2, whereas clusters deposited on close-to-perfect magnesia surfaces remain chemically inert. Charging of the supported clusters plays a key role in promoting their chemical activity. Infrared measurements of the stretch vibration of CO adsorbed on mass-selected gold octamers soft-landed on MgO(001) with coadsorbed O-2 show a red shift on an F-center-rich surface with respect to the perfect surface. The experiments agree with quantum ab initio calculations that predict that a red shift of the C-O vibration should arise via electron back-donation to the CO antibonding orbital.	Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA; Tech Univ Munich, Lehrstuhl Phys Chem 1, Dept Chem, D-85747 Garching, Germany	University System of Georgia; Georgia Institute of Technology; Technical University of Munich	Hakkinen, H (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.	uzi.landman@physics.gatech.edu; utrich.heiz@ch.tum.de	Heiz, Ulrich K/B-4116-2010; Heiz, Ulrich/X-1670-2018; Way, James Douglas/A-9408-2010; Abbet, Stéphane/E-4072-2012; Yoon, Bokwon/C-5818-2009	Heiz, Ulrich/0000-0002-9403-1486; Way, James Douglas/0000-0001-9612-8508; Hakkinen, Hannu/0000-0002-8558-5436				Abbet S, 2002, PURE APPL CHEM, V74, P1527, DOI 10.1351/pac200274091527; BARNETT RN, 1993, PHYS REV B, V48, P2081, DOI 10.1103/PhysRevB.48.2081; BLYHOLDER G, 1964, J PHYS CHEM-US, V68, P2772, DOI 10.1021/j100792a006; Cho A, 2003, SCIENCE, V299, P1684, DOI 10.1126/science.299.5613.1684; COX DM, 1991, Z PHYS D ATOM MOL CL, V19, P353, DOI 10.1007/BF01448327; DUMAS P, 1986, SURF SCI, V171, P579, DOI 10.1016/0039-6028(86)91061-7; Guzman J, 2004, J AM CHEM SOC, V126, P2672, DOI 10.1021/ja039426e; Hakkinen H, 2003, ANGEW CHEM INT EDIT, V42, P1297, DOI 10.1002/anie.200390334; HARUTA M, 1987, CHEM LETT, P405, DOI 10.1246/cl.1987.405; Haruta M, 1997, CATAL TODAY, V36, P153, DOI 10.1016/S0920-5861(96)00208-8; Heiz U, 2000, CHEM PHYS, V262, P189, DOI 10.1016/S0301-0104(00)00268-8; HOFFMANN R, 1988, REV MOD PHYS, V60, P601, DOI 10.1103/RevModPhys.60.601; Jugnet Y, 2002, SURF SCI, V521, pL639, DOI 10.1016/S0039-6028(02)02295-1; Kim YD, 2003, CHEM PHYS LETT, V377, P170, DOI 10.1016/S0009-2614(03)01130-8; Lemire C, 2004, ANGEW CHEM INT EDIT, V43, P118, DOI 10.1002/anie.200352538; LIAN L, 1993, J CHEM PHYS, V99, P2583; Lopez N, 2002, J AM CHEM SOC, V124, P11262, DOI 10.1021/ja026998a; Mavrikakis M, 2000, CATAL LETT, V64, P101, DOI 10.1023/A:1019028229377; Mills G, 2002, CHEM PHYS LETT, V359, P493, DOI 10.1016/S0009-2614(02)00746-7; Rainer DR, 1997, J VAC SCI TECHNOL A, V15, P1653, DOI 10.1116/1.580648; Ruggiero C, 1996, J CHEM SOC FARADAY T, V92, P4829, DOI 10.1039/ft9969204829; Sanchez A, 1999, J PHYS CHEM A, V103, P9573, DOI 10.1021/jp9935992; Socaciu LD, 2003, J AM CHEM SOC, V125, P10437, DOI 10.1021/ja027926m; Stolcic D, 2003, J AM CHEM SOC, V125, P2848, DOI 10.1021/ja0293406; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Wallace WT, 2002, J AM CHEM SOC, V124, P7499, DOI 10.1021/ja0175439; Winkler C, 2003, LANGMUIR, V19, P717, DOI 10.1021/la026054z; Worz AS, 2003, J AM CHEM SOC, V125, P7964, DOI 10.1021/ja0352247; Yoon B, 2003, J PHYS CHEM A, V107, P4066, DOI 10.1021/jp027596s	29	1260	1269	16	697	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					403	407		10.1126/science.1104168	http://dx.doi.org/10.1126/science.1104168			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662008				2022-12-28	WOS:000226492300040
J	Hanlon, RT; Naud, MJ; Shaw, PW; Havenhand, JN				Hanlon, RT; Naud, MJ; Shaw, PW; Havenhand, JN			Behavioural ecology - Transient sexual mimicry leads to fertilization	NATURE			English	Editorial Material							ALTERNATIVE REPRODUCTIVE STRATEGIES; SPAWNING AGGREGATION; CUTTLEFISH; SUCCESS; MOLLUSCA		Marine Biol Lab, Marine Resources Ctr, Woods Hole, MA 02543 USA; Univ London, Royal Holloway Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Flinders Univ S Australia, Sch Biol Sci, Adelaide, SA 5001, Australia; Univ Gothenburg, Tjarno Marine Biol Lab, S-45296 Stromstad, Sweden	Marine Biological Laboratory - Woods Hole; University of London; Royal Holloway University London; Flinders University South Australia; University of Gothenburg	Hanlon, RT (corresponding author), Marine Biol Lab, Marine Resources Ctr, Woods Hole, MA 02543 USA.	rhanlon@mbl.edu	Hanlon, Roger T/Q-8687-2016; Havenhand, Jon N/F-5435-2013	Hanlon, Roger T/0000-0003-0004-5674; Havenhand, Jon N/0000-0003-0253-3428; Havenhand, Jonathan/0000-0001-6721-7763				Andersson Malte, 1994; Boal JG, 1996, ANIM BEHAV, V52, P529, DOI 10.1006/anbe.1996.0195; Fu P, 2001, P ROY SOC B-BIOL SCI, V268, P1105, DOI 10.1098/rspb.2001.1625; Gross MR, 1996, TRENDS ECOL EVOL, V11, P92, DOI 10.1016/0169-5347(96)81050-0; Hall KC, 2002, MAR BIOL, V140, P533; Naud MJ, 2004, ANIM BEHAV, V67, P1043, DOI 10.1016/j.anbehav.2003.10.005; NAUD MJ, IN PRESS P R SOC L B; Norman MD, 1999, P ROY SOC B-BIOL SCI, V266, P1347, DOI 10.1098/rspb.1999.0786; Parker G.A., 1998, SPERM COMPETITION SE, P3, DOI DOI 10.1016/B978-012100543-6/50026-X; Saetre GP, 1996, AM NAT, V147, P981, DOI 10.1086/285889; SHUSTER SM, 1989, EVOLUTION, V43, P1683, DOI 10.1111/j.1558-5646.1989.tb02618.x	11	79	82	2	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					212	212		10.1038/433212a	http://dx.doi.org/10.1038/433212a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662403				2022-12-28	WOS:000226381300029
J	Semaw, S; Simpson, SW; Quade, J; Renne, PR; Butler, RF; McIntosh, WC; Levin, N; Dominguez-Rodrigo, M; Rogers, MJ				Semaw, S; Simpson, SW; Quade, J; Renne, PR; Butler, RF; McIntosh, WC; Levin, N; Dominguez-Rodrigo, M; Rogers, MJ			Early Pliocene hominids from Gona, Ethiopia	NATURE			English	Article							MIDDLE AWASH; MIOCENE; AFRICA; ARAMIS; CHAD	Comparative biomolecular studies suggest that the last common ancestor of humans and chimpanzees, our closest living relatives, lived during the Late Miocene-Early Pliocene(1,2). Fossil evidence of Late Miocene-Early Pliocene hominid evolution is rare and limited to a few sites in Ethiopia(3,4,5), Kenya(6) and Chad(7). Here we report new Early Pliocene hominid discoveries and their palaeoenvironmental context from the fossiliferous deposits of As Duma, Gona Western Margin (GWM), Afar, Ethiopia. The hominid dental anatomy (occlusal enamel thickness, absolute and relative size of the first and second lower molar crowns, and premolar crown and radicular anatomy) indicates attribution to Ardipithecus ramidus. The combined radioisotopic and palaeomagnetic data suggest an age of between 4.51 and 4.32 million years for the hominid finds at As Duma. Diverse sources of data (sedimentology, faunal composition, ecomorphological variables and stable carbon isotopic evidence from the palaeosols and fossil tooth enamel) indicate that the Early Pliocene As Duma sediments sample a moderate rainfall woodland and woodland/grassland.	Indiana Univ, CRAFT Stone Age Inst, Gosport, IN 47433 USA; Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Cleveland Museum Nat Hist, Lab Phys Anthropol, Cleveland, OH 44106 USA; Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94709 USA; New Mexico Bur Geol & Mineral Resources, Socorro, NM 87801 USA; New Mexico Inst Min & Technol, Dept Earth & Environm Sci, Socorro, NM 87801 USA; Univ Complutense Madrid, Fac Geog & Hist, Dept Prehist & Arquel, E-28040 Madrid, Spain; So Connecticut State Univ, Dept Anthropol, New Haven, CT 06515 USA	Indiana University System; Case Western Reserve University; Cleveland Museum of Natural History; University of Arizona; Berkeley Geochronolgy Center; University of California System; University of California Berkeley; New Mexico Institute of Mining Technology; Complutense University of Madrid; Connecticut State University System; Southern Connecticut State University	Semaw, S (corresponding author), Indiana Univ, CRAFT Stone Age Inst, 1392 W Dittemore Rd, Gosport, IN 47433 USA.	ssemaw@indiana.edu	Levin, Naomi E/B-4124-2010; Simpson, Scott/GRS-0081-2022; Semaw, Sileshi/M-7021-2018	Levin, Naomi E/0000-0001-5703-3717; Renne, Paul/0000-0003-1769-5235; Semaw, Sileshi/0000-0001-8377-8288				Ahmad N., 1983, DEV SOIL SCI B, V11, P91, DOI DOI 10.1016/S0166-2481(08)70614-7; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Brunet M, 2001, CR ACAD SCI II A, V332, P51, DOI 10.1016/S1251-8050(00)01492-0; BUSH ME, 1982, AM J PHYS ANTHROPOL, V57, P651, DOI 10.1002/ajpa.1330570410; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; Cerling T., 1993, AM GEOPHYS UNION GEO, V78, P217; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; DUDAL R, 1965, FAO AGR DEV PAP, V83, P161; FISHER R, 1953, PROC R SOC LON SER-A, V217, P295, DOI 10.1098/rspa.1953.0064; Fortelius Mikael, 2000, American Museum Novitates, V3301, P1, DOI 10.1206/0003-0082(2000)301<0001:FCOUMU>2.0.CO;2; Frost Stephen R., 2001, American Museum Novitates, V3350, P1, DOI 10.1206/0003-0082(2001)350<0001:NEPCMP>2.0.CO;2; Haile-Selassie Y, 2004, SCIENCE, V303, P1503, DOI 10.1126/science.1092978; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; Harris John M., 2003, P485; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; MCINTOSH WC, 1994, NEW MEX GEOL SOC, V45, P165; Renne PR, 1999, GEOL SOC AM BULL, V111, P869, DOI 10.1130/0016-7606(1999)111<0869:COTMPS>2.3.CO;2; Renne PR, 1998, CHEM GEOL, V145, P117, DOI 10.1016/S0009-2541(97)00159-9; Salem AH, 2003, P NATL ACAD SCI USA, V100, P12787, DOI 10.1073/pnas.2133766100; Semaw S, 1997, NATURE, V385, P333, DOI 10.1038/385333a0; Senut B, 2001, CR ACAD SCI II A, V332, P137, DOI 10.1016/S1251-8050(01)01529-4; Ward CV, 2001, J HUM EVOL, V41, P255, DOI 10.1006/jhev.2001.0507; White TD, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P369; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	25	108	111	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					301	305		10.1038/nature03177	http://dx.doi.org/10.1038/nature03177			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662421	Green Published			2022-12-28	WOS:000226381300052
J	Wootton, JT				Wootton, JT			Field parameterization and experimental test of the neutral theory of biodiversity	NATURE			English	Article							CAPITA INTERACTION STRENGTH; COMPETITION; MODELS; COMMUNITIES; IMPACT; SPACE; TIME	Ecologists would like to explain general patterns observed across multi-species communities, such as species-area(1) and abundance-frequency relationships(1-4), in terms of the fundamental processes of birth, death and migration underlying the dynamics of all constituent species. The unified neutral theory of biodiversity(5,6) and related theories(7,8) based on these fundamental population processes have successfully recreated general species-abundance patterns without accounting for either the variation among species and individuals or resource-releasing processes such as predation and disturbance, long emphasized in ecological theory(9-14). If ecological communities can be described adequately without estimating variation in species and their interactions(15), our understanding of ecological community organization and the predicted consequences of reduced biodiversity and environmental change would shift markedly. Here, I introduce a strong method to test the neutral theory that combines field parameterization of the underlying population dynamics with a field experiment, and apply it to a rocky intertidal community. Although the observed abundance-frequency distribution of the system follows that predicted by the neutral theory, the neutral theory predicts poorly the field experimental results, indicating an essential role for variation in species interactions.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Wootton, JT (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	twootton@uchicago.edu	Wootton, J. Timothy/F-3191-2015	Wootton, J. Timothy/0000-0002-7715-0344				Adler PB, 2004, ECOLOGY, V85, P1265, DOI 10.1890/03-0602; Bell G, 2001, SCIENCE, V293, P2413, DOI 10.1126/science.293.5539.2413; Brown J.H., 1995, MACROECOLOGY; CASWELL H, 1976, ECOL MONOGR, V46, P327, DOI 10.2307/1942257; CONNELL JH, 1961, ECOLOGY, V42, P710, DOI 10.2307/1933500; Drossel B, 2004, J THEOR BIOL, V229, P539, DOI 10.1016/j.jtbi.2004.04.033; Elton C., 1927, ANIMAL ECOLOGY; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; Gause G. F., 1934, STRUGGLE EXISTENCE; Hubbell SP, 1997, CORAL REEFS, V16, pS9, DOI 10.1007/s003380050237; Hubbell Stephen P., 2001, V32, pi; HUFFAKER C. B., 1958, HILGARDIA, V27, P343; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; Kokkoris GD, 1999, ECOL LETT, V2, P70, DOI 10.1046/j.1461-0248.1999.22058.x; Laska MS, 1998, ECOLOGY, V79, P461, DOI 10.2307/176946; MacArthur R.H., 1972, pvii; MacArthur R.H., 1969, THEORY ISLAND BIOGEO; McGill B, 2003, OIKOS, V102, P679, DOI 10.1034/j.1600-0706.2003.12617.x; MOORE JC, 1993, SCIENCE, V261, P906, DOI 10.1126/science.261.5123.906; PAINE RT, 1984, ECOLOGY, V65, P1339, DOI 10.2307/1939114; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; PAINE RT, 1992, NATURE, V355, P73, DOI 10.1038/355073a0; PRESTON FW, 1960, ECOLOGY, V41, P611, DOI 10.2307/1931793; RAFAELLI DG, 1996, FOOD WEBS INTEGRATIO, P185; Wootton JT, 2004, ECOL LETT, V7, P653, DOI 10.1111/j.1461-0248.2004.00621.x; Wootton JT, 1997, ECOL MONOGR, V67, P45, DOI 10.1890/0012-9615(1997)067[0045:EATOPC]2.0.CO;2; Wootton JT, 2001, ECOLOGY, V82, P580, DOI 10.2307/2679881	27	110	116	3	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					309	312		10.1038/nature03211	http://dx.doi.org/10.1038/nature03211			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662423				2022-12-28	WOS:000226381300054
J	Flores, G				Flores, G			Preventing hospitalisations for children	LANCET			English	Editorial Material							HOSPITALS; CARE		Med Coll Wisconsin, Ctr Advancement Undersaved Children, Dept Pediat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Ctr Advancement Undersaved Children, Dept Epidemiol, Milwaukee, WI 53226 USA; Childrens Hosp Wisconsin, Childrens Res Inst, Milwaukee, WI 53201 USA	Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital of Wisconsin	Flores, G (corresponding author), Med Coll Wisconsin, Ctr Advancement Undersaved Children, Dept Pediat, Milwaukee, WI 53226 USA.	gflores@mail.mcw.edu						Billings J, 1989, USE SMALL AREA ANAL; CASANOVA C, 1995, INT J HEALTH SERV, V25, P283, DOI 10.2190/PCF7-ALX9-6CN3-7X9G; Flores G, 2003, PEDIATRICS, V112, P1021, DOI 10.1542/peds.112.5.1021; Johnston Grant, 2004, J Health Serv Res Policy, V9 Suppl 2, P23, DOI 10.1258/1355819042349907; Martinez-Mir I, 1999, BRIT J CLIN PHARMACO, V47, P681, DOI 10.1046/j.1365-2125.1999.00943.x; Miller MR, 2004, PEDIATRICS, V113, P1741, DOI 10.1542/peds.113.6.1741; OWENS P, 2003, AHRQ PUBLICATION; Raymond J, 2000, INFECT CONT HOSP EP, V21, P260, DOI 10.1086/501755; Rennick JE, 2002, J DEV BEHAV PEDIATR, V23, DOI 10.1097/00004703-200206000-00002	9	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					201	202						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652590				2022-12-28	WOS:000226309600008
J	Bradley, J; Dai, ZR; Erni, R; Browning, N; Graham, G; Weber, P; Smith, J; Hutcheon, I; Ishii, H; Bajt, S; Floss, C; Stadermann, F; Sandfords, S				Bradley, J; Dai, ZR; Erni, R; Browning, N; Graham, G; Weber, P; Smith, J; Hutcheon, I; Ishii, H; Bajt, S; Floss, C; Stadermann, F; Sandfords, S			An astronomical 2175 angstrom feature in interplanetary dust particles	SCIENCE			English	Article							ULTRAVIOLET EXTINCTION CURVES; MOLECULAR-CLOUD MATERIAL; IDENTIFICATION; CONSTRAINTS; GRAINS; SHAPES; CARBON	The 2175 angstrom extinction feature is the strongest (visible-ultraviolet) spectral signature of dust in the interstellar medium. Forty years after its discovery, the origin of the feature and the nature of the carrier(s) remain controversial. Using a transmission electron microscope, we detected a 5.7-electron volt (2175 angstrom) feature in interstellar grains embedded within interplanetary dust particles (IDPs). The carriers are organic carbon and amorphous silicates that are abundant in IDPs and in the interstellar medium. These multiple carriers may explain the enigmatic invariant central wavelength and variable bandwidth of the astronomical 2175 angstrom feature.	Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA; Univ Calif Davis, Dept Chem Engn, Davis, CA 95616 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Natl Ctr Electron Microscopy, Berkeley, CA 94720 USA; Washington Univ, Space Sci Lab, St Louis, MO 63130 USA; NASA, Ames Res Ctr, Astrophys Branch, Moffett Field, CA 94035 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Washington University (WUSTL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Bradley, J (corresponding author), Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA.	jbradley@igpp.ucllnl.org	Bajt, Sasa/O-4695-2019; 1.4, ALS Beamline/I-1886-2014; Dai, Zurong/E-6732-2010; Bajt, Sasa/G-2228-2010; Erni, Rolf/P-7435-2014; Weber, Peter Kilian/AAP-9517-2020	Bajt, Sasa/0000-0002-7163-7602; Erni, Rolf/0000-0003-2391-5943; Weber, Peter Kilian/0000-0001-6022-6050; Browning, Nigel/0000-0003-0491-251X; Graham, Gerard/0000-0002-7801-204X; Dai, Zurong/0000-0002-4209-8718; Ishii, Hope/0000-0002-7976-5078				Bernstein MP, 2003, ASTROPHYS J, V582, pL25, DOI 10.1086/345941; Bradley JP, 2005, TREATISE GEOCHEM, V1, P689; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; BRADLEY JP, 2004, LUNAR PLANET SCI, V35; BRION CE, 1982, AM I PHYS C P, V9, P429; BROWNLEE DE, 2000, LUNAR PLANET SCI, V31, P1921; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; Draine B, 1989, INTERSTELLAR DUST, P313; Draine BT, 2003, ANNU REV ASTRON ASTR, V41, P241, DOI 10.1146/annurev.astro.41.011802.094840; FITZPATRICK EL, 1986, ASTROPHYS J, V307, P286, DOI 10.1086/164415; FITZPATRICK EL, 1990, ASTROPHYS J SUPPL S, V72, P163, DOI 10.1086/191413; Floss C, 2004, SCIENCE, V303, P1355, DOI 10.1126/science.1093283; Floss C., 2004, LUNAR PLANET SCI, VXXXV; Flynn GJ, 2004, ADV SPACE RES-SERIES, V33, P57, DOI 10.1016/j.asr.2003.09.036; Henning T, 1998, SCIENCE, V282, P2204, DOI 10.1126/science.282.5397.2204; Henning T., 2004, ASTROPHYS DUST ASP C, V309, P603; Keller LP, 2004, GEOCHIM COSMOCHIM AC, V68, P2577, DOI 10.1016/j.gca.2003.10.044; KELLER LP, 1994, AIP C P, V310, P51; Messenger S, 2003, SCIENCE, V300, P105, DOI 10.1126/science.1080576; Messenger S, 2000, NATURE, V404, P968, DOI 10.1038/35010053; Sandford SA, 1996, METEORIT PLANET SCI, V31, P449, DOI 10.1111/j.1945-5100.1996.tb02088.x; SANDFORD SA, 1989, ICARUS, V82, P146, DOI 10.1016/0019-1035(89)90028-6; STECHER TP, 1969, ASTROPHYS J, V157, pL125, DOI 10.1086/180400; STEEL TM, 1987, ASTROPHYS J, V315, P337, DOI 10.1086/165138	26	61	61	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					244	247		10.1126/science.1106717	http://dx.doi.org/10.1126/science.1106717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653501				2022-12-28	WOS:000226361900039
J	Azevedo, RBR; Lohaus, R; Braun, V; Gumbel, M; Umamaheshwar, M; Agapow, PM; Houthoofd, W; Platzer, U; Borgonie, G; Meinzer, HP; Leroi, AM				Azevedo, RBR; Lohaus, R; Braun, V; Gumbel, M; Umamaheshwar, M; Agapow, PM; Houthoofd, W; Platzer, U; Borgonie, G; Meinzer, HP; Leroi, AM			The simplicity of metazoan cell lineages	NATURE			English	Article							MORPHOLOGICAL COMPLEXITY; EVOLUTION; NEMATODE; FRAMEWORK	Developmental processes are thought to be highly complex, but there have been few attempts to measure and compare such complexity across different groups of organisms(1-5). Here we introduce a measure of biological complexity based on the similarity between developmental and computer programs(6-9). We define the algorithmic complexity of a cell lineage as the length of the shortest description of the lineage based on its constituent sublineages(9-13). We then use this measure to estimate the complexity of the embryonic lineages of four metazoan species from two different phyla. We find that these cell lineages are significantly simpler than would be expected by chance. Furthermore, evolutionary simulations show that the complexity of the embryonic lineages surveyed is near that of the simplest lineages evolvable, assuming strong developmental constraints on the spatial positions of cells and stabilizing selection on cell number. We propose that selection for decreased complexity has played a major role in moulding metazoan cell lineages.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; German Canc Res Ctr, Div Med & Biol Informat, D-69120 Heidelberg, Germany; Univ London Imperial Coll Sci Technol & Med, Dept Biol, Ascot SL5 7PY, Berks, England; Univ Ghent, Dept Biol, B-9000 Ghent, Belgium	University of Houston System; University of Houston; Helmholtz Association; German Cancer Research Center (DKFZ); Imperial College London; Ghent University	Azevedo, RBR (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.	razevedo@uh.edu	Azevedo, Ricardo/AAV-3963-2021	Azevedo, Ricardo/0000-0001-5402-7071				APTER MJ, 1965, J THEOR BIOL, V8, P244, DOI 10.1016/0022-5193(65)90075-5; Arthur W, 2002, NATURE, V415, P757, DOI 10.1038/415757a; ATLAN H, 1990, B MATH BIOL, V52, P335, DOI 10.1007/BF02458575; Bennett, 1990, COMPLEXITY ENTROPY P, P137; Bonner JT., 1988, EVOLUTION COMPLEXITY; Borgonie G, 2000, NEMATOLOGY, V2, P65, DOI 10.1163/156854100508908; Braun V, 2003, BIOINFORMATICS, V19, P851, DOI 10.1093/bioinformatics/btg087; Brooks D.R., 1988, EVOLUTION ENTROPY UN; Carroll SB, 2001, NATURE, V409, P1102, DOI 10.1038/35059227; Fontana W, 1998, SCIENCE, V280, P1451, DOI 10.1126/science.280.5368.1451; GEARD N, IN PRESS ARTIF LIFE; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GOODWIN BC, 1993, J THEOR BIOL, V163, P135, DOI 10.1006/jtbi.1993.1112; Houthoofd W, 2003, DEV BIOL, V258, P57, DOI 10.1016/S0012-1606(03)00101-5; Kauffman S. A., 1993, ORIGINS ORDER; McShea DW, 1996, EVOLUTION, V50, P477, DOI 10.1111/j.1558-5646.1996.tb03861.x; Minelli, 2003, DEV ANIMAL FORM ONTO; NISHIDA H, 1987, DEV BIOL, V121, P526, DOI 10.1016/0012-1606(87)90188-6; PAPENTIN F, 1980, J THEOR BIOL, V87, P421, DOI 10.1016/0022-5193(80)90230-1; Raff R.A., 1996, SHAPE LIFE; Richardson MK, 2003, J EXP ZOOL PART B, V296B, P8, DOI 10.1002/jez.b.00013; Schnabel R, 1997, DEV BIOL, V184, P234, DOI 10.1006/dbio.1997.8509; SOMMER RJ, 1994, DEVELOPMENT, P85; Stadler BMR, 2001, J THEOR BIOL, V213, P241, DOI 10.1006/jtbi.2001.2423; STERNBERG PW, 1982, DEV BIOL, V93, P181, DOI 10.1016/0012-1606(82)90251-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Szathmary E, 2001, SCIENCE, V292, P1315, DOI 10.1126/science.1060852; VALENTINE JW, 1994, PALEOBIOLOGY, V20, P131, DOI 10.1017/S0094837300012641; Wagner GP, 2004, MODULARITY IN DEVELOPMENT AND EVOLUTION, P338	30	28	29	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					152	156		10.1038/nature03178	http://dx.doi.org/10.1038/nature03178			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650738				2022-12-28	WOS:000226252200036
J	Hopkinson, CS; Vallino, JJ				Hopkinson, CS; Vallino, JJ			Efficient export of carbon to the deep ocean through dissolved organic matter	NATURE			English	Article							PACIFIC SUBTROPICAL GYRE; EASTERN NORTH PACIFIC; TEMPORAL VARIABILITY; SARGASSO SEA; FLUX; RADIOCARBON; PHOSPHORUS; DYNAMICS; NITROGEN; CYCLE	Oceanic dissolved organic carbon (DOC) constitutes one of the largest pools of reduced carbon in the biosphere. Estimated DOC export from the surface ocean represents 20% of total organic carbon flux to the deep ocean(1-3), which constitutes a primary control on atmospheric carbon dioxide levels(4). DOC is the carbon component of dissolved organic matter (DOM) and an accurate quantification of DOM pools, fluxes and their controls is therefore critical to understanding oceanic carbon cycling. DOC export is directly coupled with dissolved organic nitrogen and phosphorus export. However, the C:N:P stoichiometry (by atoms) of DOM dynamics is poorly understood. Here we study the stoichiometry of the DOM pool and of DOM decomposition in continental shelf, continental slope and central ocean gyre environments. We find that DOM is remineralized and produced with a C:N:P stoichiometry of 199:20:1 that is substantially lower than for bulk pools (typically >775:54:1), but greater than for particulate organic matter (106:16:1-the Redfield ratio). Thus for a given mass of new N and P introduced into surface water, more DOC can be exported than would occur at the Redfield ratio. This may contribute to the excess respiration estimated to occur in the interior ocean(5). Our results place an explicit constraint on global carbon export and elemental balance via advective pathways.	Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02543 USA	Marine Biological Laboratory - Woods Hole	Hopkinson, CS (corresponding author), Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02543 USA.	chopkins@mbl.edu	Vallino, Joseph/J-6177-2015	Vallino, Joseph/0000-0002-4184-4512; hopkinson, charles/0000-0002-7331-8322				Bauer JE, 1998, J GEOPHYS RES-OCEANS, V103, P2867, DOI 10.1029/97JC02545; BAUER JE, 1992, NATURE, V357, P667, DOI 10.1038/357667a0; Carlson C., 2002, BIOGEOCHEMISTRY MARI, P91, DOI DOI 10.1016/B978-012323841-2/50006-3; CARLSON CA, 1994, NATURE, V371, P405, DOI 10.1038/371405a0; Church MJ, 2002, LIMNOL OCEANOGR, V47, P1, DOI 10.4319/lo.2002.47.1.0001; Clark LL, 1998, NATURE, V393, P426, DOI 10.1038/30881; del Giorgio PA, 2002, NATURE, V420, P379, DOI 10.1038/nature01165; Emerson S, 1997, NATURE, V389, P951, DOI 10.1038/40111; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; GARSIDE C, 1982, MAR CHEM, V11, P159, DOI 10.1016/0304-4203(82)90039-1; Hansell D.A., 2002, BIOGEOCHEMISTRY MARI, P685716, DOI [10.1016/B978-012323841-2/50017-8, DOI 10.1016/B978-012323841-2/50017-8]; Hopkinson CS, 2002, DEEP-SEA RES PT II, V49, P4461, DOI 10.1016/S0967-0645(02)00125-X; Hopkinson CS, 1997, CONT SHELF RES, V17, P473, DOI 10.1016/S0278-4343(96)00046-5; JACKSON GA, 1985, DEEP-SEA RES, V32, P223, DOI 10.1016/0198-0149(85)90030-5; Karl DM, 1999, ECOSYSTEMS, V2, P181, DOI 10.1007/s100219900068; LE B, 1995, MAR CHEM, V51, P17; Loh AN, 2000, DEEP-SEA RES PT I, V47, P2287, DOI 10.1016/S0967-0637(00)00027-3; MARTIN JH, 1987, DEEP-SEA RES, V34, P267, DOI 10.1016/0198-0149(87)90086-0; Melillo JM, 2002, SCIENCE, V298, P2173, DOI 10.1126/science.1074153; MOPPER K, 1991, NATURE, V353, P60, DOI 10.1038/353060a0; Peltzer ET, 1996, DEEP-SEA RES PT II, V43, P1155, DOI 10.1016/0967-0645(95)00014-3; Press WH, 1992, COMPUT PHYS, V6, P274, DOI [10.1063/1.4823074, DOI 10.1063/1.4823074]; Qian JG, 1996, ANAL CHEM, V68, P3090, DOI 10.1021/ac960370z; SARMIENTO JL, 1992, ENVIR SCI R, V43, P317; Six KD, 1996, GLOBAL BIOGEOCHEM CY, V10, P559, DOI 10.1029/96GB02561; Sondergaard M, 2000, LIMNOL OCEANOGR, V45, P1097, DOI 10.4319/lo.2000.45.5.1097; TUPAS L, 1997, 977 SOEST U HAW; WALSH T, 1989, MAR CHEM, V26, P151; WILLIAMS PM, 1980, OCEANOL ACTA, V3, P471; WILLIAMS PM, 1987, NATURE, V330, P246, DOI 10.1038/330246a0	30	191	206	8	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					142	145		10.1038/nature03191	http://dx.doi.org/10.1038/nature03191			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650735				2022-12-28	WOS:000226252200033
J	Winslow, MM; Crabtree, GR				Winslow, MM; Crabtree, GR			Decoding calcium signaling	SCIENCE			English	Editorial Material							CA2+ CHANNELS; T-LYMPHOCYTES; IDENTIFICATION; CELLS		Stanford Univ, Howard Hughes Med Inst, Program Immunol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Winslow, MM (corresponding author), Stanford Univ, Howard Hughes Med Inst, Program Immunol, Stanford, CA 94305 USA.	crabtree@stanford.edu						Badou A, 2005, SCIENCE, V307, P117, DOI 10.1126/science.1100582; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Escayg A, 2000, AM J HUM GENET, V66, P1531, DOI 10.1086/302909; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Kotturi MF, 2003, J BIOL CHEM, V278, P46949, DOI 10.1074/jbc.M309268200; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Schmalhofer WA, 2002, BIOCHEMISTRY-US, V41, P7781, DOI 10.1021/bi025722c; Stokes L, 2004, J BIOL CHEM, V279, P19566, DOI 10.1074/jbc.M401481200	11	19	20	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					56	57		10.1126/science.1108163	http://dx.doi.org/10.1126/science.1108163			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637261				2022-12-28	WOS:000226214300030
J	Bloche, MG; Marks, JH				Bloche, MG; Marks, JH			When doctors go to war.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Georgetown Univ, Ctr Law, Washington, DC 20057 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Matrix Chambers, London, England	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bloche, MG (corresponding author), Georgetown Univ, Ctr Law, Washington, DC 20057 USA.		Marks, Jonathan/A-9696-2009					*JOINT INT DEBR CT, 2004, AB GHRAIB IR; Lewis Neil A, 2004, N Y Times Web, pA14; Miles SH, 2004, LANCET, V364, P725, DOI 10.1016/S0140-6736(04)16902-X; 2004, USU FAC WORKSH MIL H	4	73	77	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					3	6		10.1056/NEJMp048346	http://dx.doi.org/10.1056/NEJMp048346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635106				2022-12-28	WOS:000226112500001
J	Marlow, N; Wolke, D; Bracewell, MA; Samara, M				Marlow, N; Wolke, D; Bracewell, MA; Samara, M		EPICure Study Grp	Neurologic and developmental disability at six years of age after extremely preterm birth.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEEKS GESTATION; EXTREMELY PREMATURE; CHILDREN BORN; INFANTS BORN; WEIGHT; OUTCOMES; LESS	BACKGROUND: Birth before 26 weeks of gestation is associated with a high prevalence of neurologic and developmental disabilities in the infant during the first two years of life. METHODS: We studied at the time of early school age children who had been born at 25 or fewer completed weeks of gestation in the United Kingdom and Ireland in 1995. Each child had been evaluated at 30 months of age. The children underwent standardized cognitive and neurologic assessments at six years of age. Disability was defined as severe (indicating dependence on caregivers), moderate, or mild according to predetermined criteria. RESULTS: Of 308 surviving children, 241 (78 percent) were assessed at a median age of six years and four months; 160 classmates delivered at full term served as a comparison group. Although the use of test reference norms showed that cognitive impairment (defined as results more than 2 SD below the mean) was present in 21 percent of the children born extremely preterm (as compared with 1 percent in the standardized data), this value rose to 41 percent when the results were compared with those for their classmates. The rates of severe, moderate, and mild disability were 22 percent, 24 percent, and 34 percent, respectively; disabling cerebral palsy was present in 30 children (12 percent). Among children with severe disability at 30 months of age, 86 percent still had moderate-to-severe disability at 6 years of age. In contrast, other disabilities at the age of 30 months were poorly predictive of developmental problems at 6 years of age. CONCLUSIONS: Among extremely preterm children, cognitive and neurologic impairment is common at school age. A comparison with their classroom peers indicates a level of impairment that is greater than is recognized with the use of standardized norms.	Univ Nottingham, Sch Human Dev, Nottingham NG7 2RD, England; Univ Bristol, Dept Community Based Med, Unit Perinatal & Pediat Epidemiol, Bristol, Avon, England; Univ Hertfordshire, Dept Psychol, Hatfield AL10 9AB, Herts, England	University of Nottingham; University of Bristol; University of Hertfordshire	Marlow, N (corresponding author), Queens Med Ctr, Acad Div Child Hlth, Level E E Block, Nottingham NG7 2UH, England.	neil.marlow@nottingham.ac.uk	Fahimifar, Sepideh/M-5303-2019; Marlow, Neil/D-2918-2009; Wolke, Dieter/C-5372-2008; Samara, Muthanna/B-4101-2009	Marlow, Neil/0000-0001-5890-2953; Wolke, Dieter/0000-0003-0304-268X; 	MRC [G0401525] Funding Source: UKRI; Medical Research Council [G0401525] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; Botting N, 1997, J CHILD PSYCHOL PSYC, V38, P931, DOI 10.1111/j.1469-7610.1997.tb01612.x; BROTHWOOD M, 1986, ARCH DIS CHILD, V61, P559, DOI 10.1136/adc.61.6.559; Costeloe K, 2000, PEDIATRICS, V106, P659, DOI 10.1542/peds.106.4.659; D'Angio CT, 2002, PEDIATRICS, V110, P1094, DOI 10.1542/peds.110.6.1094; Doyle LW, 2001, PEDIATRICS, V108, P134, DOI 10.1542/peds.108.1.134; DRILLIEN CM, 1972, DEV MED CHILD NEUROL, V14, P575, DOI 10.1111/j.1469-8749.1972.tb02639.x; Emsley HCA, 1998, ARCH DIS CHILD-FETAL, V78, pF99, DOI 10.1136/fn.78.2.F99; EVANS P, 1987, DEV MED CHILD NEUROL, V29, P272; Fanaroff AA, 2003, PEDIATR RES, V53, p398A; Finnstrom O, 2003, J Matern Fetal Neonatal Med, V14, P75, DOI 10.1080/jmf.14.2.75.84; Flynn JR, 1999, AM PSYCHOL, V54, P5, DOI 10.1037/0003-066X.54.1.5; Griffiths R., 1970, ABILITIES YOUNG CHIL; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Hille ETM, 2001, LANCET, V357, P1641, DOI 10.1016/S0140-6736(00)04818-2; Jacobs SE, 2000, ACTA PAEDIATR, V89, P959; JOHNSON A, 1993, BRIT MED J, V306, P1715, DOI 10.1136/bmj.306.6894.1715; Kaufman A. S, 2004, KAUFMAN BRIEF INTELL; Korkman M, 1998, MANUAL NEPSY DEV NEU; Kraemer S, 2000, BRIT MED J, V321, P1609, DOI 10.1136/bmj.321.7276.1609; Laucht M, 2000, J AM ACAD CHILD PSY, V39, P1229, DOI 10.1097/00004583-200010000-00009; Lorenz JM, 2001, PEDIATRICS, V108, P1269, DOI 10.1542/peds.108.6.1269; Lorenz JM, 1998, ARCH PEDIAT ADOL MED, V152, P425, DOI 10.1001/archpedi.152.5.425; NELSON KB, 1982, PEDIATRICS, V69, P529; *NPEU ORHA, 1995, DIS PER CAR REP 2 WO; Piecuch RE, 1997, OBSTET GYNECOL, V90, P809, DOI 10.1016/S0029-7844(97)00429-8; Saigal S, 2003, PEDIATRICS, V112, P943, DOI 10.1542/peds.112.4.943; Taylor HG, 2000, DEV NEUROPSYCHOL, V17, P289, DOI 10.1207/S15326942DN1703_2; Taylor HG, 2002, CHILD NEUROPSYCHOL, V8, P163, DOI 10.1076/chin.8.3.163.13500; Whitfield MF, 1997, ARCH DIS CHILD-FETAL, V77, pF85, DOI 10.1136/fn.77.2.F85; WOLKE D, 1994, EUR J PEDIATR, V153, P906, DOI 10.1007/s004310050239; Wolke D, 1999, DEV MED CHILD NEUROL, V41, P94, DOI 10.1017/S0012162299000201; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	35	1305	1344	4	104	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					9	19		10.1056/NEJMoa041367	http://dx.doi.org/10.1056/NEJMoa041367			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635108				2022-12-28	WOS:000226112500003
J	Postma, E; van Noordwijk, AJ				Postma, E; van Noordwijk, AJ			Gene flow maintains a large genetic difference in clutch size at a small spatial scale	NATURE			English	Article							TIT PARUS-MAJOR; NATURAL-POPULATIONS; GREAT TIT; ADAPTIVE DIVERGENCE; ISLAND POPULATION; SELECTION; IMMIGRATION; DISPERSAL; LAKE	Understanding the capacity of natural populations to adapt to their local environment is a central topic in evolutionary biology. Phenotypic differences between populations may have a genetic basis, but showing that they reflect different adaptive optima requires the quantification of both gene flow and selection(1-3). Good empirical data are rare(4). Using data on a spatially structured island population of great tits (Parus major), we show here that a persistent difference in mean clutch size between two subpopulations only a few kilometres apart has a major genetic component. We also show that immigrants from outside the island carry genes for large clutches. But gene flow into one subpopulation is low, as a result of a low immigration rate together with strong selection against immigrant genes. This has allowed for adaptation to the island environment and the maintenance of small clutches. In the other area, however, higher gene flow prevents local adaptation and maintains larger clutches. We show that the observed small-scale genetic difference in clutch size is not due to divergent selection on the island, but to different levels of gene flow from outside the island. Our findings illustrate the large effect of immigration on the evolution of local adaptations and on genetic population structure.	Netherlands Inst Ecol, Ctr Terr Ecol, NL-6666 ZG Heteren, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Postma, E (corresponding author), Netherlands Inst Ecol, Ctr Terr Ecol, POB 40, NL-6666 ZG Heteren, Netherlands.	e.postma@nioo.knaw.nl	van noordwijk, arie/A-8880-2011; Postma, Erik/B-7258-2008	Postma, Erik/0000-0003-0856-1294				ARNOLD SJ, 1984, EVOLUTION, V38, P709, DOI [10.2307/2408383, 10.1111/j.1558-5646.1984.tb00344.x]; Bohonak AJ, 1999, Q REV BIOL, V74, P21, DOI 10.1086/392950; CLOBERT J, 1988, J ANIM ECOL, V57, P287, DOI 10.2307/4779; DHONDT AA, 1990, NATURE, V348, P723, DOI 10.1038/348723a0; Ebert D, 2002, SCIENCE, V295, P485, DOI 10.1126/science.1067485; EHRLICH PR, 1969, SCIENCE, V165, P1228, DOI 10.1126/science.165.3899.1228; GARANT D, NATURE; GROENEVELD E, 1992, ARCH TIERZUCHT, V35, P399; Hendry AP, 2002, EVOLUTION, V56, P1199; Hendry AP, 2001, EVOLUTION, V55, P459, DOI 10.1554/0014-3820(2001)055[0459:PMATAD]2.0.CO;2; Institute SAS, 1996, SAS STAT US GUID; Keller LF, 2001, P ROY SOC B-BIOL SCI, V268, P1387, DOI 10.1098/rspb.2001.1607; KING RB, 1995, EVOLUTION, V49, P885, DOI 10.1111/j.1558-5646.1995.tb02324.x; Kingsolver JG, 2001, AM NAT, V157, P245, DOI 10.1086/319193; Krebs J, 1991, BEHAV ECOLOGY EVOLUT; Kruuk LEB, 2004, PHILOS T R SOC B, V359, P873, DOI 10.1098/rstb.2003.1437; LAMBRECHTS MM, 1993, IBIS, V135, P451, DOI 10.1111/j.1474-919X.1993.tb02118.x; Lenormand T, 2002, TRENDS ECOL EVOL, V17, P183, DOI 10.1016/S0169-5347(02)02497-7; Lynch M., 1998, GENETICS ANAL QUANTI; Marr AB, 2002, EVOLUTION, V56, P131; MCCLEERY RH, 1990, POPULATION BIOL PASS, P423; Neumaier A, 1998, GENET SEL EVOL, V30, P3, DOI 10.1051/gse:19980101; Quinn GP, 2003, EXPT DESIGN DATA ANA; SLATKIN M, 1985, ANNU REV ECOL SYST, V16, P393, DOI 10.1146/annurev.ecolsys.16.1.393; Stanton ML, 1997, AM NAT, V150, P143, DOI 10.1086/286061; STEARNS SC, 1980, EVOLUTION, V34, P67; Storfer A, 1998, EVOLUTION, V52, P558, DOI 10.1111/j.1558-5646.1998.tb01654.x; VANNOORDWIJK AJ, 1981, NETH J ZOOL, V31, P342; VANTIENDEREN PH, 1988, J EVOLUTION BIOL, V1, P117, DOI 10.1046/j.1420-9101.1988.1020117.x; Verhulst S, 1996, J EVOLUTION BIOL, V9, P771, DOI 10.1046/j.1420-9101.1996.9060771.x	30	204	209	2	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2005	433	7021					65	68		10.1038/nature03083	http://dx.doi.org/10.1038/nature03083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635410				2022-12-28	WOS:000226117100036
J	Holland, R; Lenaghan, E; Harvey, I; Smith, R; Shepstone, L; Lipp, A; Christou, M; Evans, D; Hand, C				Holland, R; Lenaghan, E; Harvey, I; Smith, R; Shepstone, L; Lipp, A; Christou, M; Evans, D; Hand, C			Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY-PATIENTS; PHARMACIST; EQ-5D	Objective To determine whether home based medication review by pharmacists affects hospital readmission rates among older people. Design Randomised controlled trial. Setting Home based medication review after discharge from acute or community hospitals in Norfolk and Suffolk. Participants 872 patients aged over 80 recruited during an emergency admission (any cause) if returning to own home or warden controlled accommodation and taking two or more drugs daily on discharge. Intervention Two home visits by a pharmacist within two weeks and eight weeks of discharge to educate patients and carers about their drugs, remove out of date drugs, inform general practitioners of drug reactions or interactions, and inform the local pharmacist if a compliance aid is needed. Control arm received usual care. Main outcome measure Total emergency readmissions to hospital at six months. Secondary outcomes included death and quality of life measured with the EQ-5D. Results By six months 178 readmissions had occurred in the control group and 234 in the intervention group (rate ratio = 1.30, 95% confidence interval 1.07 to 1.58; P = 0.009, Poisson model). 49 deaths Occurred in the intervention group compared with 63 in the control group (hazard ratio = 0.75, 0.52 to 1.10; P = 0.14). EQ-5D scores decreased (worsened) by a mean of 0.14 in the control group and 0.13 in the intervention group (difference = 0.01, -0.05 to 0.06; P = 0.84 t test). Conclusions The intervention was associated with a significantly higher rate of hospital admissions and did not significantly improve quality of life or reduce deaths. Further research is needed to explain this counterintuitive finding and to identify more effective methods of medication review.	Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Acad Pharm Practice Unit, Norwich NR4 7TJ, Norfolk, England; Great Yarmouth Teaching Primary Care Trust, Great Yarmouth NR14 8AB, Norfolk, England; Suffolk Publ Hlth Network, Pharmaceut Serv, Ipswich IP3 8LS, Suffolk, England	University of East Anglia; University of East Anglia	Holland, R (corresponding author), Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England.	r.holland@uea.ac.uk		Holland, Richard/0000-0002-4663-6923; Smith, Richard/0000-0003-3837-6559				Al-Eidan FA, 2002, BRIT J CLIN PHARMACO, V53, P163, DOI 10.1046/j.0306-5251.2001.01531.x; Al-Rashed SA, 2002, BRIT J CLIN PHARMACO, V54, P657, DOI 10.1046/j.1365-2125.2002.01707.x; Begley S., 1997, INT J PHARM PRACT, V5, P111, DOI [10.1111/j.2042-7174.1997.tb00895.x, DOI 10.1111/J.2042-7174.1997.TB00895.X, DOI 10.1111/j.2042-7174.1997.tb00895.x]; Department of Health, 2001, NAT SERV FRAM OLD PE; GOODYER II, 1995, BR J CLIN PRACT, V19, P173; Holland R, 2004, HEALTH ECON, V13, P793, DOI 10.1002/hec.858; JITAPUNKUL S, 1991, AGE AGEING, V20, P332, DOI 10.1093/ageing/20.5.332; Krska J, 2001, AGE AGEING, V30, P205, DOI 10.1093/ageing/30.3.205; LAW R, 1976, BMJ-BRIT MED J, V1, P565, DOI 10.1136/bmj.1.6009.565; Lowe CJ, 2000, BRIT J CLIN PHARMACO, V50, P172, DOI 10.1046/j.1365-2125.2000.00247.x; National Health Service (NHS), GUIDANCE ROLE USE; Nazareth I, 2001, AGE AGEING, V30, P33, DOI 10.1093/ageing/30.1.33; Office for National Statistics, UK CENS 2001; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; *PRESCR SUPP UN, 2001, ASTRO PUS CHAPT STAR; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; RAYNOR DK, 1993, BRIT MED J, V306, P1158, DOI 10.1136/bmj.306.6886.1158; Stewart S, 1998, J AM GERIATR SOC, V46, P174, DOI 10.1111/j.1532-5415.1998.tb02535.x; Tidermark J, 2003, QUAL LIFE RES, V12, P1069, DOI 10.1023/A:1026193812514; Varma S, 1999, PHARMACOTHERAPY, V19, P860, DOI 10.1592/phco.19.10.860.31565; WRIGHT EC, 1993, LANCET, V342, P909, DOI 10.1016/0140-6736(93)91951-H; Zermansky AG, 2001, BRIT MED J, V323, P1340, DOI 10.1136/bmj.323.7325.1340	22	210	215	1	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2005	330	7486					293	295		10.1136/bmj.38338.674583.AE	http://dx.doi.org/10.1136/bmj.38338.674583.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15665005	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000226843700018
J	Katz, D				Katz, D			Palestine: the assault on health and other war crimes - Israeli situation is not analogous to apartheid regime	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									UCL, London WC1E 6BT, England	University of London; University College London	Katz, D (corresponding author), UCL, Mortimer St, London WC1E 6BT, England.	d.katz@ucl.ac.uk						Hendrickse R, 1998, UCT NEWS, V25, P48; Jenkins T, 2004, LANCET, V364, P36; POGRUND B, 2004, JERUSALEM SOMETHING, P251; Summerfield D, 2004, BRIT MED J, V329, P924, DOI 10.1136/bmj.329.7471.924; 2004, BMJ, V329, P1101	5	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2005	330	7485					255	255		10.1136/bmj.330.7485.255	http://dx.doi.org/10.1136/bmj.330.7485.255			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15677676	Green Published			2022-12-28	WOS:000226779400039
J	Song, CM; Havlin, S; Makse, HA				Song, CM; Havlin, S; Makse, HA			Self-similarity of complex networks	NATURE			English	Article							INTERNET	Complex networks have been studied extensively owing to their relevance to many real systems such as the world-wide web, the Internet, energy landscapes and biological and social networks(1-5). A large number of real networks are referred to as 'scale-free' because they show a power-law distribution of the number of links per node(1,6,7). However, it is widely believed that complex networks are not invariant or self-similar under a length-scale transformation. This conclusion originates from the 'small-world' property of these networks, which implies that the number of nodes increases exponentially with the 'diameter' of the network(8-11), rather than the power-law relation expected for a self-similar structure. Here we analyse a variety of real complex networks and find that, on the contrary, they consist of self-repeating patterns on all length scales. This result is achieved by the application of a renormalization procedure that coarse-grains the system into boxes containing nodes within a given 'size'. We identify a power-law relation between the number of boxes needed to cover the network and the size of the box, defining a finite self-similar exponent. These fundamental properties help to explain the scale-free nature of complex networks and suggest a common self-organization dynamics.	CUNY City Coll, Levich Inst, New York, NY 10031 USA; CUNY City Coll, Dept Phys, New York, NY 10031 USA; Bar Ilan Univ, Minerva Ctr, IL-52900 Ramat Gan, Israel; Bar Ilan Univ, Dept Phys, IL-52900 Ramat Gan, Israel	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System; City College of New York (CUNY); Bar Ilan University; Bar Ilan University	Makse, HA (corresponding author), CUNY City Coll, Levich Inst, New York, NY 10031 USA.	makse@mailaps.org	Havlin, Shlomo/ABF-1527-2020					Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 1999, NATURE, V401, P130, DOI 10.1038/43601; Amaral LAN, 2004, EUR PHYS J B, V38, P147, DOI 10.1140/epjb/e2004-00110-5; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bollobas B., 1985, RANDOM GRAPHS; BUNDE A, 1996, FRACTALS DISORDERED, pCH2; Dorogovtsev SN, 2003, EVOLUTION NETWORKS B; ERDOS P, 1960, B INT STATIST INST, V38, P343; Faloutsos M, 1999, COMP COMM R, V29, P251, DOI 10.1145/316194.316229; Feder J., 1988, FRACTALS; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; MILGRAM S, 1967, PSYCHOL TODAY, V2, P60, DOI DOI 10.1145/335305.335325; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Overbeek R, 2000, NUCLEIC ACIDS RES, V28, P123, DOI 10.1093/nar/28.1.123; Pastor-Satorras R, 2004, EVOLUTION STRUCTURE; Vicsek T, 1992, FRACTAL GROWTH PHENO; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Xenarios I, 2000, NUCLEIC ACIDS RES, V28, P289, DOI 10.1093/nar/28.1.289; 2000, DATABASE INTERACTING	19	933	993	24	224	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					392	395		10.1038/nature03248	http://dx.doi.org/10.1038/nature03248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674285	Green Submitted			2022-12-28	WOS:000226546200036
J	Tesfaye, S; Chaturvedi, N; Eaton, SEM; Ward, JD; Manes, C; Ionescu-Tirgoviste, C; Witte, DR; Fuller, JH				Tesfaye, S; Chaturvedi, N; Eaton, SEM; Ward, JD; Manes, C; Ionescu-Tirgoviste, C; Witte, DR; Fuller, JH		EURODIAB Prospective Complications	Vascular risk factors and diabetic neuropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN-RESISTANCE; PERIPHERAL NEUROPATHY; SENSORY NEUROPATHY; BLOOD-FLOW; CHOLESTEROL; PHOTOGRAPHY; RETINOPATHY; PREVALENCE; MORTALITY; SMOKING	BACKGROUND: Other than glycemic control, there are no treatments for diabetic neuropathy. Thus, identifying potentially modifiable risk factors for neuropathy is crucial. We studied risk factors for the development of distal symmetric neuropathy in 1172 patients with type 1 diabetes mellitus from 31 centers participating in the European Diabetes (EURODIAB) Prospective Complications Study. METHODS: Neuropathy was assessed at baseline (1989 to 1991) and at follow-up (1997 to 1999), with a mean (+/-SD) follow-up of 7.3+/-0.6 years. A standardized protocol included clinical evaluation, quantitative sensory testing, and autonomic-function tests. Serum lipids and lipoproteins, glycosylated hemoglobin, and the urinary albumin excretion rate were measured in a central laboratory. RESULTS: At follow-up, neuropathy had developed in 276 of 1172 patients without neuropathy at baseline (23.5 percent). The cumulative incidence of neuropathy was related to the glycosylated hemoglobin value and the duration of diabetes. After adjustment for these factors, we found that higher levels of total and low-density lipoprotein cholesterol and triglycerides, a higher body-mass index, higher von Willebrand factor levels and urinary albumin excretion rate, hypertension, and smoking were all significantly associated with the cumulative incidence of neuropathy. After adjustment for other risk factors and diabetic complications, we found that duration of diabetes, current glycosylated hemoglobin value, change in glycosylated hemoglobin value during the follow-up period, body-mass index, and smoking remained independently associated with the incidence of neuropathy. Cardiovascular disease at baseline was associated with double the risk of neuropathy, independent of cardiovascular risk factors. CONCLUSIONS: This prospective study indicates that, apart from glycemic control, the incidence of neuropathy is associated with potentially modifiable cardiovascular risk factors, including a raised triglyceride level, body-mass index, smoking, and hypertension.	Royal Hallamshire Hosp, Diabet Res Unit, Sheffield S10 2JF, S Yorkshire, England; Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, Fac Med, London, England; Papageorgiou Gen Teaching Hosp, Dept Internal Med, Thessaloniki, Greece; Papageorgiou Gen Teaching Hosp, Ctr Diabet, Thessaloniki, Greece; Inst Diabet Nutr & Metab Dis, Bucharest, Romania; UCL Royal Free & Univ Coll Med Sch, Dept Epidemiol & Publ Hlth, EURODIAB, London, England	University of Sheffield; Imperial College London; Papageorgiou Hospital; Papageorgiou Hospital; University of London; University College London; UCL Medical School	Tesfaye, S (corresponding author), Royal Hallamshire Hosp, Diabet Res Unit, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	solomon.tesfaye@sth.nhs.uk	Witte, Daniel/AAF-9535-2019; Witte, Daniel R/C-1722-2008	Witte, Daniel/0000-0002-0769-2922; Witte, Daniel R/0000-0002-0769-2922; Tesfaye, Solomon/0000-0003-1190-1472				ALDINGTON SJ, 1995, DIABETOLOGIA, V38, P437, DOI 10.1007/BF00410281; [Anonymous], 1995, ANN INTERN MED, V122, P561, DOI 10.7326/0003-4819-122-8-199504150-00001; BUCOLO G, 1973, CLIN CHEM, V19, P476; Cameron NE, 2001, DIABETOLOGIA, V44, P1973, DOI 10.1007/s001250100001; Chaturvedi N, 2001, KIDNEY INT, V60, P219, DOI 10.1046/j.1523-1755.2001.00789.x; Chaturvedi N, 2001, DIABETES CARE, V24, P284, DOI 10.2337/diacare.24.2.284; Coppini DV, 2000, J CLIN EPIDEMIOL, V53, P519, DOI 10.1016/S0895-4356(99)00170-5; DEFRONZO RA, 1982, DIABETES, V31, P795, DOI 10.2337/diab.31.9.795; Dyck PJ, 1999, DIABETES CARE, V22, P1479, DOI 10.2337/diacare.22.9.1479; Eaton SEM, 2003, DIABETOLOGIA, V46, P934, DOI 10.1007/s00125-003-1127-3; Erbey JR, 1999, METABOLISM, V48, P1337; Erbey JR, 1999, METABOLISM, V48, P531, DOI 10.1016/S0026-0495(99)90116-6; FORD I, 1992, THROMB HAEMOSTASIS, V68, P628; Forrest KYZ, 1997, DIABETES, V46, P665, DOI 10.2337/diabetes.46.4.665; Forsblom CM, 1998, DIABETOLOGIA, V41, P1253, DOI 10.1007/s001250051062; FRANKLIN GM, 1990, AM J EPIDEMIOL, V131, P633, DOI 10.1093/oxfordjournals.aje.a115547; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GADIA MT, 1987, DIABETES CARE, V10, P613, DOI 10.2337/diacare.10.5.613; HARRIS M, 1993, DIABETES CARE, V16, P1446, DOI 10.2337/diacare.16.11.1446; JOHN WG, 1993, CLIN CHEM, V39, P663; KEARNEY EM, 1987, J CLIN PATHOL, V40, P465, DOI 10.1136/jcp.40.4.465; MASER RE, 1989, DIABETES, V38, P1456, DOI 10.2337/diabetes.38.11.1456; MITCHELL BD, 1990, DIABETES CARE, V13, P434, DOI 10.2337/diacare.13.4.434; Rose G, 1982, CARDIOVASCULAR SURVE; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; SIEDEL J, 1983, CLIN CHEM, V29, P1075; Soedamah-Muthu SS, 2004, DIABETES CARE, V27, P530, DOI 10.2337/diacare.27.2.530; TESFAYE S, 1993, DIABETOLOGIA, V36, P1266, DOI 10.1007/BF00400804; Tesfaye S, 1996, DIABETOLOGIA, V39, P1377, DOI 10.1007/s001250050586; *URODIAB IDDM COMP, 1994, DIABETOLOGIA, V37, P278; Vinik AI, 2000, DIABETOLOGIA, V43, P957, DOI 10.1007/s001250051477; WARNICK GR, 1978, J LIPID RES, V19, P65; WILES PG, 1991, DIABETIC MED, V8, P157, DOI 10.1111/j.1464-5491.1991.tb01563.x; Williams KV, 2000, DIABETES, V49, P626, DOI 10.2337/diabetes.49.4.626; WITTE DR, IN PRESS DIABETOLOGI; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697; ZENERE BM, 1995, DIABETES CARE, V18, P975, DOI 10.2337/diacare.18.7.975	37	843	907	3	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					341	350		10.1056/NEJMoa032782	http://dx.doi.org/10.1056/NEJMoa032782			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673800	Green Published			2022-12-28	WOS:000226535900006
J	Bird, J; Lubkowski, Z				Bird, J; Lubkowski, Z			Managing tsunami risk	LANCET			English	Editorial Material									Ove Arup & Partners, Arup Geotech, London W1T 4BQ, England		Bird, J (corresponding author), Ove Arup & Partners, Arup Geotech, London W1T 4BQ, England.	Juliet.Bird@arup.com						CHUNG RM, 1995, EARTHQUAKE SPECTR SA, V11, P1; *NAT OC ATM ADM, 2005, DEEP OC ASS REP TSUN; National Tsunami Hazard Mitigation Program, 2001, DES TSUN 7 PRINC PLA; SOKOLOWSKI T, 2001, P INT TSUN S AUG 7 9, P317; 2005, NEW CIVIL ENG   0106	5	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					271	273						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664203				2022-12-28	WOS:000226449600004
J	Hwang, ES; Szabo, SJ; Schwartzberg, PL; Glimcher, LH				Hwang, ES; Szabo, SJ; Schwartzberg, PL; Glimcher, LH			T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3	SCIENCE			English	Article							TEC FAMILY KINASES; TYROSINE PHOSPHORYLATION; LINEAGE COMMITMENT; SIGNALING PATHWAYS; MICE LACKING; DNA-BINDING; ITK; DIFFERENTIATION; ASTHMA	Cell Lineage specification depends on both gene activation and gene silencing, and in the differentiation of T helper progenitors to Th1 or Th2 effector cells, this requires the action of two opposing transcription factors, T-bet and GATA-3. T-bet is essential for the development of Th1 cells, and GATA-3 performs an equivalent role in Th2 development. We report that T-bet represses Th2 lineage commitment through tyrosine kinase-mediated interaction between the two transcription factors that interferes with the binding of GATA-3 to its target DNA. These results provide a novel function for tyrosine phosphorylation of a transcription factor in specifying alternate fates of a common progenitor cell.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; NHGRI, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Glimcher, LH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	lglimche@hsph.harvard.edu			NIAID NIH HHS [AI56296, AI48126] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056296, R01AI048126] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; HWANG ES, UNPUB; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Lucas JA, 2003, IMMUNOL REV, V191, P119, DOI 10.1034/j.1600-065X.2003.00029.x; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Pulichino AM, 2003, GENE DEV, V17, P738, DOI 10.1101/gad.1065703; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; Schaeffer EM, 2000, J EXP MED, V192, P987, DOI 10.1084/jem.192.7.987; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Schaeffer EM, 2001, NAT IMMUNOL, V2, P1183, DOI 10.1038/ni734; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Sullivan BM, 2003, P NATL ACAD SCI USA, V100, P15818, DOI 10.1073/pnas.2636938100; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Takesono A, 2002, J CELL SCI, V115, P3039; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	22	386	433	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					430	433		10.1126/science.1103336	http://dx.doi.org/10.1126/science.1103336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662016				2022-12-28	WOS:000226492300049
J	Cruickshank, A; Beetham, R; Holbrook, I; Watson, I; Wenham, P; Keir, G; White, P; Egner, W				Cruickshank, A; Beetham, R; Holbrook, I; Watson, I; Wenham, P; Keir, G; White, P; Egner, W			Lesson of the week - Spectrophotometry of cerebrospinal fluid in suspected subarachnoid haemorrhage	BMJ-BRITISH MEDICAL JOURNAL			English	Review								To underline the importance of correctly examining cerebrospinal fluid, we describe two patients with subarachnoid haemorrhage for whom cranial computerised tomography was normal and on whom lumbar puncture was subsequently done. Both had clear and colourless cerebrospinal fluid, but subsequent spectrophotometry showed bilirubin. Cerebral angiography then showed a ruptured aneurysm in each patient.	So Gen Hosp, Dept Biochem, Glasgow G51 4TF, Lanark, Scotland; Frenchay Hosp, Bristol BS16 1LE, Avon, England; York Hosp, York, N Yorkshire, England; Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England; Victoria Hosp, Kirckaldy, England; UCL Natl Hosp Neurol & Neurosurg, Dept Neuroimmunol, London, England; No Gen Hosp, Dept Immunol, UK NEQAS Immunol & Immunochem, Sheffield S5 7AU, S Yorkshire, England	University of Glasgow; Walton Centre; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Northern General Hospital	Cruickshank, A (corresponding author), So Gen Hosp, Dept Biochem, Glasgow G51 4TF, Lanark, Scotland.	anne.cruickshank@sgh.scot.nhs.uk		Watson, Ian D/0000-0003-2294-3715				Beetham R, 2003, ANN CLIN BIOCHEM, V40, P481; Edlow JA, 2002, ARCH PATHOL LAB MED, V126, P413; Fishman RA, 1980, CEREBROSPINAL FLUID; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Wasserberg J, 1997, BRIT MED J, V315, P1598, DOI 10.1136/bmj.315.7122.1598	5	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 15	2005	330	7483					138	138		10.1136/bmj.330.7483.138	http://dx.doi.org/10.1136/bmj.330.7483.138			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889PM	15649929	Green Published			2022-12-28	WOS:000226454900025
J	Bergeron, DE; Roach, PJ; Castleman, AW; Jones, N; Khanna, SN				Bergeron, DE; Roach, PJ; Castleman, AW; Jones, N; Khanna, SN			Al cluster superatoms as halogens in polyhalides and as alkaline earths in iodide salts	SCIENCE			English	Article							S-P HYBRIDIZATION; ALUMINUM CLUSTERS; ELECTRONIC-STRUCTURE; GALLIUM CLUSTERS; SHELL STRUCTURES; GAS-PHASE; METAL; REACTIVITY; ANIONS; APPROXIMATION	Two classes of gas-phase aluminum-iodine clusters have been identified whose stability and reactivity can be understood in terms of the spherical shell jellium model. Experimental reactivity studies show that the Al(13)l(x)(-) clusters exhibit pronounced stability for even numbers of I atoms. Theoretical investigations reveal that the enhanced stability is associated with complementary pairs of I atoms occupying the on-top sites on the opposing Al atoms of the Al-13(-) core. We also report the existence of another series, Al(14)l(x)(-), that exhibits stability for odd numbers of I atoms. This series can be described as consisting of an Al(14)l(3)(-) core upon which the I atoms occupy on-top locations around the Al atoms. The potential synthetic utility of superatom chemistry built upon these motifs is addressed.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Virginia Commonwealth Univ, Dept Phys, Richmond, VA 23284 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Virginia Commonwealth University	Castleman, AW (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.	awc@psu.edu	Bergeron, Denis E/I-4332-2013; Roach, Patrick/G-5615-2012	Bergeron, Denis E/0000-0003-1150-7950; 				Alonso JA, 2002, NANOTECHNOLOGY, V13, P253, DOI 10.1088/0957-4484/13/3/303; Ashman C, 1997, PHYS REV B, V55, P15868, DOI 10.1103/PhysRevB.55.15868; Bergeron DE, 2004, J CHEM PHYS, V121, P10456, DOI 10.1063/1.1806416; Bergeron DE, 2004, SCIENCE, V304, P84, DOI 10.1126/science.1093902; Bergeron DE, 2003, CHEM PHYS LETT, V371, P189, DOI 10.1016/S0009-2614(03)00242-2; BERGERON DE, UNPUB; Burkart S, 1999, CHEM PHYS LETT, V301, P546, DOI 10.1016/S0009-2614(98)01428-6; CASTLEMAN AW, 1987, J CHEM PHYS, V86, P3829, DOI 10.1063/1.451941; CHA CY, 1994, J CHEM PHYS, V100, P995, DOI 10.1063/1.466582; DEHEER WA, 1989, PHYS REV LETT, V63, P2834, DOI 10.1103/PhysRevLett.63.2834; Ekardt W, 1997, Z PHYS B CON MAT, V103, P305, DOI 10.1007/s002570050378; EKARDT W, 1984, PHYS REV B, V29, P1558, DOI 10.1103/PhysRevB.29.1558; FAGERQUIST CK, 1991, J PHYS CHEM-US, V95, P9176, DOI 10.1021/j100176a027; FAGERQUIST CK, 1991, J PHYS CHEM-US, V95, P9169, DOI 10.1021/j100176a026; HAAS A, 1991, PURE APPL CHEM, V63, P1577, DOI 10.1351/pac199163111577; HARMS AC, 1990, J AM CHEM SOC, V112, P5673, DOI 10.1021/ja00170a060; JACKSON K, 1990, PHYS REV B, V42, P3276, DOI 10.1103/PhysRevB.42.3276; Kawamata H, 2001, CHEM PHYS LETT, V337, P255, DOI 10.1016/S0009-2614(01)00198-1; KHANNA SN, 1992, PHYS REV LETT, V69, P1664, DOI 10.1103/PhysRevLett.69.1664; KNIGHT WD, 1984, PHYS REV LETT, V52, P2141, DOI 10.1103/PhysRevLett.52.2141; Leskiw BD, 2000, CHEM PHYS LETT, V316, P31, DOI 10.1016/S0009-2614(99)01295-6; Leskiw BD, 2001, J CHEM PHYS, V114, P1165, DOI 10.1063/1.1333017; LEUCHTNER RE, 1991, J CHEM PHYS, V94, P1093, DOI 10.1063/1.460716; LEUCHTNER RE, 1989, J CHEM PHYS, V91, P2753, DOI 10.1063/1.456988; Li X, 1998, PHYS REV LETT, V81, P1909, DOI 10.1103/PhysRevLett.81.1909; Li X, 2001, SCIENCE, V291, P859, DOI 10.1126/science.291.5505.859; Mananes A, 2003, J CHEM PHYS, V119, P5128, DOI 10.1063/1.1597673; PEDERSON MR, 1990, PHYS REV B, V41, P7453, DOI 10.1103/PhysRevB.41.7453; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Porezag D, 1999, PHYS REV A, V60, P2840, DOI 10.1103/PhysRevA.60.2840; Pramann A, 2001, CHEM PHYS LETT, V347, P366, DOI 10.1016/S0009-2614(01)01046-6; Rao BK, 1999, J CHEM PHYS, V111, P1890, DOI 10.1063/1.479458; Rao BK, 1999, J CLUST SCI, V10, P477, DOI 10.1023/A:1021948806958; Schnepf A, 2002, ANGEW CHEM INT EDIT, V41, P3533, DOI 10.1002/1521-3773(20021004)41:19<3532::AID-ANIE3532>3.0.CO;2-4; Schnockel H, 2002, POLYHEDRON, V21, P489, DOI 10.1016/S0277-5387(01)01028-2; Thomas OC, 2001, J CHEM PHYS, V114, P5514, DOI 10.1063/1.1349547; Thomas OC, 2001, J CHEM PHYS, V114, P9895, DOI 10.1063/1.1365110; Weiss K, 2003, Z ANORG ALLG CHEM, V629, P1175, DOI 10.1002/zaac.200300029; Weiss K, 2002, INT J MASS SPECTROM, V214, P383, DOI 10.1016/S1387-3806(02)00543-2	39	372	384	4	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					231	235		10.1126/science.1105820	http://dx.doi.org/10.1126/science.1105820			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653497				2022-12-28	WOS:000226361900035
J	Roderick, HL; Bootman, MD				Roderick, HL; Bootman, MD			Redoxing calcium from the ER	CELL			English	Editorial Material							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	Inositol 1,4,5-trisphosphate (InsP(3))-induced calcium release from the endoplasmic reticulum (ER) intracellular calcium store regulates cellular functions from the beginning of life at fertilization until death. In this issue of Cell, Mikoshiba and colleagues describe a novel mode of regulation of the InsP(3) receptor (InsP(3)R) governed by ER luminal redox status, calcium, and pH (Higo et al., 2005).	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Roderick, HL (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.		Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451; Roderick, Hywel/0000-0001-7065-3523	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C116, BBS/E/B/00001116] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Ching LL, 2000, CIRC RES, V87, P201, DOI 10.1161/01.RES.87.3.201; Choe CU, 2004, J BIOL CHEM, V279, P35551, DOI 10.1074/jbc.M311261200; Gyorke I, 2004, BIOPHYS J, V86, P2121, DOI 10.1016/S0006-3495(04)74271-X; Hanson CJ, 2004, CURR BIOL, V14, pR933, DOI 10.1016/j.cub.2004.10.019; Higo T, 2005, CELL, V120, P85, DOI 10.1016/j.cell.2004.11.048; Joseph SK, 1999, BIOCHEM J, V342, P153, DOI 10.1042/0264-6021:3420153; Li Y, 2004, J CELL BIOL, V164, P35, DOI 10.1083/jcb.200307010; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005	10	11	11	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 14	2005	120	1					4	5		10.1016/j.cell.2004.12.034	http://dx.doi.org/10.1016/j.cell.2004.12.034			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652474	Green Accepted, Bronze			2022-12-28	WOS:000226365400003
J	Morrison, G				Morrison, G			Mortgaging our future - The cost of medical education	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Morrison, G (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							*ASS AM MED COLL, 2002, AAMC REPORTER, V11; *BUR LAB STAT, 2004, SAL PHYS; *DIV MED ED, 2003, MED SCH GRAD QUEST 2; JOLLY P, 2004, MED SCH TUITION YOUN; PETERSDORF RG, 1991, ACAD MED, V66, P61, DOI 10.1097/00001888-199102000-00001	5	32	33	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					117	119		10.1056/NEJMp048089	http://dx.doi.org/10.1056/NEJMp048089			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647572				2022-12-28	WOS:000226251700002
J	Devereaux, PJ; Bhandari, M; Clarke, M; Montori, VM; Cook, DJ; Yusuf, S; Sackett, DL; Cina, CS; Walter, SD; Haynes, B; Schunemann, HJ; Norman, GR; Guyatt, GH				Devereaux, PJ; Bhandari, M; Clarke, M; Montori, VM; Cook, DJ; Yusuf, S; Sackett, DL; Cina, CS; Walter, SD; Haynes, B; Schunemann, HJ; Norman, GR; Guyatt, GH			Need for expertise based randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LEARNING-CURVE; FRACTURES; SURGERY	Surgical procedures are less likely to be rigorously evidence based than drug treatments because of difficulties with randomisation. Expertise based trials could be the way forward.	McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada; UK Cochrane Ctr, Oxford, England; Mayo Clin Coll Med, Dept Med, Rochester, MN USA; McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8S 4L8, Canada; Trout Res & Educ Ctr Irish Lake, Markdale, ON, Canada; SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA	McMaster University; McMaster University; Cochrane Centre; Mayo Clinic; McMaster University; Population Health Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Devereaux, PJ (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	philipj@mcmaster.ca	Devereaux, PJ/AAY-1757-2021; Devereaux, PJ/AAF-2862-2019; Walter, Stephen/AAB-5548-2022; Bhandari, Mohit/AAQ-1675-2021	Walter, Stephen/0000-0003-4157-8928; Yusuf, Salim/0000-0003-4776-5601; Montori, Victor/0000-0003-0595-2898; Schunemann, Holger/0000-0003-3211-8479; Devereaux, PJ/0000-0003-2935-637X				Alderman EL, 1996, NEW ENGL J MED, V335, P217; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 1995, Lancet, V346, P1179; Bhandari M, 2002, J BONE JOINT SURG AM, V84A, P388, DOI 10.2106/00004623-200203000-00009; Black N, 1999, WORLD J SURG, V23, P789, DOI 10.1007/s002689900581; Black N, 1996, BRIT MED J, V312, P1215; BRIDGEWATER B, 2004, BRIT MED J, V329, P121; Chalmers I, 1998, BMJ-BRIT MED J, V317, P1167, DOI 10.1136/bmj.317.7167.1167; DeTurris SV, 2002, J AM COLL SURGEONS, V194, P65, DOI 10.1016/S1072-7515(01)01114-0; Devereaux PJ, 2004, CLIN TRIALS, V1, P225; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Finkemeier CG, 2000, J ORTHOP TRAUMA, V14, P187, DOI 10.1097/00005131-200003000-00007; HAMPTON JR, 1993, LANCET, V341, P573; Haynes R Brian, 2002, ACP J Club, V136, pA11; Howes N, 1997, BRIT J SURG, V84, P1220; Lobato AC, 2002, J ENDOVASC THER, V9, P262, DOI 10.1583/1545-1550(2002)009<0262:LCFEAA>2.0.CO;2; Machler HE, 1999, ANN THORAC SURG, V67, P1001, DOI 10.1016/S0003-4975(99)00072-7; Menon VS, 2003, ANN ROY COLL SURG, V85, P10, DOI 10.1308/003588403321001345; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; PHILLIPS WA, 1985, J BONE JOINT SURG AM, V67A, P67, DOI 10.2106/00004623-198567010-00010; POLLOCK AV, 1993, BRIT J SURG, V80, P964, DOI 10.1002/bjs.1800800807; Prystowsky JB, 2002, SURGERY, V132, P663, DOI 10.1067/msy.2002.127550; RUDICEL S, 1985, J BONE JOINT SURG AM, V67A, P1284, DOI 10.2106/00004623-198567080-00026; Russell RCG, 1996, LANCET, V347, P1480; SOLOMON MJ, 1993, DIS COLON RECTUM, V36, P43, DOI 10.1007/BF02050300; VANDERLINDEN W, 1980, SURGERY, V87, P258; Wehbe MA, 1998, J BONE JOINT SURG AM, V80A, P1395, DOI 10.2106/00004623-199809000-00022; WIHLBORG O, 1990, ACTA ORTHOP SCAND, V61, P415, DOI 10.3109/17453679008993552; Wyrsch B, 1996, J BONE JOINT SURG AM, V78A, P1646, DOI 10.2106/00004623-199611000-00003	29	316	328	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	2005	330	7482					88	91		10.1136/bmj.330.7482.88	http://dx.doi.org/10.1136/bmj.330.7482.88			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887GR	15637373	Green Published			2022-12-28	WOS:000226294300024
J	Chen, B; Zeng, XB; Baumeister, U; Ungar, G; Tschierske, C				Chen, B; Zeng, XB; Baumeister, U; Ungar, G; Tschierske, C			Liquid crystalline networks composed of pentagonal, square, and triangular cylinders	SCIENCE			English	Article							CALAMITIC BOLAAMPHIPHILES; BLOCK MOLECULES; STAR TERPOLYMER; MORPHOLOGY	T-shaped molecules are designed in such a way that they self-organize into nanoscale liquid crystalline honeycombs based on polygons with any chosen number of sides. One of the phases reported here is a periodic organization of identical pentagonal cylinders; the other one is a structure composed of square-shaped and triangular cylinders,in the ratio 2:1. These two different packing motifs represent duals of the same topological class. The generalization, of the concept applied here allows the prediction of a whole range of unusual complex liquid crystalline phases.	Univ Halle Wittenberg, Inst Organ Chem, D-06120 Halle An Der Saale, Germany; Univ Halle Wittenberg, Inst Phys Chem, D-06120 Halle An Der Saale, Germany; Univ Sheffield, Dept Mat Engn, Sheffield S1 3JD, S Yorkshire, England; Univ Sheffield, Ctr Mol Mat, Sheffield S1 3JD, S Yorkshire, England	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; University of Sheffield; University of Sheffield	Tschierske, C (corresponding author), Univ Halle Wittenberg, Inst Organ Chem, Kurt Mothes Str 2, D-06120 Halle An Der Saale, Germany.	carsten.tschierske@chemie.uni-halle.de		Ungar, Goran/0000-0002-9743-2656				Bushby RJ, 2002, CURR OPIN COLLOID IN, V7, P343, DOI 10.1016/S1359-0294(02)00085-7; Caspar DLD, 1996, P NATL ACAD SCI USA, V93, P14271, DOI 10.1073/pnas.93.25.14271; Chen B, 2004, J AM CHEM SOC, V126, P8608, DOI 10.1021/ja0480015; CHEN B, 2004, ANGEW CHEM INT EDIT, V43, P4540; Cheng XH, 2003, J AM CHEM SOC, V125, P10977, DOI 10.1021/ja036213g; Collings P. J., 1997, INTRO LIQUID CRYSTAL; Deza M, 2000, J CHEM INF COMP SCI, V40, P550, DOI 10.1021/ci990066h; Grunbaum B., 1987, TILINGS PATTERNS; Hales TC, 2001, DISCRETE COMPUT GEOM, V25, P1, DOI 10.1007/s004540010071; Huckstadt H, 2000, MACROMOL CHEM PHYSIC, V201, P296; IMMIRZI A, 1977, ACTA CRYSTALLOGR A, V33, P216, DOI 10.1107/S0567739477000448; Kolbel M, 2001, J AM CHEM SOC, V123, P6809, DOI 10.1021/ja003124k; Moulton B, 2001, J AM CHEM SOC, V123, P9224, DOI 10.1021/ja016637f; MULLER A, 1999, ANGEW CHEM INT EDIT, V37, P3359; Penrose R., 1978, EUREKA, V39, P16; Penrose R., 1974, B I MATH APPL, V10, P266; Simon J., 2000, DESIGN MOL MAT SUPRA; Sioula S, 1998, MACROMOLECULES, V31, P8429, DOI 10.1021/ma980622t; SUGIMOTO T, 2000, FORMA, V15, P75; Tschierske C, 2001, J MATER CHEM, V11, P2647, DOI 10.1039/b102914m; Ungar G, 2003, SCIENCE, V299, P1208, DOI 10.1126/science.1078849; Yamauchi K, 2003, MACROMOLECULES, V36, P6962, DOI 10.1021/ma034840k; Zeng XB, 2004, NATURE, V428, P157, DOI 10.1038/nature02368	23	123	124	4	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					96	99		10.1126/science.1105612	http://dx.doi.org/10.1126/science.1105612			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637274				2022-12-28	WOS:000226214300044
J	Lohi, H; Young, EJ; Fitzmaurice, SN; Rusbridge, C; Chan, EM; Vervoort, M; Turnbull, J; Zhao, XC; Ianzano, L; Paterson, AD; Sutter, NB; Ostrander, EA; Andre, C; Shelton, GD; Ackerley, CA; Scherer, SW; Minassian, BA				Lohi, H; Young, EJ; Fitzmaurice, SN; Rusbridge, C; Chan, EM; Vervoort, M; Turnbull, J; Zhao, XC; Ianzano, L; Paterson, AD; Sutter, NB; Ostrander, EA; Andre, C; Shelton, GD; Ackerley, CA; Scherer, SW; Minassian, BA			Expanded repeat in canine epilepsy	SCIENCE			English	Article							PROGRESSIVE MYOCLONUS EPILEPSY; LAFORA-DISEASE; EXPANSION		Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Wey Referrals, Surrey GU21 5BP, England; Stone Lion Vet Ctr, London SW19 5AU, England; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; CNRS Genet & Dev, F-35043 Rennes, France; Univ Calif San Diego, La Jolla, CA 92093 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Fred Hutchinson Cancer Center; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Diego	Minassian, BA (corresponding author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	bminass@sickkids.ca	Paterson, Andrew/AAQ-7511-2020; Rusbridge, Clare/K-6560-2019; Rusbridge, Clare/A-3794-2019; Paterson, Andrew D/A-4088-2011; Scherer, Stephen W./B-3785-2013; Lohi, Hannes/F-4596-2011	Paterson, Andrew/0000-0002-9169-118X; Rusbridge, Clare/0000-0002-3366-2110; Rusbridge, Clare/0000-0002-3366-2110; Paterson, Andrew D/0000-0002-9169-118X; Scherer, Stephen W./0000-0002-8326-1999; Lohi, Hannes/0000-0003-1087-5532; Ostrander, Elaine/0000-0001-6075-9738; Young, Ted (Edwin)/0000-0003-4882-6752	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200325, ZIAHG200325] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Chan EM, 2004, NEUROLOGY, V63, P565, DOI 10.1212/01.WNL.0000133215.65836.03; Jacobs L.L., 1998, EVOLUTION TERTIARY M; Minassian BA, 2002, ADV NEUROL, V89, P199; Saha T, 2001, FEBS LETT, V491, P184, DOI 10.1016/S0014-5793(01)02190-1; Schoeman T, 2002, J VET INTERN MED, V16, P201, DOI 10.1892/0891-6640(2002)016&lt;0201:PSDIAD&gt;2.3.CO;2; Weinhaeusel A, 2003, HUM MUTAT, V22, P404, DOI 10.1002/humu.10276	6	122	130	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					81	81		10.1126/science.1102832	http://dx.doi.org/10.1126/science.1102832			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637270				2022-12-28	WOS:000226214300039
J	Andersen, JS; Lam, YW; Leung, AKL; Ong, SE; Lyon, CE; Lamond, AI; Mann, M				Andersen, JS; Lam, YW; Leung, AKL; Ong, SE; Lyon, CE; Lamond, AI; Mann, M			Nucleolar proteome dynamics	NATURE			English	Article							POLYMERASE I TRANSCRIPTION; RNA-SYNTHESIS; GENE; LOCALIZATION; INHIBITION	The nucleolus is a key organelle that coordinates the synthesis and assembly of ribosomal subunits and forms in the nucleus around the repeated ribosomal gene clusters. Because the production of ribosomes is a major metabolic activity, the function of the nucleolus is tightly linked to cell growth and proliferation, and recent data suggest that the nucleolus also plays an important role in cell-cycle regulation, senescence and stress responses(1-4). Here, using mass-spectrometry-based organellar proteomics and stable isotope labelling(5), we perform a quantitative analysis of the proteome of human nucleoli. In vivo fluorescent imaging techniques are directly compared to endogenous protein changes measured by proteomics. We characterize the flux of 489 endogenous nucleolar proteins in response to three different metabolic inhibitors that each affect nucleolar morphology. Proteins that are stably associated, such as RNA polymerase I subunits and small nuclear ribonucleoprotein particle complexes, exit from or accumulate in the nucleolus with similar kinetics, whereas protein components of the large and small ribosomal subunits leave the nucleolus with markedly different kinetics. The data establish a quantitative proteomic approach for the temporal characterization of protein flux through cellular organelles and demonstrate that the nucleolar proteome changes significantly over time in response to changes in cellular growth conditions.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 4HN, Scotland; Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	University of Dundee	Lamond, AI (corresponding author), Univ Dundee, Wellcome Trust Bioctr, MSI WTB Complex, Dundee DD1 4HN, Scotland.	a.i.lamond@dundee.ac.uk; mann@bmb.sdu.dk	Andersen, Jens S/L-2100-2015; Mann, Matthias/A-3454-2013	Andersen, Jens S/0000-0002-6091-140X; Mann, Matthias/0000-0003-1292-4799; Lam, Yun Wah/0000-0001-8929-5965; Leung, Anthony/0000-0001-5569-4036; Lamond, Angus/0000-0001-6204-6045	Wellcome Trust [073980] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lamond AI, 2003, CURR BIOL, V13, pR825, DOI 10.1016/j.cub.2003.10.012; Leung AKL, 2004, J CELL BIOL, V166, P787, DOI 10.1083/jcb.200405013; Leung AKL, 2002, J CELL BIOL, V157, P615, DOI 10.1083/jcb.200201120; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Masson C, 1996, EXP CELL RES, V226, P114, DOI 10.1006/excr.1996.0209; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; MAURAMATSU M, 1963, CANCER RES, V25, P693; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Olsen JV, 2004, MOL CELL PROTEOMICS, V3, P608, DOI 10.1074/mcp.T400003-MCP200; Olson Mark O J, 2004, Sci STKE, V2004, ppe10; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Raghavan A, 2002, NUCLEIC ACIDS RES, V30, P5529, DOI 10.1093/nar/gkf682; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P752, DOI 10.1016/S0955-0674(00)00165-4; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x	30	883	936	3	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					77	83		10.1038/nature03207	http://dx.doi.org/10.1038/nature03207			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635413				2022-12-28	WOS:000226117100039
J	Blilou, I; Xu, J; Wildwater, M; Willemsen, V; Paponov, I; Friml, J; Heidstra, R; Aida, M; Palme, K; Scheres, B				Blilou, I; Xu, J; Wildwater, M; Willemsen, V; Paponov, I; Friml, J; Heidstra, R; Aida, M; Palme, K; Scheres, B			The PIN auxin efflux facilitator network controls growth and patterning in Arabidopsis roots	NATURE			English	Article							CELL FATE; TRANSPORT; GENES; GRAVITROPISM; GRADIENTS; LOCALIZATION; THALIANA; MERISTEM; ENCODES; TROPISM	Local accumulation of the plant growth regulator auxin mediates pattern formation in Arabidopsis roots and influences outgrowth and development of lateral root- and shoot-derived primordia. However, it has remained unclear how auxin can simultaneously regulate patterning and organ outgrowth and how its distribution is stabilized in a primordium-specific manner. Here we show that five PIN genes collectively control auxin distribution to regulate cell division and cell expansion in the primary root. Furthermore, the joint action of these genes has an important role in pattern formation by focusing the auxin maximum and restricting the expression domain of PLETHORA (PLT) genes, major determinants for root stem cell specification. In turn, PLT genes are required for PIN gene transcription to stabilize the auxin maximum at the distal root tip. Our data reveal an interaction network of auxin transport facilitators and root fate determinants that control patterning and growth of the root primordium.	Univ Utrecht, Dept Mol Genet, NL-3584 CH Utrecht, Netherlands; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany	Utrecht University; University of Freiburg; Eberhard Karls University of Tubingen	Scheres, B (corresponding author), Univ Utrecht, Dept Mol Genet, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	b.scheres@bio.uu.nl	Xu, Jian/I-2921-2012; Paponov, Ivan A./H-9680-2016; Aida, Mitsuhiro/AAW-7703-2020; Friml, Jiri/D-9511-2012; Palme, Klaus/A-9524-2013	Xu, Jian/0000-0001-6194-6316; Paponov, Ivan A./0000-0002-2138-0722; Aida, Mitsuhiro/0000-0001-9000-7502; Friml, Jiri/0000-0002-8302-7596; Palme, Klaus/0000-0002-2728-3835; Blilou, Ikram/0000-0001-8003-3782; Scheres, Ben/0000-0001-5400-9578				Aida M, 2004, CELL, V119, P109, DOI 10.1016/j.cell.2004.09.018; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; DAVIES PJ, 1976, PHYSIOL PLANTARUM, V36, P333, DOI 10.1111/j.1399-3054.1976.tb02252.x; Dharmasiri N, 2004, TRENDS PLANT SCI, V9, P302, DOI 10.1016/j.tplants.2004.04.003; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2003, PLANT J, V34, P115, DOI 10.1046/j.1365-313X.2003.01705.x; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Gallois JL, 2004, GENE DEV, V18, P375, DOI 10.1101/gad.291204; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Geldner N, 2004, DEVELOPMENT, V131, P389, DOI 10.1242/dev.00926; Haecker A, 2004, DEVELOPMENT, V131, P657, DOI 10.1242/dev.00963; Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; KARES C, 1990, PLANT MOL BIOL, V15, P225, DOI 10.1007/BF00036909; Ljung K, 2002, PLANT MOL BIOL, V50, P309, DOI 10.1023/A:1016024017872; Long JA, 1998, DEVELOPMENT, V125, P3027; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Noh B, 2003, NATURE, V423, P999, DOI 10.1038/nature01716; Noh B, 2001, PLANT CELL, V13, P2441, DOI 10.1105/tpc.13.11.2441; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; Ottenschlager I, 2003, P NATL ACAD SCI USA, V100, P2987, DOI 10.1073/pnas.0437936100; Rashotte AM, 2000, PLANT PHYSIOL, V122, P481, DOI 10.1104/pp.122.2.481; Reinhardt D, 2003, NATURE, V426, P255, DOI 10.1038/nature02081; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; SCHERES B, 1994, DEVELOPMENT, V120, P2475; Sieberer T, 2000, CURR BIOL, V10, P1595, DOI 10.1016/S0960-9822(00)00861-7; Srivastava L.M, 2002, PLANT GROWTH DEV HOR, DOI 10.1016/B978-012660570-9/50152-0; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; Tsugeki R, 1999, P NATL ACAD SCI USA, V96, P12941, DOI 10.1073/pnas.96.22.12941; Utsuno K, 1998, PLANT CELL PHYSIOL, V39, P1111, DOI 10.1093/oxfordjournals.pcp.a029310; Willemsen V, 1998, DEVELOPMENT, V125, P521	37	1375	1461	39	677	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					39	44		10.1038/nature03184	http://dx.doi.org/10.1038/nature03184			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635403	Green Published			2022-12-28	WOS:000226117100029
J	Griekspoor, A; Nabarro, D; Loretti, A; Smith, I				Griekspoor, A; Nabarro, D; Loretti, A; Smith, I			Commentary: Change will not happen overnight	BRITISH MEDICAL JOURNAL			English	Editorial Material									WHO, Dept Hlth Act Criscs, CH-1211 Geneva 27, Switzerland; WHO, Director Gen Off, CH-1211 Geneva, Switzerland	World Health Organization; World Health Organization	Griekspoor, A (corresponding author), WHO, Dept Hlth Act Criscs, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	griekspoora@who.int						[Anonymous], FLOOD COMM DIS FACT; Benson C, 2004, MEASURING MITIGATION; de Goyet CD, 2000, LANCET, V356, P762, DOI 10.1016/S0140-6736(00)02642-8; EGELAND J, 2005, WORLD C DIS RED KOB; *PAN AM HLTH ORG D, DIS HUM ASS; Sachs JD, 2004, B WORLD HEALTH ORGAN, V82, P947; Twigg J., 2015, DISASTER RISK REDUCT; Walker P, 2005, BRIT MED J, V330, P247, DOI 10.1136/bmj.330.7485.247; 2004, HIGH LEV FOR MILL DE; 2003, INT M GOOD HUM DON S	10	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 29	2005	330	7485					250	251		10.1136/bmj.330.7485.250	http://dx.doi.org/10.1136/bmj.330.7485.250			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15677662	Green Published			2022-12-28	WOS:000226779400028
J	Kaba, RA; Cox, D; Lewis, A; Bloom, P; Dubrey, S				Kaba, RA; Cox, D; Lewis, A; Bloom, P; Dubrey, S			Intraocular haemorrhage after thrombolysis	LANCET			English	Editorial Material									Hillingdon Hosp, Uxbridge UB8 3NN, Middx, England		Kaba, RA (corresponding author), Hillingdon Hosp, Uxbridge UB8 3NN, Middx, England.	r.kaba@imperial.ac.uk							0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2005	365	9456					330	330						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664229				2022-12-28	WOS:000226449600037
J	Thompson, SG; Higgins, JPT				Thompson, SG; Higgins, JPT			Treating Individuals 4 - Can meta-analysis help target interventions at individuals most likely to benefit?	LANCET			English	Review							PLATELET GLYCOPROTEIN IIB/IIIA; ACUTE CORONARY SYNDROMES; RANDOMIZED CLINICAL-TRIALS; MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; UNDERLYING RISK; META-REGRESSION; PATIENT DATA; HETEROGENEITY; OVERVIEWS	Meta-analyses of randomised trials aim to summarise the effects of interventions across many patients, and can seem remote from the clinical issue of how individual patients should be treated and which patient groups will benefit the most from treatment. One method that attempts to address this point entails relating the overall effect in every trial to summaries of patient characteristics. This is called meta-regression. The interpretation of such analyses is not straightforward, however, because of a combination of confounding and other biases. Much more useful is to compare the outcomes for patient subgroups within trials and combine these results across trials. Unfortunately this method is rarely possible using published information, so analyses of individual patient data from trials are necessary. Also, although meta-analyses generally summarise an intervention's effect as a relative risk reduction, the groups of patients with the greatest absolute risk reduction have the most to gain.	Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	MRC Biostatistics Unit; University of Cambridge	Thompson, SG (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.	simon.thompson@mrc-bsu.cam.ac.uk	Higgins, Julian PT/H-4008-2011	Higgins, Julian PT/0000-0002-8323-2514				Altman D.G., 1991, PRACTICAL STAT MED R; [Anonymous], 2000, GUID US GLYC 2B 3A I; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BAILEY KR, 1994, CONTROL CLIN TRIALS, V15, P15, DOI 10.1016/0197-2456(94)90024-8; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; BERLIN JA, 1995, AM J EPIDEMIOL, V142, P383, DOI 10.1093/oxfordjournals.aje.a117645; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; Boersma E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1; BOSCH X, 2001, COCHRANE DB SYST REV, V4; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; Egger M, 2001, SYSTEMATIC REV HLTH; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; Harrington RA, 2002, CIRCULATION, V105, P316; Higgins JPT, 2001, STAT MED, V20, P2219, DOI 10.1002/sim.918; Higgins Julian, 2002, J Health Serv Res Policy, V7, P51, DOI 10.1258/1355819021927674; Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; McDonagh M S, 2000, Health Technol Assess, V4, P1; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; National Institute for Clinical Excellence, GUID METH TECHN APPR; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PHILLIPS AN, 1993, J CLIN EPIDEMIOL, V46, P1203, DOI 10.1016/0895-4356(93)90120-P; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; Sharp S, 1998, STATA TECH B, V7, DOI DOI 10.1002/SIM.1187/FULL); Sharp SJ, 1996, BRIT MED J, V313, P735; Sharp SJ, 2000, STAT MED, V19, P3251, DOI 10.1002/1097-0258(20001215)19:23<3251::AID-SIM625>3.0.CO;2-2; Simoons ML, 2001, LANCET, V357, P1915; Smeeth L, 1999, BMJ-BRIT MED J, V318, P1548, DOI 10.1136/bmj.318.7197.1548; Smith GD, 1997, BMJ-BRIT MED J, V315, P1610, DOI 10.1136/bmj.315.7122.1610; Sterne JAC, 2002, STAT MED, V21, P1513, DOI 10.1002/sim.1184; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Thompson SG, 2001, STAT METHODS MED RES, V10, P375, DOI 10.1191/096228001682157616; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; WITTES RE, 1987, STAT MED, V6, P269, DOI 10.1002/sim.4780060312; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	48	136	136	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2005	365	9456					341	346		10.1016/S0140-6736(05)17790-3	http://dx.doi.org/10.1016/S0140-6736(05)17790-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664231				2022-12-28	WOS:000226449600039
J	Kaim, W				Kaim, W			Odd electron on nitrogen: A metal-stabilized aminyl radical	SCIENCE			English	Editorial Material							GALACTOSE-OXIDASE; CATALYSIS; REACTIVITY		Univ Stuttgart, Inst Anorgan Chem, D-70550 Stuttgart, Germany; No Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA	University of Stuttgart; Northern Illinois University	Kaim, W (corresponding author), Univ Stuttgart, Inst Anorgan Chem, D-70550 Stuttgart, Germany.	kaim@iac.uni-stuttgart.de						Banerjee R, 2003, CHEM REV, V103, P2083, DOI 10.1021/cr0204395; Buttner T, 2005, SCIENCE, V307, P235, DOI 10.1126/science.1106070; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; GROSS R, 1985, ANGEW CHEM INT EDIT, V24, P856, DOI 10.1002/anie.198508561; Kaim W, 2003, DALTON T, P761, DOI 10.1039/b210193a; Miller J.S., 2001, MAGNETISM MOL MAT; POHL K, 1988, INORG CHEM, V27, P440, DOI 10.1021/ic00276a003; Sieger M, 2004, DALTON T, P3815, DOI 10.1039/b411892h; SIGEL A, 1999, METAL IONS BIOL SYST, V36; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Wang YD, 1998, SCIENCE, V279, P537, DOI 10.1126/science.279.5350.537; Whittaker JW, 2003, CHEM REV, V103, P2347, DOI 10.1021/cr020425z	12	17	17	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2005	307	5707					216	217		10.1126/science.1107345	http://dx.doi.org/10.1126/science.1107345			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653492				2022-12-28	WOS:000226361900029
J	Kent, DV; Tauxe, L				Kent, DV; Tauxe, L			Corrected Late Triassic latitudes for continents adjacent to the North Atlantic	SCIENCE			English	Article							PALEOMAGNETIC CORRELATION; GEOMAGNETIC-FIELD; SEDIMENTARY-ROCKS; INCLINATION ERROR; SHALLOW BIAS; DIPOLE FIELD; FUNDY BASIN; PANGEA-B; AMERICA; RECONSTRUCTION	We use a method based on a statistical geomagnetic field model to recognize and correct for inclination error in sedimentary rocks from early Mesozoic rift basins in North America, Greenland, and Europe. The congruence of the corrected sedimentary results and independent data from igneous rocks on a regional scale indicates that a geocentric axial dipole field operated in the Late Triassic. The corrected paleolatitudes indicate a faster poleward drift of similar to0.6 degrees per million years for this part of Pangea and suggest that the equatorial humid belt in the Late Triassic was about as wide as it is today.	Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08854 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	Rutgers State University New Brunswick; Columbia University; University of California System; University of California San Diego; Scripps Institution of Oceanography	Kent, DV (corresponding author), Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08854 USA.	dvk@rci.rutgers.edu		Kent, Dennis/0000-0002-7677-2993				Briden JC, 1999, J GEOL SOC LONDON, V156, P317, DOI 10.1144/gsjgs.156.2.0317; BULLARD E, 1965, PHILOS TR R SOC S-A, V258, P41, DOI 10.1098/rsta.1965.0020; Clemmensen LB, 1998, PALAEOGEOGR PALAEOCL, V140, P135, DOI 10.1016/S0031-0182(98)00043-1; CLEMMENSEN LB, 1980, GEOL SURV GEENLAND B, V136, P5; CONSTABLE CG, 1988, J GEOPHYS RES, V93, P11; Crowley T. J, 1991, OXFORD MONOGR GEOL G, V18; DENT DV, 1999, J GEOPHYS RES, V104, P12; Gilder S, 2003, EARTH PLANET SC LETT, V206, P587, DOI 10.1016/S0012-821X(02)01074-9; HODYCH JP, 1992, GEOLOGY, V20, P51, DOI 10.1130/0091-7613(1992)020<0051:DTMITE>2.3.CO;2; HODYCH JP, 1988, CAN J EARTH SCI, V25, P1972, DOI 10.1139/e88-185; HOSPERS J, 1954, NATURE, V173, P1183, DOI 10.1038/1731183a0; HUBERT JF, 1980, GEOLOGY, V8, P516, DOI 10.1130/0091-7613(1980)8<516:EDFOLT>2.0.CO;2; Johnson CL, 1997, GEOPHYS J INT, V131, P643, DOI 10.1111/j.1365-246X.1997.tb06604.x; Kelley SP, 1997, METEORIT PLANET SCI, V32, P629, DOI 10.1111/j.1945-5100.1997.tb01548.x; Kent DV, 1996, B GEOL SOC DENMARK, V42, P121; Kent DV, 1997, GEOL SOC AM BULL, V109, P366, DOI 10.1130/0016-7606(1997)109<0366:POUTCS>2.3.CO;2; Kent DV, 2000, EARTH PLANET SC LETT, V179, P311, DOI 10.1016/S0012-821X(00)00117-5; KENT DV, 1995, J GEOPHYS RES, V100, P14; King RF., 1955, GEOPHYSICAL SUPPLEME, V7, P115, DOI [10.1111/j.1365-246X.1955.tb06558.x, DOI 10.1111/J.1365-246X.1955.TB06558.X]; Krijgsman W, 2004, EARTH PLANET SC LETT, V222, P685, DOI 10.1016/j.epsl.2004.03.007; LAROCHELLE A, 1967, J GEOPHYS RES, V72, P4163, DOI 10.1029/JZ072i016p04163; Marzoli A, 1999, SCIENCE, V284, P616, DOI 10.1126/science.284.5414.616; McElwain JC, 1999, SCIENCE, V285, P1386, DOI 10.1126/science.285.5432.1386; Merrill RT, 2003, PHYS EARTH PLANET IN, V139, P171, DOI 10.1016/j.pepi.2003.07.016; Muttoni G, 2003, EARTH PLANET SC LETT, V215, P379, DOI 10.1016/S0012-821X(03)00452-7; Olsen PE, 1996, GEOL SOC AM BULL, V108, P40, DOI 10.1130/0016-7606(1996)108<0040:HRSOTN>2.3.CO;2; OPDYKE ND, 1961, J GEOPHYS RES, V66, P1941, DOI 10.1029/JZ066i006p01941; PARRISH JT, 1993, J GEOL, V101, P215, DOI 10.1086/648217; Pohl J., 1971, Z GEOPHYS, V37, P857; PREVOT M, 1989, GEOLOGY, V17, P1007, DOI 10.1130/0091-7613(1989)017<1007:PCONSV>2.3.CO;2; Robbins E.I., 1988, TRIASSIC JURASSIC RI, P649; Robertson W. A., 1967, CAN J EARTH SCI, V4, P641; Rochette P, 2001, ANN GEOFIS, V44, P649; ROEST WR, 1989, GEOLOGY, V17, P1000, DOI 10.1130/0091-7613(1989)017<1000:SFSITL>2.3.CO;2; ROY JL, 1972, EARTH PLANET SC LETT, V14, P103, DOI 10.1016/0012-821X(72)90089-1; Si JW, 2001, TERRA NOVA, V13, P471, DOI 10.1046/j.1365-3121.2001.00383.x; SMOOT JP, 1991, PALAEOGEOGR PALAEOCL, V84, P369, DOI 10.1016/0031-0182(91)90055-V; Tauxe L, 2004, GEOPHYS MONOGR SER, V145, P101, DOI 10.1029/145GM08; TAUXE L, 1984, GEOPHYS J ROY ASTR S, V76, P543, DOI 10.1111/j.1365-246X.1984.tb01909.x; Torsvik TH, 2002, GEOPHYS J INT, V151, P771, DOI 10.1046/j.1365-246X.2002.01799.x; Van der Voo R, 2001, EARTH PLANET SC LETT, V187, P71, DOI 10.1016/S0012-821X(01)00285-0; WESTPHAL M, 1993, EARTH PLANET SC LETT, V117, P15, DOI 10.1016/0012-821X(93)90114-O; WILSON KM, 1994, GEOL SOC AM SPEC PAP, V288, P91; WITTE WK, 1991, J GEOPHYS RES, V96, P19	44	149	153	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2005	307	5707					240	244		10.1126/science.1105826	http://dx.doi.org/10.1126/science.1105826			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653500	Green Submitted			2022-12-28	WOS:000226361900038
J	Krantz, MJ; Lowery, CM				Krantz, MJ; Lowery, CM			Giant Osborn waves in hypothermia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Denver Hlth Med Ctr, Denver, CO 80204 USA	Denver Health Medical Center	Krantz, MJ (corresponding author), Denver Hlth Med Ctr, Denver, CO 80204 USA.								0	16	17	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					184	184		10.1056/NEJMicm030851	http://dx.doi.org/10.1056/NEJMicm030851			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647581				2022-12-28	WOS:000226251700011
J	Romero, HE; Bolton, K; Rosen, A; Eklund, PC				Romero, HE; Bolton, K; Rosen, A; Eklund, PC			Atom collision-induced resistivity of carbon nanotubes	SCIENCE			English	Article								We report the observation of unusually strong and systematic changes in the electron transport in metallic single-walled carbon nanotubes that are undergoing collisions with inert gas atoms or small molecules. At fixed gas temperature and pressure, changes in the resistance and thermopower of thin films are observed that scale as roughly M-1/3, where M is the mass of the colliding gas species (He, Ar, Ne, Kr, Xe, CH4, and N-2). Results of molecular dynamics simulations are also presented that show that the maximum deformation of the tube wall upon collision and the total energy transfer between the colliding atom and the nanotube also exhibit a roughly M-1/3 dependence. it appears that the transient deformation (or dent) in the tube wait may provide a previously unknown scattering mechanism needed to explain the atom collision-induced changes in the electrical transport.	Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA; Univ Gothenburg, Sch Phys & Engn Phys, Dept Expt Phys, SE-41296 Gothenburg, Sweden; Chalmers Univ Technol, SE-41296 Gothenburg, Sweden	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Gothenburg; Chalmers University of Technology	Eklund, PC (corresponding author), Penn State Univ, Dept Phys, University Pk, PA 16802 USA.	pce3@psu.edu						Adu CKW, 2001, CHEM PHYS LETT, V337, P31, DOI 10.1016/S0009-2614(01)00159-2; Allen P. B., 1980, SUPERCONDUCTIVITY D; Barnard R. D., 1972, THERMOELECTRICITY ME; Bolton K, 2002, PHYS CHEM CHEM PHYS, V4, P4481, DOI 10.1039/b200581f; Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Ghosh S, 2003, SCIENCE, V299, P1042, DOI 10.1126/science.1079080; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Lu JQ, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.156601; Park CJ, 1999, PHYS REV B, V60, P10656, DOI 10.1103/PhysRevB.60.10656; Rinzler AG, 1998, APPL PHYS A-MATER, V67, P29, DOI 10.1007/s003390050734; Romero HE, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.205410; ROMERO HE, UNPUB; Rossiter P. L., 1987, ELECT RESISTIVITY ME; Saito R, 1998, PHYS PROPERTIES CARB; Sumanasekera GU, 2000, PHYS REV LETT, V85, P1096, DOI 10.1103/PhysRevLett.85.1096; Sumanasekera GU, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.166801; Vavro J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.065503; Yu MF, 2000, PHYS REV LETT, V85, P1456, DOI 10.1103/PhysRevLett.85.1456	19	51	54	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					89	93		10.1126/science.1102004	http://dx.doi.org/10.1126/science.1102004			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637273				2022-12-28	WOS:000226214300042
J	Dansinger, ML; Gleason, JA; Griffith, JL; Selker, HP; Schaefer, EJ				Dansinger, ML; Gleason, JA; Griffith, JL; Selker, HP; Schaefer, EJ			Comparison of the Atkins, Ornish, Weight watchers, and Zone diets for weight loss and heart disease risk reduction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-CARBOHYDRATE-DIET; LOW-FAT DIET; RANDOMIZED-TRIAL; CARDIOVASCULAR RISK; BODY-COMPOSITION; POPULAR DIETS; OBESITY; OVERWEIGHT; PROGRAM; PLASMA	Context The scarcity of data addressing the health effects of popular diets is an Important public health concern, especially since patients and physicians are interested in using popular diets as individualized eating strategies for disease prevention. Objective To assess adherence rates and the effectiveness of 4 popular diets (Atkins, Zone, Weight Watchers, and Ornish) for weight loss and cardiac risk factor reduction. Design Setting, and Participants A single-center randomized trial at an academic medical center in Boston, Mass, of overweight or obese (body mass index: mean, 35; range, 27-42) adults aged 22 to 72 years with known hypertension, dyslipidemia, or fasting hyperglycemia. Participants were enrolled starting July 18, 2000, and randomized to 4 popular diet groups until January 24, 2002. Intervention A total of 1-60 participants were randomly assigned to either Atkins (carbohydrate restriction, n=40), Zone (macronutrient balance, n=40), Weight Watchers (calorie restriction, n=40), or Ornish (fat restriction, n=40) diet groups. After 2 months of maximum effort, participants selected their own levels of dietary adherence. Main Outcome Measures One-year changes in baseline weight and cardiac risk factors, and self-selected dietary adherence rates per self-report. Results Assuming no change from baseline for participants who discontinued the study, mean (SD) weight loss at 1 year was 2.1 (4.8) kg for Atkins (21 [53%] of 40 participants completed, P=.009), 3.2 (6.0) kg for Zone (26 [65%] of 40 completed,P=.002), 3.0 (4.9) kg for Weight Watchers (26 [65%] of 40 completed, P<.001), and 3.3 (7.3) kg for Ornish (20 [50%] of 40 completed, P=.007). Greater effects were observed in study completers. Each diet significantly reduced the low-density lipoprotein/high-density lipoprotein (HDL) cholesterol ratio by approximately 10% (all P<.05), with no significant effects on blood pressure or glucose at 1 year. Amount of weight loss was associated with self-reported dietary adherence level (r=0.60; P<.001) but not with diet type (r=0.07; P=.40). For each diet, decreasing levels of total/HDL cholesterol, C-reactive protein, and insulin were significantly associated with weight loss (mean r=0.36, 0.37, and 0.39, respectively) with no significant difference between diets (P=.48, P=57, P=31, respectively). Conclusions Each popular diet modestly reduced body weight and several cardiac risk factors at 1 year. Overall dietary adherence rates were low, although increased adherence was associated with greater weight loss and cardiac risk factor reductions for each diet group.	Tufts Univ, Tufts New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Atherosclerosis Res Lab, Boston, MA 02111 USA; Tufts Univ, Div Endocrinol Diabet & Metab, Boston, MA 02111 USA; Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Lipid Metab Lab, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts University; United States Department of Agriculture (USDA)	Dansinger, ML (corresponding author), Tufts Univ, Tufts New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Atherosclerosis Res Lab, Box 216,Boston Dispensary 342,750 Washington St, Boston, MA 02111 USA.	mdansinger@tufts-nemc.org	Biguzzi, Felipe A/E-4724-2015		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000060] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER; AHRQ HHS [T32 HS00060] Funding Source: Medline; NCRR NIH HHS [M01-RR00054] Funding Source: Medline; NHLBI NIH HHS [HL57477] Funding Source: Medline; NIDDK NIH HHS [P30DK46200] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson JW, 2000, J AM COLL NUTR, V19, P578, DOI 10.1080/07315724.2000.10718955; ATKINS R, 1995, ATKINS NEW DIET COOK; Atkins RC, 1998, ATKINS NEW DIET REVO; Blackburn GL, 2001, CLEV CLIN J MED, V68, P761, DOI 10.3949/ccjm.68.9.761; Bonow RO, 2003, NEW ENGL J MED, V348, P2057, DOI 10.1056/NEJMp030053; Brand-Miller JC, 2003, NUTR REV, V61, pS49, DOI 10.1301/nr.2003.may.S49-S55; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; BRINTON EA, 1990, J CLIN INVEST, V85, P144, DOI 10.1172/JCI114405; Cheuvront SN, 2003, J AM COLL NUTR, V22, P9, DOI 10.1080/07315724.2003.10719271; Connor WE, 1997, NEW ENGL J MED, V337, P566; CRAWFORD PB, 1994, J AM DIET ASSOC, V94, P626, DOI 10.1016/0002-8223(94)90158-9; Eisenstein J, 2002, NUTR REV, V60, P189, DOI 10.1301/00296640260184264; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; Jarvis M, 2002, J STRENGTH COND RES, V16, P50, DOI 10.1519/00124278-200202000-00009; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; Katan MB, 1997, NEW ENGL J MED, V337, P563; Kennedy ET, 2001, J AM DIET ASSOC, V101, P411, DOI 10.1016/S0002-8223(01)00108-0; Koertge J, 2003, AM J CARDIOL, V91, P1316, DOI 10.1016/S0002-9149(03)00320-5; Landry N, 2003, AM J CLIN NUTR, V77, P580, DOI 10.1093/ajcn/77.3.580; Lowe MR, 1999, OBES RES, V7, P51, DOI 10.1002/j.1550-8528.1999.tb00390.x; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; Meckling KA, 2004, J CLIN ENDOCR METAB, V89, P2717, DOI 10.1210/jc.2003-031606; NIH, 2017, NIH POLICY GUIDELINE; ORNISH D, 1997, EVERY DAY COOKING D; Pagano-Therrien Jesica, 2003, Nurse Pract, V28, P14, DOI 10.1097/00006205-200303000-00001; PAGANOTHERRIEN J, 2003, NURSE PRACT, V28, P14; Riley RE, 1999, CLIN SPORT MED, V18, P691, DOI 10.1016/S0278-5919(05)70176-9; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; SEARS B, 1997, ZONE PERFECT MEALS M; Sears B., 1995, ZONE DIETARY ROAD MA; Sondike SB, 2003, J PEDIATR-US, V142, P253, DOI 10.1067/mpd.2003.4; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Ware JH, 2003, NEW ENGL J MED, V348, P2136, DOI 10.1056/NEJMe030054; *WEIGHT WATCH PUBL, 1998, WEIGHT WATCH NEW COM; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	41	1100	1123	4	189	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					43	53		10.1001/jama.293.1.43	http://dx.doi.org/10.1001/jama.293.1.43			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632335				2022-12-28	WOS:000226102100020
J	Mehta, SR; Yusuf, S; Diaz, R; Zhu, J; Pais, P; Xavier, D; Paolasso, E; Ahmed, R; Xie, CC; Kazmi, K; Tai, J; Orlandini, A; Pogue, J; Liu, LS				Mehta, SR; Yusuf, S; Diaz, R; Zhu, J; Pais, P; Xavier, D; Paolasso, E; Ahmed, R; Xie, CC; Kazmi, K; Tai, J; Orlandini, A; Pogue, J; Liu, LS		CREATE-ECLA Trial Grp Investigators	Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction - The CREATE-ECLA randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FATTY-ACIDS; ARRHYTHMIAS; ISCHEMIA; DEATH; RISK	Context Glucose-insulin-potassium (GlK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine the effect of GIK on mortality in patients with STEMI. Objective To determine the effect of high-dose GlK infusion on mortality in patients with STEMI. Design, Setting, and Participants Randomized controlled trial conducted in 470 centers worldwide among 20201 patients with STEMI who presented within 0 hours of symptom onset. The mean age of patients was 58.6 years, and evidence-based therapies were commonly used. Intervention Patients were randomly assigned to receive GIK intravenous Infusion for 24 hours plus usual care (n=10091) or to receive usual care alone (controls; n=10110). Main Outcome Measures Mortality, cardiac arrest, cardiogenic shock. and reinfarction at 30 days after randomization. Results At 30 days, 976 control patients (9.7%) and 1004 GIK infusion patients(10.0%) died (hazard ratio [HR], 1.03; 95% confidence interval [0), 0.95-1.13; P=.45). There were no significant differences in the rates of cardiac arrest (1.5% [151/10107) in control and 1.4% [139/10088] in GIK infusion; HR, 0.93; 95% Cl, 0.74-1.17; P=.51), cardiogenic shock (6.3% [640/10107] vs 6.6% [667/10088]; HR. 1.05; 95% Cl, 0.94-1.17] P=.38), or reinfarction (2.4% [246/10107] vs 2.3% (236/10088]; HR, 0.98; 95% Cl, 0.82-1.17; P=.81). The rates of heart failure at 7 days after randomization were also similar between the. groups (16.9% (1711/10107) vs 17.1% (1721/ 10088]; HR, 1.01; 95 % Cl, 0.95-1.08; P=.72). The lack of benefit of GIK infusion on mortality was consistent in prespecified subgroups, including in those with and without diabetes, in those presenting with and without heart failure, in those presenting early and later after symptom onset, and in those receiving and not receiving reperfusion therapy (thrombolysis or primary percutaneous coronary intervention). Conclusion In this large, international randomized trial, high-dose GIK infusion had a neutral effect on mortality, cardiac arrest, and cardiogenic shock in patients with acute STEMI.	McMaster Univ, Dept Med, Hamilton, ON L8L 2X2, Canada; Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; Estudios Cardiol Latin Amer, Rosario, Santa Fe, Argentina; Chinese Hypertens League Inst, Cardiovasc Inst, Beijing, Peoples R China; Chinese Hypertens League Inst, Fu Wai Hosp, Beijing, Peoples R China; St Johns Med Coll, Natl Acad Hlth Sci, Bangalore, Karnataka, India; Aga Khan Univ, Karachi, Pakistan	McMaster University; McMaster University; Population Health Research Institute; Chinese Hypertension League; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Hypertension League; St. John's National Academy of Health Sciences; St. John's Medical College; Aga Khan University	Mehta, SR (corresponding author), McMaster Univ, Dept Med, 237 Barton St SE, Hamilton, ON L8L 2X2, Canada.	smehta@mcmaster.ca	Kalantri, Shriprakash/ABG-9318-2021; Paul, Sanjoy/F-8199-2010; Reis, Gilmar/I-4500-2013	Kalantri, Shriprakash/0000-0002-1633-1029; Paul, Sanjoy/0000-0003-0848-7194; Yusuf, Salim/0000-0003-4776-5601; Piegas, Leopoldo/0000-0003-1021-817X; Reis, Gilmar/0000-0002-4847-1034; Gupta, Ruchika/0000-0003-0235-063X; Joshi, Rajnish/0000-0002-4702-0522; Prabhakaran, Dorairaj/0000-0002-3172-834X; Li, Qifu/0000-0003-3904-410X				Antman E, 2002, LANCET, V360, P1189, DOI 10.1016/S0140-6736(02)11278-5; Apstein CS, 1997, CIRCULATION, V96, P1074, DOI 10.1161/01.CIR.96.4.1074; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Cave AC, 2000, CIRCULATION, V101, P2090, DOI 10.1161/01.CIR.101.17.2090; Ceremuzynski L, 1999, CARDIOVASC DRUG THER, V13, P191, DOI 10.1023/A:1007787924085; COLLINS R, 1995, LANCET, V345, P669; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; Eikelboom JW, 2001, JAMA-J AM MED ASSOC, V285, P444, DOI 10.1001/jama.285.4.444; FathOrdoubadi F, 1997, CIRCULATION, V96, P1152, DOI 10.1161/01.CIR.96.4.1152; HULTING J, 1981, ACTA MED SCAND, P109; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; NORDREHAUG JE, 1985, CIRCULATION, V71, P645, DOI 10.1161/01.CIR.71.4.645; OBEID AI, 1978, CIRC RES, V43, P601, DOI 10.1161/01.RES.43.4.601; OLIVER MF, 1968, LANCET, V1, P710; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; OPIE LH, 1977, LANCET, V2, P890; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; SODIPALLARES D, 1962, AM J CARDIOL, V9, P166, DOI 10.1016/0002-9149(62)90035-8; SOLOMON RJ, 1981, ACTA MED SCAND, P87; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; van der Horst ICC, 2003, J AM COLL CARDIOL, V42, P784, DOI 10.1016/S0735-1097(03)00830-1; Wahab NN, 2002, J AM COLL CARDIOL, V40, P1748, DOI 10.1016/S0735-1097(02)02483-X; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; Yusuf S, 2005, JAMA-J AM MED ASSOC, V293, P427; Yusuf S, 2004, AM HEART J, V148, P1068, DOI 10.1016/j.ahj.2004.08.033; YUSUF S, 1988, LANCET, V1, P1088	27	496	530	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					437	446						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890DW	15671428				2022-12-28	WOS:000226492900022
J	Close, LM; Lenzen, R; Guirado, JC; Nielsen, EL; Mamajek, EE; Brandner, W; Hartung, M; Lidman, C; Biller, B				Close, LM; Lenzen, R; Guirado, JC; Nielsen, EL; Mamajek, EE; Brandner, W; Hartung, M; Lidman, C; Biller, B			A dynamical calibration of the mass luminosity relation at very low stellar masses and young ages	NATURE			English	Article							BROWN DWARFS; AB-DORADUS; MAIN-SEQUENCE; K-DWARFS; STARS; SPECTROSCOPY; POPULATION; METALLICITY; MEMBERSHIP; PLEIADES	Mass is the most fundamental parameter of a star, yet it is also one of the most difficult to measure directly. In general, astronomers estimate stellar masses by determining the luminosity and using the 'mass-luminosity' relationship(1,2), but this relationship has never been accurately calibrated for young, low-mass stars and brown dwarfs(3). Masses for these low-mass objects are therefore constrained only by theoretical models(1,2). A new high-contrast adaptive optics camera(4-6) enabled the discovery of a young ( 50 million years) companion only 0.156 arcseconds (2.3 AU) from the more luminous (>120 times brighter) star AB Doradus A. Here we report a dynamical determination of the mass of the newly resolved low-mass companion AB Dor C, whose mass is 0.090 +/- 0.005 solar masses. Given its measured 1-2- micrometre luminosity, we have found that the standard mass-luminosity relations(1,2) overestimate the near-infrared luminosity of such objects by about a factor of similar to2.5 at young ages. The young, cool objects hitherto thought to be substellar in mass are therefore about twice as massive, which means that the frequency of brown dwarfs and planetary mass objects in young stellar clusters has been overestimated.	Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; Max Planck Inst Astron, D-69117 Heidelberg, Germany; Univ Valencia, Dept Astron & Astrofis, E-46100 Valencia, Spain; European So Observ, Santiago 19, Chile	University of Arizona; Max Planck Society; University of Valencia; European Southern Observatory	Close, LM (corresponding author), Univ Arizona, Steward Observ, Tucson, AZ 85721 USA.	lclose@as.arizona.edu	Brandner, Wolfgang/AFR-1606-2022	Brandner, Wolfgang/0000-0003-1939-6351; Nielsen, Eric/0000-0001-6975-9056; Lidman, Chris/0000-0003-1731-0497; Close, Laird/0000-0002-2167-8246; Biller, Beth/0000-0003-4614-7035				BILLER B, IN PRESS SPIE S, V5490; Bouy H, 2004, ASTRON ASTROPHYS, V423, P341, DOI 10.1051/0004-6361:20040551; Burgasser AJ, 2004, ASTROPHYS J, V604, P827, DOI 10.1086/382129; Burrows A, 2001, REV MOD PHYS, V73, P719, DOI 10.1103/RevModPhys.73.719; Chabrier G, 2000, ASTROPHYS J, V542, P464, DOI 10.1086/309513; Close LM, 2003, ASTROPHYS J, V587, P407, DOI 10.1086/368177; CLOSE LM, IN PRESS ASTRON SOC; DAntona F, 1996, ASTROPHYS J, V456, P329, DOI 10.1086/176654; Guirado JC, 1997, ASTROPHYS J, V490, P835, DOI 10.1086/304920; Hillenbrand LA, 2004, ASTROPHYS J, V604, P741, DOI 10.1086/382021; INNIS JL, 1985, P ASTRON SOC AUST, V6, P156, DOI 10.1017/S1323358000017987; Lenzen R, 2003, P SOC PHOTO-OPT INS, V4841, P944, DOI 10.1117/12.460044; LENZEN R, IN PRESS SPIE S, V5492; Lucas PW, 2000, MON NOT R ASTRON SOC, V314, P858, DOI 10.1046/j.1365-8711.2000.03515.x; Luhman KL, 1999, ASTROPHYS J, V525, P466, DOI 10.1086/307902; Maiolino R, 1996, ASTRON J, V111, P537, DOI 10.1086/117804; Marois C, 2003, PROC SPIE, V4860, P130, DOI 10.1117/12.457844; Martin EL, 2000, ASTROPHYS J, V543, P299, DOI 10.1086/317089; MARTIN EL, 1995, ASTRON ASTROPHYS, V294, P744; Mewe R, 1996, ASTRON ASTROPHYS, V315, P170; Navascues DBY, 2001, ASTROPHYS J, V549, P452, DOI 10.1086/319045; OSORIO MRZ, 2003, P IAU S, V211, P111; Randich S, 2001, ASTRON ASTROPHYS, V372, P862, DOI 10.1051/0004-6361:20010339; SEGRANSAN D, 2003, P IAU S, V211, P413; Stauffer JR, 2003, ASTRON J, V126, P833, DOI 10.1086/376739; Stelzer B, 2000, ASTRON ASTROPHYS, V361, P581; VILHU O, 1991, ASTRON ASTROPHYS, V241, P167; Wilking BA, 1999, ASTRON J, V117, P469, DOI 10.1086/300674; Zuckerman B, 2004, ASTROPHYS J, V613, pL65, DOI 10.1086/425036; [No title captured]	30	138	138	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					286	289		10.1038/nature03225	http://dx.doi.org/10.1038/nature03225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662417				2022-12-28	WOS:000226381300047
J	Heaton, T; Rowe, J; Turner, S; Aalberse, RC; de Klerk, N; Suriyaarachchi, D; Serralha, M; Holt, BJ; Hollams, E; Yerkovich, S; Holt, K; Sly, PD; Goldblatt, J; Le Souef, P; Holt, PG				Heaton, T; Rowe, J; Turner, S; Aalberse, RC; de Klerk, N; Suriyaarachchi, D; Serralha, M; Holt, BJ; Hollams, E; Yerkovich, S; Holt, K; Sly, PD; Goldblatt, J; Le Souef, P; Holt, PG			An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children	LANCET			English	Article							AIRWAY HYPERRESPONSIVENESS; BRONCHIAL RESPONSIVENESS; RESPIRATORY SYMPTOMS; ATOPIC-DERMATITIS; IMMUNE-RESPONSE; 2 POPULATIONS; ALLERGEN; TH1; INTERLEUKIN-10; EOSINOPHILS	Background Increasing evidence suggests that patterns of T-cell immunity to inhalant allergens in genetically diverse human populations are more heterogeneous than previously assumed, and that covert differences in expression patterns might underlie variations in airway disease phenotypes. We tested this proposition in a community sample of children Methods We analysed data from 172 individuals who had been recruited antenatally to a longitudinal birth cohort study. Of the 194 birth cohort participants, data from the 147 probands (age range 8.6-13.5 years) who consented to blood collection were included along with data from 25 consenting siblings (mean age 11 years [range 7.4-17.4]). We ascertained clinical phenotypes related to asthma and allergy. We measured T-cell responses to allergens and mitogens, together with blood eosinophils and IgE/IgG antibodies, and assessed associations between these indices and clinical phenotypes. Findings Atopy was associated with allergen-specific T-helper (Th)2 responses dominated by interleukin 4, interleukin 5, interleukin 9, interleukin 13, whereas interleukin 10, tumour necrosis factor a, and interferon gamma responses were common to both atopics and non-atopics. The wheal size from skin prick with allergen was positively associated with in-vitro interleukin 5 and interferon gamma responses, and negatively associated with interleukin 10. Asthma, especially in atopics, was strongly associated with eosinophilia/interleukin 5, and bronchial hyperresponsiveness (BHR) was associated with eosinophilia plus polyclonal interferon gamma production. BHR in non-atopics was associated with elevated allergen-specific and polyclonal interleukin 10 production. Interpretation Parallel immunological and clinical profiling of children identified distinctive immune response patterns related to asthma and wheeze compared with BHR, in atopics non-atopics. Immunological hyperresponsiveness, including within the Th1 cytokine compartment, is identified as a hallmark of BHR. Relevance to practice These findings highlight the heterogeneity of immune response patterns in asthmatic children, including those with seemingly homogeneous Th2-driven atopic asthma. Further elucidation of the covert relationships between wheezing phenotypes and underlying immunophenotypes in this age group will potentially lead to more effective treatments for what is an unexpectedly heterogeneous collection of disease subtypes.	Univ Western Australia, Fac Med & Dent, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; Univ Western Australia, Fac Med & Dent, Dept Paediat, Perth, WA 6009, Australia; CLB, Sanquin Res Labs, Amsterdam, Netherlands	Telethon Kids Institute; University of Western Australia; University of Western Australia	Holt, PG (corresponding author), Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Le Souef, Peter N/H-5256-2014; Holt, Patrick G/H-1548-2011; Serralha, Michael/CAA-0940-2022; de Klerk, Nicholas H/D-8388-2016; Sly, Peter D/F-1486-2010; Holt, Kathryn E/A-8108-2012	Holt, Patrick G/0000-0003-1193-0935; de Klerk, Nicholas H/0000-0001-9223-0767; Sly, Peter D/0000-0001-6305-2201; Holt, Kathryn E/0000-0003-3949-2471; Serralha, Michael/0000-0002-0121-2879; Hollams, Elysia/0000-0002-3481-6396; Yerkovich, Stephanie/0000-0003-4163-4782				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Boushey HA, 2000, LANCET, V356, P2114, DOI 10.1016/S0140-6736(00)03486-3; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; CALHOUN W J, 1992, American Review of Respiratory Disease, V145, pA638; Castro M, 2000, AM J RESP CELL MOL, V22, P143, DOI 10.1165/ajrcmb.22.2.f174; Colavita AM, 2000, J ALLERGY CLIN IMMUN, V106, P880, DOI 10.1067/mai.2000.110475; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; DEL PG, 1993, J IMMUNOL, V150, P353; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; Glass DC, 2001, ANN OCCUP HYG, V45, P275, DOI 10.1016/S0003-4878(01)00022-9; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Grunstein MM, 2001, AM J PHYSIOL-LUNG C, V281, pL1130, DOI 10.1152/ajplung.2001.281.5.L1130; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hartmann M, 2004, J CANCER RES CLIN, V130, P93, DOI 10.1007/s00432-003-0513-z; Holgate ST, 1999, J ALLERGY CLIN IMMUN, V104, P1139, DOI 10.1016/S0091-6749(99)70005-9; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 2000, THORAX, V55, P700, DOI 10.1136/thorax.55.8.700; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Li XM, 1996, J IMMUNOL, V157, P3216; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Postma DS, 2000, AM J RESP CRIT CARE, V162, pS118, DOI 10.1164/ajrccm.162.supplement_2.ras-13; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; Sharp MJ, 2003, CLIN EXP ALLERGY, V33, P435, DOI 10.1046/j.1365-2222.2003.01627.x; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; TURNER SW, 2004, IN PRESS AM J RESP C, V169; Umetsu DT, 1999, AM J RESP CELL MOL, V21, P562, DOI 10.1165/ajrcmb.21.5.f171; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VANDERZEE JS, 1986, J IMMUNOL, V137, P3566; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	44	185	205	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					142	149		10.1016/S0140-6736(05)17704-6	http://dx.doi.org/10.1016/S0140-6736(05)17704-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639296				2022-12-28	WOS:000226170700029
J	Lipworth, BJ				Lipworth, BJ			Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease	LANCET			English	Article							ARIFLO(TM) SB 207499; FLUTICASONE PROPIONATE; PDE4 INHIBITOR; CILOMILAST; 2ND-GENERATION; ROFLUMILAST; MONTELUKAST; PLACEBO	Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad range of anti-inflammatory effects on various key effector cells involved in asthma and chronic obstructive pulmonary disease (COPD). The therapeutic ratio for PDE4 inhibitors is thought to be determined by selectivity on receptor subtypes for relative effects on PDE4B (anti-inflammatory) and PDE4D (emesis). The two main orally active PDE4 inhibitors in the late phase III of clinical development are cilomilast and roflumilast; the latter (and its active metabolite N-oxide) is more selective and potent with a superior therapeutic ratio. Studies on cilomilast in COPD based on bronchial biopsy material have shown a broad range of anti-inflammatory activity, and the available evidence on clinical outcomes for up to 6 months with cilomilast 15 mg twice daily and roflumilast 500 mug once daily have shown variable but significant effects on exacerbations and quality of life, with small improvements in measures of pulmonary function. Roflumilast has a better safety and tolerability profile than cilomilast, with the main adverse effects being nausea, diarrhoea, and abdominal pain. Roflumilast also has activity in asthma as assessed by its attenuation of allergen and exercise challenges, and it shows clinical efficacy equivalent to that of beclomethasone dipropionate 400 mug daily. The emerging results of clinical trials on PDE4 inhibitors in asthma and COPD should be interpreted with cautious optimism since much of the evidence has been published only in abstract form to date. The next few years should resolve important issues about the potential role of these drugs as oral non-steroidal anti-inflammatory therapy for asthma and COPD and their place in management guidelines. Ultimately, clinicians will want to know whether PDE4 inhibitors are anything more than expensive "designer" theophylline, the archetypal non-selective phosphodiesterase inhibitor.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Med & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Med & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland.	b.j.lipworth@dundee.ac.uk						ALBRECHT A, 2002, EUR RESP J S38, V20, pS304; Altose MD, 2000, NEW ENGL J MED, V343, P1902; AUBIER M, 2004, AM J RESP CRIT CARE, V169, pA322; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; BATEMAN ED, 2004, AM J RESP CRIT CARE, V169, pA596; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; BORKER R, 2004, AM J RESP CRIT CARE, V169, pA328; BOSWELLSMITH V, 2004, AM J RESP CRIT CARE, V169, pA180; Bredenbroker D, 2002, EUR RESP J S38, V20, p374S; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; COMPTON C, 2000, AM J RESP CRIT CARE, V161, pA505; Compton CH, 2001, LANCET, V358, P265, DOI 10.1016/S0140-6736(01)05481-2; Compton CH, 1999, AM J RESP CRIT CARE, V159, pA522; COMPTON CH, 2001, AM J RESP CRIT CARE, V163, pA909; DROLLMANN A, 2002, EUR RESP J S38, V20, pS109; DROLLMANN A, 2002, EUR RESP J S38, V20, pS108; EDDLESTON JD, 2001, AM J RESP CRIT CARE, V163, pA277; EDDLESTON JD, 2001, AM J RESP CRIT CARE, V163, pA771; Essayan DM, 2001, J ALLERGY CLIN IMMUN, V108, P671, DOI 10.1067/mai.2001.119555; Gamble E, 2003, AM J RESP CRIT CARE, V168, P976, DOI 10.1164/rccm.200212-1490OC; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; HAUNS B, 2004, AM J RESP CRIT CARE, V169, pA612; Hunnemeyer A, 2002, AM J RESP CRIT CARE, V165, pA595; IZQUIERDO JL, 2003, AM J RESP CRIT CARE, V167, pA765; Kelly J, 1999, AM J RESP CRIT CARE, V159, pA807; Kelly J, 2001, ANN PHARMACOTHER, V35, P1535; LEICHTL S, 2002, EUR RESP J S38, V20, pS303; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Manegold A, 2002, EUR RESP J S38, V20, P5108; MANNING CD, BR J CLIN PHARM, V128, P1393; Moody A, 2004, THORAX, V59, P1; NELL H, 2000, AM J RESP CRIT CARE, V161, pA200; Nieman RB, 1998, AM J RESP CRIT CARE, V157, pA413; O'Donnell D., 2004, AM J RESP CRIT CARE, V169, pA602; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; RABE KF, 2004, AM J RESP CRIT CARE, V169, pA518; Souness JE, 2000, IMMUNOPHARMACOLOGY, V47, P127, DOI 10.1016/S0162-3109(00)00185-5; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; Spina D, 2003, DRUGS, V63, P2575, DOI 10.2165/00003495-200363230-00002; Timmer W, 2002, J CLIN PHARMACOL, V42, P297, DOI 10.1177/00912700222011328; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Torphy TJ, 1999, PULM PHARMACOL THER, V12, P131, DOI 10.1006/pupt.1999.0181; van Schalkwyk EM, 2002, EUR RESP J S38, V20, p110S; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Weimar C, 2002, AM J RESP CRIT CARE, V165, pA594; WOLLIN N, 2004, AM J RESP CRIT CARE, V169, pA803; Zussman BD, 2001, PHARMACOTHERAPY, V21, P653, DOI 10.1592/phco.21.7.653.34569; Zussman BD, 2001, J CLIN PHARMACOL, V41, P950; Zussman BD, 2001, CLIN THER, V23, P921, DOI 10.1016/S0149-2918(01)80079-5	51	334	368	1	41	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					167	175		10.1016/S0140-6736(05)17708-3	http://dx.doi.org/10.1016/S0140-6736(05)17708-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639300				2022-12-28	WOS:000226170700033
J	Zohrabian, A				Zohrabian, A			The long-term effects and economic consequences of treatments for obesity: work in progress	LANCET			English	Editorial Material									Ctr Dis Control & Prevent, Div Adult & Community Hlth, Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Zohrabian, A (corresponding author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.	Abz8@cdc.gov						Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Chou SY, 2004, J HEALTH ECON, V23, P565, DOI 10.1016/j.jhealeco.2003.10.003; Klein S, 2004, NEW ENGL J MED, V350, P2549, DOI 10.1056/NEJMoa033179; LADDAWALLA D, 2002, 8946 NAT BUR EC RES; PHILIPSON T, 2004, 04004 USDA EFAN EC R; PHILIPSON TJ, 1999, 7423 NAT BUR EC RES; Sturm R, 2002, HEALTH AFFAIR, V21, P245, DOI 10.1377/hlthaff.21.2.245; STURM R, 2004, RAND REV         SPR, P24; U.S. Department of Health and Human Services, 2001, SURG GEN CALL ACT PR	9	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					104	105		10.1016/S0140-6736(05)17718-6	http://dx.doi.org/10.1016/S0140-6736(05)17718-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639278				2022-12-28	WOS:000226170700007
J	Greaves, JS				Greaves, JS			Disks around stars and the growth of planetary systems	SCIENCE			English	Review							MAIN-SEQUENCE STARS; T-TAURI STARS; GIANT PLANETS; DEBRIS DISCS; YOUNG STARS; KUIPER-BELT; ACCRETION; DUST; POLARIZATION; EVOLUTION	Circumstellar disks play a vital evolutionary role, providing a way to move gas inward and onto a young star. The outward transfer of angular momentum allows the star to contract without breaking up, and the remnant disk of gas and particles is the reservoir for forming planets. High-resolution spectroscopy is uncovering planetary dynamics and motion within the remnant disk, and imaging at infrared to, millimeter wavelengths resolves disk structure over billions of years of evolution. Most stars are born with a disk, and models of planet formation need to form such bodies from the disk material within the disk's 10-million-year life-span.	Univ St Andrews, St Andrews KY16 9SS, Fife, Scotland	University of St Andrews	Greaves, JS (corresponding author), Univ St Andrews, N Haugh, St Andrews KY16 9SS, Fife, Scotland.							Alexander RD, 2004, MON NOT R ASTRON SOC, V354, P71, DOI 10.1111/j.1365-2966.2004.08161.x; ANDRE P, 1993, ASTROPHYS J, V406, P122, DOI 10.1086/172425; Bary JS, 2003, ASTROPHYS J, V586, P1136, DOI 10.1086/367719; BODENHEIMER P, 1995, ANNU REV ASTRON ASTR, V33, P199; Bonnell IA, 1998, MON NOT R ASTRON SOC, V298, P93, DOI 10.1046/j.1365-8711.1998.01590.x; Bontemps S, 1996, ASTRON ASTROPHYS, V311, P858; Boss AP, 2004, ASTROPHYS J, V610, P456, DOI 10.1086/421515; BREGER M, 1972, ASTROPHYS J, V175, P127, DOI 10.1086/151542; Brown DW, 2000, MON NOT R ASTRON SOC, V319, P154, DOI 10.1046/j.1365-8711.2000.03805.x; Chambers JE, 2004, EARTH PLANET SC LETT, V223, P241, DOI 10.1016/j.epsl.2004.04.031; Coulson IM, 2004, MON NOT R ASTRON SOC, V348, pL39, DOI 10.1111/j.1365-2966.2004.07563.x; DUQUENNOY A, 1991, ASTRON ASTROPHYS, V248, P485; Fischer DA, 2003, ASTROPHYS J, V590, P1081, DOI 10.1086/375027; Gladman B, 2005, SCIENCE, V307, P71, DOI 10.1126/science.1100553; Greaves JS, 2004, MON NOT R ASTRON SOC, V351, pL54, DOI 10.1111/j.1365-2966.2004.07957.x; Greaves JS, 2004, MON NOT R ASTRON SOC, V351, pL99, DOI 10.1111/j.1365-2966.2004.08066.x; Greaves JS, 2004, MON NOT R ASTRON SOC, V348, P1097, DOI 10.1111/j.1365-2966.2004.07440.x; Greaves JS, 2003, MON NOT R ASTRON SOC, V345, P1212, DOI 10.1046/j.1365-2966.2003.07037.x; Greaves JS, 1998, ASTROPHYS J, V506, pL133, DOI 10.1086/311652; Habing HJ, 2001, ASTRON ASTROPHYS, V365, P545, DOI 10.1051/0004-6361:20000075; Haisch KE, 2001, ASTROPHYS J, V553, pL153, DOI 10.1086/320685; HILLENBRAND LA, 1992, ASTROPHYS J, V397, P613, DOI 10.1086/171819; HUANG SS, 1967, ASTRON J, V72, P804, DOI 10.1086/110546; Johnstone D, 1998, ASTROPHYS J, V499, P758, DOI 10.1086/305658; Kenyon SJ, 2004, ASTRON J, V127, P513, DOI 10.1086/379854; Lada C. J., 1982, Submillimetre Wave Astronomy, P175; Landgraf M, 2002, ASTRON J, V123, P2857, DOI 10.1086/339704; Liou JC, 1999, ASTRON J, V118, P580, DOI 10.1086/300938; Narayan R, 2005, SCIENCE, V307, P77, DOI 10.1126/science.1105746; Nurnberger D, 1997, ASTRON ASTROPHYS, V324, P1036; Oliveira JM, 2000, ASTRON ASTROPHYS, V362, P615; Padgett DL, 1999, ASTRON J, V117, P1490, DOI 10.1086/300781; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; Pudritz RE, 1996, ASTROPHYS J, V470, pL123, DOI 10.1086/310309; Rebull LM, 2004, ASTRON J, V127, P1029, DOI 10.1086/380931; Rice WKM, 2003, ASTROPHYS J, V598, pL55, DOI 10.1086/380390; Rice WKM, 2003, MON NOT R ASTRON SOC, V342, P79, DOI 10.1046/j.1365-8711.2003.06515.x; Simon M, 2000, ASTROPHYS J, V545, P1034, DOI 10.1086/317838; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; Takeuchi T, 2002, ASTROPHYS J, V581, P1344, DOI 10.1086/344437; Tamura M, 1999, ASTROPHYS J, V525, P832, DOI 10.1086/307953; Thi WF, 2001, ASTROPHYS J, V561, P1074, DOI 10.1086/323361; VANBLERKOM D, 1976, ASTROPHYS J, V204, P775, DOI 10.1086/154224; Wood BE, 2002, ASTROPHYS J, V574, P412, DOI 10.1086/340797; Wyatt MC, 2003, MON NOT R ASTRON SOC, V342, P876, DOI 10.1046/j.1365-8711.2003.06595.x	46	36	36	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					68	71		10.1126/science.1101979	http://dx.doi.org/10.1126/science.1101979			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637266				2022-12-28	WOS:000226214300035
J	van der Wielen, PWJJ; Bolhuis, H; Borin, S; Daffonchio, D; Corselli, C; Giuliano, L; D'Auria, G; de Lange, GJ; Huebner, A; Varnavas, SP; Thomson, J; Tamburini, C; Marty, D; McGenity, TJ; Timmis, KN				van der Wielen, PWJJ; Bolhuis, H; Borin, S; Daffonchio, D; Corselli, C; Giuliano, L; D'Auria, G; de Lange, GJ; Huebner, A; Varnavas, SP; Thomson, J; Tamburini, C; Marty, D; McGenity, TJ; Timmis, KN		BioDeep Sci Party	The enigma of prokaryotic life in deep hypersaline anoxic basins	SCIENCE			English	Article							EASTERN MEDITERRANEAN-SEA; DEAD-SEA; BANNOCK BASINS; SP-NOV; BRINES; WATER; ENVIRONMENT; ANTARCTICA; DISCOVERY; SEDIMENTS	Deep hypersaline anoxic basins in the Mediterranean Sea are a legacy of dissolution of ancient subterranean salt deposits from the Miocene period. Our study revealed that these hypersaline basins are not biogeochemical dead ends, but support in situ sulfate reduction, methanogenesis, and heterotrophic activity. A wide diversity of prokaryotes was observed, including a new, abundant, deeply branching order within the Euryarchaeota. Furthermore, we demonstrated the presence of a unique,. metabolically active microbial community in the Discovery basin, which is one of the most extreme terrestrial saline environments known, as it is almost saturated with MgCl2 (5 M).	Univ Groningen, Microbial Ecol Lab, NL-9751 NN Haren, Netherlands; Univ Milan, Consorzio Nazl Interuniv Sci Mare, URL DiSTAM, I-20133 Milan, Italy; Univ Milano Bicocca, CoNISMa, URL DGSG, I-20126 Milan, Italy; CNR, Ist Ambiente Marino Costiero, I-98122 Messina, Italy; Univ Utrecht, Fac Geosci, NL-3508 TA Utrecht, Netherlands; Univ Patras, Dept Geol, Patras 26500, Greece; Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England; Univ Mediterranee, LMGEM, CNRS, UMR 6117, F-13288 Marseille 9, France; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; Gesell Biotechnol Forsch mbH, Div Microbiol, D-38124 Braunschweig, Germany	University of Groningen; University of Milan; CoNISMa; University of Milano-Bicocca; Consiglio Nazionale delle Ricerche (CNR); L'Istituto per l'Ambiente Marino Costiero (IAMC-CNR); Utrecht University; University of Patras; NERC National Oceanography Centre; University of Southampton; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Essex; Gesellschaft fur Biotechnologische Forschung mbH	van der Wielen, PWJJ (corresponding author), Kiwa Water Res, POB 1072, NL-3430 BB Nieuwegein, Netherlands.	paul.van.der.wielen@kiwa.nl	Bolhuis, Henk/S-2986-2019; Bolhuis, Henk/A-4308-2008; D'Auria, Giuseppe/E-6583-2010; Tamburini, Christian/AAO-8577-2020; Corselli, Cesare/E-9970-2011; Tamburini, Christian/I-7821-2012; Daffonchio, Daniele/AAF-4922-2019; Giuliano, Laura/P-2204-2019; McGenity, Terry/B-8661-2011; Bolhuis, Henk/M-6677-2019; De Lange, Gert J/B-9639-2014; Bolhuis, Henk/H-8535-2014; Hubner, Andreas/G-1751-2016	Bolhuis, Henk/0000-0002-4772-1898; Tamburini, Christian/0000-0003-3752-7423; Tamburini, Christian/0000-0003-3752-7423; Daffonchio, Daniele/0000-0003-0947-925X; De Lange, Gert J/0000-0002-9420-3022; Bolhuis, Henk/0000-0002-4772-1898; Hubner, Andreas/0000-0001-7342-9789; McGenity, Terence/0000-0002-1497-8822; Borin, Sara/0000-0001-7479-8199; van der Wielen, Paul/0000-0002-4851-5762; D'Auria, Giuseppe/0000-0003-0672-2541				Brusa T, 1997, MICROBIOL RES, V152, P45; Brusa T, 2001, MICROBIOL RES, V156, P49, DOI 10.1078/0944-5013-00075; CAMERLENGHI A, 1990, MAR CHEM, V31, P1; DELANGE GJ, 1990, MAR CHEM, V31, P63, DOI 10.1016/S0304-4203(05)80005-2; Dundas I, 1998, EXTREMOPHILES, V2, P375, DOI 10.1007/s007920050081; Eder W, 1999, ARCH MICROBIOL, V172, P213, DOI 10.1007/s002030050762; Gaidos EJ, 2000, NATURE, V405, P637, DOI 10.1038/35015170; HENNEKE E, 1990, MAR CHEM, V31, P113, DOI 10.1016/0304-4203(90)90033-9; HOROWITZ NH, 1972, SCIENCE, V176, P242, DOI 10.1126/science.176.4032.242; JONGSMA D, 1983, NATURE, V305, P795, DOI 10.1038/305795a0; KARGEL JS, 1991, ICARUS, V94, P368, DOI 10.1016/0019-1035(91)90235-L; Karisiddaiah SM, 2000, DEEP-SEA RES PT I, V47, P1999, DOI 10.1016/S0967-0637(00)00010-8; Knauth LP, 1998, NATURE, V395, P554, DOI 10.1038/26879; LAFERLA R, 1991, MAR ECOL PROG SER, V75, P309, DOI 10.3354/meps075309; MATSUBAYA O, 1979, GEOCHIM COSMOCHIM AC, V43, P7, DOI 10.1016/0016-7037(79)90042-5; MEDRIFF Consortium, 1995, EOS T AM GEOPHYS UN, V76, P313, DOI DOI 10.1029/95EO00189; OLLIVIER B, 1994, MICROBIOL REV, V58, P27, DOI 10.1128/MMBR.58.1.27-38.1994; OREN A, 1983, INT J SYST BACTERIOL, V33, P381, DOI 10.1099/00207713-33-2-381; OREN A, 1995, INT J SYST BACTERIOL, V45, P747, DOI 10.1099/00207713-45-4-747; OREN A, 1994, FEMS MICROBIOL REV, V13, P415, DOI 10.1111/j.1574-6976.1994.tb00060.x; Oren A, 1999, HYDROBIOLOGIA, V405, P1, DOI 10.1023/A:1003879932328; Sass AM, 2001, APPL ENVIRON MICROB, V67, P5392, DOI 10.1128/AEM.67.12.5392-5402.2001; SIEGEL BZ, 1979, NATURE, V280, P828, DOI 10.1038/280828a0; VANDERWIELEN PWJ, UNPUB; Vengosh A, 1998, GEOCHIM COSMOCHIM AC, V62, P3221, DOI 10.1016/S0016-7037(98)00236-1; Waino M, 2000, INT J SYST EVOL MICR, V50, P183, DOI 10.1099/00207713-50-1-183; Wallmann K, 2002, MAR GEOL, V186, P9, DOI 10.1016/S0025-3227(02)00170-6; Wallmann K, 1997, NATURE, V387, P31, DOI 10.1038/387031a0; WOLDA H, 1981, OECOLOGIA, V50, P296, DOI 10.1007/BF00344966; Ziebis W., 2000, J C ABSTR, V5, P1134	30	189	196	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					121	123		10.1126/science.1103569	http://dx.doi.org/10.1126/science.1103569			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637281				2022-12-28	WOS:000226214300052
J	Warren, SM; May, JW				Warren, SM; May, JW			Lipodystrophy induced by antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Warren, SM (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					63	63		10.1056/NEJMicm040628	http://dx.doi.org/10.1056/NEJMicm040628			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635113				2022-12-28	WOS:000226112500008
J	Pincock, S				Pincock, S			Fathi Arafat - Obituary	LANCET			English	Biographical-Item												stephenpincock@blueyonder.co.uk		Pincock, Stephen/0000-0003-1655-2902					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2005	365	9453					22	22		10.1016/S0140-6736(04)17651-4	http://dx.doi.org/10.1016/S0140-6736(04)17651-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15643701				2022-12-28	WOS:000226213100014
J	Pilkington, P; Kinra, S				Pilkington, P; Kinra, S			Effectiveness of speed cameras in preventing road traffic collisions and related casualties: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRITISH-COLUMBIA; PROGRAM; HIDDEN	Objectives To assess whether speed cameras reduce road traffic collisions and related casualties. Design Systematic review. Data sources Cochrane Injuries Group Specialised Register, Cochrane Central Register of Controlled Trials, Medline, Embase, Social Science Citation Index, TRANSPORT database, ZETOC, the internet (including websites of road safety and motoring organisations), and contact with key individuals and organisations. Main outcome measures Road traffic collisions, injuries, and deaths. Inclusion criteria Controlled trials and observational studies assessing the impact of fixed or mobile speed cameras on any of the selected outcomes. Results 14 observational studies met the inclusion criteria; no randomised controlled trials were found. Most studies were before-after studies without controls (n = 8). All but one of the studies showed effectiveness of cameras up to three years or le ss after their introduction; one study showed sustained longer term effects (4.6 years after introduction). Reductions in outcomes across studies ranged from 5% to 69% for collisions, 12% to 65% for injuries, and 17% to 71% for deaths in the immediate vicinity of camera sites. The reductions over wider geographical areas were of a similar order of magnitude. Conclusions Existing research consistently shows that speed cameras are an effective intervention in reducing road traffic collisions and related casualties. The level of evidence is relatively poor, however, as most studies did not have satisfactory comparison groups or adequate control for potential confounders. Controlled introduction of speed cameras with careful data collection may offer improved evidence of their effectiveness in the future.	Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England; Univ Bristol, Dept Social Med, Bristol, Avon, England	University of West England; University of Bristol	Pilkington, P (corresponding author), Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England.	paul.pilkington@uwe.ac.uk						Ali S. Y., 1997, TRANSPORT RES REC, V1595, P20; [Anonymous], 1996, LAW ORDER, V44, P75; Barker P., 2003, AUTOCAR MAGAZIN 1111, P18; Bourne Michael G, 1993, CRIME PREVENTION STU, P177; BROWNFIELD DJ, 1980, TRAFFIC ENG CONTROL, V21, P278; Cameron M., 1992, 42 MON U ACC RES CTR; Chen G, 2002, ACCIDENT ANAL PREV, V34, P129, DOI 10.1016/S0001-4575(01)00006-9; Chen G, 2000, ACCIDENT ANAL PREV, V32, P517, DOI 10.1016/S0001-4575(99)00071-8; Christie SM, 2003, INJURY PREV, V9, P302, DOI 10.1136/ip.9.4.302; Crombie H., 2002, IMPACT TRANSPORT ROA; *DEP TRANSP, 2002, COST REC SYST TRAFF; Department for Transport, 2003, COST REC SYST SPEED; Diamantopoulou K., 2002, 187 MON U ACC RES CT; Elvik R., 1997, TRANSPORT RES REC, V1597, P1; HESS S, 2003, ANAL EFFECTS SPEED L; *HIGHW AG, 1997, W LOND SPEED CAM DEM; HOOK D, 1995, HIGHWAYS TRANSPORTAT, V42, P11; Hooke A., 1996, POLICE RES SERIES PA, V20; *HOUS COMM TRANSP, 2002, 9 HOUS COMM TRANSP L, V1; Keall MD, 2002, ACCIDENT ANAL PREV, V34, P773, DOI 10.1016/S0001-4575(01)00077-X; Keall MD, 2001, ACCIDENT ANAL PREV, V33, P277, DOI 10.1016/S0001-4575(00)00042-7; MARA MK, 1996, P AUSTR ROAD RES BOA, V18, P269; MASSEY R, 2002, DAILY MAIL      0411, P1; MASSEY R, 2002, DAILY MAIL      0411, P6; Morton V, 2003, BRIT MED J, V326, P1083, DOI 10.1136/bmj.326.7398.1083; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Peden M., 2004, WORLD REPORT ROAD TR; Roberts I, 2002, BMJ-BRIT MED J, V324, P1107, DOI 10.1136/bmj.324.7346.1107; SWALI L, 1993, TRAFF MAN ROAD SAF P; Tay R, 2000, TRAFFIC AND TRANSPORTATION STUDIES, P44	30	93	94	2	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2005	330	7487					331	334		10.1136/bmj.38324.646574.AE	http://dx.doi.org/10.1136/bmj.38324.646574.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	897OZ	15653699	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000227015800015
J	Fink, GR				Fink, GR			A transforming principle	CELL			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; PRION HYPOTHESIS; PROTEIN; SUP35		Whitehead Inst, Cambridge, MA 02142 USA; MIT, Cambridge Ctr 9, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Fink, GR (corresponding author), Whitehead Inst, Cambridge, MA 02142 USA.	gfink@wi.mit.edu						Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Liebman SW, 2002, P NATL ACAD SCI USA, V99, P9098, DOI 10.1073/pnas.152318899; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	9	10	11	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 28	2005	120	2					153	154		10.1016/j.cell.2005.01.004	http://dx.doi.org/10.1016/j.cell.2005.01.004			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680318	Bronze			2022-12-28	WOS:000226740000001
J	Sousa, R				Sousa, R			Machinations of a maxwellian demon	CELL			English	Editorial Material							3.3 ANGSTROM RESOLUTION; RNA-POLYMERASE; TRANSCRIPTION ELONGATION; COMPLEX; MODEL	The mechanisms by which RNA polymerase moves along DNA during elongation have been difficult to determine experimentally. In this issue of Cell, Bar-Nahum et al. (2005) show that back and forth sliding of RNA polymerase on DNA may be coupled to bending of an alpha helix, which can alternately occlude and expose the NTP binding site. Transcription factors can regulate elongation by modulating this bending motion.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Sousa, R (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Sousa, Rui/0000-0003-4314-121X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052522] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM052522] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai L, 2004, J MOL BIOL, V344, P335, DOI 10.1016/j.jmb.2004.08.107; Bar-Nahum G, 2005, CELL, V120, P183, DOI 10.1016/j.cell.2004.11.045; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; KOMMISAROVA N, 1997, J BIOL CHEM, V272, P15329; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Toulme F, 1999, EMBO J, V18, P5052, DOI 10.1093/emboj/18.18.5052; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	9	14	15	1	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 28	2005	120	2					155	156		10.1016/j.cell.2005.01.003	http://dx.doi.org/10.1016/j.cell.2005.01.003			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680319	Bronze			2022-12-28	WOS:000226740000002
J	Bugiardini, R; Merz, CNB				Bugiardini, R; Merz, CNB			Angina with "normal" coronary arteries a changing philosophy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CARDIAC SYNDROME-X; LONG-TERM PROGNOSIS; CHEST-PAIN; ENDOTHELIAL FUNCTION; MYOCARDIAL-ISCHEMIA; NITRIC-OXIDE; CLINICAL CHARACTERISTICS; MICROVASCULAR FUNCTION; OXIDATIVE STRESS; NATIONAL-HEART	Context Many women with angina are told that they have no significant heart disease following demonstration of normal or near-normal coronary arteries and are offered no specific treatment beyond reassurance. Evidence Acquisition MEDLINE and the Cochrane Database of Systematic Reviews were searched from their start dates until June 2004 for analysis using specific key words including diagnosis and therapy of angina with normal angiography and angina with normal coronary arteries. Reference list of published articles and data of meeting presentations were also consulted. Evidence Synthesis Normal or nonobstructive coronary disease at angiography is not uncommon and occurs in 10% of women presenting with ST-segment elevation myocardial infarction compared with 6% in men. Patients with evidence of myocardial ischemia or myocardial infarction and nonobstructive atherosclerotic disease of the coronary arteries are more likely to be women and nonwhite. Symptoms are often indistinguishable from those with obstructive coronary artery disease. The prognosis of patients with unstable angina and nonobstructive atherosclerotic coronary artery disease is not benign and includes a 2% risk of death or myocardial infarction at 30 days of follow-up. Recent work has shown that at least 20% of women with normal or nonobstructive angiography have myocardial ischemia. likely due to atherosclerosis-related endothelial dysfunction, which itself is associated with an increased risk of later adverse cardiac events and development of frank future obstructive disease. Randomized placebo-controlled studies have demonstrated that tricyclic antidepressants, beta-blockers, angiotensin-converting enzyme inhibitors, L-arginine, statins, and exercise may relieve symptoms, vascular dysfunction, or both; however, longer-term studies evaluating cardiac event rates need to be performed. Conclusions Patients with chest pain and normal or nonobstructive coronary angiograms are predominantly women, and many have a prognosis that is not as benign as commonly thought. Assessment of endothelial function may help identify patients at risk for future cardiac events. Therapy should be directed at Symptom relief with tricyclic agents and beta-blockers, and aggressive antiatherosclerotic therapy with statins, angiotensin-converting enzyme inhibitors, or both should be applied when risk factors are present or prognostic risk is high. Large-scale randomized trials need to be conducted to determine optimal ways of preventing clinical events.	Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, I-40138 Bologna, Italy; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Med,Div Cardiol, Los Angeles, CA USA	University of Bologna; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bugiardini, R (corresponding author), Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, Padiglione 11,Via Massarenti 9, I-40138 Bologna, Italy.	raffaele.bugiardini@unibo.it	Bugiardini, Raffaele/L-6446-2015	Bugiardini, Raffaele/0000-0002-6819-6818				ABEBE W, 1994, AM J PHYSIOL, V266, pH2018, DOI 10.1152/ajpheart.1994.266.5.H2018; Adamson DL, 2001, MENOPAUSE, V8, P233, DOI 10.1097/00042192-200107000-00003; American Heart Association, 2003, HEART DIS STROK STAT; BERNE RM, 1963, AM J PHYSIOL, V204, P317, DOI 10.1152/ajplegacy.1963.204.2.317; BERTRAND ME, 1982, CIRCULATION, V65, P1299, DOI 10.1161/01.CIR.65.7.1299; Buchthal SD, 2000, NEW ENGL J MED, V342, P829, DOI 10.1056/NEJM200003233421201; Buffon A, 2000, AM J PHYSIOL-HEART C, V279, pH2627, DOI 10.1152/ajpheart.2000.279.6.H2627; Bugiardini R, 2004, CIRCULATION, V109, P2518, DOI 10.1161/01.CIR.0000128208.22378.E3; BUGIARDINI R, 1989, AM J CARDIOL, V63, P286, DOI 10.1016/0002-9149(89)90332-9; Bugiardini R, 1993, J AM COLL CARDIOL, V22, P417, DOI 10.1016/0735-1097(93)90045-3; CANNON RO, 1990, J AM COLL CARDIOL, V16, P1359, DOI 10.1016/0735-1097(90)90377-2; CANNON RO, 1991, CIRCULATION, V83, P1660, DOI 10.1161/01.CIR.83.5.1660; Cannon RO, 2000, NEW ENGL J MED, V342, P885, DOI 10.1056/NEJM200003233421209; CANNON RO, 1994, NEW ENGL J MED, V330, P1411, DOI 10.1056/NEJM199405193302003; CARNICI PG, 1991, J AM COLL CARDIOL, V17, P1461; CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P1468, DOI 10.1016/0735-1097(94)90141-4; Chen JW, 2002, AM J CARDIOL, V90, P974, DOI 10.1016/S0002-9149(02)02664-4; de Feyter PJ, 2004, J AM COLL CARDIOL, V44, P1238, DOI 10.1016/j.jacc.2004.06.044; Dhamrait SS, 2004, EUR HEART J, V25, P468, DOI 10.1016/j.ehj.2004.01.007; Diodati JG, 1998, CIRCULATION, V98, P17, DOI 10.1161/01.CIR.98.1.17; DIVER DJ, 1994, AM J CARDIOL, V74, P531, DOI 10.1016/0002-9149(94)90739-0; Doyle M, 2003, J CARDIOV MAGN RESON, V5, P475, DOI 10.1081/JCMR-120022263; Drexler H, 1998, AM J CARDIOL, V82, p3S, DOI 10.1016/S0002-9149(98)90420-9; Erbel R, 1996, EUR HEART J, V17, P880; Eriksson BE, 2000, J AM COLL CARDIOL, V36, P1619, DOI 10.1016/S0735-1097(00)00931-1; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Glaser R, 2002, JAMA-J AM MED ASSOC, V288, P3124, DOI 10.1001/jama.288.24.3124; HAFT JI, 1988, CHEST, V94, P731, DOI 10.1378/chest.94.4.731; Halcox JPJ, 2002, CIRCULATION, V106, P653, DOI 10.1161/01.CIR.0000025404.78001.D8; Hein TW, 1999, CIRC RES, V85, P634, DOI 10.1161/01.RES.85.7.634; Ho KY, 1998, GUT, V43, P105, DOI 10.1136/gut.43.1.105; Hochman JS, 1999, NEW ENGL J MED, V341, P226, DOI 10.1056/NEJM199907223410402; Hochman JS, 1997, J AM COLL CARDIOL, V30, P141, DOI 10.1016/S0735-1097(97)00107-1; Johnson BD, 2004, CIRCULATION, V109, P2993, DOI 10.1161/01.CIR.0000130642.79868.B2; Johnson BD, 2004, CONTEMP CARDIOL, P129; Kalinowski L, 2003, CIRCULATION, V107, P2747, DOI 10.1161/01.CIR.0000066912.58385.DE; KASKI JC, 1995, J AM COLL CARDIOL, V25, P807, DOI 10.1016/0735-1097(94)00507-M; Kayikcioglu M, 2003, EUR HEART J, V24, P1999, DOI 10.1016/S0195-668X(03)00478-0; Kelley BM, 1997, PHARMACOL BIOCHEM BE, V57, P707, DOI 10.1016/S0091-3057(96)00342-5; KEMP HG, 1986, J AM COLL CARDIOL, V7, P479, DOI 10.1016/S0735-1097(86)80456-9; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kuvin JT, 2003, CIRCULATION, V107, P3243, DOI 10.1161/01.CIR.0000075928.54461.33; Lanza GA, 1999, AM J CARDIOL, V84, P854, DOI 10.1016/S0002-9149(99)00450-6; Le NA, 2004, CURR OPIN LIPIDOL, V15, P227, DOI 10.1097/00041433-200404000-00018; Lerman A, 1998, CIRCULATION, V97, P2123, DOI 10.1161/01.CIR.97.21.2123; LICHTLEN PR, 1995, J AM COLL CARDIOL, V25, P1013, DOI 10.1016/0735-1097(94)00519-V; Linfante A, 2004, CIRCULATION, V110, P664; MACALPIN RN, 1993, AM HEART J, V125, P1011, DOI 10.1016/0002-8703(93)90108-L; Manfrini O, 2004, AM J CARDIOL, V93, P1391, DOI 10.1016/j.amjcard.2004.02.037; MARK DB, 1984, CIRCULATION, V69, P880, DOI 10.1161/01.CIR.69.5.880; MASERI A, 1991, J AM COLL CARDIOL, V17, P499, DOI 10.1016/S0735-1097(10)80122-6; Masumoto A, 2001, INT J CARDIOL, V81, P151, DOI 10.1016/S0167-5273(01)00540-X; Mayou RA, 1999, HEART, V81, P387, DOI 10.1136/hrt.81.4.387; Newby DE, 2001, CIRCULATION, V103, P1936; OPHERK D, 1984, CIRCULATION, V69, P1, DOI 10.1161/01.CIR.69.1.1; Panting JR, 2002, NEW ENGL J MED, V346, P1948, DOI 10.1056/NEJMoa012369; Panza JA, 2002, NEW ENGL J MED, V346, P1934, DOI 10.1056/NEJMp020047; Panza JA, 1997, J AM COLL CARDIOL, V29, P293, DOI 10.1016/S0735-1097(96)00481-0; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Pizzi C, 2004, CIRCULATION, V109, P53, DOI 10.1161/01.CIR.0000100722.34034.E4; QUYYUMI AA, 1992, CIRCULATION, V86, P1864, DOI 10.1161/01.CIR.86.6.1864; Reis SE, 1999, J AM COLL CARDIOL, V33, P1469, DOI 10.1016/S0735-1097(99)00072-8; Reis SE, 2001, AM HEART J, V141, P735, DOI 10.1067/mhj.2001.114198; Rosen SD, 2002, HEART, V87, P513, DOI 10.1136/heart.87.6.513; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; Schoenhagen Paul, 2003, Curr Atheroscler Rep, V5, P150, DOI 10.1007/s11883-003-0088-9; Sheps DS, 2001, AM HEART J, V142, P864, DOI 10.1067/mhj.2001.119133; Stolen KQ, 2004, AM J CARDIOL, V93, P64, DOI 10.1016/j.amjcard.2003.08.074; STRAUER BE, 1976, AM HEART J, V92, P715, DOI 10.1016/S0002-8703(76)80007-5; Sutsch G, 1995, INT J CARDIOL, V52, P135, DOI 10.1016/0167-5273(95)02458-9; SUWAIDI JA, 2000, CIRCULATION, V101, P984; Targonski PV, 2003, CIRCULATION, V107, P2805, DOI 10.1161/01.CIR.0000072765.93106.EE; Tune JD, 2004, J APPL PHYSIOL, V97, P404, DOI 10.1152/japplphysiol.01345.2003; Tuzcu EM, 2001, CIRCULATION, V103, P2705; VANE JR, 1990, NEW ENGL J MED, V323, P27; von Mering GO, 2004, CIRCULATION, V109, P722, DOI 10.1161/01.CIR.0000115525.92645.16; WALLING A, 1987, CIRCULATION, V76, P990, DOI 10.1161/01.CIR.76.5.990; Wong TY, 2003, OPHTHALMOLOGY, V110, P933, DOI 10.1016/S0161-6420(03)00084-8	78	393	407	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					477	484		10.1001/jama.293.4.477	http://dx.doi.org/10.1001/jama.293.4.477			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890DW	15671433				2022-12-28	WOS:000226492900027
J	Allain, JP				Allain, JP			Hepatitis C virus in blood donation	LANCET			English	Editorial Material							INFECTION; RECOVERY		Univ Cambridge, Dept Haematol, Div Transfus Med, Cambridge CB2 2PT, England	University of Cambridge	Allain, JP (corresponding author), Univ Cambridge, Dept Haematol, Div Transfus Med, Cambridge CB2 2PT, England.	jpa1000@cam.ac.uk						Candotti D, 2003, J VIROL, V77, P7914, DOI 10.1128/JVI.77.14.7914-7923.2003; Godkin AJ, 2001, J IMMUNOL, V166, P6720, DOI 10.4049/jimmunol.166.11.6720; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Stramer S L, 2002, Dev Biol (Basel), V108, P41; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063	6	6	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					276	278		10.1016/S0140-6736(05)17801-5	http://dx.doi.org/10.1016/S0140-6736(05)17801-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664206				2022-12-28	WOS:000226449600007
J	Guilderson, TP; Reimer, PJ; Brown, TA				Guilderson, TP; Reimer, PJ; Brown, TA			The boon and bane of radiocarbon dating	SCIENCE			English	Editorial Material							AGE CALIBRATION; C-14 DATA; VARIABILITY		Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94550 USA; Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Ocean Sci, Santa Cruz, CA 95064 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Guilderson, TP (corresponding author), Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94550 USA.	tguilderson@llnl.gov	Reimer, Paula/I-5915-2015	Brown, Tom/0000-0001-9984-7647				DEEVEY ES, 1954, P NATL ACAD SCI USA, V40, P285, DOI 10.1073/pnas.40.5.285; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; Hodell DA, 2001, SCIENCE, V292, P1367, DOI 10.1126/science.1057759; Hogg AG, 2002, RADIOCARBON, V44, P633, DOI 10.1017/S0033822200032082; Hutchinson I, 2004, QUATERNARY RES, V61, P193, DOI 10.1016/j.yqres.2003.10.004; LIBBY WF, 1949, SCIENCE, V109, P227, DOI 10.1126/science.109.2827.227; Reimer PJ, 2002, RADIOCARBON, V44, P653, DOI 10.1017/S0033822200032100; STUIVER M, 1966, RADIOCARBON, V8, P534, DOI 10.1017/S0033822200000345; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; STUIVER M, 1981, EARTH PLANET SC LETT, V53, P349, DOI 10.1016/0012-821X(81)90040-6; WEISS H, 1993, SCIENCE, V261, P995, DOI 10.1126/science.261.5124.995; WESTBROOK JA, IN PRESS IAWA B	14	71	71	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2005	307	5708					362	364		10.1126/science.1104164	http://dx.doi.org/10.1126/science.1104164			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15661996				2022-12-28	WOS:000226492300025
J	Miller, TM; Cleveland, DW				Miller, TM; Cleveland, DW			Treating neurodegenerative diseases with antibiotics	SCIENCE			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; MECHANISMS; UPDATE; ALS		Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med & Neurosci, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Miller, TM (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	dcleveland@ucsd.edu	Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027036] Funding Source: NIH RePORTER; NINDS NIH HHS [R37 NS027036] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Heath PR, 2002, MUSCLE NERVE, V26, P438, DOI 10.1002/mus.10186; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; ROTHSTEIN JD, 1991, ANN NEUROL, V30, P224, DOI 10.1002/ana.410300223; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286	8	45	49	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					361	362		10.1126/science.1109027	http://dx.doi.org/10.1126/science.1109027			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15661995				2022-12-28	WOS:000226492300024
J	Nadel, MR; Shapiro, JA; Klabunde, CN; Seeff, LC; Uhler, R; Smith, RA; Ransohoff, DF				Nadel, MR; Shapiro, JA; Klabunde, CN; Seeff, LC; Uhler, R; Smith, RA; Ransohoff, DF			A national survey of primary care physicians' methods for screening for fecal occult blood	ANNALS OF INTERNAL MEDICINE			English	Article							CANCER-SOCIETY GUIDELINES; COLORECTAL-CANCER; CLINICAL GUIDELINES; SELF-REPORT; FOLLOW-UP; SURVEILLANCE; UPDATE; SIGMOIDOSCOPY; MORTALITY; PROSTATE	Background: Screening with the fecal occult blood test (FOBT) has been shown to reduce colorectal cancer incidence and mortality in randomized, controlled trials. Although the test is simple, implementation requires adherence to specific techniques of testing and follow-up of abnormal results. Objective: To examine how FOBT and follow-up are conducted in community practice across the United States. Design: Cross-sectional national surveys of primary care physicians and the public. Setting: The Survey of Colorectal Cancer Screening Practices in Health Care Organizations and the 2000 National Health Interview Survey. Participants: 1147 primary care physicians who ordered or performed FOBT and 11 365 adults 50 years of age or older who responded to questions about FOBT use. Measurements: Self-reported data on details of FOBT implementation and follow-up of positive results. Results: Although screening guidelines recommend home tests, 32.5% (95% Cl, 29.8% to 35.3%) of physicians used only the less accurate method of single-sample in-office testing; another 41.2% (Cl, 38.3% to 44.0%) used both types of test. Follow-up of positive test results showed considerable nonadherence to guidelines, with 29.7% (Cl, 27.1% to 32.4%) of physicians recommending repeating FOBT. Furthermore, sigmoidoscopy, rather than total colon examination, was commonly recommended to work up abnormal findings. Nearly one third of adults who reported having FOBT said they had only an in-office test, and nearly one third of those who reported abnormal FOBT results reported no follow-up diagnostic procedures. Limitations: The study was based on self-reports. Data from the National Health Interview Survey may underestimate the prevalence of in-office testing and inadequate follow-up. Conclusions: mortality reductions demonstrated with FOBT in clinical trials may not be realized in community practice because of the common use of in-office tests and inappropriate follow-up of positive results. Education of providers and system-level interventions are needed to improve the quality of screening implementation.	Ctr Dis Control & Prevent, Atlanta, GA 30341 USA; Amer Canc Soc, Atlanta, GA 30329 USA; NCI, Bethesda, MD 20892 USA; Univ N Carolina, Chapel Hill, NC USA	Centers for Disease Control & Prevention - USA; American Cancer Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill	Nadel, MR (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop K-55, Atlanta, GA 30341 USA.	mrn1@cdc.gov			DIVISION OF CANCER CONTROL &POPULATION SCIENCE [N01PC085169] Funding Source: NIH RePORTER; NCI NIH HHS [N01-PC-85169] Funding Source: Medline; PHS HHS [99FED06571] Funding Source: Medline	DIVISION OF CANCER CONTROL &POPULATION SCIENCE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Control & Population Sciences); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baig N, 2003, AM J GASTROENTEROL, V98, P2078, DOI 10.1016/S0002-9270(03)00424-6; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Collins JF, 2005, ANN INTERN MED, V142, P81, DOI 10.7326/0003-4819-142-2-200501180-00006; *GUID COMM PREV SE, IMPR US BREAST CERV; Hall HI, 2004, PREV MED, V39, P27, DOI 10.1016/j.ypmed.2004.02.024; Klabunde CN, 2003, PREV MED, V36, P352, DOI 10.1016/S0091-7435(02)00066-X; KORN EL, 1999, WILEY S PRO STAT SUR, P1; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Levin B, 1997, ARCH INTERN MED, V157, P970, DOI 10.1001/archinte.157.9.970; Levin B, 2003, CA-CANCER J CLIN, V53, P44, DOI 10.3322/canjclin.53.1.44; Lieberman DA, 2001, NEW ENGL J MED, V345, P555, DOI 10.1056/NEJMoa010328; Lurie JD, 1999, J NATL CANCER I, V91, P1641, DOI 10.1093/jnci/91.19.1641; Mandel JS, 2000, NEW ENGL J MED, V343, P1603, DOI 10.1056/NEJM200011303432203; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MONTANO DE, 1995, AM J PUBLIC HEALTH, V85, P795, DOI 10.2105/AJPH.85.6.795; MYERS RE, 1993, AM J PUBLIC HEALTH, V83, P1620, DOI 10.2105/AJPH.83.11.1620; Nadel MR, 2002, PREV MED, V35, P199, DOI 10.1006/pmed.2002.1070; NASH C, 2003, GASTROENTEROLOGY S1, V124, pW1053; *NAT CTR HLTH STAT, 2000, NAT HLTH INT SURV; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; Peterson SK., 2000, SEMIN COLON RECTAL S, V11, P58; Ransohoff DF, 1997, ANN INTERN MED, V126, P811, DOI 10.7326/0003-4819-126-10-199705150-00014; Ransohoff DF, 1997, ANN INTERN MED, V126, P808, DOI 10.7326/0003-4819-126-10-199705150-00014; Research Triangle Institute, 2001, SUDAAN US MAN REL 8; SAS Institute, 2002, SAS PROC GUID VERS 9; Seeff LC, 2004, CANCER-AM CANCER SOC, V100, P2093, DOI 10.1002/cncr.20276; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Smith RA, 2001, CA-CANCER J CLIN, V51, P38, DOI 10.3322/canjclin.51.1.38; STARFIELD B, 1998, PRIMARY CARE BALANCI, P154; *US PREV SERV TASK, 2002, SCREEN COL CANC; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Winawer SJ, 2000, NEW ENGL J MED, V342, P1766, DOI 10.1056/NEJM200006153422401; Yabroff KR, 2003, MED CARE RES REV, V60, P294, DOI 10.1177/1077558703254698; Yamamoto M, 2000, HEPATO-GASTROENTEROL, V47, P396; YOUNG GP, 1996, PREVENTION EARLY DET, P241; 1996, US PREVENTIVE TASK F	39	143	145	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2005	142	2					86	94		10.7326/0003-4819-142-2-200501180-00007	http://dx.doi.org/10.7326/0003-4819-142-2-200501180-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915LQ	15657156				2022-12-28	WOS:000228306100002
J	Kearney, PM; Whelton, M; Reynolds, K; Muntner, P; Whelton, PK; He, J				Kearney, PM; Whelton, M; Reynolds, K; Muntner, P; Whelton, PK; He, J			Global burden of hypertension: analysis of worldwide data	LANCET			English	Article							BLOOD-PRESSURE LEVELS; CARDIOVASCULAR-DISEASE; HEALTH SURVEY; RISK-FACTORS; DEVELOPING-COUNTRIES; RURAL-POPULATION; URBAN-POPULATION; PREVALENCE; AWARENESS; EPIDEMIOLOGY	Background Reliable information about the prevalence of hypertension in different world regions is essential to the development of national and international health policies for prevention and control of this condition. We aimed to pool data from different regions of the world to estimate the overall prevalence and absolute burden of hypertension in 2000, and to estimate the global burden in 2025. Methods We searched the published literature from Jan 1, 1980, to Dec 31, 2002, using MEDLINE, supplemented by a manual search of bibliographies of retrieved articles. We included studies that reported sex-specific and age-specific prevalence of hypertension in representative population samples. All data were obtained independently, by two investigators with a standardised protocol and data-collection form. Results Overall, 26.4% (95% CI 26.0-26.8%) of the adult population in 2000 had hypertension (26.6% of men [26.0-27.2%] and 26.1% of women [25.5-26.6%]), and 29.2% (28.8-29.7%) were projected to have this condition by 2025 (29.0% of men [28.6-29.4%] and 29.5% of women [29.1-29.9%]). The estimated total number of adults with hypertension in 2000 was 972 million (957-987 million); 333 million (329-336 million) in economically developed countries and 639 million (625-654 million) in economically developing countries. The number of adults with hypertension in 2025 was predicted to increase by about 60% to a total of 1.56 billion (1.54-1.58 billion). Interpretation Hypertension is an important public-health challenge worldwide. Prevention, detection, treatment, and control of this condition should receive high priority.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Med, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Hypertens & Renal Ctr Excellence, New Orleans, LA 70112 USA; Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Tulane University; Tulane University; Tulane University; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave,SL18, New Orleans, LA 70112 USA.	jhe@tulane.edu	He, Jiang/AAF-5303-2020; Kearney, Patricia M/AAE-8501-2020; Reynolds, Kristi/AAN-1434-2021	He, Jiang/0000-0002-8286-9652; Reynolds, Kristi/0000-0001-7619-1649; Kearney, Patricia/0000-0001-9599-3540	NHLBI NIH HHS [R01 HL68057] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], NATL CARDIOVASCULAR; Arroyo P, 1999, J HUM HYPERTENS, V13, P671, DOI 10.1038/sj.jhh.1000909; BABA S, 1991, J HUM HYPERTENS, V5, P317; Banegas JR, 1998, HYPERTENSION, V32, P998, DOI 10.1161/01.HYP.32.6.998; BENNETT SA, 1994, MED J AUSTRALIA, V161, P519, DOI 10.5694/j.1326-5377.1994.tb127594.x; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Edwards R, 2000, J HYPERTENS, V18, P145, DOI 10.1097/00004872-200018020-00003; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Forrester T, 1996, CIBA F SYMP, V201, P17; Fuentes R, 2000, J HYPERTENS, V18, P521, DOI 10.1097/00004872-200018050-00003; Giampaoli S, 2001, Ital Heart J Suppl, V2, P294; Gordis L., 2000, EPIDEMIOLOGY, V2; Gu DF, 2002, HYPERTENSION, V40, P920, DOI 10.1161/01.HYP.0000040263.94619.D5; Gu DF, 2003, EUR J CARDIOV PREV R, V10, P249, DOI 10.1097/01.hjr.0000085254.65733.21; GUPTA R, 1994, J HUM HYPERTENS, V8, P823; GUPTA R, 1995, J HYPERTENS, V13, P1193, DOI 10.1097/00004872-199510000-00014; Gupta R, 1999, J Indian Med Assoc, V97, P74; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Halberstein RA, 1999, HUM BIOL, V71, P659; Hamet P, 2000, CAN J CARDIOL, V16, P1483; He J, 1997, MED CLIN N AM, V81, P1077, DOI 10.1016/S0025-7125(05)70568-X; Hernandez-Hernandez R, 2000, J HUM HYPERTENS, V14, pS2, DOI 10.1038/sj.jhh.1000978; IBRAHIM MM, 1995, HYPERTENSION, V26, P886, DOI 10.1161/01.HYP.26.6.886; Joffres MR, 1997, AM J HYPERTENS, V10, P1097; Kearney PM, 2004, J HYPERTENS, V22, P11, DOI 10.1097/00004872-200401000-00003; KIM JS, 1994, AM J PREV MED, V10, P200, DOI 10.1016/S0749-3797(18)30591-9; Levenson James W, 2002, Prev Cardiol, V5, P188, DOI 10.1111/j.1520-037X.2002.00564.x; Malhotra P, 1999, J HUM HYPERTENS, V13, P467, DOI 10.1038/sj.jhh.1000864; Mbanya JCN, 1998, INT J EPIDEMIOL, V27, P181, DOI 10.1093/ije/27.2.181; Mufunda T, 2000, J HUM HYPERTENS, V14, P65, DOI 10.1038/sj.jhh.1000886; Murray C.J, 1994, GLOBAL COMP ASSESSME; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Pan WH, 2001, J HUM HYPERTENS, V15, P793, DOI 10.1038/sj.jhh.1001268; Pearson TA, 1999, CARDIOVASC DRUG THER, V13, P95, DOI 10.1023/A:1007727924276; POULTER N, 2003, HEART, V89, P2; Primatesta P, 2001, HYPERTENSION, V38, P827, DOI 10.1161/hyp.38.4.827; RAMIREZ MOA, 1995, J HUM HYPERTENS, V9, P891; Riecansky I, 1991, Bratisl Lek Listy, V92, P203; Seedat YK, 2000, J HUM HYPERTENS, V14, P739, DOI 10.1038/sj.jhh.1001059; Singh RB, 2000, J HUM HYPERTENS, V14, P749, DOI 10.1038/sj.jhh.1001057; Singh RB, 1997, J HUM HYPERTENS, V11, P679, DOI 10.1038/sj.jhh.1000511; Singh RB, 1997, J HUM HYPERTENS, V11, P51, DOI 10.1038/sj.jhh.1000384; Sonmez HM, 1999, J HUM HYPERTENS, V13, P399, DOI 10.1038/sj.jhh.1000824; STATA, 2001, STAT STAT SOFTW REL; Stegmayr B, 1996, CEREBROVASC DIS, V6, P80, DOI 10.1159/000108002; Stergiou GS, 1999, AM J HYPERTENS, V12, P959, DOI 10.1016/S0895-7061(99)00136-3; Steyn K, 2001, J HYPERTENS, V19, P1717, DOI 10.1097/00004872-200110000-00004; Sulbaran T, 2000, J HUM HYPERTENS, V14, pS6, DOI 10.1038/sj.jhh.1000979; THAMM M, 1999, GESUNDHEITSWESEN; THOM TJ, 1989, INT J EPIDEMIOL, V18, pS20; Ueshima H, 2000, J HUM HYPERTENS, V14, P765, DOI 10.1038/sj.jhh.1001054; United Nations Secretariat Department of Economic and Social Affairs Population Division, 2001, WORLD POP PROSP 2000; WHELTON PK, 1994, LANCET, V344, P101, DOI 10.1016/S0140-6736(94)91285-8; *WHO, WHOMNCCCH02012002; *WHO, 2001, WORLD HLTH REP 2001, P144; *WHO COLL CTR SURV, 2001, GLOB CARD INFOBASE; Wolf-Maier K, 2003, JAMA-J AM MED ASSOC, V289, P2363, DOI 10.1001/jama.289.18.2363; Wolz M, 2000, AM J HYPERTENS, V13, P103, DOI 10.1016/S0895-7061(99)00241-1; *WORLD BANK, 1993, WORLD DEV REP 1993 I; *WORLD BANK GROUP, WORLD DEV IND 2003 C; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488	64	5175	5523	15	543	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					217	223		10.1016/S0140-6736(05)17741-1	http://dx.doi.org/10.1016/S0140-6736(05)17741-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652604				2022-12-28	WOS:000226309600027
J	Yuan, ZL; Guan, YJ; Chatterjee, D; Chin, YE				Yuan, ZL; Guan, YJ; Chatterjee, D; Chin, YE			Stat3 dimerization regulated by reversible acetylation of a single lysine residue	SCIENCE			English	Article							NF-KAPPA-B; GENE-EXPRESSION; SH2 DOMAIN; TRANSCRIPTION; DNA; ACTIVATION; CBP/P300; P300/CBP; PEPTIDE; PROTEIN	Upon cytokine treatment, members of the signal transducers and activators of transcription (STAT) family of proteins are phosphorytated on tyrosine and serine sites within the carboxyl-terminal region in cells. We show that in response to cytokine treatment, Stat3 is also acetylated on a single lysine residue, Lys(685). Histone acetyltransferase p300-mediated Stat3 acetylation on Lys(685) was reversible by type I histone deacetylase (HDAC). Use of a prostate cancer cell line (PC3) that lacks Stat3 and PC3 cells expressing wildtype Stat3 or a Stat3 mutant containing a Lys(685)-to-Arg substitution revealed that Lys(685) acetylation was critical for Stat3 to form stable dimers required for cytokine-stimulated DNA binding and transcriptional regulation, to enhance transcription of cell growth-related genes, and to promote cell cycle progression in response to treatment with oncostatin M.	Brown Univ, Rhode Isl Hosp, Sch Med, Dept Surg, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Sch Med, Dept Med, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Sch Med, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02903 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Chin, YE (corresponding author), Brown Univ, Rhode Isl Hosp, Sch Med, Dept Surg, Providence, RI 02903 USA.	y_eugene_chin@brown.edu						Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Clark J, 2003, ONCOGENE, V22, P1247, DOI 10.1038/sj.onc.1206247; Gao Q, 2004, MOL CELL PROTEOMICS, V3, P704, DOI 10.1074/mcp.M300131-MCP200; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; YUAN PZ, UNPUB; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhukovskaya NV, 2004, DEVELOPMENT, V131, P447, DOI 10.1242/dev.00927	27	590	618	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					269	273		10.1126/science.1105166	http://dx.doi.org/10.1126/science.1105166			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653507				2022-12-28	WOS:000226361900047
J	Fowler, JH; Johnson, T; Smirnov, O				Fowler, JH; Johnson, T; Smirnov, O			Human behaviour - Egalitarian motive and altruistic punishment	NATURE			English	Letter									Univ Calif Davis, Dept Polit Sci, Davis, CA 95616 USA; Max Planck Inst Human Dev, Ctr Adapt Behav & Cognit, D-14195 Berlin, Germany; Univ Oregon, Dept Polit Sci, Eugene, OR 97403 USA	University of California System; University of California Davis; Max Planck Society; University of Oregon	Fowler, JH (corresponding author), Univ Calif Davis, Dept Polit Sci, 1 Shields Ave, Davis, CA 95616 USA.	jhfowler@ucdavis.edu	Fowler, James H/C-2750-2008	Fowler, James H/0000-0001-7795-1638				Boehm C., 1999, HIERARCHY FOREST EVO; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a	2	44	44	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2005	433	7021								10.1038/nature03256	http://dx.doi.org/10.1038/nature03256			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15637787				2022-12-28	WOS:000226117100026
J	Tsai, AG; Wadden, TA				Tsai, AG; Wadden, TA			Systematic review: An evaluation of major commercial weight loss programs in the United States	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-CALORIE DIET; LONG-TERM MAINTENANCE; BEHAVIOR-THERAPY; BODY-COMPOSITION; CONTROLLED-TRIAL; OBESE-PATIENTS; FOLLOW-UP; INTERVENTION; REDUCTION; VLCD	Background: Each year millions of Americans enroll in commercial and self-help weight loss programs. Health care providers and their obese patients know little about these programs because of the absence of systematic reviews. Purpose: To describe the components, costs, and efficacy of the major commercial and organized self-help weight loss programs in the United States that provide structured in-person or online counseling. Data Sources: Review of company Web sites, telephone discussion with company representatives, and search of the MEDLINE database. Study Selection: Randomized trials at least 12 weeks in duration that enrolled only Adults and assessed interventions as they are usually provided to the public, or case series that met these criteria, stated the number of enrollees, and included a follow-up evaluation that lasted 1 year or longer. Data Extraction: Data were extracted on study design, attrition, weight loss, duration of follow-up, and maintenance of weight loss. Data Synthesis: we found studies of eDiets.com, Health Management Resources, Take Off Pounds Sensibly, OPTIFAST, and Weight Watchers. Of 3 randomized, controlled trials of Weight Watchers, the largest reported a loss of 3.2% of initial weight at 2 years. One randomized trial and several case series of medically supervised very-low-calorie diet programs found that patients who completed treatment lost approximately 15% to 25% of initial weight. These programs were associated with high costs, high attrition rates, and a high probability of regaining 50% or more of lost weight in 1 to 2 years. Commercial interventions available over the Internet and organized self-help programs produced minimal weight loss. Limitations: Because many studies did not control for high attrition rates, the reported results are probably a best-case scenario. Conclusions: With the exception of 1 trial of Weight Watchers, the evidence to support the use of the major commercial and self-help weight loss programs is suboptimal. Controlled trials are needed to assess the efficacy and cost-effectiveness of these interventions.	Univ Penn, Weight & Eating Disorders Program, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Wadden, TA (corresponding author), Univ Penn, Weight & Eating Disorders Program, Sch Med, 3535 Market St,Suite 3029, Philadelphia, PA 19104 USA.	wadden@mail.med.upenn.edu	Biguzzi, Felipe A/E-4724-2015		NIDDK NIH HHS [K24-DK-065018] Funding Source: Medline; PHS HHS [2-T32-HP-010026] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK065018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agras WS, 1996, J CONSULT CLIN PSYCH, V64, P610, DOI 10.1037/0022-006X.64.3.610; ANDERSON JW, 1994, J AM COLL NUTR, V13, P256, DOI 10.1080/07315724.1994.10718406; ANDERSON JW, 1994, DIABETES CARE, V17, P602, DOI 10.2337/diacare.17.6.602; ANDERSON JW, 1991, J AM DIET ASSOC, V91, P1582; Anderson JW, 2001, AM J CLIN NUTR, V74, P579; Anderson JW, 1999, J AM COLL NUTR, V18, P620, DOI 10.1080/07315724.1999.10718897; [Anonymous], 1993, JAMA, V270, P967; Apfelbaum M, 1999, AM J MED, V106, P179, DOI 10.1016/S0002-9343(98)00411-2; Astrup A, 2000, Obes Rev, V1, P17, DOI 10.1046/j.1467-789x.2000.00004.x; BELIARD D, 1992, INT J OBESITY, V16, P505; Brownell K. D., 2000, LEARN PROGRAM WEIGHT; Bryner RW, 1999, J AM COLL NUTR, V18, P115, DOI 10.1080/07315724.1999.10718838; Christakis G, 1996, NUTR TODAY, V31, P29; Clelland R, 2001, CRIT REV FOOD SCI, V41, P45; Daly A, 2000, J AM DIET ASSOC, V100, P1456, DOI 10.1016/S0002-8223(00)00034-1; Ditschuneit HH, 1999, AM J CLIN NUTR, V69, P198; Djuric Z, 2002, OBES RES, V10, P657, DOI 10.1038/oby.2002.89; DONNELLY JE, 1994, INT J OBESITY, V18, P469; DONNELLY JE, 1991, AM J CLIN NUTR, V54, P56, DOI 10.1093/ajcn/54.1.56; Flechtner-Mors M, 2000, OBES RES, V8, P399, DOI 10.1038/oby.2000.48; Flynn T J, 1993, Arch Fam Med, V2, P1042, DOI 10.1001/archfami.2.10.1042; FOSTER GD, 1992, AM J CLIN NUTR, V55, P811, DOI 10.1093/ajcn/55.4.811; FRANK A, 1993, JAMA-J AM MED ASSOC, V269, P2132, DOI 10.1001/jama.269.16.2132; Grodstein F, 1996, ARCH INTERN MED, V156, P1302, DOI 10.1001/archinte.156.12.1302; HARTMAN WM, 1993, INT J EAT DISORDER, V14, P87, DOI 10.1002/1098-108X(199307)14:1&lt;87::AID-EAT2260140112&gt;3.0.CO;2-2; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; HYMAN FN, 1993, ANN INTERN MED, V119, P681, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00011; Institute of Medicine, 1995, WEIGH OPT CRIT EV WE; KANDERS BS, 1989, INT J OBESITY, V13, P131; KIRSCHNER MA, 1988, INT J OBESITY, V12, P69; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Latner JD, 2000, INT J OBESITY, V24, P893, DOI 10.1038/sj.ijo.0801249; LEVITZ LS, 1974, AM J PSYCHIAT, V131, P423; Lowe MR, 2001, INT J OBESITY, V25, P325, DOI 10.1038/sj.ijo.0801521; MIURA J, 1989, INT J OBESITY, V13, P73; 2000, PRACT GUID ID EV TRE; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1110, DOI 10.1093/ajcn/49.5.1110; Pekkarinen T, 1997, ARCH INTERN MED, V157, P1581, DOI 10.1001/archinte.157.14.1581; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rippe JM, 1998, OBES RES, V6, P208, DOI 10.1002/j.1550-8528.1998.tb00339.x; Rossner S, 1997, INT J OBESITY, V21, P22, DOI 10.1038/sj.ijo.0800355; Ryttig KR, 1997, INT J OBESITY, V21, P574, DOI 10.1038/sj.ijo.0800444; Saris WHM, 2001, OBES RES, V9, p295S, DOI 10.1038/oby.2001.134; Serdula MK, 2003, JAMA-J AM MED ASSOC, V289, P1747, DOI 10.1001/jama.289.14.1747; SIKAND G, 1988, J AM DIET ASSOC, V88, P487; Stern J S, 1995, Obes Res, V3, P591; Tate DF, 2001, JAMA-J AM MED ASSOC, V285, P1172, DOI 10.1001/jama.285.9.1172; Tate DF, 2003, JAMA-J AM MED ASSOC, V289, P1833, DOI 10.1001/jama.289.14.1833; Torgerson JS, 1997, INT J OBESITY, V21, P987, DOI 10.1038/sj.ijo.0800507; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; VOLKMAR FR, 1981, ARCH INTERN MED, V141, P426, DOI 10.1001/archinte.141.4.426; Wadden T A, 1995, Obes Res, V3, P549; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WADDEN TA, 1994, J CONSULT CLIN PSYCH, V62, P165, DOI 10.1037/0022-006X.62.1.165; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961; WADDEN TA, 1986, J CONSULT CLIN PSYCH, V54, P482, DOI 10.1037/0022-006X.54.4.482; WADDEN TA, 1989, INT J OBESITY, V13, P39; WALSH MF, 1995, J FAM PRACTICE, V41, P231; WING RR, 1994, AM J MED, V97, P354, DOI 10.1016/0002-9343(94)90302-6; WING RR, 1991, ARCH INTERN MED, V151, P1334, DOI 10.1001/archinte.151.7.1334; Witherspoon Barbara, 2004, J Am Acad Nurse Pract, V16, P198, DOI 10.1111/j.1745-7599.2004.tb00442.x; WOLFE BL, 1992, ADDICT BEHAV, V17, P469, DOI 10.1016/0306-4603(92)90007-I; Womble L. G., 2002, Handbook of obesity treatment, P395; Womble LG, 2004, OBES RES, V12, P1011, DOI 10.1038/oby.2004.124; World Health Organization,, 1998, WHO TECHN REP SER; WYDEN R, 1990, MEMORANDUM SUBCOMMIT, P185; 1989, TAKE IT OFF KEEP IT; 2003, PARTNERSHIP HLTH WEI	68	469	473	0	72	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2005	142	1					56	66		10.7326/0003-4819-142-1-200501040-00012	http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00012			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916DS	15630109				2022-12-28	WOS:000228366200006
J	Van de Werf, F; Gore, JM; Avezum, A; Gulba, DC; Goodman, SG; Budaj, A; Brieger, D; White, K; Fox, KAA; Eagle, KA; Kennelly, BM				Van de Werf, F; Gore, JM; Avezum, A; Gulba, DC; Goodman, SG; Budaj, A; Brieger, D; White, K; Fox, KAA; Eagle, KA; Kennelly, BM		GRACE Investigators	Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study	BRITISH MEDICAL JOURNAL			English	Article							ELEVATION MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; GLOBAL REGISTRY; ST-ELEVATION; CONSERVATIVE STRATEGIES; FIBRINOLYTIC THERAPY; RANDOMIZED TRIALS; EVENTS GRACE; OUTCOMES; HOSPITALS	Objective To investigate the relation between access to a cardiac catheterisation laborator and clinical outcomes in patients admitted to hospital with suspected acute coronary syndrome. Design Prospective, multinational, observational registry. Setting Patients enrolled in 106 hospitals in 14 countries between April 1999 and March 2003. Participants 28 825 patients aged greater than or equal to 18 years. Main outcome measures Use of percutaneous coronary intervention or coronary artery bypass graft surgery, death, infarction after discharge, stroke, or major bleeding. Results Most patients (77%) across all regions (United States, Europe, Argentina and Brazil, Australia, New Zealand, and Canada) were admitted to hospitals with catheterisation facilities. As expected, the availability of a catheterisation laboratory was associated with more frequent use of percutaneous coronary intervention (41% v 3.9%, P < 0.001) and coronary artery bypass graft (7.1% v 0.7%, P < 0.00 1). After adjustment for baseline characteristics, medical history, and geographical region there were no significant differences in the risk of early death between patients in hospitals with or without catheterisation facilities (odds ratio 1.13, 95% confidence interval 0.98 -to 1.30, for death in hospital; hazard ratio 1.05, 0.93 to 1.18, for death-at 30 days). The risk of death at-six months was significantly higher in patients first admitted to hospitals with catheterisation facilities (hazard ratio 1.14, 1.03 to 1.26), as was the risk of bleeding complications in hospital (odds ratio 1.94, 1.57 to 2.39) and stroke (odds ratio 1.53, 1.10 to 2.14). Conclusions These findings support the current strategy of directing patients with suspected acute coronary syndrome to the nearest hospital with acute care facilities, irrespective of the availability of a catheterisation laboratory, and argue against early routine transfer of these patients to tertiary care hospitals with interventional facilities.	Univ Ziekenhuis Gasthuisberg, B-3000 Louvain, Belgium; Univ Massachusetts, Mem Hlth Care, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Worcester, MA 01604 USA; Dante Pazzanese Inst Cardiol, Div Res, BR-04012909 Sao Paulo, Brazil; Krankenhaus Duren, D-52351 Duren, NRW, Germany; Univ Toronto, St Michaels Hosp, Div Cardiol, Canadian Heart Res Ctr, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Div Cardiol, Terrence Donnelly Heart Ctr, Toronto, ON M5B 1W8, Canada; Grochowski Hosp, Ctr Med Ksztalcenia Podyplomowego, Postgrad Med Sch, PL-04073 Warsaw, Poland; Concord Repatriat Gen Hosp, Coronary Care Unit, Concord, NSW 2139, Australia; Univ Edinburgh, Royal Infirm Edinburgh, Edinburgh EH16 4SB, Midlothian, Scotland; Univ Michigan, Ctr Cardiovasc, Ann Arbor, MI 48109 USA; Hoag Mem Hosp, Newport Beach, CA 92658 USA	KU Leuven; University Hospital Leuven; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Instituto Dante Pazzanese de Cardiologia; Canadian Heart Research Centre; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Centre of Postgraduate Medical Education - Poland; Concord Repatriation General Hospital; Royal Infirmary of Edinburgh; University of Edinburgh; University of Michigan System; University of Michigan	Van de Werf, F (corresponding author), Univ Ziekenhuis Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium.	frans.vandewerf@uz.kuleuven.ac.be	Avezum, Alvaro AA/K-6137-2016; Avezum, Alvaro/AAP-7687-2020; Fox, keith A A/I-3742-2013	Avezum, Alvaro AA/0000-0002-3073-6890; Budaj, Andrzej/0000-0002-6395-2098; Van de Werf, Frans/0000-0001-9479-7767; Fox, Keith/0000-0002-0140-2752				Agnelli G, 2001, AM HEART J, V141, P190, DOI 10.1067/mhj.2001.112404; Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; Antman EM, 2004, CIRCULATION, V109, P2480, DOI 10.1161/01.CIR.0000128736.57259.48; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Eagle KA, 2004, JAMA-J AM MED ASSOC, V291, P2727, DOI 10.1001/jama.291.22.2727; Eagle KA, 2002, LANCET, V359, P373, DOI 10.1016/S0140-6736(02)07595-5; FEIT F, 1990, J AM COLL CARDIOL, V16, P1529, DOI 10.1016/0735-1097(90)90295-Z; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Goldberg RJ, 2004, AM J CARDIOL, V93, P288, DOI 10.1016/j.amjcard.2003.10.006; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Lee PY, 2001, JAMA-J AM MED ASSOC, V286, P708, DOI 10.1001/jama.286.6.708; Lupon J, 1999, J AM COLL CARDIOL, V34, P1947, DOI 10.1016/S0735-1097(99)00446-5; Marrugat J, 1997, J AM COLL CARDIOL, V30, P1187, DOI 10.1016/S0735-1097(97)00312-4; Mehta RH, 2002, J AM COLL CARDIOL, V40, P1034, DOI 10.1016/S0735-1097(02)02067-3; Rogers WJ, 2000, J AM COLL CARDIOL, V35, P371, DOI 10.1016/S0735-1097(99)00505-7; Steg PG, 2003, EUR HEART J, V24, P613, DOI 10.1016/S0195-668X(02)00805-9; Topol EJ, 2003, CIRCULATION, V107, P1463, DOI 10.1161/01.CIR.0000063680.45780.A0; Wallentin L, 1999, LANCET, V354, P708; Yusuf S, 1998, LANCET, V352, P507, DOI 10.1016/S0140-6736(97)11162-X	21	92	94	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 26	2005	330	7489					441	444B		10.1136/bmj.38335.390718.82	http://dx.doi.org/10.1136/bmj.38335.390718.82			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901XK	15665006	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000227315400015
J	Ward, PD; Botha, J; Buick, R; De Kock, MO; Erwin, DH; Garrison, GH; Kirschvink, JL; Smith, R				Ward, PD; Botha, J; Buick, R; De Kock, MO; Erwin, DH; Garrison, GH; Kirschvink, JL; Smith, R			Abrupt and gradual extinction among Late Permian land vertebrates in the Karoo Basin, South Africa	SCIENCE			English	Article							TRIASSIC BOUNDARY; STRATIGRAPHIC RANGES; CONFIDENCE-INTERVALS; MASS EXTINCTION; SUPERGROUP; PATTERNS; MARINE	The Karoo basin of South Africa exposes a succession of Upper Permian. to Lower Triassic terrestrial strata containing abundant terrestrial vertebrate fossils. Paleomagnetic/magnetostratigraphic and carbon-isotope data allow sections to be correlated across the basin. With this stratigraphy, the vertebrate fossil data show a gradual extinction in the Upper Permian punctuated by an enhanced extinction pulse at the Permian-Triassic boundary interval, particularly among the dicynodont therapsids, coinciding with negative carbon-isotope anomalies.	Univ Washington, Dept Biol, Seattle, WA 98195 USA; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; S African Museum, ZA-8000 Cape Town, South Africa; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Rand Afrikaans Univ, Dept Geol, Johannesburg, South Africa; MRC121 Smithsonian Inst, Dept Paleobiol, Washington, DC 20013 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; California Institute of Technology; University of Johannesburg; Smithsonian Institution; Smithsonian National Museum of Natural History	Ward, PD (corresponding author), Univ Washington, Dept Biol, Seattle, WA 98195 USA.	argo@u.washington.edu	Erwin, Douglas H/A-9668-2009; Botha, Jennifer/N-1893-2013	Botha, Jennifer/0000-0001-8824-9334; Erwin, Douglas/0000-0003-2518-5614; de Kock, Michiel/0000-0002-5036-3438; Buick, Roger/0000-0003-0139-1659				Arens NC, 2000, PALAIOS, V15, P314, DOI 10.2307/3515539; Basu AR, 2003, SCIENCE, V302, P1388, DOI 10.1126/science.1090852; Becker L, 2004, SCIENCE, V304, P1469, DOI 10.1126/science.1093925; Becker L, 2001, SCIENCE, V291, P1530, DOI 10.1126/science.1057243; Benton MJ, 2003, TRENDS ECOL EVOL, V18, P358, DOI 10.1016/S0169-5347(03)00093-4; BOTHA JM, UNPUB; Catuneanu O, 1998, BASIN RES, V10, P417; Cerling TE, 1992, GLOBAL BIOGEOCHEM CY, V6, P307, DOI 10.1029/92GB01102; CONEY L, 2004, LPSC, V35, P1488; De Kock MO, 2004, GONDWANA RES, V7, P175, DOI 10.1016/S1342-937X(05)70316-6; de Wit MJ, 2002, J GEOL, V110, P227, DOI 10.1086/338411; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; FOSTER C, 2002, 1 INT C PAL, P57; GROENWALD GH, 1995, GEOL SURV S AFR BIOS, V1, P35; HOLSER WT, 1992, GEOCHIM COSMOCHIM AC, V56, P3297, DOI 10.1016/0016-7037(92)90306-4; Jin YG, 2000, SCIENCE, V289, P432, DOI 10.1126/science.289.5478.432; KING DA, 1990, CHEM PHYSICS SOLID A, V3, P1; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; MacLeod KG, 2000, GEOLOGY, V28, P227, DOI 10.1130/0091-7613(2000)28<227:TOMREA>2.0.CO;2; MARSHALL CR, 1994, PALEOBIOLOGY, V20, P459, DOI 10.1017/S0094837300012938; Nawrocki J, 2004, TERRA NOVA, V16, P139, DOI 10.1111/j.1365-3121.2004.00543.x; Payne JL, 2004, SCIENCE, V305, P506, DOI 10.1126/science.1097023; Retallack GJ, 2003, GEOL SOC AM BULL, V115, P1133, DOI 10.1130/B25215.1; RUBIDGE B, 1995, GEOL SURV S AFR BIOS, V1; Schultz, 1982, GEOLOGICAL SOC AM SP, V190, P291, DOI DOI 10.1130/SPE190-P291; SHEEHAN PM, 1991, SCIENCE, V254, P835, DOI 10.1126/science.11536489; Solow AR, 2003, PALEOBIOLOGY, V29, P181, DOI 10.1666/0094-8373(2003)029<0181:EOSRWF>2.0.CO;2; SPRINGER MS, 1990, PALEOBIOLOGY, V16, P512, DOI 10.1017/S0094837300010228; STEINER M, 1989, J GEOPHYS RES-SOLID, V94, P7343, DOI 10.1029/JB094iB06p07343; Steiner MB, 2003, PALAEOGEOGR PALAEOCL, V194, P405, DOI 10.1016/S0031-0182(03)00230-X; Szurlies M, 2003, EARTH PLANET SC LETT, V212, P263, DOI 10.1016/S0012-821X(03)00288-7; Twitchett RJ, 2001, GEOLOGY, V29, P351, DOI 10.1130/0091-7613(2001)029<0351:RASCOM>2.0.CO;2; Wang SC, 2004, PALEOBIOLOGY, V30, P5, DOI 10.1666/0094-8373(2004)030<0005:ICIFET>2.0.CO;2; Ward PD, 2000, SCIENCE, V289, P1740, DOI 10.1126/science.289.5485.1740	34	257	282	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					709	714		10.1126/science.1107068	http://dx.doi.org/10.1126/science.1107068			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15661973	Green Submitted			2022-12-28	WOS:000226814900039
J	Berndt, ER				Berndt, ER			To inform or persuade? Direct-to-consumer advetising of prescription drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Berndt, ER (corresponding author), MIT, Cambridge, MA 02139 USA.							AIKIN KJ, 2003, DIR TO CONS PROM PUB; *FOOD DRUG ADM, GUID IND BRIEF SUMM; WEISSMAN JS, 2004, PHYSICIANS REPORT PA; 2004, PINK SHEET      122, P16	4	37	37	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					325	328		10.1056/NEJMp048357	http://dx.doi.org/10.1056/NEJMp048357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673797				2022-12-28	WOS:000226535900002
J	Cassell, EJ				Cassell, EJ			Medical ethics: Consent or obedience? Power and authority in medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Cassell, EJ (corresponding author), Cornell Univ, Weill Med Coll, New York, NY 10021 USA.							Blass T, 2000, OBEDIENCE TO AUTHORITY, P35; Blass T., 2004, MAN SHOCKED WORLD LI; Cassell EJ, 2001, ANN INTERN MED, V134, P1120, DOI 10.7326/0003-4819-134-12-200106190-00012; French J. R. P., 1959, STUD SOC POWER, P150, DOI DOI 10.1007/BF00228551; SCHNEIDER CE, 1998, PRACTICE AUTONOMY PA, V22, P307	5	40	41	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					328	330		10.1056/NEJMp048188	http://dx.doi.org/10.1056/NEJMp048188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673798				2022-12-28	WOS:000226535900003
J	Huskins, WC; Goldmann, DA				Huskins, WC; Goldmann, DA			Controlling meticillin-resistant Staphylococcus aureus, aka"Superbug"	LANCET			English	Editorial Material							INFECTION-CONTROL		Mayo Clin, Dept Pediat & Adolescent Med, Div Pediat Infect Dis, Rochester, MN 55905 USA; Inst Healthcare Improvement, Cambridge, MA 02138 USA; Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA	Mayo Clinic; Institute for Healthcare Improvement; Harvard University; Boston Children's Hospital	Goldmann, DA (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, Div Pediat Infect Dis, Rochester, MN 55905 USA.	dgoldmann@IHI.org		Huskins, W. Charles/0000-0002-9989-175X				[Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Barrett SP, 1998, J HOSP INFECT, V39, P85, DOI 10.1016/S0195-6701(98)90322-X; Berenholtz SM, 2004, CRIT CARE MED, V32, P2014, DOI 10.1097/01.CCM.0000142399.70913.2F; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; *DHQP, 2001, CDCS 7 HEALTHC SAF C; *EUR ANT RES SURV, EARSS ANN REP 2003; Garner Julia S., 1996, Infection Control and Hospital Epidemiology, V17, P53; *I HEALTHC IMPR, 100K LIV CAMP; Jernigan JA, 1995, INFECT CONT HOSP EP, V16, P686; Langley Gj., 1996, IMPROVEMENT GUIDE PR; Muto CA, 2003, INFECT CONT HOSP EP, V24, P362, DOI 10.1086/502213; Pittet D, 2004, J HOSP INFECT, V58, P1, DOI 10.1016/j.jhin.2004.06.002; Solomon S, 2003, AM J INFECT CONTROL, V31, P481; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Tiemersma EW, 2004, EMERG INFECT DIS, V10, P1627, DOI 10.3201/eid1009.040069; Verhoef J, 1999, EUR J CLIN MICROBIOL, V18, P461, DOI 10.1007/s100960050324	16	27	32	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					273	275						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664204				2022-12-28	WOS:000226449600005
J	Udem, T				Udem, T			Short and sharp-spectroscopy with frequency combs	SCIENCE			English	Editorial Material							2-PHOTON SPECTROSCOPY; PULSES		Max Planck Inst Quantum Opt, D-85748 Garching, Germany	Max Planck Society	Udem, T (corresponding author), Max Planck Inst Quantum Opt, D-85748 Garching, Germany.	thu@mpq.mpg.de						BAKLANOV YV, 1977, APPL PHYS, V12, P97, DOI 10.1007/BF00900075; ECKSTEIN JN, 1978, PHYS REV LETT, V40, P847, DOI 10.1103/PhysRevLett.40.847; Marian A, 2004, SCIENCE, V306, P2063, DOI 10.1126/science.1105660; Peik E, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.170801; Rafac RJ, 2000, PHYS REV LETT, V85, P2462, DOI 10.1103/PhysRevLett.85.2462; Snadden MJ, 1996, OPT COMMUN, V125, P70, DOI 10.1016/0030-4018(95)00711-3; Witte S, 2005, SCIENCE, V307, P400, DOI 10.1126/science.1106612	7	6	6	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					364	365		10.1126/science.1108159	http://dx.doi.org/10.1126/science.1108159			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15661997				2022-12-28	WOS:000226492300026
J	Witte, S; Zinkstok, RT; Ubachs, W; Hogervorst, W; Eikema, KSE				Witte, S; Zinkstok, RT; Ubachs, W; Hogervorst, W; Eikema, KSE			Deep-ultraviolet quantum interference metrology with ultrashort laser pulses	SCIENCE			English	Article							LIGHT-PULSES; 2-PHOTON SPECTROSCOPY; GROUND-STATE; LAMB SHIFT; FREQUENCY; TRANSITION; DYNAMICS; FOUNTAIN; CLOCK	Precision spectroscopy at ultraviolet and shorter wavelengths has been hindered by the poor access of narrow-band lasers to that spectral region. We demonstrate high-accuracy quantum interference metrology on atomic transitions with the use of an amplified train of phase-controlled pulses from a femtosecond frequency comb laser. The peak power of these pulses allows for efficient harmonic upconversion, paving the way for extension of frequency comb metrology in atoms and ions to the extreme ultraviolet and soft x-ray spectral regions. A proof-of-principle experiment was performed on a deep-ultraviolet (2 x 212.55 nanometers) two-photon transition in krypton; relative to measurement with single nanosecond laser pulses, the accuracy of the absolute transition frequency and isotope shifts was improved by more than an order of magnitude.	Vrije Univ Amsterdam, Ctr Laser, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Witte, S (corresponding author), Vrije Univ Amsterdam, Ctr Laser, De Boelelaan 1081, NL-1081 HV Amsterdam, Netherlands.	kjeld@nat.vu.nl	Ubachs, W./K-3256-2019; Ubachs, Wim/F-5649-2011; Witte, Stefan/C-2009-2017; Eikema, Kjeld/F-6271-2015	Ubachs, W./0000-0001-7840-3756; Ubachs, Wim/0000-0001-7840-3756; Witte, Stefan/0000-0002-1899-4395; Eikema, Kjeld/0000-0002-2546-3584				Apolonski A, 2000, PHYS REV LETT, V85, P740, DOI 10.1103/PhysRevLett.85.740; Baltuska A, 2003, NATURE, V421, P611, DOI 10.1038/nature01414; Bellini M, 1997, OPT LETT, V22, P540, DOI 10.1364/OL.22.000540; Bergeson SD, 1998, PHYS REV LETT, V80, P3475, DOI 10.1103/PhysRevLett.80.3475; Brandi F, 2002, J PHYS B-AT MOL OPT, V35, P1071, DOI 10.1088/0953-4075/35/4/329; Cavalieri S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.133002; CLAIRON A, 1991, EUROPHYS LETT, V16, P165, DOI 10.1209/0295-5075/16/2/008; DESALVO R, 1992, OPT LETT, V17, P28, DOI 10.1364/OL.17.000028; ECKSTEIN JN, 1978, PHYS REV LETT, V40, P847, DOI 10.1103/PhysRevLett.40.847; Eikema KSE, 1997, PHYS REV A, V55, P1866, DOI 10.1103/PhysRevA.55.1866; FISCHER M, 2004, PHYS REV LETT, V92, P2; Holzwarth R, 2000, PHYS REV LETT, V85, P2264, DOI 10.1103/PhysRevLett.85.2264; Jones DJ, 2000, SCIENCE, V288, P635, DOI 10.1126/science.288.5466.635; KAUFMAN V, 1993, J RES NATL INST STAN, V98, P717, DOI 10.6028/jres.098.047; Marian A, 2004, SCIENCE, V306, P2063, DOI 10.1126/science.1105660; Niering M, 2000, PHYS REV LETT, V84, P5496, DOI 10.1103/PhysRevLett.84.5496; RAMSEY NF, 1949, PHYS REV, V76, P996, DOI 10.1103/PhysRev.76.996; SALOUR MM, 1978, REV MOD PHYS, V50, P667, DOI 10.1103/RevModPhys.50.667; SALOUR MM, 1977, PHYS REV LETT, V38, P757, DOI 10.1103/PhysRevLett.38.757; Snadden MJ, 1996, OPT COMMUN, V125, P70, DOI 10.1016/0030-4018(95)00711-3; TEETS R, 1977, PHYS REV LETT, V38, P760, DOI 10.1103/PhysRevLett.38.760; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a; Udem T, 2001, PHYS REV LETT, V86, P4996, DOI 10.1103/PhysRevLett.86.4996; Uzan JP, 2003, REV MOD PHYS, V75, P403, DOI 10.1103/RevModPhys.75.403; Witte S, 2004, APPL PHYS B-LASERS O, V78, P5, DOI 10.1007/s00340-003-1307-3; Zerne R, 1997, PHYS REV LETT, V79, P1006, DOI 10.1103/PhysRevLett.79.1006	26	127	127	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					400	403		10.1126/science.1106612	http://dx.doi.org/10.1126/science.1106612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662007	Green Submitted			2022-12-28	WOS:000226492300039
J	Frist, WH				Frist, WH			Shattuck lecture: Health care in the 21st century	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Off Senate Major Leader William H Frist, Washington, DC 20510 USA		Frist, WH (corresponding author), Off Senate Major Leader William H Frist, S-230,US Capitol, Washington, DC 20510 USA.	dean_rosen@frist.senate.gov						*AG HEALTHC RES QU, 2004, 21 AG HEALTHC RES QU; APPLEBY J, 2004, USA TODAY       0317; Balas E A, 2000, Yearb Med Inform, P65; Bates David W, 2002, BMC Med Inform Decis Mak, V2, P7, DOI 10.1186/1472-6947-2-7; Carey J, 2004, BUS WEEK, P116; *CDCP, 2004, HLTH US; Chandra A, 2003, W9513 NBER; CLAXTON G, 2004, EMPLOYER HLTH BENEFI; DENAVASWALT C, 2003, P60226 BUR CENS POP; Federal Trade Commission U.S. Department of Justice, 2004, IMPROVING HLTH CARE; Frist WH, 2002, JAMA-J AM MED ASSOC, V287, P1722, DOI 10.1001/jama.287.13.1722; HOLTZEAKIN D, 2004, HLTH CARE SPENDING U; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Isaacs SL, 2004, NEW ENGL J MED, V351, P1137, DOI 10.1056/NEJMsb040329; Kohn L.T., 2000, TO ERR IS HUMAN BUIL; KRITZ FL, 2004, WASHINGTON POST 1026; LETHBRIDGECEJKU M, 2004, VITAL HLTH STAT SERI, V10; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; OBRIEN E, 2004, HJ KAISER FAMILY MAY, P8; *OFF ASS SECR PLAN, 2002, CONFR NEW HLTH CAR C; Porter ME, 2004, HARVARD BUS REV, V82, P64; Porter ME, 2004, HARVARD BUS REV, V82, P136; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.3.10; SHEILS J, 2004, COST TAXEXEMPT HLTH; Studdert DM, 2004, NEW ENGL J MED, V350, P283, DOI 10.1056/NEJMhpr035470; *URB I, 2004, EST MARCH 2003 CURR	27	76	77	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					267	272		10.1056/NEJMsa045011	http://dx.doi.org/10.1056/NEJMsa045011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659726	Bronze			2022-12-28	WOS:000226370500007
J	Kurchan, J				Kurchan, J			In and out of equilibrium	NATURE			English	Article							DYNAMICS; MODEL; GLASS	Albert Einstein's work on brownian motion showed how thermal equilibrium could be brought about by work exchanged through thermal fluctuations and viscous dissipation. Glasses are out-of-equilibrium systems in which this exchange happens at widely different timescales simultaneously. Theory then suggests the fascinating possibility that such behaviour may lead to a more general form of thermalization, in which the effective temperature shared by all components differs at each timescale.	Ecole Super Phys & Chim Ind Ville Paris, PMMH, F-75231 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Sorbonne Universite; Universite Paris Cite	Kurchan, J (corresponding author), Ecole Super Phys & Chim Ind Ville Paris, PMMH, 10 Rue Vauquelin, F-75231 Paris 05, France.	jorge@pmmh.espci.fr						Berthier L, 2002, J CHEM PHYS, V116, P6228, DOI 10.1063/1.1460862; Buisson L, 2003, EUROPHYS LETT, V63, P603, DOI 10.1209/epl/i2003-00551-4; Cugliandolo LF, 1997, PHYS REV E, V55, P3898, DOI 10.1103/PhysRevE.55.3898; CUGLIANDOLO LF, 1994, J PHYS A-MATH GEN, V27, P5749, DOI 10.1088/0305-4470/27/17/011; Edwards S. F., 1994, GRANULAR MATTER INTE, P121; Herisson D, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.257202; Israeloff NE, 1998, EUROPHYS LETT, V43, P308, DOI 10.1209/epl/i1998-00357-4; Kubo R., 1991, STAT PHYS; Makse HA, 2002, NATURE, V415, P614, DOI 10.1038/415614a; SOMPOLINSKY H, 1982, PHYS REV B, V25, P6860, DOI 10.1103/PhysRevB.25.6860; TOOL AQ, 1946, J AM CERAM SOC, V29, P240, DOI 10.1111/j.1151-2916.1946.tb11592.x	11	123	126	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					222	225		10.1038/nature03278	http://dx.doi.org/10.1038/nature03278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662408				2022-12-28	WOS:000226381300038
J	Parisi, G				Parisi, G			Brownian motion	NATURE			English	Editorial Material									Univ Roma La Sapienza, Dept Phys, I-00185 Rome, Italy	Sapienza University Rome	Parisi, G (corresponding author), Univ Roma La Sapienza, Dept Phys, Piazzale Aldo Moro 5, I-00185 Rome, Italy.							Kuhn T., 1978, BLACK BODY THEORY QU; Mezard M., 1987, WORLD SCI LECT NOT P, V9; [No title captured]	3	22	22	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					221	221		10.1038/433221a	http://dx.doi.org/10.1038/433221a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662407	Bronze			2022-12-28	WOS:000226381300037
J	Stampfer, MJ; Kang, JH; Chen, J; Cherry, R; Grodstein, F				Stampfer, MJ; Kang, JH; Chen, J; Cherry, R; Grodstein, F			Effects of moderate alcohol consumption on cognitive function in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APOLIPOPROTEIN-E EPSILON-4; RISK; SMOKING; PERFORMANCE; DRINKING; IMPAIRMENT; DEMENTIA; DISEASE; OLDER; COMMUNITY	BACKGROUND: The adverse effects of excess alcohol intake on cognitive function are well established, but the effect of moderate consumption is uncertain. METHODS: Between 1995 and 2001, we evaluated cognitive function in 12,480 participants in the Nurses' Health Study who were 70 to 81 years old, with follow-up assessments in 11,102 two years later. The level of alcohol consumption was ascertained regularly beginning in 1980. We calculated multivariate-adjusted mean cognitive scores and multivariate-adjusted risks of cognitive impairment (defined as the lowest 10 percent of the scores) and a substantial decline in cognitive function over time (defined as a change that was in the worst 10 percent of the distribution of the decline). We also stratified analyses according to the apolipoprotein E genotype in a subgroup of women. RESULTS: After multivariate adjustment, moderate drinkers (those who consumed less than 15.0 g of alcohol per day [about one drink]) had better mean cognitive scores than nondrinkers. Among moderate drinkers, as compared with nondrinkers, the relative risk of impairment was 0.77 on our test of general cognition (95 percent confidence interval, 0.67 to 0.88) and 0.81 on the basis of a global cognitive score combining the results of all tests (95 percent confidence interval, 0.70 to 0.93). The results for cognitive decline were similar; for example, on our test of general cognition, the relative risk of a substantial decline in performance over a two-year period was 0.85 (95 percent confidence interval, 0.74 to 0.98) among moderate drinkers, as compared with nondrinkers. There were no significant associations between higher levels of drinking (15.0 to 30.0 g per day) and the risk of cognitive impairment or decline. There were no significant differences in risks according to the beverage (e.g., wine or beer) and no interaction with the apolipoprotein E genotype. CONCLUSIONS: Our data suggest that in women, up to one drink per day does not impair cognitive function and may actually decrease the risk of cognitive decline.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Vanderbilt Childrens Hosp, Nashville, TN USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University	Stampfer, MJ (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482, R01AG015424] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NIA NIH HHS [AG15424, AG13482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; Bond GE, 2001, INT PSYCHOGERIATR, V13, P207, DOI 10.1017/S1041610201007591; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; Broe GA, 1998, AUST NZ J PUBL HEAL, V22, P621, DOI 10.1111/j.1467-842X.1998.tb01449.x; Carmelli D, 1999, NEUROEPIDEMIOLOGY, V18, P125, DOI 10.1159/000026204; Cervilla JA, 2000, J NEUROL NEUROSUR PS, V68, P622, DOI 10.1136/jnnp.68.5.622; CHICK JD, 1989, ALCOHOL CLIN EXP RES, V13, P512, DOI 10.1111/j.1530-0277.1989.tb00369.x; CHRISTIAN JC, 1995, J STUD ALCOHOL, V56, P414, DOI 10.15288/jsa.1995.56.414; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; Dent OF, 1997, BMJ-BRIT MED J, V314, P1655, DOI 10.1136/bmj.314.7095.1655; Dufouil C, 1997, AM J EPIDEMIOL, V146, P405, DOI 10.1093/oxfordjournals.aje.a009293; Dufouil C, 2000, EPIDEMIOLOGY, V11, P280, DOI 10.1097/00001648-200005000-00009; Edelstein SL, 1998, J WOMENS HEALTH, V7, P1271, DOI 10.1089/jwh.1998.7.1271; Elias PK, 1999, AM J EPIDEMIOL, V150, P580; Elwood PC, 1999, J EPIDEMIOL COMMUN H, V53, P9, DOI 10.1136/jech.53.1.9; Galanis DJ, 2000, AM J PUBLIC HEALTH, V90, P1254, DOI 10.2105/AJPH.90.8.1254; GANGULI M, 1993, J GERONTOL, V48, pM152, DOI 10.1093/geronj/48.4.M152; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GOODWIN JS, 1987, AM J PUBLIC HEALTH, V77, P173, DOI 10.2105/AJPH.77.2.173; Grodstein F, 2001, DIABETES CARE, V24, P1060, DOI 10.2337/diacare.24.6.1060; HEBERT LE, 1993, AM J EPIDEMIOL, V137, P881, DOI 10.1093/oxfordjournals.aje.a116749; Hendrie HC, 1996, J AM GERIATR SOC, V44, P1158, DOI 10.1111/j.1532-5415.1996.tb01364.x; Kalmijn S, 2002, AM J EPIDEMIOL, V156, P936, DOI 10.1093/aje/kwf135; KANG JH, IN PRES NEUROBIOL AG; Launer LJ, 1996, AM J EPIDEMIOL, V143, P219; Leroi I, 2002, AM J EPIDEMIOL, V156, P747, DOI 10.1093/aje/kwf107; MORRIS JC, 1993, NEUROLOGY, V43, P2457, DOI 10.1212/WNL.43.12.2457; Mukamal KJ, 2003, JAMA-J AM MED ASSOC, V289, P1405, DOI 10.1001/jama.289.11.1405; Mukamal KJ, 2001, STROKE, V32, P1939, DOI 10.1161/hs0901.095723; Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523; RIMM EB, 2000, HEART DIS UPDATE SER, V2, P1; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Small BJ, 2000, ARCH NEUROL-CHICAGO, V57, P839, DOI 10.1001/archneur.57.6.839; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Willett W., 2012, NUTR EPIDEMIOLOGY; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wilson RS, 2002, ARCH NEUROL-CHICAGO, V59, P1154, DOI 10.1001/archneur.59.7.1154; Yaffe K, 2001, NEW ENGL J MED, V344, P1207, DOI 10.1056/NEJM200104193441604	40	258	268	2	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					245	253		10.1056/NEJMoa041152	http://dx.doi.org/10.1056/NEJMoa041152			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888JP	15659724				2022-12-28	WOS:000226370500005
J	Covington, M				Covington, M			A ringing confirmation of spintronics theory	SCIENCE			English	Editorial Material							DRIVEN		Seagate Res, Pittsburgh, PA 15222 USA	Seagate Technology	Covington, M (corresponding author), Seagate Res, 1251 Waterfront Pl, Pittsburgh, PA 15222 USA.	mark.covington@seagate.com						Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; Covington M, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.184406; Fabian A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.257209; Kiselev SI, 2003, NATURE, V425, P380, DOI 10.1038/nature01967; Krivorotov IN, 2005, SCIENCE, V307, P228, DOI 10.1126/science.1105722; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Urazhdin S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.146803; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389	9	10	10	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2005	307	5707					215	216		10.1126/science.1107610	http://dx.doi.org/10.1126/science.1107610			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653491				2022-12-28	WOS:000226361900028
J	Katanaev, VL; Ponzielli, R; Semeriva, M; Tomlinson, A				Katanaev, VL; Ponzielli, R; Semeriva, M; Tomlinson, A			Trimeric G protein-dependent frizzled signaling in Drosophila	CELL			English	Article							PLANAR CELL POLARITY; TISSUE POLARITY; NUCLEOTIDE-BINDING; WINGLESS; GENE; EXPRESSION; PATHWAYS; SUBUNIT; LOCALIZATION; TRANSDUCTION	Frizzled (Fz) proteins are serpentine receptors that transduce critical cellular signals during development. Serpentine receptors usually signal to downstream effectors through an associated trimeric G protein complex. However, clear evidence for the role of trimeric G protein complexes for the Fz family of receptors has hitherto been lacking. Here, we show roles for the Go, subunit (Go) in mediating the two distinct pathways transduced by Fz receptors in Drosophila: the Writ and planar polarity pathways. Go is required for transduction of both pathways, and epistasis experiments suggest that it is an immediate transducer of Fz. While overexpression effects of the wild-type form are receptor dependent, the activated form (Go-GTP) can signal when the receptor is removed. Thus, Go is likely part of a trimeric G protein complex that directly tranduces Fz signals from the membrane to downstream components.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Ctr Neurobiol & Behav, New York, NY 10032 USA; Univ Mediterranee, Lab Genet & Physiol Dev, CNRS, UMR 6545,IBDM,INSERM,Case 907, F-13288 Marseille 09, France	Columbia University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Tomlinson, A (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Ctr Neurobiol & Behav, 701 W 168th St, New York, NY 10032 USA.	at4l@columbia.edu	Katanaev, Vladimir/F-9480-2014	Katanaev, Vladimir/0000-0002-7909-5617	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057043] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; Axelrod JD, 2001, GENE DEV, V15, P1182; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Azpiazu N, 2000, DEVELOPMENT, V127, P2685; Bastock R, 2003, DEVELOPMENT, V130, P3007, DOI 10.1242/dev.00526; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; Chen CM, 1999, DEVELOPMENT, V126, P5441; Fremion E, 1999, J CELL BIOL, V145, P1063, DOI 10.1083/jcb.145.5.1063; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Ikeda SR, 1999, NEUROSCI LETT, V271, P163, DOI 10.1016/S0304-3940(99)00555-8; INOUE S, 1995, J BIOCHEM-TOKYO, V118, P650, DOI 10.1093/oxfordjournals.jbchem.a124959; Jones KH, 1996, GENETICS, V142, P205; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PFEIFER M, 1994, DEVELOPMENT, V120, P369; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Strapps WR, 2001, DEVELOPMENT, V128, P4829; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Strutt DI, 2001, MOL CELL, V7, P367, DOI 10.1016/S1097-2765(01)00184-8; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Taylor J, 1998, GENETICS, V150, P199; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VARMUS H, 1986, TAK S, V17, P31; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wieschaus E., 1986, P199; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	50	211	218	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					111	122		10.1016/j.cell.2004.11.014	http://dx.doi.org/10.1016/j.cell.2004.11.014			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652486	Bronze			2022-12-28	WOS:000226365400015
J	Oransky, I				Oransky, I			William Silverman - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						SILVERMAN WA, PUBLICATION LIST	1	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2005	365	9454					116	116		10.1016/S0140-6736(05)17689-2	http://dx.doi.org/10.1016/S0140-6736(05)17689-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15643704				2022-12-28	WOS:000226170700014
J	Sachs, JD				Sachs, JD			Achieving the millennium development goals - The case of malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BURDEN		Columbia Univ, Earth Inst, New York, NY 10027 USA; UN, Millennium Project, New York, NY USA	Columbia University	Sachs, JD (corresponding author), Columbia Univ, Earth Inst, New York, NY 10027 USA.							Breman JG, 2004, AM J TROP MED HYG, V71, P1; Curtis C, 2003, LANCET INFECT DIS, V3, P304, DOI 10.1016/S1473-3099(03)00612-1; Kiszewski A, 2004, AM J TROP MED HYG, V70, P486, DOI 10.4269/ajtmh.2004.70.486; Narasimhan V, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-8; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a	5	31	33	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					115	117		10.1056/NEJMp048319	http://dx.doi.org/10.1056/NEJMp048319			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647571	Green Submitted			2022-12-28	WOS:000226251700001
J	Gladman, B				Gladman, B			The Kuiper belt and the solar system's comet disk	SCIENCE			English	Review							TRANS-NEPTUNIAN OBJECTS; JUPITER-FAMILY COMETS; PLANET FORMATION; ORBITAL DISTRIBUTION; SIZE DISTRIBUTION; SCATTERED DISK; CLOUD; AU; PLANETESIMALS; CONSTRAINTS	Our planetary system is embedded in a small-body disk of asteroids and comets, vestigial remnants of the original planetesimal population that formed the planets. Once formed, those planets dispersed most of the remaining small bodies. Outside of Neptune, this process has left our Kuiper belt and built the Oort cloud, as well as emplacing comets into several other identifiable structures. The orbits in these structures indicate that our outer solar system's comet disk was shaped by a variety of different physical processes, which teach us about how the giant planets formed. Recent work has shown that the scattered disk is the most likely source of short-period comets. Moreover, a growing body of evidence indicates that the sculpting of the Kuiper belt region may have involved large-scale planetary migration, the presence of other rogue planetary objects in the disk, and/or the close passage of other stars in the Sun's birth cluster.	Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6K 2S5, Canada	University of British Columbia	Gladman, B (corresponding author), Univ British Columbia, Dept Phys & Astron, 6224 Agr Rd, Vancouver, BC V6K 2S5, Canada.	gladman@astro.ubc.ca						Adams FC, 2001, ICARUS, V150, P151, DOI 10.1006/icar.2000.6567; Allen RL, 2001, ASTROPHYS J, V549, pL241, DOI 10.1086/319165; Bernstein GM, 2004, ASTRON J, V128, P1364, DOI 10.1086/422919; Boss AP, 2000, ASTROPHYS J, V536, pL101, DOI 10.1086/312737; Brown ME, 2004, ASTROPHYS J, V617, P645, DOI 10.1086/422095; Brown ME, 2001, ASTRON J, V121, P2804, DOI 10.1086/320391; Brunini A, 2002, ICARUS, V160, P32, DOI 10.1006/icar.2002.6935; Buie MW, 2003, EARTH MOON PLANETS, V92, P113, DOI 10.1023/B:MOON.0000031930.13823.be; Chiang EI, 2002, ASTRON J, V124, P3430, DOI 10.1086/344605; Doressoundiram A, 2003, EARTH MOON PLANETS, V92, P131, DOI 10.1023/B:MOON.0000031932.82944.e2; DUNCAN M, 1987, ASTRON J, V94, P1330, DOI 10.1086/114571; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; Fernandez JA, 2000, ICARUS, V145, P580, DOI 10.1006/icar.2000.6348; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Gladman B, 2002, IAU SYMP, V12, P193; Gladman B, 2002, ICARUS, V157, P269, DOI 10.1006/icar.2002.6860; Gladman B, 1998, NATURE, V396, P513, DOI 10.1038/24983; GLADMAN B, 2004, B AM ASTRON SOC, V36; Goldreich P, 2004, ANNU REV ASTRON ASTR, V42, P549, DOI 10.1146/annurev.astro.42.053102.134004; Gomes RS, 2004, ICARUS, V170, P492, DOI 10.1016/j.icarus.2004.03.011; Greaves JS, 2005, SCIENCE, V307, P68, DOI 10.1126/science.1101979; Ida S, 2000, ASTROPHYS J, V528, P351, DOI 10.1086/308179; Kenyon SJ, 2002, PUBL ASTRON SOC PAC, V114, P265, DOI 10.1086/339188; Levison HF, 2004, ASTRON J, V128, P2553, DOI 10.1086/424616; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; Morbidelli A, 2004, MON NOT R ASTRON SOC, V355, P935, DOI 10.1111/j.1365-2966.2004.08372.x; Petit JM, 1999, ICARUS, V141, P367, DOI 10.1006/icar.1999.6166; Stern SA, 1997, ASTROPHYS J, V490, P879, DOI 10.1086/304912; Trujillo CA, 2000, ASTROPHYS J, V529, pL103, DOI 10.1086/312467; Trujillo CA, 2001, ASTROPHYS J, V554, pL95, DOI 10.1086/320917; Wiegert P, 1999, ICARUS, V137, P84, DOI 10.1006/icar.1998.6040; Wuchterl G., 2000, Protostars and planets 4, P1081	34	46	47	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2005	307	5706					71	75		10.1126/science.1100553	http://dx.doi.org/10.1126/science.1100553			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637267				2022-12-28	WOS:000226214300036
J	Takaoka, A; Yanai, H; Kondo, S; Duncan, G; Negishi, H; Mizutani, T; Kano, S; Honda, K; Ohba, Y; Mak, TW; Taniguchi, T				Takaoka, A; Yanai, H; Kondo, S; Duncan, G; Negishi, H; Mizutani, T; Kano, S; Honda, K; Ohba, Y; Mak, TW; Taniguchi, T			Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors	NATURE			English	Article							PLASMACYTOID DENDRITIC CELLS; DIFFERENTIAL REGULATION; HOST-DEFENSE; STRANDED-RNA; CPG MOTIFS; KAPPA-B; MYD88; DNA; IMMUNITY; INNATE	The activation of Toll-like receptors (TLRs) is central to innate and adaptive immunity(1-3). All TLRs use the adaptor MyD88 for signalling(4), but the mechanisms underlying the MyD88-mediated gene induction programme are as yet not fully understood. Here, we demonstrate that the transcription factor IRF-5 is generally involved downstream of the TLR-MyD88 signalling pathway for gene induction of proinflammatory cytokines, such as interleukin-6 (IL-6), IL-12 and tumour-necrosis factor-alpha. In haematopoietic cells from mice deficient in the Irf5 gene (Irf5(-/-) mice), the induction of these cytokines by various TLR ligands is severely impaired, whereas interferon-alpha induction is normal. We also provide evidence that IRF-5 interacts with and is activated by MyD88 and TRAF6, and that TLR activation results in the nuclear translocation of IRF-5 to activate cytokine gene transcription. Consistently, Irf5(-/-) mice show resistance to lethal shock induced by either unmethylated DNA or lipopolysaccharide, which correlates with a marked decrease in the serum levels of proinflammatory cytokines. Thus, our study identifies IRF-5 as a new, principal downstream regulator of the TLR-MyD88 signalling pathway and a potential target of therapeutic intervention to control harmful immune responses.	Univ Toronto, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada; Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; JST, PRESTO, Informat & Cell Funct, Kawaguchi, Saitama 3320012, Japan	University of Toronto; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Mak, TW (corresponding author), Univ Toronto, Campbell Family Inst Breast Canc Res, 610 Univ Ave,Room 7-411, Toronto, ON M5G 2M9, Canada.	tmak@uhnres.utroronto.ca; tada@m.u-tokyo.ac.jp	Yanai, Hideyuki/AGK-5933-2022; Honda, Kenya/N-5297-2015; Kano, Shinichi/F-4144-2015; Mizutani, Tatsuaki/AAA-5044-2021; Ohba, Yusuke/E-7944-2011	Yanai, Hideyuki/0000-0002-0115-9000; Kano, Shinichi/0000-0002-5171-3436; Mizutani, Tatsuaki/0000-0002-4323-4347; 				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Alvarez M, 2003, GENE, V313, P43, DOI 10.1016/S0378-1119(03)00627-9; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Cowdery JS, 1999, J IMMUNOL, V162, P6770; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Levy DE, 2003, CURR OPIN IMMUNOL, V15, P52, DOI 10.1016/S0952-7915(02)00011-0; LIN R, IN PRESS J BIOL CHEM; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738	30	743	784	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 10	2005	434	7030					243	249		10.1038/nature03308	http://dx.doi.org/10.1038/nature03308			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904JU	15665823				2022-12-28	WOS:000227494500052
J	McGhee, SM; Ho, SY; Schooling, M; Ho, LM; Thomas, GN; Hedley, AJ; Mak, KH; Peto, R; Lam, TH				McGhee, SM; Ho, SY; Schooling, M; Ho, LM; Thomas, GN; Hedley, AJ; Mak, KH; Peto, R; Lam, TH			Mortality associated with passive smoking in Hong Kong	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STROKE; COHORT; RISK		Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China; Dept Hlth, Student Hlth Serv, Kowloon, Hong Kong, Peoples R China; Univ Oxford, Nuffield Dept Clin Med, Oxford OX2 6HE, England	University of Hong Kong; University of Oxford	Lam, TH (corresponding author), Univ Hong Kong, Dept Community Med, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	hrmrlth@hkucc.hku.hk	Thomas, G. Neil/A-1879-2013; Schooling, Catherine Mary/C-4386-2009; McGhee, Sarah M/A-6460-2013; Hedley, Anthony/C-4305-2009; McGhee, Sarah/C-4367-2009; Hedley, Anthony J/A-9113-2013; Lam, Tai Hing/C-4317-2009; Ho, Daniel Sai Yin/C-4307-2009	Thomas, G. Neil/0000-0002-2777-1847; McGhee, Sarah M/0000-0003-1025-5915; Lam, Tai Hing/0000-0002-2033-9971; Schooling, Mary/0000-0001-9933-5887; ho, lm/0000-0002-2709-927X; Ho, Daniel Sai Yin/0000-0001-9485-0273				Bonita R, 1999, TOB CONTROL, V8, P156, DOI 10.1136/tc.8.2.156; Hill SE, 2004, BMJ-BRIT MED J, V328, P988, DOI 10.1136/bmj.38070.503009.EE; Iribarren C, 2004, NEUROEPIDEMIOLOGY, V23, P38, DOI 10.1159/000073973; KAY R, 1992, NEUROLOGY, V42, P985, DOI 10.1212/WNL.42.5.985; Lam TH, 2001, BRIT MED J, V323, P361, DOI 10.1136/bmj.323.7309.361	5	50	53	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2005	330	7486					287	288		10.1136/bmj.38342.706748.47	http://dx.doi.org/10.1136/bmj.38342.706748.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15677632	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000226843700016
J	Bonadonna, G; Moliterni, A; Zambetti, M; Daidone, MG; Pilotti, S; Gianni, L; Valagussa, P				Bonadonna, G; Moliterni, A; Zambetti, M; Daidone, MG; Pilotti, S; Gianni, L; Valagussa, P			30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study	BRITISH MEDICAL JOURNAL			English	Article							COMBINATION CHEMOTHERAPY; PREMENOPAUSAL PATIENTS; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; THERAPY; MANAGEMENT; TAMOXIFEN; GOSERELIN; TRIALS	Objective To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of relapse, on the basis of three successive randomised trials and one observational study conducted from June 1973 to December 1980. Design Cohort study. Setting Istituto Nazionale Tumori in Milan, Italy. Main outcome measures Relapse free and overall survival, measured by univariate and multivariate analyses. Results After a median follow up of 28.5 years for the initial study, adjuvant CMF was found to reduce the relative risk of relapse significantly (hazard ratio 0.71, 95% confidence interval 0.56 to 0.91, P = 0.005) and death (0.79, 0.63 to 0.98, P = 0.04). Administration of CMF for 12 cycles does not seem superior to a shorter administration of six cycles. Tit the node negative and oestrogen receptor negative trial, intravenous CMF significantly reduced the relative risk of relapse of disease (0.65, 0.47 to 0.90, P = 0.009) and death (0.65, 0.47 to 0.92, P = 0.01) at a median follow up of 20 years. Conclusions When delivered optimally, CMF benefits patients at risk of relapse of distant disease Without evidence of detrimental effects in any of the examined subgroups.	Ist Nazl Tumori, Dept Med Oncol, Operat Off, I-20133 Milan, Italy; Ist Nazl Tumori, Div Med Oncol A, I-20133 Milan, Italy; Ist Nazl Tumori, Determinant Prognosis & Treatment Response Unit, I-20133 Milan, Italy; Ist Nazl Tumori, Div Pathol C, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Bonadonna, G (corresponding author), Ist Nazl Tumori, Dept Med Oncol, Operat Off, Via Venezian 1, I-20133 Milan, Italy.	gianni.bonadonna@istitutotumori.mi.it	Daidone, Maria Grazia/E-9232-2017	Daidone, Maria Grazia/0000-0002-4786-1321; Valagussa, Pinuccia/0000-0003-3590-7916; GIANNI, LUCA/0000-0002-2372-9625	NCI NIH HHS [N01-CM-07338, N01-CM-33714] Funding Source: Medline; DIVISION OF CANCER TREATMENT [N01CM007338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER TREATMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis)		Abe O, 1998, LANCET, V352, P930; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; BONADON G, 1975, P AM ASSOC CANC RES, V16, P254; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; Clarke M, 1998, LANCET, V351, P1451; COX DR, 1972, J R STAT SOC B, V34, P187; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; FISHER B, 1975, NEW ENGL J MED, V292, P117, DOI 10.1056/NEJM197501162920301; FISHER B, 1992, CANCER RES, V52, P2371; GOLDHIRSCH A, 1990, ANN ONCOL, V1, P183, DOI 10.1093/oxfordjournals.annonc.a057718; Jakesz R, 2002, J CLIN ONCOL, V20, P4621, DOI 10.1200/JCO.2002.09.112; Jonat W, 2002, J CLIN ONCOL, V20, P4628, DOI 10.1200/JCO.2002.05.042; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Marubini E, 1995, ANAL SURVIVAL DATA C; Menard S, 2001, J CLIN ONCOL, V19, P329, DOI 10.1200/JCO.2001.19.2.329; Miller R. G., 1981, SURVIVAL ANAL; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; Pritchard KI, 2002, J CLIN ONCOL, V20, P4611, DOI 10.1200/JCO.2002.20.24.4611; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; TANCINI G, 1983, J CLIN ONCOL, V1, P2, DOI 10.1200/JCO.1983.1.1.2; Zambetti M, 1996, ANN ONCOL, V7, P481; ZAMBETTI M, 1992, J NATL CANC I MONOGR, V11, P79	25	184	198	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 29	2005	330	7485					217	220		10.1136/bmj.38314.622095.8F	http://dx.doi.org/10.1136/bmj.38314.622095.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894GR	15649903	Green Published, Bronze			2022-12-28	WOS:000226779400015
J	Ellman, T; Culbert, H; Torres-Feced, V				Ellman, T; Culbert, H; Torres-Feced, V			Treatment of AIDS in conflict-affected settings: a failure of imagination	LANCET			English	Editorial Material									Med Sans Frontieres, London WC1R 5DJ, England	Doctors Without Borders	Ellman, T (corresponding author), Med Sans Frontieres, London WC1R 5DJ, England.	tom.ellman@msf.org						CHAIX ML, 2004, ANTIVIR THER, V9, pS176; Hankins CA, 2002, AIDS, V16, P2245, DOI 10.1097/00002030-200211220-00003; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Hehenkamp A, 2003, LANCET, V362, pS30, DOI 10.1016/S0140-6736(03)15066-0; *HUM RIGHTS WATCH, 1995, RAP WEAP WAR TOL P; *INT CRIS GROUP, 2004, HIV AIDS SEC ISS AFR; *INT CRIS GROUP, 2004, ICG CRIS WATCH; International Crisis Group, 2001, HIV AIDS SEC ISS; Tangermann RH, 2000, B WORLD HEALTH ORGAN, V78, P330; *UNAIDS, 1998, AIDS MIL; 2004, INT AIDS C BANGK THA	11	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2005	365	9456					278	280						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664207				2022-12-28	WOS:000226449600008
J	Barrow, JD				Barrow, JD			Einstein as icon	NATURE			English	Editorial Material								How Einstein became the personification of physics.	Univ Cambridge, Ctr Math Sci, Cambridge, England	University of Cambridge	Barrow, JD (corresponding author), Univ Cambridge, Ctr Math Sci, Wilburforce Rd, Cambridge, England.	j.d.barrow@damtp.cam.ac.uk							0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					218	219		10.1038/433218a	http://dx.doi.org/10.1038/433218a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662406				2022-12-28	WOS:000226381300036
J	Kurin-Csorgei, K; Epstein, IR; Orban, M				Kurin-Csorgei, K; Epstein, IR; Orban, M			Systematic design of chemical oscillators using complexation and precipitation equilibria	NATURE			English	Article								Concentration oscillations are ubiquitous in living systems, where they involve a wide range of chemical species. In contrast, early in vitro chemical oscillators were all derived from two accidentally discovered reactions(1-3) based on oxyhalogen chemistry. Over the past 25 years, the use of a systematic design algorithm(4,5), in which a slow feedback reaction periodically drives a bistable system in a flow reactor between its two steady states, has increased the list of oscillating chemical reactions to dozens of systems. But these oscillating reactions are still confined to a handful of elements that possess multiple stable oxidation states: halogens, sulphur and some transition metals(6). Here we show that linking a 'core' oscillator to a complexation or precipitation equilibrium can induce concentration oscillations in a species participating in the equilibrium. We use this method to design systems that produce periodic pulses of calcium, aluminium or fluoride ions. The ability to generate oscillations in elements possessing only a single stable oxidation state (for example, Na(+), F(-), Ca(2+)) may lead to reactions that are useful for coupling to or probing living systems, or that help us to understand new mechanisms by which periodic behaviour may arise.	Brandeis Univ, Dept Chem, Waltham, MA 02454 USA; Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Eotvos Lorand Univ, Dept Inorgan & Analyt Chem, H-1518 Budapest 112, Hungary	Brandeis University; Brandeis University; Eotvos Lorand University	Epstein, IR (corresponding author), Brandeis Univ, Dept Chem, MS 015, Waltham, MA 02454 USA.	epstein@brandeis.edu	Kurin-Csörgei, Krisztina/A-1832-2010	Kurin-Csörgei, Krisztina/0000-0001-5503-4935				Belousov BP, 1959, REFERENCE HDB RAD ME, P145; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; Bray WC, 1921, J AM CHEM SOC, V43, P1262, DOI 10.1021/ja01439a007; DEKEPPER P, 1981, J AM CHEM SOC, V103, P2133, DOI 10.1021/ja00398a061; EDBLOM EC, 1989, J PHYS CHEM-US, V93, P2722, DOI 10.1021/j100344a007; EPSTEIN IR, 1983, SCI AM, V248, P112, DOI 10.1038/scientificamerican0383-112; HARRIS DC, 1999, QUANTITATIVE CHEM AN, P312; ORBAN M, 1982, J AM CHEM SOC, V104, P2657, DOI 10.1021/ja00373a063; RABAI G, 1990, ACCOUNTS CHEM RES, V23, P258, DOI 10.1021/ar00176a004; RICHTER PH, 1981, SCIENCE, V211, P715, DOI 10.1126/science.6450447; Sagues F, 2003, DALTON T, P1201, DOI 10.1039/b210932h; Szucs A, 2000, NEUROREPORT, V11, P563; ZHABOTINSKII A. M., 1964, BIOFIZIKA, V9, P306	13	88	92	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2005	433	7022					139	142		10.1038/nature03214	http://dx.doi.org/10.1038/nature03214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650734				2022-12-28	WOS:000226252200032
J	Kastrati, A; Mehilli, J; von Beckerath, N; Dibra, A; Hausleiter, J; Pache, J; Schuhlen, H; Schmitt, C; Dirschinger, J; Schomig, A				Kastrati, A; Mehilli, J; von Beckerath, N; Dibra, A; Hausleiter, J; Pache, J; Schuhlen, H; Schmitt, C; Dirschinger, J; Schomig, A		ISAR-DESIRE Study Investigators	Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRACORONARY BETA-RADIATION; ANGIOGRAPHIC FOLLOW-UP; THERAPY; INHIBIT; PLACEMENT; STENOSIS; ARTERY	Context In patients with de novo coronary lesions, drug-eluting stents have drastically reduced restenosis risk compared with bare metal stents and conventional balloon angioplasty. it is less clear whether drug-eluting stents are superior to conventional balloon angioplasty for the treatment of patients with in-stent restenosis. Objectives To assess if drug-eluting stents are a more effective treatment of instent restenosis than conventional balloon angioplasty, and to assess the relative merits of 2 drug-eluting stents, a sirolimus-eluting stent and a paclitaxel-eluting stent. Design, Setting, and Participants Randomized, open-label, active-controlled trial conducted among 300 patients with angiographically significant in-stent restenosis in 2 tertiary German centers from June 1, 2003, to October 20, 2003. Interventions After pretreatment with 600 mg of clopidogrel for at least 2 hours before intervention, all patients were randomly assigned to 1 of 3 treatment groups: sirolimus stent, paclitaxel stent, or balloon angioplasty (100 patients in each group). Main Outcome Measures Primary end point: angiographic restenosis (diameter stenosis greater than or equal to50%) at 6-month follow-up angiography based on "in-segment" analysis. Primary analysis was comparison between stent groups and balloon angioplasty groups; a secondary analysis compared sirolimus and paclitaxel stents. Results Follow-up angiography was performed in 275 (92%) of 300 patients. The incidence of angiographic restenosis was 44.6% (41/92) in the balloon angioplasty group, 14.3% (13/91) in the sirolimus stent group (P<.001 vs balloon angioplasty), and 21.7% (20/92) in the paclitaxel stent group (P=.001 vs balloon angioplasty). When compared with balloon angioplasty, receiving a sirolimus stent had a relative risk (RR) of angiographic restenosis of 0.32 (95% confidence interval [01, 0.18-0.56); a paclitaxel stent had an RR of 0.49 (95% Cl, 0.31-0.76). The incidence of target vessel revascularization was 33.0% (33/100) in the balloon angioplasty group, 8.0% (8/100) in the sirolimus stent group (P<.001 vs balloon angioplasty), and 19.0% (19/100) in the paclitaxel stent group (P=.02 vs balloon angioplasty). The secondary analysis showed a trend toward a lower rate of angiographic restenosis (P=.19) and a significantly lower rate of target vessel revascularization (P=.02) among sirolimus stent patients compared with paclitaxel stent patients. Conclusions In patients with in-stent restenosis, a strategy based on sirolimus- or paclitaxel-eluting stents is superior to conventional balloon angioplasty for the prevention of recurrent restenosis. Sirolimus-eluting stents may be superior to paclitaxel-eluting stents for treatment of this disorder.	Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; Tech Univ Munich, Med Klin Rechts Isar, Munich, Germany	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich	Kastrati, A (corresponding author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	kastrati@dhm.mhn.de	Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019; Hausleiter, Jörg/V-4206-2019	Schuhlen, Helmut/0000-0001-8630-4264				Albiero R, 2004, J AM COLL CARDIOL, V43, P943, DOI 10.1016/j.jacc.2003.09.054; Colombo A, 2004, CIRCULATION, V109, P1244, DOI 10.1161/01.CIR.0000118474.71662.E3; Degertekin M, 2003, J AM COLL CARDIOL, V41, P184, DOI 10.1016/S0735-1097(02)02704-3; Edelman ER, 1999, CIRCULATION, V100, P896, DOI 10.1161/01.CIR.100.9.896; Elezi S, 1999, CATHETER CARDIO INTE, V48, P151, DOI 10.1002/(SICI)1522-726X(199910)48:2<151::AID-CCD6>3.0.CO;2-C; Hausleiter J, 2004, CIRCULATION, V110, P790, DOI 10.1161/01.CIR.0000138935.17503.35; Hausleiter J, 2003, AM HEART J, V146, P882, DOI 10.1016/S0002-8703(03)00435-6; Kastrati A, 2001, AM J CARDIOL, V87, P34, DOI 10.1016/S0002-9149(00)01268-6; LACHIN JM, 1977, BIOMETRICS, V33, P315, DOI 10.2307/2529781; Leon MB, 2001, NEW ENGL J MED, V344, P250, DOI 10.1056/NEJM200101253440402; Lowe HC, 2002, J AM COLL CARDIOL, V39, P183, DOI 10.1016/S0735-1097(01)01742-9; Mehran R, 1999, CIRCULATION, V100, P1872, DOI 10.1161/01.CIR.100.18.1872; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Popma JJ, 2002, CIRCULATION, V106, P1090, DOI 10.1161/01.CIR.0000027814.96651.72; Radke PW, 2003, EUR HEART J, V24, P266, DOI 10.1016/S0195-668X(02)00202-6; Radke PW, 2004, EUR HEART J, V25, P920, DOI 10.1016/j.ehj.2004.02.014; Schuhlen H, 2004, AM HEART J, V147, P317, DOI 10.1016/j.ahj.2003.10.002; Scuhlen H, 2001, AM J CARDIOL, V87, P463, DOI 10.1016/S0002-9149(00)01406-5; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Waksman R, 2000, J AM COLL CARDIOL, V36, P65, DOI 10.1016/S0735-1097(00)00681-1; Waksman R, 2000, CIRCULATION, V101, P1895, DOI 10.1161/01.CIR.101.16.1895; Waksman R, 2004, CIRCULATION, V109, P340, DOI 10.1161/01.CIR.0000109488.62415.01; Waksman R, 2002, LANCET, V359, P551, DOI 10.1016/S0140-6736(02)07741-3; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	24	486	520	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2005	293	2					165	171		10.1001/jama.293.2.165	http://dx.doi.org/10.1001/jama.293.2.165			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885QC	15644543				2022-12-28	WOS:000226171000032
J	Berkley, JA; Lowe, BS; Mwangi, I; Williams, T; Bauni, E; Mwarumba, S; Ngetsa, C; Slack, MPE; Njenga, S; Hart, CA; Maitland, K; English, M; Marsh, K; Scott, JAG				Berkley, JA; Lowe, BS; Mwangi, I; Williams, T; Bauni, E; Mwarumba, S; Ngetsa, C; Slack, MPE; Njenga, S; Hart, CA; Maitland, K; English, M; Marsh, K; Scott, JAG			Bacteremia among children admitted to a rural hospital in Kenya	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMONIA; MENINGITIS; CONJUGATE; INDICATORS; COMMUNITY; DISEASE; TRIAL	BACKGROUND: There are few epidemiologic data on invasive bacterial infections among children in sub-Saharan Africa. We studied every acute pediatric admission to a rural district hospital in Kenya to examine the prevalence, incidence, types, and outcome of community-acquired bacteremia. METHODS: Between August 1998 and July 2002, we cultured blood on admission from 19,339 inpatients and calculated the incidence of bacteremia on the basis of the population served by the hospital. RESULTS: Of a total of 1783 infants who were under 60 days old, 228 had bacteremia (12.8 percent), as did 866 of 14,787 children who were 60 or more days of age (5.9 percent). Among infants who were under 60 days old, Escherichia coli and group B streptococci predominated among a broad range of isolates (14 percent and 11 percent, respectively). Among infants who were 60 or more days of age, Streptococcus pneumoniae, nontyphoidal salmonella species, Haemophilus influenzae, and E. coli accounted for more than 70 percent of isolates. The minimal annual incidence of community-acquired bacteremia was estimated at 1457 cases per 100,000 children among infants under a year old, 1080 among children under 2 years, and 505 among children under 5 years. Of all in-hospital deaths, 26 percent were in children with community-acquired bacteremia. Of 308 deaths in children with bacteremia, 103 (33.4 percent) occurred on the day of admission and 217 (70.5 percent) within two days. CONCLUSIONS: Community-acquired bacteremia is a major cause of death among children at a rural sub-Saharan district hospital, a finding that highlights the need for prevention and for overcoming the political and financial barriers to widespread use of existing vaccines for bacterial diseases.	Ctr Geog Med Res Coast, Kilifi, Kenya; Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England; Univ Oxford, Dept Paediat, Oxford, England; John Radcliffe Hosp, Hlth Protect Agcy Haemophilus Reference Unit, Oxford OX3 9DU, England; Univ Liverpool, Dept Microbiol, Liverpool L69 3BX, Merseyside, England; Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Ctr Clin Trop Med, London SW7 2AZ, England	University of Oxford; University of Oxford; University of Oxford; University of Liverpool; Imperial College London; Imperial College London; University of London; London School of Hygiene & Tropical Medicine	Berkley, JA (corresponding author), POB 230, Kilifi, Kenya.	jberkley@kilifi.mimcom.net		Maitland, Kathryn/0000-0002-0007-0645; Berkley, James/0000-0002-1236-849X; English, Michael/0000-0002-7427-0826	Wellcome Trust [061089, 081835] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bahwere P, 2001, Int J Infect Dis, V5, P180, DOI 10.1016/S1201-9712(01)90067-0; Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; BROWN CC, 1981, AM J EPIDEMIOL, V113, P474, DOI 10.1093/oxfordjournals.aje.a113115; COTTON MF, 1992, S AFR MED J, V81, P87; FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382, DOI 10.1128/JCM.32.10.2382-2386.1994; GHIORGHIS B, 1992, E AFR MED J, V69, P74; Graham SM, 2000, LANCET, V355, P369, DOI 10.1016/S0140-6736(98)11074-7; Graham SM, 2000, LANCET, V355, P850; Karstaedt AS, 2000, PEDIATR INFECT DIS J, V19, P454, DOI 10.1097/00006454-200005000-00012; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; LEPAGE P, 1987, LANCET, V1, P1458; Luck S, 2003, LANCET, V361, P1953, DOI 10.1016/S0140-6736(03)13553-2; Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; *MIN HLTH, 2001, AIDS KEN; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Mulholland K, 1997, LANCET, V350, P524; Mulholland K, 1999, PEDIATR INFECT DIS J, V18, pS17; ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009; Peltola H, 2001, CLIN INFECT DIS, V32, P64, DOI 10.1086/317534; SAEZLLORENS X, 1995, PEDIATR INFECT DIS J, V14, P557, DOI 10.1097/00006454-199507000-00001; Shann F, 2001, LANCET, V357, P2070, DOI 10.1016/S0140-6736(00)05226-0; *UNICEF, STAT WORLDS CHILDR 2; Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; *WHO, 2001, PROP MORT 5 WORLDW; WOLF BHM, 1995, EUR J PEDIATR, V154, P299, DOI 10.1007/s004310050293; *WORLD BANK GROUP, SUBS AFR DAT PROF; World Health Organization, 2000, MAN CHILD SER INF SE	29	593	607	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					39	47		10.1056/NEJMoa040275	http://dx.doi.org/10.1056/NEJMoa040275			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635111	Green Accepted			2022-12-28	WOS:000226112500006
J	Nakano, T; Ohkuma, H				Nakano, T; Ohkuma, H			Surgery versus conservative treatment for intracerebral haemorrhage - is there an end to the long controversy?	LANCET			English	Editorial Material							PROSPECTIVE RANDOMIZED TRIAL; SURGICAL-TREATMENT; HEMATOMA		Hirosaki Univ, Sch Med, Dept Neurosurg, Hirosaki, Aomori 0368562, Japan	Hirosaki University	Nakano, T (corresponding author), Hirosaki Univ, Sch Med, Dept Neurosurg, Zaifucho 5, Hirosaki, Aomori 0368562, Japan.	naka@cc.hirosaki-u.ac.jp						AUER LM, 1989, J NEUROSURG, V70, P530, DOI 10.3171/jns.1989.70.4.0530; BATJER HH, 1990, ARCH NEUROL-CHICAGO, V47, P1103, DOI 10.1001/archneur.1990.00530100071015; Fernandes HM, 2000, STROKE, V31, P2511, DOI 10.1161/01.STR.31.10.2511; Hankey GJ, 1997, STROKE, V28, P2126, DOI 10.1161/01.STR.28.11.2126; JUVELA S, 1989, J NEUROSURG, V70, P755, DOI 10.3171/jns.1989.70.5.0755; MCKISSOCK W, 1961, LANCET, V2, P221; Morgenstern LB, 1998, NEUROLOGY, V51, P1359, DOI 10.1212/WNL.51.5.1359; Nakano T, 2003, MINIM INVAS NEUROSUR, V46, P278; Prasad K, 1997, ACTA NEUROL SCAND, V95, P103, DOI 10.1111/j.1600-0404.1997.tb00078.x; Tan SH, 2001, SURG NEUROL, V56, P287, DOI 10.1016/S0090-3019(01)00561-4; Wagner Kenneth, 1996, Stroke, V27, P183; Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833	12	10	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					361	362						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680436				2022-12-28	WOS:000226610900003
J	Ransom, SM; Hessels, JWT; Stairs, IH; Freire, PCC; Camilo, F; Kaspi, VM; Kaplan, DL				Ransom, SM; Hessels, JWT; Stairs, IH; Freire, PCC; Camilo, F; Kaspi, VM; Kaplan, DL			Twenty-one millisecond pulsars in Terzan 5 using the Green Bank Telescope	SCIENCE			English	Article							ECLIPSING MILLISECOND PULSAR; GLOBULAR-CLUSTER TERZAN-5; NEUTRON-STARS; BINARY PULSAR; RADIO PULSARS; POPULATION; DISCOVERY; DYNAMICS; SYSTEM	We have identified 21 millisecond pulsars (MSPs) in globular cluster Terzan 5 by using the Green Bank Telescope, bringing the total of known MSPs in Terzan 5 to 24. These discoveries confirm fundamental predictions of globular cluster and binary system evolution. Thirteen of the new MSPs are in binaries, of which two show eclipses and two have highly eccentric orbits. The relativistic periastron advance for the two eccentric systems indicates that at least one of these pulsars has a mass 1.68 times greater than the mass of the Sun at 95% confidence. Such large neutron star masses constrain the equation of state of matter at or beyond the nuclear equilibrium density.	Natl Radio Astron Observ, Charlottesville, VA 22903 USA; McGill Univ, Dept Phys, Montreal, PQ H3A 2T8, Canada; Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada; Arecibo Observ, Natl Astron & Ionosphere Ctr, Arecibo, PR 00612 USA; Columbia Univ, Columbia Astrophys Lab, New York, NY 10027 USA; MIT, Ctr Space Res, Cambridge, MA 02139 USA	National Radio Astronomy Observatory (NRAO); McGill University; University of British Columbia; National Aeronautics & Space Administration (NASA); Columbia University; Massachusetts Institute of Technology (MIT)	Ransom, SM (corresponding author), Natl Radio Astron Observ, 520 Edgemont Rd, Charlottesville, VA 22903 USA.	sransom@nrao.edu	Hessels, Jason/GTO-3261-2022; Freire, Paulo/ABE-8926-2021	Hessels, Jason/0000-0003-2317-1446; Freire, Paulo/0000-0003-1307-9435; Ransom, Scott/0000-0001-5799-9714				ALPAR MA, 1982, NATURE, V300, P728, DOI 10.1038/300728a0; ANDERSON SB, 1992, THESIS CALTECH PASAD; Camilo F, 2000, ASTROPHYS J, V535, P975, DOI 10.1086/308859; Cohn HN, 2002, ASTROPHYS J, V571, P818, DOI 10.1086/339874; D'Amico N, 2001, ASTROPHYS J, V561, pL89, DOI 10.1086/324562; Freire PC, 2003, MON NOT R ASTRON SOC, V340, P1359, DOI 10.1046/j.1365-8711.2003.06392.x; Freire PC, 2004, ASTROPHYS J, V606, pL53, DOI 10.1086/421085; FRUCHTER AS, 1988, NATURE, V333, P237, DOI 10.1038/333237a0; Fruchter AS, 2000, ASTROPHYS J, V536, P865, DOI 10.1086/308948; Harris WE, 1996, ASTRON J, V112, P1487, DOI 10.1086/118116; Heinke CO, 2003, ASTROPHYS J, V590, P809, DOI 10.1086/375189; KAPLAN DE, UNPUB; King AR, 2003, MON NOT R ASTRON SOC, V345, P678, DOI 10.1046/j.1365-8711.2003.06990.x; KULKARNI SR, 1996, IAU S, V174, P181; Lattimer JM, 2004, SCIENCE, V304, P536, DOI 10.1126/science.1090720; LORIMER DR, 1995, MON NOT R ASTRON SOC, V273, P411, DOI 10.1093/mnras/273.2.411; LYNE AG, 1990, NATURE, V347, P650, DOI 10.1038/347650a0; LYNE AG, 1985, MON NOT R ASTRON SOC, V213, P613, DOI 10.1093/mnras/213.3.613; Lyne AG, 2000, MON NOT R ASTRON SOC, V316, P491, DOI 10.1046/j.1365-8711.2000.03517.x; Lyne AG, 1998, MON NOT R ASTRON SOC, V295, P743, DOI 10.1046/j.1365-8711.1998.01144.x; Meylan G, 1997, ASTRON ASTROPHYS REV, V8, P1, DOI 10.1007/s001590050008; NAVARRO J, 1995, ASTROPHYS J, V455, pL55, DOI 10.1086/309816; NICE DJ, 1992, ASTROPHYS J, V397, P249, DOI 10.1086/171784; PHINNEY ES, 1994, ANNU REV ASTRON ASTR, V32, P591, DOI 10.1146/annurev.aa.32.090194.003111; Pooley D, 2003, ASTROPHYS J, V591, pL131, DOI 10.1086/377074; Possenti A., 2005, ASP C SERIES, P189; Ransom SM, 2004, ASTROPHYS J, V604, P328, DOI 10.1086/381730; Ransom SM, 2002, ASTRON J, V124, P1788, DOI 10.1086/342285; RANSOM SM, 2001, THESIS HARVARD U CAM; RASIO FA, 1995, ASTROPHYS J, V445, pL133, DOI 10.1086/187907; RASIO FA, 1991, ASTROPHYS J, V377, P559, DOI 10.1086/170385; SIGURDSSON S, 1995, ASTROPHYS J SUPPL S, V99, P609, DOI 10.1086/192199; SMARR LL, 1976, ASTROPHYS J, V207, P574, DOI 10.1086/154524; Splaver EM, 2002, ASTROPHYS J, V581, P509, DOI 10.1086/344202; TASSOUL JL, 1995, ASTROPHYS J, V444, P338, DOI 10.1086/175608; VERBUNT F, 2003, ASP C SER, V296, P245; Verbunt F., 2002, ASP C SER, V265, P289; Wex N, 1998, MON NOT R ASTRON SOC, V298, P997, DOI 10.1046/j.1365-8711.1998.01700.x; [No title captured]	39	227	231	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					892	896		10.1126/science.1108632	http://dx.doi.org/10.1126/science.1108632			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15653465	Green Submitted			2022-12-28	WOS:000226985100044
J	Ohki, K; Chung, S; Ch'ng, YH; Kara, P; Reid, RC				Ohki, K; Chung, S; Ch'ng, YH; Kara, P; Reid, RC			Functional imaging with cellular resolution reveals precise micro-architecture in visual cortex	NATURE			English	Article							NEOCORTICAL PYRAMIDAL NEURONS; RECEPTIVE-FIELD PROPERTIES; IN-VIVO; ORIENTATION SELECTIVITY; DIRECTION SELECTIVITY; PINWHEEL CENTERS; STRIATE CORTEX; SINGLE NEURONS; CAT AREA-18; CA2+ INFLUX	Neurons in the cerebral cortex are organized into anatomical columns, with ensembles of cells arranged from the surface to the white matter. Within a column, neurons often share functional properties, such as selectivity for stimulus orientation; columns with distinct properties, such as different preferred orientations, tile the cortical surface in orderly patterns. This functional architecture was discovered with the relatively sparse sampling of microelectrode recordings. Optical imaging of membrane voltage or metabolic activity elucidated the overall geometry of functional maps, but is averaged over many cells ( resolution > 100 mum). Consequently, the purity of functional domains and the precision of the borders between them could not be resolved. Here, we labelled thousands of neurons of the visual cortex with a calcium- sensitive indicator in vivo. We then imaged the activity of neuronal populations at single- cell resolution with two- photon microscopy up to a depth of 400 mum. In rat primary visual cortex, neurons had robust orientation selectivity but there was no discernible local structure; neighbouring neurons often responded to different orientations. In area 18 of cat visual cortex, functional maps were organized at a fine scale. Neurons with opposite preferences for stimulus direction were segregated with extraordinary spatial precision in three dimensions, with columnar borders one to two cells wide. These results indicate that cortical maps can be built with single- cell precision.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Reid, RC (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	clay_reid@hms.harvard.edu						Adams DL, 2003, NAT NEUROSCI, V6, P113, DOI 10.1038/nn1004; BERMAN NEJ, 1987, J NEUROPHYSIOL, V58, P676, DOI 10.1152/jn.1987.58.4.676; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Braitenberg V, 1991, ANATOMY CORTEX STAT; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; Girman SV, 1999, J NEUROPHYSIOL, V82, P301, DOI 10.1152/jn.1999.82.1.301; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Hirsch JA, 2003, CEREB CORTEX, V13, P63, DOI 10.1093/cercor/13.1.63; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Kara P, 2003, J NEUROSCI, V23, P8547; Kim DS, 1999, NEUROREPORT, V10, P2515, DOI 10.1097/00001756-199908200-00015; Maldonado PE, 1997, SCIENCE, V276, P1551, DOI 10.1126/science.276.5318.1551; Mao BQ, 2001, NEURON, V32, P883, DOI 10.1016/S0896-6273(01)00518-9; Martinez-Diaz JJ, 2002, TECTONOPHYSICS, V356, P291, DOI 10.1016/S0040-1951(02)00400-6; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; MOUNTCASTLE VB, 1988, PERCEPTUAL NEUROSCIE; Ohki K, 2000, CEREB CORTEX, V10, P593, DOI 10.1093/cercor/10.6.593; PARNAVELAS JG, 1981, NEUROSCI LETT, V27, P291, DOI 10.1016/0304-3940(81)90445-6; PAYNE BR, 1981, BRAIN RES, V211, P445, DOI 10.1016/0006-8993(81)90971-9; PETERS A, 1993, CEREB CORTEX, V3, P49, DOI 10.1093/cercor/3.1.49; Pologruto TA, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-13; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; ROSE D, 1974, EXP BRAIN RES, V20, P1; Shmuel A, 1996, J NEUROSCI, V16, P6945; Stosiek C, 2003, P NATL ACAD SCI USA, V100, P7319, DOI 10.1073/pnas.1232232100; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TSIEN RY, 1988, TRENDS NEUROSCI, V11, P419, DOI 10.1016/0166-2236(88)90192-0; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; Waters J, 2003, J NEUROSCI, V23, P8558; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; WIESENFELD Z, 1975, BRAIN RES, V94, P401, DOI 10.1016/0006-8993(75)90225-5; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S	37	796	811	4	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					597	603		10.1038/nature03274	http://dx.doi.org/10.1038/nature03274			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15660108				2022-12-28	WOS:000226862000035
J	Lin, JD; Yang, RJ; Tarr, PT; Wu, PH; Handschin, C; Li, SM; Yang, WL; Pei, LM; Uldry, M; Tontonoz, P; Newgard, CB; Spiegelman, BM				Lin, JD; Yang, RJ; Tarr, PT; Wu, PH; Handschin, C; Li, SM; Yang, WL; Pei, LM; Uldry, M; Tontonoz, P; Newgard, CB; Spiegelman, BM			Hyperlipidemic effects of dietary saturated fats mediated through PGC-1 beta cactivation of SREBP	CELL			English	Article							STEROL REGULATORY ELEMENT; LEUCINE ZIPPER PROTEIN; GENE-EXPRESSION; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; TRANSGENIC MICE; CARDIOVASCULAR-DISEASE; DIABETIC DYSLIPIDEMIA; ENERGY-METABOLISM; BINDING PROTEINS	The PGC-1 family of coactivators stimulates the activity of certain transcription factors and nuclear receptors. Transcription factors in the sterol responsive element binding protein (SREBP) family are key regulators of the lipogenic genes in the liver. We show here that high-fat feeding, which induces hyperlipidemia and atherogenesis, stimulates the expression of both PGC-1beta and SREBP1c and 1a in liver. PGC-1beta0 coactivates the SREBP transcription factor family and stimulates lipogenic gene expression. Further, PGC-1beta is required for SREBP-mediated lipogenic gene expression. However, unlike SREBP itself, PGC-1beta reduces fat accumulation in the liver while greatly increasing circulating triglycerides and cholesterol in VLDL particles. The stimulation of lipoprotein transport upon PGC-1beta expression is likely due to the simultaneous coactivation of the liver X receptor, LXRalpha, a nuclear hormone receptor with known roles in hepatic lipid transport. These data suggest a mechanism through which dietary saturated fats can stimulate hyperlipidemia and atherogenesis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Handschin, Christoph/E-6886-2015; Wu, Pei-Hsuan/AAL-1704-2020	Handschin, Christoph/0000-0003-0603-1097; Wu, Pei-Hsuan/0000-0002-6690-0744	NHLBI NIH HHS [R01HL66088] Funding Source: Medline; NIDDK NIH HHS [P01DK58398, R01DK61562, R01DK54477, K01DK065584] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054477, P01DK058398, R01DK061562, K01DK065584] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Betteridge DJ, 1999, EUR J CLIN INVEST, V29, P12; Breslow JL, 2000, ANNU REV GENET, V34, P233, DOI 10.1146/annurev.genet.34.1.233; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Goldberg IJ, 2001, J CLIN ENDOCR METAB, V86, P965, DOI 10.1210/jc.86.3.965; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Reaven G, 2004, RECENT PROG HORM RES, V59, P207, DOI 10.1210/rp.59.1.207; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Sacks FM, 2002, AM J MED, V113, P13, DOI 10.1016/S0002-9343(01)00987-1; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	48	473	499	1	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					261	273		10.1016/j.cell.2004.11.043	http://dx.doi.org/10.1016/j.cell.2004.11.043			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680331	Bronze, Green Published			2022-12-28	WOS:000226740000014
J	Arad, M; Maron, BJ; Gorham, JM; Johnson, WH; Saul, JP; Perez-Atayde, AR; Spirito, P; Wright, GB; Kanter, RJ; Seidman, CE; Seidman, JG				Arad, M; Maron, BJ; Gorham, JM; Johnson, WH; Saul, JP; Perez-Atayde, AR; Spirito, P; Wright, GB; Kanter, RJ; Seidman, CE; Seidman, JG			Glycogen storage diseases presenting as hypertrophic cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN-DEATH; MUTATIONS; GENE; IDENTIFICATION; DEFICIENCY	BACKGROUND: Unexplained left ventricular hypertrophy often prompts the diagnosis of hypertrophic cardiomyopathy, a sarcomere-protein gene disorder. Because mutations in the gene for AMP-activated protein kinase gamma(2) (PRKAG2) cause an accumulation of cardiac glycogen and left ventricular hypertrophy that mimics hypertrophic cardiomyopathy, we hypothesized that hypertrophic cardiomyopathy might also be clinically misdiagnosed in patients with other mutations in genes regulating glycogen metabolism. METHODS: Genetic analyses performed in 75 consecutive unrelated patients with hypertrophic cardiomyopathy detected 40 sarcomere-protein mutations. In the remaining 35 patients, PRKAG2, lysosome-associated membrane protein 2 (LAMP2), alpha-galactosidase (GLA), and acid alpha-1,4-glucosidase (GAA) genes were studied. RESULTS: Gene defects causing Fabry's disease (GLA) and Pompe's disease (GAA) were not found, but two LAMP2 and one PRKAG2 mutations were identified in probands with prominent hypertrophy and electrophysiological abnormalities. These results prompted the study of two additional, independent series of patients. Genetic analyses of 20 subjects with massive hypertrophy (left ventricular wall thickness, greater than or equal to 30 mm) but without electrophysiological abnormalities revealed mutations in neither LAMP2 nor PRKAG2. Genetic analyses of 24 subjects with increased left ventricular wall thickness and electrocardiograms suggesting ventricular preexcitation revealed four LAMP2 and seven PRKAG2 mutations. Clinical features associated with defects in LAMP2 included male sex, severe hypertrophy, early onset (at 8 to 17 years of age), ventricular preexcitation, and asymptomatic elevations of two serum proteins. CONCLUSIONS: LAMP2 mutations typically cause multisystem glycogen-storage disease (Danon's disease) but can also present as a primary cardiomyopathy. The glycogen-storage cardiomyopathy produced by LAMP2 or PRKAG2 mutations resembles hypertrophic cardiomyopathy but is distinguished by electrophysiological abnormalities, particularly ventricular preexcitation.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Minneapolis Heart Ind Fdn, Hypertroph Cardiomyopathy Ctr, Minneapolis, MN USA; Univ Alabama Birmingham, Dept Pediat, Div Pediat Cardiol, Birmingham, AL USA; Med Univ S Carolina, Childrens Heart Program S Carolina, Charleston, SC 29425 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Galleria Genova, Dept Cardiol, Genoa, Italy; Childrens Heart Clin, Minneapolis, MN USA; Duke Univ, Med Ctr, Div Pediat Cardiol, Durham, NC USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; Medical University of South Carolina; Harvard University; Boston Children's Hospital; Duke University	Seidman, JG (corresponding author), Harvard Univ, Sch Med, Dept Genet, NRB Rm 256,77 Ave Louis Pasteur, Boston, MA 02115 USA.	seidman@genetics.med.harvard.edu						Amato AA, 2000, NEUROL CLIN, V18, P151, DOI 10.1016/S0733-8619(05)70182-1; Arad M, 2003, CIRCULATION, V107, P2850, DOI 10.1161/01.CIR.0000075270.13497.2B; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V10; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; CHOU TC, 1996, LEFT VENTRICULAR HYP, P37; DANON MJ, 1981, NEUROLOGY, V31, P51, DOI 10.1212/WNL.31.1.51; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403; GOLLOB MH, 2002, NEW ENGL J MED, V346, P300; GOLLOB MH, 2001, NEW ENGL J MED, V345, P552; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; Maron BJ, 2003, J AM COLL CARDIOL, V42, P882, DOI 10.1016/S0735-1097(03)00855-6; MARON BJ, 1995, CIRCULATION, V92, P2748, DOI 10.1161/01.CIR.92.9.2748; Morita H, 2002, COLD SPRING HARB SYM, V67, P383, DOI 10.1101/sqb.2002.67.383; NAKAO S, 1995, NEW ENGL J MED, V333, P288, DOI 10.1056/NEJM199508033330504; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Patel VV, 2003, J AM COLL CARDIOL, V42, P942, DOI 10.1016/S0735-1097(03)00850-7; Roberts R, 2001, CIRCULATION, V104, P2249, DOI 10.1161/hc4301.097430; Sachdev B, 2002, CIRCULATION, V105, P1407, DOI 10.1161/01.CIR.0000012626.81324.38; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Spirito P, 2000, NEW ENGL J MED, V342, P1778, DOI 10.1056/NEJM200006153422403; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; Sugie K, 2002, NEUROLOGY, V58, P1773, DOI 10.1212/WNL.58.12.1773; Van den Hout H, 2000, LANCET, V356, P397, DOI 10.1016/S0140-6736(00)02533-2	29	396	433	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					362	372		10.1056/NEJMoa033349	http://dx.doi.org/10.1056/NEJMoa033349			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673802				2022-12-28	WOS:000226535900008
J	Basile-Doelsch, I; Meunier, JD; Parron, C				Basile-Doelsch, I; Meunier, JD; Parron, C			Another continental pool in the terrestrial silicon cycle	NATURE			English	Article							ISOTOPIC COMPOSITION; STABLE-ISOTOPES; SILCRETE; FRACTIONATION; DIAGENESIS; CALCRETE; DIATOMS; OCEAN	Silicon is the second most abundant element on Earth. It is an important nutrient for phytoplankton(1) and is readily absorbed by terrestrial vegetation(2); it also assists the removal of carbon dioxide from the atmosphere through the weathering of silicates(3). But the continental cycle of silicon is not well known, and only a few studies have attempted to use silicon stable isotopes (Si-28, Si-29 and Si-30)(4-13) to quantify the continental silicon reservoirs. Dissolved silicon in sea and river waters forms a reservoir of mean isotopic value 11.1parts per thousand (refs 7, 10). It is enriched in Si-30 with respect to the igneous rocks reservoir, which has a mean isotopic value of -0.3parts per thousand (refs 4, 9). This enrichment can only be produced by a major fractionation during weathering, and should result in the formation of a continental Si-30-depleted reservoir. Such a reservoir, however, has not been identified to date. Here we analyse silicon isotopes of in situ quartz from a sandstone series in France, using a new-generation secondary ion mass spectrometry apparatus. We show that quartz that precipitates as siliceous cements forms a strongly Si-30-depleted reservoir with isotopic values down to -5.7parts per thousand, a more negative value than any previously published for terrestrial samples. Our findings suggest that quartz re-precipitation plays an important role in the biogeochemical cycle of silicon.	IRD Reunion, LSTUR, F-97492 St Denis, France; Univ Paul Cezanne, IRD, Europole Arbois, CEREGE UMR CNRS, F-13545 Aix En Provence 4, France	Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD)	Basile-Doelsch, I (corresponding author), IRD Reunion, LSTUR, UR037,BP 172, F-97492 St Denis, France.	basile@cerege.fr	Shrestha, Yesha/N-8890-2014; Basile, Isabelle IBD/B-4173-2010					Abdel-Wahab A, 1998, J AFR EARTH SCI, V27, P277, DOI 10.1016/S0899-5362(98)00061-X; Alexandre A, 1997, GEOCHIM COSMOCHIM AC, V61, P677, DOI 10.1016/S0016-7037(97)00001-X; [Anonymous], 1996, SILICON ISOTOPE GEOC; ARAKEL AV, 1989, AUST J EARTH SCI, V36, P73, DOI 10.1080/14400958908527952; Berner RA, 1997, SCIENCE, V276, P544, DOI 10.1126/science.276.5312.544; CHADWICK OA, 1989, SOIL SCI SOC AM J, V53, P158, DOI 10.2136/sssaj1989.03615995005300010030x; Conley DJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2002GB001894; De La Rocha CL, 2003, GEOLOGY, V31, P423, DOI 10.1130/0091-7613(2003)031<0423:SIFBMS>2.0.CO;2; De la Rocha CL, 2000, GEOCHIM COSMOCHIM AC, V64, P2467, DOI 10.1016/S0016-7037(00)00373-2; De La Rocha CL, 1998, NATURE, V395, P680, DOI 10.1038/27174; De La Rocha CL, 1997, GEOCHIM COSMOCHIM AC, V61, P5051, DOI 10.1016/S0016-7037(97)00300-1; Ding T, 2004, GEOCHIM COSMOCHIM AC, V68, P205, DOI 10.1016/S0016-7037(03)00264-3; DOUTHITT CB, 1982, GEOCHIM COSMOCHIM AC, V46, P1449, DOI 10.1016/0016-7037(82)90278-2; DOVE PM, 1996, CHEM WEATHERING RATE, P235; Elsass F, 2000, CLAY MINER, V35, P477, DOI 10.1180/000985500546954; Girard JP, 2000, GEOCHIM COSMOCHIM AC, V64, P409, DOI 10.1016/S0016-7037(99)00299-9; KHALAF FI, 1988, J SEDIMENT PETROL, V58, P1014; MCKEEGAN KD, 1985, GEOCHIM COSMOCHIM AC, V49, P1971, DOI 10.1016/0016-7037(85)90091-2; MOLINIVELSKO C, 1986, GEOCHIM COSMOCHIM AC, V50, P2719, DOI 10.1016/0016-7037(86)90221-8; Nash DJ, 1998, J AFR EARTH SCI, V27, P11, DOI 10.1016/S0899-5362(98)00043-8; PARRON C, 1985, GEOL FR, V2, P137; Parron C., 1976, SCI GEOL B, V29, P273; Ragueneau O, 2000, GLOBAL PLANET CHANGE, V26, P317, DOI 10.1016/S0921-8181(00)00052-7; Thiry M, 1996, CATENA, V26, P1, DOI 10.1016/0341-8162(95)00044-5; Thiry M, 1997, SOILS AND SEDIMENTS, P191; TREGUER P, 1995, SCIENCE, V268, P375, DOI 10.1126/science.268.5209.375; ZIEGLER K, 2002, GEOCHIM COSMOCHIM AC, V66; ZIEGLER K, 2002, 6 INT S GEOCH EARTHS, P103; ZIEGLER K, 2000, GOLDSCHM C, P1135; ZINNER E, 1989, NEW FRONTIERS STABLE, P145	30	157	173	5	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					399	402		10.1038/nature03217	http://dx.doi.org/10.1038/nature03217			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674287				2022-12-28	WOS:000226546200038
J	Israel, EJ; Levitsky, LL; Anupindi, SA; Pitman, MB				Israel, EJ; Levitsky, LL; Anupindi, SA; Pitman, MB			A 14-year-old boy with recent slowing of growth and delayed puberty - Celiac disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							T-CELLS; GLUTEN SENSITIVITY; SHORT STATURE; GLIADIN; LYMPHOCYTES; PREVALENCE; DISORDERS; INTESTINE; DIAGNOSIS; MODULATOR		Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Pediat Gastroenterol & Nutr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Pediat Endocrinol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Israel, EJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.							Book L, 2003, AM J GASTROENTEROL, V98, P377, DOI 10.1016/S0002-9270(02)05906-3; Bottaro G, 1999, AM J GASTROENTEROL, V94, P691, DOI 10.1111/j.1572-0241.1999.00938.x; BRANDTZAEG P, 1989, GASTROENTEROLOGY, V97, P1562, DOI 10.1016/0016-5085(89)90406-X; Carbonnel F, 1998, BLOOD, V92, P3879, DOI 10.1182/blood.V92.10.3879.422k34_3879_3886; Clemente MG, 2003, GUT, V52, P218, DOI 10.1136/gut.52.2.218; COLLIN P, 1994, GUT, V35, P1215, DOI 10.1136/gut.35.9.1215; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; EICHLER I, 1991, KLIN WOCHENSCHR, V69, P825, DOI 10.1007/BF01649453; Farre C, 1999, DIGEST DIS SCI, V44, P2344, DOI 10.1023/A:1026685527228; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; Fasano A, 2000, LANCET, V355, P1518, DOI 10.1016/S0140-6736(00)02169-3; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; FENOGLIOPREISER CM, 1999, GASTROINTESTINAL PAT, P309; Forsberg G, 2002, GASTROENTEROLOGY, V123, P667, DOI 10.1053/gast.2002.35355; Goldstein NS, 2001, AM J CLIN PATHOL, V116, P63; Green PHR, 2001, AM J GASTROENTEROL, V96, P126, DOI 10.1111/j.1572-0241.2001.03462.x; GREENBERG DA, 1982, AM J MED GENET, V12, P75, DOI 10.1002/ajmg.1320120110; GREULICH WW, 1959, RADIOGRAPHIC ATLAS S, V51, P103; Hausch F, 2002, AM J PHYSIOL-GASTR L, V283, pG996, DOI 10.1152/ajpgi.00136.2002; Hoffenberg EJ, 2000, J PEDIATR-US, V137, P361, DOI 10.1067/mpd.2000.109003; Hoffman RJ, 2004, NEW ENGL J MED, V351, P1997, DOI 10.1056/NEJMcps040877; Holmes GKT, 2002, ARCH DIS CHILD, V87, P495, DOI 10.1136/adc.87.6.495; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOWELL MD, 1986, J EXP MED, V164, P333, DOI 10.1084/jem.164.1.333; Jarvinen TT, 2003, AM J GASTROENTEROL, V98, P1332, DOI 10.1016/S0002-9270(03)00230-2; LEONARD JN, 1985, ARCH DERMATOL RES, V277, P349, DOI 10.1007/BF00509231; LEVITSKY LL, 1999, AMBULATORY PEDIAT CA, P504; LUNDIN KEA, 1994, HUM IMMUNOL, V41, P285, DOI 10.1016/0198-8859(94)90047-7; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Matysiak-Budnik T, 2003, GASTROENTEROLOGY, V125, P696, DOI 10.1016/S0016-5085(03)01049-7; MEEUWISSE GW, 1970, ACTA PAEDIATR SCAND, V59, P461; Mino M, 2003, AM J SURG PATHOL, V27, P1237, DOI 10.1097/00000478-200309000-00007; Pender SLF, 1997, J IMMUNOL, V158, P1582; Pricolo VE, 1998, AM J SURG, V176, P344, DOI 10.1016/S0002-9610(98)00193-7; Qiao SW, 2004, J IMMUNOL, V173, P1757, DOI 10.4049/jimmunol.173.3.1757; ROSSI TM, 1993, J PEDIATR-US, V123, P262, DOI 10.1016/S0022-3476(05)81699-3; RUSSELL GJ, 1991, HUM PATHOL, V22, P690, DOI 10.1016/0046-8177(91)90291-V; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; van Rijn JCW, 2004, ARCH DIS CHILD, V89, P882, DOI 10.1136/adc.2004.057851; Ventura A, 1999, GASTROENTEROLOGY, V117, P297, DOI 10.1053/gast.1999.0029900297; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; Wang WL, 2000, J CELL SCI, V113, P4435; Wilson JMG, 1968, PRINCIPLES PRACTICE	46	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					393	403		10.1056/NEJMcpc049032	http://dx.doi.org/10.1056/NEJMcpc049032			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673806				2022-12-28	WOS:000226535900013
J	Taylor, EN; Stampfer, MJ; Curhan, GC				Taylor, EN; Stampfer, MJ; Curhan, GC			Obesity, weight gain, and the risk of kidney stones	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	10th International Symposium on Urolithiasis	MAY 25-28, 2004	Hong Kong, PEOPLES R CHINA				CALCIUM-OXALATE; DIETARY CALCIUM; URIC-ACID; PHOSPHATE-METABOLISM; DIABETES-MELLITUS; PHYSICAL-ACTIVITY; BODY-WEIGHT; FREQUENCY; HYPERINSULINEMIA; REPRODUCIBILITY	Context Larger body size may result in increased urinary excretion of calcium. oxalate, and uric acid, thereby increasing the risk for calcium-containing kidney stones. It is unclear if obesity increases the risk of stone formation, and it is not known if weight gain influences risk. Objective To determine if weight, weight gain, body mass index (BMI), and waist circumference are associated with kidney stone formation. Design, Setting, and Participants A prospective study of 3 large cohorts: the Heath Professionals Follow-up Study (N=45988 men; age range at baseline, 40-75 years). the Nurses' Health Study I (N =93 758 older women; age range at baseline, 34-59 years), and the Nurses' Health Study 11 (N=101 877 younger women; age range at bas-elin-e b 0 0 27-44 years). Main Outcome Measures Incidence of symptomatic kidney stones. Results We documented 4827 incident kidney stones over a combined 46 years of follow-up. After adjusting for age, dietary factors, fluid intake, and thiazide use, the relative risk (RR) for stone formation in men weighing more than 220 lb (100.0 kg) vs men less than 150 lb (68.2 kg) was 1.44 (95% confidence interval [CI], 1.11-1.86; P=.002 for trend). in older and younger women, RRs for these weight categories were 1.89 (95% Cl, 1.52-2.36; P<.001 for trend) and 1.92 (95% Cl, 1.59-2.31; P<.001 for trend), respectively. The RR in men who gained more than 35 lb (15.9 kg) since age 21 years vs men whose weight did not change was 1.39 (95% Cl. 1.14-1.70; P=.001 for trend). Corresponding RRs for the same categories of weight gain since age 18 years in older and younger women were 1.70 (95% Cl, 1.40-2.05; P<.001 for trend) and 1.82 (95% Cl, 1.50-2.21; P<.001 for trend). Body mass index was associated with the risk of kidney stone formation: the RR for men with a BMI of 30 or greater vs those with a BMI of 21 to 22.9 was 1.33 (95% CI, 1.08-1.63; P<.001 for trend). Corresponding RRs for the same categories of BMI in older and younger women were 1.90 (95% Cl, 1.61-2.25; P<.001 for trend) and 2.09 (95% Cl, 1.77-2.48; P<.001 for trend). Waist circumference was also positively associated with risk in men (P=.002 for trend) and in older and younger women (P<.001 for trend for both). Conclusions Obesity and weight gain increase the risk of kidney stone formation. The magnitude of the increased risk may be greater in women than in men.	Harvard Univ, Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr & Epidemiol, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Taylor, EN (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Med, Channing Lab, 3rd Floor,181 Longwood Ave, Boston, MA 02115 USA.	entaylor@partners.org			NATIONAL CANCER INSTITUTE [R01CA050385, P01CA087969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059583, T32DK007791] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50385, CA 87969, CA 55075] Funding Source: Medline; NIDDK NIH HHS [DK 07791, DK 59583] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abate N, 2004, KIDNEY INT, V65, P386, DOI 10.1111/j.1523-1755.2004.00386.x; Blaak E, 2001, CURR OPIN CLIN NUTR, V4, P499, DOI 10.1097/00075197-200111000-00006; COE FL, 1980, KIDNEY INT, V17, P662, DOI 10.1038/ki.1980.205; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; COE FL, 1974, NEW ENGL J MED, V291, P1344; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Curhan GC, 1997, ANN INTERN MED, V126, P497, DOI 10.7326/0003-4819-126-7-199704010-00001; Curhan GC, 2001, KIDNEY INT, V59, P2290, DOI 10.1046/j.1523-1755.2001.0590062290.x; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; Curhan GC, 1998, J AM SOC NEPHROL, V9, P1645; Elia M, 2001, OBES RES, V9, p244S, DOI 10.1038/oby.2001.126; HAMM LL, 1990, KIDNEY INT, V38, P728, DOI 10.1038/ki.1990.265; Heller HJ, 2002, J UROLOGY, V168, P1923, DOI 10.1016/S0022-5347(05)64264-4; HIATT RA, 1982, AM J EPIDEMIOL, V115, P255, DOI 10.1093/oxfordjournals.aje.a113297; Hu FB, 2001, ARCH INTERN MED, V161, P1542, DOI 10.1001/archinte.161.12.1542; JOHNSON CM, 1979, KIDNEY INT, V16, P624, DOI 10.1038/ki.1979.173; KERSTETTER J, 1991, METABOLISM, V40, P707, DOI 10.1016/0026-0495(91)90088-E; Kramer HJM, 2003, J AM SOC NEPHROL, V14, P1272, DOI 10.1097/01.ASN.0000060682.25472.C3; Krivosikova Z, 1998, PHYSIOL RES, V47, P177; Lemann J, 1996, KIDNEY INT, V49, P200, DOI 10.1038/ki.1996.27; LEMANN J, 1969, NEW ENGL J MED, V280, P232, DOI 10.1056/NEJM196901302800502; LEMANN J, 1970, J LAB CLIN MED, V75, P578; LEVY FL, 1995, AM J MED, V98, P50, DOI 10.1016/S0002-9343(99)80080-1; LINGEMAN JE, 1986, MED CARE, V24, P1151, DOI 10.1097/00005650-198612000-00007; Maalouf NM, 2004, KIDNEY INT, V65, P1422, DOI 10.1111/j.1523-1755.2004.00522.x; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Nowicki M, 1998, NEPHROL DIAL TRANSPL, V13, P2566, DOI 10.1093/ndt/13.10.2566; PAK CYC, 1975, P SOC EXP BIOL MED, V149, P930; Pearle M, 2004, UROLOGIC DIS AM, P34; Powell CR, 2000, UROLOGY, V55, P825, DOI 10.1016/S0090-4295(99)00617-2; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RUMENAPF G, 1990, CALCIFIED TISSUE INT, V46, P73, DOI 10.1007/BF02556090; Shimamoto K, 1995, TOHOKU J EXP MED, V177, P271, DOI 10.1620/tjem.177.271; Siener R, 2004, OBES RES, V12, P106, DOI 10.1038/oby.2004.14; Stamatelou KK, 2003, KIDNEY INT, V63, P1817, DOI 10.1046/j.1523-1755.2003.00917.x; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 2012, NUTR EPIDEMIOLOGY; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WOOD RJ, 1983, J NUTR, V113, P1561, DOI 10.1093/jn/113.8.1561; YAMASHITA S, 1986, INT J OBESITY, V10, P255	42	729	780	1	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2005	293	4					455	462		10.1001/jama.293.4.455	http://dx.doi.org/10.1001/jama.293.4.455			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	890DW	15671430	Bronze			2022-12-28	WOS:000226492900024
J	Leimane, V; Riekstina, V; Holtz, TH; Zarovska, E; Skripconoka, V; Thorpe, LE; Laserson, KF; Wells, CD				Leimane, V; Riekstina, V; Holtz, TH; Zarovska, E; Skripconoka, V; Thorpe, LE; Laserson, KF; Wells, CD			Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study	LANCET			English	Article							DOTS-PLUS; MYCOBACTERIUM-TUBERCULOSIS; MDR-TB; CHEMOTHERAPY; EXPERIENCE; RIFAMPIN; THERAPY; PERU	Background Latvia has one of the highest rates of multidrug-resistant tuberculosis (MDRTB). Our aim was to assess treatment outcomes for the first full cohort of MDRTB patients treated under Latvia's DOTS-Plus strategy following WHO guidelines. Methods We retrospectively reviewed all civilian patients who began treatment with individualised treatment regimens for pulmonary MDRTB in Latvia between Jan 1, and Dec 31, 2000. We applied treatment outcome definitions for MDRTB, developed by an international. expert consensus group, and assessed treatment effectiveness and risk factors associated with poor outcome. Findings Of the 204 patients assessed, 55 (27%) had been newly diagnosed with MDRTB, and 149 (73%) had earlier been treated with first-line or second-line drugs for this disease. Assessment of treatment outcomes showed that 135 (66%) patients were cured or completed therapy, 14 (7%) died, 26 (13%) defaulted, and treatment failed in 29 (14%). Of the 178 adherent patients, 135 (76%) achieved cure or treatment completion. In a multivariate Cox proportional-hazards model of these patients, independent predictors of poor outcome (death and treatment failure) included having previously received treatment for MDRTB (hazard ratio 5.7, 95% CI 1.9-16.6), the use of five or fewer drugs for 3 months or more (3.2, 1.1-9.6), resistance to ofloxacin (2.6, 1.2-5.4), and body-mass index less than 18.5 at start of treatment (2.3, 1.1-4.9). Interpretation The DOTS-Plus strategy of identifying and treating patients with MDRTB can be effectively implemented on a nationwide scale in a setting of limited resources.	State Ctr TB & Lung Dis, Riga, Latvia; Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA	Riga East University Hospital; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Leimane, V (corresponding author), Latvia State Ctr TB & Lung Dis, PO Cekule, Stopinup, Riga Region, Latvia.	vaira@tuberculosis.lv						ALLISON P, 1995, SURVIVAL ANAL USIN S; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; [Anonymous], 1995, PHYS STAT US INT ANT; Bailey KV, 1995, B WORLD HEALTH ORGAN, V73, P673; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P661; Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-1159OC; Coninx R, 1999, LANCET, V353, P969, DOI 10.1016/S0140-6736(98)08341-X; Davies GR, 1999, INT J TUBERC LUNG D, V3, P799; Dean AG, 1997, EPI INFO VERSION 6 0; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Espinal MA, 1999, INT J TUBERC LUNG D, V3, P561; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x; Hadiarto M, 1996, CHEMOTHERAPY, V42, P24, DOI 10.1159/000239511; Iseman MD, 1998, INT J TUBERC LUNG D, V2, P867; Johansen IS, 2003, INT J TUBERC LUNG D, V7, P899; Kim HJ, 2001, INT J TUBERC LUNG D, V5, P1129; Kruuner A, 1998, INT J TUBERC LUNG D, V2, P130; LASERSON KF, IN PRESS INT J TB LU; Lockman S, 2001, CLIN INFECT DIS, V32, P373, DOI 10.1086/318489; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Narita M, 2001, CHEST, V120, P343, DOI 10.1378/chest.120.2.343; Organization WH, 1997, WHOTB97229; Park SK, 1998, INT J TUBERC LUNG D, V2, P877; Riekstina V, 2003, INT J TUBERC LUNG D, V7, P903; *SAS I INC, 1999, STAT AN SYST WIND RE; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; Suo J, 1996, CHEMOTHERAPY, V42, P20, DOI 10.1159/000239510; Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303; *WHO, 2000, WHOCDSTB2000278; WHO, 2000, WHOCDSTB2000279; World Health Organization, 2003, TREATM TUB GUID NAT; Yew WW, 2000, CHEST, V117, P744, DOI 10.1378/chest.118.3.744; Zalesky R, 1997, Monaldi Arch Chest Dis, V52, P142	36	224	241	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					318	326						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664227				2022-12-28	WOS:000226449600035
J	Schankin, CJ; Birnbaum, T; Linn, J; Bruning, R; Kretzschmar, HA; Straube, A; Krebs, L				Schankin, CJ; Birnbaum, T; Linn, J; Bruning, R; Kretzschmar, HA; Straube, A; Krebs, L			A fatal encephalitis	LANCET			English	Article							RABIES		Univ Munich, Ctr Priondis & Neuropathol, D-81377 Munich, Germany; Univ Munich Hosp Grosshadern, Dept Neurol, D-81377 Munich, Germany; Univ Munich Hosp Grosshadern, Dept Neuroradiol, D-81377 Munich, Germany	University of Munich; University of Munich; University of Munich	Krebs, L (corresponding author), Univ Munich, Ctr Priondis & Neuropathol, Feodor Lynen Str 23, D-81377 Munich, Germany.	bjarne.Krebs@med.um-muenchen.de	Linn, Jennifer/H-8202-2013; Linn, Jennifer/AAE-1567-2021	Linn, Jennifer/0000-0003-0797-2761				Hemachudha T, 2002, LANCET NEUROL, V1, P101, DOI 10.1016/S1474-4422(02)00041-8; Jackson AC, 2003, CLIN INFECT DIS, V36, P60, DOI 10.1086/344905; *WHO, 2000, WHOCDSCSRAPH996; World Health Organization, 1998, WHOEMCZDI984; 2004, MMWR MORB MORTAL WKL, V53, P1171	5	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					358	358						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664235				2022-12-28	WOS:000226449600043
J	Chevalier, ML; Ryerson, FJ; Tapponnier, P; Finkel, RC; Van der Woerd, J; Li, HB; Liu, Q				Chevalier, ML; Ryerson, FJ; Tapponnier, P; Finkel, RC; Van der Woerd, J; Li, HB; Liu, Q			Slip-rate measurements on the Karakorum Fault may imply secular variations in fault motion	SCIENCE			English	Article							ALTYN TAGH FAULT; SAN-ANDREAS; TIBET; SYSTEM; DEFORMATION; EVOLUTION; MORAINES; HIMALAYA; BE-10; CHINA	Beryllium-10 surface exposure dating of offset moraines on one branch of the Karakorum Fault west of the Gar basin yields a long-term (140- to 20-thousand-year) right-lateral slip rate of similar to10.7 +/- 0.7 millimeters per year. This rate is 10 times larger than that inferred from recent InSAR analyses (similar to1 +/- 3 millimeters per year) that span similar to8 years and sample all branches of the fault. The difference in slip-rate determinations suggests-that large rate fluctuations may exist over centennial or millennial time scales. Such fluctuations would be consistent with mechanical coupling between the seismogenic, brittle-creep, and ductile shear sections of faults that reach deep into the crust.	Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA; Inst Phys Globe Strasbourg, CNRS, UMR 7578, Lab Tecton Mecan Lithosphere, F-75252 Paris 05, France; Inst Phys Globe Strasbourg, CNRS, UMR 7516, F-67084 Strasbourg, France; Chinese Acad Geol Sci, Inst Geol, Lab Continental Dynam, Beijing 100037, Peoples R China; Total Fina Elf, Total Explorat China, Beijing 100004, Peoples R China	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Chinese Academy of Geological Sciences	Ryerson, FJ (corresponding author), Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Livermore, CA 94550 USA.	ryerson@ltnl.gov	Ryerson, Frederick J/A-2105-2012; Tapponnier, .Paul E/B-7033-2011	Tapponnier, .Paul E/0000-0002-7135-1962; Chevalier, Marie-Luce/0000-0001-9110-2456				ARMIJO R, 1989, J GEOPHYS RES-SOLID, V94, P2787, DOI 10.1029/JB094iB03p02787; AVOUAC JP, 1993, GEOPHYS RES LETT, V20, P895, DOI 10.1029/93GL00128; Banerjee P, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015184; Bendick R, 2000, NATURE, V404, P69, DOI 10.1038/35003555; Bennett RA, 2004, GEOLOGY, V32, P961, DOI 10.1130/G20806.1; Brown ET, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000100; Finkel RC, 2003, GEOLOGY, V31, P561, DOI 10.1130/0091-7613(2003)031<0561:BDOMEM>2.0.CO;2; Hubert-Ferrari A, 2003, GEOPHYS J INT, V153, P111, DOI 10.1046/j.1365-246X.2003.01872.x; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; Lacassin R, 2004, EARTH PLANET SC LETT, V219, P255, DOI 10.1016/S0012-821X(04)00006-8; Lasserre C, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000060; LASSERRE C, 2001, EOS, V42, pF271; Liu Q., 1993, THESIS U PARIS 7; MERIAUX A, IN PRESS J GEOPHYS R; Meriaux AS, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002558; Murphy MA, 2002, GEOL SOC AM BULL, V114, P428, DOI 10.1130/0016-7606(2002)114<0428:SEOTGM>2.0.CO;2; Owen LA, 2003, GEOL SOC AM BULL, V115, P1356, DOI 10.1130/B25314.1; Peltzer G, 2001, GEOLOGY, V29, P975, DOI 10.1130/0091-7613(2001)029<0975:TSAAFI>2.0.CO;2; Perfettini H, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002917; SAVAGE JC, 1978, J GEOPHYS RES, V83, P3369, DOI 10.1029/JB083iB07p03369; Segall P, 2002, INT GEOL REV, V44, P62, DOI 10.2747/0020-6814.44.1.62; Van Der Woerd J, 2002, GEOPHYS J INT, V148, P356, DOI 10.1046/j.1365-246x.2002.01556.x; Wallace K, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019724; Wang Q, 2001, SCIENCE, V294, P574, DOI 10.1126/science.1063647; Weldon R., 2004, GSA TODAY, V14, P4, DOI [10.1130/1052-5173(2004)014%3C4:watecw%3E2.0.co;2, DOI 10.1130/1052-5173(2004)0142.0.CO;2,2004]; Wright TJ, 2004, SCIENCE, V305, P236, DOI 10.1126/science.1096388; Zhang PZ, 2004, GEOLOGY, V32, P809, DOI 10.1130/G20554.1	27	169	191	4	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					411	414		10.1126/science.1105466	http://dx.doi.org/10.1126/science.1105466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662010				2022-12-28	WOS:000226492300042
J	Abella, BS; Alvarado, JP; Myklebust, H; Edelson, DP; Barry, A; O'Hearn, N; Vanden Hoek, TL; Becker, LB				Abella, BS; Alvarado, JP; Myklebust, H; Edelson, DP; Barry, A; O'Hearn, N; Vanden Hoek, TL; Becker, LB			Quality of cardiopulmonary resuscitation during in-hospital cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASIC LIFE-SUPPORT; CHEST COMPRESSIONS; VENTRICULAR-FIBRILLATION; PRECORDIAL COMPRESSION; CPR PERFORMANCE; BYSTANDER CPR; DEFIBRILLATION; SURVIVAL; SYSTEM	Context The survival benefit of well-performed cardiopulmonary resuscitation (CPR) is well-documented, but little objective data exist regarding actual CPR quality during cardiac arrest. Recent studies have challenged the notion that CPR is uniformly performed according to established international guidelines. Objectives To measure multiple parameters of in-hospital CPR quality and to determine compliance with published American Heart Association and international guidelines. Design and Setting A prospective observational study of 67 patients who experienced in-hospital cardiac arrest at the University of Chicago Hospitals, Chicago, III, between December 11, 2002, and April 5, 2004. Using a monitor/defibrillator with novel additional sensing capabilities, the parameters of CPR quality including chest compression rate, compression depth, ventilation rate, and the fraction of arrest time without chest compressions (no-flow fraction) were recorded. Main Outcome Measure Adherence to American Heart Association and international CPR guidelines. Results Analysis of the first 5 minutes of each resuscitation by 30-second segments revealed that chest compression rates were less than 90/min in 28.1% of segments. Compression depth was too shallow (defined as <38 mm) for 37.4% of compressions. Ventilation rates were high, with 60.9% of segments containing a rate of more than 20/min. Additionally, the mean (SD) no-flow fraction was 0.24 (0.18). A 10-second pause each minute of arrest would yield a no-flow fraction of 0.17. A total of 27 patients (40.3%) achieved return of spontaneous circulation and 7 (10.4%) were discharged from the hospital. Conclusions In this study of in-hospital cardiac arrest, the quality of multiple parameters of CPR was inconsistent and often did not meet published guideline recommendations, even when performed by well-trained hospital staff. The importance of high-quality CPR suggests the need for rescuer feedback and monitoring of CPR quality during resuscitation efforts.	Univ Chicago Hosp, Sect Emergency Med, Chicago, IL 60637 USA; Univ Chicago Hosp, Sect Crit Care, Chicago, IL 60637 USA; Laerdal Med Corp, Stavanger, Norway	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System	Becker, LB (corresponding author), Univ Chicago Hosp, Sect Emergency Med, 5841 S Maryland Ave,MC 5068, Chicago, IL 60637 USA.	lbecker@medicine.bsd.uchicago.edu	Abella, Benjamin/G-3579-2010	Abella, Benjamin/0000-0003-2521-0891				Aase SO, 2000, IEEE T BIO-MED ENG, V47, P1440, DOI 10.1109/10.880095; Aase SO, 2002, IEEE T BIO-MED ENG, V49, P263, DOI 10.1109/10.983461; ABELLA BS, IN PRESS CIRCULATION; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Becker L, 1996, CARDIAC ARREST SCI P, P28; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; Donnelly P, 2000, RESUSCITATION, V45, P195, DOI 10.1016/S0300-9572(00)00186-6; Dowie R, 2003, RESUSCITATION, V56, P173, DOI 10.1016/S0300-9572(02)00343-X; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; FENELEY MP, 1988, CIRCULATION, V77, P240, DOI 10.1161/01.CIR.77.1.240; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; Handley AJ, 2003, RESUSCITATION, V57, P57, DOI 10.1016/S0300-9572(02)00400-8; HIGHTOWER D, 1995, ANN EMERG MED, V26, P300, DOI 10.1016/S0196-0644(95)70076-5; *INT CONS SCI, 2000, CIRCULATION S1, V102, P1; KAYE W, 1986, CRIT CARE MED, V14, P620, DOI 10.1097/00003246-198607000-00007; Keim SM, 2001, RESUSCITATION, V51, P269, DOI 10.1016/S0300-9572(01)00418-X; Kern KB, 2003, RESUSCITATION, V58, P273, DOI 10.1016/S0300-9572(03)00269-7; Koster RW, 2003, RESUSCITATION, V58, P275, DOI 10.1016/S0300-9572(03)00270-3; Marsch SCU, 2004, RESUSCITATION, V60, P51, DOI 10.1016/j.resuscitation.2003.08.004; MILANDER MM, 1995, ACAD EMERG MED, V2, P708, DOI 10.1111/j.1553-2712.1995.tb03622.x; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Pellis T, 2002, CRIT CARE MED, V30, pS176, DOI 10.1097/00003246-200204001-00012; Rea TD, 2003, CIRCULATION, V108, P1196, DOI 10.1161/01.CIR.0000087403.24467.A4; Sato Y, 1997, CRIT CARE MED, V25, P733, DOI 10.1097/00003246-199705000-00005; Steen S, 2003, RESUSCITATION, V58, P249, DOI 10.1016/S0300-9572(03)00265-X; Sunde K, 1997, RESUSCITATION, V34, P235, DOI 10.1016/S0300-9572(96)01087-8; Timerman S, 2004, RESUSCITATION, V61, P273, DOI 10.1016/j.resuscitation.2004.01.025; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; WHITE RD, 1994, ANN EMERG MED, V23, P25, DOI 10.1016/S0196-0644(94)70003-6; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; Wik L, 2001, RESUSCITATION, V50, P167, DOI 10.1016/S0300-9572(01)00331-8; Wik L, 2000, RESUSCITATION, V47, P7, DOI 10.1016/S0300-9572(00)00190-8; Yu T, 2002, CIRCULATION, V106, P368, DOI 10.1161/01.CIR.0000021429.22005.2E	36	891	958	2	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					305	310		10.1001/jama.293.3.305	http://dx.doi.org/10.1001/jama.293.3.305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657323	Bronze			2022-12-28	WOS:000226358400024
J	Whitney, EJ; Krasuski, RA; Personius, BE; Michalek, JE; Maranian, AM; Kolasa, MW; Monick, E; Brown, BG; Gotto, AM				Whitney, EJ; Krasuski, RA; Personius, BE; Michalek, JE; Maranian, AM; Kolasa, MW; Monick, E; Brown, BG; Gotto, AM			A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events	ANNALS OF INTERNAL MEDICINE			English	Article							ARTERY-DISEASE; COMBINATION THERAPY; PREVENTION; MEN; ATHEROSCLEROSIS; PRAVASTATIN; REGRESSION; GEMFIBROZIL; BEZAFIBRATE; INFARCTION	Background: The high-density lipoprotein (HDL) cholesterol level is a strong predictor of cardiovascular events in epidemiologic studies. Until recently, it has been less extensively studied as a therapeutic target. Objective: To assess the angiographic and clinical effects of a pharmacologic strategy to increase HDL cholesterol levels. Design: Randomized, double-blind, placebo-controlled trial conducted from 1993 to 1996. Setting: Outpatient specialty clinic of a large U.S. military medical center. Participants: 143 military retirees younger than 76 years of age with low HDL cholesterol levels and angiographically evident coronary disease. Intervention: Gemfibrozil, niacin, and cholestyramine or corresponding placebos, with aggressive dietary and lifestyle intervention at baseline. Measurements: Change from baseline to 30 months and a composite measure of clinical events that included hospitalization for angina, myocardial infarction, transient ischemic attack and stroke, death, and cardiovascular procedures. Results: At baseline, mean (+/- SD) lipid values were as follows: total cholesterol, 5.1 +/- 0.8 mmol/L (196 +/- 31 mg/dL); low-density lipoprotein (LDL) cholesterol, 3.3 +/- 0.7 mmol/L (128 +/- 27 mg/dL); and HDL cholesterol, 0.9 +/- 0.2 mmol/L (34 +/- 6 mg/dL). Compared with placebo, the pharmacologically treated group experienced a 20% (95% Cl, 14.8% to 24.3%) decrease in total cholesterol level, a 36% (Cl, 28.4% to 43.5%) increase in HDL cholesterol level, a 26% (Cl, 19.1% to 33.7%) decrease in LDL cholesterol level, and a 50% (Cl, 40.5% to 59.2%) reduction in triglycericle levels. Focal coronary stenosis increased by 1.4% in the placebo group but decreased by 0.8% in the drug group (difference, -2.2 percentage points [Cl, -4.2 to -0.1 percentage points]). A composite cardiovascular event end point was reached in 26% of patients in the placebo group and 13% of those in the drug group (difference, 13.7 percentage points [Cl, 0.9 to 26.5 percentage points]). Side effects, particularly flushing and gastrointestinal intolerance, were more common in the drug group but rarely led to withdrawal from the study. Limitations: The study was small and used a composite clinical outcome. Whether improvements in angiographic findings were due to reductions in LDL cholesterol or increases in HDL cholesterol was not established. Flushing may have led to inadvertent unblinding in patients who were randomly assigned to active study drugs. Conclusions: A combination regimen aimed at increasing HDL cholesterol levels improves cholesterol profiles, helps prevent angiographic progression of coronary stenosis, and may prevent cardiovascular events in some people who exercise regularly and eat low-fat diets.	Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA; Heart & Vasc Inst San Antonio, San Antonio, TX USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Cardiol Consultants, Grants Pass, OR USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Washington, Sch Med, Seattle, WA USA; Cornell Univ, Weill Med Coll, New York, NY USA	United States Department of Defense; United States Air Force; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Northwestern University; University of Washington; University of Washington Seattle; Cornell University	Krasuski, RA (corresponding author), Wilford Hall USAF Med Ctr, 759 MSGS-MCCC,2200 Bergquist Dr,Suite 1, Lackland AFB, TX 78236 USA.	Richard.krasuski@lackland.af.mil	Krasuski, Richard/AAI-8177-2020	Krasuski, Richard/0000-0003-3150-5215				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Assmann G, 1996, ATHEROSCLEROSIS, V124, pS11, DOI 10.1016/0021-9150(96)05852-2; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; Brousseau ME, 2004, NEW ENGL J MED, V350, P1505, DOI 10.1056/NEJMoa031766; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Elisaf M, 2002, CURR MED RES OPIN, V18, P269, DOI 10.1185/030079902125000516; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; Frick MH, 1997, CIRCULATION, V96, P2137; Fruchart J C, 2001, Curr Atheroscler Rep, V3, P83, DOI 10.1007/s11883-001-0015-x; Goldenberg I, 2003, J AM COLL CARDIOL, V41, p316A; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Grundy SM, 2002, ARCH INTERN MED, V162, P1568, DOI 10.1001/archinte.162.14.1568; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Kamanna V S, 2000, Curr Atheroscler Rep, V2, P36, DOI 10.1007/s11883-000-0093-1; Knopp RH, 2000, AM J CARDIOL, V86, p51L; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; OLIVER MF, 1994, LANCET, V344, P633; Pasternak RC, 1996, ANN INTERN MED, V125, P529, DOI 10.7326/0003-4819-125-7-199610010-00001; Pasternak RC, 2002, J AM COLL CARDIOL, V40, P567, DOI 10.1016/S0735-1097(02)02030-2; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WHITNEY EJ, 1991, MIL MED, V156, P422, DOI 10.1093/milmed/156.8.422; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; Xydakis AM, 2002, AM J CARDIOL, V90, p21K	33	187	191	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2005	142	2					95	104		10.7326/0003-4819-142-2-200501180-00008	http://dx.doi.org/10.7326/0003-4819-142-2-200501180-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915LQ	15657157				2022-12-28	WOS:000228306100003
J	Holowiecki, J				Holowiecki, J			NOTCH1 pathway: a molecular target in T-cell cancers?	LANCET			English	Editorial Material							GAMMA-SECRETASE; EXPRESSION; SURVIVAL; LEUKEMIA		Silesian Med Univ, Dept Haematol & BMT, PL-40023 Katowice, Poland	Medical University Silesia	Holowiecki, J (corresponding author), Silesian Med Univ, Dept Haematol & BMT, PL-40023 Katowice, Poland.	holow@slam.katowice.pl	Holowiecki, Jerzy/AAW-7928-2021					Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Hadland BK, 2004, BLOOD, V104, P3097, DOI 10.1182/blood-2004-03-1224; HOUDE C, 2004, BLOOD           0803; Iwata M, 2004, BLOOD, V103, P4496, DOI 10.1182/blood-2004-01-0256; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kantarjian HM, 2004, BLOOD, V104, P1979, DOI 10.1182/blood-2004-02-0711; Laws AM, 2004, EUR J IMMUNOL, V34, P726, DOI 10.1002/eji.200324772; Lleo A, 2003, J BIOL CHEM, V278, P47370, DOI 10.1074/jbc.M308480200; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Oakley F, 2003, J BIOL CHEM, V278, P24359, DOI 10.1074/jbc.M211051200; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200	14	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					197	199						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652588				2022-12-28	WOS:000226309600006
J	Jiang, H; Guo, W; Liang, XH; Rao, Y				Jiang, H; Guo, W; Liang, XH; Rao, Y			Both the establishment and the maintenance of neuronal polarity require active mechanisms: Critical roles of GSK-3 beta and its upstream regulators	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; HIPPOCAMPAL-NEURONS; PROTEIN-KINASE; TUMOR-SUPPRESSOR; AXON; PHOSPHORYLATION; INHIBITION; GROWTH; TAU; FAMILY	Axon-dendrite polarity is a cardinal feature of neuronal morphology essential for information flow. Here we report a differential distribution of GSK-3beta activity in the axon versus the dendrites. A constitutively active GSK-3beta mutant inhibited axon formation, whereas multiple axons formed from a single neuron when GSK-3beta activity was reduced by pharmacological inhibitors, a peptide inhibitor, or siRNAs. An active mechanism for maintaining neuronal polarity was revealed by the conversion of preexisting dendrites into axons upon GSK-3 inhibition. Biochemical and functional data show that the Akt kinase and the PTEN phosphatase are upstream of GSK-3beta in determining neuronal polarity. Our results demonstrate that there are active mechanisms for maintaining as well as establishing neuronal polarity, indicate that GSK-3beta relays signaling from Akt and PTEN to play critical roles in neuronal polarity, and suggest that application of GSK-3beta inhibitors can be a novel approach to promote generation of new axons after neural injuries.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Grad Sch, Shanghai 200031, Peoples R China; Natl Inst Biol Sci, Beijing 102206, Peoples R China; Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; National Institute of Biological Sciences, Beijing; Northwestern University; Feinberg School of Medicine	Rao, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Grad Sch, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	y-rao@northwestem.edu		Jiang, Hui/0000-0002-0277-9711; Rao, Yi/0000-0002-0405-5426; Guo, Wei/0000-0002-9937-7152				AHMAD FJ, 1994, NEURON, V12, P271, DOI 10.1016/0896-6273(94)90270-4; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BANKER GA, 1979, J COMP NEUROL, V187, P469, DOI 10.1002/cne.901870302; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; Cajal S.R., 1911, HISTOLOGY NERVOUS SY; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; DOTTI CG, 1987, NATURE, V330, P254, DOI 10.1038/330254a0; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Esch T, 1999, J NEUROSCI, V19, P6417; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Goold RG, 1999, J CELL SCI, V112, P3373; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; Lamoureux P, 2002, J CELL BIOL, V159, P499, DOI 10.1083/jcb.200207174; LEIN PJ, 1992, DEV BRAIN RES, V69, P191, DOI 10.1016/0165-3806(92)90159-T; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu GF, 2004, NAT NEUROSCI, V7, P1222, DOI 10.1038/nn1331; Lucas FR, 1998, J CELL SCI, V111, P1351; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mandell JW, 1996, J NEUROSCI, V16, P5727; Menager C, 2004, J NEUROCHEM, V89, P109, DOI 10.1046/j.1471-4159.2004.02302.x; Ning K, 2004, J NEUROSCI, V24, P4052, DOI 10.1523/JNEUROSCI.5449-03.2004; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rolls MM, 2004, NAT NEUROSCI, V7, P1293, DOI 10.1038/nn1346; Ruthel G, 2000, J NEUROSCI, V20, P2266; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shi SH, 2004, CURR BIOL, V14, P2025, DOI 10.1016/j.cub.2004.11.009; Steward O, 2002, NEURON, V36, P338, DOI 10.1016/S0896-6273(02)01006-1; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; WANG QM, 1994, J BIOL CHEM, V269, P14566; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	55	441	461	2	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					123	135		10.1016/j.cell.2004.12.033	http://dx.doi.org/10.1016/j.cell.2004.12.033			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652487	Bronze			2022-12-28	WOS:000226365400016
J	Komatsu, K; Murata, M; Murata, Y				Komatsu, K; Murata, M; Murata, Y			Encapsulation of molecular hydrogen in fullerene C 60 by organic synthesis	SCIENCE			English	Article							ENDOHEDRAL METALLOFULLERENES; ORIFICE; HELIUM; XENON; C-120; ATOMS	In spite of their importance in fundamental and applied studies, the preparation of endohedral fullerenes has relied on difficult-to-control physical methods. We report a four-step organic reaction that completely closes a 13-membered ring orifice of an open-cage fullerene. This process can be used to synthesize a fullerene C-60 encapsulating molecular hydrogen, which can be isolated as a pure product. This molecular surgical method should make possible the preparation of a series of C-60 fullerenes, encapsulating either small atoms or molecules, that are not accessible by conventional physical methods.	Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan	Kyoto University	Komatsu, K (corresponding author), Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan.	komatsu@scl.kyoto-u.ac.jp	Murata, Michihisa/N-8564-2014	Murata, Michihisa/0000-0002-5479-2993				BETHUNE DS, 1993, NATURE, V366, P123, DOI 10.1038/366123a0; Cross RJ, 2003, J ORG CHEM, V68, P8281, DOI 10.1021/jo034851b; Kato H, 2003, J AM CHEM SOC, V125, P4391, DOI 10.1021/ja027555+; Kobayashi S, 2003, J AM CHEM SOC, V125, P8116, DOI 10.1021/ja034944a; Komatsu K, 1998, J ORG CHEM, V63, P9358, DOI 10.1021/jo981319t; Liu SY, 2000, J ORGANOMET CHEM, V599, P74, DOI 10.1016/S0022-328X(99)00756-1; MCMURRY JE, 1989, CHEM REV, V89, P1513, DOI 10.1021/cr00097a007; Murata Y, 2003, J AM CHEM SOC, V125, P7152, DOI 10.1021/ja0354162; Murata Y, 2003, CHEM-EUR J, V9, P1600, DOI 10.1002/chem.200390184; Nagase S, 1996, B CHEM SOC JPN, V69, P2131, DOI 10.1246/bcsj.69.2131; Rubin Y, 2001, ANGEW CHEM INT EDIT, V40, P1543, DOI 10.1002/1521-3773(20010417)40:8<1543::AID-ANIE1543>3.0.CO;2-6; Rubin Y, 1999, TOP CURR CHEM, V199, P67; Ruttimann M, 1997, CHEM-EUR J, V3, P1071, DOI 10.1002/chem.19970030714; SAUNDERS M, 1994, NATURE, V367, P256, DOI 10.1038/367256a0; SAUNDERS M, 1994, J AM CHEM SOC, V116, P2193, DOI 10.1021/ja00084a089; Saunders M, 1996, SCIENCE, V271, P1693, DOI 10.1126/science.271.5256.1693; Schick G, 1999, ANGEW CHEM INT EDIT, V38, P2360, DOI 10.1002/(SICI)1521-3773(19990816)38:16<2360::AID-ANIE2360>3.0.CO;2-V; Scott LT, 2002, SCIENCE, V295, P1500, DOI 10.1126/science.1068427; Shinohara H, 2000, REP PROG PHYS, V63, P843, DOI 10.1088/0034-4885/63/6/201; Syamala MS, 2002, J AM CHEM SOC, V124, P6216, DOI 10.1021/ja012676f; Wang GW, 1997, NATURE, V387, P583, DOI 10.1038/42439; Yamamoto K, 1999, J AM CHEM SOC, V121, P1591, DOI 10.1021/ja9831498	22	498	503	3	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2005	307	5707					238	240		10.1126/science.1106185	http://dx.doi.org/10.1126/science.1106185			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	888GJ	15653499				2022-12-28	WOS:000226361900037
J	Puig, S; Askeland, E; Thiele, DJ				Puig, S; Askeland, E; Thiele, DJ			Coordinated remodeling of cellular metabolism during iron deficiency through targeted mRNA degradation	CELL			English	Article							ZINC-FINGER PROTEINS; GENOME-WIDE ANALYSIS; AU-RICH ELEMENTS; SACCHAROMYCES-CEREVISIAE; TRISTETRAPROLIN BINDS; ESCHERICHIA-COLI; GENE-EXPRESSION; CDNA ARRAYS; YEAST; TRANSCRIPTION	Iron (Fe) is an essential micronutrient for virtually all organisms and serves as a cofactor for a wide variety of vital cellular processes. Although Fe deficiency is the primary nutritional disorder in the world, cellular responses to Fe deprivation are poorly understood. We have discovered a posttranscriptional regulatory process controlled by Fe deficiency, which coordinately drives widespread metabolic reprogramming. We demonstrate that, in response to Fe deficiency, the Saccharomyces cerevisiae Cth2 protein specifically downregulates mRNAs encoding proteins that participate in many Fe-dependent processes. mRNA turnover requires the binding of Cth2, an RNA binding protein conserved in plants and mammals, to specific AU-rich elements in the 3' untranslated region of mRNAs targeted for degradation. These studies elucidate coordinated global metabolic reprogramming in response to Fe deficiency and identify a mechanism for achieving this by targeting specific mRNA molecules for degradation, thereby facilitating the utilization of limited cellular Fe levels.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA	Duke University	Thiele, DJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Sarah W Stedman Nutr & Metab Ctr, Res Dr LSRC-C351, Durham, NC 27710 USA.	dennis.thiele@duke.edu	Puig, Sergi/E-4788-2010	Puig, Sergi/0000-0002-1856-490X	NIGMS NIH HHS [GM41840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYNES RD, 1990, ANNU REV NUTR, V10, P133, DOI [10.1146/annurev.nutr.10.1.133, 10.1146/annurev.nu.10.070190.001025]; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Brewer BY, 2004, J BIOL CHEM, V279, P27870, DOI 10.1074/jbc.M402551200; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Khodursky AB, 2003, TRENDS GENET, V19, P113, DOI 10.1016/S0168-9525(02)00047-1; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; McHugh JP, 2003, J BIOL CHEM, V278, P29478, DOI 10.1074/jbc.M303381200; Nittis T, 2002, SEMIN HEMATOL, V39, P282, DOI 10.1053/shem.2002.35633; Puig S, 2004, J BIOL CHEM, V279, P30298, DOI 10.1074/jbc.M313463200; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Putz U, 1996, NUCLEIC ACIDS RES, V24, P4838, DOI 10.1093/nar/24.23.4838; Roy CN, 2001, HUM MOL GENET, V10, P2181, DOI 10.1093/hmg/10.20.2181; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Shakoury-Elizeh M, 2004, MOL BIOL CELL, V15, P1233, DOI 10.1091/mbc.E03-09-0642; Stoecklin G, 2001, RNA, V7, P1578; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Theil EC, 2000, BIOCHEM PHARMACOL, V59, P87, DOI 10.1016/S0006-2952(99)00300-7; Thompson MJ, 1996, GENE, V174, P225, DOI 10.1016/0378-1119(96)00084-4; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Wilderman PJ, 2004, P NATL ACAD SCI USA, V101, P9792, DOI 10.1073/pnas.0403423101; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x	38	307	317	1	23	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 14	2005	120	1					99	110		10.1016/j.cell.2004.11.032	http://dx.doi.org/10.1016/j.cell.2004.11.032			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652485	Bronze			2022-12-28	WOS:000226365400014
J	Allen, PA; Hoffman, PF				Allen, PA; Hoffman, PF			Extreme winds and waves in the aftermath of a Neoproterozoic glaciation	NATURE			English	Article							PROTEROZOIC CAP CARBONATES; ANCIENT SEA CONDITIONS; SNOWBALL EARTH; ISOTOPIC EXCURSIONS; CONSTRAINTS; NAMIBIA; RECORD	The most severe excursions in the Earth's climatic history are thought to be associated with Proterozoic glaciations. According to the 'Snowball Earth' hypothesis, the Marinoan glaciation, which ended about 635 million years ago, involved global or nearly global ice cover. At the termination of this glacial period, rapid melting of continental ice sheets must have caused a large rise in sea level. Here we show that sediments deposited during this sea level rise contain remarkable structures that we interpret as giant wave ripples. These structures occur at homologous stratigraphic levels in Australia, Brazil, Canada, Namibia and Svalbard. Our hydrodynamic analysis of these structures suggests maximum wave periods of 21 to 30 seconds, significantly longer than those typical for today's oceans. The reconstructed wave conditions could only have been generated under sustained high wind velocities exceeding 20 metres per second in fetch-unlimited ocean basins. We propose that these extraordinary wind and wave conditions were characteristic of the climatic transit, and provide observational targets for atmospheric circulation models.	ETH, Dept Earth Sci, CH-8092 Zurich, Switzerland; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Harvard University	Allen, PA (corresponding author), ETH, Dept Earth Sci, Sonneggstr 5, CH-8092 Zurich, Switzerland.	philip.allen@erdw.ethz.ch						Aitken J. D., 1991, GEOLOGICAL SURVEY CA, V404, P1; ALLEN PA, 1981, MAR GEOL, V43, pM59, DOI 10.1016/0025-3227(81)90176-6; ALLEN PA, 1984, MAR GEOL, V60, P455, DOI 10.1016/0025-3227(84)90162-2; ALLEN PA, 1981, SEDIMENTOLOGY, V28, P369, DOI 10.1111/j.1365-3091.1981.tb01686.x; BAGNOLD RA, 1946, PROC R SOC LON SER-A, V187, P1, DOI 10.1098/rspa.1946.0062; Clifton HE, 1976, SPECIAL PUBLICATION, V24, P126; CLOUD P, 1974, GEOL SOC AM BULL, V85, P1869, DOI 10.1130/0016-7606(1974)85<1869:GSAAVT>2.0.CO;2; Coastal Engineering Research Center, 1973, SHOR PROT MAN, V1; De Raaf J.F.M., 1977, SEDIMENTOLOGY, V4, P1; ECKART C, 1952, 521 US NBS; Evans DAD, 2000, AM J SCI, V300, P347, DOI 10.2475/ajs.300.5.347; Fanning CM, 2004, GEOLOGY, V32, P881, DOI 10.1130/G20609.1; Folling PG, 2002, BASIN RES, V14, P69, DOI 10.1046/j.1365-2117.2002.00167.x; Gimenez-Curto LA, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2002JC001474; Gimenez-Curto LA, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2000JC000729; GimenezCurto LA, 1996, J GEOPHYS RES-OCEANS, V101, P20745, DOI 10.1029/96JC01824; Grotzinger JP, 1995, PALAIOS, V10, P578, DOI 10.2307/3515096; Halverson GP, 2004, BASIN RES, V16, P297, DOI 10.1111/j.1365-2117.2004.00234.x; HARMS JC, 1969, GEOL SOC AM BULL, V80, P363, DOI 10.1130/0016-7606(1969)80[363:HSOSSR]2.0.CO;2; Hegenberger W., 1987, COMMUNS GEOL SURV SW, V3, P49; Higgins JA, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000403; Hoffman PF, 2002, GEOLOGY, V30, P286, DOI 10.1130/0091-7613(2002)030<0286:APCCAI>2.0.CO;2; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; HOFFMAN PF, 2002, EXCURSION GUIDE; Hoffmann KH, 2004, GEOLOGY, V32, P817, DOI 10.1130/G20519.1; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; James NP, 2001, CAN J EARTH SCI, V38, P1229, DOI 10.1139/e01-046; KENDALL CGS, 1987, SEDIMENTOLOGY, V34, P1007, DOI 10.1111/j.1365-3091.1987.tb00590.x; Kennedy MJ, 1996, J SEDIMENT RES, V66, P1050, DOI 10.2110/jsr.66.1050; Kennedy MJ, 2001, GEOLOGY, V29, P443, DOI 10.1130/0091-7613(2001)029<0443:APCCAI>2.0.CO;2; KOMAR PD, 1974, J SEDIMENT PETROL, V44, P169; KOMAR PD, 1973, J SEDIMENT PETROL, V43, P1101; MCCOWAN J, 1894, PHILOS MAG, V38, P351, DOI DOI 10.1080/14786449408620643; Miche A., 1944, ANN PONTS CHAUSSE, V114; Miche R., 1944, ANN PONTS CHAUSSEES, P131; Miche R., 1944, ANN PONTS CHAUSSEES, P25; Miche R., 1944, ANN PONTS CHAUSSEES, P270; MILLER MC, 1980, J SEDIMENT PETROL, V50, P183, DOI 10.2110/jsr.50.183; MILLER MC, 1980, J SEDIMENT PETROL, V50, P173; Nogueira ACR, 2003, GEOLOGY, V31, P613, DOI 10.1130/0091-7613(2003)031<0613:SDATBO>2.0.CO;2; PERYT TM, 1990, SEDIMENTOLOGY, V37, P279, DOI 10.1111/j.1365-3091.1990.tb00959.x; PIERSON WJ, 1955, PUBL US NAVAL OCEANO, V603; Porter SM, 2004, PRECAMBRIAN RES, V130, P99, DOI 10.1016/j.precamres.2003.10.015; Sleath J.F.A., 1976, J HYDRAUL RES, V14, P69, DOI DOI 10.1080/00221687609499689; TANNER WF, 1971, SEDIMENTOLOGY, V16, P71, DOI 10.1111/j.1365-3091.1971.tb00219.x; Wiegel RL, 1964, OCEANOGRAPHICAL ENG; Xiao SH, 2004, PRECAMBRIAN RES, V130, P1, DOI 10.1016/j.precamres.2003.10.013	47	147	165	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					123	127		10.1038/nature03176	http://dx.doi.org/10.1038/nature03176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650730				2022-12-28	WOS:000226252200028
J	Bever, JD; Wang, M				Bever, JD; Wang, M			Arbuscular mycorrhizal fungi - Hyphal fusion and multigenomic structure	NATURE			English	Editorial Material							ANASTOMOSIS FORMATION; EXCHANGE; NUCLEAR		Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA	Indiana University System; Indiana University Bloomington; University of Chicago	Bever, JD (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	jbever@indiana.edu						Bever JD, 1999, AM J BOT, V86, P1209, DOI 10.2307/2656768; Giovannetti M, 2001, NEW PHYTOL, V151, P717, DOI 10.1046/j.0028-646x.2001.00216.x; Giovannetti M, 1999, APPL ENVIRON MICROB, V65, P5571; Hijri M, 2004, FUNGAL GENET BIOL, V41, P253, DOI 10.1016/j.fgb.2003.10.011; Kuhn G, 2001, NATURE, V414, P745, DOI 10.1038/414745a; Pawlowska TE, 2004, NATURE, V427, P733, DOI 10.1038/nature02290	6	39	44	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2005	433	7022					E3	E4		10.1038/nature03294	http://dx.doi.org/10.1038/nature03294			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650700				2022-12-28	WOS:000226252200026
J	Cosgrove, SE; Fishman, NO; Talbot, TR; Woeltje, KF; Schaffner, W; Fraser, VJ; McMillan, JA; Perl, TM				Cosgrove, SE; Fishman, NO; Talbot, TR; Woeltje, KF; Schaffner, W; Fraser, VJ; McMillan, JA; Perl, TM			Strategies for use of a limited influenza vaccine supply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SERUM ANTIBODY-RESPONSES; VIRUS VACCINE; LIVE; TRIVALENT; SAFETY; IMMUNOGENICITY; EFFICACY		Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37212 USA; Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; University of Pennsylvania; Vanderbilt University; Washington University (WUSTL); Johns Hopkins University	Cosgrove, SE (corresponding author), Johns Hopkins Univ Hosp, Osler 425,600 N Wolfe St, Baltimore, MD 21287 USA.	scosgro1@jhmi.edu		Talbot, Thomas/0000-0002-6139-212X; Fraser, Victoria/0000-0001-6251-0733; Woeltje, Keith/0000-0002-6385-3970				Belshe RB, 2004, CLIN INFECT DIS, V39, P920, DOI 10.1086/423001; Belshe RB, 2004, NEW ENGL J MED, V351, P2286, DOI 10.1056/NEJMoa043555; Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655; Cha TA, 2000, J CLIN MICROBIOL, V38, P839, DOI 10.1128/JCM.38.2.839-845.2000; *DEP HLTH HUM SERV, RESP HYG COUGH ET HE; *DEP HLTH HUM SERV, CDCP ADV COMM IMM PR; Hayden Frederick G., 1997, American Journal of Medicine, V102, P55, DOI 10.1016/S0002-9343(97)80013-7; Jackson LA, 1999, VACCINE, V17, P1905, DOI 10.1016/S0264-410X(98)00471-X; KEITEL WA, 1993, J INFECT DIS, V167, P305, DOI 10.1093/infdis/167.2.305; Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540; King JC, 2000, J INFECT DIS, V181, P725, DOI 10.1086/315246; King JC, 2001, PEDIATR INFECT DIS J, V20, P1124, DOI 10.1097/00006454-200112000-00006; Murphy BR, 2002, VIRAL IMMUNOL, V15, P295, DOI 10.1089/08828240260066242; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; Sartor C, 2002, INFECT CONT HOSP EP, V23, P615, DOI 10.1086/501981; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; TALBOT TR, 2004, SOC HEALTHC EP AM 14; Treanor J, 2002, VACCINE, V20, P1099, DOI 10.1016/S0264-410X(01)00440-6; VESIKARI T, 2001, 41 INT C ANT AG CHEM; Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908	20	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2005	293	2					229	232		10.1001/jama.293.2.229	http://dx.doi.org/10.1001/jama.293.2.229			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885QC	15644550				2022-12-28	WOS:000226171000039
J	Saraswat, A				Saraswat, A			Lesson of the week - Child abuse and trichotillomania	BRITISH MEDICAL JOURNAL			English	Review									Eras Lucknow Med Coll & Hosp, Dept Dermatol, Lucknow 226016, Uttar Pradesh, India		Saraswat, A (corresponding author), Eras Lucknow Med Coll & Hosp, Dept Dermatol, Lucknow 226016, Uttar Pradesh, India.	abirsaraswat@yahoo.com		Saraswat, Abir/0000-0003-3319-2080				Boughn S, 2003, J NURS SCHOLARSHIP, V35, P165, DOI 10.1111/j.1547-5069.2003.00165.x; COHEN LJ, 1995, J CLIN PSYCHIAT, V56, P319; Duarte A M, 1995, Adv Dermatol, V10, P329; HALLOPEAU H, 1889, ANN DERMATOL SYPHIL, V10, P440; JOHNSON CF, 1990, PEDIATR CLIN N AM, V37, P791; KENNEDY CTC, 1999, TXB DERMATOLOGY, P777; MEHREGAN AH, 1970, ARCH DERMATOL, V102, P129, DOI 10.1001/archderm.102.2.129; ORANJE AP, 1986, J AM ACAD DERMATOL, V15, P614, DOI 10.1016/S0190-9622(86)70213-2; RAIMER BG, 1981, J AM ACAD DERMATOL, V5, P203, DOI 10.1016/S0190-9622(81)80059-X; SCHNEIDER D, 1994, CUTIS, V53, P289; SCHNEIDER D, 1994, CUTIS, V53, P294; SMITH RA, 1994, CLIN EXP DERMATOL, V19, P441, DOI 10.1111/j.1365-2230.1994.tb02707.x; TRUEB RM, 1995, CUTIS, V55, P178	13	11	13	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 8	2005	330	7482					83	84		10.1136/bmj.330.7482.83	http://dx.doi.org/10.1136/bmj.330.7482.83			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	887GR	15637371	Green Published			2022-12-28	WOS:000226294300022
J	Ratnieks, FLW; Wenseleers, T				Ratnieks, FLW; Wenseleers, T			Policing insect societies	SCIENCE			English	Editorial Material							WORKER REPRODUCTION; APIS-MELLIFERA; CONFLICT; HONEYBEE; EGGS		Univ Sheffield, Dept Anim & Plant Sci, Lab Apiculture & Social Insects, Sheffield S10 2TN, S Yorkshire, England; Inst Adv Study, D-14193 Berlin, Germany	University of Sheffield	Ratnieks, FLW (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Lab Apiculture & Social Insects, Sheffield S10 2TN, S Yorkshire, England.		Wenseleers, Tom/J-3960-2013	Wenseleers, Tom/0000-0002-1434-861X				Bourke A. F., 1995, SOCIAL EVOLUTION ANT; D'Ettorre P, 2004, P ROY SOC B-BIOL SCI, V271, P1427, DOI 10.1098/rspb.2004.2742; DETTORRE P, UNPUB; Endler A, 2004, P NATL ACAD SCI USA, V101, P2945, DOI 10.1073/pnas.0308447101; Grabosky P., 1988, EFFICIENCY EFFECTIVE; HELANTERA H, 2004, THESIS U HELSINKI; Martin SJ, 2002, NATURE, V415, P163, DOI 10.1038/415163a; Oldroyd BP, 2000, BEHAV ECOL SOCIOBIOL, V47, P268, DOI 10.1007/s002650050665; RATNIEKS FLW, 1989, NATURE, V342, P796, DOI 10.1038/342796a0; Skogan W., 2004, FAIRNESS EFFECTIVENE; Szathmary E, 1995, MAJOR TRANSITIONS EV; Wenseleers T, 2004, P ROY SOC B-BIOL SCI, V271, pS310, DOI 10.1098/rsbl.2003.0159; Wenseleers T, 2003, J EVOLUTION BIOL, V16, P647, DOI 10.1046/j.1420-9101.2003.00574.x; Wenseleers T, 2004, ETHOLOGY, V110, P725, DOI 10.1111/j.1439-0310.2004.01008.x; Wenseleers T, 2004, J EVOLUTION BIOL, V17, P1035, DOI 10.1111/j.1420-9101.2004.00751.x; WENSELEERS T, IN PRESS P R SOC B S	16	82	84	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2005	307	5706					54	56		10.1126/science.1106934	http://dx.doi.org/10.1126/science.1106934			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637260	Green Accepted			2022-12-28	WOS:000226214300029
J	Ridker, PM; Cannon, CP; Morrow, D; Rifai, N; Rose, LM; McCabe, CH; Pfeffer, MA; Braunwald, E				Ridker, PM; Cannon, CP; Morrow, D; Rifai, N; Rose, LM; McCabe, CH; Pfeffer, MA; Braunwald, E		PROVE IT-TIMI 22 Investigators	C-reactive protein levels and outcomes after statin therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; ACUTE CORONARY SYNDROMES; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; RISK; INFLAMMATION; PRAVASTATIN; PREDICTION; MARKERS; ATORVASTATIN	BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.	Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Dept Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Donald W Reynolds Ctr Cardiovasc Res, Dept Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Thrombolysis Myocardial Infarct Study Grp, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ridker, PM (corresponding author), Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	pridker@partners.org	Cannon, Christopher P/AAY-7644-2020	Cannon, Christopher P/0000-0003-4596-2791				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Ballantyne CM, 2004, CIRCULATION, V109, P837, DOI 10.1161/01.CIR.0000116763.91992.F1; Cannon CP, 2002, AM J CARDIOL, V89, P860, DOI 10.1016/S0002-9149(02)02201-4; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804; Davignon J, 2004, CIRCULATION, V109, P39, DOI 10.1161/01.CIR.0000131517.20177.5a; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Jialal I, 2001, CIRCULATION, V103, P1933; Kinlay S, 2002, AM J CARDIOL, V89, P1205, DOI 10.1016/S0002-9149(02)02306-8; Kinlay S, 2003, CIRCULATION, V108, P1560, DOI 10.1161/01.CIR.0000091404.09558.AF; Koenig W, 2004, CIRCULATION, V109, P1349, DOI 10.1161/01.CIR.0000120707.98922.E3; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Morrow DA, 1998, J AM COLL CARDIOL, V31, P1460, DOI 10.1016/S0735-1097(98)00136-3; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Ridker PM, 2001, CIRCULATION, V103, P1191; Ridker PM, 1997, NEW ENGL J MED, V337, P356; Ridker PM, 2004, CIRCULATION, V109, P2818, DOI 10.1161/01.CIR.0000132467.45278.59; Ridker PM, 2003, CIRCULATION, V108, P2292, DOI 10.1161/01.CIR.0000100688.17280.E6; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 2004, CIRCULATION, V109, P1955, DOI 10.1161/01.CIR.0000125690.80303.A8; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993	28	1739	1830	0	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					20	28		10.1056/NEJMoa042378	http://dx.doi.org/10.1056/NEJMoa042378			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635109				2022-12-28	WOS:000226112500004
J	Wong, TY; Rosamond, W; Chang, PP; Couper, DJ; Sharrett, AR; Hubbard, LD; Folsom, AR; Klein, R				Wong, TY; Rosamond, W; Chang, PP; Couper, DJ; Sharrett, AR; Hubbard, LD; Folsom, AR; Klein, R			Retinopathy and risk of congestive heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETINAL MICROVASCULAR ABNORMALITIES; IDIOPATHIC DILATED CARDIOMYOPATHY; POSITRON-EMISSION-TOMOGRAPHY; LEFT-VENTRICULAR DYSFUNCTION; ATHEROSCLEROSIS RISK; DIABETIC HEART; HYPERTROPHIC CARDIOMYOPATHY; CARDIOVASCULAR-DISEASE; CORONARY CIRCULATION; MYOCARDIAL-ISCHEMIA	Context Congestive heart failure (CHF) affects a substantial proportion of adults including those without preexisting coronary heart disease. The pathogenesis of CHF is uncertain, but microvascular disease has been hypothesized as a possible factor. Objective To determine the relationship of retinopathy, a marker of systemic microvascular disease, to risk of CHF. Design, Setting, and Participants Population-based, prospective 7-year cohort study in 4 US communities using the Atherosclerosis Risk in Communities Study database. Participants (n=11612, aged 49 to 73 years) had retinal photographs taken between 1993 and 1995. The photographs were graded according to a standardized protocol for the presence of retinopathy (eg, microaneurysms, retinal hemorrhages; soft exudates), arteriovenous nicking, focal arteriolar narrowing, and generalized arteriolar narrowing. Main Outcome Measures Association between retinopathy and incident CHF, identified from hospitalization and death records. Results The 7-year cumulative incidence of CHF was 5.4% (492 events). Participants with retinopathy had a higher incidence of CHF compared with those without retinopathy (15.1% vs 4.8%, P<.001). After controlling for age, sex, race, preexisting coronary heart disease, mean arterial blood pressure, diabetes, glucose level, cholesterol level,,smoking, body mass index, and study site, the presence of retinopathy was associated with a 2-fold higher risk of CHF (relative risk, 1.96; 95% confidence interval, 1.51-2.54). Among participants without preexisting coronary heart disease, diabetes, or hypertension, retinopathy was associated with a 3-fold higher risk of CHF (relative risk, 2.98; 95% confidence interval, 1.50-5.92). Conclusions Retinopathy is an independent predictor of CHF, even in persons without preexisting coronary heart disease, diabetes, or hypertension. This suggests that microvascular disease may play an important role in the development of heart failure in the general population. Some asymptomatic persons with retinopathy on an ophthalmologic examination may benefit from further assessment of CHF risk.	Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia; Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore; Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; Univ N Carolina, Div Cardiol, Chapel Hill, NC USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; Univ Wisconsin, Dept Ophthalmol, Madison, WI 53706 USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN USA	Centre for Eye Research Australia; University of Melbourne; National University of Singapore; Singapore National Eye Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; University of Wisconsin System; University of Wisconsin Madison; University of Minnesota System; University of Minnesota Twin Cities	Wong, TY (corresponding author), Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.	ophwty@nus.edu.sg	Cerviño, Alejandro/L-5853-2014; Wong, Tien Yin/AAC-9724-2020	Cerviño, Alejandro/0000-0001-8014-3279; Wong, Tien Yin/0000-0002-8448-1264; Couper, David/0000-0002-4313-9235	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055022, N01HC035125, N01HC055021, N01HC055020, N01HC055015, N01HC035126, N01HC055018, N01HC055019, N01HC055016] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55022, N01-HC-55021, N01-HC-55020, N01-HC-55019, N01-HC-55018, N01-HC-55016, N01-HC-55015, N01-HC-35126, N01-HC-35125] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HEART ASS, 2002, HEART DIS STROK STAT; Arnold JMO, 2003, CIRCULATION, V107, P1284, DOI 10.1161/01.CIR.0000054165.93055.42; Blendea Mihaela C, 2003, Curr Diab Rep, V3, P223, DOI 10.1007/s11892-003-0068-z; Camici PG, 1996, EUR HEART J, V17, P25; Cecchi F, 2003, NEW ENGL J MED, V349, P1027, DOI 10.1056/NEJMoa025050; Chen JW, 1999, INT J CARDIOL, V69, P251, DOI 10.1016/S0167-5273(99)00042-X; Chilian WM, 1997, CIRCULATION, V95, P522; DESILVA R, 1994, CARDIOVASC RES, V28, P1595; FACTOR SM, 1980, NEW ENGL J MED, V302, P384, DOI 10.1056/NEJM198002143020706; Gavin JB, 1998, J MOL CELL CARDIOL, V30, P2531, DOI 10.1006/jmcc.1998.0824; Hayashi T, 2003, HEART, V89, P1236, DOI 10.1136/heart.89.10.1236; Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0; Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; Kaufmann PA, 2000, J AM COLL CARDIOL, V36, P103, DOI 10.1016/S0735-1097(00)00697-5; Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644; Lawrenson JG, 2002, MICROVASC RES, V64, P65, DOI 10.1006/mvre.2002.2403; Levy BI, 2001, CIRCULATION, V104, P735, DOI 10.1161/hc3101.091158; Liu PP, 1999, AM J CARDIOL, V84, p23L; MARCUS ML, 1990, CIRCULATION, V82, P1, DOI 10.1161/01.CIR.82.1.1; McDonagh PF, 2000, MICROCIRCULATION, V7, P163, DOI 10.1038/sj.mn.7300106; MOSSERI M, 1986, CIRCULATION, V74, P964, DOI 10.1161/01.CIR.74.5.964; *NAT HEART LUNG BL, 1988, ATH RISK COMM STUD O; Neglia D, 2002, CIRCULATION, V105, P186, DOI 10.1161/hc0202.102119; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Shikama N, 1999, AM J CARDIOL, V84, P434, DOI 10.1016/S0002-9149(99)00329-X; Shizukuda Y, 1999, Congest Heart Fail, V5, P208; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Strauer B E, 1997, Blood Press Suppl, V2, P6; STRAUER BE, 1990, AM J CARDIOL, V65, pG34; STRAUER BE, 1991, J HYPERTENS, V9, pS11, DOI 10.1097/00004872-199112002-00003; TANAKA M, 1987, CIRCULATION, V75, P1130, DOI 10.1161/01.CIR.75.6.1130; van den Heuvel AFM, 2000, J AM COLL CARDIOL, V35, P19, DOI 10.1016/S0735-1097(99)00499-4; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; VATNER SF, 1988, AM J CARDIOL, V62, pE94, DOI 10.1016/S0002-9149(88)80020-1; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153; Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X; YAROM R, 1992, J PATHOL, V166, P265, DOI 10.1002/path.1711660308; ZONERAICH S, 1995, AM J CARDIOL, V76, P746, DOI 10.1016/S0002-9149(99)80218-5	42	164	171	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					63	69		10.1001/jama.293.1.63	http://dx.doi.org/10.1001/jama.293.1.63			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632337	Bronze			2022-12-28	WOS:000226102100022
J	Hossain, P; Seetho, IW; Browning, AC; Amoaku, WM				Hossain, P; Seetho, IW; Browning, AC; Amoaku, WM			Science, medicine, and the future - Artificial means for restoring vision	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ELECTRICAL-STIMULATION; RETINAL PROSTHESIS; VISUAL-PERCEPTION; BLIND; RELEASE		Univ Nottingham, Queens Med Ctr, Eye Ear Nose & Throat Ctr, Acad Dept Ophthalmol, Nottingham NG7 2UH, England	University of Nottingham	Amoaku, WM (corresponding author), Univ Nottingham, Queens Med Ctr, Eye Ear Nose & Throat Ctr, Acad Dept Ophthalmol, Nottingham NG7 2UH, England.	wma@nottingham.ac.uk	Hossain, Parwez/AAB-6065-2022	Amoaku, Winfried/0000-0001-5028-7984; Hossain, Parwez/0000-0002-3131-2395				BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223; Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460; DAWSON WW, 1977, INVEST OPHTH VIS SCI, V16, P249; Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002; Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9; Gerding H, 2001, MED RAD DIA IMG, P55; Grossniklaus HE, 2002, AM J OPHTHALMOL, V133, P129, DOI 10.1016/S0002-9394(01)01292-2; GUEVEN D, 2003, INVEST OPHTHALMOL VI; HAMILL MB, 2003, INVEST OPHTHALMOL VI; Humayun M S, 2001, Trans Am Ophthalmol Soc, V99, P271; Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8; Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006; Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7; HUMAYUN MS, 2004, INVEST OPHTHALMOL VI; Hunt DWC, 2003, IDRUGS, V6, P464; IKUNO Y, 2003, INVEST OPHTHALMOL VI; KANDA H, 2003, INVEST OPHTHALMOL VI; Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4; Lakhanpal Rohit R, 2003, Curr Opin Ophthalmol, V14, P122, DOI 10.1097/00055735-200306000-00002; LIU W, 2003, INVEST OPHTHALMOL VI; Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P2073; Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9; MATSUO T, 2003, INVEST OPHTHALMOL VI; NAKAUCHI K, 2003, INVEST OPHTHALMOL VI; PALANKER DV, 2003, INVEST OPHTHALMOL VI; Peterman MC, 2004, P NATL ACAD SCI USA, V101, P9951, DOI 10.1073/pnas.0402089101; Peterman MC, 2003, INVEST OPHTH VIS SCI, V44, P3144, DOI 10.1167/iovs.02-1097; Rizzo JF, 2001, OPHTHALMOLOGY, V108, P13, DOI 10.1016/S0161-6420(00)00430-9; Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507; SIPPY BD, 2003, INVESTIGATIVE OPHTHA; Uhlig CE, 2001, OPHTHALMOLOGE, V98, P1089, DOI 10.1007/s003470170031; VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5; Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9; WANG K, 2003, INVEST OPHTHALMOL VI; WEILAND JD, 2003, INVEST OPHTHALMOL VI; Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5; Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996	37	16	25	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					30	33		10.1136/bmj.330.7481.30	http://dx.doi.org/10.1136/bmj.330.7481.30			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15626803	Green Published			2022-12-28	WOS:000226176700018
J	Gragoudas, ES; Adamis, AP; Cunningham, ET; Feinsod, M; Guyer, DR				Gragoudas, ES; Adamis, AP; Cunningham, ET; Feinsod, M; Guyer, DR		VEGF Inhibition Study Ocular Neova	Pegaptanib for neovascular age-related macular degeneration	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; CHOROIDAL NEOVASCULARIZATION; NONHUMAN PRIMATE; IRIS NEOVASCULARIZATION; INHIBITION; RNA	BACKGROUND: Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration. METHODS: We conducted two concurrent, prospective, randomized, double-blind, multicenter, dose-ranging, controlled clinical trials using broad entry criteria. Intravitreous injection into one eye per patient of pegaptanib (at a dose of 0.3 mg, 1.0 mg, or 3.0 mg) or sham injections were administered every 6 weeks over a period of 48 weeks. The primary end point was the proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks. RESULTS: In the combined analysis of the primary end point (for a total of 1186 patients), efficacy was demonstrated, without a dose-response relationship, for all three doses of pegaptanib (P<0.001 for the comparison of 0.3 mg with sham injection; P<0.001 for the comparison of 1.0 mg with sham injection; and P=0.03 for the comparison of 3.0 mg with sham injection). In the group given pegaptanib at 0.3 mg, 70 percent of patients lost fewer than 15 letters of visual acuity, as compared with 55 percent among the controls (P<0.001). The risk of severe loss of visual acuity (loss of 30 letters or more) was reduced from 22 percent in the sham-injection group to 10 percent in the group receiving 0.3 mg of pegaptanib (P<0.001). More patients receiving pegaptanib (0.3 mg), as compared with sham injection, maintained their visual acuity or gained acuity (33 percent vs. 23 percent; P=0.003). As early as six weeks after beginning therapy with the study drug, and at all subsequent points, the mean visual acuity among patients receiving 0.3 mg of pegaptanib was better than in those receiving sham injections (P<0.002). Among the adverse events that occurred, endophthalmitis (in 1.3 percent of patients), traumatic injury to the lens (in 0.7 percent), and retinal detachment (in 0.6 percent) were the most serious and required vigilance. These events were associated with a severe loss of visual acuity in 0.1 percent of patients. CONCLUSIONS: Pegaptanib appears to be an effective therapy for neovascular age-related macular degeneration. Its long-term safety is not known.	Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02114 USA; Eyetech Pharmaceut, New York, NY USA	Harvard University; Massachusetts Eye & Ear Infirmary	Gragoudas, ES (corresponding author), Massachusetts Eye & Ear Infirm, Retina Serv, 243 Charles St, Boston, MA 02114 USA.	evangelos_gragoudas@meei.harvard.edu	Larsen, Michael/E-9620-2010; Schlingemann, Reinier/E-6287-2013	Larsen, Michael/0000-0002-5172-5891; 				ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18; Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gass J.D., 1967, AM J OPHTHALMOL, V63, pS1; Green W R, 1999, Mol Vis, V5, P27; GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]; Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010; Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2	24	1807	1942	2	119	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2805	2816		10.1056/NEJMoa042760	http://dx.doi.org/10.1056/NEJMoa042760			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625332	Green Published			2022-12-28	WOS:000226004300005
J	Lieberman, RL; Rosenzweig, AC				Lieberman, RL; Rosenzweig, AC			Crystal structure of a membrane-bound metalloenzyme that catalyses the biological oxidation of methane	NATURE			English	Article							METHYLOCOCCUS-CAPSULATUS BATH; CYTOCHROME-C-OXIDASE; MONOOXYGENASE; COPPER; ACTIVATION; HYDROXYLATION; SPECTROSCOPY; BIOCHEMISTRY; PARAMETERS; PROTEINS	Particulate methane monooxygenase ( pMMO) is an integral membrane metalloenzyme that catalyses the conversion of methane to methanol. Knowledge of how pMMO performs this extremely challenging chemistry may have an impact on the use of methane as an alternative energy source by facilitating the development of new synthetic catalysts. We have determined the structure of pMMO from the methanotroph Methylococcus capsulatus ( Bath) to a resolution of 2.8 Angstrom. The enzyme is a trimer with an alpha(3)beta(3)gamma(3) polypeptide arrangement. Two metal centres, modelled as mononuclear copper and dinuclear copper, are located in soluble regions of each pmoB subunit, which resembles cytochrome c oxidase subunit II. A third metal centre, occupied by zinc in the crystal, is located within the membrane. The structure provides new insight into the molecular details of biological methane oxidation.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	amyr@northwestern.edu						Arp DJ, 2002, ARCH MICROBIOL, V178, P250, DOI 10.1007/s00203-002-0452-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barondeau DP, 2004, BIOCHEMISTRY-US, V43, P8038, DOI 10.1021/bi0496081; Basu P, 2003, BIOCHEM J, V369, P417, DOI 10.1042/BJ20020823; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chan SI, 2004, BIOCHEMISTRY-US, V43, P4421, DOI 10.1021/bi0497603; Chen P, 2004, P NATL ACAD SCI USA, V101, P13105, DOI 10.1073/pnas.0402114101; Choi DW, 2003, J BACTERIOL, V185, P5755, DOI 10.1128/JB.185.19.5755-5764.2003; Cook SA, 2002, ARCH BIOCHEM BIOPHYS, V398, P32, DOI 10.1006/abbi.2001.2628; DeLano W.L, PYMOL MOL GRAPHICS S; Elliott SJ, 1998, J AM CHEM SOC, V120, P3247, DOI 10.1021/ja972968+; George SD, 2001, J AM CHEM SOC, V123, P5757, DOI 10.1021/ja004109i; Gray HB, 2003, Q REV BIOPHYS, V36, P341, DOI 10.1017/S0033583503003913; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Harford C, 1997, ACCOUNTS CHEM RES, V30, P123, DOI 10.1021/ar9501535; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kim HJ, 2004, SCIENCE, V305, P1612, DOI 10.1126/science.1098322; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; Lemos S. S., 2002, CURR TOP BIOPHYS, V26, P43; Lieberman RL, 2004, CRIT REV BIOCHEM MOL, V39, P147, DOI 10.1080/10409230490475507; Lieberman RL, 2003, P NATL ACAD SCI USA, V100, P3820, DOI 10.1073/pnas.0536703100; Maneg O, 2004, BBA-BIOENERGETICS, V1655, P274, DOI 10.1016/j.bbabio.2003.10.010; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Mirica LM, 2004, CHEM REV, V104, P1013, DOI 10.1021/cr020632z; Nguyen HHT, 1998, J BIOL CHEM, V273, P7957, DOI 10.1074/jbc.273.14.7957; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; Park S, 2002, WASTE MANAGE RES, V20, P434, DOI 10.1177/0734242X0202000507; Periana RA, 2004, J MOL CATAL A-CHEM, V220, P7, DOI 10.1016/j.molcata.2004.05.036; PERIANA RA, 1993, SCIENCE, V259, P340, DOI 10.1126/science.259.5093.340; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SEMRAU JD, 1995, J BACTERIOL, V177, P3071, DOI 10.1128/jb.177.11.3071-3079.1995; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Stolyar S, 1999, MICROBIOL-UK, V145, P1235, DOI 10.1099/13500872-145-5-1235; Sullivan JP, 1998, CRIT REV MICROBIOL, V24, P335, DOI 10.1080/10408419891294217; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TSUPRUN VL, 1987, DOKL AKAD NAUK SSSR+, V292, P490; Ward N, 2004, PLOS BIOL, V2, P1616, DOI 10.1371/journal.pbio.0020303; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; Yu SSF, 2003, J BACTERIOL, V185, P5915, DOI 10.1128/JB.185.20.5915-5924.2003	48	477	493	7	236	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 10	2005	434	7030					177	182		10.1038/nature03311	http://dx.doi.org/10.1038/nature03311			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904JU	15674245				2022-12-28	WOS:000227494500036
J	de la Sierra-Gallay, IL; Pellegrini, O; Condon, C				de la Sierra-Gallay, IL; Pellegrini, O; Condon, C			Structural basis for substrate binding, cleavage and allostery in the tRNA maturase RNase Z	NATURE			English	Article							BETA-LACTAMASE; END MATURATION; PRECURSOR; CCA; ENZYME; GENE	Transfer RNAs ( tRNAs) are synthesized as part of longer primary transcripts that require processing of both their 30 and 50 extremities in every living organism known. The 50 side is processed ( matured) by the ubiquitously conserved endonucleolytic ribozyme, RNase P-1, whereas removal of the 30 tails can be either exonucleolytic(2,3) or endonucleolytic(4). The endonucleolytic pathway is catalysed by an enzyme known as RNase Z, or 3' tRNase(5,6). RNase Z cleaves precursor tRNAs immediately after the discriminator base ( the unpaired nucleotide 30 to the last base pair of the acceptor stem, used as an identity determinant by many aminoacyl- tRNA synthetases) in most cases(6 - 8), yielding a tRNA primed for addition of the CCA motif by nucleotidyl transferase. Here we report the crystal structure of Bacillus subtilis RNase Z at 2.1 Angstrom resolution, and propose a mechanism for tRNA recognition and cleavage. The structure explains the allosteric properties of the enzyme, and also sheds light on the mechanisms of inhibition by the CCA motif and long 50 extensions. Finally, it highlights the extraordinary adaptability of the metallo- hydrolase domain of the beta- lactamase family for the hydrolysis of covalent bonds.	Univ Paris 07, CNRS, UPR 9073, F-75221 Paris 05, France; Inst Biol Physicochim, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Condon, C (corresponding author), Univ Paris 07, CNRS, UPR 9073, F-75221 Paris 05, France.	condon@ibpc.fr	Condon, Ciaran/F-6798-2011	Condon, Ciaran/0000-0002-2199-9621; Li de la Sierra-Gallay, Ines/0000-0003-2770-7439				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; GARBER RL, 1979, CELL, V18, P817, DOI 10.1016/0092-8674(79)90134-X; GARBER RL, 1979, CELL, V17, P389, DOI 10.1016/0092-8674(79)90165-X; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Mohan A, 1999, RNA, V5, P245, DOI 10.1017/S1355838299981256; Nashimoto M, 1997, NUCLEIC ACIDS RES, V25, P1148, DOI 10.1093/nar/25.6.1148; Nashimoto M, 1999, NUCLEIC ACIDS RES, V27, P2770, DOI 10.1093/nar/27.13.2770; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schiffer S, 2001, BIOCHEMISTRY-US, V40, P8264, DOI 10.1021/bi0101953; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200	29	127	131	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					657	661		10.1038/nature03284	http://dx.doi.org/10.1038/nature03284			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15654328				2022-12-28	WOS:000226862000050
J	Bano, D; Young, KW; Guerin, CJ; LeFeuvre, R; Rothwell, NJ; Naldini, L; Rizzuto, R; Carafoli, E; Nicotera, P				Bano, D; Young, KW; Guerin, CJ; LeFeuvre, R; Rothwell, NJ; Naldini, L; Rizzuto, R; Carafoli, E; Nicotera, P			Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity	CELL			English	Article							EXCITATORY AMINO-ACIDS; CARDIAC NA+-CA2+ EXCHANGER; CEREBELLAR GRANULE CELLS; ISCHEMIC BRAIN-INJURY; GLUTAMATE EXCITOTOXICITY; PERMEABILITY TRANSITION; CA2+-BINDING DOMAIN; NEURONAL APOPTOSIS; PROTEOLYTIC SYSTEM; NMDA RECEPTOR	In brain ischemia, gating of postsynaptic glutamate receptors and other membrane channels triggers intracellular Ca2+ overload and cell death. In excitotoxic settings, the initial Ca2+ influx through glutamate receptors is followed by a second uncontrolled Ca2+ increase that leads to neuronal demise. Here we report that the major plasma membrane Ca2+ extruding system, the Na+/Ca2+ exchanger (NCX), is cleaved during brain ischemia and in neurons undergoing excitotoxicity. Inhibition of Ca2+-activated proteases (calpains) by overexpressing their endogenous inhibitor protein, calpastatin or the expression of an NCX isoform not cleaved by calpains, prevented Ca2+ overload and rescued neurons from excitotoxic death. Conversely, down-regulation of NCX by siRNA compromised neuronal Ca2+ handling, transforming the Ca2+ transient elicited by non-excitotoxic glutamate concentrations into a lethal Ca2+ overload. Thus, proteolytic in,activation of NCX-driven neuronal Ca2+ extrusion is responsible for the delayed excitotoxic Ca2+ deregulation and neuronal death.	Univ Leicester, MRC Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; San Raffaele Telethon Inst Gene Therapy, I-20132 Milan, Italy; Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy; VIMM, I-35129 Padua, Italy	University of Leicester; University of Leicester; University of Manchester; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); University of Padua; Veneto Institute Molecular Medicine	Nicotera, P (corresponding author), Univ Leicester, MRC Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	pn10@le.ac.uk	Carafoli, Ernesto/K-5192-2016; Naldini, Luigi/E-9083-2012; Guerin, Christopher/AAM-3233-2020; Le Feuvre, Rosalind/A-7034-2013; Rizzuto, Rosario/B-6312-2008; Bano, Daniele/AAZ-9371-2020	Carafoli, Ernesto/0000-0002-7826-0094; NALDINI, Luigi/0000-0002-7835-527X; Rizzuto, Rosario/0000-0001-7044-5097	MRC [G19/24] Funding Source: UKRI; Medical Research Council [G19/24] Funding Source: Medline; Telethon [TGT03D01, TGT06S01] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Telethon(Fondazione Telethon)		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Branca D, 1999, EUR J BIOCHEM, V265, P839, DOI 10.1046/j.1432-1327.1999.00817.x; Brini M, 2002, J BIOL CHEM, V277, P38693, DOI 10.1074/jbc.M206075200; Budd SL, 1996, J NEUROCHEM, V67, P2282; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; EMORI Y, 1988, J BIOL CHEM, V263, P2364; Follenzi Antonia, 2002, Methods Mol Med, V69, P259; Fryer HJL, 1999, J NEUROCHEM, V72, P500, DOI 10.1046/j.1471-4159.1999.0720500.x; Guerini D, 2003, J BIOL CHEM, V278, P38141, DOI 10.1074/jbc.M302400200; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Jekabsons MB, 2004, J BIOL CHEM, V279, P32989, DOI 10.1074/jbc.M401540200; Jeon D, 2003, NEURON, V38, P965, DOI 10.1016/S0896-6273(03)00334-9; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MELLGREN RL, 1989, RBC-CELL BIOL REV, V20, P139; Murachi T, 1987, NEUROPEPTIDES THEIR, P202; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; OLNEY JW, 1969, SCIENCE, V166, P386, DOI 10.1126/science.166.3903.386; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; THUMEYSEN T, 2002, BRAIN RES MOL BRAIN, V107, P145; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; Ward MW, 2000, J NEUROSCI, V20, P7208; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026	55	428	445	0	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					275	285		10.1016/j.cell.2004.11.049	http://dx.doi.org/10.1016/j.cell.2004.11.049			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680332	Bronze			2022-12-28	WOS:000226740000015
J	Krause, RM				Krause, RM			Maclyn McCarty (1911-2005) - Obituary	NATURE			English	Biographical-Item									NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Krause, RM (corresponding author), NIAID, NIH, 16 Ctr Dr, Bethesda, MD 20892 USA.	richard_krause@nih.gov						MCCARTY M, PUBLICATION LIST	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2005	433	7024					372	372		10.1038/433372a	http://dx.doi.org/10.1038/433372a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674278				2022-12-28	WOS:000226546200028
J	Monto, AS				Monto, AS			The threat of an avian influenza pandemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							H5N1		Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Monto, AS (corresponding author), Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.							Govorkova EA, 2001, ANTIMICROB AGENTS CH, V45, P2723, DOI 10.1128/AAC.45.10.2723-2732.2001; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Monto AS, 2003, VACCINE, V21, P1796, DOI 10.1016/S0264-410X(03)00075-6	3	96	120	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					323	325		10.1056/NEJMp048343	http://dx.doi.org/10.1056/NEJMp048343			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15668220				2022-12-28	WOS:000226535900001
J	Amonlirdviman, K; Khare, NA; Tree, DRP; Chen, WS; Axelrod, JD; Tomlin, CJ				Amonlirdviman, K; Khare, NA; Tree, DRP; Chen, WS; Axelrod, JD; Tomlin, CJ			Mathematical modeling of planar cell polarity to understand domineering nonautonomy	SCIENCE			English	Article							DROSOPHILA EYE; ASYMMETRIC LOCALIZATION; TISSUE POLARITY; VAN-GOGH; PRICKLE; ABDOMEN; GENE; MELANOGASTER; STRABISMUS; AUTONOMY	Planar cell polarity (PCP) signaling generates subcellular asymmetry along an axis orthogonal to the epithelia[ apical-basal axis. Through a poorly understood mechanism, cell clones that have mutations in some PCP signaling components, including some, but not all, alleles of the receptor frizzled, cause polarity disruptions of neighboring wild-type cells, a phenomenon referred to as domineering nonautonomy. Here, a contact-dependent signaling hypothesis, derived from experimental results, is shown by reaction-diffusion, partial differential equation modeling and simulation to fully reproduce PCP phenotypes, including domineering nonautonomy, in the Drosophila wing. The sufficiency of this model and the experimental validation of model predictions reveal how specific protein-protein interactions produce autonomy or domineering nonautonomy.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Aeronaut & Astronaut, Stanford, CA 94305 USA	Stanford University; Stanford University	Axelrod, JD (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.	jaxetrod@stanford.edu; tomlin@stanford.edu			NIGMS NIH HHS [R01-GM59823] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059823] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER PM, COMMUNICATION; Adler PN, 2000, MECH DEVELOP, V96, P197, DOI 10.1016/S0925-4773(00)00392-0; Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; AMONLIRDVIMAN K, UNPUB; Axelrod JD, 2001, GENE DEV, V15, P1182; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bastock R, 2003, DEVELOPMENT, V130, P3007, DOI 10.1242/dev.00526; Casal J, 2002, CURR BIOL, V12, P1189, DOI 10.1016/S0960-9822(02)00974-0; Fanto M, 2003, DEVELOPMENT, V130, P763, DOI 10.1242/dev.00304; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Gubb D, 1999, GENE DEV, V13, P2315, DOI 10.1101/gad.13.17.2315; Hannus M, 2002, DEVELOPMENT, V129, P3493; Jones KH, 1996, GENETICS, V142, P205; Lawrence PA, 2004, DEVELOPMENT, V131, P4651, DOI 10.1242/dev.01351; Lawrence PA, 2002, DEVELOPMENT, V129, P2749; Lawrence PA, 1999, DEVELOPMENT, V126, P2441; Ma D, 2003, NATURE, V421, P543, DOI 10.1038/nature01366; Struhl G, 1997, DEVELOPMENT, V124, P2155; Strutt D, 2002, CURR BIOL, V12, P813, DOI 10.1016/S0960-9822(02)00841-2; Strutt DI, 2001, MOL CELL, V7, P367, DOI 10.1016/S1097-2765(01)00184-8; Strutt H, 2002, DEV CELL, V3, P851, DOI 10.1016/S1534-5807(02)00363-5; Taylor J, 1998, GENETICS, V150, P199; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Tree DRP, 2002, SEMIN CELL DEV BIOL, V13, P217, DOI 10.1016/S1084-9521(02)00042-3; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wehrli M, 1998, DEVELOPMENT, V125, P1421; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342	31	216	219	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					423	426		10.1126/science.1105471	http://dx.doi.org/10.1126/science.1105471			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662015				2022-12-28	WOS:000226492300047
J	O'Rahilly, S; Barroso, I; Wareham, NJ				O'Rahilly, S; Barroso, I; Wareham, NJ			Genetic factors in type 2 diabetes: The end of the beginning?	SCIENCE			English	Editorial Material							NUCLEAR FACTOR-4-ALPHA GENE; INSULIN-RESISTANCE; ASSOCIATION; POLYMORPHISM; MELLITUS; OBESITY; RISK; SUSCEPTIBILITY; CONTRIBUTE; MUTATIONS	The intensive search for genetic variants that predispose to type 2 diabetes was launched with optimism, but progress has been slower than was hoped. Even so, major advances have been made in the understanding of monogenic forms of the disease which together represent a substantial health burden, and a few common gene variants that influence susceptibility have now been unequivocally identified. Armed with a better understanding of the tools needed to detect such genes, it seems inevitable that the rate of progress will increase and the relevance of genetic information to the diagnosis, treatment, and prevention of diabetes will become increasingly tangible.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; MRC, Epidemiol Unit, Elsie Widdowson Lab, Cambridge CB1 9NL, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England.	so104@medscht.cam.ac.uk	O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Barroso, Ines/0000-0001-5800-4520				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Barroso I, 2003, PLOS BIOL, V1, P41, DOI 10.1371/journal.pbio.0000020; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Beck-Nielsen H, 2003, BEST PRACT RES CL EN, V17, P445, DOI 10.1016/S1521-690X(03)00041-1; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Friedman JM, 2004, NAT MED, V10, P563, DOI 10.1038/nm0604-563; Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Hegele RA, 1999, DIABETES CARE, V22, P524, DOI 10.2337/diacare.22.3.524b; Horikawa Y, 2000, NAT GENET, V26, P502; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Huxtable SJ, 2000, DIABETES, V49, P126, DOI 10.2337/diabetes.49.1.126; Love-Gregory L, 2003, DIABETOLOGIA, V46, P136, DOI 10.1007/s00125-002-0947-x; Love-Gregory LD, 2004, DIABETES, V53, P1134, DOI 10.2337/diabetes.53.4.1134; McCarthy MI, 2002, AM J PHYSIOL-ENDOC M, V283, pE217, DOI 10.1152/ajpendo.00099.2002; O'Rahilly S, 2003, ENDOCRINOLOGY, V144, P3757, DOI 10.1210/en.2003-0373; O'Rahilly S, 2002, EUR J ENDOCRINOL, V147, P435, DOI 10.1530/eje.0.1470435; Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581; Sargeant LA, 2000, INT J OBESITY, V24, P1333, DOI 10.1038/sj.ijo.0801383; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; Stride A, 2002, ANN MED, V34, P207, DOI 10.1080/713782136; 't Hart LM, 1999, J CLIN ENDOCR METAB, V84, P1002, DOI 10.1210/jc.84.3.1002; Tsai YS, 2004, J CLIN INVEST, V114, P240, DOI 10.1172/JCI200420964; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Zhu Q, 2003, DIABETOLOGIA, V46, P567, DOI 10.1007/s00125-003-1067-y	27	199	205	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					370	373		10.1126/science.1104346	http://dx.doi.org/10.1126/science.1104346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662000				2022-12-28	WOS:000226492300030
J	Shiratori, Y; Ito, Y; Yokosuka, O; Imazeki, F; Nakata, R; Tanaka, N; Arakawa, Y; Hashimoto, E; Hirota, K; Yoshida, H; Ohashi, Y; Omata, M				Shiratori, Y; Ito, Y; Yokosuka, O; Imazeki, F; Nakata, R; Tanaka, N; Arakawa, Y; Hashimoto, E; Hirota, K; Yoshida, H; Ohashi, Y; Omata, M		Tokyo-Chiba Hepatitis Res Grp	Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival	ANNALS OF INTERNAL MEDICINE			English	Article							PERCUTANEOUS-ETHANOL-INJECTION; VIRUS-RELATED CIRRHOSIS; INTERFERON THERAPY; PEGINTERFERON ALPHA-2A; NONCIRRHOTIC PATIENTS; RANDOMIZED TRIAL; PLUS RIBAVIRIN; LIVER-DISEASE; FOLLOW-UP; NON-A	Background: Although cirrhosis is a major risk factor for development of hepatocellular carcinoma, no definitive prospective analyses have assessed the long-term efficacy of antiviral therapy in cirrhotic patients. Objective: To elucidate the role of antiviral therapy in the suppression of liver tumors and survival over a long-term follow-up period. Design: Prospective cohort study. Setting: 25 clinical centers. Patients: 345 patients with chronic hepatitis C and cirrhosis enrolled in previous trials. Intervention: 271 patients received 6 to 9 million U of interferon 3 times weekly for 26 to 88 weeks; 74 received no treatment. Measurements: Blood tests and abdominal ultrasonography were done regularly to detect hepatocellular carcinoma. Results: Hepatocellular carcinoma was detected in 119 patients during a 6.8-year follow-up: 84 (31%) in the interferon-treated group and 35 (47%) in the untreated group. Cumulative incidence of hepatocellular carcinoma among interferon-treated patients was significantly lower than in untreated patients (Cox model: age-adjusted hazard ratio, 0.65 [95% Cl, 0.43 to 0.97]; P = 0.03), especially sustained virologic responders. A total of 69 patients died during follow-up: 45 (17%) in the treated group and 24 (32%) in the untreated group. Interferon-treated patients had a better chance of survival than the untreated group (Cox model: age-adjusted hazard ratio, 0.54 [Cl, 0.33 to 0.89]; P = 0.02). This was especially evident in sustained virologic responders. Limitation: This was not a randomized, controlled study. Patients enrolled in the control group had declined to receive interferon treatment even though they were eligible for treatment. Conclusion: Interferon therapy for cirrhotic patients with chronic hepatitis C, especially those in whom the infection had been cured, inhibited the development of hepatocellular carcinoma and improved survival.	Univ Tokyo, Japanese Red Cross Med Ctr, Tokyo, Japan; Nippon Univ, Sch Med, Tokyo, Japan; Tokyo Womens Med Coll, Tokyo 162, Japan; Chiba Univ, Sch Med, Chiba, Japan; Mito Saiseikai Hosp, Ibaraki, Japan	Japanese Red Cross Medical Center; University of Tokyo; Nihon University; Tokyo Women's Medical University; Chiba University	Shiratori, Y (corresponding author), Okayama Univ, Sch Med, Dept Gastroenterol Hepatol & Infect Dis, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	shirato@cc.okayama-u.ac.jp	Ito, Yoichi/E-2042-2012	Ito, Yoichi M./0000-0001-5073-0827				Brunetto MR, 1998, LANCET, V351, P1535; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; FARMER DG, 1994, ANN SURG, V219, P236, DOI 10.1097/00000658-199403000-00003; Fattovich G, 1997, J HEPATOL, V27, P201, DOI 10.1016/S0168-8278(97)80302-9; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Idilman R, 1997, J VIRAL HEPATITIS, V4, P81, DOI 10.1111/j.1365-2893.1997.tb00209.x; Imai Y, 1998, ANN INTERN MED, V129, P94, DOI 10.7326/0003-4819-129-2-199807150-00005; JOUET P, 1994, GASTROENTEROLOGY, V106, P686, DOI 10.1016/0016-5085(94)90703-X; KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1002/hep.1840180104; KLEINBAUM D, 1995, SURVIVAL ANAL SELF L; Livraghi T, 2003, RADIOLOGY, V226, P441, DOI 10.1148/radiol.2262012198; LIVRAGHI T, 1995, RADIOLOGY, V197, P101, DOI 10.1148/radiology.197.1.7568806; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; McHutchison JG, 2002, GASTROENTEROLOGY, V123, P1061, DOI 10.1053/gast.2002.35950; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; Okanoue T, 1999, J HEPATOL, V30, P653, DOI 10.1016/S0168-8278(99)80196-2; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Seki T, 1999, CANCER, V85, P1694, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1694::AID-CNCR8>3.3.CO;2-V; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; Shiina S, 1997, SEMIN INTERVENT RAD, V14, P295; Shiratori Y, 1999, HEPATOLOGY, V29, P1573, DOI 10.1002/hep.510290529; Shiratori Y, 2000, LIVER, V20, P271, DOI 10.1034/j.1600-0676.2000.020004271.x; TAKAYASU K, 1992, HEPATOLOGY, V16, P906, DOI 10.1002/hep.1840160409; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Valla DC, 1999, HEPATOLOGY, V29, P1870, DOI 10.1002/hep.510290616; Yoshida H, 1999, ANN INTERN MED, V131, P174, DOI 10.7326/0003-4819-131-3-199908030-00003; Yoshida H, 2002, GASTROENTEROLOGY, V123, P483, DOI 10.1053/gast.2002.34785	35	233	246	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2005	142	2					105	114		10.7326/0003-4819-142-2-200501180-00009	http://dx.doi.org/10.7326/0003-4819-142-2-200501180-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915LQ	15657158				2022-12-28	WOS:000228306100004
J	Zar, HJ; Honslo, D; Apolles, P; Swingler, G; Hussey, G				Zar, HJ; Honslo, D; Apolles, P; Swingler, G; Hussey, G			Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study	LANCET			English	Article							DIAGNOSIS; INDUCTION; YIELD; SMEAR	Background For microbiological confirmation of diagnosis of pulmonary tuberculosis in young children, sequential gastric lavages are recommended; sputum induction has not been regarded as feasible or useful. We aimed to compare the yield of Mycobacterium tuberculosis from repeated induced sputum with that from gastric lavage in young children from an area with a high rate of HIV and tuberculosis. Methods We studied 250 children aged 1 month to 5 years who were admitted for suspected pulmonary tuberculosis in Cape Town, South Africa. Sputum induction and gastric lavage were done on three consecutive days according to a standard procedure. Specimens were stained for acid-fast bacilli; each sample was cultured singly for M tuberculosis. Findings Median age of children was 13 months (IQR 6-24). A positive smear or culture for M tuberculosis was obtained from 62 (25%) children; of these, 58 (94%) were positive by culture, whereas almost half (29 [47%]) were smear positive. Samples from induced sputum and gastric lavage were positive in 54 (87%) and 40 (65%) children, respectively (difference in yield 5.6% [1.4-9.8%], p=0.018). The yield from one sample from induced sputum was similar to that from three gastric lavages (p=1.0). Microbiological yield did not differ between HIV-infected and HIV-uninfected children (p=0.17, odds ratio 0.7 [95% Cl 0.3-1.3]). All sputum induction procedures were well tolerated; minor side-effects were increased coughing, epistaxis, vomiting, or wheezing. Interpretation Sputum induction is safe and useful for microbiological confirmation of tuberculosis in young children. This technique is preferable to gastric lavage for diagnosis of pulmonary tuberculosis in both HIV-infected and HIV-uninfected infants and children.	Univ Cape Town, Red Cross War Mem Childrens Hosp, Sch Child & Adolescent Hlth, ZA-7700 Rondebosch, South Africa	University of Cape Town	Zar, HJ (corresponding author), 5th Floor ICH Bldg,Klipfontein Rd, ZA-7700 Rondebosch, South Africa.	hzars@ich.uct.ac.za	Zar, Heather/GZL-5350-2022	Zar, Heather/0000-0002-9046-759X				Al Zahrani K, 2001, INT J TUBERC LUNG D, V5, P855; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; CARR DT, 1967, MAYO CLIN PROC, V42, P23; Conde MB, 2003, AM J RESP CRIT CARE, V167, P723, DOI 10.1164/rccm.2111019; Granich Reuben., 1999, GUIDELINES PREVENTIO; Hartung TK, 2002, SAMJ S AFR MED J, V92, P455; Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038; JONES FL, 1966, DIS CHEST, V50, P403; Kawada H, 1996, Kekkaku, V71, P603; Li LM, 1999, INT J TUBERC LUNG D, V3, P1137; LILLEHEI JP, 1961, AM REV RESPIR DIS, V84, P276; Lloyd A V, 1968, East Afr Med J, V45, P140; Lobato MN, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.4.e40; Menzies D, 2003, AM J RESP CRIT CARE, V167, P676, DOI 10.1164/rccm.2212008; Nelson SM, 1998, J CLIN MICROBIOL, V36, P467, DOI 10.1128/JCM.36.2.467-469.1998; PARRY CM, 1995, TUBERCLE LUNG DIS, V76, P72, DOI 10.1016/0962-8479(95)90583-9; Shata AMA, 1996, ARCH DIS CHILD, V74, P535, DOI 10.1136/adc.74.6.535; Shingadia D, 2003, LANCET INFECT DIS, V3, P624, DOI 10.1016/S1473-3099(03)00771-0; Siddiqi K, 2003, LANCET INFECT DIS, V3, P288, DOI 10.1016/S1473-3099(03)00609-1; Starke JR, 2000, PEDIATR INFECT DIS J, V19, P1095, DOI 10.1097/00006454-200011000-00015; STARKE JR, 1989, PEDIATRICS, V84, P28; VALLEJO JG, 1994, PEDIATRICS, V94, P1; Zar HJ, 2000, ARCH DIS CHILD, V82, P305, DOI 10.1136/adc.82.4.305; Zar HJ, 2003, PEDIATR PULM, V36, P58, DOI 10.1002/ppul.10302	24	352	368	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					130	134		10.1016/S0140-6736(05)17702-2	http://dx.doi.org/10.1016/S0140-6736(05)17702-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639294				2022-12-28	WOS:000226170700027
J	Saez, AG; Lozano, E				Saez, AG; Lozano, E			Body doubles	NATURE			English	Editorial Material									Museo Nacl Ciencias Nat, Dept Biodiversidad & Biol Evolut, Madrid 28006, Spain; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ascot SL5 7PY, Berks, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); Imperial College London	Saez, AG (corresponding author), Museo Nacl Ciencias Nat, Dept Biodiversidad & Biol Evolut, Madrid 28006, Spain.		Sáez, Alberto García/B-5018-2008; Lozano, Encarnacion/C-5161-2008	Sáez, Alberto García/0000-0003-0209-7179; Lozano, Encarnacion/0000-0003-0254-0935				Hebert PDN, 2004, P NATL ACAD SCI USA, V101, P14812, DOI 10.1073/pnas.0406166101; KNOWLTON N, 1993, ANNU REV ECOL SYST, V24, P189, DOI 10.1146/annurev.es.24.110193.001201; Saez AG, 2003, P NATL ACAD SCI USA, V100, P7163, DOI 10.1073/pnas.1132069100; Thierstein HR, 2004, COCCOLITHOPHORES: FROM MOLECULAR PROCESSES TO GLOBAL IMPACT, P455; Zhang DY, 2004, ECOL LETT, V7, P165, DOI 10.1111/j.1461-0248.2004.00569.x	5	160	164	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					111	111		10.1038/433111a	http://dx.doi.org/10.1038/433111a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650721	Bronze			2022-12-28	WOS:000226252200018
J	van Gils, CH; Peeters, PHT; Bueno-De-Mesquita, HB; Boshuizen, HC; Lahmann, PH; Clavel-Chapelon, F; Thiebaut, A; Kesse, E; Sieri, S; Palli, D; Tumino, R; Panico, S; Vineis, P; Gonzalez, CA; Ardanaz, E; Sanchez, MJ; Amiano, P; Navarro, C; Quiros, JR; Key, TJ; Allen, N; Khaw, KT; Bingham, SA; Psaltopoulou, T; Koliva, M; Trichopoulou, A; Nagel, G; Linseisen, J; Boeing, H; Berglund, G; Wirfalt, E; Hallmans, G; Lenner, P; Overvad, K; Tjonneland, A; Olsen, A; Lund, E; Engeset, D; Alsaker, E; Norat, TA; Kaaks, R; Slimani, N; Riboli, E				van Gils, CH; Peeters, PHT; Bueno-De-Mesquita, HB; Boshuizen, HC; Lahmann, PH; Clavel-Chapelon, F; Thiebaut, A; Kesse, E; Sieri, S; Palli, D; Tumino, R; Panico, S; Vineis, P; Gonzalez, CA; Ardanaz, E; Sanchez, MJ; Amiano, P; Navarro, C; Quiros, JR; Key, TJ; Allen, N; Khaw, KT; Bingham, SA; Psaltopoulou, T; Koliva, M; Trichopoulou, A; Nagel, G; Linseisen, J; Boeing, H; Berglund, G; Wirfalt, E; Hallmans, G; Lenner, P; Overvad, K; Tjonneland, A; Olsen, A; Lund, E; Engeset, D; Alsaker, E; Norat, TA; Kaaks, R; Slimani, N; Riboli, E			Consumption of vegetables and fruits and risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							24-HOUR DIET RECALL; CALIBRATION; FOOD; QUESTIONNAIRES; VALIDITY; NITROGEN	Context The intake of vegetables and fruits has been thought to protect against breast cancer. Most of the evidence comes from case-control studies, but a recent pooled analysis of the relatively few published cohort studies suggests no significantly reduced breast cancer risk is associated with vegetable and fruit consumption. Objective To examine the relation between total and specific vegetable and fruit intake and the incidence of breast cancer. Design, Setting, and Participants Prospective study of 285526 women between the ages of 25 and 70 years, participating in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study, recruited from 8 of the 10 participating European countries. Participants completed a dietary questionnaire in 1992-1998 and were followed up for incidence of cancer until 2002. Main Outcome Measures Relative risks for breast cancer by total and specific vegetable and fruit intake. Analyses were stratified by age at recruitment and study center. Relative risks were adjusted for established breast cancer risk factors. Results During 1486402 person-years (median duration of follow-up, 5.4 years), 3659 invasive incident breast cancer cases were reported. No significant associations between vegetable or fruit intake and breast cancer risk were observed. Relative risks for the highest vs the lowest quintile were 0.98 (95% confidence interval [CI], 0.84-1.14) for total vegetables, 1.09 (95% Cl, 0.94-1.25) for total fruit, and 1.05 (95% Cl, 0.92-1.20) for fruit and vegetable juices. For 6 specific vegetable subgroups no associations with breast cancer risk were observed either. Conclusion Although the period of follow-up is limited for now, the results suggest that total or specific vegetable and fruit intake is not associated with risk for breast cancer.	Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, Ctr Nutr & Hlth, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Ctr Informat Technol & Methodol, NL-3720 BA Bilthoven, Netherlands; German Inst Human Nutr Potsdam Rehbrucke, Nuthetal, Germany; Inst Gustave Roussy, INSERM, Equipe Nutr Hormones & Canc, F-94805 Villejuif, France; Ist Nazl Tumori, Epidemiol Unit, I-20133 Milan, Italy; Sci Inst Tuscany, CSPO, Mol & Nutr Epidemiol Unit, Florence, Italy; Azienda Osped Civile MP Arezzo, Canc Registry, Ragusa, Italy; Univ Naples Federico II, Dept Clin & Expt Med, Naples, Italy; Univ Turin, I-10124 Turin, Italy; Univ London Imperial Coll Sci Technol & Med, London, England; Catalan Inst Oncol, Dept Epidemiol, Barcelona, Spain; Inst Publ Hlth, Navarra, Spain; Andalusian Sch Publ Hlth, Granada, Spain; Hlth Dept Basque Country, Publ Hlth Div Gipuzkoa, San Sebastian, Spain; Murcia Hlth Council, Dept Epidemiol, Murcia, Spain; Principal Asturias, Hlth & Hlth Serv Council, Publ Hlth & Planning Directorate, Hlth Informat Unit, Oviedo, Spain; Univ Oxford, Canc Res UK Epidemiol Unit, Oxford OX1 2JD, England; Univ Cambridge, Sch Clin Med, Dept Publ Hlth & Primary Care, Cambridge, England; MRC, Dunn Human Nutr Unit, Cambridge, England; Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-10679 Athens, Greece; Deutsch Krebsforschungszentrum, Div Clin Epidemiol, D-6900 Heidelberg, Germany; Lund Univ, Malmo Univ Hosp, Dept Med, Malmo, Sweden; Umea Univ, Unit Nutr Res, S-90187 Umea, Sweden; Umea Univ, Unit Oncol, S-90187 Umea, Sweden; Umea Univ, Dept Radiat Sci, S-90187 Umea, Sweden; Aarhus Univ Hosp, Aalborg Hosp, Dept Clin Epidemiol, Aalborg, Denmark; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; Univ Tromso, Inst Community Med, Tromso, Norway; WHO, Int Agcy Res Canc, Lyon, France	Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Fondazione IRCCS Istituto Nazionale Tumori Milan; Civile M.P. Arezzo Hospital; University of Naples Federico II; University of Turin; Imperial College London; Catalan Institute of Oncology; Public Health Institute of Navarra; Escuela Andaluza de Salud Publica; Murcia Regional Health Council; Cancer Research UK; University of Oxford; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Athens Medical School; National & Kapodistrian University of Athens; Helmholtz Association; German Cancer Research Center (DKFZ); Lund University; Skane University Hospital; Umea University; Umea University; Umea University; Aalborg University; Aalborg University Hospital; Aarhus University; Danish Cancer Society; UiT The Arctic University of Tromso; World Health Organization; International Agency for Research on Cancer (IARC)	Peeters, PHT (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Room Str 6-131,POB 85500, NL-3508 GA Utrecht, Netherlands.	P.H.M.Peeters@umcutrecht.nl	Linseisen, Jakob/B-5353-2014; Panico, Salvatore/K-6506-2016; Sieri, Sabina/K-4667-2016; Boshuizen, Hendriek C/B-3718-2014; Kesse-Guyot, Emmanuelle/K-4689-2012; Psaltopoulou, Theodora/AAA-6878-2020; Clavel-Chapelon, Francoise/G-6733-2014; Khaw, Kay-Tee/AAZ-3209-2021; Sánchez, Maria-José/D-1087-2011; TRICHOPOULOU, ANTONIA/ABF-8727-2021; Nagel, Gabriele/C-3635-2012; Kesse-Guyot, Emmanuelle/ABH-7347-2020; Kesse-Guyot, Emmanuelle/F-2692-2017; Thiébaut, Anne C.M./O-1788-2018; Engeset, Dagrun/A-4508-2008; Boshuizen, Hendriek/M-3415-2014	Linseisen, Jakob/0000-0002-9386-382X; Panico, Salvatore/0000-0002-5498-8312; Sieri, Sabina/0000-0001-5201-172X; Psaltopoulou, Theodora/0000-0002-1404-9716; Sánchez, Maria-José/0000-0003-4817-0757; TRICHOPOULOU, ANTONIA/0000-0002-7204-6396; Nagel, Gabriele/0000-0001-6185-8535; Kesse-Guyot, Emmanuelle/0000-0002-9715-3534; Thiébaut, Anne C.M./0000-0003-2651-2795; Boshuizen, Hendriek/0000-0002-3916-9095; LAHMANN, Petra/0000-0002-9563-1635; Overvad, Kim/0000-0001-6429-7921; Lund, Eiliv/0000-0002-8071-8711; Olsen, Anja/0000-0003-4788-503X; Tjonneland, Anne/0000-0003-4385-2097; tumino, rosario/0000-0003-2666-414X; PALLI, Domenico/0000-0002-5558-2437; Riboli, Elio/0000-0001-6795-6080; Navarro, Carmen/0000-0001-8896-7483				Agudo A, 2002, PUBLIC HEALTH NUTR, V5, P1179, DOI 10.1079/PHN2002398; BINGHAM SA, 1994, BRIT J NUTR, V72, P619, DOI 10.1079/BJN19940064; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Day NE, 2001, INT J EPIDEMIOL, V30, P309, DOI 10.1093/ije/30.2.309; Ferrari P, 2002, PUBLIC HEALTH NUTR, V5, P1329, DOI 10.1079/PHN2002409; Gandini S, 2000, EUR J CANCER, V36, P636, DOI 10.1016/S0959-8049(00)00022-8; Gaudet MM, 2004, CANCER EPIDEM BIOMAR, V13, P1485; *IARC WORK GROUP E, 2003, IARC WORK GROUP EV C, V8; Kaaks R, 1997, INT J EPIDEMIOL, V26, pS15, DOI 10.1093/ije/26.suppl_1.S15; KAAKS R, 1995, AM J EPIDEMIOL, V142, P548, DOI 10.1093/oxfordjournals.aje.a117673; Kipnis V, 2001, AM J EPIDEMIOL, V153, P394, DOI 10.1093/aje/153.4.394; Lahmann PH, 2004, INT J CANCER, V111, P762, DOI 10.1002/ijc.20315; Margetts BM, 1997, INT J EPIDEMIOL, V26, pS1, DOI 10.1093/ije/26.suppl_1.S1; Miller AB, 2004, INT J CANCER, V108, P269, DOI 10.1002/ijc.11559; Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S; Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; Slimani N, 2002, PUBLIC HEALTH NUTR, V5, P1125, DOI 10.1079/PHN2002395; Slimani N, 2003, CANCER EPIDEM BIOMAR, V12, P784; Slimani N, 2000, EUR J CLIN NUTR, V54, P900, DOI 10.1038/sj.ejcn.1601107; Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769; Wareham NJ, 2003, PUBLIC HEALTH NUTR, V6, P407, DOI 10.1079/PHN2002439; *WHO, 1997, FOOD NUTR PREV CANC; Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P547, DOI 10.1093/jnci/91.6.547	24	188	192	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2005	293	2					183	193		10.1001/jama.293.2.183	http://dx.doi.org/10.1001/jama.293.2.183			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885QC	15644545	Bronze, Green Published			2022-12-28	WOS:000226171000034
J	Yamashita, T; Hige, T; Takahashi, T				Yamashita, T; Hige, T; Takahashi, T			Vesicle endocytosis requires dynamin-dependent GTP hydrolysis at a fast CNS synapse	SCIENCE			English	Article							PRESYNAPTIC CAPACITANCE; SINGLE; EXOCYTOSIS; MEMBRANE; CELLS; GAMMA; TIME; TRANSMISSION; TRANSMITTER; RECRUITMENT	Molecular dependence of vesicular endocytosis was investigated with capacitance measurements at the calyx of Held terminal in brainstem slices. Intraterminal loading of botulinum toxin E revealed that the rapid capacitance transient implicated as "kiss-and-run" was unrelated to transmitter release. The release-related capacitance. change decayed with an endocytotic time constant of 10 to 25 seconds, depending on the magnitude of exocytosis. Presynaptic loading of the nonhydrolyzable guanosine, 5'-triphosphate (GTP) analog GTPgammaS or dynamin-1 proline-rich domain peptide abolished endocytosis. These compounds had no immediate effect on exocytosis, but caused a use-dependent rundown of exocytosis. Thus, the guanosine triphosphatase dynamin-1 is indispensable for vesicle endocytosis at this fast central nervous system (CNS) synapse.	Univ Tokyo, Grad Sch Med, Dept Neurophysiol, Tokyo 1130033, Japan	University of Tokyo	Takahashi, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Neurophysiol, Tokyo 1130033, Japan.	ttakahas-tky@umin.ac.jp	Takahashi, Tomoyuki/G-5951-2015; Yamashita, Takayuki/F-7589-2010	Takahashi, Tomoyuki/0000-0002-8771-7666; Yamashita, Takayuki/0000-0002-1849-9837; Hige, Toshihide/0000-0002-0007-3192				Aravanis AM, 2003, NATURE, V423, P643, DOI 10.1038/nature01686; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; Augustine GJ, 1999, J PHYSIOL-LONDON, V520, P33, DOI 10.1111/j.1469-7793.1999.00033.x; BINZ T, 1994, J BIOL CHEM, V269, P1617; de Lange RPJ, 2003, J NEUROSCI, V23, P10164; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Heidelberger R, 2001, J NEUROSCI, V21, P6467, DOI 10.1523/JNEUROSCI.21-17-06467.2001; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Ishikawa T, 2002, NEURON, V34, P613, DOI 10.1016/S0896-6273(02)00692-X; Kajikawa Y, 2001, P NATL ACAD SCI USA, V98, P8054, DOI 10.1073/pnas.141031298; Kjaerulff O, 2002, NAT CELL BIOL, V4, pE245, DOI 10.1038/ncb1102-e245; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; Royle SJ, 2003, J PHYSIOL-LONDON, V553, P345, DOI 10.1113/jphysiol.2003.049221; Sakaba T, 2001, NEURON, V32, P1119, DOI 10.1016/S0896-6273(01)00543-8; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sun JY, 2002, NATURE, V417, P555, DOI 10.1038/417555a; Sun JY, 2001, NEURON, V30, P171, DOI 10.1016/S0896-6273(01)00271-9; Takahashi T, 2000, SCIENCE, V289, P460, DOI 10.1126/science.289.5478.460; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Taschenberger H, 2002, NEURON, V36, P1127, DOI 10.1016/S0896-6273(02)01137-6; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Wolfel M, 2003, J NEUROSCI, V23, P7059, DOI 10.1523/JNEUROSCI.23-18-07059.2003; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1	29	130	134	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					124	127		10.1126/science.1103631	http://dx.doi.org/10.1126/science.1103631			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637282				2022-12-28	WOS:000226214300053
J	Barthel, A; Bornstein, SR				Barthel, A; Bornstein, SR			Images in clinical medicine - Obstructive lingual thyroid.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Hosp Duesseldorf, D-40225 Dusseldorf, Germany; Tech Univ Dresden, D-01307 Dresden, Germany	Technische Universitat Dresden	Barthel, A (corresponding author), Univ Hosp Duesseldorf, D-40225 Dusseldorf, Germany.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					E1	E1		10.1056/ENEJMicm040431	http://dx.doi.org/10.1056/ENEJMicm040431			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635105				2022-12-28	WOS:000226112500009
J	Klass, P				Klass, P			Doctors and patients - Shifting sands.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Med, Boston, MA 02118 USA; Boston Med Ctr, Boston, MA 02118 USA	Boston University; Boston Medical Center	Klass, P (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					6	8		10.1056/NEJMp048077	http://dx.doi.org/10.1056/NEJMp048077			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635107				2022-12-28	WOS:000226112500002
J	Terabe, K; Hasegawa, T; Nakayama, T; Aono, M				Terabe, K; Hasegawa, T; Nakayama, T; Aono, M			Quantized conductance atomic switch	NATURE			English	Article							CARBON NANOTUBE; POINT-CONTACT; NANOWIRES; DEVICES; NANOTECHNOLOGY; TRANSISTORS; TRANSPORT; SINGLE	A large variety of nanometre-scale devices have been investigated in recent years(1-7) that could overcome the physical and economic limitations of current semiconductor devices(8). To be of technological interest, the energy consumption and fabrication cost of these 'nanodevices' need to be low. Here we report a new type of nanodevice, a quantized conductance atomic switch (QCAS), which satisfies these requirements. The QCAS works by controlling the formation and annihilation of an atomic bridge at the crossing point between two electrodes. The wires are spaced approximately 1 nm apart, and one of the two is a solid electrolyte wire from which the atomic bridges are formed. We demonstrate that such a QCAS can switch between 'on' and 'off ' states at room temperature and in air at a frequency of 1 MHz and at a small operating voltage (600 mV). Basic logic circuits are also easily fabricated by crossing solid electrolyte wires with metal electrodes.	Natl Inst Mat Sci, Nanomat Labs, Tsukuba, Ibaraki 3050044, Japan; Japan Sci & Technol Agcy, ICORP, SORST, Kawaguchi, Saitama 3320012, Japan; RIKEN, Wako, Saitama 3510198, Japan	National Institute for Materials Science; Japan Science & Technology Agency (JST); RIKEN	Hasegawa, T (corresponding author), Natl Inst Mat Sci, Nanomat Labs, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.	HASEGAWA.Tsuyoshi@nims.go.jp	TERABE, Kazuya/H-2628-2011; Nakayama, Tomonobu/H-2752-2011	TERABE, Kazuya/0000-0003-3988-3456; Nakayama, Tomonobu/0000-0001-9696-475X				Agrait N, 2003, PHYS REP, V377, P81, DOI 10.1016/S0370-1573(02)00633-6; Chen Y, 2003, APPL PHYS LETT, V82, P1610, DOI 10.1063/1.1559439; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; CostaKramer JL, 1997, PHYS REV B, V55, P5416, DOI 10.1103/PhysRevB.55.5416; Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851; Duan XF, 2003, NATURE, V425, P274, DOI 10.1038/nature01996; Enomoto A, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.125410; Fueki, 1990, SOLID STATE IONICS; Hansen K, 1997, PHYS REV B, V56, P2208, DOI 10.1103/PhysRevB.56.2208; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; KRANS JM, 1995, NATURE, V375, P767, DOI 10.1038/375767a0; Li CZ, 1998, APPL PHYS LETT, V72, P894, DOI 10.1063/1.120928; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; Mathur N, 2002, NATURE, V419, P573, DOI 10.1038/419573a; OHASHI K, 1981, SOLID STATE IONICS, V3-4, P127, DOI 10.1016/0167-2738(81)90069-2; Ohnishi H, 1998, NATURE, V395, P780, DOI 10.1038/27399; OLESEN L, 1994, PHYS REV LETT, V72, P2251, DOI 10.1103/PhysRevLett.72.2251; Oshima Y, 2003, SURF SCI, V531, P209, DOI 10.1016/S0039-6028(03)00568-5; PASCUAL JI, 1993, PHYS REV LETT, V71, P1852, DOI 10.1103/PhysRevLett.71.1852; Peercy PS, 2000, NATURE, V406, P1023, DOI 10.1038/35023223; Rodrigues V, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.153402; SLATER R, 1989, PORTRAITS SILICON, pCH3; SMITH DPE, 1995, SCIENCE, V269, P371, DOI 10.1126/science.269.5222.371; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Terabe K, 2002, J APPL PHYS, V91, P10110, DOI 10.1063/1.1481775; Terabe K., 2001, RIKEN REV, V37, P7; Terabe K., 1999, P 9 INT C PROD ENG, P711; Xu BQ, 2002, J AM CHEM SOC, V124, P13568, DOI 10.1021/ja027810q	29	954	1034	5	344	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					47	50		10.1038/nature03190	http://dx.doi.org/10.1038/nature03190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635405				2022-12-28	WOS:000226117100031
J	Pace, CA; Emanuel, EJ				Pace, CA; Emanuel, EJ			The ethics of research in developing countries: assessing voluntariness	LANCET			English	Editorial Material							AFRICA		NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Boston, MA USA	National Institutes of Health (NIH) - USA; Harvard University; Harvard Medical School	Emanuel, EJ (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA.	eemanuel@nih.gov		Pace, Christine/0000-0003-4937-7602				Annas GJ, 1998, AM J PUBLIC HEALTH, V88, P560, DOI 10.2105/AJPH.88.4.560; [Anonymous], 1986, HIST THEORY INFORM C; BARSDORF NW, IN PRESS SOC SCI MED; CHRISTAKIS NA, 1988, HASTINGS CENT REP, V18, P31, DOI 10.2307/3562201; Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709; HARTH SC, 1995, SOC SCI MED, V41, P1673; Karim QA, 1998, AM J PUBLIC HEALTH, V88, P637, DOI 10.2105/AJPH.88.4.637; LAFRANIERE S, 2000, WASHINGTON POST 1219, pA1; PACE C, 2005, IN PRESS AM J PUBLIC; PACE C, WHAT WE DONT KNOW IN; Participants 2001 Conference Ethical, 2004, HASTINGS CENT REP, V34, P17; Wertheimer Alan, 1996, EXPLOITATION; Wertheimer Alan, 1987, COERCION; White MT, 1999, J LAW MED ETHICS, V27, P87, DOI 10.1111/j.1748-720X.1999.tb01440.x	14	20	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					11	12		10.1016/S0140-6736(04)17679-4	http://dx.doi.org/10.1016/S0140-6736(04)17679-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	886FU	15639664				2022-12-28	WOS:000226213100008
J	Wilson, GT; Shafran, R				Wilson, GT; Shafran, R			Eating disorders guidelines-from NICE	LANCET			English	Review							BULIMIA-NERVOSA	Context January, 2004, marked the publication of NICE guidelines for the treatment of eating disorders, a series of recommendations from a multidisciplinary, comprehensive, and rigorous process. The recommendations are assigned a grade from A (strong empirical support from well-conducted randomised trials) to C (expert opinion without strong empirical data). Over 100 recommendations were made, most of which were given a C grade. No specific recommendations were made for anorexia nervosa. Cognitive behavioural therapy for bulimia nervosa was assigned grade A because of the evidence showing that it is superior to other psychological and drug treatments. Antidepressants for bulimia nervosa were given grade B. No specific recommendations were made for atypical eating disorders except for binge-eating disorder (cognitive behavioural therapy was recommended [A]). Starting point The methodological rigour of the NICE guidelines is in contrast with the current Practice Guideline for Eating Disorders (PGED) of the American Psychiatric Association. PGED does not detail criteria for evaluating supporting research. Instead of making clear recommendations, PGED is uncritically inclusive and emphasises subjective judgment of individual clinicians. The NICE guidelines balance recommending specific treatments against the importance of clinical judgment when guideline recommendations are not readily applicable. Where next Evidence-based guidelines are limited by the quality of the available research and its clinical relevance. The NICE guidelines underscore the absence of sufficient evidence for guidance in several important areas, such as atypical eating disorders (eating disorders not otherwise specified) which are the most common. Research on the treatment of these atypical eating disorders is needed. Evidence-based psychological treatments are not routinely implemented in general practice. Dissemination of these demonstrably effective treatments poses a challenge, and learning how to implement evidence-based psychological treatments and monitor their use is a research priority.	Rutgers State Univ, Grad Sch Appl & Profess Psychol, Piscataway, NJ 08854 USA; Univ Oxford, Dept Psychiat, Oxford, England	Rutgers State University New Brunswick; University of Oxford	Wilson, GT (corresponding author), Rutgers State Univ, Grad Sch Appl & Profess Psychol, Piscataway, NJ 08854 USA.	tewilson@rci.rutgers.edu		Shafran, Roz/0000-0003-2729-4961				Agras WS, 2000, AM J PSYCHIAT, V157, P1302, DOI 10.1176/appi.ajp.157.8.1302; [Anonymous], 2000, Am J Psychiatry, V157, P1; Barlow DH, 1999, BEHAV RES THER, V37, pS147, DOI 10.1016/S0005-7967(99)00054-6; DAWES RM, 1994, HOUSE CARDS; *DEP HLTH, 2004, STAND BETT HLTH HLTH; Fairburn CG, 2003, LANCET, V361, P407, DOI 10.1016/S0140-6736(03)12378-1; Fairburn CG, 2003, ARCH GEN PSYCHIAT, V60, P850, DOI 10.1001/archpsyc.60.8.850-a; Fairburn Christopher G., 1993, P361; Hayes SC, 2001, BEHAV THER, V32, P211, DOI 10.1016/S0005-7894(01)80002-2; McAlpine DE, 2004, INT J EAT DISORDER, V35, P27, DOI 10.1002/eat.10217; Mussell MP, 2000, INT J EAT DISORDER, V27, P230, DOI 10.1002/(SICI)1098-108X(200003)27:2<230::AID-EAT11>3.0.CO;2-0; *NAT I CLIN EXC, 2004, QUICK REF GUID EAT D; Nathan P.E., 2002, GUIDE TREATMENTS WOR; Nathan PE, 1998, AM PSYCHOL, V53, P290, DOI 10.1037/0003-066X.53.3.290; NICE, 2004, NICE CLIN GUID; Walsh BT, 2000, AM J PSYCHIAT, V157, P1332, DOI 10.1176/appi.ajp.157.8.1332; Wilson G. T., 2002, GUIDE TREATMENTS WOR, P559; Wilson GT, 1996, BEHAV RES THER, V34, P295, DOI 10.1016/0005-7967(95)00084-4	18	109	113	1	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					79	81		10.1016/S0140-6736(04)17669-1	http://dx.doi.org/10.1016/S0140-6736(04)17669-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639682				2022-12-28	WOS:000226213100031
J	Markel, H				Markel, H			"Who's on first?" - Medical discoveries and scientifc priority	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Markel, H (corresponding author), Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA.							GALEN, 1916, NATURAL FACULTIES, P279; Gallo RC, 2003, NEW ENGL J MED, V349, P2283, DOI 10.1056/NEJMp038194; MADDOX B, 2002, R FRANKLIN DARK LADY, pR18; Markey T, 2000, J INDO-EUR STUD, V28, P31; WATSON JD, 1998, DOUBLE HELIX PERSONA	5	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2792	2794		10.1056/NEJMp048166	http://dx.doi.org/10.1056/NEJMp048166			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625330				2022-12-28	WOS:000226004300003
J	Melyan, Z; Tarttelin, EE; Bellingham, J; Lucas, RJ; Hankins, MW				Melyan, Z; Tarttelin, EE; Bellingham, J; Lucas, RJ; Hankins, MW			Addition of human melanopsin renders mammalian cells photoresponsive	NATURE			English	Article							RETINAL GANGLION-CELLS; ACTION SPECTRUM; LIGHT; OPSIN; RESPONSES; PIGMENT; SYSTEM; SUPPRESSION; PROTEINS; EXPOSURE	A small number of mammalian retinal ganglion cells act as photoreceptors for regulating certain non-image forming photoresponses(1-10). These intrinsically photosensitive retinal ganglion cells express the putative photopigment melanopsin(11-13). Ablation of the melanopsin gene renders these cells insensitive to light(14); however, the precise role of melanopsin in supporting cellular photosensitivity is unconfirmed. Here we show that heterologous expression of human melanopsin in a mouse paraneuronal cell line (Neuro-2a) is sufficient to render these cells photoreceptive. Under such conditions, melanopsin acts as a sensory photopigment, coupled to a native ion channel via a G-protein signalling cascade, to drive physiological light detection. The melanopsin photoresponse relies on the presence of cis-isoforms of retinaldehyde and is selectively sensitive to short-wavelength light. We also present evidence to show that melanopsin functions as a bistable pigment in this system, having an intrinsic photoisomerase regeneration function that is chromatically shifted to longer wavelengths.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ London Imperial Coll Sci Technol & Med, Div Neurosci & Psychol Med, Dept Visual Neurosci, London W6 8RF, England	University of Manchester; Imperial College London	Lucas, RJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg, Manchester M13 9PT, Lancs, England.	robert.lucas@manchester.ac.uk; m.hankins@imperial.ac.uk	谭, 德华 德/D-1910-2009; Bellingham, James/GVS-8955-2022	Bellingham, James/0000-0003-3368-5221; Lucas, Robert/0000-0002-1088-8029				ASANO T, 1986, MOL PHARMACOL, V29, P244; Beindl W, 1996, MOL PHARMACOL, V50, P415; Bellingham J, 2002, MOL BRAIN RES, V107, P128, DOI 10.1016/S0169-328X(02)00454-0; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Brainard GC, 2001, J NEUROSCI, V21, P6405; CZEISLER CA, 1995, NEW ENGL J MED, V332, P6, DOI 10.1056/NEJM199501053320102; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768; Hankins MW, 2002, CURR BIOL, V12, P191, DOI 10.1016/S0960-9822(02)00659-0; Hannibal J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0002.2002; Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; HUBBARD R, 1958, J GEN PHYSIOL, V41, P501, DOI 10.1085/jgp.41.3.501; Koyanagi M, 2004, P NATL ACAD SCI USA, V101, P6687, DOI 10.1073/pnas.0400819101; Leszkiewicz DN, 2000, J PHYSIOL-LONDON, V524, P365, DOI 10.1111/j.1469-7793.2000.t01-1-00365.x; LIU RSH, 1986, BIOCHEMISTRY-US, V25, P7026, DOI 10.1021/bi00370a040; Lockley SW, 1997, J CLIN ENDOCR METAB, V82, P3763, DOI 10.1210/jc.82.11.3763; Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; Lucas RJ, 2001, BEHAV BRAIN RES, V125, P97, DOI 10.1016/S0166-4328(01)00274-1; Mrosovsky N, 2001, J BIOL RHYTHM, V16, P585, DOI 10.1177/074873001129002277; Newman LA, 2003, BIOCHEMISTRY-US, V42, P12734, DOI 10.1021/bi035418z; Panda S, 2005, SCIENCE, V307, P600, DOI 10.1126/science.1105121; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Sekaran S, 2003, CURR BIOL, V13, P1290, DOI 10.1016/S0960-9822(03)00510-4; Thapan K, 2001, J PHYSIOL-LONDON, V535, P261, DOI 10.1111/j.1469-7793.2001.t01-1-00261.x; Warren EJ, 2003, EUR J NEUROSCI, V17, P1727, DOI 10.1046/j.1460-9568.2003.02594.x; Zemelman BV, 2002, NEURON, V33, P15, DOI 10.1016/S0896-6273(01)00574-8	31	304	352	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					741	745		10.1038/nature03344	http://dx.doi.org/10.1038/nature03344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15674244				2022-12-28	WOS:000227039200039
J	Kim, YK; Furic, L; DesGroseillers, L; Maquat, LE				Kim, YK; Furic, L; DesGroseillers, L; Maquat, LE			Mammalian Staufen1 recruits Upf1 to specific mRNA 3'UTRs so as to elicit mRNA decay	CELL			English	Article							EXON JUNCTION COMPLEX; NONSENSE-MEDIATED DECAY; ROUGH ENDOPLASMIC-RETICULUM; BINDING PROTEIN STAUFEN; HUMAN TELOMERASE RNA; RAT-BRAIN; HIPPOCAMPAL-NEURONS; TERMINATION-CODON; LOCALIZATION; DROSOPHILA	Mammalian Staufen (Stau)1 is an RNA binding protein that is thought to function in mRNA transport and translational control. Nonsense-mediated mRNA decay(NMD) degrades abnormal and natural mRNAs that terminate translation sufficiently upstream of a splicing-generated exon-exon junction. Here we describe an mRNA decay mechanism that involves Stau1, the NMD factor Upf1, and a termination codon. Unlike NMD, this mechanism does not involve pre-mRNA splicing and occurs when Upf2 or Upf3X is downregulated. Stau1 binds directly to Upf1 and elicits mRNA decay when tethered downstream of a termination codon. Stau1 also interacts with the 3'-untranslated region of ADP-ribosylation factor (Arf)1 mRNA. Accordingly, downregulating either Stau1 or Upf1 increases Arf1 mRNA stability. These findings suggest that Arf1 mRNA is a natural target for Stau1-mediated decay, and data indicate that other mRNAs are also natural targets. We discuss this pathway as a means for cells to downregulate the expression of Stau1 binding transcripts.	Univ Rochester, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	University of Rochester; Universite de Montreal	Maquat, LE (corresponding author), Univ Rochester, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	lynne_maquat@urmc.rochester.edu	Furic, Luc/F-4886-2012	Furic, Luc/0000-0002-1893-9812; Maquat, Lynne/0000-0002-2789-2075; Kim, Yoon Ki/0000-0003-1303-072X				Bachand F, 2001, NUCLEIC ACIDS RES, V29, P3385, DOI 10.1093/nar/29.16.3385; Belanger G, 2003, J NEUROCHEM, V86, P669, DOI 10.1046/j.1471-4159.2003.01883.x; BELGRADER P, 1994, MOL CELL BIOL, V14, P6326, DOI 10.1128/MCB.14.9.6326; Bono F, 2004, EMBO REP, V5, P304, DOI 10.1038/sj.embor.7400091; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; Chin SY, 2004, GENE DEV, V18, P745, DOI 10.1101/gad.1170204; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; Goodrich JS, 2004, DEVELOPMENT, V131, P1949, DOI 10.1242/dev.01078; Grentzmann G, 1998, RNA, V4, P479; Hachet O, 2004, NATURE, V428, P959, DOI 10.1038/nature02521; Hachet O, 2001, CURR BIOL, V11, P1666, DOI 10.1016/S0960-9822(01)00508-5; Hammond LE, 1997, MOL CELL BIOL, V17, P7260, DOI 10.1128/MCB.17.12.7260; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hillman RT, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r8; Inoue K, 2004, NAT GENET, V36, P361, DOI 10.1038/ng1322; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; IWAHANA H, 1995, BBA-GENE STRUCT EXPR, V1261, P369, DOI 10.1016/0167-4781(95)00036-G; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Kielkopf CL, 2002, BIOCHEMISTRY-US, V41, P11711, DOI 10.1021/bi020393+; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; Lau CK, 2003, CURR BIOL, V13, P933, DOI 10.1016/S0960-9822(03)00328-2; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Le SY, 2000, MOL BIOL CELL, V11, P999, DOI 10.1091/mbc.11.3.999; LEE CM, 1992, J BIOL CHEM, V267, P9028; Lejeune F, 2004, NAT STRUCT MOL BIOL, V11, P992, DOI 10.1038/nsmb824; Lejeune F, 2003, MOL CELL, V12, P675, DOI 10.1016/S1097-2765(03)00349-6; Lejeune F, 2002, EMBO J, V21, P3536, DOI 10.1093/emboj/cdf345; Li C, 2003, MOL CELL BIOL, V23, P7363, DOI 10.1128/MCB.23.20.7363-7376.2003; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Luo M, 2002, BIOCHEM J, V365, P817, DOI 10.1042/BJ20020263; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Macchi P, 2003, J NEUROSCI, V23, P5778; Mallardo M, 2003, P NATL ACAD SCI USA, V100, P2100, DOI 10.1073/pnas.0334355100; Maquat LE, 2004, CURR GENOMICS, V5, P175, DOI 10.2174/1389202043349453; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Marion RM, 1999, MOL CELL BIOL, V19, P2212; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366; Mohr SE, 2001, GENE DEV, V15, P2886; Monshausen M, 2002, J NEUROCHEM, V81, P557, DOI 10.1046/j.1471-4159.2002.00887.x; Monshausen M, 2001, J NEUROCHEM, V76, P155, DOI 10.1046/j.1471-4159.2001.00061.x; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Mouland AJ, 2000, J VIROL, V74, P5441, DOI 10.1128/JVI.74.12.5441-5451.2000; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; Pal M, 2001, RNA, V7, P5, DOI 10.1017/S1355838201000127; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; SIEBEL CW, 1994, GENE DEV, V8, P1713, DOI 10.1101/gad.8.14.1713; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; van Eeden FJM, 2001, J CELL BIOL, V154, P511, DOI 10.1083/jcb.200105056; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Wilusz CJ, 2001, GENE DEV, V15, P2781; Zhang J, 1998, RNA, V4, P801, DOI 10.1017/S1355838298971849	74	375	390	3	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					195	208		10.1016/j.cell.2004.11.050	http://dx.doi.org/10.1016/j.cell.2004.11.050			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680326	Bronze			2022-12-28	WOS:000226740000009
J	Jacoby, GA; Munoz-Price, LS				Jacoby, GA; Munoz-Price, LS			Mechanisms of disease: The new beta-lactamases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESISTANT KLEBSIELLA-PNEUMONIAE; BLOOD-STREAM INFECTIONS; GRAM-NEGATIVE BACTERIA; INTENSIVE-CARE-UNIT; ULTRAHIGH-RESOLUTION STRUCTURE; AERUGINOSA PRODUCING VIM-1; IN-VITRO ACTIVITIES; EXTENDED-SPECTRUM; ESCHERICHIA-COLI; RISK-FACTORS		Lahey Clin Fdn, Dept Infect Dis, Burlington, MA 01805 USA; Harvard Univ, Sch Med, Boston, MA USA; Tufts New England Med Ctr, Dept Geog Med & Infect Dis, Boston, MA USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Lahey Hospital & Medical Center; Harvard University; Harvard Medical School; Tufts Medical Center; Tufts University	Jacoby, GA (corresponding author), Lahey Clin Fdn, Dept Infect Dis, 41 Mall Rd, Burlington, MA 01805 USA.	george.a.jacoby@lahey.org	Jacoby, George A/G-2604-2011	Munoz-Price, L. Silvia/0000-0001-8654-5746				Ahmad M, 1999, CLIN INFECT DIS, V29, P352, DOI 10.1086/520214; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; Arlet G, 1997, FEMS MICROBIOL LETT, V152, P163, DOI 10.1111/j.1574-6968.1997.tb10423.x; ARLET G, 1994, J CLIN MICROBIOL, V32, P2553, DOI 10.1128/JCM.32.10.2553-2558.1994; Arpin C, 2003, ANTIMICROB AGENTS CH, V47, P3506, DOI 10.1128/AAC.47.11.3506-3514.2003; Babini GS, 2000, ANTIMICROB AGENTS CH, V44, P2230, DOI 10.1128/AAC.44.8.2230-2230.2000; Bisson G, 2002, INFECT CONT HOSP EP, V23, P254, DOI 10.1086/502045; Black JA, 2003, 43 INT C ANT AG CHEM; Bonnet R, 2000, ANTIMICROB AGENTS CH, V44, P3061, DOI 10.1128/AAC.44.11.3061-3068.2000; Bonnet R, 2004, ANTIMICROB AGENTS CH, V48, P1, DOI 10.1128/AAC.48.1.1-14.2004; Bradford PA, 2004, CLIN INFECT DIS, V39, P55, DOI 10.1086/421495; Bradford PA, 2001, CLIN MICROBIOL REV, V14, P933, DOI 10.1128/CMR.14.4.933-951.2001; Bradford PA, 1997, ANTIMICROB AGENTS CH, V41, P563, DOI 10.1128/AAC.41.3.563; Burgess DS, 2003, PHARMACOTHERAPY, V23, P1232, DOI 10.1592/phco.23.12.1232.32706; BURWEN DR, 1994, J INFECT DIS, V170, P1622, DOI 10.1093/infdis/170.6.1622; BUSH K, 1989, INFECTION, V17, P429, DOI 10.1007/BF01645566; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Carattoli A, 2002, ANTIMICROB AGENTS CH, V46, P1269, DOI 10.1128/AAC.46.5.1269-1272.2002; Chaves J, 2001, ANTIMICROB AGENTS CH, V45, P2856, DOI 10.1128/AAC.45.10.2856-2861.2001; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; Cornaglia G, 2000, CLIN INFECT DIS, V31, P1119, DOI 10.1086/317448; D'Agata E, 1998, J INFECTION, V36, P279, DOI 10.1016/S0163-4453(98)94171-8; Dalla-Costa LM, 2003, J CLIN MICROBIOL, V41, P3403, DOI 10.1128/JCM.41.7.3403-3406.2003; Danel F, 1999, ANTIMICROB AGENTS CH, V43, P1362, DOI 10.1128/AAC.43.6.1362; DECHAMPS C, 1991, J HOSP INFECT, V18, P5, DOI 10.1016/0195-6701(91)90088-P; Du B, 2002, INTENS CARE MED, V28, P1718, DOI 10.1007/s00134-002-1521-1; Dunne EF, 2000, JAMA-J AM MED ASSOC, V284, P3151, DOI 10.1001/jama.284.24.3151; Endimiani A, 2004, CLIN INFECT DIS, V38, P243, DOI 10.1086/380645; Garau G, 2004, ANTIMICROB AGENTS CH, V48, P2347, DOI 10.1128/AAC.48.7.2347-2349.2004; Giakkoupi P, 2000, ANTIMICROB AGENTS CH, V44, P2247, DOI 10.1128/AAC.44.9.2247-2253.2000; GO ES, 1994, LANCET, V344, P1329, DOI 10.1016/S0140-6736(94)90694-7; Haeggman S, 1997, ANTIMICROB AGENTS CH, V41, P2705, DOI 10.1128/AAC.41.12.2705; Hall BG, 2004, DRUG RESIST UPDATE, V7, P111, DOI 10.1016/j.drup.2004.02.003; HEDGES RW, 1974, MOL GEN GENET, V132, P31, DOI 10.1007/BF00268228; HEFFRON F, 1979, CELL, V18, P1153, DOI 10.1016/0092-8674(79)90228-9; HERITAGE J, 1992, ANTIMICROB AGENTS CH, V36, P1981, DOI 10.1128/AAC.36.9.1981; Hirakata Y, 2003, CLIN INFECT DIS, V37, P26, DOI 10.1086/375594; Ho PL, 2002, SCAND J INFECT DIS, V34, P567, DOI 10.1080/00365540210147516; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; Jacoby G, 1997, ANTIMICROB AGENTS CH, V41, P1830, DOI 10.1128/AAC.41.8.1830; JACOBY G, AMINO ACID SEQUENCES; JACOBY GA, 1990, ANTIMICROB AGENTS CH, V34, P858, DOI 10.1128/AAC.34.5.858; JETT BD, 1995, ANTIMICROB AGENTS CH, V39, P1187, DOI 10.1128/AAC.39.5.1187; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; Joshi SG, 2003, J MED MICROBIOL, V52, P1125, DOI 10.1099/0022-1317-52-12-1125; Karlowsky JA, 2003, ANTIMICROB AGENTS CH, V47, P1672, DOI 10.1128/AAC.47.5.1672-1680.2003; Kim YK, 2002, ANTIMICROB AGENTS CH, V46, P1481, DOI 10.1128/AAC.46.5.1481-1491.2002; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; Kurokawa H, 1999, LANCET, V354, P955, DOI 10.1016/S0140-6736(05)75707-X; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Lautenbach E, 2001, CLIN INFECT DIS, V33, P1288, DOI 10.1086/322667; Lautenbach E, 2001, CLIN INFECT DIS, V32, P1162, DOI 10.1086/319757; Lin MF, 2003, J HOSP INFECT, V53, P39, DOI 10.1053/jhin.2002.1331; Lucet JC, 1999, CLIN INFECT DIS, V29, P1411, DOI 10.1086/313511; Lucet JC, 1996, CLIN INFECT DIS, V22, P430, DOI 10.1093/clinids/22.3.430; Mangeney N, 2000, J APPL MICROBIOL, V88, P504, DOI 10.1046/j.1365-2672.2000.00989.x; Martinez-Martinez L, 1999, ANTIMICROB AGENTS CH, V43, P1669, DOI 10.1128/AAC.43.7.1669; MartinezMartinez L, 1996, ANTIMICROB AGENTS CH, V40, P342, DOI 10.1128/AAC.40.2.342; Matsumoto Y, 1999, ANTIMICROB AGENTS CH, V43, P307, DOI 10.1128/AAC.43.2.307; Mebis J, 1998, LEUKEMIA, V12, P1627, DOI 10.1038/sj.leu.2401158; Medeiros AA, 1997, CLIN INFECT DIS, V24, pS19, DOI 10.1093/clinids/24.Supplement_1.S19; MEDEIROS AA, 1986, BETA LACTAM ANTIBIOT, P49; Menashe G, 2001, SCAND J INFECT DIS, V33, P188, DOI 10.1080/00365540151060806; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; Moland ES, 2003, ANTIMICROB AGENTS CH, V47, P2382, DOI 10.1128/AAC.47.7.2382-2383.2003; Naas T, 1999, CURR PHARM DESIGN, V5, P865; Nordmann P, 2002, CLIN MICROBIOL INFEC, V8, P321, DOI 10.1046/j.1469-0691.2002.00401.x; Nukaga M, 2003, J MOL BIOL, V328, P289, DOI 10.1016/S0022-2836(03)00210-9; Oguri Toyoko, 2002, Jpn J Antibiot, V55 Suppl A, P1; Pai H, 2004, ANTIMICROB AGENTS CH, V48, P3720, DOI 10.1128/AAC.48.10.3720-3728.2004; PANGON B, 1989, J INFECT DIS, V159, P1005, DOI 10.1093/infdis/159.5.1005; Paterson DL, 2004, ANN INTERN MED, V140, P26, DOI 10.7326/0003-4819-140-1-200401060-00008; Paterson DL, 2001, J CLIN MICROBIOL, V39, P2206, DOI 10.1128/JCM.39.6.2206-2212.2001; Paterson DL, 2004, CLIN INFECT DIS, V39, P31, DOI 10.1086/420816; Paterson DL, 2000, CLIN INFECT DIS, V30, P473, DOI 10.1086/313719; Paterson DL, 2003, ANTIMICROB AGENTS CH, V47, P3554, DOI 10.1128/AAC.47.11.3554-3560.2003; Pena C, 1997, J HOSP INFECT, V35, P9, DOI 10.1016/S0195-6701(97)90163-8; Pena C, 1998, ANTIMICROB AGENTS CH, V42, P53, DOI 10.1128/AAC.42.1.53; Philippon A, 2002, ANTIMICROB AGENTS CH, V46, P1, DOI 10.1128/AAC.46.1.1-11.2002; Piroth L, 1998, CLIN INFECT DIS, V27, P76, DOI 10.1086/514643; Poirel L, 2004, ANTIMICROB AGENTS CH, V48, P15, DOI 10.1128/AAC.48.1.15-22.2004; Poirel L, 2003, ANTIMICROB AGENTS CH, V47, P755, DOI 10.1128/AAC.47.2.755-758.2003; Preston KE, 2004, PLASMID, V51, P48, DOI 10.1016/j.plasmid.2003.09.005; Quale JM, 2002, CLIN INFECT DIS, V35, P834, DOI 10.1086/342577; Queenan AM, 2004, J CLIN MICROBIOL, V42, P269, DOI 10.1128/JCM.42.1.269-275.2004; QUINTEIRA S, AY560837 GENBANK; Radice M, 2002, ANTIMICROB AGENTS CH, V46, P602, DOI 10.1128/AAC.46.2.602-604.2002; Randegger CC, 2000, ANTIMICROB AGENTS CH, V44, P2759, DOI 10.1128/AAC.44.10.2759-2763.2000; Rasheed JK, 1997, ANTIMICROB AGENTS CH, V41, P647, DOI 10.1128/AAC.41.3.647; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; Rice LB, 1996, CLIN INFECT DIS, V23, P118, DOI 10.1093/clinids/23.1.118; Sabate M, 2002, ANTIMICROB AGENTS CH, V46, P2656, DOI 10.1128/AAC.46.8.2656-2661.2002; Sader HS, 2003, DIAGN MICR INFEC DIS, V47, P361, DOI 10.1016/S0732-8893(03)00052-X; Safdar N, 2002, ANN INTERN MED, V136, P834, DOI 10.7326/0003-4819-136-11-200206040-00013; Schiappa DA, 1996, J INFECT DIS, V174, P529, DOI 10.1093/infdis/174.3.529; Shibata N, 2003, J CLIN MICROBIOL, V41, P5407, DOI 10.1128/JCM.41.12.5407-5413.2003; Silva J, 2000, ANTIMICROB AGENTS CH, V44, P997, DOI 10.1128/AAC.44.4.997-1003.2000; Sirot D, 1997, ANTIMICROB AGENTS CH, V41, P1322, DOI 10.1128/AAC.41.6.1322; Stevenson KB, 2003, DIAGN MICR INFEC DIS, V47, P303, DOI 10.1016/S0732-8893(03)00092-0; Tenover FC, 1999, J CLIN MICROBIOL, V37, P4065, DOI 10.1128/JCM.37.12.4065-4070.1999; Tenover FC, 2001, J CLIN MICROBIOL, V39, P241, DOI 10.1128/JCM.39.1.241-250.2001; Thomson KS, 2001, ANTIMICROB AGENTS CH, V45, P3548, DOI 10.1128/AAC.45.12.3548-3554.2001; Thomson KS, 2000, MICROBES INFECT, V2, P1225, DOI 10.1016/S1286-4579(00)01276-4; Toleman MA, 2004, ANTIMICROB AGENTS CH, V48, P329, DOI 10.1128/AAC.48.1.329-332.2004; Tsakris A, 2000, J CLIN MICROBIOL, V38, P1290, DOI 10.1128/JCM.38.3.1290-1292.2000; Vahaboglu H, 1997, ANTIMICROB AGENTS CH, V41, P2265, DOI 10.1128/AAC.41.10.2265; Vahaboglu H, 1998, ANTIMICROB AGENTS CH, V42, P484; Vercauteren E, 1997, J CLIN MICROBIOL, V35, P2191, DOI 10.1128/JCM.35.9.2191-2197.1997; Weldhagen GF, 2003, ANTIMICROB AGENTS CH, V47, P2385, DOI 10.1128/AAC.47.8.2385-2392.2003; Wiener J, 1999, JAMA-J AM MED ASSOC, V281, P517, DOI 10.1001/jama.281.6.517; Winokur PL, 2001, CLIN INFECT DIS, V32, pS94, DOI 10.1086/320182; Wong-Beringer A, 2002, CLIN INFECT DIS, V34, P135, DOI 10.1086/324742; Wong-Beringer A, 2001, PHARMACOTHERAPY, V21, P583, DOI 10.1592/phco.21.6.583.34537; Woodford N, 2004, J ANTIMICROB CHEMOTH, V54, P735, DOI 10.1093/jac/dkh424; Yong DG, 2003, ANTIMICROB AGENTS CH, V47, P1749, DOI 10.1128/AAC.47.5.1749-1751.2003; Yuan MF, 1998, J ANTIMICROB CHEMOTH, V41, P527, DOI 10.1093/jac/41.5.527; Zanetti G, 2003, ANTIMICROB AGENTS CH, V47, P3442, DOI 10.1128/AAC.47.11.3442-3447.2003	118	562	625	1	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					380	391		10.1056/NEJMra041359	http://dx.doi.org/10.1056/NEJMra041359			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673804				2022-12-28	WOS:000226535900010
J	Ungchusak, K; Auewarakul, P; Dowell, SF; Kitphati, R; Auwanit, W; Puthavathana, P; Uiprasertkul, M; Boonnak, K; Pittayawonganon, C; Cox, NJ; Zaki, SR; Thawatsupha, P; Chittaganpitch, M; Khontong, R; Simmerman, JM; Chunsutthiwat, S				Ungchusak, K; Auewarakul, P; Dowell, SF; Kitphati, R; Auwanit, W; Puthavathana, P; Uiprasertkul, M; Boonnak, K; Pittayawonganon, C; Cox, NJ; Zaki, SR; Thawatsupha, P; Chittaganpitch, M; Khontong, R; Simmerman, JM; Chunsutthiwat, S			Probable person-to-person transmission of avian influenza A (H5N1)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HONG-KONG; VIRUS; ORIGIN; HEMAGGLUTININ; INFECTION; ANTIBODY; SUBTYPES; DISEASE; DUCKS; RISK	BACKGROUND: During 2004, a highly pathogenic avian influenza A (H5N1) virus caused poultry disease in eight Asian countries and infected at least 44 persons, killing 32; most of these persons had had close contact with poultry. No evidence of efficient person-to-person transmission has yet been reported. We investigated possible person-to-person transmission in a family cluster of the disease in Thailand. METHODS: For each of the three involved patients, we reviewed the circumstances and timing of exposures to poultry and to other ill persons. Field teams isolated and treated the surviving patient, instituted active surveillance for disease and prophylaxis among exposed contacts, and culled the remaining poultry surrounding the affected village. Specimens from family members were tested by viral culture, microneutralization serologic analysis, immunohistochemical assay, reverse-transcriptase-polymerase-chain-reaction (RT-PCR) analysis, and genetic sequencing. RESULTS: The index patient became ill three to four days after her last exposure to dying household chickens. Her mother came from a distant city to care for her in the hospital, had no recognized exposure to poultry, and died from pneumonia after providing 16 to 18 hours of unprotected nursing care. The aunt also provided unprotected nursing care; she had fever five days after the mother first had fever, followed by pneumonia seven days later. Autopsy tissue from the mother and nasopharyngeal and throat swabs from the aunt were positive for influenza A (H5N1) by RT-PCR. No additional chains of transmission were identified, and sequencing of the viral genes identified no change in the receptor-binding site of hemagglutinin or other key features of the virus. The sequences of all eight viral gene segments clustered closely with other H5N1 sequences from recent avian isolates in Thailand. CONCLUSIONS: Disease in the mother and aunt probably resulted from person-to-person transmission of this lethal avian influenzavirus during unprotected exposure to the critically ill index patient.	Thai Minist Publ Hlth, Bur Epidemiol, Dept Dis Control, Nonthaburi 11000, Thailand; Thai Minist Publ Hlth, Dept Med Sci, Nonthaburi 11000, Thailand; Thai Minist Publ Hlth, Kamphang Phet Hosp, Nonthaburi 11000, Thailand; Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok 10700, Thailand; Thai Minist Publ Hlth, Int Emerging Infect Program, Nonthaburi 11000, Thailand; US Ctr Dis Control & Prevent, Nonthaburi, Thailand; Ctr Dis Control & Prevent, Atlanta, GA USA	Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Mahidol University; Ministry of Public Health - Thailand; Centers for Disease Control & Prevention - USA	Ungchusak, K (corresponding author), Thai Minist Publ Hlth, Bur Epidemiol, Dept Dis Control, Tivanon Rd, Nonthaburi 11000, Thailand.	kum@health.moph.go.th	Auewarakul, Prasert/D-6015-2011	Auewarakul, Prasert/0000-0002-4745-4291; Boonnak, Kobporn/0000-0002-7536-8964				[Anonymous], 2004, LANCET INFECT DIS, V4, P595; Barry John, 2004, THE GREAT INFLUENZA; Bridges CB, 2000, J INFECT DIS, V181, P344, DOI 10.1086/315213; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Guarner J, 2000, AM J CLIN PATHOL, V114, P227, DOI 10.1309/HV74-N24T-2K2C-3E8Q; Harvey R, 2004, J VIROL, V78, P502, DOI 10.1128/JVI.78.1.502-507.2004; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Horimoto T, 2004, J VET MED SCI, V66, P303, DOI 10.1292/jvms.66.303; Katz JM, 1999, J INFECT DIS, V180, P1763, DOI 10.1086/315137; Kuiken T, 2004, SCIENCE, V306, P241, DOI 10.1126/science.1102287; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; *MIN PUBL HLTH, 2004, INFL H5N1 LAB TRAIN; Mounts AW, 1999, J INFECT DIS, V180, P505, DOI 10.1086/314903; Perkins LEL, 2002, AVIAN DIS, V46, P53, DOI 10.1637/0005-2086(2002)046[0053:POAHKO]2.0.CO;2; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8; Sims LD, 2003, AVIAN DIS, V47, P832, DOI 10.1637/0005-2086-47.s3.832; Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002; Sturm-Ramirez KM, 2004, J VIROL, V78, P4892, DOI 10.1128/JVI.78.9.4892-4901.2004; Taubenberger JK, 2001, PHILOS T ROY SOC B, V356, P1829, DOI 10.1098/rstb.2001.1020; World Health Organization, 2002, WHO MAN AN INFL DIAG; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; 2004, MMWR MORB MORTAL WKL, V53, P97; 2004, WKLY EPIDEMIOL REC, V79, P96; 2004, MMWR MORB MORTAL WKL, V53, P100	25	633	713	0	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					333	340		10.1056/NEJMoa044021	http://dx.doi.org/10.1056/NEJMoa044021			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15668219				2022-12-28	WOS:000226535900005
J	Eustace, K				Eustace, K			Colorectal cancer	LANCET			English	Article																			0	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2005	365	9454					166	166		10.1016/S0140-6736(05)17707-1	http://dx.doi.org/10.1016/S0140-6736(05)17707-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639299				2022-12-28	WOS:000226170700032
J	Ikeda, M				Ikeda, M			Family bias by proxy	LANCET			English	Editorial Material									Pharmaceut & Med Devices Agcy, Chiyoda Ku, Tokyo 1000013, Japan		Ikeda, M (corresponding author), Pharmaceut & Med Devices Agcy, Chiyoda Ku, Tokyo 1000013, Japan.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2005	365	9454					187	187		10.1016/S0140-6736(05)17710-1	http://dx.doi.org/10.1016/S0140-6736(05)17710-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639302				2022-12-28	WOS:000226170700035
J	Lipton, P				Lipton, P			Testing hypotheses: Prediction and prejudice	SCIENCE			English	Review							ACCOMMODATION	Observations that fit a hypothesis may be made before or after the hypothesis is formulated. Can that difference be relevant to the amount of support that the observations provide for the hypothesis? Philosophers of science and statisticians are both divided on this question, but there is an argument that predictions ought to count more than accommodations, because of the risk of "fudging" that accommodations run and predictions avoid.	Univ Cambridge, Dept Hist & Philosophy Sci, Cambridge CB2 3RH, England	University of Cambridge	Lipton, P (corresponding author), Univ Cambridge, Dept Hist & Philosophy Sci, Free Sch Lane, Cambridge CB2 3RH, England.	Peter.Lipton@Kings.cam.ac.uk						BRUSH SG, 1989, SCIENCE, V246, P1124, DOI 10.1126/science.246.4934.1124; Glymour C., 1980, THEORY EVIDENCE; GROSSER M, 1970, DICT SCI BIOGRAPHY, V1, P53; Hitchcock C, 2004, BRIT J PHILOS SCI, V55, P1, DOI 10.1093/bjps/55.1.1; HORWICH P, 1982, PROBABILITY EVIDENCE, P108; Howson C, 1989, OPEN COURT, V2nd; Keynes J. M, 1921, COLLECTED WRITINGS J, VVIII; Kuhn ThomasS., 1957, COPERNICAN REVOLUTIO; Lipton P, 2004, INFERENCE BEST EXPLA; MILL JS, 2004, SYSTEM LOGIC, pR3; NOZICK R, 1983, MANY QUESTIONS, P105; Popper K., 1959, LOGIC SCI DISCOVERY; SCHLESINGER GN, 1987, AUSTRALAS J PHILOS, V65, P33, DOI 10.1080/00048408712342751; Worrall J., 1989, USES EXPT STUDIES NA, P135	14	76	78	4	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2005	307	5707					219	221		10.1126/science.1103024	http://dx.doi.org/10.1126/science.1103024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653494				2022-12-28	WOS:000226361900031
J	Steer, A; Daley, AJ; Curtis, N				Steer, A; Daley, AJ; Curtis, N			Suppurative sequelae of symbiosis	LANCET			English	Editorial Material							MEDICINAL LEECH; THERAPY		Univ Melbourne, Dept Gen Med, Paediat Infect Dis Unit, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Microbiol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	University of Melbourne; University of Melbourne; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Curtis, N (corresponding author), Univ Melbourne, Dept Gen Med, Paediat Infect Dis Unit, Flemington Rd, Parkville, Vic 3052, Australia.	nigel.curtis@rch.org.au	Curtis, Nigel/B-3491-2012; Steer, Andrew C/C-2840-2013	Curtis, Nigel/0000-0003-3446-4594; Daley, Andrew/0000-0001-8470-6438				Chepeha DB, 2002, ARCH OTOLARYNGOL, V128, P960, DOI 10.1001/archotol.128.8.960; HERMANSDORFER J, 1988, BRIT J PLAST SURG, V41, P649, DOI 10.1016/0007-1226(88)90176-2; LENT CM, 1988, J EXP BIOL, V137, P513; Ouderkirk JP, 2004, CLIN INFECT DIS, V38, pE36, DOI 10.1086/381438; Whitaker IS, 2004, BRIT J PLAST SURG, V57, P348, DOI 10.1016/j.bjps.2003.12.016	5	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					188	188		10.1016/S0140-6736(05)17711-3	http://dx.doi.org/10.1016/S0140-6736(05)17711-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639303				2022-12-28	WOS:000226170700036
J	Kendall, JM; Stuart, GW; Ebinger, CJ; Bastow, ID; Keir, D				Kendall, JM; Stuart, GW; Ebinger, CJ; Bastow, ID; Keir, D			Magma-assisted rifting in Ethiopia	NATURE			English	Article							SEISMIC ANISOTROPY; CONTINENTAL BREAKUP; MANTLE DEFORMATION; BENEATH; FLOW; MELT; EXAMPLE; REGION; STRAIN; ZONES	The rifting of continents and evolution of ocean basins is a fundamental component of plate tectonics, yet the process of continental break-up remains controversial. Plate driving forces have been estimated to be as much as an order of magnitude smaller than those required to rupture thick continental lithosphere(1,2). However, Buck(1) has proposed that lithospheric heating by mantle upwelling and related magma production could promote lithospheric rupture at much lower stresses. Such models of mechanical versus magma-assisted extension can be tested, because they predict different temporal and spatial patterns of crustal and upper-mantle structure. Changes in plate deformation produce strain-enhanced crystal alignment and increased melt production within the upper mantle, both of which can cause seismic anisotropy(3). The Northern Ethiopian Rift is an ideal place to test break-up models because it formed in cratonic lithosphere with minor far-field plate stresses(4,5). Here we present evidence of seismic anisotropy in the upper mantle of this rift zone using observations of shear-wave splitting. Our observations, together with recent geological data, indicate a strong component of melt-induced anisotropy with only minor crustal stretching, supporting the magma-assisted rifting model in this area of initially cold, thick continental lithosphere.	Univ Leeds, Sch Earth Sci, Leeds LS2 9JT, W Yorkshire, England; Univ London, Royal Holloway, Dept Geol, Egham TW20 0EX, Surrey, England	University of Leeds; University of London; Royal Holloway University London	Kendall, JM (corresponding author), Univ Leeds, Sch Earth Sci, Leeds LS2 9JT, W Yorkshire, England.	m.kendall@earth.leeds.ac.uk	Bastow, Ian/AAL-2933-2020; Keir, Derek/AAB-6110-2020; Bastow, Ian D/I-3783-2013; Kendall, Michael/D-5973-2011	Bastow, Ian/0000-0003-1468-9278; Keir, Derek/0000-0001-8787-8446; Bastow, Ian D/0000-0003-1468-9278; Kendall, Michael/0000-0002-1486-3945; Ebinger, Cynthia/0000-0002-6211-3399				Abdelsalam MG, 1996, J AFR EARTH SCI, V23, P289, DOI 10.1016/S0899-5362(97)00003-1; Ayele A, 2004, GEOPHYS J INT, V157, P354, DOI 10.1111/j.1365-246X.2004.02206.x; Barruol G, 2001, GEOPHYS J INT, V146, P549, DOI 10.1046/j.0956-540x.2001.01481.x; Bastow ID, 2005, GEOPHYS J INT, V162, P479, DOI 10.1111/j.1365-246X.2005.02666.x; Bilham R, 1999, GEOPHYS RES LETT, V26, P2789, DOI 10.1029/1998GL005315; Blackman DK, 1996, GEOPHYS J INT, V127, P415, DOI 10.1111/j.1365-246X.1996.tb04730.x; BOTT MHP, 1991, PHILOS T ROY SOC A, V337, P83, DOI 10.1098/rsta.1991.0108; Buck WR, 2004, MARG THEOR EXP EARTH, P1; Chu DH, 1999, NATURE, V398, P64, DOI 10.1038/18014; Ebinger CJ, 2001, GEOLOGY, V29, P527, DOI 10.1130/0091-7613(2001)029<0527:CBIMPA>2.0.CO;2; Gao S, 1997, J GEOPHYS RES-SOL EA, V102, P22781, DOI 10.1029/97JB01858; Gashawbeza EM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020471; HADIOUCHE O, 1989, PHYS EARTH PLANET IN, V58, P61, DOI 10.1016/0031-9201(89)90096-4; Holtzman BK, 2003, SCIENCE, V301, P1227, DOI 10.1126/science.1087132; Kendall J., 2000, GEOPHYSICS MONOGRAPH, V117, P133; KENDALL JM, 1994, GEOPHYS RES LETT, V21, P301, DOI 10.1029/93GL02791; Mackenzie GD, 2005, GEOPHYS J INT, V162, P994, DOI 10.1111/j.1365-246X.2005.02710.x; Maguire P.K.H., 2003, EOS T AM GEOPHYS UN, V84, P3, DOI [10.1029/2003EO350002, DOI 10.1029/2003EO350002]; McClusky S, 2003, GEOPHYS J INT, V155, P126, DOI 10.1046/j.1365-246X.2003.02023.x; MOORE JM, 1978, TECTONOPHYSICS, V46, P159, DOI 10.1016/0040-1951(78)90111-7; Rooney TO, 2005, GEOCHIM COSMOCHIM AC, V69, P3889, DOI 10.1016/j.gca.2005.03.043; Rumpker G, 2000, GEOPHYS RES LETT, V27, P2005, DOI 10.1029/2000GL011423; Savage MK, 1999, REV GEOPHYS, V37, P65, DOI 10.1029/98RG02075; Silver PG, 1996, ANNU REV EARTH PL SC, V24, P385, DOI 10.1146/annurev.earth.24.1.385; Sleep NH, 1997, J GEOPHYS RES-SOL EA, V102, P10001, DOI 10.1029/97JB00551; Vauchez A, 2000, PHYS CHEM EARTH PT A, V25, P111, DOI 10.1016/S1464-1895(00)00019-3; Walker KT, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002866; WERNICKE B, 1981, NATURE, V291, P645, DOI 10.1038/291645a0; Wolfe CJ, 1998, SCIENCE, V280, P1230, DOI 10.1126/science.280.5367.1230; Wolfenden E, 2004, EARTH PLANET SC LETT, V224, P213, DOI 10.1016/j.epsl.2004.04.022	30	275	278	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2005	433	7022					146	148		10.1038/nature03161	http://dx.doi.org/10.1038/nature03161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650736				2022-12-28	WOS:000226252200034
J	Kimmelman, J				Kimmelman, J			Recent developments in gene transfer: risk and ethics	BRITISH MEDICAL JOURNAL			English	Review							HEMATOPOIETIC STEM-CELLS; CLINICAL-RESEARCH; THERAPY; TRIALS		McGill Univ, Fac Med, Clin Trials Res Grp, Biomed Eth Unit, Montreal, PQ H3A 1X1, Canada	McGill University	Kimmelman, J (corresponding author), McGill Univ, Fac Med, Clin Trials Res Grp, Biomed Eth Unit, 3647 Peel St, Montreal, PQ H3A 1X1, Canada.	jonathan.kimmelman@mcgill.ca						Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; Brewer T, 1999, JAMA-J AM MED ASSOC, V281, P824, DOI 10.1001/jama.281.9.824; Dettweiler U, 2001, BIOETHICS, V15, P491, DOI 10.1111/1467-8519.00257; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kimmelman J, 2003, CAN MED ASSOC J, V169, P781; King NMP, 2003, HASTINGS CENT REP, V33, P23, DOI 10.2307/3528151; King NMP, 2000, J LAW MED ETHICS, V28, P332, DOI 10.1111/j.1748-720X.2000.tb00685.x; Kohn DB, 2003, MOL THER, V8, P180, DOI 10.1016/S1525-0016(03)00212-0; Kohn DB, 2003, NAT REV CANCER, V3, P477, DOI 10.1038/nrc1122; Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18; Marshall E, 2001, SCIENCE, V294, P1640, DOI 10.1126/science.294.5547.1640; Nevin Norman C, 2000, Hum Gene Ther, V11, P1253; Orkin S, REPORT RECOMMENDATIO; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Welin S, 2000, J MED ETHICS, V26, P231, DOI 10.1136/jme.26.4.231; Williams D, 2001, Med Device Technol, V12, P12	20	60	70	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 8	2005	330	7482					79	82		10.1136/bmj.330.7482.79	http://dx.doi.org/10.1136/bmj.330.7482.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	887GR	15637370	Green Published			2022-12-28	WOS:000226294300017
J	Quintyne, NJ; Reing, JE; Hoffelder, DR; Gollin, SM; Saunders, WS				Quintyne, NJ; Reing, JE; Hoffelder, DR; Gollin, SM; Saunders, WS			Spindle multipolarity is prevented by centrosomal clustering	SCIENCE			English	Article							MAMMALIAN MITOTIC SPINDLE; ORAL-CANCER CELLS; CHROMOSOMAL INSTABILITY; NUMA; PROGRESSION; DEFECTS; AMPLIFICATION; MICROTUBULES; ORGANIZATION; DUPLICATION	Most tumor cells are characterized by increased genomic instability and chromosome segregational defects, often associated with hyperamplification of the centrosome and the formation of multipolar spindles. However, extra centrosomes do not always lead to multipolarity. Here, we describe a process of centrosomal clustering that prevented the formation of multipolar spindles in noncancer cells. Noncancer cells needed to overcome this clustering mechanism to allow multipolar spindles to form at a high frequency. The microtubule motor cytoplasmic dynein was a critical part of this coalescing machinery, and in some tumor cells overexpression of the spindle protein NuMA interfered with dynein localization, promoting multipolarity.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Saunders, WS (corresponding author), Univ Pittsburgh, Dept Biol Sci, 4249 5th Ave, Pittsburgh, PA 15260 USA.	wsaund@pitt.edu		Quintyne, Nicholas/0000-0002-8817-2936; Gollin, Susanne/0000-0001-5438-6808	NIDCR NIH HHS [P60DE13059, DE016086] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013059] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; COMPTON DA, 1995, J CELL SCI, V108, P621; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pihan GA, 2001, CANCER RES, V61, P2212; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; RING D, 1982, J CELL BIOL, V94, pS49; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; SHARP GA, 1982, EUR J CELL BIOL, V29, P97; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; YOSHIDA T, 1985, CELL STRUCT FUNCT, V10, P245, DOI 10.1247/csf.10.245	27	318	326	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					127	129		10.1126/science.1104905	http://dx.doi.org/10.1126/science.1104905			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637283				2022-12-28	WOS:000226214300054
J	Carreiras, M; Lopez, J; Rivero, F; Corina, D				Carreiras, M; Lopez, J; Rivero, F; Corina, D			Linguistic perception: Neural processing of a whistled language	NATURE			English	Article							SPEECH-PERCEPTION; CORTEX		Univ La Laguna, Dept Psicol Cognit, Tenerife 38205, Spain; Hosp Univ Canarias, IMETISA, Tenerife 28320, Spain; Univ Washington, Dept Psychol, Seattle, WA 98195 USA	Universidad de la Laguna; Universidad de la Laguna; University of Washington; University of Washington Seattle	Carreiras, M (corresponding author), Univ La Laguna, Dept Psicol Cognit, Tenerife 38205, Spain.	mcarreir@ull.es	Rivero, Francisco/AHI-1281-2022; Carreiras, Manuel/D-5267-2009	Carreiras, Manuel/0000-0001-6726-7613; Rivero, Francisco/0000-0002-6129-8053				Belin P, 2000, NAT NEUROSCI, V3, P965, DOI 10.1038/79890; Binder JR, 2000, CEREB CORTEX, V10, P512, DOI 10.1093/cercor/10.5.512; Giraud AL, 2001, J COGNITIVE NEUROSCI, V13, P754, DOI 10.1162/08989290152541421; Hickok G, 2000, TRENDS COGN SCI, V4, P131, DOI 10.1016/S1364-6613(00)01463-7; Hickok G, 2004, COGNITION, V92, P67, DOI 10.1016/j.cognition.2003.10.011; Hickok G, 2003, J COGNITIVE NEUROSCI, V15, P673, DOI 10.1162/089892903322307393; Joanisse MF, 2003, NEUROIMAGE, V19, P64, DOI 10.1016/S1053-8119(03)00046-6; Kircher TTJ, 2001, NEUROPSYCHOLOGIA, V39, P798, DOI 10.1016/S0028-3932(01)00014-8; Petitto LA, 2000, P NATL ACAD SCI USA, V97, P13961, DOI 10.1073/pnas.97.25.13961; Scott SK, 2003, TRENDS NEUROSCI, V26, P100, DOI 10.1016/S0166-2236(02)00037-1; Specht K, 2003, NEUROIMAGE, V20, P1944, DOI 10.1016/j.neuroimage.2003.07.034; Trujillo Ramon, 1978, SILBO GOMERO ANAL LI; Warren JD, 2003, J NEUROSCI, V23, P5799	13	31	31	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					31	32		10.1038/433031a	http://dx.doi.org/10.1038/433031a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635400				2022-12-28	WOS:000226117100024
J	Levine, RJ; Thadhani, R; Qian, C; Lam, C; Lim, KH; Yu, KF; Blink, AL; Sachs, BP; Epstein, FH; Sibai, BM; Sukhatme, VP; Karumanchi, SA				Levine, RJ; Thadhani, R; Qian, C; Lam, C; Lim, KH; Yu, KF; Blink, AL; Sachs, BP; Epstein, FH; Sibai, BM; Sukhatme, VP; Karumanchi, SA			Urinary placental growth factor and risk of preeclampsia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TYROSINE KINASE-1; FACTOR RECEPTOR; HYPERTENSION; CALCIUM; TRIAL; WOMEN	Context Preeclampsia may be caused by an imbalance of angiogenic factors. We previously demonstrated that high serum levels of soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic protein, and low levels of placental growth factor (PIGF), a proangiogenic protein, predict subsequent development of preeclampsia. In the absence of glomerular disease leading to proteinuria, sFlt1 is too large a molecule to be filtered into the urine, while PIGF is readily filtered. Objective To test the hypothesis that urinary PIGF is reduced prior to onset of hypertension and proteinuria and that this reduction predicts preeclampsia. Design, Setting, and Patients Nested case-control study within the Calcium for Preeclampsia Prevention trial of healthy nulliparous women enrolled at 5 US university medical centers during 1992-1995. Each woman with preeclampsia was matched to 1 normotensive control by enrollment site, gestational age at collection of the first serum specimen, and sample Storage time at -70degreesC. One hundred twenty pairs of women were randomly chosen for analysis of serum and urine specimens obtained before labor. Main Outcome Measure Cross-sectional urinary PIGF concentrations, before and after normalization for urinary creatinine. Results Among normotensive controls, urinary PIGF increased during the first 2 trimesters, peaked at 29 to 32 weeks, and decreased thereafter. Among cases, before onset of preeclampsia the pattern of urinary PIGF was similar, but levels were significantly reduced beginning at 25 to 28 weeks. There were particularly large differences between controls and cases of preeclampsia with subsequent early onset of the disease or small-for-gestational-age infants. After onset of clinical disease, mean urinary PIGF in women with preeclampsia was 32 pg/mL, compared with 234 pg/mL in controls with fetuses of similar gestational age (P<.001). The adjusted odds ratio for the risk of preeclampsia to begin before 37 weeks of gestation for specimens obtained at 21 to 32 weeks, which were in the lowest quartile of control PIGF concentrations (<118 pg/mL), compared with all other quartiles, was 22.5 (95% confidence interval, 7.4-67.8). Conclusion Decreased urinary PIGF at mid gestation is strongly associated with subsequent early development of preeclampsia.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Allied Technol Grp, Rockville, MD USA; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; NICHHD, Div Epidemiol Stat & Prevent Res, US Dept HHS, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Obstet, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Karumanchi, SA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Div, Dana 517,330 Brookline Ave, Boston, MA 02215 USA.	sananth@bidmc.harvard.edu	Sukhatme, Vikas/W-2776-2019; Karumanchi, Subbian Ananth/AAI-1694-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD013124, N01HD013121, N01HD013126, N01HD013122, N01HD053246, R01HD039223, N01HD013125, N01HD013123, Z01HD000373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002825] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD-3-9223, N01-HD-5-3246, N01-HD-3154, N01-HD-1-3126, N01-HD-1-3125, N01-HD-1-3124, N01-HD-1-3123, N01-HD-1-3122, N01-HD-1-3121] Funding Source: Medline; NIDDK NIH HHS [KO8-DK-002825] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN LF, 1992, KIDNEY INT, V42, P1457, DOI 10.1038/ki.1992.441; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Koga K, 2003, J CLIN ENDOCR METAB, V88, P2348, DOI 10.1210/jc.2002-021942; Levine RJ, 2004, AM J OBSTET GYNECOL, V190, P707, DOI 10.1016/j.ajog.2003.12.019; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Levine RJ, 1996, CONTROL CLIN TRIALS, V17, P442, DOI 10.1016/S0197-2456(96)00106-7; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Roberts JM, 1998, SEMIN REPROD ENDOCR, V16, P5, DOI 10.1055/s-2007-1016248; Roes EM, 2004, INT J BIOL MARKER, V19, P72, DOI 10.1177/172460080401900110; Sibai BM, 2003, SEMIN PERINATOL, V27, P239, DOI 10.1016/S0146-0005(03)00022-3; Sibai BM, 2003, OBSTET GYNECOL, V102, P181, DOI 10.1016/S0029-7844(03)00475-7; SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240, DOI 10.1152/ajprenal.1995.268.2.F240; Taylor RN, 2003, AM J OBSTET GYNECOL, V188, P177, DOI 10.1067/mob.2003.111; Thadhani R, 2004, J CLIN ENDOCR METAB, V89, P770, DOI 10.1210/jc.2003-031244; Torry DS, 1998, AM J OBSTET GYNECOL, V179, P1539, DOI 10.1016/S0002-9378(98)70021-3; Tsatsaris V, 2003, J CLIN ENDOCR METAB, V88, P5555, DOI 10.1210/jc.2003-030528; Walker JJ, 2000, LANCET, V356, P1260, DOI 10.1016/S0140-6736(00)02800-2; ZHANG J, 1995, OBSTET GYNECOL, V86, P200, DOI 10.1016/0029-7844(95)00142-E; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388	20	245	276	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					77	85		10.1001/jama.293.1.77	http://dx.doi.org/10.1001/jama.293.1.77			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632339	Bronze			2022-12-28	WOS:000226102100024
J	Summerskill, W				Summerskill, W			Evidence-based practice and the individual	LANCET			English	Editorial Material							EVIDENCE-BASED MEDICINE		The Lancet, London NW1 7BY, England		Summerskill, W (corresponding author), The Lancet, London NW1 7BY, England.							General Medical Council, 2002, TOM DOCT; Ghosh AK, 2004, LANCET, V364, P1108, DOI 10.1016/S0140-6736(04)17119-5; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Sackett DL, 1997, EVIDENCE BASED MED P, P167; Summerskill WSM, 2002, FAM PRACT, V19, P605, DOI 10.1093/fampra/19.6.605; VALORI RM, 2002, KEY TOPICS EVIDENCE	7	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2005	365	9453					13	14		10.1016/S0140-6736(04)17680-0	http://dx.doi.org/10.1016/S0140-6736(04)17680-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639665				2022-12-28	WOS:000226213100009
J	Melton, DA; Daley, GQ; Jennings, CG				Melton, DA; Daley, GQ; Jennings, CG			Altered nuclear transfer in stem-cell research - A flawed proposal.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Stem Cell Inst, Boston, MA 02115 USA; Harvard Univ, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Melton, DA (corresponding author), Harvard Univ, Stem Cell Inst, Boston, MA 02115 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				Chawengsaksophak K, 2004, P NATL ACAD SCI USA, V101, P7641, DOI 10.1073/pnas.0401654101; HURLBUT WB, ALTERED NUCL TRANSFE; ZUCKER HA, SESSION 6 SEEKING MO	3	50	51	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2791	2792		10.1056/NEJMp048348	http://dx.doi.org/10.1056/NEJMp048348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625329				2022-12-28	WOS:000226004300002
J	Jordan, IK; Kondrashov, FA; Adzhubei, IA; Wolf, YI; Koonin, EV; Kondrashov, AS; Sunyaev, S				Jordan, IK; Kondrashov, FA; Adzhubei, IA; Wolf, YI; Koonin, EV; Kondrashov, AS; Sunyaev, S			A universal trend of amino acid gain and loss in protein evolution	NATURE			English	Article							FREQUENCIES; SEQUENCES; ALIGNMENT; GENE	Amino acid composition of proteins varies substantially between taxa and, thus, can evolve. For example, proteins from organisms with ( G+C)- rich ( or ( A+T)- rich) genomes contain more ( or fewer) amino acids encoded by ( G+C)- rich codons(1 - 4). However, no universal trends in ongoing changes of amino acid frequencies have been reported. We compared sets of orthologous proteins encoded by triplets of closely related genomes from 15 taxa representing all three domains of life ( Bacteria, Archaea and Eukaryota), and used phylogenies to polarize amino acid substitutions. Cys, Met, His, Ser and Phe accrue in at least 14 taxa, whereas Pro, Ala, Glu and Gly are consistently lost. The same nine amino acids are currently accrued or lost in human proteins, as shown by analysis of non- synonymous single-nucleotide polymorphisms. All amino acids with declining frequencies are thought to be among the first incorporated into the genetic code; conversely, all amino acids with increasing frequencies, except Ser, were probably recruited late(5 - 7). Thus, expansion of initially under- represented amino acids, which began over 3,400 million years ago(8,9), apparently continues to this day.	Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kondrashov, AS (corresponding author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.	kondrashov@ncbi.nlm.nih.gov; ssunyaev@rics.bwh.harvard.edu	Kondrashov, Fyodor Alexeevich/H-6331-2015	Kondrashov, Fyodor Alexeevich/0000-0001-8243-4694; Wolf, Yuri/0000-0002-0247-8708; Adzhubey, Ivan/0000-0002-1483-9259	NATIONAL LIBRARY OF MEDICINE [Z01LM000095] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Brooks DJ, 2002, MOL BIOL EVOL, V19, P1645, DOI 10.1093/oxfordjournals.molbev.a003988; Brooks DJ, 2002, MOL CELL PROTEOMICS, V1, P125, DOI 10.1074/mcp.M100001-MCP200; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Clark MA, 1999, MOL BIOL EVOL, V16, P1586, DOI 10.1093/oxfordjournals.molbev.a026071; Cronin J R, 1983, Adv Space Res, V3, P5, DOI 10.1016/0273-1177(83)90036-4; Eyre-Walker A, 1998, J MOL EVOL, V47, P686, DOI 10.1007/PL00006427; Feng DF, 1996, METHOD ENZYMOL, V266, P368; FITCH WM, 1970, BIOCHEM GENET, V4, P579, DOI 10.1007/BF00486096; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Goldman N, 2002, MOL BIOL EVOL, V19, P1821, DOI 10.1093/oxfordjournals.molbev.a004007; Gu X, 1998, GENETICA, V102-3, P383, DOI 10.1023/A:1017028102013; Henikoff S, 2000, ADV PROTEIN CHEM, V54, P73, DOI 10.1016/S0065-3233(00)54003-0; HOLM S, 1979, SCAND J STAT, V6, P65; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KNIGHT RD, 2001, GENOME BIOL, V4; Kondrashov AS, 2002, P NATL ACAD SCI USA, V99, P14878, DOI 10.1073/pnas.232565499; MILLER SL, 1987, COLD SPRING HARB SYM, V52, P17, DOI 10.1101/SQB.1987.052.01.005; Muller T, 2000, J COMPUT BIOL, V7, P761, DOI 10.1089/10665270050514918; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; Smith NGC, 2002, NATURE, V415, P1022, DOI 10.1038/4151022a; Sorhannus U, 1999, J MOL EVOL, V48, P209, DOI 10.1007/PL00006459; SUEOKA N, 1961, P NATL ACAD SCI USA, V47, P1141, DOI 10.1073/pnas.47.8.1141; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tice MM, 2004, NATURE, V431, P549, DOI 10.1038/nature02888; Trifonov EN, 2004, J BIOMOL STRUCT DYN, V22, P1; Veerassamy S, 2003, J COMPUT BIOL, V10, P997, DOI 10.1089/106652703322756195; Wang HC, 2004, MOL BIOL EVOL, V21, P90, DOI [10.1093/molbev/msh003, 10.1093/molbev/msg003]; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061	30	196	200	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					633	638		10.1038/nature03306	http://dx.doi.org/10.1038/nature03306			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15660107				2022-12-28	WOS:000226862000045
J	Pray-Grant, MG; Daniel, JA; Schieltz, D; Yates, JR; Grant, PA				Pray-Grant, MG; Daniel, JA; Schieltz, D; Yates, JR; Grant, PA			Chd1 chromodomain links histone H3 methylation with SAGA- and SLIK-dependent acetylation	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ELONGATION-FACTORS; ACTIVE GENES; CHROMATIN; YEAST; H3; TRANSCRIPTION; COMPLEXES; DOMAIN; ASSOCIATION	The specific post-translational modifications to histones influence many nuclear processes including gene regulation, DNA repair and replication(1). Recent studies have identified effector proteins that recognize patterns of histone modification and transduce their function in downstream processes(2). For example, histone acetyltransferases (HATs) have been shown to participate in many essential cellular processes, particularly those associated with activation of transcription(3). Yeast SAGA (Spt-Ada-Gcn5 acetyltransferase) and SLIK (SAGA-like) are two highly homologous and conserved multi-subunit HAT complexes, which preferentially acetylate histones H3 and H2B and deubiquitinate histone H2B. Here we identify the chromatin remodelling protein Chd1 (chromo-ATPase/helicase-DNAbinding domain 1) as a component of SAGA and SLIK. Our findings indicate that one of the two chromodomains of Chd1 specifically interacts with the methylated lysine 4 mark on histone H3 that is associated with transcriptional activity. Furthermore, the SLIK complex shows enhanced acetylation of a methylated substrate and this activity is dependent upon a functional methyl-binding chromodomain, both in vitro and in vivo. Our study identifies the first chromodomain that recognizes methylated histone H3 (Lys 4) and possibly identifies a larger subfamily of chromodomain proteins with similar recognition properties.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Diversa Corp, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Virginia; Scripps Research Institute	Grant, PA (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	pag9n@virginia.edu	Daniel, Jeremy/S-4729-2016	Daniel, Jeremy/0000-0002-1981-5571				Bernstein NA, 1999, MOTOR CONTROL, V3, P4; Bottomley MJ, 2004, EMBO REP, V5, P464, DOI 10.1038/sj.embor.7400146; Brehm A, 2004, BIOESSAYS, V26, P133, DOI 10.1002/bies.10392; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Kelley DE, 1999, CHROMOSOMA, V108, P10, DOI 10.1007/s004120050347; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Stokes DG, 1996, P NATL ACAD SCI USA, V93, P7137, DOI 10.1073/pnas.93.14.7137; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Torok MS, 2004, ADV PROTEIN CHEM, V67, P181; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472	30	372	401	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					434	438		10.1038/nature03242	http://dx.doi.org/10.1038/nature03242			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15647753				2022-12-28	WOS:000226546200047
J	Rockey, DC; Poulson, E; Niedzwiecki, D; Davis, W; Bosworth, HB; Sanders, L; Yee, J; Henderson, J; Hatten, P; Burdick, S; Sanyal, A; Rubin, DT; Sterling, M; Akerkar, G; Bhutani, MS; Binmoeller, K; Garvie, J; Bini, EJ; Mcuaid, K; Foster, WL; Thompson, WM; Dachman, A; Halvorsen, R				Rockey, DC; Poulson, E; Niedzwiecki, D; Davis, W; Bosworth, HB; Sanders, L; Yee, J; Henderson, J; Hatten, P; Burdick, S; Sanyal, A; Rubin, DT; Sterling, M; Akerkar, G; Bhutani, MS; Binmoeller, K; Garvie, J; Bini, EJ; Mcuaid, K; Foster, WL; Thompson, WM; Dachman, A; Halvorsen, R			Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison	LANCET			English	Article							COLORECTAL POLYPS; VIRTUAL COLONOSCOPY; CT COLONOGRAPHY; NEOPLASIA; CANCER; PERFORMANCE; SENSITIVITY; SCREEN; COLON	Background The usefulness of currently available colon imaging tests, including air contrast barium enema (ACBE), computed tomographic colonography (CTC), and colonoscopy, to detect colon polyps and cancers is uncertain. We aimed to assess the sensitivity of these three imaging tests. Methods Patients with faecal occult blood, haematochezia, iron-deficiency anaemia, or a family history of colon cancer underwent three separate colon-imaging studies-ACBE, followed 7-14 days later by CTC and colonoscopy on the same day. The primary outcome was detection of colonic polyps and cancers. Outcomes were assessed by building an aggregate view of the colon, taking into account results of all three tests. Findings 614 patients completed all three imaging tests. When analysed on a per-patient basis, for lesions 10 mm or larger in size (n=63), the sensitivity of ACBE was 48% (95% Cl 35-61), CTC 59% (46-71, p=0.1083 for CTC vs ACBE), and colonoscopy 98% (91-100, p<0.0001 for colonoscopy vs CTC). For lesions 6-9 mm in size (n=116), sensitivity was 35% for ACBE (27-45), 51% for CTC (41-60, p=0.0080 for CTC vs ACBE), and 99% for colonoscopy (95-100, p<0.0001 for colonoscopy vs CTC). For lesions of 10 mm or larger in size, the specificity was greater for colonoscopy (0.996) than for either ACBE (0.90) or CTC (0.96) and declined for ACBE and CTC when smaller lesions were considered. Interpretation Colonoscopy was more sensitive than other tests, as currently undertaken, for detection of colonic polyps and cancers. These data have important implications for diagnostic use of colon imaging tests.	Duke Univ, Med Ctr, Durham, NC 27710 USA; Durham VA Med Ctr, Durham, NC USA; Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA; Troy Internal Med, Troy, NY USA; Indian River Radiol, Vero Beach, FL USA; Univ Texas Dallas, Dallas, TX 75230 USA; Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA; Univ Chicago, Chicago, IL 60637 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Seacoast Gastroenterol, Exeter, NH USA; Univ Texas Dallas, Med Branch, Galveston, TX 77550 USA; Calif Pacific Med Ctr, San Francisco, CA 94115 USA; Univ Calif San Diego, San Diego, CA 92103 USA; NYU, New York, NY USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of Texas System; University of Texas Dallas; Virginia Commonwealth University; University of Chicago; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Texas System; University of Texas Dallas; University of Texas Medical Branch Galveston; California Pacific Medical Center; University of California System; University of California San Diego; New York University	Rockey, DC (corresponding author), Duke Univ, Med Ctr, Box 3083,Sands Bldg,Rm 334,Res Dr, Durham, NC 27710 USA.	dcrockey@acpub.duke.edu		Dachman, Abraham/0000-0002-7035-2752; Niedzwiecki, Donna/0000-0002-3566-0450	NATIONAL CANCER INSTITUTE [R01CA082344] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82344] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATO DA, 1995, AIDS CLIN TRIALS, P155; BRADY AP, 1994, RADIOLOGY, V192, P373, DOI 10.1148/radiology.192.2.8029400; BREWSTER NT, 1994, BRIT J SURG, V81, P445, DOI 10.1002/bjs.1800810341; Cotton PB, 2004, JAMA-J AM MED ASSOC, V291, P1713, DOI 10.1001/jama.291.14.1713; De Zwart IM, 2001, CLIN RADIOL, V56, P401, DOI 10.1053/crad.2000.0672; DURDEY P, 1987, LANCET, V2, P549; DURRLEMAN S, 1990, BIOMETRICS, V46, P329, DOI 10.2307/2531438; Fenlon HM, 1999, NEW ENGL J MED, V341, P1496, DOI 10.1056/NEJM199911113412003; FORK FT, 1983, GUT, V24, P672, DOI 10.1136/gut.24.7.672; Glick S, 2000, AM J ROENTGENOL, V174, P1529, DOI 10.2214/ajr.174.6.1741529; HIXSON LJ, 1991, GASTROINTEST ENDOSC, V37, P125, DOI 10.1016/S0016-5107(91)70668-8; JENSEN J, 1990, BRIT J SURG, V77, P270, DOI 10.1002/bjs.1800770311; Johnson CD, 2003, GASTROENTEROLOGY, V125, P688, DOI 10.1016/S0016-5085(03)01058-8; Johnson CD, 2003, GASTROENTEROLOGY, V125, P311, DOI 10.1016/S0016-5085(03)00894-1; LAUFER I, 1994, TXB GASTROINTESTINAL, P1028; McFarland EG, 2002, RADIOLOGY, V225, P380, DOI 10.1148/radiol.2252011625; Ott DJ, 1996, SEMIN ROENTGENOL, V31, P125, DOI 10.1016/S0037-198X(96)80007-1; OTT DJ, 1989, SOUTHERN MED J, V82, P197, DOI 10.1097/00007611-198902000-00013; Pickhardt PJ, 2004, ANN INTERN MED, V141, P352, DOI 10.7326/0003-4819-141-5-200409070-00009; Pickhardt PJ, 2003, NEW ENGL J MED, V349, P2191, DOI 10.1056/NEJMoa031618; Pineau BC, 2003, GASTROENTEROLOGY, V125, P304, DOI 10.1016/S0016-5085(03)00885-0; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; SIMPKINS KC, 1984, CLIN GASTROENTEROL, V13, P99; STEINE S, 1994, RADIOLOGY, V191, P99, DOI 10.1148/radiology.191.1.8134605; Strom E, 1999, RADIOLOGY, V211, P211, DOI 10.1148/radiology.211.1.r99ap37211; Van Dam J, 2004, GASTROENTEROLOGY, V127, P970, DOI 10.1053/j.gastro.2004.07.003; Winawer SJ, 2000, NEW ENGL J MED, V342, P1766, DOI 10.1056/NEJM200006153422401; Yee J, 2001, RADIOLOGY, V219, P685, DOI 10.1148/radiology.219.3.r01jn40685	28	444	461	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					305	311						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664225				2022-12-28	WOS:000226449600033
J	Lazar, MA				Lazar, MA			How obesity causes diabetes: Not a tall tale	SCIENCE			English	Editorial Material							INDUCED INSULIN-RESISTANCE; FREE FATTY-ACIDS; METABOLIC SYNDROME; STRESS-RESPONSE; ADIPOSE-TISSUE; LINKS OBESITY; PPAR-GAMMA; MELLITUS; INFLAMMATION; LEPTIN	The epidemic of obesity-associated diabetes is a major crisis in modern societies, in which food is plentiful and exercise is optional. The biological basis of this problem has been explored from evolutionary and mechanistic perspectives. Evolutionary theories, focusing on the potential survival advantages of "thrifty" genes that are now maladaptive, are of great interest but are inherently speculative and difficult to prove. Mechanistic studies have revealed numerous fat-derived molecules and a link to inflammation that, together, are hypothesized to underlie the obesity-diabetes connection and thereby represent prospective targets for therapeutic intervention.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.	lazar@mait.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019					Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Agwunobi AO, 2000, J CLIN ENDOCR METAB, V85, P3770, DOI 10.1210/jc.85.10.3770; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4; Black PH, 2003, BRAIN BEHAV IMMUN, V17, P350, DOI 10.1016/S0889-1591(03)00048-5; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Damcott CM, 2003, ENDOCRIN METAB CLIN, V32, P761, DOI 10.1016/S0889-8529(03)00076-8; Das M, 2004, Obes Rev, V5, P13, DOI 10.1111/j.1467-789X.2004.00115.x; Diamond J, 2003, NATURE, V423, P599, DOI 10.1038/423599a; Dietz WH, 2004, NEW ENGL J MED, V350, P855, DOI 10.1056/NEJMp048008; Farooqi IS, 2001, NATURE, V414, P34, DOI 10.1038/35102112; Fernandez-Real JM, 1999, DIABETOLOGIA, V42, P1367, DOI 10.1007/s001250051451; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; GOULD SJ, 1996, NAT HIST, V5, P18; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; Haluzik M, 2004, PHYSIOL RES, V53, P123; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Narayan KMV, 2003, JAMA-J AM MED ASSOC, V290, P1884, DOI 10.1001/jama.290.14.1884; NEEL JV, 1962, AM J HUM GENET, V14, P353; O'Rahilly S, 2003, ENDOCRINOLOGY, V144, P3757, DOI 10.1210/en.2003-0373; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Osawa H, 2004, AM J HUM GENET, V75, P678, DOI 10.1086/424761; Ottaviani E, 1998, DOMEST ANIM ENDOCRIN, V15, P291, DOI 10.1016/S0739-7240(98)00021-6; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Petersen M, 2003, DIABETES CARE, V26, P917; Rajala MW, 2004, DIABETES, V53, P1671, DOI 10.2337/diabetes.53.7.1671; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Shi H, 2004, J BIOL CHEM, V279, P34733, DOI 10.1074/jbc.M403886200; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Unger RH, 2003, TRENDS ENDOCRIN MET, V14, P398, DOI 10.1016/j.tem.2003.09.008; Van den Berghe G, 2004, J CLIN INVEST, V114, P1187, DOI 10.1172/JCI200423506; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Welt CK, 2004, NEW ENGL J MED, V351, P987, DOI 10.1056/NEJMoa040388; Weyer C, 2001, MOL GENET METAB, V72, P231, DOI 10.1006/mgme.2001.3147; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zimmet P, 2003, J INTERN MED, V254, P114, DOI 10.1046/j.1365-2796.2003.01170.x	51	425	460	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					373	375		10.1126/science.1104342	http://dx.doi.org/10.1126/science.1104342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662001				2022-12-28	WOS:000226492300031
J	Mohanan, JL; Arachchige, IU; Brock, SL				Mohanan, JL; Arachchige, IU; Brock, SL			Porous semiconductor chalcogenide aerogels	SCIENCE			English	Article							PORE ORGANIZATION; CRYSTALS; DESIGN; CDSE; CDTE; SE	Chalcogenide aerogels based entirely on semiconducting II-VI or IV-VI frameworks have been prepared from a general strategy that involves oxidative aggregation of metal chalcogenide nanoparticle building blocks followed by supercritical solvent removal. The resultant materials are mesoporous, exhibit high surface areas, can be prepared as monoliths, and demonstrate the characteristic quantum-confined optical properties of their nanoparticle components. These materials can be synthesized from a variety of building blocks by chemical or photochemical oxidation, and the properties can be further tuned by heat treatment. Aerogel formation represents a powerful yet facile method for metal chalcogenide nanoparticle assembly and the creation of mesoporous semiconductors.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Brock, SL (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.	sbrock@chem.wayne.edu	Brock, Stephanie/AAS-5974-2021					Aldana J, 2001, J AM CHEM SOC, V123, P8844, DOI 10.1021/ja016424q; Braun PV, 1999, NATURE, V402, P603, DOI 10.1038/45137; Braun PV, 1999, J AM CHEM SOC, V121, P7302, DOI 10.1021/ja9833725; Dong W, 2000, ELECTROCHEM SOLID ST, V3, P457; Gacoin T, 2001, J PHYS CHEM B, V105, P10228, DOI 10.1021/jp0117381; Husing N, 1998, ANGEW CHEM INT EDIT, V37, P23, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<22::AID-ANIE22>3.0.CO;2-I; Janssen AH, 2002, J PHYS CHEM B, V106, P11905, DOI 10.1021/jp025971a; Li HL, 1999, SCIENCE, V283, P1145, DOI 10.1126/science.283.5405.1145; Long JW, 2000, ELECTROCHEM SOLID ST, V3, P453; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Park W, 2002, PHYS STATUS SOLIDI B, V229, P949, DOI 10.1002/1521-3951(200201)229:2<949::AID-PSSB949>3.0.CO;2-K; Peng ZA, 2001, J AM CHEM SOC, V123, P183, DOI 10.1021/ja003633m; Rabatic BM, 2003, CHEM MATER, V15, P1249, DOI 10.1021/cm020899e; Rangan KK, 2002, NANO LETT, V2, P513, DOI 10.1021/nl025502k; Reichenauer G, 2001, J NON-CRYST SOLIDS, V285, P167, DOI 10.1016/S0022-3093(01)00449-5; Riley AE, 2003, J AM CHEM SOC, V125, P4551, DOI 10.1021/ja0275919; Rolison DR, 2003, SCIENCE, V299, P1698, DOI 10.1126/science.1082332; Rolison DR, 2001, J MATER CHEM, V11, P963, DOI 10.1039/b007591o; Ryan JV, 2000, NATURE, V406, P169, DOI 10.1038/35018040; So WW, 2001, J COLLOID INTERF SCI, V237, P136, DOI 10.1006/jcis.2001.7489; STEIGERWALD ML, 1990, ACCOUNTS CHEM RES, V23, P183, DOI 10.1021/ar00174a003; Tang ZY, 2002, SCIENCE, V297, P237, DOI 10.1126/science.1072086; Trikalitis PN, 2002, J AM CHEM SOC, V124, P2604, DOI 10.1021/ja017245b; Trikalitis PN, 2001, NATURE, V410, P671, DOI 10.1038/35070533; Vlasov YA, 1999, ADV MATER, V11, P165, DOI 10.1002/(SICI)1521-4095(199902)11:2<165::AID-ADMA165>3.0.CO;2-3; Webb P.A., 1997, ANAL METHODS FINE PA; Zhang ZR, 2002, J AM CHEM SOC, V124, P12294, DOI 10.1021/ja0208299; Zheng NF, 2003, NATURE, V426, P428, DOI 10.1038/nature02140; Zheng NF, 2002, SCIENCE, V298, P2366, DOI 10.1126/science.1078663	29	461	471	20	349	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					397	400		10.1126/science.1106525	http://dx.doi.org/10.1126/science.1106525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662006				2022-12-28	WOS:000226492300038
J	de Garidel-Thoron, T; Rosenthal, Y; Bassinot, F; Beaufort, L				de Garidel-Thoron, T; Rosenthal, Y; Bassinot, F; Beaufort, L			Stable sea surface temperatures in the western Pacific warm pool over the past 1.75 million years	NATURE			English	Article							LAST GLACIAL MAXIMUM; CLIMATE; FORAMINIFERA; MAGNITUDE; PATTERNS; ATLANTIC; RATIOS; SST	About 850,000 years ago, the period of the glacial cycles changed from 41,000 to 100,000 years. This mid-Pleistocene climate transition has been attributed to global cooling, possibly caused by a decrease in atmospheric carbon dioxide concentrations(1,2). However, evidence for such cooling is currently restricted to the cool upwelling regions in the eastern equatorial oceans(3,4), although the tropical warm pools on the western side of the ocean basins are particularly sensitive to changes in radiative forcing(5,6). Here we present high-resolution records of sea surface temperatures spanning the past 1.75 million years, obtained from oxygen isotopes and Mg/Ca ratios in planktonic foraminifera from the western Pacific warm pool. In contrast with the eastern equatorial regions, sea surface temperatures in the western Pacific warm pool are relatively stable throughout the Pleistocene epoch, implying little long-term change in the tropical net radiation budget. Our results challenge the hypothesis of a gradual decrease in atmospheric carbon dioxide concentrations as a dominant trigger of the longer glacial cycles since 850,000 years ago. Instead, we infer that the temperature contrast across the equatorial Pacific Ocean increased, which might have had a significant influence on the mid-Pleistocene climate transition.	Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Geol Sci, New Brunswick, NJ 08901 USA; CEA, Lab Sci Climat & Environm, F-91198 Gif Sur Yvette, France; Univ Aix Marseille 3, CNRS, CEREGE, F-135345 Aix En Provence 4, France	Rutgers State University New Brunswick; Rutgers State University New Brunswick; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	de Garidel-Thoron, T (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, 71 Dudley Rd, New Brunswick, NJ 08901 USA.	garidel@marine.rutgers.edu	Beaufort, Luc/ABG-2289-2021; Beaufort, Luc/AAH-5305-2021; de Garidel-Thoron, Thibault/B-1204-2008	Beaufort, Luc/0000-0001-6055-9373; de Garidel-Thoron, Thibault/0000-0001-8983-9571				Bemis BE, 1998, PALEOCEANOGRAPHY, V13, P150, DOI 10.1029/98PA00070; Berger A, 1999, QUATERNARY SCI REV, V18, P1, DOI 10.1016/S0277-3791(98)00033-X; BOYLE EA, 1985, EARTH PLANET SC LETT, V76, P135, DOI 10.1016/0012-821X(85)90154-2; Broccoli AJ, 2000, J CLIMATE, V13, P951, DOI 10.1175/1520-0442(2000)013<0951:TCATLG>2.0.CO;2; Carcaillet JT, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017550; CONKRIGHT M, 1998, 16 NODC; Delcroix T, 1998, J GEOPHYS RES-OCEANS, V103, P18611, DOI 10.1029/98JC00814; DELCROIX T, 2002, J GEOPHYS RES-OCEANS, V107, P22135; HALPERT MS, 1992, J CLIMATE, V5, P577, DOI 10.1175/1520-0442(1992)005<0577:STPAWT>2.0.CO;2; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; Kawahata H, 2002, DEEP-SEA RES PT II, V49, P2783, DOI 10.1016/S0967-0645(02)00058-9; KIEFER T, IN PRESS QUAT SCI RE; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Lea DW, 2004, J CLIMATE, V17, P2170, DOI 10.1175/1520-0442(2004)017<2170:TYCITS>2.0.CO;2; Liu ZH, 2004, NATURE, V427, P720, DOI 10.1038/nature02338; Marlow JR, 2000, SCIENCE, V290, P2288; Mix A.C., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P839, DOI 10.2973/odp.proc.sr.138.160.1995; Nurnberg D, 2000, PALEOCEANOGRAPHY, V15, P124, DOI 10.1029/1999PA000370; Philander SG, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000837; Ravelo AC, 2004, NATURE, V429, P263, DOI 10.1038/nature02567; Raymo ME, 1997, PALEOCEANOGRAPHY, V12, P577, DOI 10.1029/97PA01169; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; Rosenthal Y, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000749; Rosenthal Y, 1999, ANAL CHEM, V71, P3248, DOI 10.1021/ac981410x; Schefuss E, 2003, NATURE, V422, P418, DOI 10.1038/nature01500; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; Sun DZ, 2003, J CLIMATE, V16, P185, DOI 10.1175/1520-0442(2003)016<0185:APEOAI>2.0.CO;2; Tziperman E, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2001PA000627; Visser K, 2003, NATURE, V421, P152, DOI 10.1038/nature01297; Yin JH, 2001, J CLIMATE, V14, P565, DOI 10.1175/1520-0442(2001)014<0565:TIOTSS>2.0.CO;2	30	190	196	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					294	298		10.1038/nature03189	http://dx.doi.org/10.1038/nature03189			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662419				2022-12-28	WOS:000226381300050
J	Rothwell, PM; Mehta, Z; Howard, SC; Gutnikov, SA; Warlow, CP				Rothwell, PM; Mehta, Z; Howard, SC; Gutnikov, SA; Warlow, CP			Treating Individuals 3 - From subgroups to individuals: general principles and the example of carotid endarterectomy	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIALS; ACUTE MYOCARDIAL-INFARCTION; CORONARY-HEART-DISEASE; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; RISK-FACTORS; EXTERNAL VALIDITY; POOLED DATA; STROKE; PREDICTION	Clinicians often have to make treatment decisions based on the likelihood that an individual patient will benefit. In this article we consider the relevance of relative and absolute risk reductions, and draw attention to the importance of expressing the results of trials and subgroup analyses in terms of absolute risk. We describe the limitations of univariate subgroup analysis in situations in which there are several determinants of treatment effect, and review the potential for targeting treatments with risk models, especially when benefit is probably going to be dependent on the absolute risk of adverse outcomes with or without treatment. The ability to systematically take into account the characteristics of an individual patient and their interactions, to consider the risks and benefits of interventions separately if needed, and to provide patients with personalised estimates of their likelihood of benefit is shown using the example of endarterectomy for symptomatic carotid stenosis.	Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England; Western Gen Hosp, Neurosci Trials Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Radcliffe Infirmary; University of Oxford; University of Edinburgh	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England.	peter.rothwell@dneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; ASHER R, 1961, LANCET, V2, P1403; Baker S, 2000, BMJ-BRIT MED J, V320, P680, DOI 10.1136/bmj.320.7236.680; BOISSEL JP, 1993, J CARDIOVASC PHARM, V22, P356, DOI 10.1097/00005344-199309000-00003; Bond R, 2004, CEREBROVASC DIS, V18, P37, DOI 10.1159/000078606; Bond R, 2003, STROKE, V34, P2290, DOI 10.1161/01.STR.0000087785.01407.CC; BOND R, IN PRESS CEREBROVASC; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; BUNDAJ A, 2002, CIRCULATION, V106, P1622; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Ebrahim S, 1999, J HUM HYPERTENS, V13, P721, DOI 10.1038/sj.jhh.1000919; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Elwin G, 2001, LANCET, V358, P571, DOI 10.1016/S0140-6736(01)05709-9; Filippini G, 2003, LANCET, V361, P545, DOI 10.1016/S0140-6736(03)12512-3; Furukawa TA, 2002, INT J EPIDEMIOL, V31, P72, DOI 10.1093/ije/31.1.72; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GROVER SA, 1995, BRIT MED J, V310, P975, DOI 10.1136/bmj.310.6985.975; Hampton JR, 2002, STAT MED, V21, P2807, DOI 10.1002/sim.1284; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; HILL AB, 1952, NEW ENGL J MED, V247, P113, DOI 10.1056/NEJM195207242470401; Ioannidis JPA, 1997, J CLIN EPIDEMIOL, V50, P1089, DOI 10.1016/S0895-4356(97)00149-2; Isles CG, 2000, BMJ-BRIT MED J, V320, P690, DOI 10.1136/bmj.320.7236.690; Jackson R, 2000, BMJ-BRIT MED J, V320, P709, DOI 10.1136/bmj.320.7236.709; Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140-6736(02)08761-5; Kastrup A, 2003, STROKE, V34, P813, DOI 10.1161/01.STR.0000058160.53040.5F; Kernan WN, 2000, STROKE, V31, P456, DOI 10.1161/01.STR.31.2.456; Lauer MS, 2002, NEW ENGL J MED, V346, P1468, DOI 10.1056/NEJMcp012672; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Li W, 1998, ARCH MAL COEUR VAISS, V91, P1059; Montgomery AA, 2000, BRIT MED J, V320, P686, DOI 10.1136/bmj.320.7236.686; Morris PJ, 1999, LANCET, V354, P1147, DOI 10.1016/S0140-6736(99)01104-6; NADEAU SE, 1993, STROKE, V24, P2128, DOI 10.1161/01.STR.24.12.2128; Nanchahal K, 2002, BRIT MED J, V325, P194, DOI 10.1136/bmj.325.7357.194; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; Pearce LA, 2000, AM J MED, V109, P45, DOI 10.1016/S0002-9343(00)00440-X; Pocock SJ, 2001, BMJ-BRIT MED J, V323, P75, DOI 10.1136/bmj.323.7304.75; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; Rathore SS, 2003, CIRCULATION, V107, P811, DOI 10.1161/01.CIR.0000049743.45748.02; Robson J, 2000, BRIT MED J, V320, P702, DOI 10.1136/bmj.320.7236.702; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rothwell PM, 1997, BMJ-BRIT MED J, V315, P1571, DOI 10.1136/bmj.315.7122.1571; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Rothwell PM, 2003, CEREBROVASC DIS, V16, P2, DOI 10.1159/000070271; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; Rothwell PM, 2003, STROKE, V34, P514, DOI 10.1161/01.STR.0000054671.71777.C7; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; SACKETT DL, 1995, J CLIN EPIDEMIOL, V48, P61, DOI 10.1016/0895-4356(94)00085-5; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Sanmuganathan PS, 2001, HEART, V85, P265, DOI 10.1136/heart.85.3.265; Schulz U., 2001, J NEUROL SCI, V187, pS127; Shepherd J, 1996, LANCET, V348, P1339; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401; WILCOX RG, 1986, BRIT MED J, V293, P1204, DOI 10.1136/bmj.293.6556.1204; Woods KL, 1999, BMJ-BRIT MED J, V318, P328, DOI 10.1136/bmj.318.7179.328b; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	66	186	188	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					256	265						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652609				2022-12-28	WOS:000226309600032
J	Bloom, S; Rguig, A; Berraho, A; Zniber, L; Bouazzaoui, N; Zaghloul, K; Reef, S; Zidouh, A; Papania, M; Seward, J				Bloom, S; Rguig, A; Berraho, A; Zniber, L; Bouazzaoui, N; Zaghloul, K; Reef, S; Zidouh, A; Papania, M; Seward, J			Congenital rubella syndrome burden in Morocco: a rapid retrospective assessment	LANCET			English	Article							DEVELOPING-COUNTRIES; SYNDROME CRS; CHILDREN; ABNORMALITIES; DISEASE; SCHOOL; DEAF	Background WHO recommends that countries considering introduction of rubella vaccine into their immunisation programme assess their burden of congenital rubella syndrome, to determine whether vaccination is warranted. However, few guidelines exist for such assessments in developing countries. We retrospectively estimated the burden of congenital rubella syndrome in Morocco, and assessed our methods of rapid case finding. Methods We undertook case finding in the two cities with Morocco's main tertiary care referral centres, using medical records from births between Jan 1, 1990, and May 31, 2002, disability records from 1965 to 1997, and retinal examinations from deaf students born between 1985 and 1994, applying the WHO definition for a clinically confirmed case of congenital rubella syndrome. We also reviewed disability data for evidence of epidemic periodicity and estimated yearly incidence of the syndrome from congenital cataract data for births between 1990 and 2001. Findings We identified 62 clinically confirmed cases of congenital rubella syndrome from medical records, 148 from disability records, and 15 in deaf students. We noted no epidemic periodicity in disability data, and estimated a yearly incidence of the syndrome in Morocco of 8.1-12.7 cases per 100 000 livebirths. Interpretation We show evidence of congenital rubella syndrome in Morocco and support the addition of rubella vaccination to the national programme. Various data sources can be explored to rapidly assess burden of the syndrome; ophthalmology departments and outpatient cardiology clinics could offer the most potential for such case finding, dependent on documentation practices.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA; Minist Hlth, Dept Epidemiol & Dis Prevent, Rabat, Morocco; Ibn Sina Univ Hosp, Dept Ophthalmol, Rabat, Morocco; Ctr Cardiol, Rabat, Morocco; Ibn Sina Univ Hosp, Childrens Hosp, Dept Neonatol, Rabat, Morocco; Ibn Rochd Univ Hosp, Dept Paediat Ophthalmol, Casablanca, Morocco	Centers for Disease Control & Prevention - USA; Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat; Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat; Hassan II University of Casablanca; Ibn Rochd University Hospital Center of Casablanca	Bloom, S (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, MS E-61, Atlanta, GA 30333 USA.	SBloom@cdc.gov						[Anonymous], 2003, B WORLD HEAL ORGAN; AZELMAT M, 1999, NATL SURVEY MOTHER C; BLICHTEINWINICK.D, 2002, ANALES FACULTAD MED, V63, P1; BLITCHTEINWINIC.D, 2002, ANALES FACULTAD MED, V63, P93; BOUAZZAOUI NL, 1994, B ACAD NAT MED PARIS, V178, P1013; Cooper L Z, 1969, Dis Mon, P3; Cutts FT, 1999, INT J EPIDEMIOL, V28, P1176, DOI 10.1093/ije/28.6.1176; Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55; CUTTS FT, 1999, WHOVB9922; DUDGEON JA, 1972, POSTGRAD MED J, V48, P7; Durkin MS, 2000, AM J EPIDEMIOL, V152, P1024, DOI 10.1093/aje/152.11.1024; Eckstein M, 1996, BRIT J OPHTHALMOL, V80, P628, DOI 10.1136/bjo.80.7.628; ELANGO S, 1994, ANN TROP PAEDIATR, V14, P149, DOI 10.1080/02724936.1994.11747708; GUESSOUSIDRISSI N, 1984, PATHOL BIOL, V32, P761; Hanioglu-Kargi S, 2003, TURKISH J PEDIATR, V45, P39; ISACSOHN M, 1979, ISRAEL J MED SCI, V15, P17; Nejmi S, 1972, Maroc Med, V52, P420; NEJMI S, 2000, P 5 NAT C NEON OCT 2, P77; ORENSTEIN WA, 1985, REV INFECT DIS, V7, pS22; PECKHAM CS, 1972, ARCH DIS CHILD, V47, P571, DOI 10.1136/adc.47.254.571; Preblud S R, 1980, Epidemiol Rev, V2, P171; Rahman M. M., 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P811; Reef SE, 2000, CLIN INFECT DIS, V31, P85, DOI 10.1086/313928; ROBERTSON SE, 2004, REV PANAM SALUD PUBL, V14, P306; RUDOLPH A J, 1972, International Ophthalmology Clinics, V12, P3, DOI 10.1097/00004397-197201220-00003; SHIFF GM, 1970, PERINATAL INFECT, P31; SIEGEL M, 1968, JAMA-J AM MED ASSOC, V203, P116; Wolf SM, 1973, J PEDIATR OPHTHALMOL, V10, P101; World Health Organization, 2000, WKLY EPIDEMIOL REC, V75, P161	30	22	28	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					135	141		10.1016/S0140-6736(05)17703-4	http://dx.doi.org/10.1016/S0140-6736(05)17703-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639295				2022-12-28	WOS:000226170700028
J	Hart, DNJ				Hart, DNJ			Dendritic cell biology evolves into clinical application	LANCET			English	Editorial Material							LANGERHANS CELLS; IN-VIVO; RECEPTORS; MATURATION; ANTIGENS; SKIN		Mater Med Res Inst, Dendrit Cell Lab, Brisbane, Qld 4101, Australia	Mater Research	Hart, DNJ (corresponding author), Mater Med Res Inst, Dendrit Cell Lab, Raymond Terrace, Brisbane, Qld 4101, Australia.	dhart@mmri.mater.org.au	Hart, Derek NJ/B-9505-2014					Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Burns S, 2004, CELL MOTIL CYTOSKEL, V57, P118, DOI 10.1002/cm.10163; COLLIN M, IN PRESS TRANSPLANTA; Delamarre L, 2003, J EXP MED, V198, P111, DOI 10.1084/jem.20021542; Fehervari Z, 2004, INT IMMUNOL, V16, P1769, DOI 10.1093/intimm/dxh178; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Garg S, 2003, NAT IMMUNOL, V4, P907, DOI 10.1038/ni962; Jocham D, 2004, LANCET, V363, P594, DOI 10.1016/S0140-6736(04)15590-6; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kato M, 2000, INT IMMUNOL, V12, P1511, DOI 10.1093/intimm/12.11.1511; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; Miller MJ, 2004, P NATL ACAD SCI USA, V101, P998, DOI 10.1073/pnas.0306407101; Munster DJ, 2004, INT IMMUNOL, V16, P33, DOI 10.1093/intimm/dxh004; Salio M, 2003, EUR J IMMUNOL, V33, P1052, DOI 10.1002/eji.200323676; Soumelis V, 2004, SPRINGER SEMIN IMMUN, V25, P325, DOI 10.1007/s00281-003-0152-0; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Xu MQ, 2004, WORLD J GASTROENTERO, V10, P2361	19	4	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2005	365	9454					102	104		10.1016/S0140-6736(05)17717-4	http://dx.doi.org/10.1016/S0140-6736(05)17717-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639277				2022-12-28	WOS:000226170700006
J	Maruyama, K; Kawahara, N; Shin, M; Tago, M; Kishimoto, J; Kurita, H; Kawamoto, S; Morita, A; Kirino, T				Maruyama, K; Kawahara, N; Shin, M; Tago, M; Kishimoto, J; Kurita, H; Kawamoto, S; Morita, A; Kirino, T			The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GAMMA-KNIFE RADIOSURGERY; LINEAR-ACCELERATOR RADIOSURGERY; FOLLOW-UP DATA; NATURAL-HISTORY; STEREOTACTIC RADIOSURGERY; NIDUS OBLITERATION; BRAIN; SURGERY; EXPERIENCE	Background: Angiography shows that stereotactic radiosurgery obliterates most cerebral arteriovenous malformations after a latency period of a few years. However, the effect of this procedure on the risk of hemorrhage is poorly understood. Methods: We performed a retrospective observational study of 500 patients with malformations who were treated with radiosurgery with use of a gamma knife. The rates of hemorrhage were assessed during three periods: before radiosurgery, between radiosurgery and the angiographic documentation of obliteration of the malformation (latency period), and after angiographic obliteration. Results: Forty-two hemorrhages were documented before radiosurgery (median follow-up, 0.4 year), 23 during the latency period (median follow-up, 2.0 years), and 6 after obliteration (median follow-up, 5.4 years). As compared with the period between diagnosis and radiosurgery, the risk of hemorrhage decreased by 54 percent during the latency period (hazard ratio, 0.46; 95 percent confidence interval, 0.26 to 0.80; P=0.006) and by 88 percent after obliteration (hazard ratio, 0.12; 95 percent confidence interval, 0.05 to 0.29; P<0.001). The risk was significantly reduced during the period after obliteration, as compared with the latency period (hazard ratio, 0.26; 95 percent confidence interval, 0.10 to 0.68; P=0.006). The reduction was greater among patients who presented with hemorrhage than among those without hemorrhage at presentation and similar in analyses that took into account the delay in confirming obliteration by means of angiography and analyses that excluded data obtained during the first year after diagnosis. Conclusions: Radiosurgery significantly decreases the risk of hemorrhage in patients with cerebral arteriovenous malformations, even before there is angiographic evidence of obliteration. The risk of hemorrhage is further reduced, although not eliminated, after obliteration.	Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Dept Radiol, Tokyo 1138655, Japan; Tokyo Univ Hosp, Dept Clin Bioinformat, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Maruyama, K (corresponding author), Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kskmaru-tky@umin.ac.jp	Kawamoto, Shunsuke/E-9947-2013	Kawamoto, Shunsuke/0000-0002-1388-1287; Morita, Akio/0000-0002-2497-5772				Chang SD, 1997, CLIN NEUROPATHOL, V16, P111; COLOMBO F, 1994, NEUROSURGERY, V34, P14; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1; CROWLEY J, 1977, J AM STAT ASSOC, V72, P27, DOI 10.2307/2286902; Duong DH, 1999, NEW ENGL J MED, V340, P1812; Fabrikant J I, 1992, Neurosurg Clin N Am, V3, P99; Fleetwood IG, 2002, LANCET, V359, P863, DOI 10.1016/S0140-6736(02)07946-1; Friedman WA, 1996, J NEUROSURG, V84, P912, DOI 10.3171/jns.1996.84.6.0912; FRIEDMAN WA, 1995, J NEUROSURG, V82, P180, DOI 10.3171/jns.1995.82.2.0180; FULTS D, 1984, NEUROSURGERY, V15, P658, DOI 10.1227/00006123-198411000-00003; GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331; ITOYAMA Y, 1989, J NEUROSURG, V71, P805, DOI 10.3171/jns.1989.71.6.0805; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karlsson B, 1997, NEUROSURGERY, V40, P425, DOI 10.1097/00006123-199703000-00001; Karlsson B, 1996, MINIM INVAS NEUROSUR, V39, P21, DOI 10.1055/s-2008-1052210; Karlsson B, 2001, INT J RADIAT ONCOL, V49, P1045, DOI 10.1016/S0360-3016(00)01432-2; LEVY RP, 1989, NEUROSURGERY, V24, P841, DOI 10.1227/00006123-198906000-00009; Lindquist C, 1988, MODERN STEREOTACTIC, P491; Lindqvist M, 2000, NEUROSURGERY, V46, P803, DOI 10.1097/00006123-200004000-00006; LUNSFORD LD, 1991, J NEUROSURG, V75, P512, DOI 10.3171/jns.1991.75.4.0512; Maruyama K, 2004, J NEUROSURG, V100, P407, DOI 10.3171/jns.2004.100.3.0407; Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7; Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458; ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387; PHILLIPS TL, 1991, RAD INJURY NERVOUS S, P37; Pollock BE, 1996, NEUROSURGERY, V38, P652, DOI 10.1227/00006123-199604000-00004; Schneider BF, 1997, J NEUROSURG, V87, P352, DOI 10.3171/jns.1997.87.3.0352; Shin M, 2004, J NEUROSURG, V101, P18, DOI 10.3171/jns.2004.101.1.0018; Shin M, 2002, J NEUROSURG, V97, P779, DOI 10.3171/jns.2002.97.4.0779; SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476; STEINBERG GK, 1990, NEW ENGL J MED, V323, P96, DOI 10.1056/NEJM199007123230205; STEINER L, 1992, J NEUROSURG, V77, P1, DOI 10.3171/jns.1992.77.1.0001; Szeifert GT, 2003, NEUROL RES, V25, P718, DOI 10.1179/016164103101202228; YAMAMOTO M, 1992, SURG NEUROL, V37, P219, DOI 10.1016/0090-3019(92)90235-F	35	229	237	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					146	153		10.1056/NEJMoa040907	http://dx.doi.org/10.1056/NEJMoa040907			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886TG	15647577				2022-12-28	WOS:000226251700007
J	Telesco, CM; Fisher, RS; Wyatt, MC; Dermott, SF; Kehoe, TJJ; Novotny, S; Marinas, N; Radomski, JT; Packham, C; De Buizer, J; Hayward, TL				Telesco, CM; Fisher, RS; Wyatt, MC; Dermott, SF; Kehoe, TJJ; Novotny, S; Marinas, N; Radomski, JT; Packham, C; De Buizer, J; Hayward, TL			Mid-infrared images of beta Pictoris and the possible role of planetesimal collisions in the central disk	NATURE			English	Article							CIRCUMSTELLAR DISK; DUST; DEBRIS; PLANETS; SYSTEM; MODELS; CLUMPS; AGE	When viewed in optical starlight scattered by dust, the nearly edge-on debris disk surrounding the A5V star beta Pictoris (distance 19.3 pc; ref. 1) extends farther than 1,450 AU from the star(2). Its large-scale complexity has been well characterized, but the detailed structure of the disk's central similar to200-AU region has remained elusive. This region is of special interest, because planets may have formed there during the star's 10-20-million-year lifetime(3,4), perhaps resulting in both the observed tilt of 4.6 degrees relative to the large-scale main disk(5,6) and the partial clearing of the innermost dust(7-9). A peculiarity of the central disk (also possibly related to the presence of planets) is the asymmetry in the brightness of the 'wings'(9,10), in which the southwestern wing is brighter and more extended at 12 mum than the northeastern wing. Here we present thermal infrared images of the central disk that imply that the brightness asymmetry results from the presence of a bright clump composed of particles that may differ in size from dust elsewhere in the disk. We suggest that this clump results from the collisional grinding of resonantly trapped planetesimals or the cataclysmic break-up of a planetesimal.	Univ Florida, Dept Astron, Gainesville, FL 32611 USA; Gemini Observ No Operat Ctr, Hilo, HI 96720 USA; Royal Observ, UK Astron Technol Ctr, Edinburgh EH9 3HJ, Midlothian, Scotland; AURA, Gemini Observ So Operat Ctr, La Serena, Chile; Natl Opt Astron Observ, Cerro Tololo Inter Amer Observ, La Serena, Chile	State University System of Florida; University of Florida; University of Edinburgh; National Optical Astronomy Observatory	Telesco, CM (corresponding author), Univ Florida, Dept Astron, Gainesville, FL 32611 USA.	telesco@astro.ufl.edu	Kehoe, Thomas/J-6657-2013	Kehoe, Thomas/0000-0003-2212-8008; Telesco, Charles M./0000-0002-0036-9292				BACKMAN DE, 1992, ASTROPHYS J, V385, P670, DOI 10.1086/170973; BEUST H, 1994, ASTROPHYS SPACE SCI, V212, P147, DOI 10.1007/BF00984518; Brandeker A, 2004, ASTRON ASTROPHYS, V413, P681, DOI 10.1051/0004-6361:20034326; CRIFO F, 1997, ASTRON ASTROPHYS, V320, P29; DERMOTT SF, 1994, NATURE, V369, P719, DOI 10.1038/369719a0; DERMOTT SF, 2002, ESA, P319; Dominik C, 2003, ASTROPHYS J, V598, P626, DOI 10.1086/379169; Heap SR, 2000, ASTROPHYS J, V539, P435, DOI 10.1086/309188; LAGAGE PO, 1994, NATURE, V369, P628, DOI 10.1038/369628a0; LAGRANGEHENRI AM, 1988, ASTRON ASTROPHYS, V190, P275; Larwood JD, 2001, MON NOT R ASTRON SOC, V323, P402, DOI 10.1046/j.1365-8711.2001.04212.x; Li AG, 1998, ASTRON ASTROPHYS, V331, P291; Mouillet D, 1997, MON NOT R ASTRON SOC, V292, P896, DOI 10.1093/mnras/292.4.896; Navascues DBY, 1999, ASTROPHYS J, V520, pL123, DOI 10.1086/312162; Okamoto YK, 2004, NATURE, V431, P660, DOI 10.1038/nature02948; Ozernoy LM, 2000, ASTROPHYS J, V537, pL147, DOI 10.1086/312779; Pantin E, 1997, ASTRON ASTROPHYS, V327, P1123; Sicardy B, 1993, CELEST MECH DYN ASTR, V57, P373, DOI 10.1007/BF00692487; TELESCO CM, 1988, NATURE, V335, P51, DOI 10.1038/335051a0; VANPARADIJS J, 1994, ASTROPHYS J, V429, pL19, DOI 10.1086/187403; Wahhaj Z, 2003, ASTROPHYS J, V584, pL27, DOI 10.1086/346123; Weinberger AJ, 2003, ASTROPHYS J, V584, pL33, DOI 10.1086/368065; Wyatt MC, 1999, ASTROPHYS J, V527, P918, DOI 10.1086/308093; Wyatt MC, 2002, MON NOT R ASTRON SOC, V334, P589, DOI 10.1046/j.1365-8711.2002.05533.x; Wyatt MC, 2003, ASTROPHYS J, V598, P1321, DOI 10.1086/379064; Zuckerman B, 2001, ASTROPHYS J, V562, pL87, DOI 10.1086/337968	28	114	114	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2005	433	7022					133	136		10.1038/nature03255	http://dx.doi.org/10.1038/nature03255			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650732				2022-12-28	WOS:000226252200030
J	Jones, DG; Savage, R; Highton, J				Jones, DG; Savage, R; Highton, J			Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome	BRITISH MEDICAL JOURNAL			English	Article									Dunedin Publ Hosp, Dept Orthopaed Surg, Dunedin 9001, New Zealand; Dunedin Publ Hosp, Dept Rheumatol, Dunedin 9001, New Zealand; New Zealand Pharmacovigilance Ctr, Ctr Adverse Monitoring, Dunedin, New Zealand	Dunedin Public Hospital; Dunedin Public Hospital	Jones, DG (corresponding author), Dunedin Publ Hosp, Dept Orthopaed Surg, Great King St, Dunedin 9001, New Zealand.	David.gwynne-jones@stonebow.otago.ac.nz						Sharpe M, 2001, DRUGS, V61, P999, DOI 10.2165/00003495-200161070-00010; 2001, DRUG THER B, V39, P68	2	10	10	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 8	2005	330	7482					74	74		10.1136/bmj.330.7482.74	http://dx.doi.org/10.1136/bmj.330.7482.74			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887GR	15637369	Green Published, Bronze			2022-12-28	WOS:000226294300015
J	Hall, N; Karras, M; Raine, JD; Carlton, JM; Kooij, TWA; Berriman, M; Florens, L; Janssen, CS; Pain, A; Christophides, GK; James, K; Rutherford, K; Harris, B; Harris, D; Churcher, C; Quail, MA; Ormond, D; Doggett, J; Trueman, HE; Mendoza, J; Bidwell, SL; Rajandream, MA; Carucci, DJ; Yates, JR; Kafatos, FC; Janse, CJ; Barrell, B; Turner, CMR; Waters, AP; Sinden, RE				Hall, N; Karras, M; Raine, JD; Carlton, JM; Kooij, TWA; Berriman, M; Florens, L; Janssen, CS; Pain, A; Christophides, GK; James, K; Rutherford, K; Harris, B; Harris, D; Churcher, C; Quail, MA; Ormond, D; Doggett, J; Trueman, HE; Mendoza, J; Bidwell, SL; Rajandream, MA; Carucci, DJ; Yates, JR; Kafatos, FC; Janse, CJ; Barrell, B; Turner, CMR; Waters, AP; Sinden, RE			A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses	SCIENCE			English	Article							PROTEIN FAMILY; GENE FAMILY; MALARIA; FALCIPARUM; EXPRESSION; SEQUENCE; SPOROZOITES; SELECTION; BERGHEI; MOUSE	Plasmodium berghei and Plasmodium chabaudi are widely used model malaria species. Comparison of their genomes, integrated with proteomic and microarray data, with the genomes of Plasmodium falciparum and Plasmodium yoelii revealed a conserved core of 4500 Plasmodium genes in the central regions of the 14 chromosomes and highlighted genes evolving rapidly because of stage-specific selective pressures. Four strategies for gene expression are apparent during the parasites' life cycle: (i) housekeeping; (ii) host-related; (iii) strategy-specific related to invasion, asexual replication, and sexual development; and (iv) stage-specific. We observed posttranscriptional gene silencing through translational repression of messenger RNA during sexual development, and a 47-base 3' untranslated region motif is implicated in this process.	Wellcome Trust Sanger Inst, Pathogen Sequencing Unit, Cambridge CB10 1SA, England; Leiden Univ, Med Ctr, Dept Parasitol, Malaria Grp, NL-2300 RA Leiden, Netherlands; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Immunol & Infect Sect, London SW7 2AZ, England; Inst Genom Res, Rockville, MD 20850 USA; Univ Florida, Coll Vet Med, Dept Pathobiol, Gainesville, FL 32608 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; European Mol Biol Lab, D-69117 Heidelberg, Germany; Naval Med Res Ctr, Malaria Program IDD, Silver Spring, MD 20910 USA	Wellcome Trust Sanger Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Imperial College London; J. Craig Venter Institute; State University System of Florida; University of Florida; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Scripps Research Institute; University of Glasgow; European Molecular Biology Laboratory (EMBL); Naval Medical Research Center (NMRC)	Hall, N (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	nhall@tigr.org; a.p.waters@tumc.nl; r.sinden@imperial.ac.uk	Hall, Neil/A-8717-2013; Waters, Andy P/C-9377-2009; Pain, Arnab/L-5766-2015; Quail, michael/ABE-6131-2020; Rutherford, Kim/Y-7995-2018; Kooij, Taco W.A./L-5623-2015; Berriman, Matthew/A-7618-2011; Trueman, Holly/C-7883-2012	Hall, Neil/0000-0002-7995-3810; Waters, Andy P/0000-0001-8900-2982; Pain, Arnab/0000-0002-1755-2819; Rutherford, Kim/0000-0001-6277-726X; Kooij, Taco W.A./0000-0002-8547-7523; Berriman, Matthew/0000-0002-9581-0377; Florens, Laurence/0000-0002-9310-6650; Christophides, George/0000-0002-3323-1687; Janse, Chris J/0000-0002-6410-6205; Hall, Neil/0000-0003-2808-0009				Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Coulson RMR, 2004, GENOME RES, V14, P1548, DOI 10.1101/gr.2218604; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Cui LW, 2002, NUCLEIC ACIDS RES, V30, P4607, DOI 10.1093/nar/gkf600; del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118; Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629; Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575; Fischer K, 2003, MOL MICROBIOL, V48, P1209, DOI 10.1046/j.1365-2958.2003.03491.x; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Hayward RE, 2000, MOL MICROBIOL, V35, P6, DOI 10.1046/j.1365-2958.2000.01730.x; Janssen CS, 2002, P ROY SOC B-BIOL SCI, V269, P431, DOI 10.1098/rspb.2001.1903; Kaiser K, 2004, MOL BIOCHEM PARASIT, V133, P15, DOI 10.1016/j.molbiopara.2003.08.009; Krungkrai J, 2000, PARASITE, V7, P19, DOI 10.1051/parasite/2000071019; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; Plotkin JB, 2004, NATURE, V428, P942, DOI 10.1038/nature02458; Sam-Yellowe TY, 2004, GENOME RES, V14, P1052, DOI 10.1101/gr.2126104; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Waters AP, 2003, SCIENCE, V301, P1487, DOI 10.1126/science.1089799; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	27	637	689	1	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2005	307	5706					82	86		10.1126/science.1103717	http://dx.doi.org/10.1126/science.1103717			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637271				2022-12-28	WOS:000226214300040
J	Peoples, GE; Jezior, JR; Shriver, CD				Peoples, GE; Jezior, JR; Shriver, CD			Caring for the wounded in Iraq - A photo essay	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Walter Reed Army Med Ctr, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Peoples, GE (corresponding author), Walter Reed Army Med Ctr, Washington, DC 20307 USA.								0	20	23	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	2004	351	24					2476	2480		10.1056/NEJMp048327	http://dx.doi.org/10.1056/NEJMp048327			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877TE	15622566				2022-12-28	WOS:000225593100002
J	Gonzalez, E; Kulkarni, H; Bolivar, H; Mangano, A; Sanchez, R; Catano, G; Nibbs, RJ; Freedman, BI; Quinones, MP; Bamshad, MJ; Murthy, KK; Rovin, BH; Bradley, W; Clark, RA; Anderson, SA; O'Connell, RJ; Agan, BK; Ahuja, SS; Bologna, R; Sen, L; Dolan, MJ; Ahuja, SK				Gonzalez, E; Kulkarni, H; Bolivar, H; Mangano, A; Sanchez, R; Catano, G; Nibbs, RJ; Freedman, BI; Quinones, MP; Bamshad, MJ; Murthy, KK; Rovin, BH; Bradley, W; Clark, RA; Anderson, SA; O'Connell, RJ; Agan, BK; Ahuja, SS; Bologna, R; Sen, L; Dolan, MJ; Ahuja, SK			The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; BETA-CHEMOKINES; IN-VITRO; MACROPHAGE; INFECTION; CCR5; LYMPHOCYTES; PROTECTION; EVOLUTION	Segmental duplications in the human genome are selectively enriched for genes involved in immunity, although the phenotypic consequences for host defense are unknown. We show that there are significant interindividual and interpopulation differences in the copy number of a segmental duplication encompassing the gene encoding CCL3L1 (MIP-1alphaP), a potent human immunodeficiency virus-1 (HIV-1)-suppressive chemokine and ligand for the HIV coreceptor CCR5. Possession of a CCL3L1 copy number lower than the population average is associated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility. This susceptibility is even greater in individuals who also possess disease-accelerating CCR5 genotypes. This relationship between CCL3L1 dose and altered HIV/AIDS susceptibility points to a central role for CCL3L1 in HIV/AIDS pathogenesis and indicates that differences in the dose of immune response genes may constitute a genetic basis for variable responses to infectious diseases.	Univ Texas, Hlth Sci Ctr, Vet Adm Res Ctr AIDS & HIV1 Infect, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Consejo Nacl Invest Cient & Tecn, Lab Biol Celular & Retrovirus, RA-1245 Buenos Aires, DF, Argentina; Hosp Pediat JP Garrahan, Serv Infectol, RA-1245 Buenos Aires, DF, Argentina; Cancer Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA; SW Fdn Biomed Res, San Antonio, TX 78227 USA; Ohio State Univ, Div Nephrol, Columbus, OH 43210 USA; Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA; Wilford Hall USAF Med Ctr, Tri Serv AIDS Clin Consortium, Lackland AFB, TX 78236 USA; Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA; Def Inst Med Operat, Brooks AFB, TX 78235 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Hospital de Pediatria Doctor Juan Garrahan; University of Buenos Aires; Beatson Institute; Wake Forest University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Texas Biomedical Research Institute; University System of Ohio; Ohio State University; United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force	Ahuja, SK (corresponding author), Univ Texas, Hlth Sci Ctr, Vet Adm Res Ctr AIDS & HIV1 Infect, S Texas Vet Hlth Care Syst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	matthew.dolan@brooks.af.mil; ahujas@uthscsa.edu	Catano, Gabriel/AAQ-5387-2020; Clark, Robert/Q-6764-2019; Kulkarni, Hemant/AEM-5750-2022	Clark, Robert/0000-0002-4892-3619; Nibbs, Robert/0000-0002-8150-0044; Agan, Brian/0000-0002-5114-1669	NIAID NIH HHS [AI043279, AI046326] Funding Source: Medline; NIMH NIH HHS [MH069270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046326, R01AI043279, R21AI046326, R37AI046326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahmed RKS, 2002, CLIN EXP IMMUNOL, V129, P11, DOI 10.1046/j.1365-2249.2002.01894.x; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; DeVico AL, 2004, NAT REV MICROBIOL, V2, P401, DOI 10.1038/nrmicro878; Garzino-Demo A, 1999, P NATL ACAD SCI USA, V96, P11986, DOI 10.1073/pnas.96.21.11986; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; Heeney JL, 1998, P NATL ACAD SCI USA, V95, P10803, DOI 10.1073/pnas.95.18.10803; Mangano A, 2001, J INFECT DIS, V183, P1574, DOI 10.1086/320705; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359-6101(02)00045-X; Mummidi S, 2000, J BIOL CHEM, V275, P18946, DOI 10.1074/jbc.M000169200; Paxton WA, 2001, J INFECT DIS, V183, P1678, DOI 10.1086/320701; REYNES J, 2003, J ACQ IMMUN DEF SYND, V34, P114; Salkowitz JR, 2003, CLIN IMMUNOL, V108, P234, DOI 10.1016/S1521-6616(03)00147-5; Samonte RV, 2002, NAT REV GENET, V3, P65, DOI 10.1038/nrg705; Tang Jianming, 2003, AIDS, V17 Suppl 4, pS51, DOI 10.1097/00002030-200317004-00006; Townson JR, 2002, EUR J IMMUNOL, V32, P3016, DOI 10.1002/1521-4141(2002010)32:10<3016::AID-IMMU3016>3.0.CO;2-D; Ullum H, 1998, J INFECT DIS, V177, P331, DOI 10.1086/514192; Weed DL, 2000, HEMATOL ONCOL CLIN N, V14, P797, DOI 10.1016/S0889-8588(05)70312-9; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3857, DOI 10.1073/pnas.95.7.3857	21	885	989	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 4	2005	307	5714					1434	1440		10.1126/science.1101160	http://dx.doi.org/10.1126/science.1101160			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904MT	15637236				2022-12-28	WOS:000227503100037
J	Yamamoto, A; Nagano, T; Takehara, S; Hibi, M; Aizawa, S				Yamamoto, A; Nagano, T; Takehara, S; Hibi, M; Aizawa, S			Shisa promotes head formation through the inhibition of receptor protein maturation for the caudalizing factors, Wnt and FGF	CELL			English	Article							ENDOPLASMIC-RETICULUM; MESODERM INDUCTION; QUALITY-CONTROL; HOMEOBOX GENE; XENOPUS; SPECIFICATION; ANTAGONIST; EXPRESSION; ORGANIZER; WINGLESS	Head formation requires simultaneous inhibition of multiple caudalizing signals during early vertebrate embryogenesis. We identified a novel antagonist against Wnt and FGF signaling for head formation, Shisa, which functions cell autonomously in the endoplasmic reticulum (ER). Shisa is specifically expressed in the prospective head ectoderm and the Spemann organizer of Xenopus gastrulae. Overexpression of Shisa inhibited both Wnt and FGF signaling in Xenopus embryos and in a cell line. Loss of Shisa function sensitized the neuroectoderm to Wnt signaling and suppressed head formation during gastrulation. Shisa physically interacted with immature forms of the Wnt receptor Frizzled and the FGF receptor within the ER and inhibited their posttranslational maturation and trafficking to the cell surface. Taken together, these findings indicate that Shisa is a novel molecule that controls head formation by regulating the establishment of the receptors for caudalizing factors.	RIKEN, Ctr Dev Biol, Lab Vertebrate Body Plan, Chuou Ku, Kobe, Hyogo 6500047, Japan; RIKEN, Ctr Dev Biol, Lab Vertebrate Axis Format, Chuou Ku, Kobe, Hyogo 6500047, Japan	RIKEN; RIKEN	Yamamoto, A (corresponding author), RIKEN, Ctr Dev Biol, Lab Vertebrate Body Plan, Chuou Ku, 2-2-3 Minatojima Minami, Kobe, Hyogo 6500047, Japan.	akihito@cdb.riken.jp; saizawa@cdb.riken.jp	Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CORNELL RA, 1994, DEVELOPMENT, V120, P453; Cox WG, 1995, DEVELOPMENT, V121, P4349; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; Domingos PM, 2001, DEV BIOL, V239, P148, DOI 10.1006/dbio.2001.0431; Dorsky RI, 2003, DEVELOPMENT, V130, P1937, DOI 10.1242/dev.00402; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Heisenberg CP, 2001, GENE DEV, V15, P1427, DOI 10.1101/gad.194301; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Hunter T, 1998, Harvey Lect, V94, P81; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Kazanskaya O, 2000, DEVELOPMENT, V127, P4981; Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kudoh T, 2002, DEVELOPMENT, V129, P4335; LABONNE C, 1994, DEVELOPMENT, V120, P463; LAMB TM, 1995, DEVELOPMENT, V121, P3627; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; McGrew LL, 1997, MECH DEVELOP, V69, P105, DOI 10.1016/S0925-4773(97)00160-3; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Monsoro-Burq AH, 2003, DEVELOPMENT, V130, P3111, DOI 10.1242/dev.00531; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Niehrs C, 1999, TRENDS GENET, V15, P314, DOI 10.1016/S0168-9525(99)01767-9; PANNESE M, 1995, DEVELOPMENT, V121, P707; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pownall ME, 1996, DEVELOPMENT, V122, P3881; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Thisse C, 1999, DEVELOPMENT, V126, P229; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8	48	123	129	5	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					223	235		10.1016/j.cell.2004.11.051	http://dx.doi.org/10.1016/j.cell.2004.11.051			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680328	Bronze			2022-12-28	WOS:000226740000011
J	Morguet, AJ; Schultheiss, H				Morguet, AJ; Schultheiss, H			Embolization of the tip of a central venous catheter into the pulmonary artery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Morguet, AJ (corresponding author), Charite Campus Benjamin Franklin, D-12200 Berlin, Germany.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					E3	E3		10.1056/NEJMicm030965	http://dx.doi.org/10.1056/NEJMicm030965			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673796				2022-12-28	WOS:000226535900012
J	Netuveli, G; Hurwitz, B; Levy, M; Fletcher, M; Barnes, G; Durham, SR; Sheikh, A				Netuveli, G; Hurwitz, B; Levy, M; Fletcher, M; Barnes, G; Durham, SR; Sheikh, A			Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis	LANCET			English	Article							CHILDHOOD ASTHMA; ASIAN PATIENTS; PREVALENCE; ILLNESS; HOSPITALIZATION; ADMISSIONS; SYMPTOMS; CHILDREN; ADULTS; RATES	Background The frequency of asthma varies between countries, and may also vary between ethnic groups in more geographically confined areas. We sought evidence of such ethnic variations in the UK for asthma frequency, morbidity, and health-services use, and to understand possible reasons for any differences. Methods We searched MEDLINE, EMBASE, CINAHL, PSYCHInfo, PREMEDLINE, HEALTHSTAR, Cambridge Register of Conference Abstracts, the Dissertation and Thesis Database, and the National Registry of Research. Additionally, we searched the bibliographies of reports identified and websites of health authorities, and contacted experts in this discipline. Our main outcomes were comparisons of asthma rate, morbidity, and health-services use. We did meta-analyses using random-effects models. Findings 13 studies contained relevant data. All prevalence studies were of children and showed that south Asian children had a lower frequency of symptoms suggestive of asthma compared with black and white children (pooled rate of history of wheeze in the previous 12 months: south Asians 9.6% [95% CI 8.0-11.2%], black people 16.2% [12.8-19.6%], white people 14.6% [11.5-17.8%]). The pooled frequency of clinician-diagnosed asthma in children followed a similar pattern (south Asians 7.6% [3.7-11.4%], black people 15.0% [3.5-26.5%], white people 10.6% [4.6-16.7%]. However, relative to white people, the risk of admission for asthma in children and adults was higher for south Asians (odds ratio 2.9 [2.4-3.4]) and black people (2.1 [1.8-2.5]). Interpretation The differences in admission are not explained by differences in asthma frequency between groups; they could relate to ethnic variations in asthma severity, differences in health-seeking behaviour, or difficulties in accessing high-quality primary care services.	Univ Edinburgh, Div Community Hlth Sci, Gen Practice Sect, Edinburgh EH8 9DX, Midlothian, Scotland; Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, London, England; Kings Coll London, Sch Humanities, London WC2R 2LS, England; Natl Resp Training Ctr, Warwick, England; Asthma UK, London, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	University of Edinburgh; Imperial College London; University of London; King's College London; Imperial College London	Sheikh, A (corresponding author), Univ Edinburgh, Div Community Hlth Sci, Gen Practice Sect, 20 W Richmond St, Edinburgh EH8 9DX, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Fletcher, Monica/0000-0002-9700-3552				Acheson D., 1998, INDEPENDENT INQUIRY; Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; AYERS JG, 1989, BMJ-BRIT MED J, V299, P1338; AYRES JG, 1986, BRIT J DIS CHEST, V80, P242, DOI 10.1016/0007-0971(86)90059-8; BAHL V, 1998, ASSESSING HLTH NEEDS, P3; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bhopal RS, 2002, BRIT MED J, V325, P903; Carey OJ, 1996, AM J RESP CRIT CARE, V154, P537, DOI 10.1164/ajrccm.154.2.8756835; Department of Health, 2000, NHS PLAN PLAN INV PL; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Duran-Tauleria E, 1999, THORAX, V54, P476, DOI 10.1136/thx.54.6.476; DuranTauleria E, 1996, BRIT MED J, V313, P148, DOI 10.1136/bmj.313.7050.148; FERRARO KF, 1983, J GERONTOL, V38, P90, DOI 10.1093/geronj/38.1.90; Gilthorpe MS, 1998, RESP MED, V92, P642, DOI 10.1016/S0954-6111(98)90511-X; Griffiths C, 2001, BRIT MED J, V323, P962, DOI 10.1136/bmj.323.7319.962; HARDING S, 1997, INEQUALITIES HLTH, P108; HULL D, 1979, SOC SCI MED-MED SOC, VA13, P25, DOI 10.1016/0271-7123(79)90005-1; JACKSON SHD, 1981, POSTGRAD MED J, V57, P777, DOI 10.1136/pgmj.57.674.777; JOHNSTON IDA, 1987, THORAX, V42, P542, DOI 10.1136/thx.42.7.542; Jones COH, 1996, THORAX, V51, P1134, DOI 10.1136/thx.51.11.1134; Marmot MG, 1984, IMMIGRANT MORTALITY; MELIA RJW, 1988, BRIT MED J, V296, P1438, DOI 10.1136/bmj.296.6634.1438; Meren M, 2001, RESP MED, V95, P954, DOI 10.1053/rmed.2001.1188; Moudgil H, 1998, THORAX, V53, P490, DOI 10.1136/thx.53.6.490; MOUDGIL H, 2000, ASTHMA J, V5, P16; MYERS P, 1992, RESP MED, V86, P297, DOI 10.1016/S0954-6111(06)80027-2; *NAT STAT, 2001, CENS; NAZROO J, 1999, HLTH SURVEY ENGLAND; Nazroo JY, 1998, SOCIOL HEALTH ILL, V20, P710, DOI 10.1111/1467-9566.00126; NETUVELI G, 2002, SAPC ANN SCI M; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; ORMEROD LP, 1995, RESP MED, V89, P415, DOI 10.1016/0954-6111(95)90209-0; PARARAJASINGAM CD, 1992, THORAX, V313, P148; Partridge MR, 2000, THORAX, V55, P175, DOI 10.1136/thorax.55.3.175; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; Scott A, 2001, Popul Trends, P6; SMAJE C, 1995, HLTH RACE ETHNICITY; SOLOMONS R, 1996, PREVALENCE ASTHMA E; SUNDQUIST J, 1995, SOC SCI MED, V40, P777, DOI 10.1016/0277-9536(94)00146-K; Wilkinson P, 1996, BMJ-BRIT MED J, V312, P1330, DOI 10.1136/bmj.312.7042.1330; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371, DOI 10.1164/ajrccm.158.2.9608039	46	107	111	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					312	317						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664226				2022-12-28	WOS:000226449600034
J	Pincock, S				Pincock, S			Madyn McCarty - Obituary	LANCET			English	Biographical-Item												stephenpincock@blueyonder.co.uk		Pincock, Stephen/0000-0003-1655-2902					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2005	365	9456					288	288						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15672484				2022-12-28	WOS:000226449600016
J	Bardy, GH; Lee, KL; Mark, DB; Poole, JE; Packer, DL; Boineau, R; Domanski, M; Troutman, C; Anderson, J; Johnson, G; McNulty, SE; Clapp-Channing, N; Davidson-Ray, LD; Fraulo, ES; Fishbein, DP; Luceri, RM; Ip, JH				Bardy, GH; Lee, KL; Mark, DB; Poole, JE; Packer, DL; Boineau, R; Domanski, M; Troutman, C; Anderson, J; Johnson, G; McNulty, SE; Clapp-Channing, N; Davidson-Ray, LD; Fraulo, ES; Fishbein, DP; Luceri, RM; Ip, JH		SCD-HeFT Investigators	Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONISCHEMIC DILATED CARDIOMYOPATHY; RANDOMIZED-TRIAL; VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; HIGH-RISK	BACKGROUND: Sudden death from cardiac causes remains a leading cause of death among patients with congestive heart failure (CHF). Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD) has been proposed to improve the prognosis in such patients. METHODS: We randomly assigned 2521 patients with New York Heart Association (NYHA) class II or III CHF and a left ventricular ejection fraction (LVEF) of 35 percent or less to conventional therapy for CHF plus placebo (847 patients), conventional therapy plus amiodarone (845 patients), or conventional therapy plus a conservatively programmed, shock-only, single-lead ICD (829 patients). Placebo and amiodarone were administered in a double-blind fashion. The primary end point was death from any cause. RESULTS: The median LVEF in patients was 25 percent; 70 percent were in NYHA class II, and 30 percent were in class III CHF. The cause of CHF was ischemic in 52 percent and nonischemic in 48 percent. The median follow-up was 45.5 months. There were 244 deaths (29 percent) in the placebo group, 240 (28 percent) in the amiodarone group, and 182 (22 percent) in the ICD group. As compared with placebo, amiodarone was associated with a similar risk of death (hazard ratio, 1.06; 97.5 percent confidence interval, 0.86 to 1.30; P=0.53) and ICD therapy was associated with a decreased risk of death of 23 percent (0.77; 97.5 percent confidence interval, 0.62 to 0.96; P=0.007) and an absolute decrease in mortality of 7.2 percentage points after five years in the overall population. Results did not vary according to either ischemic or nonischemic causes of CHF, but they did vary according to the NYHA class. CONCLUSIONS: In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.	Seattle Inst Cardiac Res, Seattle, WA 98103 USA; Univ Washington, Seattle, WA 98195 USA; Duke Univ, Durham, NC USA; Mayo Clin, Rochester, MN USA; NHLBI, Bethesda, MD 20892 USA; Florida Arrhythmia Consultants, Ft Lauderdale, FL USA; Ingham Med Ctr, Lansing, MI USA	University of Washington; University of Washington Seattle; Duke University; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bardy, GH (corresponding author), Seattle Inst Cardiac Res, 7900 E Greenlake Dr N,300, Seattle, WA 98103 USA.	gbardy@sicr.org	omidvari, elham/Q-6686-2016; Tang, Anthony S/E-6203-2014; Boineau, Robin/AAR-4452-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL055297, U01HL055496, U01HL055766] Funding Source: NIH RePORTER; NHLBI NIH HHS [UO1 HL55496, UO1 HL55297, UO1 HL55766] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bardy G., 2000, ARRHYTHMIA TREATMENT, P323; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Cairns JA, 1997, LANCET, V349, P1776; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; COX DR, 1972, J R STAT SOC B, V34, P187; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; JULIAN DG, 1997, LANCET, V349, P1180; Kadish A, 2004, NEW ENGL J MED, V350, P2151, DOI 10.1056/NEJMoa033088; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; Strickberger SA, 2003, J AM COLL CARDIOL, V41, P1707, DOI 10.1016/S0735-1097(03)00297-3; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115	19	4046	4166	1	161	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					225	237		10.1056/NEJMoa043399	http://dx.doi.org/10.1056/NEJMoa043399			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659722				2022-12-28	WOS:000226370500003
J	Moore, JP				Moore, JP			Topical microbicides become topical	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SEXUAL TRANSMISSION; PREVENTION; INFECTION; HIV		Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Moore, JP (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.							Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833	5	25	25	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					298	300		10.1056/NEJMcibr043727	http://dx.doi.org/10.1056/NEJMcibr043727			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659734				2022-12-28	WOS:000226370500015
J	Gluckman, TJ; Sachdev, M; Schulman, SP; Blumenthal, RS				Gluckman, TJ; Sachdev, M; Schulman, SP; Blumenthal, RS			A simplified approach to the management of non-ST-segment elevation acute coronary syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GLYCOPROTEIN IIB/IIIA INHIBITORS; ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR DYSFUNCTION; HEALTH-CARE PROFESSIONALS; RECURRENT ISCHEMIC EVENTS; EARLY INVASIVE MANAGEMENT; ASSOCIATION TASK-FORCE; C-REACTIVE PROTEIN; HIGH-RISK PATIENTS; UNSTABLE ANGINA	Context While current practice guidelines provide an evidence-based approach to management of acute coronary syndromes (ACS), application of the evidence by Individual physicians has been suboptimal. Objective To assess and synthesize the evidence regarding optimal management of non-ST-segment elevation ACS (NSTE-ACS). Data Sources Systematic searches of peer-reviewed publications were performed in MEDLINE and the Cochrane Database from January 1990 through November 2004, with consultation by content experts. Search terms included antiplatelet therapy, antithrombotic therapy, angiotensin-converting enzyme inhibition, angiotensin receptor blockade, beta-blockade, hypertension, hyperlipidemia, cigarette smoking, diet, diabetes mellitus, exercise, myocardial ischemia, and coronary artery disease. Study Selection and Data Extraction Criteria for selection of studies included controlled study design, English language, and clinical pertinence. Data quality was based on the publishing journal and relevance to clinical management of NSTE-ACS. Data Synthesis While outcomes of controlled studies support a comprehensive approach in the management of patients with NSTE-ACS, many physicians perceive existing guidelines as lengthy and complex. After risk stratification to identify :hose patients most likely to benefit from an early invasive vs early conservative strategy, a comprehensive management plan can be assembled through an "ABCDE" approach. The elements of this include "A" for antiplatelet therapy, anticoagulation, angiotensin-converting enzyme inhibition, and angiotensin receptor blockade; "B" for beta-blockade and blood pressure control; "C" for cholesterol treatment and cigarette smoking cessation; "D" for diabetes management and diet; and "E" for exercise. Conclusion An "ABCDE" approach for the management of NSTE-ACS provides a practical and systematic means to implement evidence-based medicine into clinical practice.	Johns Hopkins Univ, Ciccarone Prevent Cardiol Ctr, Baltimore, MD 21287 USA; Johns Hopkins Univ, Johns Hopkins Hosp, Div Cardiol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Blumenthal, RS (corresponding author), Johns Hopkins Univ, Ciccarone Prevent Cardiol Ctr, 600 N Wolfe St,Blalock 524C, Baltimore, MD 21287 USA.	rblument@jhmi.edu	Gluckman, Ty/AAU-2990-2021; Blumenthal, Roger S/H-3223-2018	Blumenthal, Roger S/0000-0003-1910-3168				Ades PA, 2001, NEW ENGL J MED, V345, P892, DOI 10.1056/NEJMra001529; Al Suwaidi J, 2002, CIRCULATION, V106, P974, DOI 10.1161/01.CIR.0000027560.41358.B3; American Diabetes Association, 2003, DIABETES CARE, V26, ps33, DOI DOI 10.2337/DIACARE.26.2007.S33; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Bach RG, 2004, ANN INTERN MED, V141, P186, DOI 10.7326/0003-4819-141-3-200408030-00007; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Bhatt DL, 2004, JAMA-J AM MED ASSOC, V292, P2096, DOI 10.1001/jama.292.17.2096; Blazing MA, 2004, JAMA-J AM MED ASSOC, V292, P55, DOI 10.1001/jama.292.1.55; Boersma E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1; Braunstein J B, 2001, Cardiol Rev, V9, P96, DOI 10.1097/00045415-200103000-00008; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; Brown DL, 2001, AM J CARDIOL, V87, P537, DOI 10.1016/S0002-9149(00)01427-2; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Cairns JA, 2001, CHEST, V119, p228S, DOI 10.1378/chest.119.1_suppl.228S; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; CURB JD, 1983, JAMA-J AM MED ASSOC, V250, P2814; Dalby M, 2004, J AM COLL CARDIOL, V43, P162, DOI 10.1016/j.jacc.2003.08.033; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; de Lemos JA, 2004, EUR HEART J, V25, P1688, DOI 10.1016/j.ehj.2004.06.028; de Lemos JA, 2004, JAMA-J AM MED ASSOC, V292, P1307, DOI 10.1001/jama.292.11.1307; Eagle KA, 2004, JAMA-J AM MED ASSOC, V291, P2727, DOI 10.1001/jama.291.22.2727; Eisenberg MJ, 2004, AM J CARDIOL, V93, P744, DOI 10.1016/j.amjcard.2003.11.071; Ferguson JJ, 2004, JAMA-J AM MED ASSOC, V292, P45; Fiore M C, 2000, Respir Care, V45, P1200; Fletcher GF, 1997, CIRCULATION, V96, P355; Fox KAA, 2004, CIRCULATION, V110, P1202, DOI 10.1161/01.CIR.0000140675.85342.1B; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Fox KM, 2003, LANCET, V362, P782; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gibbons RJ, 2002, CIRCULATION, V106, P1883, DOI 10.1161/01.CIR.0000034670.06526.15; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; GLUCKMAN TJ, 2004, TXB CARDIOVASCULAR M, V7, P1; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Heeschen C, 2004, CIRCULATION, V110, P3206, DOI 10.1161/01.CIR.0000147611.92021.2B; HJALMARSON A, 1985, AM J CARDIOL, V56, pG15; Hoekstra JW, 2002, ACAD EMERG MED, V9, P1146, DOI 10.1111/j.1553-2712.2002.tb01569.x; Hongo RH, 2002, J AM COLL CARDIOL, V40, P231, DOI 10.1016/S0735-1097(02)01954-X; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Jacobs DR, 1999, CIRCULATION, V100, P599, DOI 10.1161/01.CIR.100.6.599; James SK, 2003, CIRCULATION, V108, P275, DOI 10.1161/01.CIR.0000079170.10579.DC; Januzzi JL, 2003, AM HEART J, V146, P764, DOI 10.1016/S0002-8703(03)00437-X; Kaul P, 2003, J AM COLL CARDIOL, V41, P371, DOI 10.1016/S0735-1097(02)02824-3; Kruse MW, 2004, AM HEART J, V148, P582, DOI 10.1016/j.ahj.2004.04.015; LANCASTER T, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001292; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; Mahoney EM, 2002, JAMA-J AM MED ASSOC, V288, P1851, DOI 10.1001/jama.288.15.1851; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Montalescot G, 2004, CIRCULATION, V110, P392, DOI 10.1161/01.CIR.0000136830.65073.C7; Mora, 2001, Curr Treat Options Cardiovasc Med, V3, P67, DOI 10.1007/s11936-001-0086-6; Morrow DA, 2003, J AM COLL CARDIOL, V41, P1264, DOI 10.1016/S0735-1097(03)00168-2; Morrow DA, 1998, J AM COLL CARDIOL, V31, P1460, DOI 10.1016/S0735-1097(98)00136-3; Morrow DA, 2003, CIRCULATION, V108, P250, DOI 10.1161/01.CIR.0000078080.37974.D2; Neumann FJ, 2003, JAMA-J AM MED ASSOC, V290, P1593, DOI 10.1001/jama.290.12.1593; Newby LK, 1998, CIRCULATION, V98, P1853, DOI 10.1161/01.CIR.98.18.1853; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; O'Shea JC, 2001, JAMA-J AM MED ASSOC, V285, P2468, DOI 10.1001/jama.285.19.2468; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Pepine CJ, 2004, JAMA-J AM MED ASSOC, V292, P2271, DOI 10.1001/jama.292.18.2271; Peters RJG, 2003, CIRCULATION, V108, P1682, DOI 10.1161/01.CIR.0000091201.39590.CB; Petersen JL, 2004, JAMA-J AM MED ASSOC, V292, P89, DOI 10.1001/jama.292.1.89; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pitt B, 2004, NEW ENGL J MED, V351, P2115, DOI 10.1056/NEJMe048255; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; Quinn MJ, 2002, CIRCULATION, V106, P379, DOI 10.1161/01.CIR.0000019581.22812.B2; Sabatine MS, 2003, J AM COLL CARDIOL, V41, p89S, DOI 10.1016/S0735-1097(02)03019-X; Sabatine MS, 2004, CIRCULATION, V109, P874, DOI 10.1161/01.CIR.0000112604.74713.35; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; Samaha FF, 2002, AM J CARDIOL, V90, P922, DOI 10.1016/S0002-9149(02)02654-1; SCHECHTMAN KB, 1989, CIRCULATION, V80, P1148, DOI 10.1161/01.CIR.80.5.1148; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Simoons ML, 2001, LANCET, V357, P1915; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; Steg PG, 2004, EUR HEART J, V25, P1667, DOI 10.1016/j.ehj.2004.07.028; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; van Domburg RT, 1998, J AM COLL CARDIOL, V31, P1534, DOI 10.1016/S0735-1097(98)00140-5; Wallentin L, 1999, LANCET, V354, P708; Waters D, 1996, CIRCULATION, V94, P614, DOI 10.1161/01.CIR.94.4.614; Woolacott N F, 2002, Health Technol Assess, V6, P1; Yende S, 2001, CRIT CARE MED, V29, P2271, DOI 10.1097/00003246-200112000-00006; Yusuf S, 2003, CIRCULATION, V107, P966, DOI 10.1161/01.CIR.0000051362.96946.15; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2000, NEW ENGL J MED, V342, P145; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259	97	40	42	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2005	293	3					349	357		10.1001/jama.293.3.349	http://dx.doi.org/10.1001/jama.293.3.349			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888FA	15657328				2022-12-28	WOS:000226358400029
J	Janssen, HLA; van Zonneveld, M; Senturk, H; Zeuzem, S; Akarca, US; Cakaloglu, Y; Simon, C; So, TMJ; Gerken, G; de Man, RA; Niesters, HGM; Zondervan, P; Hansen, B; Schalm, SW				Janssen, HLA; van Zonneveld, M; Senturk, H; Zeuzem, S; Akarca, US; Cakaloglu, Y; Simon, C; So, TMJ; Gerken, G; de Man, RA; Niesters, HGM; Zondervan, P; Hansen, B; Schalm, SW		HBV 99-01 Study Grp	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised	LANCET			English	Article							TERM-FOLLOW-UP; E-ANTIGEN SEROCONVERSION; INITIAL TREATMENT; VIRUS-INFECTION; PLUS RIBAVIRIN; THERAPY; ALPHA; TRIAL; EFFICACY; ALFA	Background Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response. Methods 307 HBeAg-positive patients with chronic hepatitis B were assigned combination therapy (100 mug/week pegylated interferon alfa-2b and 100 mg/day lamivudine) or monotherapy (100 mug/week pegylated interferon alfa-2b and placebo) for 52 weeks. During weeks 32-52 the pegylated interferon dose was 50 mug/week in both treatment groups. The analyses were based on the modified intention-to-treat population after exclusion of 24 patients from one centre withdrawn for misconduct, ten who lost HBeAg before the study start, and seven who received no study medication. All included patients were followed up for 26 weeks after treatment. Findings 49 (36%) of 136 patients assigned monotherapy and 46 (35%) of 130 assigned combination therapy had lost HBeAg at the end of follow-up (p=0.91). More of the combination-therapy than of the monotherapy group had cleared HBeAg at the end of treatment (57 [44%] vs 40 [29%]; p=0.01) but relapsed during follow-up. Patterns were similar when response was assessed by suppression of serum hepatitis B virus (HBV) DNA or change in concentrations of alanine aminotransferase. Response rates (HBeAg loss) varied by HBV genotype (p=0.01): A, 42 (47%) patients; B, ten (44%); C, 11 (28%); and D, 26 (25%). Interpretation Treatment with pegylated interferon alfa-2b is effective for HBeAg-positive chronic hepatitis B. Combination with lamivudine in the regimen used is not superior to monotherapy. HBV genotype is an important predictor of response to treatment.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus MC, Dept Virol, NL-3015 GD Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus MC, Dept Pathol, NL-3015 GD Rotterdam, Netherlands; Univ Med Ctr Rotterdam, Erasmus MC, Dept Biostat, NL-3015 GD Rotterdam, Netherlands; Istanbul Univ, Cerraphasa Med Fac, Dept Internal Med, Istanbul, Turkey; Istanbul Univ, Cerraphasa Med Fac, Dept Gastroenterohepatol, Istanbul, Turkey; Saarland Univ Hosp, Dept Med, Div Gastroenterol Hepatol & Endocrinol, Homburg, Germany; Ege Univ Hosp, Dept Gastroenterol, Izmir, Turkey; Med Univ, Dept & Clin Infect Dis, Wroclaw, Poland; Princess Margaret Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hosp Essen, Dept Gastroenterol & Hepatol, Essen, Germany	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Istanbul University; Istanbul University - Cerrahpasa; Istanbul University; Istanbul University - Cerrahpasa; Universitatsklinikum des Saarlandes; Ege University; Wroclaw Medical University; University of Duisburg Essen	Janssen, HLA (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Gastroenterol & Hepatol, Dr Molewaterpl 40,Room Ca 326, NL-3015 GD Rotterdam, Netherlands.	h.janssen@erasmusmc.nl	Zeuzem, Stefan/AAE-7435-2019; Niesters, Hubert/AAH-6808-2019; Hansen, Bettina/P-5468-2014	Gerken, Guido/0000-0001-6734-5001; Niesters, Hubert/0000-0002-1758-0430; Simon, Krzysztof/0000-0002-8040-0412; Hansen, Bettina/0000-0001-8307-3341				Barbaro G, 2001, J HEPATOL, V35, P406, DOI 10.1016/S0168-8278(01)00145-3; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; Cooksley WGE, 2003, J VIRAL HEPATITIS, V10, P298, DOI 10.1046/j.1365-2893.2003.00450.x; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; EASL jury, 2003, J HEPATOL, V38, P533, DOI DOI 10.1016/S0168-8278(03)00083-7; Erhardt A, 2000, HEPATOLOGY, V31, P716, DOI 10.1002/hep.510310323; Feld J, 2003, HEPATOLOGY, V38, P545, DOI 10.1053/jhep.2003.50389; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Janssen HLA, 1999, HEPATOLOGY, V30, P238, DOI 10.1002/hep.510300113; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870; Leung NWY, 2001, HEPATOLOGY, V33, P1527, DOI 10.1053/jhep.2001.25084; Lin SM, 1999, HEPATOLOGY, V29, P971, DOI 10.1002/hep.510290312; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Lok ASF, 2001, HEPATOLOGY, V34, P1225, DOI 10.1053/jhep.2001.29401; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; McHutchison JG, 2002, GASTROENTEROLOGY, V123, P1061, DOI 10.1053/gast.2002.35950; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Pas SD, 2000, J CLIN MICROBIOL, V38, P2897, DOI 10.1128/JCM.38.8.2897-2901.2000; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; Schalm SW, 2000, GUT, V46, P562, DOI 10.1136/gut.46.4.562; Schiff ER, 2003, J HEPATOL, V38, P818, DOI 10.1016/S0168-8278(03)00076-X; Song BC, 2000, HEPATOLOGY, V32, P803, DOI 10.1053/jhep.2000.16665; van Nunen AB, 2003, GUT, V52, P420, DOI 10.1136/gut.52.3.420; van Zonneveld M, 2004, HEPATOLOGY, V39, P804, DOI 10.1002/hep.20128; Wai CT, 2002, HEPATOLOGY, V36, P1425, DOI 10.1053/jhep.2002.37139; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	30	860	955	3	59	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					123	129		10.1016/S0140-6736(05)17701-0	http://dx.doi.org/10.1016/S0140-6736(05)17701-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639293				2022-12-28	WOS:000226170700026
J	O'Shea, JJ; Kanno, Y; Chen, XM; Levy, DE				O'Shea, JJ; Kanno, Y; Chen, XM; Levy, DE			Stat acetylation - A key facet of cytokine signaling?	SCIENCE			English	Editorial Material							DEACETYLASE ACTIVITY; GENE-EXPRESSION; TRANSACTIVATION; TRANSCRIPTION		NIAMSD, NIH, Bethesda, MD 20892 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Texas System; UTMD Anderson Cancer Center; New York University; New York University	O'Shea, JJ (corresponding author), NIAMSD, NIH, Bethesda, MD 20892 USA.		Kanno, Yuka/B-5802-2013; Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Kanno, Yuka/0000-0001-5668-9319; Levy, David/0000-0002-7320-7788; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Genin P, 2003, J VIROL, V77, P7113, DOI 10.1128/JVI.77.12.7113-7119.2003; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Sakamoto S, 2004, J BIOL CHEM, V279, P40362, DOI 10.1074/jbc.M406400200; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166	14	46	48	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					217	218		10.1126/science.1108164	http://dx.doi.org/10.1126/science.1108164			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653493				2022-12-28	WOS:000226361900030
J	Berjak, P				Berjak, P			Protector of the seeds: Seminal reflections from southern Africa	SCIENCE			English	Article									Univ ZKwaZulu Natal, Dept Life & Environm Sci, Durban, South Africa	University of Kwazulu Natal	Berjak, P (corresponding author), Univ ZKwaZulu Natal, Dept Life & Environm Sci, Durban, South Africa.	berjak@ukzn.ac.za	Berjak, Patricia/E-9362-2010						0	12	14	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					47	49		10.1126/science.1108429	http://dx.doi.org/10.1126/science.1108429			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637256				2022-12-28	WOS:000226214300025
J	Mayntz, D; Raubenheimer, D; Salomon, M; Toft, S; Simpson, SJ				Mayntz, D; Raubenheimer, D; Salomon, M; Toft, S; Simpson, SJ			Nutrient-specific foraging in invertebrate predators	SCIENCE			English	Article							MACRONUTRIENT SELF-SELECTION; INSECTS; FOOD	Many herbivores and omnivores adjust their food selection behavior to. regulate the intake of multiple nutrients. Carnivores, however, are generally assumed to optimize the rate of prey capture rather than select prey according to nutrient composition. We showed experimentally that invertebrate predators can forage selectively for protein and lipids to redress specific nutritional imbalances. This selection can take place at different stages of prey handling: The predator may select, among foods of different nutritional composition, eat more of a prey if it is rich in nutrients that the predator is deficient in, or extract specific nutrients from a single prey item.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Aarhus Univ, Dept Ecol & Genet, DK-8000 Aarhus C, Denmark; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, Dept Psychol, Auckland, New Zealand; Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Mitrani Dept Desert Ecol, IL-84105 Beer Sheva, Israel	University of Oxford; Aarhus University; University of Auckland; University of Auckland; Ben Gurion University; Ben Gurion University	Mayntz, D (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	david.mayntz@zoology.oxford.ac.uk		Simpson, Stephen J./0000-0003-0256-7687; Raubenheimer, David/0000-0001-9050-1447				Barker D, 1998, ZOO BIOL, V17, P123, DOI 10.1002/(SICI)1098-2361(1998)17:2&lt;123::AID-ZOO7&gt;3.0.CO;2-B; Fagan WF, 2002, AM NAT, V160, P784, DOI 10.1086/343879; Galef BG, 1996, NEUROSCI BIOBEHAV R, V20, P67, DOI 10.1016/0149-7634(95)00041-C; GREENSTONE MH, 1979, NATURE, V282, P501, DOI 10.1038/282501a0; Mayntz D, 2001, OECOLOGIA, V127, P207, DOI 10.1007/s004420000591; Raubenheimer D, 1997, NUTR RES REV, V10, P151, DOI 10.1079/NRR19970009; RAUBENHEIMER D, 1992, ENTOMOL EXP APPL, V62, P221, DOI 10.1007/BF00353441; REDFORD KH, 1984, J ZOOL, V203, P385, DOI 10.1111/j.1469-7998.1984.tb02339.x; Sanchez-Vazquez FJ, 1999, PHYSIOL BEHAV, V66, P45, DOI 10.1016/S0031-9384(98)00313-8; Seeley, 2000, NEURAL METABOLIC CON; Slansky F. Jr, 1985, P87; Stephens DW, 1986, MONOGRAPHS BEHAV ECO; Sterner R.W, 2002, ECOLOGICAL STOICHIOM, DOI DOI 10.1086/382444; Toft S, 1999, J ARACHNOL, V27, P301; Vivas M, 2003, AQUAC RES, V34, P271, DOI 10.1046/j.1365-2109.2003.00799.x	15	347	357	4	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2005	307	5706					111	113		10.1126/science.1105493	http://dx.doi.org/10.1126/science.1105493			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15637278				2022-12-28	WOS:000226214300049
J	Williams, J; Wake, M; Hesketh, K; Maher, E; Waters, E				Williams, J; Wake, M; Hesketh, K; Maher, E; Waters, E			Health-related quality of life of overweight and obese children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPORTED HEALTH; PARENT; QUESTIONNAIRE; FEASIBILITY; RELIABILITY; VALIDITY	Context The negative effects of childhood overweight and obesity on quality of life (QOL) have been shown in clinical samples but not yet in population-based community samples. Objective To determine relationships between weight and health-related QOL reported by parent-proxy and child self-report in a population sample of elementary school children. Design, Setting, and Participants Cross-sectional data collected in 2000 within the Health of Young Victorians Study, a longitudinal cohort study commenced in 1997. individuals were recruited via a random 2-stage sampling design from primary schools in Victoria, Australia. Of the 1943 children in the original cohort, 1569 (80.8%) were, resurveyed 3 years later at a mean age of 10.4 years. Main Outcome Measures Health-related QOL using the PedsQL 4.0 survey completed by both parent-proxy and by child self-report. Summary scores for children's total, physical, and psychosocial health and subscale scores for emotional, social, and school functioning were compared by weight category based on International Obesity Task Force cut points. Results Of 1456 participants, 1099 (75.5%) children were classified as not overweight; 294 (20.2%) overweight; and 63 (4.3%) obese. Parent-proxy and child self-reported PedsQL scores decreased with increasing child weight. The parent-proxy total PedsQL mean (SD) score for children who were not overweight was 83.1 (12.5); overweight, 80.0 (13.6); and obese, 75.0 (14.5); P<.001. The respective child self-reported total PedsQL mean (SD) scores were 80.5 (12.2), 79.3 (12.8), and 74.0 (14.2); P<.001. At the subscale level, child and parent-proxy reported scores were similar, showing decreases in physical and social functioning for obese children compared with children who were not overweight (all P<.001). Decreases in emotional and school functioning scores by weight category were not significant. Conclusion The effects of child overweight and obesity on health-related QOL in this community-based sample were significant but smaller than in a clinical sample using the same measure.	Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; Deakin Univ, Sch Hlth & Social Dev, Melbourne, Vic, Australia	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; Deakin University	Williams, J (corresponding author), Royal Childrens Hosp, Ctr Community Child Hlth, Flemington Rd, Parkville, Vic 3052, Australia.	jo.williams@mcri.edu.au	Wake, Melissa/J-1396-2012; Hesketh, Kylie/B-7031-2013	Wake, Melissa/0000-0001-7501-9257; Hesketh, Kylie/0000-0002-2702-7110; Williams, Joanne/0000-0002-5633-1592; Davis, Elise/0000-0002-5076-2869				ARGLE M, 1996, PURSUIT QUALITY LIFE, P18; *AUSTR BUR STAT CO, 1998, SOC IND AR 1996; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Department of Health, 2019, MAT HLTH 1 2000 DAYS; Dietz WH, 1998, J NUTR, V128, p411S, DOI 10.1093/jn/128.2.411S; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; FigueroaColon R, 1996, OBES RES, V4, P419, DOI 10.1002/j.1550-8528.1996.tb00250.x; Friedlander SL, 2003, ARCH PEDIAT ADOL MED, V157, P1206, DOI 10.1001/archpedi.157.12.1206; Hesketh K, 2004, PUBLIC HEALTH NUTR, V7, P303, DOI 10.1079/PHN2003537; Janicke DM, 2001, MED CARE, V39, P990, DOI 10.1097/00005650-200109000-00009; Kolotkin RL, 2002, OBES RES, V10, P748, DOI 10.1038/oby.2002.102; Kuczmarski RJ, 2000, CDC GROWTH CHARTS US; Lobstein T., 2004, OBES REV S1, V5, P4, DOI [https://doi.org/10.1111/j.1467-789X.2004.00133.x, DOI 10.1111/J.1467-789X.2004.00133.X]; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; Sherman EMS, 2002, EPILEPSIA, V43, P1230, DOI 10.1046/j.1528-1157.2002.03602.x; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Vitale MG, 2001, J PEDIATR ORTHOPED, V21, P622, DOI 10.1097/00004694-200109000-00014; Wake M, 2000, DIABETIC MED, V17, P700, DOI 10.1046/j.1464-5491.2000.00360.x; Wake M, 2002, INT J OBESITY, V26, P717, DOI 10.1038/sj.ijo.0801974; Waters E, 2000, AUST NZ J PUBL HEAL, V24, P207, DOI 10.1111/j.1467-842X.2000.tb00145.x; Waters E, 2000, PEDIATRICS, V106, P1422, DOI 10.1542/peds.106.6.1422; Webber LS, 1995, AM J MED SCI, V310, pS53, DOI 10.1097/00000441-199512000-00010; World Health Organization, 2021, WHO GUID HLTH WORKF; [No title captured]	24	443	452	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					70	76		10.1001/jama.293.1.70	http://dx.doi.org/10.1001/jama.293.1.70			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632338				2022-12-28	WOS:000226102100023
J	Cohen, JP; Paquette, C; Cairns, CP				Cohen, JP; Paquette, C; Cairns, CP			Switching prescription drugs to over the counter	BRITISH MEDICAL JOURNAL			English	Article									Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA	Tufts University	Cohen, JP (corresponding author), Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, 192 South St,Suite 550, Boston, MA 02111 USA.	joshua.cohen@tufts.edu						[Anonymous], 2004, LANCET, V363, P1659; *BRIST MYERS SQUIB, ADV COMM M BRIEF BOO; COHEN J, 2003, AM J THER, P1370; DiMasi J, 2001, J RES PHARMA EC, V11, P43, DOI [10.1300/J063v11n03_04, DOI 10.1300/J063V11N03_04]; *MED HEALTHC PROD, 2003, CONS DOC ARM 18 REQ; *NONPR MED AC, JOINT FDA ADV COMM R; *US FDA, FY 2004 FDA BUDG BRI; *WELLP, ISS PAP FDA PET PRES; *WORLD SELF MED IN, OTC INGR TABL	9	42	42	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 1	2005	330	7481					39	41		10.1136/bmj.330.7481.39	http://dx.doi.org/10.1136/bmj.330.7481.39			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15626806	Green Published			2022-12-28	WOS:000226176700021
J	Matthews, T				Matthews, T			Sudden unexpected infant death: infanticide or SIDS?	LANCET			English	Editorial Material									Univ Coll Dublin, Childrens Univ Hosp, Dept Paediat, Dublin 1, Ireland; Rotunda Hosp, Dublin 1, Ireland	Childrens University Hospital - Temple Street; University College Dublin	Matthews, T (corresponding author), Univ Coll Dublin, Childrens Univ Hosp, Dept Paediat, Dublin 1, Ireland.	tommatt@iol.ie						[Anonymous], 2001, ROYAL LIV CHILDR INQ; Bacon CJ, 1997, ARCH DIS CHILD, V76, P171, DOI 10.1136/adc.76.2.171; BECKWITH JB, SUDDEN INFANT DEATH; Carpenter RG, 2004, LANCET, V363, P185, DOI 10.1016/S0140-6736(03)15323-8; EMERY JL, 1985, ARCH DIS CHILD, V60, P505, DOI 10.1136/adc.60.6.505; McGarvey C, 2003, ARCH DIS CHILD, V88, P1058, DOI 10.1136/adc.88.12.1058; Meadow R, 1999, ARCH DIS CHILD, V80, P7, DOI 10.1136/adc.80.1.7; Milroy CM, 2003, BRIT MED J, V326, P294, DOI 10.1136/bmj.326.7384.294; Oyen N, 1996, AM J EPIDEMIOL, V144, P300, DOI 10.1093/oxfordjournals.aje.a008925; Sheehan KM, 2003, J CLIN PATHOL, V56, P753, DOI 10.1136/jcp.56.10.753; VUJANIC GM, 1995, J CLIN PATHOL, V48, P998, DOI 10.1136/jcp.48.11.998; 1999, LANCET, V353, P161	12	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					3	4		10.1016/S0140-6736(04)17673-3	http://dx.doi.org/10.1016/S0140-6736(04)17673-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639658				2022-12-28	WOS:000226213100002
J	Jaenisch, R				Jaenisch, R			Human cloning - The science and ethics of nuclear transportation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), MIT, Cambridge, MA 02139 USA.							Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397; Jaenisch R, 2004, BIOL NUCL CLONING PO; McHugh PR, 2004, NEW ENGL J MED, V351, P209, DOI 10.1056/NEJMp048147	3	84	91	1	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2787	2791		10.1056/NEJMp048304	http://dx.doi.org/10.1056/NEJMp048304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625328				2022-12-28	WOS:000226004300001
J	Bernstein, BE; Kamal, M; Lindblad-Toh, K; Bekiranov, S; Bailey, DK; Huebert, DJ; McMahon, S; Karlsson, EK; Kulbokas, EJ; Gingeras, TR; Schreiber, SL; Lander, ES				Bernstein, BE; Kamal, M; Lindblad-Toh, K; Bekiranov, S; Bailey, DK; Huebert, DJ; McMahon, S; Karlsson, EK; Kulbokas, EJ; Gingeras, TR; Schreiber, SL; Lander, ES			Genomic maps and comparative analysis of histone modifications in human and mouse	CELL			English	Article							DROSOPHILA BITHORAX COMPLEX; BETA-GLOBIN LOCUS; ACTIVE GENES; INTERGENIC TRANSCRIPTION; CHROMATIN; METHYLATION; MEMORY; H3; WIDE; HUMAN-CHROMOSOME-21	We mapped histone H3 lysine 4 di- and trimethylation and lysine 9/14 acetylation across the nonrepetitive portions of human chromosomes 21 and 22 and compared patterns of lysine 4 dimethylation for several orthologous human and mouse loci. Both chromosomes show punctate sites enriched for modified histones. Sites showing trimethylation correlate with transcription starts, while those showing mainly dimethylation occur elsewhere in the vicinity of active genes. Punctate methylation patterns are also evident at the cytokine and IL-4 receptor loci. The Hox clusters present a strikingly different picture, with broad lysine 4-methylated regions that overlay multiple active genes. We suggest these regions represent active chromatin domains required for the maintenance of Hox gene expression. Methylation patterns at orthologous loci are strongly conserved between human and mouse even though many methylated sites do not show sequence conservation notably higher than background. This suggests that the DNA elements that direct the methylation represent only a small fraction of the region or lie at some distance from the site.	Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Broad Inst Harvard, Cambridge, MA 02139 USA; MIT, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Affymetrix, Santa Clara, CA 95051 USA; Whitehead Inst Biomed Res, Cambridge, MA 02139 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Affymetrix; Massachusetts Institute of Technology (MIT); Whitehead Institute	Bernstein, BE (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	bbernst@fas.harvard.edu; lander@broad.mit.edu		Karlsson, Elinor/0000-0002-4343-3776; Gingeras, Thomas/0000-0001-9106-3573	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038627] Funding Source: Medline; PHS HHS [N01-C0-12400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bae E, 2002, P NATL ACAD SCI USA, V99, P16847, DOI 10.1073/pnas.222671299; Benson DA, 2004, NUCLEIC ACIDS RES, V32, pD23, DOI 10.1093/nar/gkh045; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Blanchette M, 2004, GENOME RES, V14, P708, DOI 10.1101/gr.1933104; Bolland DJ, 2004, NAT IMMUNOL, V5, P630, DOI 10.1038/ni1068; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hollander M., 2014, NONPARAMETRIC STAT M, V3rd ed.; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Liu CL, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-19; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Rank G, 2002, MOL CELL BIOL, V22, P8026, DOI 10.1128/MCB.22.22.8026-8034.2002; Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Smith ST, 2004, NAT CELL BIOL, V6, P162, DOI 10.1038/ncb1088; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	46	1135	1175	1	80	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					169	181		10.1016/j.cell.2005.01.001	http://dx.doi.org/10.1016/j.cell.2005.01.001			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680324	Bronze			2022-12-28	WOS:000226740000007
J	Alvarez-Vasquez, F; Sims, KJ; Cowart, LA; Okamoto, Y; Voit, EO; Hannun, YA				Alvarez-Vasquez, F; Sims, KJ; Cowart, LA; Okamoto, Y; Voit, EO; Hannun, YA			Simulation and validation of modelled sphingolipid metabolism in Saccharomyces cerevisiae	NATURE			English	Article							BINDING-PROTEIN; STRESS; SPHINGOSINE-1-PHOSPHATE; INHIBITION; CERAMIDE; SYSTEMS; GENE	Mathematical models have become a necessary tool for organizing the rapidly increasing amounts of large-scale data on biochemical pathways and for advanced evaluation of their structure and regulation. Most of these models have addressed specific pathways using either stoichiometric(1) or flux-balance analysis(2), or fully kinetic Michaelis - Menten representations(3), metabolic control analysis(4), or biochemical systems theory(5-7). So far, the predictions of kinetic models have rarely been tested using direct experimentation. Here, we validate experimentally a biochemical systems theoretical model of sphingolipid metabolism in yeast(8). Simulations of metabolic fluxes, enzyme deletion and the effects of inositol ( a key regulator of phospholipid metabolism) led to predictions that show significant concordance with experimental results generated post hoc. The model also allowed the simulation of the effects of acute perturbations in fatty-acid precursors of sphingolipids, a situation that is not amenable to direct experimentation. The results demonstrate that modelling now allows testable predictions as well as the design and evaluation of hypothetical 'thought experiments' that may generate new metabolomic approaches.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Emory Med Sch, Atlanta, GA 30332 USA	Medical University of South Carolina; Medical University of South Carolina; University System of Georgia; Georgia Institute of Technology	Voit, EO (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	eberhard.voit@bme.gatech.edu; hannun@musc.edu	OKAMOTO, Yasuo/J-8438-2015	Alvarez-Vasquez, Fernando/0000-0003-4008-9858				Alvarez-Vasquez F, 2004, J THEOR BIOL, V226, P265, DOI 10.1016/j.jtbi.2003.08.010; BIELAWSKA J, IN PRESS SIMULTANEOU; Fell D., 1997, UNDERSTANDING CONTRO; FERREIRA AEN, 1995, PLAS WINDOWS; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Heinrich R., 1996, REGULATION CELLULAR; JENKINS GM, 1999, APOPTOSIS PRACTICAL; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; MANDALA SM, 1994, J ANTIBIOT, V47, P376, DOI 10.7164/antibiotics.47.376; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mulquiney P. J., 2003, MODELING METABOLISM; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P365, DOI 10.1016/S0022-5193(69)80026-3; Schilling CH, 2000, BIOTECHNOL BIOENG, V71, P286, DOI 10.1002/1097-0290(2000)71:4<286::AID-BIT1018>3.0.CO;2-R; Shirra MK, 2001, MOL CELL BIOL, V21, P5710, DOI 10.1128/MCB.21.17.5710-5722.2001; Sims KJ, 2004, BIOCHEM CELL BIOL, V82, P45, DOI 10.1139/o03-086; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Voit E. O., 2000, COMPUTATIONAL ANAL B; Voit EO, 2004, MATH BIOSCI, V191, P83, DOI 10.1016/j.mbs.2004.04.004; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	26	125	126	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					425	430		10.1038/nature03232	http://dx.doi.org/10.1038/nature03232			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674294				2022-12-28	WOS:000226546200045
J	Czupryniak, L; Loba, J				Czupryniak, L; Loba, J			Unrecognised comorbidities	LANCET			English	Editorial Material									Med Univ Lodz, Barlicki Univ Hosp No 1, Dept Diabetol, PL-90153 Lodz, Poland	Medical University Lodz	Czupryniak, L (corresponding author), Med Univ Lodz, Barlicki Univ Hosp No 1, Dept Diabetol, PL-90153 Lodz, Poland.								0	0	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2005	365	9456					357	357						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664234				2022-12-28	WOS:000226449600042
J	El Nahas, AM; Bello, AK				El Nahas, AM; Bello, AK			Chronic kidney disease: the global challenge	LANCET			English	Review							STAGE RENAL-DISEASE; BLOOD-PRESSURE CONTROL; GROWTH-FACTOR; BONE-MARROW; CARDIOVASCULAR-DISEASE; RISK-FACTOR; DIABETES PREVENTION; COST-EFFECTIVENESS; PROGRESSION; END	The worldwide rise in the number of patients with chronic kidney disease (CKD) and consequent end-stage renal failure necessitating renal replacement therapy is threatening to reach epidemic proportions over the next decade, and only a small number of countries have robust economies able to meet the challenges posed. A change in global approach to CKD from treatment of end-stage renal disease (ESRD) to much more aggressive primary and secondary prevention is therefore imperative. In this Seminar, we examine the epidemiology of CKD worldwide, with emphasis on early detection and prevention, and the feasibility of methods for detection and primary prevention of CKD. We also review the risk factors and markers of progressive CKD. We explore current understanding of the mechanisms underlying renal scarring leading to ESRD to inform on current and future interventions as well as evidence relating to interventions to slow the progression of CKD. Finally, we make strategic recommendations based on future research to stem the worldwide growth of CKD. Consideration is given to health economics. A global and concerted approach to CKD must be adopted in both more and less developed countries to avoid a major catastrophe.	Univ Sheffield, Sheffield Teaching Hosp NHS Fdn Trust, Sheffield Kidney Inst, Sheffield S5 7AU, S Yorkshire, England	University of Sheffield	El Nahas, AM (corresponding author), Univ Sheffield, Sheffield Teaching Hosp NHS Fdn Trust, Sheffield Kidney Inst, No Gen Hosp Campus, Sheffield S5 7AU, S Yorkshire, England.	m.el-nahas@sheffield.ac.uk	Bello, Aminu K/D-2213-2013; Wilson, Matthew H/K-3193-2013; zhao, yong/C-7712-2009	Bello, Aminu K/0000-0002-6905-5937				Adler AI, 2003, KIDNEY INT, V63, P225, DOI 10.1046/j.1523-1755.2003.00712.x; Appel LJ, 2003, J AM SOC NEPHROL, V14, pS99, DOI 10.1097/01.ASN.0000070141.69483.5A; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Basile DP, 1999, CURR OPIN NEPHROL HY, V8, P21, DOI 10.1097/00041552-199901000-00005; Beaglehole R., 2003, WORLD HLTH REPORT 20; Bergman S, 1996, AM J KIDNEY DIS, V27, P341, DOI 10.1016/S0272-6386(96)90356-X; Bonnet F, 2001, AM J KIDNEY DIS, V37, P720, DOI 10.1016/S0272-6386(01)80120-7; Boulware LE, 2003, JAMA-J AM MED ASSOC, V290, P3101, DOI 10.1001/jama.290.23.3101; BRENNER BM, 1994, AM J KIDNEY DIS, V23, P171, DOI 10.1016/S0272-6386(12)80967-X; Brown WW, 2003, AM J KIDNEY DIS, V42, P22, DOI 10.1016/S0272-6386(03)00405-0; Buck K, 1997, NEPHROL DIAL TRANSPL, V12, P1555, DOI 10.1093/ndt/12.8.1555; Chadban SJ, 2003, J AM SOC NEPHROL, V14, pS131, DOI 10.1097/01.ASN.0000070152.11927.4A; Chen MLW, 2003, AM J KIDNEY DIS, V42, P623, DOI 10.1016/S0272-6386(03)00870-9; Clase CM, 2002, J AM SOC NEPHROL, V13, P2812; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Cornacchia F, 2001, J CLIN INVEST, V108, P1649; Craig JC, 2002, INTERN MED J, V32, P6, DOI 10.1046/j.1445-5994.2002.d01-11.x; Cybulsky AV, 2000, CURR OPIN NEPHROL HY, V9, P217, DOI 10.1097/00041552-200005000-00003; de Jong PE, 2002, INT J OBESITY, V26, pS21, DOI 10.1038/sj.ijo.0802213; De Vecchi AF, 1999, NEPHROL DIAL TRANSPL, V14, P31, DOI 10.1093/ndt/14.suppl_6.31; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; El Nahas AM, 2003, KIDNEY INT, V64, P1553, DOI 10.1046/j.1523-1755.2003.00255.x; ELNAHAS AM, 1988, NEPHROLOGY, V2, P1206; Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x; Feldman HI, 2003, J AM SOC NEPHROL, V14, pS148, DOI 10.1097/01.ASN.0000070149.78399.CE; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Frame P S, 1975, J Fam Pract, V2, P189; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Golan L, 1999, ANN INTERN MED, V131, P660, DOI 10.7326/0003-4819-131-9-199911020-00005; Guan YF, 2001, KIDNEY INT, V60, P14, DOI 10.1046/j.1523-1755.2001.00766.x; Hallan S, 2004, AM J KIDNEY DIS, V44, P84, DOI 10.1053/j.ajkd.2004.03.027; HANNEDOUCHE T, 1993, CLIN NEPHROL, V39, P312; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Haroun MK, 2003, J AM SOC NEPHROL, V14, P2934, DOI 10.1097/01.ASN.0000095249.99803.85; Hebert LA, 2001, KIDNEY INT, V59, P1211, DOI 10.1046/j.1523-1755.2001.0590041211.x; Hilgers KF, 2004, PEDIATR NEPHROL, V19, P956, DOI 10.1007/s00467-004-1554-5; Hillege HL, 2002, CIRCULATION, V106, P1777, DOI 10.1161/01.CIR.0000031732.78052.81; Hillege HL, 2001, J INTERN MED, V249, P519, DOI 10.1046/j.1365-2796.2001.00833.x; Hsu CY, 2003, J AM SOC NEPHROL, V14, P2902, DOI 10.1097/01.ASN.0000091586.46532.B4; Hsu CY, 2002, KIDNEY INT, V61, P1567, DOI 10.1046/j.1523-1755.2002.00299.x; Imai E, 2002, CURR OPIN NEPHROL HY, V11, P49, DOI 10.1097/00041552-200201000-00008; Imasawa T, 2002, EXP NEPHROL, V10, P51; Imasawa T, 2001, J AM SOC NEPHROL, V12, P1401, DOI 10.1681/ASN.V1271401; *INT OB TASK FORC, 2002, WORLD HLTH DAY APR 7; Iseki K, 2003, KIDNEY INT, V63, P1468, DOI 10.1046/j.1523-1755.2003.00868.x; Iseki K, 2003, J AM SOC NEPHROL, V14, pS127, DOI 10.1097/01.ASN.0000070153.91733.09; Ito T, 2001, J AM SOC NEPHROL, V12, P2625, DOI 10.1681/ASN.V12122625; Iwano M, 2004, CURR OPIN NEPHROL HY, V13, P279, DOI 10.1097/00041552-200405000-00003; Jafar TH, 2003, ANN INTERN MED, V139, P244, DOI 10.7326/0003-4819-139-4-200308190-00006; Johnson RJ, 1999, AM J KIDNEY DIS, V33, P225, DOI 10.1016/S0272-6386(99)70295-7; Jungers P, 1996, NEPHROL DIAL TRANSPL, V11, P1542; K/DOQI work group, 2004, AM J KIDNEY DIS S, V43, P1; Kambham N, 2001, KIDNEY INT, V59, P1498, DOI 10.1046/j.1523-1755.2001.0590041498.x; Kang DH, 2003, CURR OPIN NEPHROL HY, V12, P43, DOI 10.1097/00041552-200301000-00008; KEANE WF, 1991, AM J KIDNEY DIS, V17, P38; Keane WF, 1999, AM J KIDNEY DIS, V33, P1004, DOI 10.1016/S0272-6386(99)70442-7; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Klag M J, 1996, Curr Opin Nephrol Hypertens, V5, P236, DOI 10.1097/00041552-199605000-00009; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Lindstrom J, 2003, J AM SOC NEPHROL, V14, pS108, DOI 10.1097/01.ASN.0000070157.96264.13; Ludewig D, 2000, CELL TISSUE RES, V299, P97, DOI 10.1007/s004419900118; Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37; Mattix HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341034; McClellan WM, 2003, J AM SOC NEPHROL, V14, pS81, DOI 10.1097/01.ASN.0000070144.86024.04; McDonald SP, 2002, AM J KIDNEY DIS, V40, P1122, DOI 10.1053/ajkd.2002.36943; Molitch ME, 2003, J AM SOC NEPHROL, V14, pS103, DOI 10.1097/01.ASN.0000070140.62190.97; MORLANS M, 1990, BRIT J CLIN PHARMACO, V30, P717, DOI 10.1111/j.1365-2125.1990.tb03841.x; Moser Marvin, 2004, J Clin Hypertens (Greenwich), V6, P4, DOI 10.1111/j.1524-6175.2004.03830.x; Orth SR, 1998, KIDNEY INT, V54, P926, DOI 10.1046/j.1523-1755.1998.00067.x; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Pereira BJG, 2000, KIDNEY INT, V57, P351, DOI 10.1046/j.1523-1755.2000.00840.x; Perneger TV, 2001, AM J KIDNEY DIS, V38, P49, DOI 10.1053/ajkd.2001.25181; Perneger TV, 1999, AM J EPIDEMIOL, V150, P1275, DOI 10.1093/oxfordjournals.aje.a009958; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; Pinto-Sietsma SJ, 2000, ANN INTERN MED, V133, P585, DOI 10.7326/0003-4819-133-8-200010170-00008; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Remuzzi G, 2002, ANN INTERN MED, V136, P604, DOI 10.7326/0003-4819-136-8-200204160-00010; Rockhill B, 2000, EPIDEMIOL REV, V22, P176, DOI 10.1093/oxfordjournals.epirev.a018017; Ruggenenti P, 2001, LANCET, V357, P1601, DOI 10.1016/S0140-6736(00)04728-0; SAMAK MJ, 2003, CIRCULATION, V108, P2154; Savoca MR, 2004, ARCH PEDIAT ADOL MED, V158, P473, DOI 10.1001/archpedi.158.5.473; Schaeffner ES, 2003, J AM SOC NEPHROL, V14, P2084, DOI 10.1681/ASN.V1482084; Schieppati A, 2003, ACTA PAEDIATR, V92, P9, DOI 10.1080/08035320310000384; Schieppati A, 2003, KIDNEY INT, V63, P1948, DOI 10.1046/j.1523-1755.2003.00926.x; Schrier RW, 2000, NEW ENGL J MED, V343, P1969, DOI 10.1056/NEJM200012283432614; Shankland SJ, 1999, KIDNEY INT, V56, P1208, DOI 10.1046/j.1523-1755.1999.00709.x; Sharpe CC, 2003, J AM SOC NEPHROL, V14, P261, DOI 10.1097/01.ASN.0000048223.05219.E4; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; The Renal Association, 6 REN ASS UK REN REG; Tofovic SP, 1999, J CARDIOVASC PHARM, V33, P360, DOI 10.1097/00005344-199903000-00003; Trivedi HS, 2002, AM J KIDNEY DIS, V39, P721, DOI 10.1053/ajkd.2002.31990; *US REN DAT SYST, 2003, AM J KIDNEY DIS S, V42, pS37; VERANI RR, 1992, AM J KIDNEY DIS, V20, P629, DOI 10.1016/S0272-6386(12)70230-5; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wardle EN, 2002, NEPHRON, V90, P239, DOI 10.1159/000049056; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Zeisberg M, 2001, CURR OPIN NEPHROL HY, V10, P315, DOI 10.1097/00041552-200105000-00004; Zoja C, 2002, J AM SOC NEPHROL, V13, P2898, DOI 10.1097/01.ASN.0000034912.55186.EC	104	845	889	1	84	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					331	340		10.1016/S0140-6736(05)17789-7	http://dx.doi.org/10.1016/S0140-6736(05)17789-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664230				2022-12-28	WOS:000226449600038
J	Hailigan, S; Atkin, W				Hailigan, S; Atkin, W			Unbiased studies are needed before virtual colonoscopy can be dismissed	LANCET			English	Editorial Material							COLORECTAL NEOPLASIA; COLONOGRAPHY; RATES		St Marks Hosp, Dept Intestinal Imaging, Harrow HA1 3UJ, Middx, England; St Marks Hosp, Canc Res UK Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Imperial College London; Imperial College London	Hailigan, S (corresponding author), St Marks Hosp, Dept Intestinal Imaging, Northwick Pk, Harrow HA1 3UJ, Middx, England.	s.halligan@imperial.ac.uk		Halligan, Steve/0000-0003-0632-5108				Atkin W, 2004, GASTROENTEROLOGY, V126, P1247, DOI 10.1053/j.gastro.2004.01.023; BURLING D, 2004, ESGAR ANN M GEN; Cotton PB, 2004, JAMA-J AM MED ASSOC, V291, P1713, DOI 10.1001/jama.291.14.1713; Ferrucci J, 2004, JAMA-J AM MED ASSOC, V292, P431, DOI 10.1001/jama.292.4.431-b; Fletcher RH, 2000, NEW ENGL J MED, V342, P1823, DOI 10.1056/NEJM200006153422409; Halligan S, 2004, JAMA-J AM MED ASSOC, V292, P432, DOI 10.1001/jama.292.4.432-a; Halligan S, 2003, CLIN RADIOL, V58, P948, DOI 10.1016/S0009-9260(03)00317-9; HALLIGAN S, 2004, EUR RADIOL, V14, P15; Illes J, 2003, RADIOLOGY, V228, P346, DOI 10.1148/radiol.2282021083; Pickhardt PJ, 2003, NEW ENGL J MED, V349, P2191, DOI 10.1056/NEJMoa031618; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Taylor SA, 2004, EUR RADIOL, V14, P1025, DOI 10.1007/s00330-004-2262-z; Vining DJ, 1994, AM J ROENTGENOL, V162, P104	13	15	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					275	276						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664205				2022-12-28	WOS:000226449600006
J	Schulz, HN; Schulz, HD				Schulz, HN; Schulz, HD			Large sulfur bacteria and the formation of phosphorite	SCIENCE			English	Article							WASTE-WATER; SEDIMENTS; OXYGEN; PHOSPHOGENESIS; POLYPHOSPHATE; REMOVAL	Phosphorite deposits in marine sediments are a long-term sink for an essential nutrient, phosphorus. Here we show that apatite abundance in sediments on the Namibian shelf correlates with the abundance and activity of the giant sulfur bacterium Thiomargarita namibiensis, which suggests that sulfur bacteria drive phosphogenesis. Sediments populated by Thiomargarita showed sharp peaks of pore water phosphate (less than or equal to300 micromolar) and massive phosphorite accumulations (greater than or equal to50 grams of phosphorus per kilogram). Laboratory experiments revealed that under anoxic conditions, Thiomargarita released enough phosphate to account for the precipitation of hydroxyapatite observed in the environment.	Univ Hannover, Inst Microbiol, D-30167 Hannover, Germany; Univ Bremen, Dept Geosci, D-28359 Bremen, Germany	Leibniz University Hannover; University of Bremen	Schulz, HN (corresponding author), Univ Hannover, Inst Microbiol, Schneiderberg 50, D-30167 Hannover, Germany.	schulz@ifmb.uni-hannover.de	Schulz-Vogt, Heide/I-1397-2012	Schulz-Vogt, Heide/0000-0003-1445-0291				Follmi KB, 1996, EARTH-SCI REV, V40, P55, DOI 10.1016/0012-8252(95)00049-6; GALLARDO VA, 1977, NATURE, V268, P331, DOI 10.1038/268331a0; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KRAJEWSKI KP, 1994, ECLOGAE GEOL HELV, V87, P701; Larkin JM, 1996, MICROSC RES TECHNIQ, V33, P23; MAIER S, 1990, CAN J MICROBIOL, V36, P438, DOI 10.1139/m90-077; Mino T, 2000, BIOCHEMISTRY-MOSCOW+, V65, P341; NATHAN Y, 1993, GEOMICROBIOL J, V11, P69, DOI 10.1080/01490459309377935; Parkhurst D.L, 1999, WATER RESOUR INVESTI; Reimers CE, 1996, GEOCHIM COSMOCHIM AC, V60, P4037, DOI 10.1016/S0016-7037(96)00231-1; REIMERS CE, 1990, PHOSPHATE DEPOSITS W, V3, P300; Schenau S, 2000, MAR GEOL, V169, P1, DOI 10.1016/S0025-3227(00)00083-9; Schmaljohann R, 2001, MAR ECOL PROG SER, V220, P295; SCHULZ HD, 2000, MARINE GEOCHEMISTRY, P417; Schulz HN, 2002, APPL ENVIRON MICROB, V68, P5746, DOI 10.1128/AEM.68.11.5746-5749.2002; Schulz HN, 1999, SCIENCE, V284, P493, DOI 10.1126/science.284.5413.493; Thiede J., 1983, COASTAL UPWELLING, VB, P11; vanLoosdrecht MCM, 1997, ANTON LEEUW INT J G, V71, P109, DOI 10.1023/A:1000150523030; WILLIAMS LA, 1983, GEOLOGY, V11, P267, DOI 10.1130/0091-7613(1983)11<267:ROBMIO>2.0.CO;2	19	292	302	5	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2005	307	5708					416	418		10.1126/science.1103096	http://dx.doi.org/10.1126/science.1103096			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662012				2022-12-28	WOS:000226492300044
J	Bilukha, OO; Brennan, M				Bilukha, OO; Brennan, M			Injuries and deaths caused by unexploded ordnance in Afganistan: review of surveillance data, 1997-2002	BMJ-BRITISH MEDICAL JOURNAL			English	Article								In 2000-2, Afghanistan had the highest number of casualties due to landmines and unexploded ordnance in the world.(1) Increasing international awareness of the public health threat posed by landmines is the legacy of the International Campaign to Ban Landmines. More attention must be paid to, the growing and equally deadly threat posed by unexploded ordnance.	Ctr Dis Control & Prevent, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Bilukha, OO (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop C-09, Atlanta, GA 30341 USA.	obilukha@cdc.gov	Bilukha, Oleg/ABC-5095-2020					Gall C, 2002, NY TIMES, pA15; *HUM RIGHTS WATCH, 2001, LANDM US AFGH; *INT CAMP BAN LAND, 2002, LANDM MON REP 2003; *INT COMM RED CROS, 2002, SEM REP JAN JUN 2002	4	11	11	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 15	2005	330	7483					127	128		10.1136/bmj.38337.361782.82	http://dx.doi.org/10.1136/bmj.38337.361782.82			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889PM	15640249	Green Published, Bronze			2022-12-28	WOS:000226454900019
J	Ritson, B				Ritson, B			ABC of alcohol - Treatment for alcohol related problems	BRITISH MEDICAL JOURNAL			English	Review								When hazardous or harmful drinking is first identified in primary care or the hospital setting, patients should be offered brief intervention. This consists of 10 minutes of discussion and explanation, provision of a self-help booklet, and the offer of a further appointment in one or two weeks. Its cost effectiveness has been proved, although time may have to be set aside rather than trying to undertake intervention within normal practice. Training and employing a member of staff for die purpose is worth consideration.	Royal Edinburgh & Associated Hosp, Edinburgh EH10 5HD, Midlothian, Scotland	Royal Infirmary of Edinburgh		drbruceritson@zoom.co.uk						Edwards G., 2003, TREATMENT DRINKING P; FREEMANTLE N, 1993, EFFECTIVE HLTH CARE, V7, P1; Fuller RK, 2004, ADDICTION, V99, P21, DOI 10.1111/j.1360-0443.2004.00597.x; Garbutt JC, 1999, JAMA-J AM MED ASSOC, V281, P1318, DOI 10.1001/jama.281.14.1318; Miller WR, 2002, ADDICTION, V97, P265, DOI 10.1046/j.1360-0443.2002.00019.x; SLATTERY J, 2002, PREVENTION RELAPSE A	6	6	7	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 15	2005	330	7483					139	141		10.1136/bmj.330.7483.139	http://dx.doi.org/10.1136/bmj.330.7483.139			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889PM	15649930	Green Published			2022-12-28	WOS:000226454900026
J	Huibregtse, JM				Huibregtse, JM			UPS shipping and handling	CELL			English	Editorial Material							PROTEASOME; RECEPTORS; RAD23	It is now clear that the two broad sets of reactions in the ubiquitin-proteasome system (UPS), the conjugative and degradative steps, are intricately coupled in vivo and that there are numerous factors that aid in the handling and delivery of ubiquitylated proteins to the proteasome. The report from Richly et al. (2005 [this issue of CeII]) suggests how several of the known players in this process might work together in guiding and delivering some substrates to their final destinations.	Univ Texas, Inst Cellular & Mol Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Huibregtse, JM (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.							Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Kim I, 2004, MOL BIOL CELL, V15, P3357, DOI 10.1091/mbc.E03-11-0835; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Shcherbik N, 2004, J BIOL CHEM, V279, P53892, DOI 10.1074/jbc.M410325200; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014	7	6	6	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 14	2005	120	1					2	4		10.1016/j.cell.2004.12.029	http://dx.doi.org/10.1016/j.cell.2004.12.029			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652473	Bronze			2022-12-28	WOS:000226365400002
J	Krivorotov, IN; Emley, NC; Sankey, JC; Kiselev, SI; Ralph, DC; Buhrman, RA				Krivorotov, IN; Emley, NC; Sankey, JC; Kiselev, SI; Ralph, DC; Buhrman, RA			Time-domain measurements of nanomagnet dynamics driven by spin-transfer torques	SCIENCE			English	Article							MAGNETIZATION REVERSAL	We present time-resolved measurements of gigahertz-scale magnetic dynamics caused by torque from a spin-polarized current. By working in the time domain, we determined the motion of the magnetic moment throughout the process of spin-transfer-driven switching, and we measured turn-on times of steady-state precessional modes. Time-resolved studies of magnetic relaxation allow for the direct measurement of magnetic damping in a nanomagnet and prove that this damping can be controlled electrically using spin-polarized currents.	Cornell Univ, Ithaca, NY 14853 USA	Cornell University	Krivorotov, IN (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.	ink3@cornell.edu	Krivorotov, Ilya/Q-5760-2019; Ralph, Daniel C/G-3251-2010; Sankey, Jack C/K-5072-2012; Sankey, Jack C/H-1373-2012	Krivorotov, Ilya/0000-0002-1658-2565; Childress (Sankey), Jack/0000-0002-7997-8727				Bazaliy YB, 1998, PHYS REV B, V57, pR3213, DOI 10.1103/PhysRevB.57.R3213; Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; Covington M, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.184406; Fabian A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.257209; Grollier J, 2001, APPL PHYS LETT, V78, P3663, DOI 10.1063/1.1374230; Heinrich B, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.187601; Katine JA, 2000, PHYS REV LETT, V84, P3149, DOI 10.1103/PhysRevLett.84.3149; Kiselev SI, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.036601; Kiselev SI, 2003, NATURE, V425, P380, DOI 10.1038/nature01967; Koch RH, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.088302; Koch RH, 1998, PHYS REV LETT, V81, P4512, DOI 10.1103/PhysRevLett.81.4512; Krivorotov IN, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.166603; Miltat J, 2001, J APPL PHYS, V89, P6982, DOI 10.1063/1.1355329; Mizukami S, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.104413; Myers EB, 1999, SCIENCE, V285, P867, DOI 10.1126/science.285.5429.867; Ozyilmaz B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.067203; Pufall MR, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.214409; Slonczcwski JC, 2002, J MAGN MAGN MATER, V247, P324, DOI 10.1016/S0304-8853(02)00291-3; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Stiles MD, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.014407; Sun JZ, 2000, PHYS REV B, V62, P570, DOI 10.1103/PhysRevB.62.570; Sun JZ, 1999, J MAGN MAGN MATER, V202, P157, DOI 10.1016/S0304-8853(99)00289-9; Tserkovnyak Y, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.140404; Tsoi M, 2000, NATURE, V406, P46, DOI 10.1038/35017512; Tsoi M, 1998, PHYS REV LETT, V81, P493, DOI 10.1103/PhysRevLett.81.493; Urazhdin S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.146803; Wegrowe JE, 1999, EUROPHYS LETT, V45, P626, DOI 10.1209/epl/i1999-00213-1; Zhu XC, 2004, J APPL PHYS, V95, P7318, DOI 10.1063/1.1689908	29	466	484	4	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					228	231		10.1126/science.1105722	http://dx.doi.org/10.1126/science.1105722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653496				2022-12-28	WOS:000226361900034
J	Moncada, S				Moncada, S			John R. Vane (1927-2004) - Obituary	NATURE			English	Biographical-Item									UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Moncada, S (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	s.moncada@ucl.ac.uk							0	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2005	433	7021					28	28		10.1038/433028a	http://dx.doi.org/10.1038/433028a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635398	Bronze			2022-12-28	WOS:000226117100023
J	Poland, GA				Poland, GA			Smallpox vaccines: from first to second to third generation	LANCET			English	Editorial Material							VACCINATION		Mayo Clin, Dept Internal Med, Mayo Vaccine Res Grp, Rochester, MN 55905 USA; Mayo Clin, Dept Internal Med, Program Translat Immunovirol & Biodef, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Poland, GA (corresponding author), Mayo Clin, Dept Internal Med, Mayo Vaccine Res Grp, Rochester, MN 55905 USA.	poland.gregory@mayo.edu						*CDCP, 2003, MMWR-MORBID MORTAL W, V52, P475; *CDCP, 2004, SMALLP VACC VACC CON; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; Poland GA, 2003, IMMUNOL ALLERGY CLIN, V23, P731, DOI 10.1016/S0889-8561(03)00096-1	5	14	14	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					362	363						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680437				2022-12-28	WOS:000226610900004
J	Katz, D; Aharoni, D				Katz, D; Aharoni, D			Lytic lesions in breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hadassah Hebrew Univ, Med Ctr, IL-91120 Jerusalem, Israel; Shaare Zedek Med Ctr, IL-91031 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Katz, D (corresponding author), Hadassah Hebrew Univ, Med Ctr, IL-91120 Jerusalem, Israel.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2850	2850		10.1056/NEJMicm040763	http://dx.doi.org/10.1056/NEJMicm040763			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625336				2022-12-28	WOS:000226004300010
J	Morgan, JF; Murphy, H; Lacey, JH; Conway, G				Morgan, JF; Murphy, H; Lacey, JH; Conway, G			Long term psychological outcome for women with congenital adrenal hyperplasia: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							INTERSEX		Univ London St Georges Hosp, Sch Med, Dept Mental Hlth, London SW17 0RE, England; Middlesex Hosp, Dept Endocrinol, London W1T 3AA, England	St Georges University London; University of London; University College London	Morgan, JF (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Mental Hlth, London SW17 0RE, England.	jmorgan@sghms.ac.uk						COOPER P, 1982, BRIT J PSYCHIAT, V141, P68, DOI 10.1192/bjp.141.1.68; Creighton S, 2001, BMJ-BRIT MED J, V323, P1264, DOI 10.1136/bmj.323.7324.1264; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Meyer-Bahlburg HFL, 2001, ENDOCRIN METAB CLIN, V30, P155, DOI 10.1016/S0889-8529(08)70024-0; Slijper FME, 1998, ARCH SEX BEHAV, V27, P125, DOI 10.1023/A:1018670129611	5	27	27	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 12	2005	330	7487					340	341		10.1136/bmj.38334.427361.D3	http://dx.doi.org/10.1136/bmj.38334.427361.D3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15677365	Bronze, Green Published			2022-12-28	WOS:000227015800018
J	Otomo, T; Tomchick, DR; Otomo, C; Panchal, SC; Machius, M; Rosen, MK				Otomo, T; Tomchick, DR; Otomo, C; Panchal, SC; Machius, M; Rosen, MK			Structural basis of actin filament nucleation and processive capping by a formin homology 2 domain	NATURE			English	Article							DIAPHANOUS-RELATED FORMINS; DIFFRACTION DATA; FISSION YEAST; CELL-DIVISION; MOUSE FORMIN; PROFILIN; PROTEIN; POLYMERIZATION; CYTOKINESIS; MECHANISM	The conserved formin homology 2 (FH2) domain nucleates actin filaments and remains bound to the barbed end of the growing filament. Here we report the crystal structure of the yeast Bni1p FH2 domain in complex with tetramethylrhodamine - actin. Each of the two structural units in the FH2 dimer binds two actins in an orientation similar to that in an actin filament, suggesting that this structure could function as a filament nucleus. Biochemical properties of heterodimeric FH2 mutants suggest that the wild-type protein equilibrates between two bound states at the barbed end: one permitting monomer binding and the other permitting monomer dissociation. Interconversion between these states allows processive barbed-end polymerization and depolymerization in the presence of bound FH2 domain. Kinetic and/or thermodynamic differences in the conformational and binding equilibria can explain the variable activity of different FH2 domains as well as the effects of the actin-binding protein profilin on FH2 function.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rosen, MK (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mrosen@biochem.swmed.edu	Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643; Otomo, Takanori/0000-0003-3589-238X				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang F, 1999, CURR BIOL, V9, P849, DOI 10.1016/S0960-9822(99)80372-8; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DeLano WL, 2002, PYMOL USERS MANUAL; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Evangelista Marie, 2002, Nature Cell Biology, V4, P260; Galkin VE, 2002, CURR BIOL, V12, P570, DOI 10.1016/S0960-9822(02)00742-X; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Mogilner A, 2003, CURR BIOL, V13, pR721, DOI 10.1016/j.cub.2003.08.050; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Schmid MF, 2004, NATURE, V431, P104, DOI 10.1038/nature02881; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	36	272	277	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					488	494		10.1038/nature03251	http://dx.doi.org/10.1038/nature03251			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15635372				2022-12-28	WOS:000226727200039
J	Diemand, J; Moore, B; Stadel, J				Diemand, J; Moore, B; Stadel, J			Earth-mass dark-matter haloes as the first structures in the early Universe	NATURE			English	Article							DENSITY PROFILES; SUPERNOVAE; CLUSTERS; PROJECT; LAMBDA; CDM	The Universe was nearly smooth and homogeneous before a redshift of z = 100, about 20 million years after the Big Bang(1). After this epoch, the tiny fluctuations imprinted upon the matter distribution during the initial expansion began to collapse because of gravity. The properties of these fluctuations depend on the unknown nature of dark matter(2-4), the determination of which is one of the biggest challenges in present-day science(5-7). Here we report supercomputer simulations of the concordance cosmological model, which assumes neutralino dark matter ( at present the preferred candidate), and find that the first objects to form are numerous Earth-mass dark-matter haloes about as large as the Solar System. They are stable against gravitational disruption, even within the central regions of the Milky Way. We expect over 10(15) to survive within the Galactic halo, with one passing through the Solar System every few thousand years. The nearest structures should be among the brightest sources of gamma-rays ( from particle - particle annihilation).	Univ Zurich, Inst Theoret Phys, CH-8057 Zurich, Switzerland	University of Zurich	Moore, B (corresponding author), Univ Zurich, Inst Theoret Phys, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	moore@physik.unizh.ch	Diemand, Juerg/G-9448-2011	Stadel, Joachim Gerhard/0000-0001-7565-8622				Berezinsky V, 2003, PHYS REV D, V68, DOI 10.1103/PhysRevD.68.103003; Bergstrom L, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.043506; BERTONE G, 2004, PARTICLE DARK MATTER; Bertschinger E, 2001, ASTROPHYS J SUPPL S, V137, P1, DOI 10.1086/322526; Calcaneo-Roldan C, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.123005; COGAN P, 2004, OVERVIEW VERITAS PRO; CORTINA J, 2004, STATUS 1 RESULTS MAG; Diemand J, 2004, MON NOT R ASTRON SOC, V352, P535, DOI 10.1111/j.1365-2966.2004.07940.x; Diemand J, 2004, MON NOT R ASTRON SOC, V353, P624, DOI 10.1111/j.1365-2966.2004.08094.x; Ellis J, 2002, NEW J PHYS, V4, DOI 10.1088/1367-2630/4/1/332; Green AM, 2004, MON NOT R ASTRON SOC, V353, pL23, DOI 10.1111/j.1365-2966.2004.08232.x; Hinton JA, 2004, NEW ASTRON REV, V48, P331, DOI 10.1016/j.newar.2003.12.004; Hofmann S, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.083507; Jungman G, 1996, PHYS REP, V267, P195, DOI 10.1016/0370-1573(95)00058-5; Koushiappas SM, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.043501; LAKE G, 1990, NATURE, V346, P39, DOI 10.1038/346039a0; Moore B, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.063508; Mori M, 2001, AIP CONF PROC, V558, P578, DOI 10.1063/1.1370827; PEEBLES PJE, 1982, ASTROPHYS J, V263, pL1, DOI 10.1086/183911; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; PRADA F, 2004, ASTROPHYSICAL INPUTS; Reed D, 2003, MON NOT R ASTRON SOC, V346, P565, DOI 10.1046/j.1365-2966.2003.07113.x; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Schmidt R, 1998, ASTRON ASTROPHYS, V335, P379; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; Tasitsiomi A, 2004, ASTROPHYS J, V607, P125, DOI 10.1086/383219; Tegmark M, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.103501; Tegmark M, 1997, ASTROPHYS J, V474, P1, DOI 10.1086/303434; Turner MS, 2002, ASTROPHYS J, V576, pL101, DOI 10.1086/343782	30	333	334	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2005	433	7024					389	391		10.1038/nature03270	http://dx.doi.org/10.1038/nature03270			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674284				2022-12-28	WOS:000226546200035
J	Grassly, NC; Fraser, C; Garnett, GP				Grassly, NC; Fraser, C; Garnett, GP			Host immunity and synchronized epidemics of syphilis across the United States	NATURE			English	Article							TRANSMISSION DYNAMICS; MODELS; GONORRHEA; MORTALITY; REGIONS; AIDS; MEN; SEX	A central question in population ecology is the role of 'exogenous' environmental factors versus density-dependent 'endogenous' biological factors in driving changes in population numbers(1). This question is also central to infectious disease epidemiology, where changes in disease incidence due to behavioural or environmental change must be distinguished from the nonlinear dynamics of the parasite population(2). Repeated epidemics of primary and secondary syphilis infection in the United States over the past 50 yr have previously been attributed to social and behavioural changes(3). Here, we show that these epidemics represent a rare example of unforced, endogenous oscillations in disease incidence, with an 8-11-yr period that is predicted by the natural dynamics of syphilis infection, to which there is partially protective immunity(4). This conclusion is supported by the absence of oscillations in gonorrhoea cases, where a protective immune response is absent(5,6). We further demonstrate increased synchrony of syphilis oscillations across cities over time, providing empirical evidence for an increasingly connected sexual network in the United States.	Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England	Imperial College London	Grassly, NC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, Norfolk Pl, London W2 1PG, England.	n.grassly@imperial.ac.uk	Grassly, Nicholas C/C-6381-2008; Garnett, Geoffrey P/A-9312-2008; Fraser, Christophe/A-8109-2008	Grassly, Nicholas C/0000-0001-6067-4507; Fraser, Christophe/0000-0003-2399-9657				Aral SO, 1996, SEX TRANSM DIS, V23, P9, DOI 10.1097/00007435-199601000-00005; Bailey NTJ, 1975, MATH THEORY INFECT D; Bjornstad ON, 1999, TRENDS ECOL EVOL, V14, P427, DOI 10.1016/S0169-5347(99)01677-8; Bjornstad ON, 2001, SCIENCE, V293, P638, DOI 10.1126/science.1062226; Chatfield C., 2003, ANAL TIME SERIES INT, V6, DOI 10.4324/9780203491683; Chesson HW, 2003, SEX TRANSM DIS, V30, P419, DOI 10.1097/00007435-200305000-00008; Cliff A, 1998, DECIPHERING GLOBAL E; Fox KK, 1999, AM J EPIDEMIOL, V149, P353, DOI 10.1093/oxfordjournals.aje.a009820; Garnett GP, 1999, PHILOS T R SOC B, V354, P787, DOI 10.1098/rstb.1999.0431; Garnett GP, 1997, SEX TRANSM DIS, V24, P185, DOI 10.1097/00007435-199704000-00002; Gibson Campbell, 1998, 27 US CENS BUR POP D; Greenberg Judith B, 2002, J Public Health Manag Pract, V8, P59; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; HAMERS FF, 1995, AM J PUBLIC HEALTH, V85, P1104, DOI 10.2105/AJPH.85.8_Pt_1.1104; Hethcote H.W., 1984, LECT NOTES BIOMATH, V56; Hook EW, 1997, SEX TRANSM DIS, V24, P443, DOI 10.1097/00007435-199709000-00001; Kahn RH, 2002, SEX TRANSM DIS, V29, P285, DOI 10.1097/00007435-200205000-00006; Keeling MJ, 2002, ECOL LETT, V5, P20, DOI 10.1046/j.1461-0248.2002.00268.x; Kuperman M, 2001, PHYS REV LETT, V86, P2909, DOI 10.1103/PhysRevLett.86.2909; Lloyd AL, 1996, J THEOR BIOL, V179, P1, DOI 10.1006/jtbi.1996.0042; Lloyd AL, 2004, MATH BIOSCI, V188, P1, DOI 10.1016/j.mbs.2003.09.003; Morgan CA, 2003, INFECT IMMUN, V71, P5605, DOI 10.1128/IAI.71.10.5605-5612.2003; Nakashima AK, 1996, SEX TRANSM DIS, V23, P16, DOI 10.1097/00007435-199601000-00006; Nasell I, 2002, MATH BIOSCI, V179, P1, DOI 10.1016/S0025-5564(02)00098-6; Pascual M, 2000, SCIENCE, V289, P1766, DOI 10.1126/science.289.5485.1766; Schmidt KA, 2001, SEX TRANSM DIS, V28, P555, DOI 10.1097/00007435-200110000-00001; *US DEP TRANSP BUR, 2003, NAT TRANSP STAT 2003; Wallace R, 1997, SOC SCI MED, V44, P935, DOI 10.1016/S0277-9536(96)00197-9; Wasserheit J.N., 1996, J INFECT DIS S2, V174, P201; Wolitski RJ, 2001, AM J PUBLIC HEALTH, V91, P883, DOI 10.2105/AJPH.91.6.883	30	155	160	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2005	433	7024					417	421		10.1038/nature03072	http://dx.doi.org/10.1038/nature03072			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674292				2022-12-28	WOS:000226546200043
J	Moynihan, R				Moynihan, R			The marketing of a disease: female sexual dysfunction	BRITISH MEDICAL JOURNAL			English	Article							WOMEN				Moynihan, R (corresponding author), 1312 21st St NW,Apt 4, Washington, DC 20036 USA.	raymond.moynihan@verizon.net	Moynihan, Ray/ABC-3010-2020					Bancroft J, 2003, ARCH SEX BEHAV, V32, P193, DOI 10.1023/A:1023420431760; Bassetto A, 2004, J HIGH ENERGY PHYS; DALY R, 2004, TORONTO STAR    1208, P1; *FOOD DRUG ADM DIV, 2004, 21769 NDA FOOD DRUG; Moynihan R, 2004, BRIT MED J, V329, P1363, DOI 10.1136/bmj.329.7479.1363; Moynihan R, 2002, BRIT MED J, V324, P886, DOI 10.1136/bmj.324.7342.886; Moynihan R, 2003, BRIT MED J, V326, P45, DOI 10.1136/bmj.326.7379.45; *NAT WOM HLTH NETW, 1995, TAK HORM WOM HLTH CH; *PROCT GAMBL PHARM, REP GUID TEST ROL WO; Richters J, 2003, AUST NZ J PUBL HEAL, V27, P164, DOI 10.1111/j.1467-842X.2003.tb00804.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; UTIAN W, 2004, ANN M INT SOC STUD W; Wilson RA, 1966, FEMININE FOREVER	13	48	51	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 22	2005	330	7484					192	194		10.1136/bmj.330.7484.192	http://dx.doi.org/10.1136/bmj.330.7484.192			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891OQ	15661785	Green Published			2022-12-28	WOS:000226590800026
J	Lowell, BB; Shulmanz, GI				Lowell, BB; Shulmanz, GI			Mitochondrial dysfunction and type 2 diabetes	SCIENCE			English	Editorial Material							BETA-CELL LIPOTOXICITY; FREE FATTY-ACIDS; STIMULATED INSULIN-SECRETION; UNCOUPLING PROTEIN-2; RESISTANCE; OBESITY; FAILURE; MUSCLE; PATHOGENESIS; MECHANISMS	Maintenance of normal blood glucose levels depends on a complex interplay between the insulin responsiveness of skeletal muscle and liver and glucose-stimutated insulin secretion by pancreatic beta cells. Defects in the former are responsible for insulin resistance, and defects in the latter are responsible for progression to hyperglycemia. Emerging evidence supports the potentially unifying hypothesis that both of these prominent features of type 2 diabetes are caused by mitochondrial dysfunction.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Yale Univ, Sch Med, Dept Internal Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; Yale University; Yale University	Lowell, BB (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, 99 Brookline Ave, Boston, MA 02215 USA.	blowell@bidmc.harvard.edu; gerald.shulman@yale.edu	Northe, Hilda/I-1916-2012; Shulman, Gerald I./P-7176-2019	Northe, Hilda/0000-0002-8873-5014; Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azen SP, 1998, CONTROL CLIN TRIALS, V19, P217, DOI 10.1016/S0197-2456(97)00151-7; Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Brown JEP, 2002, FEBS LETT, V513, P189, DOI 10.1016/S0014-5793(02)02296-2; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Dickson LM, 2004, AM J PHYSIOL-ENDOC M, V287, pE192, DOI 10.1152/ajpendo.00031.2004; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Dufour E, 2004, BBA-BIOENERGETICS, V1658, P122, DOI 10.1016/j.bbabio.2004.04.020; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Gerich JE, 2003, MAYO CLIN PROC, V78, P447, DOI 10.4065/78.4.447; Hui HX, 2004, J CELL PHYSIOL, V200, P177, DOI 10.1002/jcp.20021; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Joseph JW, 2002, DIABETES, V51, P3211, DOI 10.2337/diabetes.51.11.3211; Kashyap S, 2003, DIABETES, V52, P2461, DOI 10.2337/diabetes.52.10.2461; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Koshkin V, 2003, J BIOL CHEM, V278, P19709, DOI 10.1074/jbc.M209709200; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS189, DOI 10.1055/s-2001-18581; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Krempler F, 2002, DIABETES, V51, P3331, DOI 10.2337/diabetes.51.11.3331; Langin D, 2001, NEW ENGL J MED, V345, P1772, DOI 10.1056/NEJM200112133452412; Laybutt DR, 2002, J BIOL CHEM, V277, P10912, DOI 10.1074/jbc.M111751200; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Petersen M, 2003, DIABETES CARE, V26, P917; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Poitout V, 2004, ENDOCRINOLOGY, V145, P3563, DOI 10.1210/en.2004-0479; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Prentki M, 2002, DIABETES, V51, pS405, DOI 10.2337/diabetes.51.2007.S405; RANDLE PJ, 1963, LANCET, V1, P785; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Sasahara M, 2004, DIABETES, V53, P482, DOI 10.2337/diabetes.53.2.482; Sesti G, 2003, DIABETES, V52, P1280, DOI 10.2337/diabetes.52.5.1280; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; VONDRA K, 1977, DIABETOLOGIA, V13, P527, DOI 10.1007/BF01234508; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; Winzell MS, 2003, DIABETES, V52, P2057; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yamashita T, 2004, ENDOCRINOLOGY, V145, P3566, DOI 10.1210/en.2003-1602; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	58	1502	1594	4	195	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2005	307	5708					384	387		10.1126/science.1104343	http://dx.doi.org/10.1126/science.1104343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15662004				2022-12-28	WOS:000226492300034
J	Hahn, MW; Mezey, JG; Begun, DJ; Gillespie, JH; Kern, AD; Langley, CH; Moyle, LC				Hahn, MW; Mezey, JG; Begun, DJ; Gillespie, JH; Kern, AD; Langley, CH; Moyle, LC			Evolutionary genomics - Codon bias and selection on single genomes	NATURE			English	Editorial Material							USAGE; SEQUENCES		Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA; Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Hahn, MW (corresponding author), Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA.	mwhahn@ucdavis.edu		Hahn, Matthew/0000-0002-5731-8808				AKASHI H, 1994, GENETICS, V136, P927; Akashi H, 2001, CURR OPIN GENET DEV, V11, P660, DOI 10.1016/S0959-437X(00)00250-1; Chiapello H, 1998, GENE, V209, pGC1, DOI 10.1016/S0378-1119(97)00671-9; Coghlan A, 2000, YEAST, V16, P1131, DOI 10.1002/1097-0061(20000915)16:12<1131::AID-YEA609>3.0.CO;2-F; GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; Marais G, 2001, P NATL ACAD SCI USA, V98, P5688, DOI 10.1073/pnas.091427698; Plotkin JB, 2004, NATURE, V428, P942, DOI 10.1038/nature02458; SHARP PM, 1991, J MOL EVOL, V33, P23, DOI 10.1007/BF02100192	9	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					E5	E6		10.1038/nature03221	http://dx.doi.org/10.1038/nature03221			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662370				2022-12-28	WOS:000226381300030
J	Wilczek, F				Wilczek, F			In search of symmetry lost	NATURE			English	Review							HIGGS-BOSON; GAUGE; MODEL; SUPERSYMMETRY; CONSERVATION; BREAKING; BEHAVIOR; UNIVERSE; MASS	Powerful symmetry principles have guided physicists in their quest for nature's fundamental laws. The successful gauge theory of electroweak interactions postulates a more extensive symmetry for its equations than are manifest in the world. The discrepancy is ascribed to a pervasive symmetry-breaking field, which fills all space uniformly, rendering the Universe a sort of exotic superconductor. So far, the evidence for these bold ideas is indirect. But soon the theory will undergo a critical test depending on whether the quanta of this symmetry-breaking field, the so-called Higgs particles, are produced at the Large Hadron Collider (due to begin operation in 2007).	MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Wilczek, F (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	wilczek@mit.edu						Abbaneo D, 2003, PHYS LETT B, V565, P61, DOI 10.1016/S0370-2693(03)00614-2; AMALDI U, 1991, PHYS LETT B, V260, P447, DOI 10.1016/0370-2693(91)91641-8; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; BJORKEN J, 1976, SLAC PUBLICATIONS, V198; DIMOPOULOS S, 1981, NUCL PHYS B, V193, P150, DOI 10.1016/0550-3213(81)90522-8; DIMOPOULOS S, 1981, PHYS REV D, V24, P1681, DOI 10.1103/PhysRevD.24.1681; Einhorn M. B., 1991, STANDARD MODEL HIGGS; Einstein A, 1905, ANN PHYS-BERLIN, V18, P639; ELLIS J, 1990, PHYS LETT B, V249, P441, DOI 10.1016/0370-2693(90)91013-2; ENGLERT F, 1964, PHYS REV LETT, V13, P321, DOI 10.1103/PhysRevLett.13.321; FERRARA S, 1987, SUPERSYMMETRY; Gell-Mann M., 1979, Supergravity, P315; GEORGI H, 1974, PHYS REV LETT, V32, P438, DOI 10.1103/PhysRevLett.32.438; Georgi H., 1974, AIP Conference Proceedings, P575; GEORGI H, 1974, PHYS REV LETT, V33, P451, DOI 10.1103/PhysRevLett.33.451; GEORGI HM, 1978, PHYS REV LETT, V40, P692, DOI 10.1103/PhysRevLett.40.692; GILDENER E, 1976, PHYS REV D, V13, P3333, DOI 10.1103/PhysRevD.13.3333; GLASHOW SL, 1961, NUCL PHYS, V22, P579, DOI 10.1016/0029-5582(61)90469-2; GROSS DJ, 1973, PHYS REV LETT, V30, P1343, DOI 10.1103/PhysRevLett.30.1343; Gunion J. F., 1990, HIGGS HUNTERS GUIDE; GUTH AH, 1981, PHYS REV D, V23, P347, DOI 10.1103/PhysRevD.23.347; HIGGS PW, 1964, PHYS REV LETT, V13, P508, DOI 10.1103/PhysRevLett.13.508; KIRZHNITS DA, 1976, ANN PHYS-NEW YORK, V101, P195, DOI 10.1016/0003-4916(76)90279-7; KUTI J, 1988, PHYS REV LETT, V61, P678, DOI 10.1103/PhysRevLett.61.678; Lederman Leon M., 1993, GOD PARTICLE; LEE TD, 1956, PHYS REV, V104, P254, DOI 10.1103/PhysRev.104.254; London F., 1950, SUPERFLUIDS, VI; London F., 1927, Z PHYS, V42, P375; PATI JC, 1973, PHYS REV D, V8, P1240, DOI 10.1103/PhysRevD.8.1240; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; POLITZER HD, 1973, PHYS REV LETT, V30, P1346, DOI 10.1103/PhysRevLett.30.1346; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Salam A., 1968, Elementary particle theory, relativistic groups and analyticity, P367; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; THOOFT G, 1972, NUCL PHYS B, VB-44, P189, DOI 10.1016/0550-3213(72)90279-9; WEINBERG S, 1967, PHYS REV LETT, V19, P1264, DOI 10.1103/PhysRevLett.19.1264; Weinberg S., 2000, QUANTUM THEORY FIELD; Weinberg S., 1995, QUANTUM THEORY FIELD, Vvol 1; WESS J, 1974, PHYS LETT B, VB 49, P52, DOI 10.1016/0370-2693(74)90578-4; Weyl H, 1929, Z PHYS, V56, P330, DOI 10.1007/BF01339504; Wilczek F, 1999, REV MOD PHYS, V71, pS85, DOI 10.1103/RevModPhys.71.S85; Wilczek F, 2002, PHYS TODAY, V55, P10, DOI 10.1063/1.1510264; WILCZEK F, 1977, PHYS REV LETT, V39, P1304, DOI 10.1103/PhysRevLett.39.1304; WILCZEK F, 2003, ANN PHYS MIT, V16, P24; WITTEN E, 1981, NUCL PHYS B, V188, P513, DOI 10.1016/0550-3213(81)90006-7; YANAGIDA T, 1979, WORKSH UN THEOR, P95; YANG CN, 1954, PHYS REV, V96, P191, DOI 10.1103/PhysRev.96.191; 2004, COMPACT MUONSOLENOID	49	36	37	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					239	247		10.1038/nature03281	http://dx.doi.org/10.1038/nature03281			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662411				2022-12-28	WOS:000226381300041
J	Yan, AT; Yan, RT; Liu, PP				Yan, AT; Yan, RT; Liu, PP			Narrative review: Pharmacotherapy for chronic heart failure: Evidence from recent clinical trials	ANNALS OF INTERNAL MEDICINE			English	Review							LEFT-VENTRICULAR DYSFUNCTION; CONVERTING-ENZYME-INHIBITORS; MATRIX-METALLOPROTEINASE INHIBITION; ACUTE MYOCARDIAL-INFARCTION; CARDIAC-RESYNCHRONIZATION THERAPY; ENDOTHELIN-RECEPTOR ANTAGONIST; BETA-BLOCKER THERAPY; LONG-TERM TREATMENT; RANDOMIZED-TRIAL; DOUBLE-BLIND	Heart failure is an important cause of morbidity and mortality. Clinical trials over the past 2 decades have revolutionized the care of patients with systolic heart failure, and substantial data support the use of angiotensin-converting enzyme inhibitors, beta-blockers, angiotensin-receptor blockers, and aldosterone blockers in the management of this serious condition. This article reviews the evidence on the pharmacologic treatment of heart failure, with a focus on recent clinical trials.	Toronto Gen Hosp, Univ Hlth Network, Heart & Stroke RL Ctr Excellence, Toronto, ON M5G 2C4, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Liu, PP (corresponding author), Toronto Gen Hosp, Univ Hlth Network, Heart & Stroke RL Ctr Excellence, NCSB 11-1266,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	peter.liu@utoronto.ca	Kwong, Raymond Y/R-1925-2016	Kwong, Raymond Y/0000-0001-8212-0759				Abraham WT, 2003, CIRCULATION, V108, P2596, DOI 10.1161/01.CIR.0000096580.26969.9A; Adams KF, 2002, J AM COLL CARDIOL, V39, P946, DOI 10.1016/S0735-1097(02)01708-4; [Anonymous], 1990, Lancet, V336, P1; [Anonymous], 1988, JAMA, V259, P539; BALL SG, 1993, LANCET, V342, P821; BARDY G, 2004, AM COLL CARD 53 ANN; Baruch L, 1999, CIRCULATION, V99, P2658, DOI 10.1161/01.CIR.99.20.2658; Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044; Bozkurt B, 2003, J AM COLL CARDIOL, V41, P211, DOI 10.1016/S0735-1097(02)02694-3; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; Braunwald E, 2000, CIRCULATION, V102, P14; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Bristow MR, 2003, J CARD FAIL, V9, P444, DOI 10.1016/j.cardfail.2003.10.009; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; Brophy JM, 2001, ANN INTERN MED, V134, P550, DOI 10.7326/0003-4819-134-7-200104030-00008; Chung ES, 2003, CIRCULATION, V107, P3133, DOI 10.1161/01.CIR.0000077913.60364.D2; Cicoira M, 2002, AM J CARDIOL, V89, P403, DOI 10.1016/S0002-9149(01)02261-5; Cirillo W, 2000, CIRCULATION, V101, P378, DOI 10.1161/01.CIR.101.4.378; Cleland JGF, 2004, AM HEART J, V148, P157, DOI 10.1016/j.ahj.2004.03.010; Cleland JGF, 2002, LANCET, V360, P1631, DOI 10.1016/S0140-6736(02)11601-1; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Cohn JN, 1997, CIRCULATION, V96, P856, DOI 10.1161/01.cir.96.3.856; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; De Marco T, 1998, J AM COLL CARDIOL, V31, P1341; de Vries RJM, 2000, AM HEART J, V139, P185, DOI 10.1016/S0002-8703(00)90224-2; Di Lenarda A, 1999, J AM COLL CARDIOL, V33, P1926, DOI 10.1016/S0735-1097(99)00134-5; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Domanski M, 2003, J AM COLL CARDIOL, V42, P705, DOI 10.1016/S0735-1097(03)00765-4; Doughty RN, 1997, EUR HEART J, V18, P560; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Faris R, 2002, INT J CARDIOL, V82, P149, DOI 10.1016/S0167-5273(01)00600-3; Felker GM, 2001, AM HEART J, V142, P393, DOI 10.1067/mhj.2001.117606; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GHEORGHIADE M, 1991, CIRCULATION, V84, P2181, DOI 10.1161/01.CIR.84.5.2181; Gheorghiade M, 2003, CIRCULATION, V107, P2690, DOI 10.1161/01.CIR.0000070422.41439.04; GHEORGHIADE M, 1992, AM J CARDIOL, V69, pG48, DOI 10.1016/0002-9149(92)91254-2; GHEORGHIADE M, 1992, AM J CARDIOL, V69, pG62; GOLDSTEIN RE, 1991, CIRCULATION, V83, P52, DOI 10.1161/01.CIR.83.1.52; Goldstein S, 2001, J AM COLL CARDIOL, V38, P932, DOI 10.1016/S0735-1097(01)01516-9; Granger CB, 2003, LANCET, V362, P772, DOI 10.1016/S0140-6736(03)14284-5; Groenning BA, 2000, J AM COLL CARDIOL, V36, P2072, DOI 10.1016/S0735-1097(00)01006-8; Haldeman GA, 1999, AM HEART J, V137, P352, DOI 10.1053/hj.1999.v137.95495; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; Heyndrickx G, 1996, HEART, V76, P223, DOI 10.1136/hrt.76.3.223; Hjalmarson A, 1999, LANCET, V353, P2001; Hjalmarson A, 2003, LANCET, V362, P1077, DOI 10.1016/S0140-6736(03)14422-4; Hood WB, 2004, J CARD FAIL, V10, P155, DOI 10.1016/j.cardfail.2003.12.005; HUNT SA, 2001, ACC AHA GUID EV MAN; Jong P, 2003, LANCET, V361, P1843, DOI 10.1016/S0140-6736(03)13501-5; Jong P, 2002, J AM COLL CARDIOL, V39, P463, DOI 10.1016/S0735-1097(01)01775-2; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Kadish A, 2004, NEW ENGL J MED, V350, P2151, DOI 10.1056/NEJMoa033088; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Krum H, 2003, JAMA-J AM MED ASSOC, V289, P712, DOI 10.1001/jama.289.6.712; Kukin ML, 1999, CIRCULATION, V99, P2645, DOI 10.1161/01.CIR.99.20.2645; Lechat P, 1999, LANCET, V353, P9; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; Lee DS, 2004, AM J MED, V116, P581, DOI 10.1016/j.amjmed.2003.11.025; Levin ER, 1998, NEW ENGL J MED, V339, P321; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Lindsey ML, 2002, CIRCULATION, V105, P753, DOI 10.1161/hc0602.103674; Lip GY, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003333, DOI 10.1002/14651858.CD003333]; LITTLER WA, 1995, BRIT HEART J, V73, P428; Loh E, 1997, NEW ENGL J MED, V336, P251, DOI 10.1056/NEJM199701233360403; Luscher TF, 2002, CIRCULATION, V106, P2666, DOI 10.1161/01.CIR.0000038497.80095.E1; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; MacMahon S, 1997, LANCET, V349, P375; Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2; Mann DL, 2003, NEW ENGL J MED, V349, P1963, DOI 10.1056/NEJMe038163; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MASSIE BM, 2004, AM COLL CARD 53 ANN; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; McMurray J, 2002, CIRCULATION, V105, P2223, DOI 10.1161/01.CIR.0000014771.38666.22; McMurray J, 2002, CIRCULATION, V105, P2099, DOI 10.1161/01.CIR.0000014763.63528.9D; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; Metra M, 2000, CIRCULATION, V102, P546; Metra M, 2002, J AM COLL CARDIOL, V40, P1248, DOI 10.1016/S0735-1097(02)02134-4; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Nohria A, 2002, JAMA-J AM MED ASSOC, V287, P628, DOI 10.1001/jama.287.5.628; Packer M, 2003, J CARD FAIL, V9, P429, DOI 10.1016/j.cardfail.2003.08.003; Packer M, 1999, CIRCULATION, V100, P2312, DOI 10.1161/01.CIR.100.23.2312; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Packer M, 2002, CIRCULATION, V106, P920, DOI 10.1161/01.CIR.0000029801.86489.50; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, AM COLL CARD 51 ANN; PACKER M, AM COLL CARD 49 ANN; Perry G, 1997, NEW ENGL J MED, V336, P525; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Poole-Wilson PA, 2003, LANCET, V362, P7, DOI 10.1016/S0140-6736(03)13800-7; Pullicino PM, 2000, NEUROLOGY, V54, P288, DOI 10.1212/WNL.54.2.288; Rathore SS, 2002, NEW ENGL J MED, V347, P1403, DOI 10.1056/NEJMoa021266; Rathore SS, 2003, JAMA-J AM MED ASSOC, V289, P871, DOI 10.1001/jama.289.7.871; Remme WJ, 2004, CARDIOVASC DRUG THER, V18, P57, DOI 10.1023/B:CARD.0000025756.32499.6f; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Rich MW, 2001, J AM COLL CARDIOL, V38, P806, DOI 10.1016/S0735-1097(01)01442-5; Riegger GAJ, 1999, CIRCULATION, V100, P2224, DOI 10.1161/01.CIR.100.22.2224; Roger VL, 2004, JAMA-J AM MED ASSOC, V292, P344, DOI 10.1001/jama.292.3.344; Rohde LE, 1999, CIRCULATION, V99, P3063, DOI 10.1161/01.CIR.99.23.3063; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Rouleau JL, 2000, LANCET, V356, P615, DOI 10.1016/S0140-6736(00)02602-7; Rouleau JL, 2004, J AM COLL CARDIOL, V43, P1423, DOI 10.1016/j.jacc.2003.11.037; Russell SD, 2003, AM HEART J, V145, P179, DOI 10.1067/mhj.2003.39; Schrier RW, 1999, NEW ENGL J MED, V341, P577, DOI 10.1056/NEJM199908193410806; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; Spieker LE, 2001, J AM COLL CARDIOL, V37, P1493, DOI 10.1016/S0735-1097(01)01210-4; Spinale FG, 1999, CIRC RES, V85, P364, DOI 10.1161/01.RES.85.4.364; STEVENSON WG, 1993, CIRCULATION, V88, P2953, DOI 10.1161/01.CIR.88.6.2953; Stewart S, 2003, HEART, V89, P49, DOI 10.1136/heart.89.1.49; Sutsch G, 1998, CIRCULATION, V98, P2262, DOI 10.1161/01.CIR.98.21.2262; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Swedberg K, 2004, EUR HEART J, V25, P357, DOI 10.1016/j.ehj.2003.12.023; Taylor AL, 2004, NEW ENGL J MED, V351, P2049, DOI 10.1056/NEJMoa042934; Teo KK, 2002, LANCET, V360, P1037, DOI 10.1016/S0140-6736(02)11138-X; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201; Torp-Pedersen C, 1999, LANCET, V354, P9, DOI 10.1016/S0140-6736(98)09374-X; Torre-Amione G, 2001, CIRCULATION, V103, P973; Turnbull F, 2003, LANCET, V362, P1527; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Weber KT, 2001, NEW ENGL J MED, V345, P1689, DOI 10.1056/NEJMra000050; Weber MA, 2001, LANCET, V358, P1525, DOI 10.1016/S0140-6736(01)06584-9; Wikstrand J, 2003, LANCET, V362, P1076, DOI 10.1016/S0140-6736(03)14421-2; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Yan AT, 2001, CHEST, V120, P1675, DOI 10.1378/chest.120.5.1675; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Zannad F, 2000, CIRCULATION, V102, P2700, DOI 10.1161/01.CIR.102.22.2700; Zile MR, 2002, CIRCULATION, V105, P1503, DOI 10.1161/hc1202.105290; Zile MR, 2002, CIRCULATION, V105, P1387, DOI 10.1161/hc1102.105289; 2002 3 CAN CARD SOC	150	29	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2005	142	2					132	145		10.7326/0003-4819-142-2-200501180-00013	http://dx.doi.org/10.7326/0003-4819-142-2-200501180-00013			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915LQ	15657162				2022-12-28	WOS:000228306100007
J	Kublin, JG; Patnaik, P; Jere, CS; Miller, WC; Hoffman, IF; Chimbiya, N; Pendame, R; Taylor, TE; Molyneux, ME				Kublin, JG; Patnaik, P; Jere, CS; Miller, WC; Hoffman, IF; Chimbiya, N; Pendame, R; Taylor, TE; Molyneux, ME			Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NATURAL-HISTORY; VIRAL LOAD; IMMUNE ACTIVATION; HIV-INFECTION; TRANSMISSION; TUBERCULOSIS; REPLICATION; PARASITEMIA; INDUCTION	Background Raised HIV viral load in blood has been associated with accelerated disease progression and increased transmission of infection. To assess the effect of Plasmodium falciparum malaria on concentrations of HIV in blood, we did a prospective cohort study in Malawi. Methods We recruited 367 HIV-1-infected adults. Among 334 people aparasitaemic at baseline, 148 had at least one malaria episode during follow-up and received antimalarial treatment. Of these, 77 had HIV-1-RNA measurements at baseline, during malaria, and post-malaria. We used linear regression with generalised estimating equations to assess effect of four definitions of malaria (any parasitaemia, parasite density greater than or equal to2000/muL, febrile parasitaemia, and febrile parasitaemia with parasite density greater than or equal to2000/mul) on changes in log HIV-1 RNA, overall and by baseline CD4 count. Findings With malaria defined as any parasitaemia, HIV-1-RNA concentration almost doubled between baseline (median 96 215 copies per mL) and malaria (168 901 copies per mL), a 0.25 (95% CI 0.11-0.39) log increase in mean RNA concentration. HIV-1-RNA concentration fell to median 82 058 copies per mL by about 8-9 weeks postmalaria. Increases in HIV-1-RNA were greatest for people with fever, parasite density 2000/muL or greater, and CD4 count more than 300 cells per p,L, in whom concentrations rose from median 38 483 copies per mL at baseline to 196 098 copies per mL during malaria, a mean log increase of 0.82 (95% CI 0.55-1.10, p<0.0001), and fell to median 75 331 copies per mL post-malaria. People who remained aparasitaemic showed no changes in HIV-1-RNA concentration. Interpretation HIV-infected individuals with malaria have a significantly increased viral load, which might enhance HIV transmission and accelerate disease progression.	Univ Malawi, Coll Med, Dept Community Hlth, Blantyre, Malawi; Univ Malawi, Coll Med, Dept Microbiol, Blantyre, Malawi; Univ Malawi, Coll Med, Blantyre Malaria Project, Blantyre, Malawi; Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Minist Hlth & Populat, Llongwe, Malawi; Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA; Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi	University of Malawi; University of Malawi; University of Malawi; University System of Maryland; University of Maryland Baltimore; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Michigan State University; Michigan State University College of Osteopathic Medicine; University of Malawi	Kublin, JG (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,EL-500, Seattle, WA 98109 USA.	jkublin@fhcrc.com	Miller, William C/H-4800-2014	Miller, William C/0000-0002-1934-7827; Kublin, James/0000-0003-1279-3741	FOGARTY INTERNATIONAL CENTER [D43TW001039] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TWO1039-05 S1] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Artzrouni M, 2002, AIDS, V16, pW1; BATE CAW, 1988, IMMUNOLOGY, V64, P227; Chandramohan D, 1998, INT J EPIDEMIOL, V27, P296, DOI 10.1093/ije/27.2.296; Delley V, 2000, TROP MED INT HEALTH, V5, P404, DOI 10.1046/j.1365-3156.2000.00566.x; French N, 2001, AIDS, V15, P899, DOI 10.1097/00002030-200105040-00010; Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Jaffar S, 2004, B WORLD HEALTH ORGAN, V82, P462; Lawn SD, 1999, AIDS, V13, P2231, DOI 10.1097/00002030-199911120-00005; Lyles CM, 1999, EUR J EPIDEMIOL, V15, P99, DOI 10.1023/A:1007556327269; Lyles RH, 1999, AIDS, V13, P341, DOI 10.1097/00002030-199902250-00006; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Morgan D, 2001, NAT MED, V7, P143, DOI 10.1038/84564; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Pisell TL, 2002, AIDS, V16, P1503, DOI 10.1097/00002030-200207260-00007; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rowland-Jones SL, 2002, MICROBES INFECT, V4, P1265, DOI 10.1016/S1286-4579(02)01655-6; Steketee RW, 1996, AM J TROP MED HYG, V55, P17, DOI 10.4269/ajtmh.1996.55.17; Steketee RW, 1996, AM J TROP MED HYG, V55, P42, DOI 10.4269/ajtmh.1996.55.42; Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x; Whitty CJM, 2002, LANCET, V359, P80, DOI 10.1016/S0140-6736(02)07300-2; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; Xiao LH, 1998, J INFECT DIS, V177, P437, DOI 10.1086/514212	29	179	191	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2005	365	9455					233	240		10.1016/S0140-6736(05)17743-5	http://dx.doi.org/10.1016/S0140-6736(05)17743-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887MG	15652606				2022-12-28	WOS:000226309600029
J	Hijri, M; Sanders, IR				Hijri, M; Sanders, IR			Low gene copy number shows that arbuscular mycorrhizal fungi inherit genetically different nuclei	NATURE			English	Article							GLOMUS-INTRARADICES; DNA CONTENT; DIVERSITY; GLOMALES	Arbuscular mycorrhizal fungi (AMF) are ancient asexually reproducing organisms that form symbioses with the majority of plant species, improving plant nutrition and promoting plant diversity(1,2). Little is known about the evolution or organization of the genomes of any eukaryotic symbiont or ancient asexual organism. Direct evidence shows that one AMF species is heterokaryotic; that is, containing populations of genetically different nuclei(3). It has been suggested, however, that the genetic variation passed from generation to generation in AMF is simply due to multiple chromosome sets (that is, high ploidy)(4). Here we show that previously documented genetic variation in Pol-like sequences, which are passed from generation to generation, cannot be due to either high ploidy or repeated gene duplications. Our results provide the clearest evidence so far for substantial genetic differences among nuclei in AMF. We also show that even AMF with a very large nuclear DNA content are haploid. An underlying principle of evolutionary theory is that an individual passes on one or half of its genome to each of its progeny. The coexistence of a population of many genomes in AMF and their transfer to subsequent generations, therefore, has far-reaching consequences for understanding genome evolution.	Univ Lausanne, Dept Ecol & Evolut, CH-1015 Lausanne, Switzerland	University of Lausanne	Sanders, IR (corresponding author), Univ Lausanne, Dept Ecol & Evolut, CH-1015 Lausanne, Switzerland.	ian.sanders@unil.ch	Hijri, Mohamed/ABC-5969-2021; Sanders, Ian R/T-9988-2017; Hijri, Mohamed/AAL-5737-2021	Hijri, Mohamed/0000-0001-6112-8372; Sanders, Ian R/0000-0002-9591-8214; 				BIANCIOTTO V, 1992, MYCOL RES, V96, P1071, DOI 10.1016/S0953-7562(09)80118-4; Corradi N, 2004, FUNGAL GENET BIOL, V41, P262, DOI 10.1016/j.fgb.2003.11.001; Giovannetti M, 1999, APPL ENVIRON MICROB, V65, P5571; GRAUT D, 2000, FUNDAMENTALS MOL EVO; Helgason T, 2003, FEMS MICROBIOL LETT, V229, P127, DOI 10.1016/S0378-1097(03)00802-4; Hijri M, 2004, FUNGAL GENET BIOL, V41, P253, DOI 10.1016/j.fgb.2003.10.011; Hosny M, 1998, GENOME, V41, P422, DOI 10.1139/gen-41-3-422; HOSNY M, 1997, GENOME SIZE GLOMALES; Kuhn G, 2001, NATURE, V414, P745, DOI 10.1038/414745a; Pawlowska TE, 2004, NATURE, V427, P733, DOI 10.1038/nature02290; Rosendahl S, 1997, MOL ECOL, V6, P821, DOI 10.1046/j.1365-294X.1997.d01-213.x; Schussler A, 1999, NEW PHYTOL, V144, P205, DOI 10.1046/j.1469-8137.1999.00526.x; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932	14	130	144	4	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					160	163		10.1038/nature03069	http://dx.doi.org/10.1038/nature03069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650740				2022-12-28	WOS:000226252200038
J	Lindorff-Larsen, K; Best, RB; DePristo, MA; Dobson, CM; Vendruscolo, M				Lindorff-Larsen, K; Best, RB; DePristo, MA; Dobson, CM; Vendruscolo, M			Simultaneous determination of protein structure and dynamics	NATURE			English	Article							X-RAY; COUPLING-CONSTANTS; ORDER PARAMETERS; BACKBONE MOTION; NATIVE PROTEINS; NMR RELAXATION; UBIQUITIN; TRANSITION; SIMULATIONS; STATE	We present a protocol for the experimental determination of ensembles of protein conformations that represent simultaneously the native structure and its associated dynamics. The procedure combines the strengths of nuclear magnetic resonance spectroscopy-for obtaining experimental information at the atomic level about the structural and dynamical features of proteins-with the ability of molecular dynamics simulations to explore a wide range of protein conformations. We illustrate the method for human ubiquitin in solution and find that there is considerable conformational heterogeneity throughout the protein structure. The interior atoms of the protein are tightly packed in each individual conformation that contributes to the ensemble but their overall behaviour can be described as having a significant degree of liquid-like character. The protocol is completely general and should lead to significant advances in our ability to understand and utilize the structures of native proteins.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge; University of Cambridge	Vendruscolo, M (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cmd44@cam.ac.uk; mv245@cam.ac.uk	Vendruscolo, Michele/F-5901-2012; Best, Robert/H-7588-2016; Lindorff-Larsen, Kresten/K-6469-2014	Vendruscolo, Michele/0000-0002-3616-1610; Best, Robert/0000-0002-7893-3543; Lindorff-Larsen, Kresten/0000-0002-4750-6039				Benitez-Cardoza CG, 2004, BIOCHEMISTRY-US, V43, P5195, DOI 10.1021/bi0361620; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Best RB, 2004, J AM CHEM SOC, V126, P8090, DOI 10.1021/ja0396955; Best RB, 2004, J AM CHEM SOC, V126, P7734, DOI 10.1021/ja049078w; BONVIN AMJJ, 1993, PROTEINS, V15, P385, DOI 10.1002/prot.340150406; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Buck M, 1999, J AM CHEM SOC, V121, P9645, DOI 10.1021/ja991309p; Chou JJ, 2003, J AM CHEM SOC, V125, P8959, DOI 10.1021/ja029972s; Choy WY, 2001, J MOL BIOL, V308, P1011, DOI 10.1006/jmbi.2001.4750; Clore GM, 2004, J AM CHEM SOC, V126, P2923, DOI 10.1021/ja0386804; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; DePristo MA, 2004, STRUCTURE, V12, P831, DOI 10.1016/j.str.2004.02.031; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; Fox T, 1996, PROTEINS, V25, P315, DOI 10.1002/(SICI)1097-0134(199607)25:3<315::AID-PROT4>3.0.CO;2-E; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; HOCH JC, 1985, BIOCHEMISTRY-US, V24, P3831, DOI 10.1021/bi00336a003; Johnson EC, 1999, STRUCTURE, V7, P967, DOI 10.1016/S0969-2126(99)80123-3; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; Kitao A, 2000, P NATL ACAD SCI USA, V97, P2064, DOI 10.1073/pnas.030540397; Korzhnev DM, 2004, NATURE, V430, P586, DOI 10.1038/nature02655; Lee AL, 1999, J AM CHEM SOC, V121, P2891, DOI 10.1021/ja983758f; Lee AL, 2001, NATURE, V411, P501, DOI 10.1038/35078119; Lindorff-Larsen K, 2004, NAT STRUCT MOL BIOL, V11, P443, DOI 10.1038/nsmb765; Lindorff-Larsen K, 2004, J AM CHEM SOC, V126, P3291, DOI 10.1021/ja039250g; Markley JL, 1998, J MOL BIOL, V280, P933, DOI 10.1006/jmbi.1998.1852; MIERKE DF, 1994, BIOPOLYMERS, V34, P559, DOI 10.1002/bip.360340411; Ottiger M, 1999, J AM CHEM SOC, V121, P4690, DOI 10.1021/ja984484z; Paci E, 1999, J MOL BIOL, V288, P441, DOI 10.1006/jmbi.1999.2670; Peti W, 2002, J AM CHEM SOC, V124, P5822, DOI 10.1021/ja011883c; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; SCHEEK RM, 1991, NATO ADV SCI I A-LIF, V225, P209; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; STILLINGER FH, 1990, J CHEM PHYS, V93, P6013, DOI 10.1063/1.459488; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Vendruscolo M, 2003, J AM CHEM SOC, V125, P15686, DOI 10.1021/ja036523z; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wong CF, 2003, ANNU REV PHARMACOL, V43, P31, DOI 10.1146/annurev.pharmtox.43.100901.140216; Yang DW, 1996, J MOL BIOL, V263, P369, DOI 10.1006/jmbi.1996.0581; Zhou YQ, 1999, J MOL BIOL, V285, P1371, DOI 10.1006/jmbi.1998.2374	46	548	557	6	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2005	433	7022					128	132		10.1038/nature03199	http://dx.doi.org/10.1038/nature03199			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886TH	15650731				2022-12-28	WOS:000226252200029
J	MacArthur, BD; Oreffo, ROC				MacArthur, BD; Oreffo, ROC			Bridging the gap	NATURE			English	Editorial Material									Univ Southampton, Southampton Gen Hosp, Div Dev Origins Hlth & Dis, Bone & Joint Res Grp, Southampton SO16 6YD, Hants, England	University of Southampton	MacArthur, BD (corresponding author), Univ Southampton, Southampton Gen Hosp, Div Dev Origins Hlth & Dis, Bone & Joint Res Grp, Southampton SO16 6YD, Hants, England.		; Oreffo, Richard/A-4615-2011	MacArthur, Ben/0000-0002-5396-9750; Oreffo, Richard/0000-0001-5995-6726				Lanza R.P., 2000, PRINCIPLES TISSUE EN; Lauffenburger DA, 2001, P NATL ACAD SCI USA, V98, P4282, DOI 10.1073/pnas.081083698; Murray JD, 2003, MATH BIOL, V3; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Warnke PH, 2004, LANCET, V364, P766, DOI 10.1016/S0140-6736(04)16935-3	5	88	90	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2005	433	7021					19	19		10.1038/433019a	http://dx.doi.org/10.1038/433019a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635390				2022-12-28	WOS:000226117100016
J	Nissen, SE; Tuzcu, EM; Schoenhagen, P; Crowe, T; Sasiela, WJ; Tsai, J; Orazem, J; Magorien, RD; O'Shaughnessy, C; Ganz, P				Nissen, SE; Tuzcu, EM; Schoenhagen, P; Crowe, T; Sasiela, WJ; Tsai, J; Orazem, J; Magorien, RD; O'Shaughnessy, C; Ganz, P		REVERSAL Investigators	Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL; INTRAVASCULAR ULTRASOUND; CARDIOVASCULAR-DISEASE; HEART-DISEASE; PREVENTION; EVENTS; SIMVASTATIN; ATHEROSCLEROSIS; ATORVASTATIN	BACKGROUND: Recent trials have demonstrated better outcomes with intensive than with moderate statin treatment. Intensive treatment produced greater reductions in both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship between these two biomarkers and disease progression. METHODS: We performed intravascular ultrasonography in 502 patients with angiographically documented coronary disease. Patients were randomly assigned to receive moderate treatment (40 mg of pravastatin orally per day) or intensive treatment (80 mg of atorvastatin orally per day). Ultrasonography was repeated after 18 months to measure the progression of atherosclerosis. Lipoprotein and CRP levels were measured at baseline and follow-up. RESULTS: In the group as a whole, the mean LDL cholesterol level was reduced from 150.2 mg per deciliter (3.88 mmol per liter) at baseline to 94.5 mg per deciliter (2.44 mmol per liter) at 18 months (P<0.001), and the geometric mean CRP level decreased from 2.9 to 2.3 mg per liter (P<0.001). The correlation between the reduction in LDL cholesterol levels and that in CRP levels was weak but significant in the group as a whole (r=0.13, P=0.005), but not in either treatment group alone. In univariate analyses, the percent change in the levels of LDL cholesterol, CRP, apolipoprotein B-100, and non-high-density lipoprotein cholesterol were related to the rate of progression of atherosclerosis. After adjustment for the reduction in these lipid levels, the decrease in CRP levels was independently and significantly correlated with the rate of progression. Patients with reductions in both LDL cholesterol and CRP that were greater than the median had significantly slower rates of progression than patients with reductions in both biomarkers that were less than the median (P=0.001). CONCLUSIONS: For patients with coronary artery disease, the reduced rate of progression of atherosclerosis associated with intensive statin treatment, as compared with moderate statin treatment, is significantly related to greater reductions in the levels of both atherogenic lipoproteins and CRP.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Ohio State Univ, Med Ctr, Columbus, OH 43210 USA; Pfizer Inc, New York, NY USA; N Ohio Heart Care, Elyria, OH USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Cleveland Clinic Foundation; University System of Ohio; Ohio State University; Pfizer; Harvard University; Brigham & Women's Hospital	Nissen, SE (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nissens@ccf.org	Schoenhagen, Paul/A-2808-2012	Schoenhagen, Paul/0000-0002-7751-5243; Ganz, Peter/0000-0002-0437-8882				ABRAMOWICZ M, 2004, MED LETT DRUGS THER, V46, P37; Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; Chambers J. M., 1983, GRAPHICAL METHODS DA, DOI DOI 10.1201/9781351072304; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Eisen HJ, 2003, NEW ENGL J MED, V349, P847, DOI 10.1056/NEJMoa022171; Jarvisalo MJ, 2002, ARTERIOSCL THROM VAS, V22, P1323, DOI 10.1161/01.ATV.0000024222.06463.21; Kent SM, 2003, AM J CARDIOL, V92, P1224, DOI 10.1016/j.amjcard.2003.07.040; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; Neter J., 1983, APPL LINEAR REGRESSI; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Nissen SE, 2001, CIRCULATION, V103, P604, DOI 10.1161/01.CIR.103.4.604; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; PEDERSEN TR, 1994, LANCET, V344, P1383; Plenge JK, 2002, CIRCULATION, V106, P1447, DOI 10.1161/01.CIR.0000029743.68247.31; Ridker PM, 2003, CIRCULATION, V108, P2292, DOI 10.1161/01.CIR.0000100688.17280.E6; Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Sacks FM, 2004, JAMA-J AM MED ASSOC, V291, P1132, DOI 10.1001/jama.291.9.1132; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schoenhagen P, 2003, J AM SOC ECHOCARDIOG, V16, P277, DOI 10.1067/mje.2003.45; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Topol EJ, 2004, NEW ENGL J MED, V350, P1562, DOI 10.1056/NEJMe048061; Torzewski M, 2000, ARTERIOSCL THROM VAS, V20, P2094, DOI 10.1161/01.ATV.20.9.2094; Verma S, 2002, CIRCULATION, V106, P913, DOI 10.1161/01.CIR.0000029802.88087.5E; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561	31	1033	1097	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2005	352	1					29	38		10.1056/NEJMoa042000	http://dx.doi.org/10.1056/NEJMoa042000			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884UP	15635110				2022-12-28	WOS:000226112500005
J	McFalls, EO; Ward, HB; Moritz, TE; Goldman, S; Krupski, WC; Littooy, F; Pierpont, G; Santilli, S; Rapp, J; Hattler, B; Shunk, K; Jaenicke, C; Thottapurathu, L; Ellis, N; Reda, DJ; Henderson, WG				McFalls, EO; Ward, HB; Moritz, TE; Goldman, S; Krupski, WC; Littooy, F; Pierpont, G; Santilli, S; Rapp, J; Hattler, B; Shunk, K; Jaenicke, C; Thottapurathu, L; Ellis, N; Reda, DJ; Henderson, WG			Coronary-artery revascularization before elective major vascular surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONCARDIAC SURGERY; BYPASS-SURGERY; CARDIAC RISK; MYOCARDIAL-INFARCTION; DISEASE; ANGIOPLASTY; GUIDELINE; MORTALITY; SURVIVAL; OUTCOMES	BACKGROUND: The benefit of coronary-artery revascularization before elective major vascular surgery is unclear. METHODS: We randomly assigned patients at increased risk for perioperative cardiac complications and clinically significant coronary artery disease to undergo either revascularization or no revascularization before elective major vascular surgery. The primary end point was long-term mortality. RESULTS: Of 5859 patients scheduled for vascular operations at 18 Veterans Affairs medical centers, 510 (9 percent) were eligible for the study and were randomly assigned to either coronary-artery revascularization before surgery or no revascularization before surgery. The indications for a vascular operation were an expanding abdominal aortic aneurysm (33 percent) or arterial occlusive disease of the legs (67 percent). Among the patients assigned to preoperative coronary-artery revascularization, percutaneous coronary intervention was performed in 59 percent, and bypass surgery was performed in 41 percent. The median time from randomization to vascular surgery was 54 days in the revascularization group and 18 days in the group not undergoing revascularization (P<0.001). At 2.7 years after randomization, mortality in the revascularization group was 22 percent and in the no-revascularization group 23 percent (relative risk, 0.98; 95 percent confidence interval, 0.70 to 1.37; P=0.92). Within 30 days after the vascular operation, a postoperative myocardial infarction, defined by elevated troponin levels, occurred in 12 percent of the revascularization group and 14 percent of the no-revascularization group (P=0.37). CONCLUSIONS: Coronary-artery revascularization before elective vascular surgery does not significantly alter the long-term outcome. On the basis of these data, a strategy of coronary-artery revascularization before elective vascular surgery among patients with stable cardiac symptoms cannot be recommended.	Vet Adm Med Ctr, Div Cardiol, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Med, Div Cardiol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Div Cardiovasc & Thorac Surg, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Cooperat Studies Program Coordinating Ctr, Hines, IL USA; Vet Affairs Med Ctr, Div Peripheral Vasc Surg, Hines, IL USA; So Arizona VA Hlth Care Syst, Tucson, AZ USA; Univ Arizona, Sarver Heart Ctr, Tucson, AZ USA; Denver VA Med Ctr, Denver, CO USA; Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA 94143 USA; Univ Colorado, Hlth Outcomes Program, Aurora, CO USA; Univ Colorado, Dept Prevent Med & Biometr, Denver, CO 80202 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Arizona; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Denver	McFalls, EO (corresponding author), Vet Adm Med Ctr, Div Cardiol, 1 Vet Dr, Minneapolis, MN 55417 USA.	mcfal001@tc.umn.edu		, Domenic/0000-0003-1831-4270				Alderman EL, 1996, NEW ENGL J MED, V335, P217; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; Ellis SG, 1996, AM J CARDIOL, V77, P1126, DOI 10.1016/S0002-9149(96)00130-0; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; Hassan SA, 2001, AM J MED, V110, P260, DOI 10.1016/S0002-9343(00)00717-8; HERTZER NR, 1979, ARCH SURG-CHICAGO, V114, P1336; HERTZER NR, 1987, CLEV CLIN J MED, V54, P15, DOI 10.3949/ccjm.54.1.15; Kaluza GL, 2000, J AM COLL CARDIOL, V35, P1288, DOI 10.1016/S0735-1097(00)00521-0; KRUPSKI WC, 1992, J VASC SURG, V15, P354, DOI 10.1016/0741-5214(92)90257-9; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Mangano DT, 1997, NEW ENGL J MED, V336, P1039; McFalls EO, 1999, CONTROL CLIN TRIALS, V20, P297, DOI 10.1016/S0197-2456(99)00004-5; MCFALLS EO, 1993, J AM COLL CARDIOL, V21, P1347, DOI 10.1016/0735-1097(93)90307-M; Mesh CL, 1997, ANN VASC SURG, V11, P612, DOI 10.1007/s100169900099; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; Pierpont GL, 2004, AM J CARDIOL, V94, P1124, DOI 10.1016/j.amjcard.2004.07.077; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; RIHAL CS, 1995, CIRCULATION, V91, P46, DOI 10.1161/01.CIR.91.1.46; Shaw LJ, 1996, J AM COLL CARDIOL, V27, P787, DOI 10.1016/0735-1097(95)00549-8; The Bypass Angioplasty Revascularization Investigation (BARI) Investigators, 1997, NEW ENGL J MED, V336, P147	24	808	844	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2795	2804		10.1056/NEJMoa041905	http://dx.doi.org/10.1056/NEJMoa041905			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625331	Bronze			2022-12-28	WOS:000226004300004
J	Lum, JJ; Bauer, DE; Kong, M; Harris, MH; Li, C; Lindsten, T; Thompson, CB				Lum, JJ; Bauer, DE; Kong, M; Harris, MH; Li, C; Lindsten, T; Thompson, CB			Growth factor regulation of autophagy and cell survival in the absence of apoptosis	CELL			English	Article							MALIGNANT GLIOMA-CELLS; DROSOPHILA FAT-BODY; SACCHAROMYCES-CEREVISIAE; DEATH; MUTANTS; MACROAUTOPHAGY; PATHWAY; YEAST; GENE; SIZE	In animals, cells are dependent on extracellular signals to prevent apoptosis. However, using growth factor-dependent cells from Bax/Bak-deficient mice, we demonstrate that apoptosis is not essential to limit cell autonomous survival. Following growth factor withdrawal, Bax(-/-)Bak(-/-) cells activate autophagy, undergo progressive atrophy, and ultimately succumb to death. These effects result from loss of the ability to take up sufficient nutrients to maintain cellular bioenergetics. Despite abundant extracellular nutrients, growth factor-deprived cells maintain ATP production from catabolism of intracellular substrates through autophagy. Autophagy is essential for maintaining cell survival following growth factor withdrawal and can sustain viability for several weeks. During this time, cells respond to growth factor readdition by rapid restoration of the ability to take up and metabolize glucose and by subsequent recovery of their original size and proliferative potential. Thus, growth factor signal transduction is required to direct the utilization of sufficient exogenous nutrients to maintain cell viability.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA.	craig@mail.upenn.edu		Lum, Julian/0000-0002-5624-3541				Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Aubert S, 1996, J CELL BIOL, V133, P1251, DOI 10.1083/jcb.133.6.1251; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KUMA A, 2004, NATURE, V433, P1; Lam E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Nelson DA, 2004, GENE DEV, V18, P1223, DOI 10.1101/gad.1212404; Otto GP, 2004, J BIOL CHEM, V279, P15621, DOI 10.1074/jbc.M311139200; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Paglin S, 2001, CANCER RES, V61, P439; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 1999, MOL CELL, V3, P159; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266	48	1209	1269	4	131	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	2005	120	2					237	248		10.1016/j.cell.2004.11.046	http://dx.doi.org/10.1016/j.cell.2004.11.046			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680329	Bronze			2022-12-28	WOS:000226740000012
J	Burrows, A				Burrows, A			A theoretical look at the direct detection of giant planets outside the Solar System	NATURE			English	Review							EXTRASOLAR PLANET; BROWN DWARFS; TRANSITING PLANET; SPECTRA; EVOLUTION; SEPARATION; CHEMISTRY; JUPITER; MISSION; MODELS	Astronomy is at times a science of unexpected discovery. When it is, and if we are lucky, new intellectual territories emerge to challenge our views of the cosmos. The recent indirect detections using high-precision Doppler spectroscopy of more than 100 giant planets orbiting more than 100 nearby stars is an example of such rare serendipity. What has been learned has shaken out preconceptions, for none of the planetary systems discovered so far is like our own. The key to unlocking a planet's chemical, structural, and evolutionary secrets, however, is the direct detection of the planet's light. Because there have been as yet no confirmed detections, a theoretical analysis of such a planet's atmosphere is necessary for guiding our search.	Univ Arizona, Dept Astron, Tucson, AZ 85724 USA	University of Arizona	Burrows, A (corresponding author), Univ Arizona, Dept Astron, Tucson, AZ 85724 USA.	burrows@as.arizona.edu						Akeson R, 2000, ASTR SOC P, V212, P300; Akeson RL, 2000, P SOC PHOTO-OPT INS, V4006, P321, DOI 10.1117/12.390222; ALONSO R, IN PRESS ASTROPHYS J; Antonello E., 2002, Memorie della Societa Astronomica Italiana, V73, P1241; Aristidi E, 2003, ASTRON ASTROPHYS, V406, pL19, DOI 10.1051/0004-6361:20030836; ARNOLD I, 2004, DETECTABILITY EXTRAS, V1; Baraffe I, 2003, ASTRON ASTROPHYS, V402, P701, DOI 10.1051/0004-6361:20030252; Beichman C, 2002, P SOC PHOTO-OPT INS, V4835, P115, DOI 10.1117/12.461532; BEUZIT JL, 2004, SF2A 2004 SEM ASTR F, P32; Boss AP, 2001, ASTROPHYS J, V563, P367, DOI 10.1086/323694; Bouchy F, 2004, ASTRON ASTROPHYS, V421, pL13, DOI 10.1051/0004-6361:20040170; Brown TM, 2001, ASTROPHYS J, V552, P699, DOI 10.1086/320580; Burgasser AJ, 2002, ASTROPHYS J, V564, P421, DOI 10.1086/324033; BURKERT A, 2004, SURFACE HEATING SYNC; Burrows A, 1997, ASTROPHYS J, V491, P856, DOI 10.1086/305002; Burrows A, 2004, ASTROPHYS J, V609, P407, DOI 10.1086/420974; Burrows A, 2004, ASTROPHYS J, V610, pL53, DOI 10.1086/423173; BURROWS A, 1995, NATURE, V378, P333, DOI 10.1038/378333a0; Burrows A, 2003, ASTROPHYS J, V594, P545, DOI 10.1086/376897; Burrows A, 2001, REV MOD PHYS, V73, P719, DOI 10.1103/RevModPhys.73.719; Burrows A, 1999, ASTROPHYS J, V512, P843, DOI 10.1086/306811; Charbonneau D, 2000, ASTROPHYS J, V529, pL45, DOI 10.1086/312457; Charbonneau D, 2002, ASTROPHYS J, V568, P377, DOI 10.1086/338770; Cho JYK, 2003, ASTROPHYS J, V587, pL117, DOI 10.1086/375016; Davison W, 2003, P SOC PHOTO-OPT INS, V4840, P533, DOI 10.1117/12.459855; DYUDINA UA, 2004, PHASE LIGHT CURVES E; Guillot T, 2002, ASTRON ASTROPHYS, V385, P156, DOI 10.1051/0004-6361:20011624; Hawarden TG, 2003, ASTR SOC P, V294, P581; HENRY GW, 2000, APJ, V529, P41; Hinz P, 2000, P SOC PHOTO-OPT INS, V4006, P349, DOI 10.1117/12.390225; HINZ PM, 2001, THESIS U ARIZONA; Hubbard WB, 2001, ASTROPHYS J, V560, P413, DOI 10.1086/322490; KEATS J, 1884, 1 LOOKING CHAPMANS H; Koch D, 1998, P SOC PHOTO-OPT INS, V3356, P599, DOI 10.1117/12.324482; Konacki M, 2003, NATURE, V421, P507, DOI 10.1038/nature01379; Lodders K, 2002, ICARUS, V155, P393, DOI 10.1006/icar.2001.6740; Lodders K, 1999, ASTROPHYS J, V519, P793, DOI 10.1086/307387; MACARTHUR B, UNPUB ASTROPHYS J; Macintosh B, 2003, P SOC PHOTO-OPT INS, V5170, P272, DOI 10.1117/12.506836; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; Mather J, 2000, PROC SPIE, V4013, P2, DOI 10.1117/12.394042; MATTHEWS JM, 2001, ESA, P385; Menou K, 2003, ASTROPHYS J, V587, pL113, DOI 10.1086/375015; MIZUNO H, 1980, PROG THEOR PHYS, V64, P544, DOI 10.1143/PTP.64.544; PARESCE F, 2001, MESSENGER, V104, P5; Perryman MAC, 2003, ASTR SOC P, V298, P3; PONT F, 2004, IN PRESS ASTRON ASTR; Racine R, 1999, PUBL ASTRON SOC PAC, V111, P587, DOI 10.1086/316367; Sasselov DD, 2003, ASTROPHYS J, V596, P1327, DOI 10.1086/378145; Saumon D, 2004, ASTROPHYS J, V609, P1170, DOI 10.1086/421257; SCHNEIDER G, 2002, DOMAINS OBSERVABILIT; SCHNEIDER J, 2004, EXTRASOLAR PLANET EN; Seager S, 2000, ASTROPHYS J, V537, P916, DOI 10.1086/309088; Seager S, 2000, ASTROPHYS J, V540, P504, DOI 10.1086/309292; SHAO M, 2003, BAAS, V203; Showman AP, 2002, ASTRON ASTROPHYS, V385, P166, DOI 10.1051/0004-6361:20020101; STROM S, 2003, BAAS, V203; Sudarsky D, 2003, ASTROPHYS J, V588, P1121, DOI 10.1086/374331; Sudarsky D, 2000, ASTROPHYS J, V538, P885, DOI 10.1086/309160; TAMURA I, 2003, P IAU 8 AS PAC REG M, V1, P73; Torres G, 2004, ASTROPHYS J, V609, P1071, DOI 10.1086/421286; TRAUGER J, 2001, BAAS, V199, P1431; TRAUGER J, 2000, BAAS, V197, P1486; Trilling DE, 1998, ASTROPHYS J, V500, P428, DOI 10.1086/305711; Unwin SC, 2000, PROC SPIE, V4006, P754, DOI 10.1117/12.390275; Vidal-Madjar A, 2003, NATURE, V422, P143, DOI 10.1038/nature01448	69	80	82	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					261	268		10.1038/nature03244	http://dx.doi.org/10.1038/nature03244			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662414	Green Submitted			2022-12-28	WOS:000226381300044
J	Cote, IM; Cheney, KL				Cote, IM; Cheney, KL			Animal mimicry: Choosing when to be a cleaner-fish mimic - A dangerous fish can discard a seemingly harmless disguise to suit its circumstances	NATURE			English	Editorial Material									Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Cote, IM (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England.	i.cote@uea.ac.uk	Cheney, Karen L/A-6827-2013; Cote, Isabelle/ABD-5898-2021; Cheney, Karen/L-3427-2018	Cheney, Karen L/0000-0001-5622-9494; Cheney, Karen/0000-0001-5622-9494				Cote IM, 2004, P ROY SOC B-BIOL SCI, V271, P2627, DOI 10.1098/rspb.2004.2904; Grutter AS, 1999, NATURE, V398, P672, DOI 10.1038/19443; Kuwamura T., 1981, Nanki Seibutu, V23, P61; Randall JE, 1997, FISHES GREAT BARRIER; RUSSELL BC, 1976, J ZOOL, V180, P407; SMITHVANIZ WF, 1976, ACAD NAT SCI PHILADE, V19, P1	6	31	33	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2005	433	7023					211	212		10.1038/433211a	http://dx.doi.org/10.1038/433211a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662402				2022-12-28	WOS:000226381300028
J	Ahn, SH; Cheung, WL; Hsu, JY; Diaz, RL; Smith, MM; Allis, CD				Ahn, SH; Cheung, WL; Hsu, JY; Diaz, RL; Smith, MM; Allis, CD			Sterile 20 kinase phosphorylates histone H2B at serine 10 during hydrogen peroxide-induced apoptosis in S. cerevisiae	CELL			English	Article							PROGRAMMED CELL-DEATH; PROTEIN-KINASE; YEAST; DNA; PCR; PROLIFERATION; MODULES; STE20P; GROWTH; HIPPO	Apoptosis is a highly coordinated cell suicide mechanism in vertebrates. Phosphorylation of serine 14 of histone H2B, catalyzed by Mst1 kinase, has been linked to chromatin compaction during apoptosis. We extend these results to unicellular eukaryotes by demonstrating that H2B is specifically phosphorylated at serine 10 (S10) in a hydrogen peroxide-induced cell death pathway in S. cerevisiae. H2B S10A mutants are resistant to cell death elicited by H2O2 while H2B S10E phospho-site mimics promote cell death and induce the "constitutive" formation of condensed chromatin. Ste20 kinase, a yeast homolog of mammalian Mst1 kinase, translocates into the nucleus in a caspase-independent fashion and directly phosphorylates H2B at S10. Conservation of targeted H2B phosphorylation and the enzyme system responsible for the process point to an ancient mechanism of chromatin remodeling that likely plays an important role in governing cellular homeostasis in a wide range of organisms.	Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Biochem, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Mol Genet, Charlottesville, VA 22908 USA	Rockefeller University; University of Virginia; University of Virginia; University of Virginia	Allis, CD (corresponding author), Rockefeller Univ, Lab Chromatin Biol, Box 78, New York, NY 10021 USA.	alliscd@rockefeller.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040922] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40922] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; de la Barre AE, 2001, EMBO J, V20, P6383, DOI 10.1093/emboj/20.22.6383; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fernandez-Capetillo O, 2004, J EXP MED, V199, P1671, DOI 10.1084/jem.20032247; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kitazono AA, 2002, YEAST, V19, P141, DOI 10.1002/yea.806; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ludovico P, 2001, MICROBIOL-SGM, V147, P3335, DOI 10.1099/00221287-147-12-3335; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Narasimhan ML, 2001, MOL CELL, V8, P921, DOI 10.1016/S1097-2765(01)00365-3; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rose MD., 1990, METHODS YEAST GENETI; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; SIKORSKI RS, 1989, GENETICS, V122, P19; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang Z, 2003, BIOCHEM PHARMACOL, V65, P1767, DOI 10.1016/S0006-2952(03)00117-5; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhang Q, 2003, J BIOL CHEM, V278, P47145, DOI 10.1074/jbc.M306998200	37	198	212	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					25	36		10.1016/j.cell.2004.11.016	http://dx.doi.org/10.1016/j.cell.2004.11.016			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652479	Bronze			2022-12-28	WOS:000226365400008
J	Balco, G; Rovey, CW; Stone, JOH				Balco, G; Rovey, CW; Stone, JOH			The first glacial maximum in North America	SCIENCE			English	Article							HISTORY		Univ Washington, Quaternary Res Ctr, Seattle, WA 98915 USA; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98915 USA; SW Missouri State Univ, Dept Geog Geol & Planning, Springfield, MO 65804 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Missouri State University	Balco, G (corresponding author), Univ Washington, Quaternary Res Ctr, Seattle, WA 98915 USA.	balcs@u.washington.edu						JOYCE JE, 1993, GEOLOGY, V21, P483, DOI 10.1130/0091-7613(1993)021<0483:NAGMHF>2.3.CO;2; Partridge TC, 2003, SCIENCE, V300, P607, DOI 10.1126/science.1081651; Rovey CW, 1996, QUATERNARY RES, V45, P17, DOI 10.1006/qres.1996.0002; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0	4	71	75	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2005	307	5707					222	222		10.1126/science.1103406	http://dx.doi.org/10.1126/science.1103406			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653495				2022-12-28	WOS:000226361900032
J	Balmford, A; Bennun, L; ten Brink, B; Cooper, D; Cote, IM; Crane, P; Dobson, A; Dudley, N; Dutton, I; Green, RE; Gregory, RD; Harrison, J; Kennedy, ET; Kremen, C; Leader-Williams, N; Lovejoy, TE; Mace, G; May, R; Mayaux, P; Morling, P; Phillips, J; Redford, K; Ricketts, TH; Rodriguez, JP; Sanjayan, M; Schei, PJ; van Jaarsveld, AS; Walther, BA				Balmford, A; Bennun, L; ten Brink, B; Cooper, D; Cote, IM; Crane, P; Dobson, A; Dudley, N; Dutton, I; Green, RE; Gregory, RD; Harrison, J; Kennedy, ET; Kremen, C; Leader-Williams, N; Lovejoy, TE; Mace, G; May, R; Mayaux, P; Morling, P; Phillips, J; Redford, K; Ricketts, TH; Rodriguez, JP; Sanjayan, M; Schei, PJ; van Jaarsveld, AS; Walther, BA			The convention on biological diversity's 2010 target	SCIENCE			English	Article									Royal Bot Gardens, Richmond, England; Univ Cambridge, Cambridge CB2 1TN, England; Univ Cape Town, ZA-7700 Rondebosch, South Africa; BirdLife Int, Cambridge, England; RIVM, Bilthoven, Netherlands; Univ E Anglia, Norwich NR4 7TJ, Norfolk, England; Princeton Univ, Princeton, NJ 08544 USA; Royal Soc Protect Birds, Sandy SG19 2DL, Beds, England; UN, Environm Program, World Conservat Monitoring Ctr, New York, NY USA; Conservat Int, Washington, DC USA; Univ Kent, Canterbury CT2 7NZ, Kent, England; Zool Soc London, London, England; Univ Oxford, Oxford OX1 2JD, England; Commiss European Communities, Joint Res Ctr, I-21020 Ispra, Italy; Wildlife Conservat Soc, Bronx, NY USA; World Wildlife Fund, Washington, DC 20037 USA; Inst Venezolano Invest Cient, Caracas, Venezuela; Univ Stellenbosch, ZA-7600 Stellenbosch, South Africa	Royal Botanic Gardens, Kew; University of Cambridge; University of Cape Town; BirdLife International; Netherlands National Institute for Public Health & the Environment; University of East Anglia; Princeton University; Royal Society for Protection of Birds; United Nations Environment Programme; Conservation International; University of Kent; Zoological Society of London; University of Oxford; European Commission Joint Research Centre; EC JRC ISPRA Site; Wildlife Conservation Society; World Wildlife Fund; Venezuelan Institute Science Research; Stellenbosch University	Dobson, A (corresponding author), Royal Bot Gardens, Richmond, England.	dobber@prince-ton.edu	Rodriguez, Jon P/A-1491-2009; Mace, Georgina M/I-3072-2016; Rodriguez, Jon P/G-7224-2012; Cote, Isabelle/ABD-5898-2021; van Jaarsveld, Albert/H-5368-2013	Rodriguez, Jon P/0000-0001-5019-2870; Mace, Georgina M/0000-0001-8965-5211; Cooper, David/0000-0003-4538-205X; Gregory, Richard/0000-0002-7419-5053; Crane, Peter/0000-0003-4331-6948; Balmford, Andrew/0000-0002-0144-3589				Adams WM, 2004, SCIENCE, V306, P1146, DOI 10.1126/science.1097920; [Anonymous], 1997, NATURES SERVICES; Balmford A, 2002, SCIENCE, V297, P950, DOI 10.1126/science.1073947; BUTCHART SHM, IN PRESS NATURE; CDB, 2002, CONTRIBUTION 6 NATL; COTE IM, IN PRESS PHILOS T B; Department of Environment Food and Rural Affairs (DEFRA), 2002, ACH BETT QUAL LIF RE; Donald PF, 2001, P ROY SOC B-BIOL SCI, V268, P25, DOI 10.1098/rspb.2000.1325; *EUR COUNC, 2001, SN200101 EC, P8; GREGORY RD, IN PRESS T R SOC L B; Heinz Center, 2002, STAT NAT EC MEAS LAN; Homewood KM, 2004, ENVIRON SCI POLICY, V7, P125, DOI 10.1016/j.envsci.2003.12.006; HUTCHINGS JA, IN PRESS PHILOS T B; LOH J, IN PRESS PHILOS T B; MAYAUX P, IN PRESS PHILOS T B; MEA (Millenium Ecosystem Assessment), 2003, ECOSYSTEMS HUMAN WEL; PAULY D, IN PRESS PHILOS T B; Ten Brink B J E, 2000, 402001014 RIVM NAT I; *UNEP, 2003, UNEPCCBDSBSTTA9INF26; *UNEP, 2004, C PART CONV BIOL DIV	20	299	319	7	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					212	213		10.1126/science.1106281	http://dx.doi.org/10.1126/science.1106281			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653489				2022-12-28	WOS:000226361900026
J	Evason, K; Huang, C; Yamben, I; Covey, DF; Kornfeld, K				Evason, K; Huang, C; Yamben, I; Covey, DF; Kornfeld, K			Anticonvulsant medications extend worm life-span	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; MUTANTS; ETHOSUXIMIDE; LONG	Genetic studies have elucidated mechanisms that regulate aging, but there has been little progress in identifying drugs that delay aging. Here, we report that ethosuximide, trimethadione, and 3,3-diethyl-2-pyrrolidinone increase mean and maximum life-span of Caenorhabditis elegans and delay age-related declines of physiological processes, indicating that these compounds retard the aging process. These compounds, two of which are approved for human use, are anticonvulsants that modulate neural activity. These compounds also regulated neuromuscular activity in nematodes. These findings suggest that the life-span-extending activity of these compounds is related to the anticonvulsant activity and implicate neural activity in the regulation of aging.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, K (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.	kornfeid@molecool.wustl.edu	Evason, Kimberley/AAC-2506-2020		NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG05681] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ailion M, 1999, P NATL ACAD SCI USA, V96, P7394, DOI 10.1073/pnas.96.13.7394; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; COULTER DA, 1989, ANN NEUROL, V25, P582, DOI 10.1002/ana.410250610; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gems D, 2002, AGING CELL, V1, P1, DOI 10.1046/j.1474-9728.2002.00003.x; Gems D, 2000, GENETICS, V154, P1597; Gomora JC, 2001, MOL PHARMACOL, V60, P1121, DOI 10.1124/mol.60.5.1121; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Huang C, 2004, P NATL ACAD SCI USA, V101, P8084, DOI 10.1073/pnas.0400848101; KATZUNG BG, 1998, BASIC CLIN PHARM; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Leresche N, 1998, J NEUROSCI, V18, P4842; Levy R.H., 2002, ANTIEPILEPTIC DRUGS, V5th ed.; McKay JP, 2004, GENETICS, V166, P161, DOI 10.1534/genetics.166.1.161; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; Reddy PA, 1996, J MED CHEM, V39, P1898, DOI 10.1021/jm9600196; Riddle D. L, 1997, COLD SPRING HARBOR M, V33; TRENT C, 1983, GENETICS, V104, P619	20	149	171	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					258	262		10.1126/science.1105299	http://dx.doi.org/10.1126/science.1105299			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653505				2022-12-28	WOS:000226361900044
J	Kotwal, RS; Wenzel, RB; Sterling, RA; Porter, WD; Jordan, NN; Petruccelli, BP				Kotwal, RS; Wenzel, RB; Sterling, RA; Porter, WD; Jordan, NN; Petruccelli, BP			An outbreak of malaria in US Army Ranges returning from Afghanistan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS-SYNDROME; PLASMODIUM-VIVAX MALARIA; UNITED-STATES; PRIMAQUINE; WAR; CHEMOPROPHYLAXIS; RESISTANCE; SOLDIERS; VIETNAM; SOMALIA	Context With numerous US military personnel currently deployed throughout the world, military and civilian health care professionals may encounter imported malaria from this population. Objective To identify malaria in US Army personnel deployed to a combat zone. Design, Setting, and Patients Case series in the US Army health care system. A total of 38 cases of malaria were identified in a 725-man Ranger Task Force that deployed to eastern Afghanistan between June and September 2002. Main Outcome Measures Identification of malaria cases and soldiers' self-report of compliance with antimalarial measures. Results A total of 38 patients were infected with Plasmodium vivax, yielding an attack rate of 52.4 cases per 1000 soldiers. Diagnosis was confirmed a median of 233 days (range, 1-339 days) after return from the malaria endemic region, with additional laboratory findings noting anemia and thrombocytopenia. One case was complicated with acute respiratory distress syndrome during the patient's primary attack and a spontaneous pneumothorax during relapse. This case accounted for 1 of 2 relapse cases in the study population. From an anonymous postdeployment survey of 72% (521/725) of the task force, the self-reported compliance rate was 52% for weekly chemoprophylaxis, 41% for terminal (postdeployment) chemoprophylaxis, 31% for both weekly and terminal chemoprophylaxis, 82% for treating uniforms with permethrin, and 29% for application of insect repellent. Conclusions Delayed clinical presentation can occur with P vivax. Symptoms are often vague, but malaria should be included in the differential diagnosis for soldiers returning from an endemic region. Suboptimal compliance with preventive measures can result in a malaria outbreak.	Naval Operat Med Inst, Army Navy Aerosp Med Residency, Pensacola, FL 32508 USA; Univ Texas, Med Branch, Dept Prevent Med, Galveston, TX 77550 USA; Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Bethesda, MD 20814 USA; 75th Ranger Regiment, Ft Benning, GA USA; 1st Cavalry Div, Div Prevent Med, Ft Hood, TX USA; USA, Ctr Hlth Promot & Prevent Med, Aberdeen Proving Ground, MD USA	University of Texas System; University of Texas Medical Branch Galveston; Uniformed Services University of the Health Sciences - USA	Kotwal, RS (corresponding author), Naval Operat Med Inst, Army Navy Aerosp Med Residency, Pensacola, FL 32508 USA.	russ.kotwal@us.army.mil						Addington W, 2003, ANN INTERN MED, V139, P305, DOI 10.7326/0003-4819-139-4-200308190-00024; *AFMIC, 2002, 05202 AFMIC; *AFMIC, 2002, 04002 AFMIC; *ARM MED SURV ACT, 2004, DEF MED EP DAT VERS; Baird JK, 2004, CLIN INFECT DIS, V39, P1336, DOI 10.1086/424663; BARRETT O, 1969, AM J TROP MED HYG, V18, P495, DOI 10.4269/ajtmh.1969.18.495; BEADLE C, 1993, CLIN INFECT DIS, V16, P320, DOI 10.1093/clind/16.2.320; Carlini ME, 1999, CLIN INFECT DIS, V28, P1182, DOI 10.1086/517779; *CDCP, 2001, MAL SURV US 2001; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P22; *CDCP, 2003, HLTH INF INT TRAV 20; Chin J, 2001, CONTROL COMMUNICABLE, P310; COATES JB, 1963, PREVENTIVE MED WORLD; Collins WE, 1996, AM J TROP MED HYG, V55, P243, DOI 10.4269/ajtmh.1996.55.243; Curlin ME, 1999, CLIN INFECT DIS, V28, P1166, DOI 10.1086/517767; Gambel JM, 1998, J TRAVEL MED, V5, P217, DOI 10.1111/j.1708-8305.1998.tb00511.x; ISLAM N, 1995, TROP GEOGR MED, V47, P141; Joy RJT, 1999, MED HIST, V43, P192, DOI 10.1017/S002572730006508X; NEWTON JA, 1994, JAMA-J AM MED ASSOC, V272, P397, DOI 10.1001/jama.272.5.397; PUKRITTAYAKAMEE S, 1994, J INFECT DIS, V169, P932, DOI 10.1093/infdis/169.4.932; Robert L L, 2001, Med Trop (Mars), V61, P67; SHANKS GD, 1991, MIL MED, V156, P684, DOI 10.1093/milmed/156.12.684; Shanks GD, 2001, CLIN INFECT DIS, V33, P381, DOI 10.1086/321866; SHANKS GD, 1995, MED J AUSTRALIA, V162, P306, DOI 10.5694/j.1326-5377.1995.tb139906.x; Smoak BL, 1997, AM J TROP MED HYG, V56, P231, DOI 10.4269/ajtmh.1997.56.231; Tanios MA, 2001, CRIT CARE MED, V29, P665, DOI 10.1097/00003246-200103000-00037; *US DEP ARM, 2000, FIELD MAN 4 02 17 PR; *WHO EXP COMM MAL, 1998, WHO TECHN REP SER, V892	28	83	86	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2005	293	2					212	216		10.1001/jama.293.2.212	http://dx.doi.org/10.1001/jama.293.2.212			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885QC	15644548	Bronze			2022-12-28	WOS:000226171000037
J	Paton, A				Paton, A			ABC of alcohol - Alcohol in the body	BRITISH MEDICAL JOURNAL			English	Review												PatonAlex@aol.com						LEWIS KO, 1987, BRIT MED J, V295, P800, DOI 10.1136/bmj.295.6602.800; LIEBER CS, 1992, WRIGHTS LIVER BILIAR, P899; PATON A, 2000, ALCOHOL USE, P25	3	70	73	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 8	2005	330	7482					85	87		10.1136/bmj.330.7482.85	http://dx.doi.org/10.1136/bmj.330.7482.85			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887GR	15637372	Green Published			2022-12-28	WOS:000226294300023
J	Garant, D; Kruuk, LEB; Wilkin, TA; McCleery, RH; Sheldon, BC				Garant, D; Kruuk, LEB; Wilkin, TA; McCleery, RH; Sheldon, BC			Evolution driven by differential dispersal within a wild bird population	NATURE			English	Article							GREAT TITS; GENE FLOW; SELECTION; BLUE; HERITABILITY; COMPETITION; TRAITS; SIZE	Evolutionary theory predicts that local population divergence will depend on the balance between the diversifying effect of selection and the homogenizing effect of gene flow(1-3). However, spatial variation in the expression of genetic variation will also generate differential evolutionary responses. Furthermore, if dispersal is non-random it may actually reinforce, rather than counteract, evolutionary differentiation. Here we document the evolution of differences in body mass within a population of great tits, Parus major, inhabiting a single continuous woodland, over a 36-year period. We show that genetic variance for nestling body mass is spatially variable, that this generates different potential responses to selection, and that this diversifying effect is reinforced by non-random dispersal. Matching the patterns of variation, selection and evolution with population ecological data, we argue that the small-scale differentiation is driven by density-related differences in habitat quality affecting settlement decisions. Our data show that when gene flow is not homogeneous, evolutionary differentiation can be rapid and can occur over surprisingly small spatial scales. Our findings have important implications for questions of the scale of adaptation and speciation, and challenge the usual treatment of dispersal as a force opposing evolutionary differentiation.	Univ Oxford, Dept Zool, Edward Grey Inst, Oxford OX1 3PS, England; Univ Edinburgh, Sch Biol Sci, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Oxford; University of Edinburgh	Garant, D (corresponding author), Univ Oxford, Dept Zool, Edward Grey Inst, S Parks Rd, Oxford OX1 3PS, England.	dany.garant@zoology.oxford.ac.uk	Kruuk, Loeske/AAB-8714-2019; Kruuk, Loeske E. B./J-3295-2012; Sheldon, Ben C/A-8056-2010; Garant, Dany/D-7406-2013; Wilkin, Teddy/B-9979-2008	Kruuk, Loeske/0000-0001-8588-1123; Kruuk, Loeske E. B./0000-0001-8588-1123; Sheldon, Ben C/0000-0002-5240-7828; Garant, Dany/0000-0002-8091-1044; 				Barton Nick H., 2001, P329; Blondel J, 1999, SCIENCE, V285, P1399, DOI 10.1126/science.285.5432.1399; Braillet C, 2002, J AVIAN BIOL, V33, P446, DOI 10.1034/j.1600-048X.2002.02956.x; Doebeli M, 2003, NATURE, V421, P259, DOI 10.1038/nature01274; Endler J.A., 1977, Monographs in Population Biology, pi; Endler J.A., 1986, Monographs in Population Biology, pviii; Fairbairn DJ, 1996, EVOLUTION, V50, P1549, DOI 10.1111/j.1558-5646.1996.tb03927.x; FELSENSTEIN J, 1976, ANNU REV GENET, V10, P253, DOI 10.1146/annurev.ge.10.120176.001345; Garant D, 2004, AM NAT, V164, pE115, DOI 10.1086/424764; GarciaRamos G, 1997, EVOLUTION, V51, P21, DOI [10.2307/2410956, 10.1111/j.1558-5646.1997.tb02384.x]; GROENEVELD E, 1992, ARCH TIERZUCHT, V35, P399; HARVEY PH, 1979, J ANIM ECOL, V48, P305, DOI 10.2307/4115; Hendry AP, 2001, EVOLUTION, V55, P459, DOI 10.1554/0014-3820(2001)055[0459:PMATAD]2.0.CO;2; Hoffmann AA, 1999, TRENDS ECOL EVOL, V14, P96, DOI 10.1016/S0169-5347(99)01595-5; Jensen H, 2003, J EVOLUTION BIOL, V16, P1296, DOI 10.1046/j.1420-9101.2003.00614.x; Lynch M., 1998, GENETICS ANAL QUANTI; Merila J, 2001, NATURE, V412, P76, DOI 10.1038/35083580; MINOT EO, 1981, J ANIM ECOL, V50, P375, DOI 10.2307/4061; MINOT EO, 1986, J ANIM ECOL, V55, P331, DOI 10.2307/4712; Naef-Daenzer B, 2001, J ANIM ECOL, V70, P730, DOI 10.1046/j.0021-8790.2001.00533.x; Neumaier A, 1998, GENET SEL EVOL, V30, P3, DOI 10.1051/gse:19980101; PERRINS CM, 1965, J ANIM ECOL, V34, P601, DOI 10.2307/2453; Postma E, 2005, NATURE, V433, P65, DOI 10.1038/nature03083; RHYNSBURGER D, 1973, GEOGR ANAL, V5, P133; SLATKIN M, 1987, SCIENCE, V236, P787, DOI 10.1126/science.3576198; Smith TB, 1997, SCIENCE, V276, P1855, DOI 10.1126/science.276.5320.1855; SPITZE K, 1993, GENETICS, V135, P367; van der Jeugd HP, 2002, J EVOLUTION BIOL, V15, P380, DOI 10.1046/j.1420-9101.2002.00411.x; Verhulst S, 1997, ECOLOGY, V78, P864, DOI 10.1890/0012-9658(1997)078[0864:NDOGTI]2.0.CO;2; *VSN INT, 2003, GENSTAT VERS 7 1	30	227	236	1	102	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					60	65		10.1038/nature03051	http://dx.doi.org/10.1038/nature03051			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635409				2022-12-28	WOS:000226117100035
J	Raine, TR; Harper, CC; Rocca, CH; Fischer, R; Padian, N; Klausner, JD; Darney, PD				Raine, TR; Harper, CC; Rocca, CH; Fischer, R; Padian, N; Klausner, JD; Darney, PD			Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY PHARMACIES; ADVANCE PROVISION; NATIONAL-SURVEY; USERS; PILLS; FDA	Context It is estimated that half of unintended pregnancies could be averted if emergency contraception (EC) were easily accessible and used. Objective To evaluate the effect of direct access to EC through pharmacies and advance provision on reproductive health outcomes. Design, Setting, and Participants A randomized, single-blind, controlled trial (July 2001-June 2003) of 2117 women, ages 15 to 24 years, attending 4 California clinics providing family planning services, who were not desiring pregnancy, using long-term hormonal contraception or requesting EC. Intervention Participants were assigned to 1 of the following groups: (1) pharmacy access to EC; (2) advance provision of 3 packs of levonorgestrel EC; or (3) clinic access (control). Main Outcome Measures Primary outcomes were use of EC, pregnancies, and sexually transmitted infections (STIs) assessed at 6 months; secondary outcomes were changes in contraceptive and condom use and sexual behavior. Results Women in the pharmacy access group were no more likely to use EC (24.2%) than controls (21.0%) (P=.25). Women in the advance provision group (37.4%) were almost twice as likely to use EC than controls (21.0%) (P<.001) even though the frequency of unprotected intercourse was similar (39.8% vs 41.0%, respectively, P=.46). Only half (46.7%) of study participants who had unprotected intercourse used EC over the study period. Eight percent of participants became pregnant and 12% acquired an STI; compared with controls, women in the pharmacy access and advance provision groups did not experience a significant reduction in pregnancy rate (pharmacy access group: adjusted odds ratio [OR], 0.98; 95% confidence interval [CI], 0.58-1.64; P=.93; advance provision group: OR, 1.10; 95% CI, 0.66-1.84, P=.71) or increase in STIs (pharmacy access group: adjusted OR, 1.08, 95% CI, 0.71-1.63, P=.73; advance provision group: OR, 0.94, 95% CI, 0.62-1.44, P=.79). There were no differences in patterns of contraceptive or condom use or sexual behaviors by study group. Conclusions While removing the requirement to go through pharmacists or clinics to obtain EC increases use, the public health impact may be negligible because of high rates of unprotected intercourse and relative underutilization of the method. Given that there is clear evidence that neither pharmacy access nor advance provision compromises contraceptive or sexual behavior, it seems unreasonable to restrict access to EC to clinics.	Univ Calif San Francisco, Ctr Reprod Hlth Res & Policy, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Planned Parenthood Mar Monte, San Jose, CA USA; San Francisco Dept Publ Hlth, San Francisco, CA USA	University of California System; University of California San Francisco; San Francisco Department of Public Health	Raine, TR (corresponding author), San Francisco Gen Hosp, Dept Obstet Gynecol & Reprod Sci, 1001 Potrero Ave, San Francisco, CA 94110 USA.	rainet@obgyn.ucsf.edu						Bissell P, 2003, SOC SCI MED, V57, P2367, DOI 10.1016/S0277-9536(03)00129-1; Drazen JM, 2004, NEW ENGL J MED, V350, P1561, DOI 10.1056/NEJMe048057; Ellertson C, 2001, OBSTET GYNECOL, V98, P570, DOI 10.1016/S0029-7844(01)01506-X; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Gardner JS, 2001, FAM PLANN PERSPECT, V33, P172, DOI 10.2307/2673721; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Glasier A, 2004, CONTRACEPTION, V69, P361, DOI 10.1016/j.contraception.2004.01.002; Gold MA, 1997, FAM PLANN PERSPECT, V29, P15, DOI 10.2307/2953348; Gold Melanie A, 2004, J Pediatr Adolesc Gynecol, V17, P87, DOI 10.1016/j.jpag.2003.11.018; Grimes D, 1998, LANCET, V352, P428; Harvey SM, 1999, FAM PLANN PERSPECT, V31, P237, DOI 10.2307/2991571; Jackson RA, 2003, OBSTET GYNECOL, V102, P8, DOI 10.1016/S0029-7844(03)00478-2; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Lovvorn A, 2000, CONTRACEPTION, V61, P287, DOI 10.1016/S0010-7824(00)00107-4; Mosher WD, 1998, FAM PLANN PERSPECT, V30, P43, DOI 10.2307/2991525; Paukku M, 2003, OBSTET GYNECOL, V101, P534, DOI 10.1016/S0029-7844(02)02717-5; Porco TC, 2004, AIDS, V18, P81, DOI 10.1097/00002030-200401020-00010; Raine T, 2000, OBSTET GYNECOL, V96, P1, DOI 10.1016/S0029-7844(00)00830-9; Raine T, 2002, OBSTET GYNECOL, V99, P241, DOI 10.1016/S0029-7844(01)01714-8; Roye CF, 2001, J ADOLESCENT HEALTH, V28, P165, DOI 10.1016/S1054-139X(01)00203-8; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857; Vastag B, 2004, JAMA-J AM MED ASSOC, V291, P2805, DOI 10.1001/jama.291.23.2805	22	237	243	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2005	293	1					54	62		10.1001/jama.293.1.54	http://dx.doi.org/10.1001/jama.293.1.54			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QY	15632336	Bronze			2022-12-28	WOS:000226102100021
J	Brocklehurst, P; McGuire, W				Brocklehurst, P; McGuire, W			ABC of preterm birth - Evidence based care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRIAL; CONSENT		Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford, England; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland	University of Oxford; University of Dundee	Brocklehurst, P (corresponding author), Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Oxford, England.		Brocklehurst, Peter/B-5804-2011	McGuire, William/0000-0001-8572-3467				Field D, 1999, ARCH DIS CHILD-FETAL, V81, pF161, DOI 10.1136/fn.81.3.F161; Horbar JD, 2004, BMJ-BRIT MED J, V329, P1004, DOI 10.1136/bmj.329.7473.1004; Leviton LC, 1999, JAMA-J AM MED ASSOC, V281, P46, DOI 10.1001/jama.281.1.46; Manning DJ, 2000, J MED ETHICS, V26, P249, DOI 10.1136/jme.26.4.249; Mason SA, 2000, LANCET, V356, P2045, DOI 10.1016/S0140-6736(00)03401-2; Tin W, 1998, ARCH DIS CHILD-FETAL, V79, pF83, DOI 10.1136/fn.79.2.F83	6	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					36	38		10.1136/bmj.330.7481.36	http://dx.doi.org/10.1136/bmj.330.7481.36			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15626805	Green Published			2022-12-28	WOS:000226176700020
J	Lucassen, A; Watson, E				Lucassen, A; Watson, E			10-minute consultation - Family history of breast cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England; Univ Oxford, Canc Res UK Primary Care Educ Res Grp, Oxford OX3 7LF, England	Cancer Research UK; University of Oxford	Lucassen, A (corresponding author), Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England.	aiinekel@soton.ac.uk	Watson, Eila/R-1182-2019; Lucassen, Anneke/D-7764-2017	Watson, Eila/0000-0002-3592-1315; Lucassen, Anneke/0000-0003-3324-4338				*CANC RES UK PRIM, FAM BREAST OV CANC P; LUCASSEN A, 1994, BRIT MED J, V322, P1040; *NAT I CLIN EV, CG014 NICE	3	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					26	26		10.1136/bmj.330.7481.26	http://dx.doi.org/10.1136/bmj.330.7481.26			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15626802	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000226176700016
J	Pereira, MA; Kartashov, AI; Ebbeling, CB; Van Horn, L; Slattery, M; Jacobs, DR; Ludwig, DS				Pereira, MA; Kartashov, AI; Ebbeling, CB; Van Horn, L; Slattery, M; Jacobs, DR; Ludwig, DS			Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis	LANCET			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY-HEART-DISEASE; GLYCEMIC INDEX; DIABETES-MELLITUS; DIETARY FIBER; OBESITY; CHILDREN; WOMEN; RISK; PREVALENCE	Background Fast-food consumption has increased greatly in the USA during the past three decades. However, the effect of fast food on risk of obesity and type 2 diabetes has received little attention. We aimed to investigate the association between reported fast-food habits and changes in bodyweight and insulin resistance over a 15-year period in the USA. Methods Participants for the CARDIA study included 3031 young (age 18-30 years in 1985-86) black and white adults who were followed up with repeated dietary assessment. We used multiple linear regression models to investigate the association of frequency of fast-food restaurant visits (fast-food frequency) at baseline and follow-up with 15-year changes in bodyweight and the homoeostasis model (HOMA) for insulin resistance. Findings Fast-food frequency was lowest for white women (about 1.3 times per week) compared with the other ethnic-sex groups (about twice a week). After adjustment for lifestyle factors, baseline fast-food frequency was directly associated with changes in bodyweight in both black (p=0.0050) and white people (p=0.0013). Change in fast-food frequency over 15 years was directly associated with changes in bodyweight in white individuals (p<0.0001), with a weaker association recorded in black people (p=0.1004). Changes were also directly associated with insulin resistance in both ethnic groups (p=0.0015 in black people, p<0.0001 in white people). By comparison with the average 15-year weight gain in participants with infrequent (less than once a week) fast-food restaurant use at baseline and follow-up (n=203), those with frequent (more than twice a week) visits to fast-food restaurants at baseline and follow-up (n=87) gained an extra 4.5 kg of bodyweight (p=0.0054) and had a two-fold greater increase in insulin resistance (p=0.0083). Interpretation Fast-food consumption has strong positive associations with weight gain and insulin resistance, suggesting that fast food increases the risk of obesity and type 2 diabetes.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA; Childrens Hosp, Clin Res Program, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA; Univ Utah, Sch Med, Salt Lake City, UT USA; Univ Oslo, Dept Nutr, Oslo, Norway	Harvard University; Boston Children's Hospital; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Boston Children's Hospital; Northwestern University; Utah System of Higher Education; University of Utah; University of Oslo	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu		Pereira, Mark/0000-0002-6704-5276; Jacobs, David/0000-0002-7232-0543; Ludwig, David/0000-0003-3307-8544	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC048049, N01HC048047, N01HC095095, N01HC048048, N01HC048050] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059240] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR02172] Funding Source: Medline; NHLBI NIH HHS [N01-HC-95095, N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050] Funding Source: Medline; NIDDK NIH HHS [1R01DK59240] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; American Diabetes Association, 2002, DIABETES CARE, V25, pS50, DOI DOI 10.2337/DIACARE.25.2007.S50; BIINGHWAN L, 1997, FOOD REV, P33; Binkley JK, 2000, INT J OBESITY, V24, P1032, DOI 10.1038/sj.ijo.0801356; Bowman SA, 2004, PEDIATRICS, V113, P112, DOI 10.1542/peds.113.1.112; Colditz GA, 1999, MED SCI SPORT EXER, V31, pS663, DOI 10.1097/00005768-199911001-00026; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5; French SA, 2000, INT J OBESITY, V24, P1353, DOI 10.1038/sj.ijo.0801429; FRENCH SA, 1994, INT J OBESITY, V18, P145; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; Frost G, 1998, METABOLISM, V47, P1245, DOI 10.1016/S0026-0495(98)90331-6; Guthrie JF, 2002, J NUTR EDUC BEHAV, V34, P140, DOI 10.1016/S1499-4046(06)60083-3; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Jacobs David R Jr, 1989, J Cardiopulm Rehabil, V9, P448, DOI 10.1097/00008483-198911000-00003; Jarvi AE, 1999, DIABETES CARE, V22, P10, DOI 10.2337/diacare.22.1.10; Liu Kiang, 1994, Ethnicity and Disease, V4, P15; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Ludwig DS, 2001, JAMA-J AM MED ASSOC, V286, P1427, DOI 10.1001/jama.286.12.1427; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MCDONALD A, 1991, J AM DIET ASSOC, V91, P1104; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Pereira MA, 2002, JAMA-J AM MED ASSOC, V287, P2081, DOI 10.1001/jama.287.16.2081; Prentice A M, 2003, Obes Rev, V4, P187, DOI 10.1046/j.1467-789X.2003.00117.x; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Sturm R, 2002, HEALTH AFFAIR, V21, P245, DOI 10.1377/hlthaff.21.2.245; *TECN INF SERV, 2002, US FOODS IND FOR; Thompson D, 1999, ARCH INTERN MED, V159, P2177, DOI 10.1001/archinte.159.18.2177; *USDA, 1997, CONT SURV FOOD INT I	33	854	874	2	143	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					36	42		10.1016/S0140-6736(04)17663-0	http://dx.doi.org/10.1016/S0140-6736(04)17663-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639678				2022-12-28	WOS:000226213100026
J	Rothwell, PM				Rothwell, PM			Treating Individuals 1 - External validity of randomised controlled trials: "To whom do the results of this trial apply?"'	LANCET			English	Review							ACUTE MYOCARDIAL-INFARCTION; EVIDENCE-BASED MEDICINE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CLINICAL-TRIALS; GENERAL-PRACTICE; PRIMARY-CARE; DOUBLE-BLIND; HEART-FAILURE; ANTIHYPERTENSIVE DRUGS; NONRANDOMIZED PATIENTS	In making treatment decisions, doctors and patients must take into account relevant randomised controlled trials (RCTs) and systematic reviews. Relevance depends on external validity (or generalisability)-ie, whether the results can be reasonably applied to a definable group of patients in a particular clinical setting in routine practice. There is concern among clinicians that external validity is often poor, particularly for some pharmaceutical industry trials, a perception that has led to underuse of treatments that are effective. Yet researchers, funding agencies, ethics committees, the pharmaceutical industry, medical journals, and governmental regulators alike all neglect external validity, leaving clinicians to make judgments. However, reporting of the determinants of external validity in trial publications and systematic reviews is usually inadequate. This review discusses those determinants, presents a checklist for clinicians, and makes recommendations for greater consideration of external validity in the design and reporting of RCTs.	Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; AMERY W, 1975, J CLIN PHARMACOL, V15, P674, DOI 10.1002/j.1552-4604.1975.tb05919.x; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1986, Lancet, V1, P397; Antani MR, 1996, J GEN INTERN MED, V11, P713, DOI 10.1007/BF02598984; *AS CAR ATH STUD G, 1909, JAMA-J AM MED ASSOC, V273, P1421; BARNETT HJM, 1992, STROKE, V23, P1048, DOI 10.1161/01.STR.23.8.1048; Benech I, 1996, J Eval Clin Pract, V2, P249, DOI 10.1111/j.1365-2753.1996.tb00055.x; Benson J, 2002, BRIT MED J, V325, P873, DOI 10.1136/bmj.325.7369.873; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; BINNIE CD, 1995, SEIZURE, V4, P187, DOI 10.1016/S1059-1311(05)80059-7; Bjorn M, 1998, J Card Fail, V4, P225, DOI 10.1016/S1071-9164(98)80009-2; Black D, 1998, J ROY COLL PHYS LOND, V32, P23; Black N, 1996, BRIT MED J, V312, P1215; Black NA, 1996, BRIT J UROL, V78, P497, DOI 10.1046/j.1464-410X.1996.01422.x; BOND R, 2003, CEREBROVASC DIS, V16, P65; BOWEN JT, 1994, HUM PSYCHOOPHARMACOL, V9, P432; Britton A, 1999, J Health Serv Res Policy, V4, P112; Brown N, 1999, HEART, V81, P598, DOI 10.1136/hrt.81.6.598; BUNGEJA G, 1997, BMJ-BRIT MED J, V315, P1059; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Califf RM, 1997, AM HEART J, V134, P44, DOI 10.1016/S0002-8703(97)70105-4; CALIFF RM, 1986, CIRCULATION, V74, P1191, DOI 10.1161/01.CIR.74.6.1191; Camm AJ, 1996, CONTROL CLIN TRIALS, V17, pS4, DOI 10.1016/S0197-2456(96)00068-2; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; Caplan LR, 2001, J NEUROL NEUROSUR PS, V71, P569, DOI 10.1136/jnnp.71.5.569; CHARLSON ME, 1984, BRIT MED J, V289, P1281, DOI 10.1136/bmj.289.6454.1281; Charlton BG, 1998, QJM-MON J ASSOC PHYS, V91, P371, DOI 10.1093/qjmed/91.5.371; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; COSTE J, 1995, STAT MED, V14, P331, DOI 10.1002/sim.4780140402; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Egglin TKP, 1996, ACAD RADIOL, V3, P1, DOI 10.1016/S1076-6332(96)80324-2; EVANS JG, 1995, AGE AGEING, V24, P461, DOI 10.1093/ageing/24.6.461; Fahey T, 1998, BRIT J GEN PRACT, V48, P1173; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; FORD LG, 1987, J CLIN ONCOL, V5, P504, DOI 10.1200/JCO.1987.5.3.504; Franke CL, 1997, ANN NEUROL, V42, P857; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; Garfield FB, 2000, INT J TECHNOL ASSESS, V16, P1050, DOI 10.1017/S0266462300103113; Gilbody S, 2002, ACTA PSYCHIAT SCAND, V105, P243, DOI 10.1034/j.1600-0447.2002.00242.x; GOMEZMARIN O, 1991, CONTROL CLIN TRIALS, V12, P408, DOI 10.1016/0197-2456(91)90020-M; Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Hall JC, 1996, SURGERY, V119, P466, DOI 10.1016/S0039-6060(96)80149-8; HALLSTROM AP, 1991, CONTROL CLIN TRIALS, V12, P486, DOI 10.1016/0197-2456(91)90009-B; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Hampton JR, 2002, STAT MED, V21, P2807, DOI 10.1002/sim.1284; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; HENDERSON RA, 1995, QJM-INT J MED, V88, P167; HENNEN BK, 1984, J MED EDUC, V59, P487; Horton R, 2000, STAT MED, V19, P3149, DOI 10.1002/1097-0258(20001215)19:23<3149::AID-SIM617>3.0.CO;2-E; IDANPAANHEIKKILA JE, 1994, ANN MED, V26, P89, DOI 10.3109/07853899409147334; Ioannidis JPA, 1998, LANCET, V352, P1752, DOI 10.1016/S0140-6736(05)79825-1; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Jacobson LD, 1997, BRIT J GEN PRACT, V47, P449; JONES JK, 1995, BMJ-BRIT MED J, V311, P293, DOI 10.1136/bmj.311.7000.293; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; Jorgensen HS, 1999, BRIT MED J, V319, P288, DOI 10.1136/bmj.319.7205.288; JULIAN DG, 1997, CLIN TRIALS CARDIOLO, P33; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; KAY L, 1994, AGE AGEING, V23, P146, DOI 10.1093/ageing/23.2.146; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; KRUM H, 1995, CIRCULATION, V92, P212; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LARUE LJ, 1988, STROKE, V19, P950, DOI 10.1161/01.STR.19.8.950; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEBARON S, 1985, J FAM PRACTICE, V21, P56; Leber PD, 1998, CONTROL CLIN TRIALS, V19, P178, DOI 10.1016/S0197-2456(97)00118-9; Light RW, 1997, BRIT J PSYCHIAT, V170, P264, DOI 10.1192/bjp.170.3.264; Lip GYH, 1997, BRIT J GEN PRACT, V47, P285; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; Mant D, 1999, LANCET, V353, P743, DOI 10.1016/S0140-6736(98)09102-8; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marshall M, 2000, BRIT J PSYCHIAT, V176, P249, DOI 10.1192/bjp.176.3.249; Masuhr F, 1998, STROKE, V29, P339, DOI 10.1161/01.STR.29.2.339; MAYNARD C, 1991, AM J CARDIOL, V68, P529, DOI 10.1016/0002-9149(91)90791-I; McAlister FA, 1997, DRUGS, V54, P235, DOI 10.2165/00003495-199754020-00003; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCORMACK J, 1994, BRIT J GEN PRACT, V44, P50; McKee M, 1999, BMJ-BRIT MED J, V319, P312, DOI 10.1136/bmj.319.7205.312; McPherson K, 2004, BRIT MED J, V328, P518, DOI 10.1136/bmj.328.7438.518; *MED RES COUNC, 1998, MRC GUID GOOD CLIN P; *MED RES COUNC, 2003, CLIN TRIALS TOM; Merlo J, 2001, EUR J CLIN PHARMACOL, V57, P71, DOI 10.1007/s002280100266; Messerli F H, 2000, Proc (Bayl Univ Med Cent), V13, P128; Moore D A, 2000, HIV Med, V1, P149, DOI 10.1046/j.1468-1293.2000.00019.x; Moore WS, 1996, J VASC SURG, V23, P323, DOI 10.1016/S0741-5214(96)70277-X; Morgan W K, 1997, J Eval Clin Pract, V3, P117, DOI 10.1046/j.1365-2753.1997.00077.x; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; OLSCHEWSKI M, 1992, CONTROL CLIN TRIALS, V13, P226, DOI 10.1016/0197-2456(92)90005-K; Onel E, 1998, UROLOGY, V51, P63, DOI 10.1016/S0090-4295(97)00494-9; Oswald N, 1999, FAM PRACT, V16, P414, DOI 10.1093/fampra/16.4.414; Pablos-Mendez A, 1998, JAMA-J AM MED ASSOC, V279, P222, DOI 10.1001/jama.279.3.222; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; Pocock SJ., 2013, CLIN TRIALS PRACTICA; QUITKIN FM, 1981, J CLIN PSYCHOPHARM, V1, P283, DOI 10.1097/00004714-198109000-00003; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; RICCI S, 1996, CEREBROVASC DIS, V6, P133; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Roberts C, 1999, STAT MED, V18, P2605, DOI 10.1002/(SICI)1097-0258(19991015)18:19<2605::AID-SIM237>3.0.CO;2-N; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580; Rothwell PM, 1996, STROKE, V27, P260, DOI 10.1161/01.STR.27.2.260; Rovers MM, 2001, INT J PEDIATR OTORHI, V60, P29, DOI 10.1016/S0165-5876(01)00504-3; SACCO RL, 1995, STROKE, V26, P14, DOI 10.1161/01.STR.26.1.14; Schmoor C, 1996, STAT MED, V15, P263, DOI 10.1002/(SICI)1097-0258(19960215)15:3<263::AID-SIM165>3.0.CO;2-K; Sellors J, 2002, FAM PRACT, V19, P99, DOI 10.1093/fampra/19.1.99; Shapiro SH, 2000, J CLIN EPIDEMIOL, V53, P973, DOI 10.1016/S0895-4356(00)00227-4; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; Smith GD, 1998, J CLIN EPIDEMIOL, V51, P289, DOI 10.1016/S0895-4356(97)00293-X; Sonis J, 1998, JAMA-J AM MED ASSOC, V280, P1746, DOI 10.1001/jama.280.20.1746-a; STEINER T J, 1986, Neuroepidemiology, V5, P121, DOI 10.1159/000110823; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; SUETA CA, 1995, AM J CARDIOL, V75, pA34, DOI 10.1016/S0002-9149(99)80381-6; Swales JD, 1999, J HYPERTENS, V17, P1511, DOI 10.1097/00004872-199917110-00002; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; Thornley B, 1998, BRIT MED J, V317, P1181, DOI 10.1136/bmj.317.7167.1181; VANGIJN J, 1992, CEREBROVASC DIS, V2, P244; Walker MC, 1997, NEUROLOGY, V49, P333, DOI 10.1212/WNL.49.2.333; Wermeling DP, 1999, AM J HEALTH-SYST PH, V56, P252, DOI 10.1093/ajhp/56.3.252; Wilson S, 2000, BMJ-BRIT MED J, V321, P24, DOI 10.1136/bmj.321.7252.24; Woods KL, 1999, BMJ-BRIT MED J, V318, P328, DOI 10.1136/bmj.318.7179.328b; Yee KM, 1997, EUR HEART J, V18, P1860; [No title captured]	148	1579	1598	2	100	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					82	93		10.1016/S0140-6736(04)17670-8	http://dx.doi.org/10.1016/S0140-6736(04)17670-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639683				2022-12-28	WOS:000226213100032
J	Wright, P				Wright, P			John R La Montagne - Obituary	LANCET			English	Biographical-Item												pearce.wright@dial.pipex.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	2004	364	9450					2014	2014		10.1016/S0140-6736(04)17537-5	http://dx.doi.org/10.1016/S0140-6736(04)17537-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876KM	15630764	Green Published, Bronze			2022-12-28	WOS:000225495700013
J	Hagel, BE; Pless, IB; Goulet, C; Platt, RW; Robitaille, Y				Hagel, BE; Pless, IB; Goulet, C; Platt, RW; Robitaille, Y			Effectiveness of helmets in skiers and snowboarders: case-control and case crossover study	BRITISH MEDICAL JOURNAL			English	Article							SKIING INJURIES; ADOLESCENTS; CHILDREN	Objective To determine the effect of helmets oil the risk of head and neck injuries in skiers and snowboarders. Design Matched case-control and case crossover Study. Setting 19 sk areas in Quebec, Canada, November 2001 to April 2002. Participants 1082 skiers and snowboarders (cases) with head and neck injuries reported by the ski patrol and 3295 skiers and snowboarders (controls) with non-head or ion-neck injuries matched to cases at each hill. Main outcome measures Estimates of matched odds ratios for the effect of helmet use on the risk of any head or neck injury and for people requiring evacuation by ambulance. Results The adjusted odds ratio for helmet use in participants with any head injury was 0.71 (95% confidence interval 0.55 to 0.92), indicating a 29% reduction in the risk of head injury. For participants who required evacuation by ambulance for head injuries, the adjusted odds ratio for helmet use was 0.44 (0.24 to 0.81). Similar results occurred with the case crossover design (odds ratio 0.43, 0.09 to 1.83). The adjusted odds ratio for helmet use for participants with any neck injury was 0.62 (0.33 to 1.19) and for participants who required evacuation by ambulance for neck injuries it was 1.29 (0.41 to 4.04). Conclusions Helmets protect skiers and snowboarders against head injuries. We cannot rule out the possibility of an increased risk of neck injury with helmet use, but the estimates on which this assumption is based are imprecise.	Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB T6G 2E1, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 1A2, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 1A2, Canada; Minist Affaires Municipales Sport & Loisir, Direct Promot Secur, Trois Rivieres, PQ G9A 5S9, Canada; Inst Natl Sante Publ Quebec, Montreal, PQ H2J 3G8, Canada	University of Alberta; McGill University; McGill University; Institut national de sante publique du Quebec (INSPQ)	Hagel, BE (corresponding author), Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB T6G 2E1, Canada.	brent.hagel@ualberta.ca	Hagel, Brent/AAK-3319-2020	Platt, Robert/0000-0002-5981-8443				Bridges EJ, 2003, BRIT J SPORT MED, V37, P511, DOI 10.1136/bjsm.37.6.511; Cadman R, 1996, AM SOC TEST MATER, V1266, P58, DOI 10.1520/STP37914S; Davidson TM, 1996, WESTERN J MED, V164, P310; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; Greenland S, 2000, AM J EPIDEMIOL, V151, P531; Hagel BE, 2004, INJURY PREV, V10, P275, DOI 10.1136/ip.2004.005546; Hagel BE, 1999, CLIN J SPORT MED, V9, P9, DOI 10.1097/00042752-199901000-00003; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; KATAGI K, 2000, SKI MAGAZINE     OCT, P219; KLEINBAUM DG, 1996, LOGISTIC REGRESSION; Macnab AJ, 2002, INJURY PREV, V8, P324, DOI 10.1136/ip.8.4.324; OH S, 1983, Z KINDERCHIR, V38, P66; Parkinson GW, 2003, PEDIATRICS, V112, P320, DOI 10.1542/peds.112.2.320; Rothman K., 1998, MODERN EPIDEMIOLOGY; Thompson DC, 2000, COCHRANE DB SYST REV, V2	16	118	119	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 5	2005	330	7486					281	283		10.1136/bmj.38314.480035.7C	http://dx.doi.org/10.1136/bmj.38314.480035.7C			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15632094	Green Published, Bronze			2022-12-28	WOS:000226843700014
J	Srinivasan, R; Feenstra, JS; Park, ST; Xu, SJ; Zewail, AH				Srinivasan, R; Feenstra, JS; Park, ST; Xu, SJ; Zewail, AH			Dark structures in molecular radiationless transitions determined by ultrafast diffraction	SCIENCE			English	Article							NONRADIATIVE ELECTRONIC RELAXATION; EXCITATION-ENERGY DEPENDENCE; FLUORESCENCE EMISSIONS; CONICAL INTERSECTIONS; FEMTOSECOND DYNAMICS; METHYL-DERIVATIVES; GAS-PHASE; PYRIDINE; BENZALDEHYDE; BENZENE	The intermediate structures formed through radiationless transitions are termed "dark" because their existence is inferred indirectly from radiative transitions. We used ultrafast electron diffraction to directly determine these transient structures on both ground-state and excited-state potential energy surfaces of several aromatic molecules. The resolution in space and time (0.01 angstrom and 1 picosecond) enables differentiation between competing nonradiative pathways of bond breaking, vibronic coupling, and spin transition. For the systems reported here, the results reveal unexpected dynamical behavior. The observed ring opening of the structure depends on molecular substituents. This, together with the parallel bifurcation into physical and chemical channels, redefines structural dynamics of the energy landscape in radiationless processes.	CALTECH, Lab Mol Sci, Arthur Amos Noyes Lab Chem Phys, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Zewail, AH (corresponding author), CALTECH, Lab Mol Sci, Arthur Amos Noyes Lab Chem Phys, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	zewail@caltech.edu	Park, Sang Tae/E-2743-2010	gaber, sarah/0000-0002-5995-7291				[Anonymous], 1970, J AM CHEM SOC, DOI DOI 10.1021/JA00710A088; Baldwin J. E., 2004, REACTIVE INTERMEDIAT, P899; BERGER M, 1973, J AM CHEM SOC, V95, P1717, DOI 10.1021/ja00787a004; BIXON M, 1968, J CHEM PHYS, V48, P715, DOI 10.1063/1.1668703; BRUHLMANN U, 1983, CHEM PHYS, V81, P439, DOI 10.1016/0301-0104(83)85335-X; CALLOMON JH, 1972, CHEM PHYS LETT, V13, P125, DOI 10.1016/0009-2614(72)80059-9; Chachisvilis M, 1999, J PHYS CHEM A, V103, P7408, DOI 10.1021/jp991821x; CHAPMAN OL, 1973, J AM CHEM SOC, V95, P614, DOI 10.1021/ja00783a066; Crespo-Hernandez CE, 2004, CHEM REV, V104, P1977, DOI 10.1021/cr0206770; EISENTHAL K, 1984, APPL PICOSECOND SPEC; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; HENRY BR, 1968, ANNU REV PHYS CHEM, V19, P161, DOI 10.1146/annurev.pc.19.100168.001113; HIRATA Y, 1980, J CHEM PHYS, V72, P5505, DOI 10.1063/1.438967; Ihee H, 2001, SCIENCE, V291, P458, DOI 10.1126/science.291.5503.458; JOHNSTONE DE, 1991, J PHYS CHEM-US, V95, P165, DOI 10.1021/j100154a033; KISTIAKO.GB, 1965, J CHEM PHYS, V42, P2942, DOI 10.1063/1.1703267; Kudoh S, 1999, CHEM PHYS LETT, V308, P403, DOI 10.1016/S0009-2614(99)00624-7; Kudoh S, 1999, J PHOTOCH PHOTOBIO A, V123, P25, DOI 10.1016/S1010-6030(99)00035-0; Lim EC, 1997, ADV PHOTOCH, V23, P165; LIM EC, 1969, MOL LUMINESCENCE; Liu RF, 2000, J PHYS CHEM A, V104, P8368, DOI 10.1021/jp000821q; Lobastov VA, 2001, J PHYS CHEM A, V105, P11159, DOI 10.1021/jp013705b; MICHL J, 2004, CONICAL INTERSECTION, pR9; OHMORI N, 1988, J PHYS CHEM-US, V92, P1086, DOI 10.1021/j100316a019; Pavlik JW, 1999, J AM CHEM SOC, V121, P5666, DOI 10.1021/ja990773r; PAVLIK JW, COMMUNICATION; POLEVOY AV, 1984, KHIM VYS ENERG, V18, P195; Porcinai S, 1997, NUOVO CIMENTO D, V19, P889; PRATHER KA, 1994, ISRAEL J CHEM, V34, P43; ROBINSON GW, 1963, J CHEM PHYS, V38, P1187, DOI 10.1063/1.1733823; Ruan CY, 2004, SCIENCE, V304, P80, DOI 10.1126/science.1094818; Ruan CY, 2004, P NATL ACAD SCI USA, V101, P1123, DOI 10.1073/pnas.0307302101; Silva CR, 1997, J PHYS CHEM A, V101, P7934, DOI 10.1021/jp9707551; SOBOLEWSKI AL, 1991, CHEM PHYS LETT, V180, P381, DOI 10.1016/0009-2614(91)90337-9; Srinivasan R, 2003, HELV CHIM ACTA, V86, P1763; Thomas JM, 2004, ANGEW CHEM INT EDIT, V43, P2606, DOI 10.1002/anie.200301746; VILLA E, 1988, J PHYS CHEM-US, V92, P5393, DOI 10.1021/j100330a015; YAMAZAKI I, 1979, J LUMIN, V18-9, P425, DOI 10.1016/0022-2313(79)90154-6; YAMAZAKI I, 1979, J CHEM PHYS, V71, P381, DOI 10.1063/1.438081; YAMAZAKI I, 1983, FARADAY DISCUSS, V75, P395, DOI 10.1039/dc9837500395; YAMAZAKI I, 1982, CHEM PHYS LETT, V92, P421, DOI 10.1016/0009-2614(82)83440-4; Zewail A H, 2000, PRIX NOBEL NOBEL PRI, P103; Zhong DP, 1998, CHEM PHYS LETT, V298, P129, DOI 10.1016/S0009-2614(98)01160-9	43	131	133	6	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					558	563		10.1126/science.1107291	http://dx.doi.org/10.1126/science.1107291			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15637234				2022-12-28	WOS:000226694000041
J	Esnault, C; Heidmann, O; Delebecque, F; Dewannieux, M; Ribet, D; Hance, AJ; Heidmann, T; Schwartz, O				Esnault, C; Heidmann, O; Delebecque, F; Dewannieux, M; Ribet, D; Hance, AJ; Heidmann, T; Schwartz, O			APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses	NATURE			English	Article							EDITING ENZYME APOBEC3G; MAMMALIAN-CELLS; VIF PROTEIN; ANTIRETROVIRAL FACTOR; INDICATOR GENE; HIV-1; DNA; RETROELEMENTS; GENOME; MOBILE	Endogenous retroviruses are multicopy retroelements accounting for nearly 10% of murine or human genomes(1,2). These retroelements spread into our ancestral genome millions of years ago and have acted as a driving force for genome evolution(2-4). Endogenous retroviruses may also be deleterious for their host, and have been implicated in cancers and autoimmune diseases(5). Most retroelements have lost replication competence because of the accumulation of inactivating mutations, but several, including some murine intracisternal A-particle (IAP) and MusD sequences, are still mobile(6,7). These elements encode a reverse transcriptase activity and move by retrotransposition, an intracellular copy-and-paste process involving an RNA intermediate. The host has developed mechanisms to silence their expression, mainly cosuppression and gene methylation(4,8). Here we identify another level of antiviral control, mediated by APOBEC3G, a member of the cytidine deaminase family that was previously shown to block HIV replication(9-12). We show that APOBEC3G markedly inhibits retrotransposition of IAP and MusD elements, and induces G-to-A hypermutations in their DNA copies. APOBEC3G, by editing viral genetic material, provides an ancestral wide cellular defence against endogenous and exogenous invaders.	Inst Gustave Roussy, CNRS, UMR8122, Unite Retrovirus Endogenes & Elements Retroides E, F-94805 Villejuif, France; Inst Pasteur, Dept Virol, CNRS, URA 1930,Virus & Immun Grp, F-75015 Paris, France; Hop Bichat Claude Bernard, INSERM, U552, F-75018 Paris, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR8122, Unite Retrovirus Endogenes & Elements Retroides E, Rue Camille Desmoulins, F-94805 Villejuif, France.	heidmann@igr.fr; schwartz@pasteur.fr	Ribet, David/AAA-6659-2020; Schwartz, Olivier/AAZ-3765-2021	Ribet, David/0000-0003-1175-6471; Schwartz, Olivier/0000-0002-0729-1475; Dewannieux, Marie/0000-0003-3918-2414				Bannert N, 2004, P NATL ACAD SCI USA, V101, P14572, DOI 10.1073/pnas.0404838101; Baust C, 2003, J VIROL, V77, P11448, DOI 10.1128/JVI.77.21.11448-11458.2003; Bishop KN, 2004, SCIENCE, V305, P645, DOI 10.1126/science.1100658; Boeke J. D., 1997, P343; Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886; Dewannieux M, 2004, NAT GENET, V36, P534, DOI 10.1038/ng1353; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; Esnault C, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.11.e49; Goodier JL, 2001, GENOME RES, V11, P1677, DOI 10.1101/gr.198301; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Johnson WE, 1999, P NATL ACAD SCI USA, V96, P10254, DOI 10.1073/pnas.96.18.10254; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Lower R, 1999, TRENDS MICROBIOL, V7, P350, DOI 10.1016/S0966-842X(99)01565-6; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Ribet D, 2004, GENOME RES, V14, P2261, DOI 10.1101/gr.2924904; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Suspene R, 2004, NUCLEIC ACIDS RES, V32, P2421, DOI 10.1093/nar/gkh554; Turelli P, 2004, J BIOL CHEM, V279, P43371, DOI 10.1074/jbc.C400334200; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758	30	261	271	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2005	433	7024					430	433		10.1038/nature03238	http://dx.doi.org/10.1038/nature03238			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674295				2022-12-28	WOS:000226546200046
J	Stewart, AF				Stewart, AF			Hypercalcemia associated with cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANCY-ASSOCIATED HYPERCALCEMIA; HORMONE-RELATED PROTEIN; PARATHYROID-HORMONE; PRIMARY HYPERPARATHYROIDISM; HUMORAL HYPERCALCEMIA; PAMIDRONATE DISODIUM; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; BREAST-CANCER; DOSE-RESPONSE		Univ Pittsburgh, Sch Med, Div Endocrinol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stewart, AF (corresponding author), Univ Pittsburgh, Sch Med, Div Endocrinol & Metab, BST E-1140,200 Lothrop St, Pittsburgh, PA 15213 USA.	stewart@dom.pitt.edu			NIDDK NIH HHS [DK 51081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348; Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305; Berenson JR, 1997, J CLIN PHARMACOL, V37, P285, DOI 10.1002/j.1552-4604.1997.tb04304.x; Bilezikian JP, 2004, NEW ENGL J MED, V350, P1746, DOI 10.1056/NEJMcp032200; BINSTOCK ML, 1980, ANN INTERN MED, V93, P269, DOI 10.7326/0003-4819-93-2-269; Body JJ, 1999, J BONE MINER RES, V14, P1557, DOI 10.1359/jbmr.1999.14.9.1557; BONJOUR JP, 1988, BONE, V9, P123, DOI 10.1016/8756-3282(88)90001-4; CARDELLA CJ, 1979, CLIN NEPHROL, V12, P285; Cheer SM, 2001, DRUGS, V61, P799, DOI 10.2165/00003495-200161060-00010; CLINES GA, 2003, PRIMER METABOLIC BON, P251; Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80; GODSALL JW, 1986, RECENT PROG HORM RES, V42, P705; GOLDSMITH RS, 1966, NEW ENGL J MED, V274, P1, DOI 10.1056/NEJM196601062740101; GUCALP R, 1992, J CLIN ONCOL, V10, P134, DOI 10.1200/JCO.1992.10.1.134; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017; Hillner BE, 2004, J CLIN ONCOL, V22, P1351; Horwitz M. J., 2003, PRIMER METABOLIC BON, V5th, P246; Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P1603, DOI 10.1210/jc.2002-020773; JACOBS TP, 1981, ANN INTERN MED, V94, P312, DOI 10.7326/0003-4819-94-3-312; Jara A, 1999, KIDNEY INT, V55, P1434, DOI 10.1046/j.1523-1755.1999.00395.x; John R, 1997, ANN CLIN BIOCHEM, V34, P694, DOI 10.1177/000456329703400618; JUNG A, 1982, AM J MED, V72, P221, DOI 10.1016/0002-9343(82)90813-0; Koo WS, 1996, NEPHRON, V72, P424, DOI 10.1159/000188907; LADERSON JH, 1978, J CLIN ENDOCR METAB, V48, P393; LEBOFF MS, 2003, PRIMER METABOLIC BON, P225; LENTZ RD, 1978, ANN INTERN MED, V89, P941, DOI 10.7326/0003-4819-89-6-941; Leyland-Jones B, 2003, SEMIN ONCOL, V30, P13, DOI 10.1016/S0093-7754(03)00171-4; Machado CE, 1996, CLIN NEPHROL, V45, P175; Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558; Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523-1755.2003.00071.x; Nakayama K, 1996, J CLIN ENDOCR METAB, V81, P607, DOI 10.1210/jc.81.2.607; NUSSBAUM SR, 1993, AM J MED, V95, P297, DOI 10.1016/0002-9343(93)90282-T; NUSSBAUM SR, 1990, NEW ENGL J MED, V323, P1324, DOI 10.1056/NEJM199011083231907; Pecherstorfer M, 2003, SUPPORT CARE CANCER, V11, P539, DOI 10.1007/s00520-003-0477-1; Perlia C P, 1970, Cancer, V25, P389, DOI 10.1002/1097-0142(197002)25:2<389::AID-CNCR2820250217>3.0.CO;2-X; RALSTON SH, 1990, ANN INTERN MED, V112, P499, DOI 10.7326/0003-4819-112-7-499; Ralston SH, 1997, BRIT J CANCER, V75, P295, DOI 10.1038/bjc.1997.48; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sato K, 2003, SEMIN ONCOL, V30, P167, DOI 10.1053/j.seminoncol.2003.08.019; SEYMOUR JF, 1994, ANN INTERN MED, V121, P633, DOI 10.7326/0003-4819-121-9-199411010-00001; Shah S, 2002, BRIT J CANCER, V86, P1235, DOI 10.1038/sj.bjc.6600249; STEWART AF, 1982, J CLIN ENDOCR METAB, V55, P219, DOI 10.1210/jcem-55-2-219; STEWART AF, IN PRESS ENDOCRINOLO; STEWART AF, 2004, CECIL ESSENTIALS MED, P683; WATSON L, 1980, LANCET, V1, P1320; WISNESKI LA, 1978, CLIN PHARMACOL THER, V24, P219	47	493	519	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2005	352	4					373	379		10.1056/NEJMcp042806	http://dx.doi.org/10.1056/NEJMcp042806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	890UH	15673803				2022-12-28	WOS:000226535900009
J	Silove, D; Zwi, AB				Silove, D; Zwi, AB			Translating compassion into psychosocial aid after the tsunami	LANCET			English	Editorial Material							MENTAL-HEALTH; CONFLICT; INTERVENTIONS		Univ New S Wales, Sch Psychiat, Psychiat Res & Teaching Unit, Sydney, NSW, Australia; Univ New S Wales, Sch Psychiat, Ctr Populat Mental Hlth Res, Sydney, NSW, Australia; Liverpool Hosp, Sydney S W Area Hlth Serv, Liverpool, NSW, Australia; Univ New S Wales, Sch Publ Hlth & Community Med, Kensington, NSW 2033, Australia	University of New South Wales Sydney; University of New South Wales Sydney; Liverpool Hospital; University of New South Wales Sydney	Silove, D (corresponding author), Univ New S Wales, Sch Psychiat, Psychiat Res & Teaching Unit, Sydney, NSW, Australia.	d.silove@unsw.edu.au	Zwi, Anthony/AAP-8731-2020; Zwi, Anthony/AAP-7026-2021	Zwi, Anthony/0000-0001-6902-6602				Banatvala N, 2000, BMJ-BRIT MED J, V321, P101, DOI 10.1136/bmj.321.7253.101; *CTR MENT HLTH SER, 2003, DEV CULT COMP DIS ME; de Jong K, 2002, LANCET, V359, P1517, DOI 10.1016/S0140-6736(02)08420-9; Kamau M., 2004, INTERVENTION, V2, P84; Mollica RF, 2004, LANCET, V364, P2058, DOI 10.1016/S0140-6736(04)17519-3; Raphael B, 2004, PSYCHIAT CLIN N AM, V27, P407, DOI 10.1016/j.psc.2004.03.003; Silove D, 2004, AUST NZ J PSYCHIAT, V38, P929, DOI 10.1080/j.1440-1614.2004.01483.x; Silove D, 2000, LANCET, V355, P1548, DOI 10.1016/S0140-6736(00)02177-2; Silove Derrick, 2004, Prehosp Disaster Med, V19, P90; van Ommeren M, 2005, B WORLD HEALTH ORGAN, V83, P71; Weine S, 2002, PSYCHIATRY, V65, P156, DOI 10.1521/psyc.65.2.156.19936; Weiss MG, 2003, J NERV MENT DIS, V191, P611, DOI 10.1097/01.nmd.0000087188.96516.a3; 2005, SYDNEY MORNING  0105, P1	13	26	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					269	271						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889NL	15664202				2022-12-28	WOS:000226449600003
J	Yamaguchi, M; Shiga, M; Kaburaki, H				Yamaguchi, M; Shiga, M; Kaburaki, H			Grain boundary decohesion by impurity segregation in a nickel-sulfur system	SCIENCE			English	Article							EMBRITTLEMENT; COHESION; ENERGY; BORON; MODEL	The sulfur-induced embrittlement of nickel has long been wrapped in mystery as to why and how sulfur weakens the grain boundaries of nickel and why a critical intergranular sulfur concentration is required. From first-principles calculations, we found that a large grain-boundary expansion is caused by a short-range overlap repulsion among densely segregated and neighboring sulfur atoms. This expansion results in a drastic grain-boundary decohesion that reduces the grain-boundary tensile strength by one order of magnitude. This decohesion may directly cause the embrittlement, because the critical sulfur concentration of this decohesion agrees well with experimental data on the embrittlement.	Japan Atom Energy Res Inst, Ctr Promot Computat Sci & Engn, Tokai, Ibaraki 3191195, Japan	Japan Atomic Energy Agency	Yamaguchi, M (corresponding author), Japan Atom Energy Res Inst, Ctr Promot Computat Sci & Engn, Tokai, Ibaraki 3191195, Japan.	yamagu@popsvr.tokai.jaeri.go.jp	Yamaguchi, Masatake/E-3497-2013	Yamaguchi, Masatake/0000-0001-8839-2261				BARBOUTH N, 1969, CR ACAD SCI C CHIM, V269, P1618; BUCH A, 1999, PURE METALS PROPERTI; EBERHART ME, 1984, ACTA METALL MATER, V32, P955, DOI 10.1016/0001-6160(84)90033-6; Heuer JK, 2002, J NUCL MATER, V301, P129, DOI 10.1016/S0022-3115(02)00707-9; HEUER JK, 2000, THESIS U ILLINOIS UR; Kelly A., 1986, STRONG SOLIDS; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; LARERE A, 1982, ACTA METALL MATER, V30, P685, DOI 10.1016/0001-6160(82)90118-3; McLean D, 1957, GRAIN BOUNDARIES MET; MEHROTRA GM, 1985, J ELECTROCHEM SOC, V132, P247, DOI 10.1149/1.2113773; MESSMER RP, 1982, ACTA METALL MATER, V30, P457, DOI 10.1016/0001-6160(82)90226-7; MEYER B, 1976, CHEM REV, V76, P367, DOI 10.1021/cr60301a003; MIYAHARA T, 1985, SCRIPTA METALL MATER, V19, P117, DOI 10.1016/0036-9748(85)90276-5; OUDAR J, 1980, MATER SCI ENG, V42, P101, DOI 10.1016/0025-5416(80)90017-8; PAINTER GS, 1987, PHYS REV LETT, V58, P234, DOI 10.1103/PhysRevLett.58.234; RICE JR, 1989, MAT SCI ENG A-STRUCT, V107, P23, DOI 10.1016/0921-5093(89)90372-9; WU RQ, 1994, SCIENCE, V265, P376, DOI 10.1126/science.265.5170.376	19	264	273	7	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2005	307	5708					393	397		10.1126/science.1104624	http://dx.doi.org/10.1126/science.1104624			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890DQ	15637235				2022-12-28	WOS:000226492300037
J	Clarke, JA; Tambussi, CP; Noriega, JI; Erickson, GM; Ketcham, RA				Clarke, JA; Tambussi, CP; Noriega, JI; Erickson, GM; Ketcham, RA			Definitive fossil evidence for the extant avian radiation in the Cretaceous	NATURE			English	Article							BIRDS; EVOLUTION	Long-standing controversy(1-9) surrounds the question of whether living bird lineages emerged after non-avian dinosaur extinction at the Cretaceous/Tertiary (K/T) boundary(1,6) or whether these lineages coexisted with other dinosaurs and passed through this mass extinction event(2-5,7-9). Inferences from biogeography(4,8) and molecular sequence data(2,3,5,9) (but see ref. 10) project major avian lineages deep into the Cretaceous period, implying their 'mass survival'(3) at the K/T boundary. By contrast, it has been argued that the fossil record refutes this hypothesis, placing a 'big bang' of avian radiation only after the end of the Cretaceous(1,6). However, other fossil data-fragmentary bones referred to extant bird lineages(11-13)-have been considered inconclusive(1,6,14). These data have never been subjected to phylogenetic analysis. Here we identify a rare, partial skeleton from the Maastrichtian of Antarctica(15) as the first Cretaceous fossil definitively placed within the extant bird radiation. Several phylogenetic analyses supported by independent histological data indicate that a new species, Vegavis iaai, is a part of Anseriformes ( waterfowl) and is most closely related to Anatidae, which includes true ducks. A minimum of five divergences within Aves before the K/T boundary are inferred from the placement of Vegavis; at least duck, chicken and ratite bird relatives were coextant with non-avian dinosaurs.	N Carolina State Univ, Dept Marine Earth & Atmospher Sci, Raleigh, NC 27695 USA; N Carolina Museum Nat Sci, Raleigh, NC 27601 USA; Consejo Nacl Invest Cient & Tecn, Museo La Plata, RA-1900 La Plata, Argentina; Ctr Invest Cient, RA-3105 Diamante, Entre Rios, Argentina; TTP CONICET Matteri & Espana, RA-3105 Diamante, Entre Rios, Argentina; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; Univ Texas, Jackson Sch Geosci, High Resolut Xray Computed Tomog Facil, Austin, TX 78712 USA	University of North Carolina; North Carolina State University; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); State University System of Florida; Florida State University; American Museum of Natural History (AMNH); Field Museum of Natural History (Chicago); University of Texas System; University of Texas Austin	Clarke, JA (corresponding author), N Carolina State Univ, Dept Marine Earth & Atmospher Sci, Campus Box 8208, Raleigh, NC 27695 USA.	Julia_Clarke@NCSU.edu	/B-4978-2011; Ketcham, Richard/B-5431-2011	/0000-0003-2218-2637; Ketcham, Richard/0000-0002-2748-0409				Chinsamy Anusuya, 2002, P421; Clarke JA, 2002, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2002)387<0001:TMAPPO>2.0.CO;2; Cooper A, 1998, TRENDS ECOL EVOL, V13, P151, DOI 10.1016/S0169-5347(97)01277-9; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; Cracraft J, 2001, P ROY SOC B-BIOL SCI, V268, P459, DOI 10.1098/rspb.2000.1368; Dyke GJ, 2004, ZOOL J LINN SOC-LOND, V141, P153, DOI 10.1111/j.1096-3642.2004.00118.x; Ericson Per G.P., 2000, Paleobios, V20, P1; Ericson PGP, 2002, P ROY SOC B-BIOL SCI, V269, P235, DOI 10.1098/rspb.2001.1877; Ericson PGP, 1999, SM C PALEOB, P245; Feduccia A, 2003, TRENDS ECOL EVOL, V18, P172, DOI 10.1016/S0169-5347(03)00017-X; FEDUCCIA A, 1995, SCIENCE, V267, P637, DOI 10.1126/science.267.5198.637; FRANCILLONVIELL, 1990, BIOMINERALIZATION PA, P471; Groth JG, 1999, MOL PHYLOGENET EVOL, V12, P115, DOI 10.1006/mpev.1998.0603; Harrison GL, 2004, MOL BIOL EVOL, V21, P974, DOI 10.1093/molbev/msh065; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Hope Sylvia, 2002, P339; Ketcham RA, 2001, COMPUT GEOSCI-UK, V27, P381, DOI 10.1016/S0098-3004(00)00116-3; Kurochkin EN, 2002, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2002)386<0001:ANPBAA>2.0.CO;2; Livezey BC, 1997, ZOOL J LINN SOC-LOND, V121, P361, DOI 10.1111/j.1096-3642.1997.tb01285.x; Marenssi S, 2001, CONTRIBUCION I ANTAR, V530, P1; Mayr G, 2003, CLADISTICS, V19, P527, DOI [10.1016/j.cladistics.2003.10.003, 10.1111/j.1096-0031.2003.tb00387.x]; Noriega Jorge I., 1995, Ameghiniana, V32, P57; Olson S.L., 1980, Smithsonian Contributions to Zoology, P1; Olson SL, 1999, SM C PALEOB, P231; Padian K, 2001, NATURE, V412, P405, DOI 10.1038/35086500; Stidham TA, 1998, NATURE, V396, P29, DOI 10.1038/23841; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; van Tuinen M, 2003, TRENDS ECOL EVOL, V18, P442, DOI 10.1016/S0169-5347(03)00212-X; van Tuinen M, 2001, MOL BIOL EVOL, V18, P206, DOI 10.1093/oxfordjournals.molbev.a003794	29	226	238	0	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					305	308		10.1038/nature03150	http://dx.doi.org/10.1038/nature03150			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662422	Green Published			2022-12-28	WOS:000226381300053
J	McClellan, MB; Tunis, SR				McClellan, MB; Tunis, SR			Medicare coverage of ICDs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYOCARDIAL-INFARCTION; DEFIBRILLATOR		Ctr Medicare & Medicaid Serv, Off Clin Stand & Qual, Baltimore, MD USA	Centers for Medicare & Medicaid Services	McClellan, MB (corresponding author), Ctr Medicare & Medicaid Serv, Off Clin Stand & Qual, Baltimore, MD USA.							Hohnloser SH, 2004, NEW ENGL J MED, V351, P2481, DOI 10.1056/NEJMoa041489; Moss AJ, 2004, CIRCULATION, V110, P3760, DOI 10.1161/01.CIR.0000150390.04704.B7; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Phurrough S., 2003, DECISION MEMORANDUM; Wilber DJ, 2004, CIRCULATION, V109, P1082, DOI 10.1161/01.CIR.0000121328.12536.07	5	122	123	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2005	352	3					222	224		10.1056/NEJMp048354	http://dx.doi.org/10.1056/NEJMp048354			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888JP	15659721				2022-12-28	WOS:000226370500002
J	Cole, ST; Alzari, PM				Cole, ST; Alzari, PM			TB - A new target, a new drug	SCIENCE			English	Editorial Material							TUBERCULOSIS		Inst Pasteur, Genet Mol Bacterienne Unit, F-75724 Paris 15, France; Inst Pasteur, Biochim Struct Unit, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cole, ST (corresponding author), Inst Pasteur, Genet Mol Bacterienne Unit, F-75724 Paris 15, France.	stcote@pasteur.fr; alzari@pasteur.fr		Alzari, Pedro/0000-0002-4233-1903				Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753; Barry C, 2001, TUBERCULOSIS, V81, P1, DOI 10.1054/tube.2001.0288; Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6; Nuermberger EL, 2004, AM J RESP CRIT CARE, V169, P421, DOI 10.1164/rccm.200310-1380OC; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; van der Werf TS, 2003, LANCET, V362, P1062, DOI 10.1016/S0140-6736(03)14417-0; Zhang Y, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P115	9	42	43	2	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					214	215		10.1126/science.1108379	http://dx.doi.org/10.1126/science.1108379			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653490				2022-12-28	WOS:000226361900027
J	Demotes-Mainard, J; Ohmann, C				Demotes-Mainard, J; Ohmann, C			European Clinical Research Infrastructures Network: promoting harmonisation and quality in European clinical research	LANCET			English	Editorial Material									CHU Bordeaux, CIC INSERM, ECRIN Coordinat, F-33604 Pessac, France; KKS, ECRIN Network Comm, Dusseldorf, Germany	CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm)	Demotes-Mainard, J (corresponding author), CHU Bordeaux, CIC INSERM, ECRIN Coordinat, F-33604 Pessac, France.	demotes@bordeaux.inserm.fr	Ohmann, Christian/AAV-8608-2020					[Anonymous], 2003, LANCET, V361, P2167; Bassand JP, 2002, LANCET, V360, P1866, DOI 10.1016/S0140-6736(02)11776-4; BELL J, 2003, BRIT MED J, V327, P104; Clumeck N, 2004, LANCET, V363, P901, DOI 10.1016/S0140-6736(04)15757-7; Crawley FP, 2004, BMJ-BRIT MED J, V328, P522, DOI 10.1136/bmj.328.7438.522; Mayor S, 2004, BRIT MED J, V328, P1036, DOI 10.1136/bmj.328.7447.1036; Meunier F, 2003, LANCET, V362, P663, DOI 10.1016/S0140-6736(03)14163-3; Remuzzi G, 2004, LANCET, V364, P1723, DOI 10.1016/S0140-6736(04)17360-1	8	36	37	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					107	108		10.1016/S0140-6736(05)17720-4	http://dx.doi.org/10.1016/S0140-6736(05)17720-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639280				2022-12-28	WOS:000226170700009
J	Rappley, MD				Rappley, MD			Attention deficit-hyperactivity disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; PRESCHOOL-CHILDREN; METHYLPHENIDATE TREATMENT; PSYCHOTROPIC MEDICATION; BEHAVIORAL-PROBLEMS; MENTAL-RETARDATION; CONTROLLED TRIAL; ATOMOXETINE; ADHD		Michigan State Univ, Coll Human Med, Dept Pediat & Human Dev, E Lansing, MI 48824 USA	Michigan State University; Michigan State University College of Human Medicine	Rappley, MD (corresponding author), Michigan State Univ, Coll Human Med, Dept Pediat & Human Dev, A118 E Fee Hall, E Lansing, MI 48824 USA.	rappley@msu.edu						ABBOUD L, 2004, WALL STREET J    DEC, pB4; Abikoff H, 2004, J AM ACAD CHILD PSY, V43, P802, DOI 10.1097/01.chi.0000128791.10014.ac; *AM AC CHILD AD PS, 2003, GUID POCK MAN ATT DE; Aman MG, 2003, J CHILD ADOL PSYCHOP, V13, P29, DOI 10.1089/104454603321666171; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barbaresi W, 2002, ARCH PEDIAT ADOL MED, V156, P217, DOI 10.1001/archpedi.156.3.217; BARKLEY RA, 1990, PEDIATRICS, V86, P184; BARRICKMAN LL, 1995, J AM ACAD CHILD PSY, V34, P649, DOI 10.1097/00004583-199505000-00017; Bor W, 2002, J ABNORM CHILD PSYCH, V30, P571, DOI 10.1023/A:1020807613155; Bussing R, 2003, J AM ACAD CHILD PSY, V42, P842, DOI 10.1097/01.CHI.0000046876.27264.BF; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Conners CK, 1996, J AM ACAD CHILD PSY, V35, P1314, DOI 10.1097/00004583-199610000-00018; DeBar LL, 2003, ARCH PEDIAT ADOL MED, V157, P150, DOI 10.1001/archpedi.157.2.150; DIXON SD, 2000, ENCOUNTERS CHILDREN; Dulcan MK, 1997, J AM ACAD CHILD PSY, V36, P1311; DuPaul G.J., 2014, ADHD SCH ASSESSMENT, V3rd; Durston S, 2003, MENT RETARD DEV D R, V9, P184, DOI 10.1002/mrdd.10079; Efron D, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e6; Efron D, 1997, PEDIATRICS, V100, P662, DOI 10.1542/peds.100.4.662; Green M, 1999, AHCPR PUBLICATION, V99-0050; GrossTsur V, 1997, J PEDIATR-US, V130, P670, DOI 10.1016/S0022-3476(97)70258-0; Hille ETM, 2001, LANCET, V357, P1641, DOI 10.1016/S0140-6736(00)04818-2; Homer CJ, 2000, PEDIATRICS, V105, P1158; JADAD AR, 1999, AHRQ PUBLICATION; Jensen PS, 2004, PEDIATRICS, V113, P762; Jensen PS, 2004, PEDIATRICS, V113, P754; Jensen PS, 2001, J DEV BEHAV PEDIATR, V22, P60, DOI 10.1097/00004703-200102000-00008; Katusic S, 2003, J DEV BEHAV PEDIATR, V24, P396; Kelsey DK, 2004, PEDIATRICS, V114, pE1, DOI 10.1542/peds.114.1.e1; Kratochvil CJ, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00008; Kurlan R, 2002, NEUROLOGY, V58, P527; Lee TSW, 2004, J AM ACAD CHILD PSY, V43, P1068, DOI 10.1097/01.chi.0000132833.12842.4e; LeFever GB, 1999, AM J PUBLIC HEALTH, V89, P1359, DOI 10.2105/AJPH.89.9.1359; Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028; Michelson D, 2004, J AM ACAD CHILD PSY, V43, P896, DOI 10.1097/01.chi.0000125089.35109.81; *NAT IN CHILDR HEA, 2002, CAR CHILDR ADHD RES; Nigg JT, 1999, J ABNORM CHILD PSYCH, V27, P51, DOI 10.1023/A:1022614407893; O'Brien LM, 2003, SLEEP MED, V4, P309, DOI 10.1016/S1389-9457(03)00071-6; Pearson DA, 2003, J AM ACAD CHILD PSY, V42, P209, DOI 10.1097/00004583-200302000-00015; Perrin JM, 2001, PEDIATRICS, V108, P1033; Rappley MD, 1999, ARCH PEDIAT ADOL MED, V153, P1039, DOI 10.1001/archpedi.153.10.1039; RAPPLEY MD, 1995, ARCH PEDIAT ADOL MED, V149, P675, DOI 10.1001/archpedi.1995.02170190085015; Rappley MD, 2002, J DEV BEHAV PEDIATR, V23, P23, DOI 10.1097/00004703-200202000-00005; Reiff M. I., 2004, ADHD COMPLETE AUTHOR; Rieppi R, 2002, J AM ACAD CHILD PSY, V41, P269, DOI 10.1097/00004583-200203000-00006; Sawant S, 2004, AM J PSYCHIAT, V161, P757, DOI 10.1176/appi.ajp.161.4.757; *SCOTT INT GUID NE, 2001, 52 SCOTT INT GUID NE; Short EJ, 2004, J AM ACAD CHILD PSY, V43, P251, DOI 10.1097/00004583-200403000-00005; Sonuga-Barke EJS, 2001, J AM ACAD CHILD PSY, V40, P402, DOI 10.1097/00004583-200104000-00008; Spencer T, 2002, J CLIN PSYCHIAT, V63, P1140, DOI 10.4088/JCP.v63n1209; Taylor E, 1998, EUR CHILD ADOLES PSY, V7, P184, DOI 10.1007/s007870050067; Voigt RG, 2001, J PEDIATR-US, V139, P189, DOI 10.1067/mpd.2001.116050; Wilens E, 2004, JAMA-J AM MED ASSOC, V292, P619, DOI 10.1001/jama.292.5.619; Wilens TE, 2003, PEDIATRICS, V111, P179, DOI 10.1542/peds.111.1.179; Wolraich M L, 1997, Pediatr Rev, V18, P266, DOI 10.1542/pir.18-8-266; WOLRAICH ML, 1995, JAMA-J AM MED ASSOC, V274, P1617, DOI 10.1001/jama.274.20.1617; Zito JM, 2000, JAMA-J AM MED ASSOC, V283, P1025, DOI 10.1001/jama.283.8.1025; 1998, REVISED CONNERS PARE; 2004, 2003 INFOPOEM	59	192	201	3	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2005	352	2					165	173		10.1056/NEJMcp032387	http://dx.doi.org/10.1056/NEJMcp032387			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	886TG	15647579				2022-12-28	WOS:000226251700009
J	Adolphs, R; Gosselin, F; Buchanan, TW; Tranel, D; Schyns, P; Damasio, AR				Adolphs, R; Gosselin, F; Buchanan, TW; Tranel, D; Schyns, P; Damasio, AR			A mechanism for impaired fear recognition after amygdala damage	NATURE			English	Article							BILATERAL DAMAGE; FACIAL EMOTION; INDIVIDUALS; PERCEPTION; PATTERNS; GAZE	Ten years ago, we reported that SM, a patient with rare bilateral amygdala damage, showed an intriguing impairment in her ability to recognize fear from facial expressions(1). Since then, the importance of the amygdala in processing information about facial emotions has been borne out by a number of lesion(2-4) and functional imaging studies(5,6). Yet the mechanism by which amygdala damage compromises fear recognition has not been identified. Returning to patient SM, we now show that her impairment stems from an inability to make normal use of information from the eye region of faces when judging emotions, a defect we trace to a lack of spontaneous fixations on the eyes during free viewing of faces. Although SM fails to look normally at the eye region in all facial expressions, her selective impairment in recognizing fear is explained by the fact that the eyes are the most important feature for identifying this emotion. Notably, SM's recognition of fearful faces became entirely normal when she was instructed explicitly to look at the eyes. This finding provides a mechanism to explain the amygdala's role in fear recognition, and points to new approaches for the possible rehabilitation of patients with defective emotion perception.	Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; CALTECH, Div Humanities & Social Sci, Pasadena, CA 91125 USA; Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; Univ Glasgow, Dept Psychol, Glasgow G12 8QB, Lanark, Scotland	University of Iowa; California Institute of Technology; Universite de Montreal; University of Glasgow	Adolphs, R (corresponding author), Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA.	radolphs@hss.caltech.edu	Schyns, Philippe/C-8127-2009; Damasio, Antonio/AAD-1342-2019; Schyns, Philippe/AAT-6989-2020	Tranel, Daniel/0000-0002-1338-1389; Schyns, Philippe/0000-0002-8542-7489; Buchanan, Tony/0000-0002-9166-8457				Adams RB, 2003, SCIENCE, V300, P1536, DOI 10.1126/science.1082244; Adolphs R, 1999, NEUROPSYCHOLOGIA, V37, P1111, DOI 10.1016/S0028-3932(99)00039-1; Adolphs R, 1998, NATURE, V393, P470, DOI 10.1038/30982; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Adolphs R., 2000, AMYGDALA FUNCTIONAL, P587; AMARAL DG, 1984, J COMP NEUROL, V230, P465, DOI 10.1002/cne.902300402; Anderson AK, 2001, NATURE, V411, P305, DOI 10.1038/35077083; Anderson AK, 2000, NEUROPSYCHOLOGY, V14, P526, DOI 10.1037/0894-4105.14.4.526; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Ekman P., 1976, PICTURES FACIAL AFFE; Emery NJ, 2000, NEUROSCI BIOBEHAV R, V24, P581, DOI 10.1016/S0149-7634(00)00025-7; Gosselin F, 2001, VISION RES, V41, P2261, DOI 10.1016/S0042-6989(01)00097-9; HAITH MM, 1977, SCIENCE, V198, P853, DOI 10.1126/science.918670; Holland PC, 1999, TRENDS COGN SCI, V3, P65, DOI 10.1016/S1364-6613(98)01271-6; Howard MA, 2000, NEUROREPORT, V11, P2931, DOI 10.1097/00001756-200009110-00020; KAPP BS, 1992, AMYGDALA NEUROBIOLOG, P254; Kawashima R, 1999, BRAIN, V122, P779, DOI 10.1093/brain/122.4.779; KEATING CF, 1982, PERCEPTION, V11, P211, DOI 10.1068/p110211; Klin A, 2002, ARCH GEN PSYCHIAT, V59, P809, DOI 10.1001/archpsyc.59.9.809; Lundqvist D., 1998, KAROLINSKA DIRECTED; Morris JS, 2002, NEUROIMAGE, V17, P214, DOI 10.1006/nimg.2002.1220; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Pelphrey KA, 2002, J AUTISM DEV DISORD, V32, P249, DOI 10.1023/A:1016374617369; Schmolck H, 2001, NEUROPSYCHOLOGY, V15, P30, DOI 10.1037/0894-4105.15.1.30; Schyns PG, 2002, PSYCHOL SCI, V13, P402, DOI 10.1111/1467-9280.00472; SMITH ML, IN PRESS PSYCHOL SCI; Vuilleumier P, 2004, NAT NEUROSCI, V7, P1271, DOI 10.1038/nn1341; Whalen PJ, 1998, CURR DIR PSYCHOL SCI, V7, P177, DOI 10.1111/1467-8721.ep10836912; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15	30	914	943	4	200	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					68	72		10.1038/nature03086	http://dx.doi.org/10.1038/nature03086			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635411				2022-12-28	WOS:000226117100037
J	Levine, B				Levine, B			Eating oneself and uninvited guests: Autophagy-related pathways in cellular defense	CELL			English	Review								The eukaryotic cell uses an evolutionarily conserved lysosomal pathway of self-digestion (autophagy) for survival when extracellular nutrients are limited. In this issue of Cell, new evidence indicates that autophagy is used to for survival when intracellular nutrients are limited by growth factor deprivation (Lum et al., 2005). Other recent studies indicate that the autophagy machinery is also used to degrade foreign microbial invaders (xenophagy).	Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75330 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Levine, B (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75330 USA.	beth.levine@utsouthwestern.edu						Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0; CODOGNO P, 2004, AUTOPHAGY, P26; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; OGAWA M, 2004, SCIENCE; PALUDAN C, 2004, SCIENCE; Seay M, 2005, MODULATION OF HOST GENE EXPRESSION AND INNATE IMMUNITY BY VIRUSES, P245, DOI 10.1007/1-4020-3242-0_11; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Vergne I, 2004, ANNU REV CELL DEV BI, V20, P367, DOI 10.1146/annurev.cellbio.20.010403.114015	15	657	696	3	77	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 28	2005	120	2					159	162		10.1016/j.cell.2005.01.005	http://dx.doi.org/10.1016/j.cell.2005.01.005			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	893SR	15680321	Bronze			2022-12-28	WOS:000226740000004
J	Allard, P; Burton, M; Mure, F				Allard, P; Burton, M; Mure, F			Spectroscopic evidence for a lava fountain driven by previously accumulated magmatic gas	NATURE			English	Article							MOUNT-ETNA; REMOTE MEASUREMENTS; KILAUEA VOLCANO; BASALTIC MAGMA; ERUPTION; HAWAII; CO2; DYNAMICS; ASCENT; H2O	Lava fountains are spectacular continuous gas jets, propelling lava fragments to heights of several hundred metres, which occasionally occur during eruptions of low-viscosity magmas(1-5). Whether they are generated by the effervescent disruption of fast-rising bubbly melt(2-5) or by the separate ascent of a bubble foam layer accumulated at depth(6,7) still remains a matter of debate(8). No field measurement has yet allowed firm discrimination between these two models. A key insight into the origin of lava fountains may be gained by measuring the chemical composition of the driving gas phase. This composition should differ markedly depending on whether the magma degassing occurs before or during eruption(9,10). Here we report the analysis of magmatic gas during a powerful (250 - 600 m high) lava fountain, measured with Fourier transform infrared spectroscopy(11-14) on Mount Etna, Sicily. The abundances of volcanic gas species, determined from absorption spectra of lava radiation, reveal a fountain gas having higher CO2/S and S/Cl ratios than other etnean emissions(14-18), and which cannot derive from syn-eruptive bulk degassing of Etna basalt(19,20). Instead, its composition suggests violent emptying of a gas bubble layer previously accumulated at about 1.5 km depth below the erupting crater.	INGV, I-95123 Catania, Italy; CE Saclay, CEA, CNRS, Lab Pierre Sue, F-91191 Gif Sur Yvette, France	Istituto Nazionale Geofisica e Vulcanologia (INGV); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Allard, P (corresponding author), INGV, Piazza Roma 2, I-95123 Catania, Italy.	patrick.allard@cea.fr	ALLARD, Patrick/H-9480-2017; Burton, Mike/B-5716-2014	ALLARD, Patrick/0000-0001-7836-3117; Burton, Mike/0000-0003-3779-4812				ALLARD P, 1991, NATURE, V351, P387, DOI 10.1038/351387a0; ALLARD P, 1999, ENV4960288 MVRRS RTD; ALLARD P, 2003, GEOPHYS RES ABSTR, V5, P13079; ALLARD P, 1986, THESIS PARIS 7 U; ALLARD P, 2000, GEOCHEMICAL MONITORI; Alparone S, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001866; BURTON M, 2003, SPECIAL PUBLICATION, V2213, P281; Burton MR, 2000, GEOLOGY, V28, P915, DOI 10.1130/0091-7613(2000)28<915:RSOCAH>2.0.CO;2; Francis P, 1998, NATURE, V396, P567, DOI 10.1038/25115; GERLACH TM, 1986, J GEOPHYS RES-SOLID, V91, P2177, DOI 10.1029/JB091iB12p12177; Giggenbach WF, 1996, MONITORING MITIGATIO; HEAD JW, 1987, J GEOPHYS RES-SOLID, V92, P13715, DOI 10.1029/JB092iB13p13715; JAUPART C, 1988, NATURE, V331, P58, DOI 10.1038/331058a0; Metrich N, 1996, GEOCHIM COSMOCHIM AC, V60, P4151, DOI 10.1016/S0016-7037(96)00229-3; METRICH N, 1993, J VOLCANOL GEOTH RES, V59, P131, DOI 10.1016/0377-0273(93)90082-3; Metrich N, 2004, EARTH PLANET SC LETT, V228, P1, DOI 10.1016/j.epsl.2004.09.036; MORI T, 1995, EARTH PLANET SC LETT, V134, P219, DOI 10.1016/0012-821X(95)00119-W; NAUGHTON JJ, 1969, J GEOPHYS RES, V74, P3273, DOI 10.1029/JB074i012p03273; Parfitt E. A., 2004, J VOLCANOL GEOTHERM, V134, P131; Parfitt EA, 1995, B VOLCANOL, V57, P440, DOI 10.1007/BF00300988; Pennisi M, 1998, J GEOPHYS RES-SOL EA, V103, P5061, DOI 10.1029/97JB03011; RODGERS CD, 1976, REV GEOPHYS, V14, P609, DOI 10.1029/RG014i004p00609; Rothman LS, 1998, J QUANT SPECTROSC RA, V60, P665, DOI 10.1016/S0022-4073(98)00078-8; SPARKS RSJ, 1978, J VOLCANOL GEOTH RES, V3, P1, DOI 10.1016/0377-0273(78)90002-1; SPILLIAERT N, 2004, GEOPH RES ABSTR, V6; SWANSON DA, 1979, US GEOL SURV PROF PA, V1056, P1; VERGNIOLLE S, 1990, J GEOPHYS RES-SOLID, V95, P2793, DOI 10.1029/JB095iB03p02793; WILSON L, 1981, J GEOPHYS RES, V86, P2971, DOI 10.1029/JB086iB04p02971	28	199	200	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2005	433	7024					407	410		10.1038/nature03246	http://dx.doi.org/10.1038/nature03246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	890XZ	15674289				2022-12-28	WOS:000226546200040
J	Semmo, N; Barnes, E; Taylor, C; Kurtz, J; Harcourt, G; Smith, N; Klenerman, P				Semmo, N; Barnes, E; Taylor, C; Kurtz, J; Harcourt, G; Smith, N; Klenerman, P			T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors	LANCET			English	Article							INFECTION	Blood donors are routinely screened for hepatitis C virus infection. Some individuals have weak or restricted virus-specific antibody responses, and are classed as indeterminate. Such donors are almost always negative for viral RNA in blood. We postulated that previous transient virus exposure might account for some of these cases. With sensitive ex-vivo analyses of T-cell responses, we identified virus-specific responses in 15 of 30 indeterminate blood donors tested, compared with none in controls (p=0.0013). Additionally, these responses were typically focused on core. derived peptides. These findings suggest previous exposure to the virus in many indeterminate blood donors.	Univ Oxford, Oxford OX1 3SY, England; Natl Brood Serv, Birmingham, W Midlands, England	University of Oxford	Klenerman, P (corresponding author), Univ Oxford, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 3SY, England.	paul.klenerman@medawar.ox.ac.uk		Barnes, Eleanor/0000-0002-0860-0831; klenerman, paul/0000-0003-4307-9161				Barnes E, 2002, HEPATOLOGY, V36, P743, DOI 10.1053/jhep.2002.35344; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; Dufour DR, 2003, CLIN CHEM, V49, P479, DOI 10.1373/49.3.479; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; *NAT BLOOD SERV IN, 2003, MONTHL DON TEST REP; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; Wedemeyer H, 2001, J VIROL, V75, P11392, DOI 10.1128/JVI.75.23.11392-11400.2001	7	44	48	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2005	365	9456					327	329						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889NL	15664228				2022-12-28	WOS:000226449600036
J	Maeda, T; Hobbs, RM; Merghoub, T; Guernah, I; Zelent, A; Cordon-Cardo, C; Teruya-Feldstein, J; Pandolfi, PP				Maeda, T; Hobbs, RM; Merghoub, T; Guernah, I; Zelent, A; Cordon-Cardo, C; Teruya-Feldstein, J; Pandolfi, PP			Role of the proto-oncogene Pokemon in cellular transformation and ARF repression	NATURE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REPRESSOR; TISSUE MICROARRAY; BMI-1 ONCOPROTEIN; GENE-EXPRESSION; CYCLE ARREST; C-MYC; LYMPHOMA; SENESCENCE	Aberrant transcriptional repression through chromatin remodelling and histone deacetylation has been postulated to represent a driving force underlying tumorigenesis because histone deacetylase inhibitors have been found to be effective in cancer treatment. However, the molecular mechanisms by which transcriptional derepression would be linked to tumour suppression are poorly understood. Here we identify the transcriptional repressor Pokemon (encoded by the Zbtb7 gene) as a critical factor in oncogenesis. Mouse embryonic fibroblasts lacking Zbtb7 are completely refractory to oncogene-mediated cellular transformation. Conversely, Pokemon overexpression leads to overt oncogenic transformation both in vitro and in vivo in transgenic mice. Pokemon can specifically repress the transcription of the tumour suppressor gene ARF through direct binding. We find that Pokemon is aberrantly overexpressed in human cancers and that its expression levels predict biological behaviour and clinical outcome. Pokemon's critical role in cellular transformation makes it an attractive target for therapeutic intervention.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Maeda, Takahiro/AAC-4563-2019; Zelent, Arthur/B-3532-2009; Hobbs, Robin/I-2577-2014	Maeda, Takahiro/0000-0003-4530-6460; Zelent, Arthur/0000-0002-7968-9888; Hobbs, Robin/0000-0002-3853-2614	NATIONAL CANCER INSTITUTE [R01CA102142] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102142] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhikary S, 2003, MOL CELL BIOL, V23, P7648, DOI 10.1128/MCB.23.21.7648-7657.2003; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DONLON JA, 1977, NEW ENGL J MED, V297, P461, DOI 10.1056/NEJM197709012970901; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hedvat CV, 2002, HUM PATHOL, V33, P968, DOI 10.1053/hupa.2002.127438; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jaffe E.S., 2001, PATHOLOGY GENETICS T, VVolume 3; Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; QUELLE DE, 1995, CELL, V83, P993; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Whitehurst CE, 1999, IMMUNITY, V10, P313, DOI 10.1016/S1074-7613(00)80031-X; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	49	272	325	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					278	285		10.1038/nature03203	http://dx.doi.org/10.1038/nature03203			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15662416				2022-12-28	WOS:000226381300046
J	Bertone-Johnson, ER				Bertone-Johnson, ER			Epidemiology of ovarian cancer: a status report	LANCET			English	Editorial Material							FOLLOW-UP; RISK; WOMEN		Univ Massachusetts, Dept Publ Hlth, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Bertone-Johnson, ER (corresponding author), Univ Massachusetts, Dept Publ Hlth, Amherst, MA 01003 USA.	ebertone@schoolph.umass.edu						Anderson JP, 2004, CANCER-AM CANCER SOC, V100, P1515, DOI 10.1002/cncr.20146; Barnett GL, 2004, CURR OPIN OBSTET GYN, V16, P79, DOI 10.1097/00001703-200402000-00014; Bray F, 2005, INT J CANCER, V113, P977, DOI 10.1002/ijc.20649; Engeland A, 2003, JNCI-J NATL CANCER I, V95, P1244, DOI 10.1093/jnci/djg010; Kashyap S, 2004, OBSTET GYNECOL, V103, P785, DOI 10.1097/01.AOG.0000119226.39514.1d; Kjaer SK, 2004, INT J EPIDEMIOL, V33, P596, DOI 10.1093/ije/dyh046; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Larsson SC, 2004, AM J CLIN NUTR, V80, P1353, DOI 10.1093/ajcn/80.5.1353; Purdie DM, 2003, GYNECOL ONCOL, V88, pS145, DOI 10.1006/gyno.2002.6706; Riman T, 2004, ACTA OBSTET GYN SCAN, V83, P783, DOI 10.1111/j.0001-6349.2004.00550.x	10	35	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					101	102		10.1016/S0140-6736(05)17716-2	http://dx.doi.org/10.1016/S0140-6736(05)17716-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639276				2022-12-28	WOS:000226170700005
J	Croxall, JP; Silk, JRD; Phillips, RA; Afanasyev, V; Briggs, DR				Croxall, JP; Silk, JRD; Phillips, RA; Afanasyev, V; Briggs, DR			Global circumnavigations: Tracking year-round ranges of nonbreeding albatrosses	SCIENCE			English	Article							AUSTRALIA; OCEAN	Although albatrosses are paradigms of oceanic specialization, their foraging areas and migration routes when not breeding remain essentially unknown. Our continuous remote tracking of 22 adult gray-headed albatrosses for over 30 bird-years reveals three distinct strategies: (i) Stay in breeding home range; (ii) make return migrations to a specific area of the southwest Indian Ocean; and (iii) make one or more global circumnavigations (the fastest in just 46 days). The consistencies in patterns, routes, and timings offer the first hope of identifying areas of critical habitat for nonbreeding albatrosses, wherein appropriate management of longline fisheries might alleviate the plight of the world's most threatened family of birds.	British Antarctic Survey, NERC, Cambridge CB3 0ET, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Croxall, JP (corresponding author), British Antarctic Survey, NERC, High Cross,Madingley Rd, Cambridge CB3 0ET, England.							Brothers N, 1998, IBIS, V140, P446, DOI 10.1111/j.1474-919X.1998.tb04606.x; Croxall JP, 1998, ALBATROSS: BIOLOGY AND CONSERVATION, P69; Huin N, 2002, AQUAT CONSERV, V12, P89, DOI 10.1002/aqc.479; NICHOLLS D, 1995, EMU, V95, P223, DOI 10.1071/MU9950223; Nicholls DG, 2002, MAR ECOL PROG SER, V231, P269, DOI 10.3354/meps231269; Phillips RA, 2004, P ROY SOC B-BIOL SCI, V271, P1283, DOI 10.1098/rspb.2004.2718; Phillips RA, 2004, MAR ECOL PROG SER, V266, P265, DOI 10.3354/meps266265; Prince PA, 1998, ALBATROSS: BIOLOGY AND CONSERVATION, P137; Tickell W. L. N., 1968, Antarctic Research Series Washington, V12, P1; Tuck GN, 2003, BIOL CONSERV, V114, P1, DOI 10.1016/S0006-3207(02)00378-6; Weimerskirch H, 2000, NATURE, V406, P955, DOI 10.1038/35023068	11	228	241	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2005	307	5707					249	250		10.1126/science.1106042	http://dx.doi.org/10.1126/science.1106042			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15653503				2022-12-28	WOS:000226361900041
J	Papania, MJ; Strebel, PM				Papania, MJ; Strebel, PM			Measles surveillance: the importance of finding the tip of the iceberg	LANCET			English	Editorial Material							REPORTING EFFICIENCY; CITY		Ctr Dis Control & Prevent, Measles Rubella Mumps Eliminat Team, Natl Immunizat Program, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Global Immunizat Div, Natl Immunizat Program, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Papania, MJ (corresponding author), Ctr Dis Control & Prevent, Measles Rubella Mumps Eliminat Team, Natl Immunizat Program, Atlanta, GA 30333 USA.	mpapania@cdc.gov						CHERRY JD, 1972, J PEDIATR-US, V81, P217, DOI 10.1016/S0022-3476(72)80287-7; DAVIS SF, 1993, AM J PUBLIC HEALTH, V83, P1011, DOI 10.2105/AJPH.83.7.1011; EWERT DP, 1994, AM J PUBLIC HEALTH, V84, P868, DOI 10.2105/AJPH.84.5.868-a; EWERT DP, 1995, PUBLIC HEALTH REP, V110, P161; Harpaz R, 2004, J INFECT DIS, V189, pS185, DOI 10.1086/378501; Hinman A R, 1980, Epidemiol Rev, V2, P153; SYDENSTRICKER E., 1926, Public Health Reports, V41, P2069, DOI 10.2307/4578020; Sydenstricker E, 1926, PUBLIC HLTH REP, V41, P2186; van Isterdael CED, 2004, J CLIN EPIDEMIOL, V57, P633, DOI 10.1016/j.jclinepi.2003.11.012	9	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2005	365	9454					100	101		10.1016/S0140-6736(05)17715-0	http://dx.doi.org/10.1016/S0140-6736(05)17715-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885PZ	15639275				2022-12-28	WOS:000226170700004
J	Vousden, KH; Prives, C				Vousden, KH; Prives, C			P53 and prognosis: New insights and further complexity	CELL			English	Review							MUTANT P53; TUMOR-SUPPRESSOR; GAIN; MDM2; POLYMORPHISM; PATHWAY	Despite the massive amount of knowledge that has accumulated about p53, there is still much to learn about its role in tumor suppression. New papers now provide evidence that levels of Mdm2 in humans or presence of mutant forms of p53 in mice can have profound impacts on survival and tumorigenesis. These findings may lead to new diagnostic and therapeutic approaches to treating cancer patients.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Beatson Institute; Columbia University	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	cip3@columbia.edu						Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Corcoran CA, 2004, CANCER BIOL THER, V3, P721, DOI 10.4161/cbt.3.8.1068; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Sigal A, 2000, CANCER RES, V60, P6788; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	19	226	236	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	2005	120	1					7	10		10.1016/j.cell.2004.12.027	http://dx.doi.org/10.1016/j.cell.2004.12.027			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	888HS	15652475	Bronze			2022-12-28	WOS:000226365400004
J	Ballentine, CJ; Marty, B; Lollar, BS; Cassidy, M				Ballentine, CJ; Marty, B; Lollar, BS; Cassidy, M			Neon isotopes constrain convection and volatile origin in the Earth's mantle	NATURE			English	Article							PRIMORDIAL NOBLE-GASES; POPPING ROCK; SOLAR NEON; HELIUM; EVOLUTION; MODELS; XENON; ARGON; CO2; SYSTEMATICS	Identifying the origin of primordial volatiles in the Earth's mantle provides a critical test between models that advocate magma-ocean equilibration with an early massive solar-nebula atmosphere and those that require subduction of volatiles implanted in late accreting material. Here we show that neon isotopes in the convecting mantle, resolved in magmatic CO2 well gases, are consistent with a volatile source related to solar corpuscular irradiation of accreting material. This contrasts with recent results that indicated a solar-nebula origin for neon in mantle plume material, which is thought to be sampling the deep mantle. Neon isotope heterogeneity in different mantle sources suggests that models in which the plume source supplies the convecting mantle with its volatile inventory require revision. Although higher than accepted noble gas concentrations in the convecting mantle may reduce the need for a deep mantle volatile flux, any such flux must be dominated by the neon ( and helium) isotopic signature of late accreting material.	Univ Manchester, Dept Earth Sci, Manchester M13 9LP, Lancs, England; Ctr Rech Petrog & Geochim, F-54501 Vandoeuvre Les Nancy, France; Ecole Natl Super Geol, F-54501 Vandoeuvre Les Nancy, France; Univ Toronto, Dept Geol, Toronto, ON M5S 3B1, Canada; Univ Houston, Dept Geosci, Houston, TX 77204 USA	University of Manchester; Universite de Lorraine; Universite de Lorraine; University of Toronto; University of Houston System; University of Houston	Ballentine, CJ (corresponding author), Univ Manchester, Dept Earth Sci, Oxford Rd, Manchester M13 9LP, Lancs, England.	chris.ballentine@manchester.ac.uk		Ballentine, Chris/0000-0001-9382-070X	Natural Environment Research Council [NER/A/S/2002/00960] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; BALLENTINE CJ, 1992, EARTH PLANET SC LETT, V113, P553, DOI 10.1016/0012-821X(92)90131-E; Ballentine CJ, 2002, REV MINERAL GEOCHEM, V47, P481, DOI 10.2138/rmg.2002.47.12; Ballentine CJ, 2002, PHILOS T ROY SOC A, V360, P2611, DOI 10.1098/rsta.2002.1083; Ballentine CJ, 2002, GEOCHIM COSMOCHIM AC, V66, P2483, DOI 10.1016/S0016-7037(02)00850-5; Ballentine CJ, 2001, NATURE, V409, P327, DOI 10.1038/35053046; BALLENTINE CJ, 2001, SCIENCE, V291, pA2269; Becker TW, 1999, EARTH PLANET SC LETT, V171, P351, DOI 10.1016/S0012-821X(99)00160-0; Bercovici D, 2003, NATURE, V425, P39, DOI 10.1038/nature01918; BLACK DC, 1972, GEOCHIM COSMOCHIM AC, V36, P347, DOI 10.1016/0016-7037(72)90028-2; Broadhead R.F., 1993, W TEXAS GEOL SOC B, V32, P5; Burnard P, 1997, SCIENCE, V276, P568, DOI 10.1126/science.276.5312.568; Caffee MW, 1999, SCIENCE, V285, P2115, DOI 10.1126/science.285.5436.2115; DAVIES GF, 1992, J GEOL, V100, P151, DOI 10.1086/629582; Dixon ET, 2000, EARTH PLANET SC LETT, V180, P309, DOI 10.1016/S0012-821X(00)00164-3; Halliday AN, 2001, SPACE SCI REV, V96, P197, DOI 10.1023/A:1011997206080; Harrison D, 1999, EARTH PLANET SC LETT, V171, P199, DOI 10.1016/S0012-821X(99)00143-0; HART R, 1979, NATURE, V278, P156, DOI 10.1038/278156a0; Honda M, 1998, GEOPHYS RES LETT, V25, P1951, DOI 10.1029/98GL01329; Kallenbach R, 1997, J GEOPHYS RES-SPACE, V102, P26895, DOI 10.1029/97JA02325; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Kleine T, 2002, NATURE, V418, P952, DOI 10.1038/nature00982; Kunz J, 1998, SCIENCE, V280, P877, DOI 10.1126/science.280.5365.877; Lollar BS, 1997, GEOCHIM COSMOCHIM AC, V61, P2295; Marty B, 1997, EARTH PLANET SC LETT, V152, P101, DOI 10.1016/S0012-821X(97)00153-2; Marty B, 1998, CHEM GEOL, V145, P233, DOI 10.1016/S0009-2541(97)00145-9; Moreira M, 1998, SCIENCE, V279, P1178, DOI 10.1126/science.279.5354.1178; Moreira M, 2001, EARTH PLANET SC LETT, V185, P15, DOI 10.1016/S0012-821X(00)00351-4; ONIONS RK, 1983, NATURE, V306, P429, DOI 10.1038/306429a0; Ott U, 2002, REV MINERAL GEOCHEM, V47, P71, DOI 10.2138/rmg.2002.47.3; PHINNEY D, 1978, J GEOPHYS RES, V83, P2313, DOI 10.1029/JB083iB05p02313; Porcelli D, 2001, EARTH PLANET SC LETT, V193, P237, DOI 10.1016/S0012-821X(01)00493-9; Porcelli D, 2002, REV MINERAL GEOCHEM, V47, P411, DOI 10.2138/rmg.2002.47.11; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P4921, DOI 10.1016/0016-7037(95)00336-3; Porcelli D, 2001, EARTH PLANET SC LETT, V192, P45, DOI 10.1016/S0012-821X(01)00418-6; Reid MR, 1996, EARTH PLANET SC LETT, V144, P213, DOI 10.1016/0012-821X(96)00166-5; Saal AE, 2002, NATURE, V419, P451, DOI 10.1038/nature01073; STAUDACHER T, 1987, NATURE, V325, P605, DOI 10.1038/325605a0; SU Y, 2003, GLOBAL MORB CHEM COM; TOLSTIKHIN I, IN PRESS PHYS EARTH; Torgersen T, 1999, EARTH PLANET SC LETT, V167, P239, DOI 10.1016/S0012-821X(99)00021-7; Trieloff M, 2000, SCIENCE, V288, P1036, DOI 10.1126/science.288.5468.1036; Trieloff M, 2002, EARTH PLANET SC LETT, V200, P297, DOI 10.1016/S0012-821X(02)00639-8; van Keken PE, 1999, J GEOPHYS RES-SOL EA, V104, P7137, DOI 10.1029/1999JB900003; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; Vidale JE, 2001, GEOPHYS RES LETT, V28, P859, DOI 10.1029/2000GL012428; Wetherill G. W, 1986, ORIGIN MOON, P519; Wieler R, 2002, REV MINERAL GEOCHEM, V47, P21, DOI 10.2138/rmg.2002.47.2; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995; Yokochi R, 2004, EARTH PLANET SC LETT, V225, P77, DOI 10.1016/j.epsl.2004.06.010	50	129	133	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2005	433	7021					33	38		10.1038/nature03182	http://dx.doi.org/10.1038/nature03182			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884WJ	15635402				2022-12-28	WOS:000226117100028
J	Scholes, D; Hooton, TM; Roberts, PL; Gupta, K; Stapleton, AE; Stamm, WE				Scholes, D; Hooton, TM; Roberts, PL; Gupta, K; Stapleton, AE; Stamm, WE			Risk factors associated with acute pyelonephritis in healthy women	ANNALS OF INTERNAL MEDICINE			English	Article							URINARY-TRACT-INFECTION; SPERMICIDE-COATED CONDOMS; POSTMENOPAUSAL WOMEN; YOUNG-WOMEN; ESCHERICHIA-COLI; ASYMPTOMATIC BACTERIURIA; SEXUAL-ACTIVITY; HOSPITALIZATION; PREVALENCE; CYSTITIS	Background: Although most cases of acute pyelonephritis occur in otherwise healthy women, data on risk factors for this condition are lacking. Objective: To evaluate infection characteristics, incidence, and risk factors associated with acute pyelonephritis in a sample of women. Design: Population-based case-control study. Setting: Group Health Cooperative, a prepaid health plan in Washington. Participants: 788 nonpregnant women, 18 to 49 years of age. Case-patients (n = 242) were women with pyelonephritis who were identified from computerized databases. Controls were 546 similar-age women with no pyelonephritis diagnosis in the previous 5 years who were randomly selected from enrollment databases. Response rates for case-patients and controls were 73% and 64%, respectively. Measurements: Characteristics of infection and potential risk factors for pyelonephritis, ascertained through computer-assisted telephone interview and computerized databases. Results: 7% of case-patients were hospitalized. Escherichia coli was the infecting pathogen in 85% of cases. In multivariable models, factors associated with pyelonephritis risk were frequency of sexual intercourse in the previous 30 days (odds ratio, 5.6 [95% CI, 2.8 to 11.0] for >= 3 times per week), recent urinary tract infection (UTI) (odds ratio, 4.4 [CI, 2.8 to 7.1]), diabetes (odds ratio, 4.1 [CI, 1.6 to 10.9]), recent incontinence (odds ratio, 3.9 [CI. 2.6 to 5.9]), new sexual partner in the previous year (odds ratio, 2.2 [CI, 1.4 to 3.6]), recent spermicide use (odds ratio, 1.7 [CI, 1.1 to 2.8]), and UTI history in the participant's mother (odds ratio, 1.6 [CI, 1.1 to 2.5]). Risk factors for selected subgroups (patients <= 30 years of age, patients > 30 years of age, patients with no UTI history, and inpatients) were also evaluated. Limitations: Potential recall bias, reliance on automated case definition criteria, and limited data on diabetes and incontinence variables. Conclusions: Few nonpregnant, community-dwelling women younger than 50 years of age with pyelonephritis are hospitalized. As with cystitis in reproductive-age women, sexual behaviors and patient and family history of UTI are associated with increased pyelonephritis risk. Diabetes and incontinence also seem to independently increase the risk for pyelonephritis.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Seattle, WA 98195 USA	Group Health Cooperative; University of Washington; University of Washington Seattle	Scholes, D (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,16th Floor, Seattle, WA 98101 USA.	scholes.d@ghc.org	Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK002660, R01DK062863, P01DK053369] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK053369-019001, P01 DK053369-020002, 1 PO DK53369, R01 DK062863-02, P01 DK053369, K23 DK002660, P01 DK053369-029001, P01 DK053369-07, K23 DK02660, P01 DK053369-010002, R01 DK062863, P01 DK053369-06A1, R01 DK062863-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boyko EJ, 2002, DIABETES CARE, V25, P1778, DOI 10.2337/diacare.25.10.1778; Brown, 2000, Curr Infect Dis Rep, V2, P513, DOI 10.1007/s11908-000-0054-4; Brown JS, 2001, OBSTET GYNECOL, V98, P1045, DOI 10.1016/S0029-7844(01)01630-1; Fihn SD, 1996, AM J EPIDEMIOL, V144, P512, DOI 10.1093/oxfordjournals.aje.a008958; Fihn SD, 1998, ARCH INTERN MED, V158, P281, DOI 10.1001/archinte.158.3.281; Foxman B, 2003, ANN EPIDEMIOL, V13, P144, DOI 10.1016/S1047-2797(02)00272-7; FOXMAN B, 1995, EPIDEMIOLOGY, V6, P162, DOI 10.1097/00001648-199503000-00013; Foxman B, 2001, J CLIN EPIDEMIOL, V54, P710, DOI 10.1016/S0895-4356(00)00352-8; Geerlings SE, 2002, DIABETES CARE, V25, P1405, DOI 10.2337/diacare.25.8.1405; Gupta K, 1998, J INFECT DIS, V178, P446, DOI 10.1086/515635; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; Hannestad YS, 2000, J CLIN EPIDEMIOL, V53, P1150, DOI 10.1016/S0895-4356(00)00232-8; HOOTEN TM, 1994, CLIN INFECT DIS, V19, P274, DOI 10.1093/clinids/19.2.274; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; Hooton TM, 2000, NEW ENGL J MED, V343, P992, DOI 10.1056/NEJM200010053431402; Hu KK, 2004, ARCH INTERN MED, V164, P989, DOI 10.1001/archinte.164.9.989; Nicolle LE, 1996, CLIN INFECT DIS, V22, P1051, DOI 10.1093/clinids/22.6.1051; Nicolle LE, 1997, URINARY TRACT INFECT, P8; Pabich WL, 2003, J INFECT DIS, V188, P1054, DOI 10.1086/378203; Raz R, 1999, INFECT DIS CLIN PRAC, V8, P335, DOI 10.1097/00019048-199909000-00011; Raz R, 2000, CLIN INFECT DIS, V30, P152, DOI 10.1086/313596; RUBIN RH, 1992, CLIN INFECT DIS, V15, pS216, DOI 10.1093/clind/15.Supplement_1.S216; Scholes D, 2000, J INFECT DIS, V182, P1177, DOI 10.1086/315827; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427	27	129	133	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2005	142	1					20	27		10.7326/0003-4819-142-1-200501040-00008	http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916DS	15630106	Green Accepted			2022-12-28	WOS:000228366200003
J	Vanhorebeek, I; De Vos, R; Mesotten, D; Wouters, PJ; De Wolf-Peeters, C; Van den Berghe, G				Vanhorebeek, I; De Vos, R; Mesotten, D; Wouters, PJ; De Wolf-Peeters, C; Van den Berghe, G			Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients	LANCET			English	Article							OXIDATIVE STRESS; CRITICAL ILLNESS; ORGAN DYSFUNCTION; MODEL; THERAPY; PHOSPHORYLATION; SEVERITY; MUSCLE; LIPIDS; DAMAGE	Background Maintenance of normoglycaemia by use of insulin reduces morbidity and mortality of patients in surgical intensive care. Studies on mitochondrial function in critical illness or diabetes suggest that effects of intensive insulin therapy on mitochondrial integrity contribute to the clinical benefits. Methods Enzyme activities of the respiratory-chain complexes and oxidative-stress-sensitive glyceraldehyde-3. phosphate dehydrogenase (GAPDH) were measured by spectrophotometry in 36 snap-frozen samples of liver and skeletal muscle obtained after death from patients who had been randomly assigned intensive (normoglycaemia) or conventional (hyperglycaemia) insulin therapy and who were similar in terms of admission diagnoses and causes of death. Mitochondrial ultrastructure was examined by electron microscopy in a random subgroup (n=20). Findings In the liver, hypertrophic mitochondria with an increased number of abnormal and irregular cristae and reduced matrix electron density were observed in seven of nine conventionally treated patients. Only one of 11 patients given intensive insulin treatment had these morphological abnormalities (p=0.005). The effect on ultrastructure was associated with higher activities of respiratory-chain complex I (median 1.53 [IQR 1.14-3.01] vs 0.81 [0.54-1.43] U/g liver; p=0.008) and complex IV (1.69 [1.40-1.97] vs 1.16 [0.97-1.40] U/g; p=0.008) in the intensive group than in the conventional group. There was no detectable difference in GAPDH activity. In skeletal muscle, mitochondrial ultrastructure and function were not affected by intensive insulin therapy. Interpretation Strict glycaemic control with intensive insulin therapy prevented or reversed ultrastructural and functional abnormalities of hepatocyte mitochondria. The lack of effect on skeletal-muscle mitochondria suggests a direct effect of glucose toxicity and glucose control, rather than of insulin, as the likely explanation. Relevance to practice Maintenance or restoration of mitochondrial function and cellular energetics is another therapeutic target, in addition to optimisation of cardiac output, systemic oxygen delivery, and regional blood flow, that might improve outcome for critically ill patients. Our findings could help to explain the mechanism underlying the reduction in mortality found when normoglycaemia was maintained with insulin, and further support use of intensive insulin therapy in this setting.	Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Van den Berghe, G (corresponding author), Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium.	greta.vandenberghe@med.kuleuven.ac.be	Mesotten, Dieter/ABE-4176-2020; Van den Berghe, Greet/J-6788-2018	Mesotten, Dieter/0000-0002-3258-4720; Van den Berghe, Greet/0000-0002-5320-1362; Vanhorebeek, Ilse/0000-0002-5261-5192				Baumgart E, 2001, AM J PATHOL, V159, P1477, DOI 10.1016/S0002-9440(10)62534-5; BERGMEYER HU, 1985, METHOD ENZYMAT AN, P211; Bissler JJ, 2002, LAB INVEST, V82, P335, DOI 10.1038/labinvest.3780427; Bonnefont-Rousselot D, 2002, CURR OPIN CLIN NUTR, V5, P561, DOI 10.1097/00075197-200209000-00016; Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003; Brealey D, 2002, LANCET, V360, P219, DOI 10.1016/S0140-6736(02)09459-X; BREALEY DA, 2003, 16 ANN C AMST NETH O, pS134; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bulger EM, 2001, ARCH SURG-CHICAGO, V136, P1201, DOI 10.1001/archsurg.136.10.1201; Crouser ED, 2002, CRIT CARE MED, V30, P2722, DOI 10.1097/00003246-200212000-00017; Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002; Fink MP, 2002, INTENS CARE MED, V28, P369, DOI 10.1007/s00134-001-1205-2; Fink MP, 2001, CRIT CARE CLIN, V17, P219, DOI 10.1016/S0749-0704(05)70161-5; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; HALL JC, 1960, J BIOL CHEM, V235, P1536; HALL JC, 1960, J BIOL CHEM, V235, P6; Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P1082, DOI 10.1210/jc.2002-021478; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Mesotten D, 2004, J CLIN ENDOCR METAB, V89, P219, DOI 10.1210/jc.2003-030760; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; Munnich A., 2001, METABOLIC MOL BASES, P2261; Oldham KM, 1998, J AM DIET ASSOC, V98, P1001, DOI 10.1016/S0002-8223(98)00230-2; Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311; RINEHART RW, 1982, ARCH BIOCHEM BIOPHYS, V213, P341, DOI 10.1016/0003-9861(82)90559-8; Singer M, 1999, BIOCHEM SOC SYMP, V66, P149, DOI 10.1042/bss0660149; Tirone TA, 2001, WORLD J SURG, V25, P461, DOI 10.1007/s002680020338; Tomita M, 1996, JPN CIRC J, V60, P673, DOI 10.1253/jcj.60.673; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VESTER JW, 1957, J BIOL CHEM, V227, P669; Wakabayashi T, 2002, J CELL MOL MED, V6, P497, DOI 10.1111/j.1582-4934.2002.tb00452.x; Weekers F, 2002, ENDOCRINOLOGY, V143, P764, DOI 10.1210/en.143.3.764; West IC, 2000, DIABETIC MED, V17, P171, DOI 10.1046/j.1464-5491.2000.00259.x; Wolfe RR, 2000, WORLD J SURG, V24, P639, DOI 10.1007/s002689910105	35	312	336	1	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2005	365	9453					53	59		10.1016/S0140-6736(04)17665-4	http://dx.doi.org/10.1016/S0140-6736(04)17665-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886FU	15639679				2022-12-28	WOS:000226213100028
J	Tinetti, ME; Bogardus, ST; Agostini, JV				Tinetti, ME; Bogardus, ST; Agostini, JV			Potential pitfalls of disease-specific guidelines for patients with multiple conditions	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AMERICAN-HEART-ASSOCIATION; ADVERSE DRUG EVENTS; RANDOMIZED-TRIALS; STATEMENT; THERAPY; DOCTORS; QUALITY; ADULT		Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT USA; Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Tinetti, ME (corresponding author), Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.				NATIONAL INSTITUTE ON AGING [P60AG010469] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alter DA, 2004, AM J MED, V116, P540, DOI 10.1016/j.amjmed.2003.10.039; Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213; BERENSON RA, 2003, CONFRONTING BARRIERS; Berry DC, 1997, PSYCHOL HEALTH, V12, P467, DOI 10.1080/08870449708406723; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Elwyn G, 2003, BMJ-BRIT MED J, V327, P864, DOI 10.1136/bmj.327.7419.864; Epstein RM, 2004, JAMA-J AM MED ASSOC, V291, P2359, DOI 10.1001/jama.291.19.2359; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gross CP, 2002, ANN INTERN MED, V137, P10, DOI 10.7326/0003-4819-137-1-200207020-00007; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Haynes RB, 1996, LANCET, V348, P383; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Institute of Medicine, 2001, CROSSING QUALITY CHA; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Lewis DK, 2003, BMJ-BRIT MED J, V327, P841, DOI 10.1136/bmj.327.7419.841; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; *NAT COMM QUAL ASS, 2003, STAT HLTH CAR QUAL 2; National Osteoporosis Foundation, 1999, PHYS GUID PREV TREAT; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Townsend A, 2003, BRIT MED J, V327, P837, DOI 10.1136/bmj.327.7419.837; Tsevat J, 1998, JAMA-J AM MED ASSOC, V279, P371, DOI 10.1001/jama.279.5.371; Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2	31	615	618	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2004	351	27					2870	2874		10.1056/NEJMsb042458	http://dx.doi.org/10.1056/NEJMsb042458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	883IH	15625341				2022-12-28	WOS:000226004300017
